<SEC-DOCUMENT>0001628280-22-028752.txt : 20221108
<SEC-HEADER>0001628280-22-028752.hdr.sgml : 20221108
<ACCEPTANCE-DATETIME>20221108070615
ACCESSION NUMBER:		0001628280-22-028752
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221108
DATE AS OF CHANGE:		20221108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		221367181

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>adc-20220930.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5,d:3a35353e827141feb6a74cba3e652509--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:adc="http://adctherapeutics.com/20220930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>adc-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV8xLTEtMS0xLTg2NzA3_223f03d3-ae4f-437d-9c07-f55abd614966">September 30, 2022</ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV8yLTEtMS0xLTg2NzA3_c8fd79cc-8705-4ea4-b081-f7362806b49d">0001771910</ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV8zLTEtMS0xLTg2NzA3_611eb58d-9eca-4176-a8b6-f55d60ab69b1">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV80LTEtMS0xLTg2NzA3_bf46951d-2d49-4248-9a89-41766f596e01">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV81LTEtMS0xLTg2NzA3_dea7c57d-601f-43d0-b26b-77763d0b01a9">2022</ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV82LTEtMS0xLTg2NzA3_cdeb853e-637a-4080-ade6-a94b301327b2">Q3</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="adc-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf907986f9804ac79096e6421bac5248_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia10551f99c2f4f2cba09a2c4825b83fb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c7edac15bd64992b9404d86947ee31e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0adb4408d5b64d2eb32d81b113d64564_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i938ba22ab3bc44038aab586a16722948_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia884bbbb5b2d4ef6bea649be380f3574_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b077300e1064ae1bddacda3d1e0be4a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28b78358bf294bc5b11aea256ecda3f4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id894c180529648fe9b583c546c2b3660_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i002154ec55ee4138b998ace2483bb162_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59c7697f17a94ce9a360033092cabb0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd2e5e5704574aebbaa2380a7fde3845_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f34ddf4b844d758babc0b90fe80e66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d737f742272444ea08949e847328dde_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:ConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf4592fe28044fabfe4047cabbd76e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:ConvertibleLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4ab23200b64567b35b0dc47c38e42b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5bb52172f94f6abd0bb6713cb6131b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35596c2c71984cccaef883c93b78c04e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246b440f84cd4fefaca5cc8ab1014c64_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3e54de10ce40b29aa3c37bcd67ea64_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027b22679fb54ad388c26ce8c669aac5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28832b49da3403a8b557a594e965059_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea2e58acd5f40adb6d20b24a516fd32_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a70943059b47938af04f86d913bf7f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421702717ad84eeaa1925dceb63c2981_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa267740ce54fae899738589cb13c74_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a3d958595654cd685c236012143b763_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97eb94da1244cedb49b709a60205ff8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic96fd76ea6094201873babaf44147e90_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a369d72d0de4d07b601c6485cd111ac_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2800d230b840698a1df635aef0fb1e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1275b5a441e64681a4536db9f8517583_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678984f32c6242569e8813e4669c4d66_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf2a41c1b0f412dbadb0ec7cc9807ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3987240b95a941f3a745b6bce9358ab2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d159e8735254990a623ac7081d8a5e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i223e1c18b9e048b4a57a8347875e6217_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e72f4f26f6741079eb2df83e9327373_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48cd9a814c44291b865fd727b17518f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31afbe725ae54907a860c98c67e10f1a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71b176729574174b972671a573dc05e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e733662e17549aebf656747ad4422c8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2584a401285d424c9fba045da1553201_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe83d69badf4b52947c1251a39d7037_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ca719fc24c4758a77b58d789173cfc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3cdb002a7f247dba0b4723c76def055_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aadc701136f486fb9d540ba984fa396_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6300840ba2e145df92c265753e78fc30_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3732a765dbee4267b31e29ecc8de0b94_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a916c5c42b145e7ab29ea4d88cb1cff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402dfab004dd492aae570021cbed2be1_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2644136b7844bd8f3ed9546fa55a15_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99128419613143609193e10731703076_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic08137b9d07d47458bd80e38918070fb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00516d757c74b41ab5ec5b14024dbfd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e3d0984c7640a6812965fc4399b0ab_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09effb3b4b9b463691f066e4f85ccde9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819688b0196b4f8180d3a454630743bf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie65cd89c7bf24557946ea885c4873749_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62705c1b99444245ac17369673cc7dcf_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04c2941ce0a845c4ad2292d13e712648_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8a9da342b454067adcd289ef23fbf0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e12d33e41234842815adf403479484b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3ac90d7b74494ab57a78dc23262650_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e071b05a6648619ca531f90eac8afe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a1526b17d348e3a7c97fc3293c2a37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a3acb2e8256494bb21952f83d8f6892_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85b8fd87bd6425ebe37b622aaa8b6fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9070db993da44bb4b9180949625e0bfe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba43579460b45abb618bce784d2265a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab68b9957bd493da33d7c58f46e02a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f104a5fe60467090a2d49a6f15319b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>adc:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313fda5b91c745ca8a9287f47d161560_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie29ccfe5e9104ba781990be9d5a74c93_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417e476b63a34ff7a49e6530cd7b944c_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementFutureTranchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e5a1305a7604d6e87bd11283adef044_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2b93ddb8d53d4ec2872793932c99d612_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i474416e45737460d849fb01685ad11e6_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7754055a3c2b48f1973108a8654c2f44_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1a14874532471a96f7d73129d6c1ca_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:PurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c9b855c1f247cdae6ad0bac21a2df8_D20220815-20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:PurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-15</xbrli:startDate><xbrli:endDate>2022-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerGBP"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i77985cac7eeb4add951edd6bccf0d37e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:ShareSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196dad762149431fa1779f78c8388406_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:ShareSubscriptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914b59538ffb4aff97128d35a7aec14f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac01c43c0d9347968cf7c0f6d6589b05_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib75271c7003f455ea3762473084eeb29_D20220118-20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-18</xbrli:startDate><xbrli:endDate>2022-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">adc:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f1b9c6855e4deba1fc15d4e267a2c3_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">adc:ApplicationApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>adc:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0531f2c694374cb1b481540b22706efe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05957f8cf6440c0b15060319d7b1f2a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ManufacturingOfAntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c36d77e8cc54708a0792a5def59ba80_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ManufacturingOfAntibodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i589e24d9d8e0409fb5e40f80435eaa18_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExecutiveCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1269616118a045b48128c0d3db3063c8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5e11a889cb4519ad08ba38236480fd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158d2be3e937431ea999c2367040412b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia84b491c52c74ac69be308c96ea954a1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife2c56e209614e089bacd12b15145e97_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfcf3a44f2c4765be8da06698d39b1c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa06a2e32fd743d8a7b60007f9ae048d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e033a22ecb478bb31362e9dd46dcbe_I20200519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6e0c7ae1fc42dabeef85f1e367666d_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f345e8135d943ddb82dfb8c7d312b08_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ZYNLONTAForRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52142027ddf44c8eab013214816b70f1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ZYNLONTAForRDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6898024e6a424206b1716d13c24b930b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:DosingOfSpecificNumberOfPatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6510f05326e840eb9346f0cb3062ac1e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:SuccessfulCompletionOfInVivoEfficacyStudiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieea878441dfa4efc8a9b70801ddadd56_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicenseToAcquireAnAntibodyZYNLONTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f1e1d5ebdb414f9b5247864591ca9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766d2e3cc1bf4d91a572ee7391121b0e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:ZYNLONTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cd70bd278774a99b8e19ac8da87c400_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:LicensePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3831a84c41e469fa75f28c8e4d66842_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0af6d42a54a4ea29ac6d823b1489254_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9911d0f78184a2082a9741569f80af9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8c5ec28bf64c13b28d322cc15764ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2aa78bd37e48d8afb1437f35585633_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090393068e7e4ce2a9bf4269cb47d7aa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fe126a6d63476e9d69e3a8dd0f33b0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56be2cd7a6c41c7bcd4c44c05784db9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576b3e5ad10f4c98a00d3c16839a707c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c1a842a7a74eb19e9e9fb576dfa486_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0735d735202d4e8fa9fe0243e3d57875_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ecc9946c714265bbb8a89418c63c01_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bd5f9550f6048c28bee5f1bfdd5d74d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b225beffa44b3d87f67b9e69f699fa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8151bd1bc2a04b71adee09c08447999a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0a40aaa46242f9b8c656439b48a32c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6029eb697ae4501b1bce9cb044843bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8f1760047640c38a5d3005f9bc6157_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32707d201834dc793295ca00533da1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c4fdcd15f36441b91d6a6497571a82b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b42fc0ddec473598e886ec0f5e3c9b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd15bcdf0a64b5898e159fda31b9d99_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b68b5b42e242f1985aa0054fda3aaa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3ffc2c26d6241199c0010549c56f460_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb5c39e47594c269f24f5e7a5544869_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b175bbb0a9439e8c3c4647daa448dc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1870dc5d8b164d9ebd63b4021e920cd6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da30f3755c743e08b48e072dc09209d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06eae1c2401f49908e95968065439f57_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ac58a635804353bcd123924428ff13_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f3dddcfe8e2427c8d4ff2eee0c6350f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i668c47e9660643d9a0bc7afaf9b7bc1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e692aa8462f4f09aaf7e7b3b896724f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2450f8f780347a6b493d4432cbc51da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3cf7b0b5824c3fbf851545e1194289_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc4fa9f79eb4710ae4034d037363f25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35cab614c8934a419edc6f7cccb644a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i335db87da9ad4f00b7b7b94870fddfb6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0468c473d542f88ffed8e8f6fa3499_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fae3e626a164280b7a488b6bde2fb6b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50390a1027184daa809325bb39041f9e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bfcb651885a4be4a64db35b2e3b0dfe_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i334c4a99388b47a7ab36175bbe1622f3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde88f7e0bcd430389cd38d465e25601_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18ce56a8c03a4b7889fd8e92506bdba4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i244793ab5a7249738bab95a309aaad60_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d06ca9dbb9943bf87caccfc0bdd279c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0dfcc8b323e454089332943aea91f52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0721e1ef08f74225930b348ccc978392_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3456ecf300704b57b6adcd05b7963d67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792cccf378ee4050923e53f4a38c7136_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68593cdfc71c4bbd922f69c3283cf601_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31cbfc1404b44ac995974a2da34c1713_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia197fa03b4e0485c894377210f9a37ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a6a0f0a03341b7a23b2a47027ce477_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia441c664cd094fa08cfec8c6325f59c0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f566215e8c446edbf6ba6023c4a6697_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe02702964a4fedba3bbd1c9e2ed7a0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a88ce2c37e481c91710d8d7e711e27_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7ddc9b4e1e4c0f82705cfe7c527db7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328297d89f3241aa834368d0776dfb39_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ad95fb7fdc49e69f2db1a90d8872e9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib728077ca1d24854ad85579c7c79d6de_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72ecf67eda5b4214b2a1b3dec7c45988_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i228965fb30b84e8ebf7eb20761e08272_D20201214-20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>adc:product</xbrli:measure></xbrli:unit><xbrli:context id="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7428455ece4b7882dc15984214fcea_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a6d95c9c71c445896f3f224ee1f25ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic66b9b3ea6b24e6596d461fd96900933_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d1c8d670234c8ea810b1ad8b5d520f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id388d0fa6213478cba6b2c29801561e0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b56cf9b484847d5ab3c287aa7060a0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b4ebc1ad16249d59d9a2b9574c68a62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0cfdd333541408ba83d32b7e1c51e80_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4d6ad6c402432badd52332e50082ba_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc44f11da71445b9bd1dd055c47f9f73_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef43b851dc04cf9825b1deb88d8f139_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161a5506dfed4a31a2fb1ac7f5c47782_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaada04dc38054738b85ebb285ca09c21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5477a4b1928548ebbe20d629b66b14ce_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3ba12574b44bb38c8be7706e8aac18_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0b55146cdb49e48b45bad254647bc6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e763260b1f442488b72bf74a7c49c11_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834b4d3caeae4e77b67d0f0dc2d552e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638129f1bcc5425ba52dd51ffd7e9490_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401425c5856840c4a0bb4fd8fb8835ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2efd49a30baa4077ae95107fcc999447_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5abfbc2b76094ac5a51ad5a1de5beced_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135ebd8bed6a4537b47040a2f4e822d3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ff798d025b459fa18da647bcec866b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15cd499c06e344418b49e009c7d8d193_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80cd1d5cda1f4e74862567135c82703e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a94dcf4e4844cf92a3de1535f49f1e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b5c8e6664d477fa65cefde7362ee81_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibce8feac9624457fae2210499d43d84a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqm"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:context id="ie83b9d46aa9540e49e84d64af9846e39_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e6d9b588aa47d19ad6aad08a538bf5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b0181426584e10a750977ea6280fb4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a67346f88234740b156f2c58bfbebe1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1961636ee14e4def8d8cc7b2018774e3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5672677502cf4414a866c09aa425cb21_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06457785463e407c8483fbe337aa3902_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c884b0bc284c6388a42f8607e2d444_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28da2485dc9a4fa783f820e72033822c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic61fb64598ff4cd0ad1e2271aed1a821_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie22662b5873248c984d6c1930b5c5647_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i614c4a744d9442189dae06d6e76db4c9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3f2601891941a49171d77873081724_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fee265512e746a9a555451fac8020e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied99ac8b277c4b408fb02863f8dffb5e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b95a2cc92564802b7a6cf3d8824d376_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icada6f229ced49ecacd2e102988715eb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80fc52680e63461a82201650861575d2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0f3a3c6371f4c089828c4cce5d73dd3_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:FirstFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f2ae527c2944308bb08da4da7ab273_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:FirstFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4435c71c4fa4639bb03f664766ee514_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:AfterFirstFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e15f9b287246acba0bdc6c93bd00b7_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:AfterFirstFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf3da50e0c50456c822d82239d1251be_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31c404deeed4a629f5368280fa99dd7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98de5d1ddb2243a1b01f6acc1c57c72e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77b99ef7cc0b4e7ab11c5073c019b286_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f57aba65894b669b8fadd39cc8a133_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89faf473a32b42bd935a511f8ee7a191_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff9bc94da04d47ae9a9b849234ad3c6e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8358f51a2445159e899b48be721e8d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9091a412696c4780b52173364c99f1bd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d4e15e2a100434397a55b4e43e929c3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea17a01e38b140129bf22b46808b9404_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0d75589019241a5b049c49c03ebd9c4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed9dd529b364aa5a0dfd1de03035963_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda45a536b784d9a83b51c5690223542_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df49cf53777407aaff962bcab6cbb00_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:DeferredFinancingCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5b2446ccaa4c5c85766d73baef671b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:DeferredFinancingCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9114014f71e4e669763623118aa0ba8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:DeferredFinancingCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0581d534bc684ee0bee89a6945a375ad_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:NetCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328f49717bbc4a43869005d9a11ccde6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552db3596e754dcaac31cd578b8a44be_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4202329f3c4f6f8e9950a5e0783159_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63733b9453004d72806e33eea5e62eb1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia734cd26f3504a1883266d439ca95b0d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic29dc84c1b3c4a498fd95b9388f8e481_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07af9d83010848bb8b52ef3ad5f34f34_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d2b5b155c54c47aefdb36bca46343a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1d37dac85a149669ce03adcbf4ccc8e_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf3fa17cff6e42feb53051b533840f31_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ee928b02464d82ab56ff3cd45a2c59_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0957db7bd16a421a88aa3e02e84a59f4_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dba557902d64fd2b341f02674834b60_I20200424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4282540cb4d245d89cd058fd40102cd0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c1c3f7a35f3450ca62c6907d078e8e2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1a8de23046f4460ad2c010b046624fc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424298b8a03c4c6291deae71a0a00390_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8541b30e628240598a82d1a6e8ece81c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510177f707e04303ad7498a272eb89fe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfbbc2c610147c3a34fba908fd852ec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47d31600d9f0428d8b62b78002cda536_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78bbf9c8e62844d986598b81c243a4e8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f2235b8f984b71a72137b6c9c711ed_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff0912cb42094f0b8c2cf9d89bea012a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bdc445f4e04e91a6b705a99bc90fa5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i025881af419e4a3192fb9cf499462a5f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff062fd0475a492786d931f7f5c45f6e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82d563da995d45569288f830e5149dfb_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7c1b8716664d0c8a84d93d75702409_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3bdac45860479dabcb75dfdd6867f4_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97aa7f5a5df243008d7ef0e4a3eb306e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d81122c2c840e4b693968f8c508748_D20200519-20200519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:InitialPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-19</xbrli:startDate><xbrli:endDate>2020-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i710642318daa4f7daf7095ef7f4be22a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id466e5c2487a4ac1b5b6504272a8f609_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac273354477741cf86e47def8ffcd7a1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f4af969dd2458582b9d874b88cbbf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8931b5a8351240ac87b0246c2abe8dd9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8669ba09764fbb9a618a4a6edae470_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9928a9264d740c89377de3cdebcd1e5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c66eb70f2894de98ed215565f60df64_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de9014907024e3189eac77111a06a63_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45da12590d9f4047b6bd3403ac33f3c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef057b084c9401b842b0fe5bdd4e853_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>adc:period</xbrli:measure></xbrli:unit><xbrli:context id="i3f8646e19d5e4d45b7ef56c2360fcbc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86670cf410ee493e8877ad4c966d0671_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b3ec2e705764730bd7acdc7796976e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib148dbac37274e269a90f2f14e60f877_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090c3d455bb74e6281428f2f07643108_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f702cd53b354e9881252bcbf57c2f1c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8afbb48cf2d48cfbd405ff609f28cc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56eace5f28ad4674b7f788baea9f47e8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e9f713f46b436eb737b72a7e01713b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibffd8b0c78d841a5a370b35fad8ace99_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03318851c1c0465f8efb9f6dbe913d26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef20d84bc4a4f9589901030b1ae9dde_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20780f1e715242878284103f33e5a95b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d107c4c0c244c4986cf5e94e684cfa3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b8a345318c14c5cb9e3dd2c0e1b53e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc325fcfe32426097e9538a2b3302b5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b376657412246a595f43060ab7c5581_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379eff6d11204554bf233766e8da501f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13a616afebd445f954de55db94ff515_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c15e42527ff44a3a5c93c9c96208bcf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19368979b8a145d5a6a63e3b0d6e8636_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic268075c47794e01a968504730a874e2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e5cd27137b4e10b214c3577489cc0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5c4b1a0cc67448cbc5473e914944c11_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4621be8061f40f29a22f85bd1a3ce97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bb83ca124504d81bae6bd67b59bdcad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8696a50af25a4d5698814222277a2b26_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71dfb6d248ff4198a8951d34e0f3e61b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2027858cad46a39efcfcb65c359818_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb58365b3f6457d8705fd6e8d0e13d4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7aa01b4ce9b4ddf9ea12f4230135446_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica385bd851294fa8a39c826b2ecb7376_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad41e5db92cf4b05819e5ee0b2c622f0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785f01a211a243bda6e912eb3ec1e0a2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib977e7d27b6240c08c35a9a983b92e2b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22eebd39c0444c7a8b3ec579b6376df0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5dfc30cca8047389598bb92059469df_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ecc2b598dba46c28662f729e6defde9_I20220815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26abd4a41954e9e9346a99a9f049985_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExercisePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca945cdabd9410cbc9c13e7257adfb4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596a372cc69b47f19dc090d174f662f3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b3bb514320f434fb2c8f0bbf4378a14_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i164cd50484d545a2af9114f0c1debbd9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f02e5be548f4f8dbc48b21e80389512_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a71734534bd4767beb6925c131abf14_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5908e3933d294f34ad3a587158cb41e9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i079987d8ff4843f5aa3402f23485ad3e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676dd5e5964f478cb2a4ee69ccbedc9c_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2afee1f6b2004f1493e2dcbd25a219d0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d4b84bf34674d74a74743921df55fbc_D20210322-20210322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i554dfdb979b34373ae4b5733abf1276e_D20210322-20210322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99eeeb04107b4ce58f0f4c3600598f48_D20220511-20220511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-11</xbrli:startDate><xbrli:endDate>2022-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b2f8cecf45438c8f21adf9eec38ecf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03009233bf004bb08cea9b8dc88563c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe39b129e824b348d51d6de645307b0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a10848ed433473dacbefea93eb427b0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2713424043c64085a64de9bf55b5640e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a52dd4005c426b875e0cc78e2afab5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d76a10a56a3493d8f750d9aff98a946_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a1053498d5476e8f8d62e1e4575acb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:SpecialRetentionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie78f96aef8b8454a82071adaaa117569_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:SpecialRetentionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d5fe10351e4449b949a8a8feb2c71d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:SpecialRetentionAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a0283334e204aed9dac9cea1dfc698a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e58e63d94a49548e999adc4a660174_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b357e6573a4bd4b45f578e3c65b1e4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb06d614e3447ffb6c90235d957a286_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e1cf39bbc742f2bcd482dcd9e52fff_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6744fd46428b46519b3f53dabe6cec74_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:AnnualEquityAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4af9ebeb2297423eb394125254b4a972_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3811cf7e2644eda9263cf885c93077f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d5c21d03c745b5a671f6735837b959_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f74715d84641a0818c9605970c3d58_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cefde464eaa45adbdc8ce7283826a3b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3425d423d7cb4ed7841d8808eb8b91ee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85a6bc595a6484baa94ff58c1ba727d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bcf43c8d3a64ab28d95b0e02490e5a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b8e02492be4003ab27ad39ebc0924a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:IncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3528d529fe714216bcf41e3b8f352130_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:IncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idab02ef85658428ead895ef5a19a0884_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:IncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7216894bf0e483e85c7a8417528b234_I20210825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51de663eeeb43a9905288c2f5ec4bed_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08246b7245ce401f95f5c264b9f4aa66_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf7164681d554945ae3e0bb0a2aba4a1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b130040d7a4b73bd260af53f216810_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519cc478c39244318ef4ce155c0494b8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16371fe343804f21aa8c01b295fcfe36_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i048e0b2056c24818a8680d84acca00a4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa43634d02840d5a9bcbd7fa627fe61_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65354fc22fe5421c886bb333bb47840b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic02e5a8396a24328a44c3c3ca993fbf8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae551281e83e4030b20c9779e840a6db_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if17b1e60018b4848b0cc478a5439fcbe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef2d3daf96e4c52ba4ccd1c33c624a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e1e606ace84d21a6ec9a6aee9fd665_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb44ceb2a6a84f44b55476a168ce4fa4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb0fcfe2e954886a15fb411a8e3ec9a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff327b0f65fe4fce9a6d78995be93ca9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ccd7f1b706c4d9f8b0853b7bb915ab8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9715b3a7f0dc46af8427382e8c4b913b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ccb7c3256654c6bab2e6cdeb30d200f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia12624d220a540beba94b39cc8891315_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367482dece7c4a8a868d61236759bb2a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68337702bbe542648d3b07bc46ecffc9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed07caeea2c4158a84e9c7fe843387a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3724a1c9b64111a1170ea671562e28_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001771910</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3a35353e827141feb6a74cba3e652509_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTg_3b631a8b-f11c-49cc-9550-22caf5b73c16">6-K</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the month of November 2022</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV84MDU_aa8cd83b-b308-4e7e-8564-ef825bfe47f8">001-39071</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTk_4554f807-96cc-4266-8f0b-ddee7781666a">ADC Therapeutics SA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTY_3a0411de-a2d1-40d7-842c-63000648597d">Biop&#244;le</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTc_07e70199-a014-4060-a20c-564a605ebb91">Route de la Corniche 3B</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV8zNTg_4562b74e-7ba9-4fee-90c0-54d1cba846ac">1066</ix:nonNumeric> <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV84MDI_c4cda4df-2ff8-4ceb-a997-dc2d3a5f4772">Epalinges</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV84MDQ_7b319215-f6f9-40c9-9196-faaa6afee7dd">Switzerland</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive office)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form 40-F:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 20-F</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 40-F</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3a35353e827141feb6a74cba3e652509_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INCORPORATION BY REFERENCE</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Report on Form 6-K (other than Exhibit 99.3 hereto), including Exhibits 99.1 and 99.2 hereto, shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-256807, 333-267293 and 333-267295) of ADC Therapeutics SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADC Therapeutics SA</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Creel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer Creel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 8, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3a35353e827141feb6a74cba3e652509_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adc-20220930_d2.htm">Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adc-20220930_d2.htm">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adc-20220930_d2.htm"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adc-20220930_d2.htm">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adc-20220930_d2.htm"> 30, 2022</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20220930x6kex992.htm">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20220930ex993.htm">Press Release dated </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20220930ex993.htm">November</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20220930ex993.htm"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20220930ex993.htm">8</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="adct-20220930ex993.htm">, 2022</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)<br/></span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>adc-20220930_d2.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5,d:648c8e1ac91b483eb52eb5061f8475ee--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:adc="http://adctherapeutics.com/20220930" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>adc-20220930_d2</title></head><body><div id="i648c8e1ac91b483eb52eb5061f8475ee_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Exhibit 99.1</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Condensed <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_4">Consolidated Interim Statement of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_4">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Condensed <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_7">Consolidated Interim Statement of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_7">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Condensed <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_10">Consolidated Interim Balance Sheet</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_10">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Condensed <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_13">Consolidated Interim Statement of Changes in Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Condensed <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_19">Consolidated Interim Statement of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_19">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_22">Notes to the Condensed Consolidated Interim Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;text-decoration:none" href="#i648c8e1ac91b483eb52eb5061f8475ee_22">8</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Statement of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in KUSD except for per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:31.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">For the Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Product revenues, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ibf907986f9804ac79096e6421bac5248_D20220701-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTQtMS0xLTg2NzA5_b789e6c1-b047-48c8-8996-a32b5f5e2158">21,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia10551f99c2f4f2cba09a2c4825b83fb_D20210701-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTYtMS0xLTg2NzA5_83c7c907-f77c-4e52-bf7b-715dfedc34e8">13,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3c7edac15bd64992b9404d86947ee31e_D20220101-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTgtMS0xLTg2NzA5_00f42a76-6801-4bb5-9c40-353dbe0724c8">55,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0adb4408d5b64d2eb32d81b113d64564_D20210101-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTEwLTEtMS04NjcwOQ_3e6591cb-beb5-4459-8caa-eabb1a167ef9">16,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">License revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3, 5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i938ba22ab3bc44038aab586a16722948_D20220701-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTQtMS0xLTg2NzA5_1b9563d4-e26b-4174-97cb-93f363efceda">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia884bbbb5b2d4ef6bea649be380f3574_D20210701-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTYtMS0xLTg2NzA5_26991492-b907-4fa0-a195-a6aaf1d42f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6b077300e1064ae1bddacda3d1e0be4a_D20220101-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTgtMS0xLTg2NzA5_45c35fe7-1e67-4326-9e0c-765ed01af4cd">85,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i28b78358bf294bc5b11aea256ecda3f4_D20210101-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTEwLTEtMS04NjcwOQ_e80ff51f-d061-40d7-8b28-0f1c6db4f629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTQtMS0xLTg2NzA5_9c83e195-ab8d-4f10-ba64-d322b1d08bce">76,321</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTYtMS0xLTg2NzA5_b7b11c62-2f89-4d37-b41f-67f3d23f1942">13,147</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTgtMS0xLTg2NzA5_c251c425-ed03-4171-abf5-f9c66b8f5d6e">140,110</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTEwLTEtMS04NjcwOQ_9a51ca66-7e3e-4aeb-85a4-65eb47651413">16,907</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cost of product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTQtMS0xLTg2NzA5_b7c985a3-9da0-4413-ad75-575f382dd358">1,295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:CostOfSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTYtMS0xLTg2NzA5_25eda286-3cf2-4d70-889c-3cc03a86fc09">502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTgtMS0xLTg2NzA5_f89e8383-418b-4999-86cb-4e5114e19f54">4,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:CostOfSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTEwLTEtMS04NjcwOQ_8ddcf3ad-fa37-4827-98cc-aadf1f422e86">623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTQtMS0xLTg2NzA5_966511e1-7dd9-448c-ae63-3aeb44316ffe">41,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTYtMS0xLTg2NzA5_3366d125-1a72-423d-b5b8-40987c667dfa">36,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTgtMS0xLTg2NzA5_d4d56b85-76e5-4a76-8c5d-4a8e65d0a5c5">139,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTEwLTEtMS04NjcwOQ_6e1dcb40-384a-42f8-8774-e5955a205aed">115,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Selling and marketing expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTQtMS0xLTg2NzA5_f20d9ac5-5251-4902-9fac-6603ae32d50a">16,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTYtMS0xLTg2NzA5_67718635-f824-49d2-922b-f84be7ce8282">17,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTgtMS0xLTg2NzA5_e842c6b3-6fa0-422c-bcf6-49c392f9fc04">52,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTEwLTEtMS04NjcwOQ_28ba9e9f-0a36-4533-a285-82fe5aa72bc8">46,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC00LTEtMS04NjcwOQ_972a965c-a5c8-49f2-9778-f00e6f435455">19,617</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC02LTEtMS04NjcwOQ_11f87d67-adfe-4eca-be90-32b7c1c234cc">16,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC04LTEtMS04NjcwOQ_b1cbe8a5-90c6-46e3-aade-134c1d53a4e3">56,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC0xMC0xLTEtODY3MDk_db3594f6-37ff-464c-a643-d646527a73e6">53,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total operating expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS00LTEtMS04NjcwOQ_a1072a7f-70f3-4207-a5c2-534695ff8462">79,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS02LTEtMS04NjcwOQ_b5ced65d-bc7c-4aca-8a2d-03116be39a69">70,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS04LTEtMS04NjcwOQ_8944ede4-a832-4430-b766-212e71ce9381">252,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS0xMC0xLTEtODY3MDk_4523f15f-4b53-4a80-a73b-bc9bd0431765">215,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi00LTEtMS04NjcwOQ_2b85b49d-8047-42db-8acc-418058ffcec4">3,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi02LTEtMS04NjcwOQ_0e1d3872-ca48-4b82-974f-90a788dae843">57,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi04LTEtMS04NjcwOQ_17eb2222-450e-4f99-aaf4-335668054342">112,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi0xMC0xLTEtODY3MDk_0f74c9b4-58a6-4531-b0b3-16fe2512b7b6">198,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Financial income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi00LTEtMS04NjcwOQ_eee4a2b4-6b26-4f84-a235-e85bc1f6ba11">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi02LTEtMS04NjcwOQ_831f642e-dd11-42ed-939c-da35b71ada50">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi04LTEtMS04NjcwOQ_b29a2382-669b-4b99-8c4a-1c07440b72f0">18,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:FinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi0xMC0xLTEtODY3MDk_1b49b30d-0450-4b2a-aeb9-eaca70a02f0a">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Financial expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13, 14, 15, 19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy00LTEtMS04NjcwOQ_21d9fb54-4d25-426c-acb0-6036946be2e2">11,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy02LTEtMS04NjcwOQ_5028f264-071b-4e8e-bbf4-ea1a18438e6c">4,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy04LTEtMS04NjcwOQ_5eb267c8-46a5-4f20-9ef7-25b8019e7abd">29,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy0xMC0xLTEtODY3MDk_35189d22-7fbd-41d9-a2c4-3d6488f7af60">8,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Non-operating (expense) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:OtherNonOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC00LTEtMS04NjcwOQ_41629eb1-510c-49b6-8eb1-86cfc35c9259">37,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="adc:OtherNonOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC02LTEtMS04NjcwOQ_beb8ea85-7593-4f6f-b3c8-cb26ee9b592d">9,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:OtherNonOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC04LTEtMS04NjcwOQ_036469f5-5ea0-4827-a1d5-09bbbe2d75ab">10,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:OtherNonOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC0xMC0xLTEtODY3MDk_aeba0ac7-1653-4b30-8266-1996c6a0fe6d">12,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total other (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:OtherNonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS00LTEtMS04NjcwOQ_8baa9012-3388-4dbd-883e-a7e54f9b662a">48,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="adc:OtherNonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS02LTEtMS04NjcwOQ_5df17494-5660-4f07-91af-0c5feafdfd56">13,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:OtherNonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS04LTEtMS04NjcwOQ_9e23b9ec-b547-495d-9159-abf3707ed673">21,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:OtherNonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS0xMC0xLTEtODY3MDk_1a1c617c-29b5-4f55-aab7-b251bcee614f">3,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Loss before taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC00LTEtMS04NjcwOQ_5119f777-80e5-4de5-9aee-0045d66696a3">51,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC02LTEtMS04NjcwOQ_054c0c8e-c2bf-466c-8ee0-6120373e2880">71,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC04LTEtMS04NjcwOQ_7067f296-49a2-4d1a-a8e3-9f227094221e">134,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC0xMC0xLTEtODY3MDk_148e025e-193d-4db7-9dd5-5c24772cd9fa">195,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Income tax benefit (expense) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS00LTEtMS04NjcwOQ_29bb728a-0f73-49b6-b46e-16d321261c6b">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS02LTEtMS04NjcwOQ_c0c9eae2-ae92-42da-acd8-7ded76312db3">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS04LTEtMS04NjcwOQ_58391a12-debc-4041-8be4-21f6e67c024d">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS0xMC0xLTEtODY3MDk_b4719e1b-f865-450f-ae6b-54de4fdd02ec">492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi00LTEtMS04NjcwOQ_0fd6e1e4-5ee9-46a0-9a02-64e39ed52014">50,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi02LTEtMS04NjcwOQ_de972a89-2494-4006-b18c-678c773c40a5">71,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi04LTEtMS04NjcwOQ_d386fa8a-5876-4351-9aa9-4c74af34722e"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi04LTEtMS04NjcwOQ_ee5cd402-d090-4597-9a44-59d05b277822">131,643</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi0xMC0xLTEtODY3MDk_fa92adfe-ee70-481d-8111-1eb8e6f2d85e">195,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net loss attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Owners of the parent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS00LTEtMS04NjcwOQ_04011699-53fc-4a4a-abfe-d6d9c5eb8588">50,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS02LTEtMS04NjcwOQ_385f9d88-3d3a-4148-a8e8-5071b2e18505">71,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS04LTEtMS04NjcwOQ_f97e98a0-bf8e-49a6-80eb-f1bd5939242c">131,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS0xMC0xLTEtODY3MDk_76cc14fe-ade4-42c8-b3c2-da75d4ec31bf">195,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy00LTEtMS04NjcwOQ_0fcc2a70-3201-41dc-a472-5e7425ed45a8"><ix:nonFraction unitRef="usdPerShare" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy00LTEtMS04NjcwOQ_fb9dc6a4-a2e7-4ae0-a3bb-0e5905e6be29">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy02LTEtMS04NjcwOQ_65b5ab39-da29-4a13-b38e-3af098bb6aee"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy02LTEtMS04NjcwOQ_d44b7b1e-0f90-41e8-9b1e-4944c82fd0c3">0.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy04LTEtMS04NjcwOQ_12b11a32-c463-49d9-9ae0-1e7e39a6e632"><ix:nonFraction unitRef="usdPerShare" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy04LTEtMS04NjcwOQ_60ff3eb9-5872-471b-9371-859f1cd3c0dc">1.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy0xMC0xLTEtODY3MDk_8a32af70-df56-495a-bdc4-d5fda9af7f90"><ix:nonFraction unitRef="usdPerShare" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy0xMC0xLTEtODY3MDk_f905c0c8-6cba-4236-bd15-065233a1fa62">2.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated interim financial statements (Unaudited)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Statement of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in KUSD)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.495%"><tr><td style="width:1.0%"></td><td style="width:37.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTQtMS0xLTg2NzA5_04011699-53fc-4a4a-abfe-d6d9c5eb8588">50,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTYtMS0xLTg2NzA5_8062bb1d-d50c-452f-bb68-61e8c67cf3b0">71,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTgtMS0xLTg2NzA5_f97e98a0-bf8e-49a6-80eb-f1bd5939242c">131,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTEwLTEtMS04NjcwOQ_59a86ad9-be93-43f3-a7dc-212356955527">195,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Items that will not be reclassified to profit and loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Remeasurement of defined benefit pension liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTQtMS0xLTg2NzA5_80f4de30-2b3d-4f37-b04d-4327619e68fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTYtMS0xLTg2NzA5_4b08fe15-f4ad-42ec-b965-96bcdd83012b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTgtMS0xLTg2NzA5_bb9e759b-2115-4fff-8047-8d124f988bdb">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTEwLTEtMS04NjcwOQ_66ed7f3e-bed8-4d20-9a28-091f76bb4699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total items that will not be reclassified to profit and loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTQtMS0xLTg2NzA5_ff9d273e-a43a-4a78-887d-ab5dff395bdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTYtMS0xLTg2NzA5_d4f8a779-f473-4a4c-8855-4fc6fc7a486a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTgtMS0xLTg2NzA5_bca0ad94-42ea-4bfc-aca5-e8bcb8511982">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTEwLTEtMS04NjcwOQ_67eb7ccb-8524-496b-ad51-c7cbf42824f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Items that may be reclassified to profit and loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Currency translation differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC00LTEtMS04NjcwOQ_4284edb9-438c-4ff1-90c3-79f73db91d2a">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC02LTEtMS04NjcwOQ_d9ea5b6e-720c-4630-be27-874dff021d2f">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC04LTEtMS04NjcwOQ_8363d33f-1f25-40c0-bedd-fb8f3a66f305">1,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC0xMC0xLTEtODY3MDk_9f54ea06-3391-4df2-bab8-2a6cd4202bcf">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total items that may be reclassified to profit and loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS00LTEtMS04NjcwOQ_858cb7df-1e63-44dd-b6f0-05382c7aac50">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS02LTEtMS04NjcwOQ_acf19a50-73b4-413d-aa44-e81a72a4a346">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS04LTEtMS04NjcwOQ_403e0436-5056-4591-81eb-860c3862d953">1,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS0xMC0xLTEtODY3MDk_96c55d8f-38e6-4648-a09a-7311ec335d50">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Other comprehensive (loss) income for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi00LTEtMS04NjcwOQ_7cc781f5-097c-47b2-96da-5af485c16e0a">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi02LTEtMS04NjcwOQ_82c65339-76ff-4934-af77-8364e0a679b5">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi04LTEtMS04NjcwOQ_dafefe4c-0167-44c0-892a-d6794eb858b3">2,593</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi0xMC0xLTEtODY3MDk_1e45378d-dea4-41fc-bf89-83f0ab6e056f">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total comprehensive loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy00LTEtMS04NjcwOQ_07d715a6-71a8-4c5e-a8a6-dc48d1d9b943">51,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy02LTEtMS04NjcwOQ_f333eeef-3267-43dc-bc1b-e57487437d73">71,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy04LTEtMS04NjcwOQ_98a946c6-693a-4b9f-b529-a6b4361a2f52">129,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy0xMC0xLTEtODY3MDk_262c5187-9c86-4620-927e-1551386a930d">195,729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total comprehensive loss attributable to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Owners of the parent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi00LTEtMS04NjcwOQ_e5573be5-597a-4855-83f1-3da67468e57e">51,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi02LTEtMS04NjcwOQ_53e3dd4d-c538-4d93-8ba1-4cbed955da04">71,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi04LTEtMS04NjcwOQ_52ded227-e334-4f24-b30a-f18cf6335579">129,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi0xMC0xLTEtODY3MDk_fdd542b4-e234-4237-83e3-86e8c7bdd466">195,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">The accompanying notes form an integral part of these condensed consolidated interim financial statements (Unaudited)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_10"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Balance Sheet</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in KUSD)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">December 31,<br/>2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMy0zLTEtMS04NjcwOQ_d215f9cd-944d-4457-9305-c41d2304e124">380,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMy01LTEtMS04NjcwOQ_d5e493e5-532a-45ea-8d30-72afaafe29c0">466,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNC0zLTEtMS04NjcwOQ_2686f8ec-21ae-453e-85c5-883d5e8870fd">23,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNC01LTEtMS04NjcwOQ_665abd19-bbde-4a43-a8bf-8d535bef5fef">30,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNS0zLTEtMS04NjcwOQ_36d3ca28-3660-445d-8de2-18082153455a">15,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNS01LTEtMS04NjcwOQ_0da3ce43-8c57-4d32-903a-4d7544f3ccca">11,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNi0zLTEtMS04NjcwOQ_b057d93d-7c74-40c9-b6cc-05524dd8ca4b">18,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNi01LTEtMS04NjcwOQ_bce7b4c5-0292-4f8d-b03e-6a6208b89ed1">17,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNy0zLTEtMS04NjcwOQ_548b6ee7-0c7f-4e5f-b9a6-cc510e25062e">438,099</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNy01LTEtMS04NjcwOQ_339f2643-0b42-4790-b9b9-5401789d10fc">525,182</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfOS0zLTEtMS04NjcwOQ_5c9b0850-1c5b-43c3-8436-6ba8b280c0d4">3,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfOS01LTEtMS04NjcwOQ_e4a744a6-85f2-4a3b-849e-788b2ac54b76">4,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTAtMy0xLTEtODY3MDk_a0e2395e-9b11-463b-84dd-ccb6e674e622">6,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTAtNS0xLTEtODY3MDk_6ec88291-3573-4b1f-9401-076893c8084d">7,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTEtMy0xLTEtODY3MDk_8b91d21c-92e3-4d37-9286-22a193950808">14,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTEtNS0xLTEtODY3MDk_471a1db5-7f38-4a67-b751-b1b3a867c093">13,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Interest in joint venture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTItMy0xLTEtODY3MDk_a49afe57-0964-468d-8f16-ca6cc2299da6">34,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTItNS0xLTEtODY3MDk_9d4ab6a3-610a-46b5-ae99-752d2194a2b2">41,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTMtMy0xLTEtODY3MDk_024f6da3-e4aa-4535-a222-7beef78a5e09">33,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NetDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTMtNS0xLTEtODY3MDk_e987ed5e-3608-4343-b529-eac5d104c18c">26,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTQtMy0xLTEtODY3MDk_4217b55e-bf83-4bd7-9984-d45ddf78f7ee">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTQtNS0xLTEtODY3MDk_4935c74c-d1d3-4146-a3cb-8b09438fbfdf">693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTUtMy0xLTEtODY3MDk_b0d84c04-e3db-41f5-be50-9c07a1648080">93,660</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTUtNS0xLTEtODY3MDk_37f99765-d06b-4861-b722-278c3b13af47">92,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTctMy0xLTEtODY3MDk_bbc77fca-b417-460a-acc4-33d8761d128f">531,759</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTctNS0xLTEtODY3MDk_c7eeb559-f24f-44f1-a3b7-7e37f436bbc4">617,972</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">LIABILITIES AND SHAREHOLDERS' EQUITY&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjEtMy0xLTEtODY3MDk_ddd66e73-5959-4234-a329-527b6361e0f5">11,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjEtNS0xLTEtODY3MDk_14b5ca80-a031-422f-b453-16ac77c11bae">12,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjItMy0xLTEtODY3MDk_2e079f1e-6077-4e18-90e6-1e345b3fa602">62,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjItNS0xLTEtODY3MDk_5a197220-bb93-45b9-bca6-d0812137bc05">50,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Lease liabilities, short-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjMtMy0xLTEtODY3MDk_d6214f6c-e142-4b78-acdf-2b6a92a6bc64">835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjMtNS0xLTEtODY3MDk_62778250-e9ce-436c-a7b9-cec3e744b104">1,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Current income tax payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjQtMy0xLTEtODY3MDk_f4db14de-98b6-4352-9eb2-a0dda5a5cc2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CurrentTaxLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjQtNS0xLTEtODY3MDk_617c0ef7-6f09-428e-b4b8-8b0b5b0a0471">3,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Senior secured term loans, short-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtMy0xLTEtOTc2Njg_7804eba0-d656-4336-b9d5-9cd07626db44">12,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:ShortTermBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtNS0xLTEtOTc2Njg_6ee76c72-bbb4-44c5-ace6-2148105c7145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Convertible loans, short-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtMy0xLTEtODY3MDk_a45c5fd1-6651-41f9-9d48-7ebd1612780c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtNS0xLTEtODY3MDk_9136b62c-17ec-4c49-b51c-459b47d0f463">6,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjYtMy0xLTEtODY3MDk_aad4c431-58c1-4a40-845a-55173704f7e1">87,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjYtNS0xLTEtODY3MDk_f75bdf83-23bb-4779-8773-6e5570f455d0">73,935</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Senior secured term loans, long- term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ibd2e5e5704574aebbaa2380a7fde3845_I20220930" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktMy0xLTEtOTA3NTg_1abfb0cd-1124-42b9-a8a4-7c81b7d7b4ab">96,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i93f34ddf4b844d758babc0b90fe80e66_I20211231" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktNS0xLTEtOTA3NTg_5e572ea5-37c4-40cb-96d8-ecb04610ecc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Convertible loans, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i4d737f742272444ea08949e847328dde_I20220930" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjgtMy0xLTEtODY3MDk_f165c078-31d3-4db4-9ca6-151ca495a494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6cf4592fe28044fabfe4047cabbd76e3_I20211231" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjgtNS0xLTEtODY3MDk_a9efc0d6-7355-4dd5-884a-17b51654ba52">87,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Convertible loans, derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktMy0xLTEtODY3MDk_8e1f267a-9351-4ded-8772-9743c67f295d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktNS0xLTEtODY3MDk_17fcb4fe-6078-42f4-bda2-df8750dae56e">37,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Warrant obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">14, 16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentWarrantLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItMy0xLTEtOTA3NzY_0f14169d-b1a0-415c-a568-a19b7e04a0aa">4,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NoncurrentWarrantLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItNS0xLTEtOTA3NzY_11923e8d-0c37-4fdc-a88c-71fca0eeea25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Deferred royalty obligation, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:DeferredRoyaltyObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzAtMy0xLTEtODY3MDk_23299660-18f7-4ecb-b695-daa9b5454f87">208,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:DeferredRoyaltyObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzAtNS0xLTEtODY3MDk_f72f9ec7-fbda-4c65-95d4-aaeeea20948b">218,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Deferred gain of joint venture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzEtMy0xLTEtODY3MDk_4cb2aa5d-6b76-4edf-aaf9-7f3aceda4a14">23,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzEtNS0xLTEtODY3MDk_cd3dc221-11e9-4af8-a3a1-3b494f232546">23,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Lease liabilities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItMy0xLTEtODY3MDk_0be6fe50-f6ae-4f5d-9fd8-5586f28c5e00">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItNS0xLTEtODY3MDk_b409bc47-f356-409a-9090-d15517e9e39f">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Defined benefit pension liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzMtMy0xLTEtODY3MDk_1424f97b-6b82-41e2-b5d8-6d35cde7643f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzMtNS0xLTEtODY3MDk_a0f7892f-6baf-411e-a2ba-35c6933ec732">3,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzUtMy0xLTEtODY3MDk_2c3d4687-96bb-4b8c-89ad-8c4c3a70f14e">339,403</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzUtNS0xLTEtODY3MDk_9d6d4d5c-a640-4078-bc41-a88f45f80dc2">377,949</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzctMy0xLTEtODY3MDk_ce5a9220-ae49-485d-a811-d87ebf1ca666">426,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzctNS0xLTEtODY3MDk_abd6739c-140e-43a7-ae63-c0d832593723">451,884</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Equity attributable to owners of the parent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDAtMy0xLTEtODY3MDk_5be5934e-54b8-416e-943c-2901a5da24a6">6,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDAtNS0xLTEtODY3MDk_7cc2f68a-3621-449a-a00c-02825a089bbd">6,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Share premium</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDEtMy0xLTEtODY3MDk_959aae01-b85c-478f-b785-f9ad62afcd30">1,007,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDEtNS0xLTEtODY3MDk_06da9752-d02b-4bcc-9ed2-b4137f49e9c0">981,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDItMy0xLTEtODY3MDk_b1185b5c-d5ec-4841-9b8e-c8d28ffb419a">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:TreasuryShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDItNS0xLTEtODY3MDk_d4d0d0df-2207-4f3a-bdb7-94cd41949f51">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Other reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDMtMy0xLTEtODY3MDk_73d54d02-a1a4-4bf7-8e6d-d147c7931092">148,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDMtNS0xLTEtODY3MDk_fe137a18-ed68-46c2-bac0-19c19d096ed4">102,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Cumulative translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" sign="-" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDQtMy0xLTEtODY3MDk_8f22132e-54b8-4f12-8592-4e7af61d64c7">842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDQtNS0xLTEtODY3MDk_0bd54f00-e12c-48de-9d92-9639979614c5">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">Accumulated losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDUtMy0xLTEtODY3MDk_9316f0f6-60cb-45ce-a0d6-7577a5085458">1,056,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDUtNS0xLTEtODY3MDk_ac4c9526-c9fb-4b13-a121-d1b289b40b6f">924,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total equity attributable to owners of the parent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDYtMy0xLTEtODY3MDk_094240e7-5f04-4563-a599-a91b8de62700">104,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDYtNS0xLTEtODY3MDk_4af7dd10-0419-4845-9bce-2e98794841be">166,088</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDgtMy0xLTEtODY3MDk_61f28293-47fa-4e35-8bff-5e6963e336a7">531,759</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDgtNS0xLTEtODY3MDk_3527c816-7b73-4761-9c89-925f45c4c664">617,972</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated interim financial statements (Unaudited)</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_13"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Statement of Changes in Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in KUSD)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Three and Nine Months Ended September&#160;30, 2022</span></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.361%"><tr><td style="width:1.0%"></td><td style="width:26.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Share<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Premium</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reserves</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Treasury<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cumulative<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Accumulated<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">July 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3b4ab23200b64567b35b0dc47c38e42b_I20220630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0zLTEtMS04NjcwOQ_88ce685e-f592-454e-9edf-b0e441bfcd56">6,445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0b5bb52172f94f6abd0bb6713cb6131b_I20220630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS01LTEtMS04NjcwOQ_75dc3205-8612-4255-94d1-e6659b43c51b">981,818</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i35596c2c71984cccaef883c93b78c04e_I20220630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS03LTEtMS04NjcwOQ_2e287208-f3ee-48fe-a0da-dc0fa8057170">133,480</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i246b440f84cd4fefaca5cc8ab1014c64_I20220630" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS05LTEtMS04NjcwOQ_1ea0ca21-4216-481f-8220-b74d67fd2ea2">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ife3e54de10ce40b29aa3c37bcd67ea64_I20220630" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0xMS0xLTEtODY3MDk_c6e8fbc3-01dc-4d50-80c6-c5b74a5a0ba0">358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i027b22679fb54ad388c26ce8c669aac5_I20220630" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0xMy0xLTEtODY3MDk_92fdea9e-b310-480d-8b5e-4d0b525e5d2a">1,005,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic28832b49da3403a8b557a594e965059_I20220630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0xNS0xLTEtODY3MDk_d639d7a7-32de-4e42-9e80-e4ffc7744af2">115,346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i2ea2e58acd5f40adb6d20b24a516fd32_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMy0xMy0xLTEtODY3MDk_a2e60c43-7543-4a27-be2f-53d8cf34faa0">50,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMy0xNS0xLTEtODY3MDk_2aa7614e-ff76-4843-b02e-5a0735ef6416">50,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfNi0xMS0xLTEtODY3MDk_a808aa9e-61fb-4d42-8e29-cc8f5795b89a">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfNi0xNS0xLTEtODY3MDk_49224ce3-44df-4de7-97d8-7f2866435de0">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfOC03LTEtMS04NjcwOQ_be512fcd-4243-4b18-b785-de1197965204">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfOC0xMS0xLTEtODY3MDk_2460dbad-0a54-40a9-88ed-48878ed7e4ff">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfOC0xNS0xLTEtODY3MDk_d43b3fbc-9f2e-481b-b7b6-46eed9cc84c8">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total comprehensive loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtNy0xLTEtODY3MDk_1de6f727-654e-40f2-9be9-3bdd5521f079">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTEtMS0xLTg2NzA5_f4944ac4-6914-43e8-9449-5ecdc579f3e8">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i2ea2e58acd5f40adb6d20b24a516fd32_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTMtMS0xLTg2NzA5_9d50bb6c-4fbc-466c-a428-c63b7cbac73e">50,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTUtMS0xLTg2NzA5_aa2682a3-c8a3-41e2-a417-8b40d7566e9b">51,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares to be held as treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i421702717ad84eeaa1925dceb63c2981_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMy0xLTEtOTk2Njk_862217eb-34a1-4946-88e2-26a5a9615612">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtOTk2Njk_679e45d2-5354-4dad-8fe1-a7fb88a3d02e">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTUtMS0xLTEwMTQ0MA_3b8a7618-a016-4394-9111-d1fedd191d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares, Deerfield exchange agreement, net of transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930" decimals="-3" name="adc:IssueOfEquityThroughExchangeAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtNS0xLTEtOTI0NTM_3342519c-5e8d-4dab-8c52-8fab5db5f991">19,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930" decimals="-3" name="adc:IssueOfEquityThroughExchangeAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtOTI0NTM_0e4cfe6b-123d-4ec1-9955-cd5156e3b187">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="adc:IssueOfEquityThroughExchangeAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMTUtMS0xLTkyNDUz_e4c1e93e-4987-4a29-975e-2c0aec11dd53">19,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares, share purchase agreement, net of transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930" decimals="-3" name="adc:IssueOfEquityThroughPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtNS0xLTEtOTI1MDg_9ebb2027-1631-4897-86b6-f3e649805fb4">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930" decimals="-3" name="adc:IssueOfEquityThroughPurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtOTI1MDg_6e10e51b-f61b-41e1-8fe2-a59d8fdd1e33">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="adc:IssueOfEquityThroughPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMTUtMS0xLTkyNTA4_a442028d-86da-4ec4-a997-d4851bc4717b">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Exercise of options and vestings of RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930" decimals="-3" sign="-" name="adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtNS0xLTEtODY3MDk_56cbf051-b136-415f-b4e2-587b58019b8c">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930" decimals="-3" name="adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtODY3MDk_2f5a7fe3-2a8e-4211-99cb-9642a8068268">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMTUtMS0xLTg2NzA5_bd14feb8-3d78-4329-9faf-38ad9acbdcba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTQtNy0xLTEtODY3MDk_34d66dd2-cf33-4941-b562-2411d0203284">14,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTQtMTUtMS0xLTg2NzA5_7ca39be3-ecf6-4144-9508-460e5450f0ae">14,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total transactions with owners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i421702717ad84eeaa1925dceb63c2981_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtMy0xLTEtODY3MDk_6bba75ed-d395-4479-873f-827bfe47b519">254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtNS0xLTEtODY3MDk_b07bfab2-a569-4d60-a89c-64c046f1a253">25,692</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtNy0xLTEtODY3MDk_4271990c-c879-4478-b4b0-a8759e8d441d">14,565</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtOS0xLTEtODY3MDk_8d2dbd0b-44a9-45ce-8e1c-45a4151e5075">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtMTUtMS0xLTg2NzA5_b5ed0611-eadb-40f5-84a2-0d9beed8f071">40,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie97eb94da1244cedb49b709a60205ff8_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMy0xLTEtODY3MDk_bc96034f-1421-44c3-a79a-caa61cda731f">6,699</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic96fd76ea6094201873babaf44147e90_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctNS0xLTEtODY3MDk_f800dba6-abdf-4f8a-bf58-6927b067dca8">1,007,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i4a369d72d0de4d07b601c6485cd111ac_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctNy0xLTEtODY3MDk_d28d13b2-e402-4482-8568-13538829f1fc">148,045</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3f2800d230b840698a1df635aef0fb1e_I20220930" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctOS0xLTEtODY3MDk_68244e97-dbd1-4636-9be6-3b5dcd955289">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i1275b5a441e64681a4536db9f8517583_I20220930" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMTEtMS0xLTg2NzA5_48a377f8-49f0-4ae0-ba07-ba99937f01c6">842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i678984f32c6242569e8813e4669c4d66_I20220930" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMTMtMS0xLTg2NzA5_9c778851-c296-4217-a138-25a197f2b4ac">1,056,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMTUtMS0xLTg2NzA5_ceca22af-25d3-49ab-9d42-67b68ac1a9b0">104,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:26.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.403%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.416%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Share<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Share<br/>Premium</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Other<br/>Reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Treasury<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cumulative<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Accumulated<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0cf2a41c1b0f412dbadb0ec7cc9807ce_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0zLTEtMS04NjcwOQ_414d7896-3d76-4967-8ba0-92b68049a666">6,445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3987240b95a941f3a745b6bce9358ab2_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi01LTEtMS04NjcwOQ_42ea63c6-d6f8-4104-822f-6c760f0cf299">981,827</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6d159e8735254990a623ac7081d8a5e2_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi03LTEtMS04NjcwOQ_db19d541-042a-4c1a-b962-68bd94476dbd">102,646</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i223e1c18b9e048b4a57a8347875e6217_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi05LTEtMS04NjcwOQ_b1ad5e26-ba5e-446e-bd04-eae3da46757e">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3e72f4f26f6741079eb2df83e9327373_I20211231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0xMS0xLTEtODY3MDk_77b2fd5e-e21e-4e97-985e-3d16362d79e6">183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie48cd9a814c44291b865fd727b17518f_I20211231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0xMy0xLTEtODY3MDk_500d6466-b0f5-4f80-91bd-555db8301481">924,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0xNS0xLTEtODY3MDk_4de505a1-9ee5-49e8-85a0-1fcc50ac588e">166,088</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i31afbe725ae54907a860c98c67e10f1a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNC0xMy0xLTEtODY3MDk_db44bb11-ec8f-41d5-bec2-d7b742e45778">131,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNC0xNS0xLTEtODY3MDk_4f0af197-8d42-4e12-9183-f8bb9ed6ea3b">131,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Remeasurement of defined benefit pension liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNi03LTEtMS04NjcwOQ_a1da04f7-a7d4-44a8-b9e3-571e6c168817">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNi0xNS0xLTEtODY3MDk_6d3a76d9-8b98-4e9e-98b6-746b6d977b0a">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNy0xMS0xLTEtODY3MDk_e3f2dcab-fe0b-4b68-9775-92ad7b33916c">1,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNy0xNS0xLTEtODY3MDk_93878ad7-3c44-4aca-ba89-29c9f298c960">1,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfOS03LTEtMS04NjcwOQ_3f38b2a3-b067-4a01-9464-b8244bc01811">3,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfOS0xMS0xLTEtODY3MDk_06e4146c-b85b-4988-8718-c44c9bf1f914">1,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfOS0xNS0xLTEtODY3MDk_be2c056b-846d-4d94-87ed-b8d02aaa6162">2,593</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total comprehensive income (loss) for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtNy0xLTEtODY3MDk_68587201-0f0b-43be-ba4f-e682b4651ab7">3,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtMTEtMS0xLTg2NzA5_6ba4fe04-8cbc-4ce0-97d0-3ef07b443eda">1,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i31afbe725ae54907a860c98c67e10f1a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtMTMtMS0xLTg2NzA5_d3ca2daf-dc90-422f-bd33-7a1a4b1374c5">131,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtMTUtMS0xLTg2NzA5_19d961b9-4e86-4482-9d18-c0bd8e7c0041">129,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares to be held as treasury shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if71b176729574174b972671a573dc05e_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTUtMy0xLTEtODY3MDk_537d6192-0303-402f-885d-195f8b76f8cb">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTUtOS0xLTEtODY3MDk_fe9d4f41-79b8-4b48-be6d-440bba806862">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTUtMTUtMS0xLTg2NzA5_4a3a790c-4a1e-4015-bcf9-9803ff92f7b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares, Deerfield exchange agreement, net of transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930" decimals="-3" name="adc:IssueOfEquityThroughExchangeAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTYtNS0xLTEtODY3MDk_fb5e5bf5-54de-4500-9504-c2e81d81f9b9">19,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930" decimals="-3" name="adc:IssueOfEquityThroughExchangeAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTYtOS0xLTEtODY3MDk_db18ccd0-0e29-4a61-9cb6-8765fcf12ed5">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:IssueOfEquityThroughExchangeAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTYtMTUtMS0xLTg2NzA5_661d3851-e5a2-4f07-bd67-e0fe3d3221e9">19,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares, share purchase agreement, net of transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930" decimals="-3" name="adc:IssueOfEquityThroughPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTctNS0xLTEtODY3MDk_331fb640-f4f4-4c75-b43b-24db4cbbdc4b">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930" decimals="-3" name="adc:IssueOfEquityThroughPurchaseAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTctOS0xLTEtODY3MDk_ea4294a1-486b-45a1-958d-81371ddc0a57">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:IssueOfEquityThroughPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTctMTUtMS0xLTg2NzA5_880b2c91-2508-4a6c-888f-c2bd379b7fd4">6,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Exercise of options and vestings of RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930" decimals="-3" name="adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTktNS0xLTEtODY3MDk_2ed055e8-c18d-44f4-bc81-5c24d8ef7ae7">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930" decimals="-3" sign="-" name="adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTktOS0xLTEtODY3MDk_a1fcc979-0a29-4380-b24a-834552e98f7d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTktMTUtMS0xLTg2NzA5_01978bc1-b23d-4578-a075-aa61ed776e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjAtNy0xLTEtODY3MDk_13510e00-db09-4b87-bbf2-944fb93559dd">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjAtMTUtMS0xLTg2NzA5_57192abb-1fb0-4fbc-b45f-dfa5b2d7e63c">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total transactions with owners</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if71b176729574174b972671a573dc05e_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtMy0xLTEtODY3MDk_e27e9fbd-6ce8-4d03-8881-68444ab8b1fc">254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtNS0xLTEtODY3MDk_25faf00e-d4fd-45d2-9220-64f4b04bedb0">25,683</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtNy0xLTEtODY3MDk_dc6d73fd-af4c-44e0-9df0-397af473f31e">41,781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtOS0xLTEtODY3MDk_870e9b1b-a045-4beb-aa5e-1a125d7686b1">27</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtMTUtMS0xLTg2NzA5_1ec5c368-2e40-4bc4-b091-c4ae1588e693">67,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie97eb94da1244cedb49b709a60205ff8_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMy0xLTEtODY3MDk_573ca0a9-a3af-4283-ae2c-46c9f0873076">6,699</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic96fd76ea6094201873babaf44147e90_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtNS0xLTEtODY3MDk_3b89dfe7-1218-4601-b3e8-861417bc8b0d">1,007,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i4a369d72d0de4d07b601c6485cd111ac_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtNy0xLTEtODY3MDk_b6e866e4-e258-4701-9c77-6eb38e9aba20">148,045</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3f2800d230b840698a1df635aef0fb1e_I20220930" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtOS0xLTEtODY3MDk_df4ecb43-ac11-47bf-9a43-0a814adc0cc2">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i1275b5a441e64681a4536db9f8517583_I20220930" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMTEtMS0xLTg2NzA5_52b0eebf-0da2-4cbf-b0a1-8cfe81e2fca3">842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i678984f32c6242569e8813e4669c4d66_I20220930" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMTMtMS0xLTg2NzA5_8279bac4-ce42-4890-980f-52c7a509a813">1,056,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMTUtMS0xLTg2NzA5_7bf3eda6-b7ac-4fde-890f-8486a3e5b13c">104,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Condensed Consolidated Interim Statement of Changes in Equity</span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">For the Three and Nine Months Ended September&#160;30, 2021</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.083%"><tr><td style="width:1.0%"></td><td style="width:27.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.766%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.197%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.482%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Share<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Premium</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reserves</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Treasury<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cumulative<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Accumulated<br/>Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">July 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6fe83d69badf4b52947c1251a39d7037_I20210630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0zLTEtMS04NjcwOQ_4784237b-16b8-4700-baf3-b17acc1cb838">6,445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic7ca719fc24c4758a77b58d789173cfc_I20210630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS01LTEtMS04NjcwOQ_f8708617-af3d-45f3-ac33-1413c590e27f">981,290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia3cdb002a7f247dba0b4723c76def055_I20210630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS03LTEtMS04NjcwOQ_f35c6973-8cea-4438-843a-da85c0aae8e2">74,971</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aadc701136f486fb9d540ba984fa396_I20210630" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS05LTEtMS04NjcwOQ_8df2c351-9c84-4bdc-9e64-40ee01138c32">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6300840ba2e145df92c265753e78fc30_I20210630" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0xMS0xLTEtODY3MDk_513f0ec0-c2ad-45e7-94db-0ac4fb579fd3">301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3732a765dbee4267b31e29ecc8de0b94_I20210630" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0xMy0xLTEtODY3MDk_94729cf5-307d-4506-b31e-bdc6b949a383">818,955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8a916c5c42b145e7ab29ea4d88cb1cff_I20210630" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0xNS0xLTEtODY3MDk_b22b7f90-4bc9-4080-a9c9-bb4eebd73e37">243,918</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMy0xMy0xLTEtODY3MDk_de972a89-2494-4006-b18c-678c773c40a5">71,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMy0xNS0xLTEtODY3MDk_9ccea513-f150-4944-8881-6c3c9cdb2f93">71,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNS0xMS0xLTEtODY3MDk_9495d142-f8cc-43a9-b928-a9b6d0a205ce">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNS0xNS0xLTEtODY3MDk_b1281a1e-dab6-4eb3-a304-f631f11bc05a">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNi0xMS0xLTEtODY3MDk_7b40c28a-3477-4258-8fd6-88fc7c48e42e">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNi0xNS0xLTEtODY3MDk_51f04e17-8468-443c-a7f9-f635f87a85c4">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total comprehensive loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfOC0xMS0xLTEtODY3MDk_38c83dbe-97f3-438e-bfea-4b56d8b0c888">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfOC0xMy0xLTEtODY3MDk_db441d6f-bf0c-40a6-82f4-fade01fdd6dd">71,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfOC0xNS0xLTEtODY3MDk_508483eb-ea18-42d0-a949-24566fbb7d63">71,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Exercise of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i402dfab004dd492aae570021cbed2be1_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTEtNS0xLTEtODY3MDk_003587e2-7bb2-4650-8d33-0774a1907400">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ifb2644136b7844bd8f3ed9546fa55a15_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTEtOS0xLTEtODY3MDk_e70e9c23-b72e-4dda-affe-33c38c952c0e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTEtMTUtMS0xLTg2NzA5_f2c384cf-b444-4671-b786-c5699b4b20a5">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i99128419613143609193e10731703076_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTItNy0xLTEtODY3MDk_1193a9cd-0296-483d-b465-89d8071b705f">14,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTItMTUtMS0xLTg2NzA5_c5a281c5-519e-49a7-ac7a-ecc502cc17be">14,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total transactions with owners</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i402dfab004dd492aae570021cbed2be1_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtNS0xLTEtODY3MDk_b31a909f-167a-4201-8a2c-d453c919f06a">280</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i99128419613143609193e10731703076_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtNy0xLTEtODY3MDk_ad6e24e3-0ba0-4031-b4a0-d7d48d076177">14,798</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ifb2644136b7844bd8f3ed9546fa55a15_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtOS0xLTEtODY3MDk_2332fbe7-2108-4d16-a1b7-3678e395557a">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtMTUtMS0xLTg2NzA5_24239315-8e37-4cf1-a559-50136fe97030">15,079</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic08137b9d07d47458bd80e38918070fb_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMy0xLTEtODY3MDk_deac4048-5da5-4558-baf1-f5b5b0cb29af">6,445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia00516d757c74b41ab5ec5b14024dbfd_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtNS0xLTEtODY3MDk_f02c17a1-d176-4c28-a03c-23ca4dbd5cb7">981,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie6e3d0984c7640a6812965fc4399b0ab_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtNy0xLTEtODY3MDk_d61fb487-4aa8-40df-8a8b-998e22c9ca27">89,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i09effb3b4b9b463691f066e4f85ccde9_I20210930" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtOS0xLTEtODY3MDk_1304a3b9-f08f-4ddb-9b55-eba2ade6db89">133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i819688b0196b4f8180d3a454630743bf_I20210930" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMTEtMS0xLTg2NzA5_23bb69bb-2b20-4caa-ac05-47a495a770b9">161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie65cd89c7bf24557946ea885c4873749_I20210930" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMTMtMS0xLTg2NzA5_b005160f-5e0c-4ac5-a45a-a54f3559064d">890,504</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMTUtMS0xLTg2NzA5_a33d6f84-83e4-4372-9692-e694da2ab541">187,308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.138%"><tr><td style="width:1.0%"></td><td style="width:27.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>Premium</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other<br/>Reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Treasury<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cumulative</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Translation</span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjustments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i04c2941ce0a845c4ad2292d13e712648_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0zLTEtMS04NjcwOQ_205f22f6-259b-4f42-8c9e-676d1fc12a00">6,314</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id8a9da342b454067adcd289ef23fbf0f_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS01LTEtMS04NjcwOQ_0dbdb292-e94d-47f0-9f83-e033a7ad6828">981,056</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i9e12d33e41234842815adf403479484b_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS03LTEtMS04NjcwOQ_b55f18ac-389c-4236-b33a-e629a4fb8c9c">42,753</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="iea3ac90d7b74494ab57a78dc23262650_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS05LTEtMS04NjcwOQ_e3574b88-46b3-4299-b23d-49964d42e090">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic4e071b05a6648619ca531f90eac8afe_I20201231" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0xMS0xLTEtODY3MDk_01fda5ad-a769-465f-ad0c-802a0613586b">245</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if8a1526b17d348e3a7c97fc3293c2a37_I20201231" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0xMy0xLTEtODY3MDk_7e6b5dcb-74f0-495f-ab02-9106d2276224">694,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0xNS0xLTEtODY3MDk_cf83ad46-ed2c-4867-9151-2c36412ae594">335,505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss for the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if85b8fd87bd6425ebe37b622aaa8b6fd_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMy0xMy0xLTEtODY3MDk_f0d8e307-fb88-4b74-a8bd-ac3ff58b650f">195,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMy0xNS0xLTEtODY3MDk_66ae14d3-bf61-409a-bc07-1adce5ea1812">195,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNS0xMS0xLTEtODY3MDk_3f94cad2-760a-4998-9764-a2c59bbc84bf">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNS0xNS0xLTEtODY3MDk_9e37109e-6b7f-4315-a3e6-8779de4d3a98">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNy0xMS0xLTEtODY3MDk_fe2cd005-a0fd-478f-80e1-0bc32d0961b4">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNy0xNS0xLTEtODY3MDk_b700dbfd-773c-4e2b-aff1-70b061a8351d">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total comprehensive loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfOS0xMS0xLTEtODY3MDk_2c575cc2-e061-4b94-ab57-332a49209332">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if85b8fd87bd6425ebe37b622aaa8b6fd_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfOS0xMy0xLTEtODY3MDk_e63ba5f7-c88a-4510-8871-82b1379eb51b">195,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfOS0xNS0xLTEtODY3MDk_56cf5722-659d-42fb-9297-23ab95a6fb1e">195,729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares to be held as treasury shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i9070db993da44bb4b9180949625e0bfe_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTMtMy0xLTEtODY3MDk_e648b81a-98ec-4ac4-a52b-fefc5778734b">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ifba43579460b45abb618bce784d2265a_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTMtOS0xLTEtODY3MDk_855a6333-04a9-41ec-898e-547a4e835504">131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTMtMTUtMS0xLTg2NzA5_b1226f6b-92af-4a60-a022-4e1ac30772be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8ab68b9957bd493da33d7c58f46e02a6_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTQtNS0xLTEtODY3MDk_1750c0c3-7e47-44ad-90fe-b66a7df35d17">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ifba43579460b45abb618bce784d2265a_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTQtOS0xLTEtODY3MDk_7c94695f-3f85-449e-a919-55838f56dd38">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTQtMTUtMS0xLTg2NzA5_b2fd2678-79f3-49d8-9f8a-7084bac3654a">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i57f104a5fe60467090a2d49a6f15319b_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjAtNy0xLTEtODY3MDk_8613c943-d36b-4fa0-b5d7-da1db20b9800">47,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjAtMTUtMS0xLTg2NzA5_7bb74688-efcc-466d-9338-afef5e103eb3">47,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Total transactions with owners</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i9070db993da44bb4b9180949625e0bfe_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtMy0xLTEtODY3MDk_043a47e0-f6d7-42ab-9044-0f786a6ee83b">131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8ab68b9957bd493da33d7c58f46e02a6_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtNS0xLTEtODY3MDk_74149101-fc3c-4a91-b559-e34f6bceb6fd">514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i57f104a5fe60467090a2d49a6f15319b_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtNy0xLTEtODY3MDk_c186c2a8-3af1-4221-9d2e-13a2af31e127">47,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ifba43579460b45abb618bce784d2265a_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtOS0xLTEtODY3MDk_58fa49a9-0e52-484d-89f5-37391f028532">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtMTUtMS0xLTg2NzA5_3ff8b927-e6af-41f6-87d1-1a5de2b9b0f0">47,532</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic08137b9d07d47458bd80e38918070fb_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMy0xLTEtODY3MDk_1fd4a14b-6bd3-451f-b319-de0d12f3d336">6,445</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia00516d757c74b41ab5ec5b14024dbfd_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtNS0xLTEtODY3MDk_7f96b8e7-89cc-47e2-850c-09641f407d44">981,570</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie6e3d0984c7640a6812965fc4399b0ab_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtNy0xLTEtODY3MDk_7eddb428-48fb-4890-9b7c-ce0682888c1a">89,769</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i09effb3b4b9b463691f066e4f85ccde9_I20210930" decimals="-3" sign="-" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtOS0xLTEtODY3MDk_28db4813-c86a-407d-8c92-fe00f64fa595">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i819688b0196b4f8180d3a454630743bf_I20210930" decimals="-3" name="ifrs-full:Equity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMTEtMS0xLTg2NzA5_eb9ea806-71b0-45c6-bb83-e9564dccb52b">161</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie65cd89c7bf24557946ea885c4873749_I20210930" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMTMtMS0xLTg2NzA5_97f8b33c-5043-4a61-8492-ff7ed0b9c7da">890,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMTUtMS0xLTg2NzA5_577c71fe-8cbb-4823-9d4e-f491e0e52c00">187,308</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">The accompanying notes form an integral part of these condensed consolidated interim financial statements (Unaudited)</span></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_19"></div><hr style="page-break-after:always"/><div style="min-height:4.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Statement of Cash Flows (in KUSD)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:58.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">For the Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss for the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMy0zLTEtMS04NjcwOQ_6c883aa2-fbce-493a-a0b3-1341fbaa5ea1">131,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMy01LTEtMS04NjcwOQ_dc5a8265-ba85-4fde-8c13-4576c78a77c0">195,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Adjustments for non-monetary items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNS0zLTEtMS04NjcwOQ_7c19057c-2afb-4589-9c22-8f6a2f9e5035">41,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNS01LTEtMS04NjcwOQ_1ba05789-2c19-4441-9b31-9757069ea229">47,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Impairments of Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNi0zLTEtMS04NjcwOQ_f0a133ae-4e62-484b-bb7c-6bfb26171842">2,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNi01LTEtMS04NjcwOQ_f7d5d528-053d-47ee-ada6-6d7a44e8b070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNy0zLTEtMS04NjcwOQ_d2291f97-bc51-4ea7-a0cb-ef998c1b5e06">768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNy01LTEtMS04NjcwOQ_7ecbfea3-cb0b-4203-a534-6e1007e54b94">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOC0zLTEtMS04NjcwOQ_9c7e7875-cbb0-4d21-ba7a-abe72fc03e5d">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForAmortisationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOC01LTEtMS04NjcwOQ_248a1b19-7e89-4f41-9677-9027af747dd7">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:AdjustmentsForDepreciationExpenseOfRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOS0zLTEtMS04NjcwOQ_0c7073f9-22cb-486b-a582-f1cad4695d37">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:AdjustmentsForDepreciationExpenseOfRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOS01LTEtMS04NjcwOQ_4f9cf747-6da1-4291-8d14-0526c44af7c4">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Gain from reversal of inventory impairment charges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTAtMy0xLTEtODY3MDk_81c4781d-46d9-4117-afd3-955587e43b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTAtNS0xLTEtODY3MDk_78f9c1f0-e473-409e-a08f-ac2f8eb23ddb">7,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">8, 12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTEtMy0xLTEtODY3MDk_c1bfe38b-70b0-45cf-bc90-220a5b28848c">6,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTEtNS0xLTEtODY3MDk_64dd917c-a7be-464f-99a6-f9db31279de0">3,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTItMy0xLTEtODY3MDk_ffa3dbf0-34e9-40c5-ab85-2c57a6cccd68">7,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTItNS0xLTEtODY3MDk_59725019-145f-480b-9f0e-3dc568ad5c6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Change in defined benefit pension liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTMtMy0xLTEtODY3MDk_72ad332c-42b4-4166-a647-6e590aa614da">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTMtNS0xLTEtODY3MDk_91a38704-f605-4152-a194-f1e6bec0edd4">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Convertible loans, derivatives, decrease in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">8, 15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTQtMy0xLTEtODY3MDk_1d00510a-0e3e-4d53-a557-0d8f306e613f">25,650</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTQtNS0xLTEtODY3MDk_020afed9-da1a-4ef5-9b28-23991a6ae678">16,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Warrant obligations, decrease in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">8, 14, 16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtMy0xLTEtOTA4ODA_14dbc923-8a85-45c4-8dc3-5b379e59a35b">11,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtNS0xLTEtOTA4ODA_6c183b91-c339-4174-b009-73fe2bcd0569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Financial income&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtMy0xLTEtODY3MDk_53bfd35c-14b0-4afb-b6b1-e390817434a3">18,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtNS0xLTEtODY3MDk_c4ae3f14-e1ae-41ed-b48c-5f50321fa3b1">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">8, 14 ,15 ,19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTYtMy0xLTEtODY3MDk_e6895bc0-f4a7-495d-80f6-2ee636069577">29,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTYtNS0xLTEtODY3MDk_5e8fad53-af7a-418f-add9-1f6e945e8453">8,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Loss on extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">8, 15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:GainsLossOnExtinguishmentOfBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtMy0xLTEtOTkxMjU_6919b394-dc3c-48a8-ac4d-e03a231e1120">42,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:GainsLossOnExtinguishmentOfBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtNS0xLTEtOTkxMjU_5e05f4a8-586b-4b67-a4e0-a10fd5edc212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTctMy0xLTEtODY3MDk_8ac5f676-91e4-4684-acd5-1ae60d69e458">322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTctNS0xLTEtODY3MDk_f399ddbf-3221-405c-946b-0f9d08a11da3">311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Operating loss before working capital changes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtMy0xLTEtODY3MDk_a6f5bcc9-3382-476a-a02a-7ded69990909">71,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtNS0xLTEtODY3MDk_c26d10f5-ae1d-4e37-9023-c17e3b8c449f">157,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Decrease (increase) in accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjAtMy0xLTEtODY3MDk_6e5c85de-2823-4945-a75e-18e74073108d">6,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjAtNS0xLTEtODY3MDk_897d84b8-74e8-4c41-9743-e66b2bbeb6c4">15,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Increase in inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjEtMy0xLTEtODY3MDk_70f09bfc-ec8f-49b6-8bd0-4b528b92ec73">6,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjEtNS0xLTEtODY3MDk_69d54af1-ebfc-4eb9-aead-22be61ce5e83">959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Decrease (increase) in other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjItMy0xLTEtODY3MDk_395fc023-ef1e-407a-a809-3dc81e05dede">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjItNS0xLTEtODY3MDk_01b935f4-02c4-44f0-8fd9-677c786db009">3,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(Decrease) increase in accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjQtMy0xLTEtODY3MDk_efbb0491-47b7-4183-b588-f28d0fc0cb52">411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjQtNS0xLTEtODY3MDk_0b2f24c2-16e5-4048-b5a3-5449ea1a23cc">5,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Increase in income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjUtMy0xLTEtODY3MDk_2d5d7b8f-9d4f-4399-bd46-ae35188b38d7">4,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForIncomeTaxExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjUtNS0xLTEtODY3MDk_d2fb1d60-768f-43b4-bcce-c4996af43a2d">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Increase in other liabilities and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjYtMy0xLTEtODY3MDk_63cc0423-a7a5-4dba-b7eb-b004eea16108">4,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjYtNS0xLTEtODY3MDk_b5c0c74b-ef65-48e9-b45f-2f9765490311">4,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjctMy0xLTEtODY3MDk_2653f84c-3830-4208-9056-8b31977f45e5">61,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjctNS0xLTEtODY3MDk_8e80b368-0115-427d-bac5-dfc4b1c56038">167,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjktMy0xLTEtODY3MDk_a1aadfcc-06f2-4244-9836-2b9dbb5ffca6">6,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjktNS0xLTEtODY3MDk_e00450b4-f259-40cc-8c37-0321134acdaf">3,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Interest received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzAtMy0xLTEtODY3MDk_ab6b2d7c-3d3d-487d-bfde-9562fd5be7f1">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzAtNS0xLTEtODY3MDk_62e98837-931d-46d0-8917-415a65eec08b">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Interest expense on lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzEtMy0xLTEtODY3MDk_92c26aa8-4fc8-4f28-bdd2-b486f6194309">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzEtNS0xLTEtODY3MDk_63c3442c-7ec2-457f-a9e8-c7693891dca4">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Interest paid under royalty financing transaction</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:PaymentsMadeUnderRoyaltyFinancingTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzItMy0xLTEtODY3MDk_21e3b45c-1be2-4be8-a80e-a402ded16729">5,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:PaymentsMadeUnderRoyaltyFinancingTransactions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzItNS0xLTEtODY3MDk_09981e98-dc43-491d-be5d-72e1368891ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Taxes paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzMtMy0xLTEtODY3MDk_4c8d396e-d7e8-442b-82b9-088dc0306a70">11,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzMtNS0xLTEtODY3MDk_b28471c7-6aad-4f5e-b558-2f0c0e6fea1f">618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzQtMy0xLTEtODY3MDk_40a9ed1d-635e-4b7b-b7d5-9f24d22f9765">84,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzQtNS0xLTEtODY3MDk_ded6a062-8f0b-4c39-ae2c-3f97aba8225d">171,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Payment for purchase of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzctMy0xLTEtODY3MDk_cf856931-aaca-4cb4-88b9-346e0b250741">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzctNS0xLTEtODY3MDk_8475b6b5-c902-456f-89d8-c5abc3ba0485">3,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Payment for purchase of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzgtMy0xLTEtODY3MDk_eaf415c9-ffcb-4eb6-a439-8593e5ad0914">1,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzgtNS0xLTEtODY3MDk_c285ac6f-d34e-4663-bf24-388c6421b0c1">2,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Payment for deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:PaymentForRentDeposits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzktMy0xLTEtODY3MDk_56bfa934-f361-40ac-be93-218d4c65ffb4">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:PaymentForRentDeposits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzktNS0xLTEtODY3MDk_3c12123b-7905-4c74-a812-6f5890619f1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDAtMy0xLTEtODY3MDk_9238c757-e0b6-4fc4-82a6-7e214fe84aad">2,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDAtNS0xLTEtODY3MDk_06140de3-6a44-42b4-9fc7-f7cfa4319dba">5,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from senior secured term loans, net of transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ProceedsFromCurrentBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDQtMy0xLTEtODY3MDk_28af995a-b650-4456-b9dd-e022e2995a4b">114,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ProceedsFromCurrentBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDQtNS0xLTEtODY3MDk_1f98be85-bd4d-45c7-976c-9e5f262895c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from equity issuance, net of transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtMy0xLTEtOTUwMTY_6c79c61f-1752-4af1-8e57-0846a46b6931">6,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtNS0xLTEtOTUwMTY_780b0776-7e46-4ad6-aa7f-bce6305109b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Convertible loans exchange</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">14, 15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:ConvertibleLoansExchange" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtMy0xLTEtOTUwMTY_b8654fd1-039a-40de-9fae-e70fd4748113">118,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:ConvertibleLoansExchange" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtNS0xLTEtOTUwMTY_48983b34-c268-46b1-be2d-38d6935212b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from convertible loans, net of transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDUtMy0xLTEtODY3MDk_66541b53-5211-4988-ba6b-7c2a42d30987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDUtNS0xLTEtODY3MDk_cb6a6a99-db05-4a7b-b4d5-277d60805e55">49,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from deferred royalty transaction, net of transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtMy0xLTEtODY3MDk_2d515161-a866-4dd2-8f8c-e38eb265ca86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtNS0xLTEtODY3MDk_5a061de7-d87f-431e-acaf-03c8eeb2f16e">219,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Proceeds from the exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDctMy0xLTEtODY3MDk_235ca409-5723-482b-bd84-3a9303e86dbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDctNS0xLTEtODY3MDk_b240dec6-ad50-4b88-a3f6-1af8bcc83c35">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Principal portion of lease obligation payments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtMy0xLTEtODY3MDk_8e60178d-1500-4426-b4b7-777c81bdf37c">757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtNS0xLTEtODY3MDk_e899ea0d-f6a1-4c7a-abfa-50e2fbb328c2">746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDktMy0xLTEtODY3MDk_41b0a5b4-1cf6-40b2-ba92-468acd1bf4c4">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDktNS0xLTEtODY3MDk_735b89e7-e7ee-4c74-b19d-65db143d07e3">268,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTEtMy0xLTEtODY3MDk_7d70e77b-97b4-4401-828f-7ab4fca57a3f">85,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTEtNS0xLTEtODY3MDk_765deed9-a3bf-473c-947c-1b37dde9a0b2">91,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Exchange losses on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTItMy0xLTEtODY3MDk_9245548f-b33b-4dc3-968c-04e89dc96b3b">451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTItNS0xLTEtODY3MDk_d726abc7-deca-494b-92f1-05affd42aa60">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cash and cash equivalents at beginning of the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTMtMy0xLTEtODY3MDk_158501b0-3c56-48a8-8a7b-feeb8d5a8120">466,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTMtNS0xLTEtODY3MDk_3cefa338-3a15-42e4-8cc0-7249949a6cc4">439,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Cash and cash equivalents at end of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTQtMy0xLTEtODY3MDk_8fbe6101-e87d-4d78-972a-40d2b9c50afd">380,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTQtNS0xLTEtODY3MDk_01912548-ff79-47c7-94a3-4dd33b0d89a3">530,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Supplemental Non-Cash Investing Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Issuance of shares, Deerfield exchange agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:IssuanceOfShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNjEtMy0xLTEtOTcwNjc_769bac1c-9a48-4aec-a493-df0381dd270e">19,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:IssuanceOfShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNjEtNS0xLTEtOTcwNjc_7c4c2c17-dd55-4d30-a15e-710a91478a88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Transaction costs recorded in Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtMy0xLTEtOTQ5NDY_0ec772bd-40ca-45bf-85fc-67fe4ae44cdc">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtNS0xLTEtOTQ5NDY_da015c09-17a8-4088-9fe6-41b55742c8c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Capital expenditures and intangible asset acquisitions recorded in Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTctMy0xLTEtODY3MDk_2d678b78-9fdf-4926-be6b-6f27ce0ded4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTctNS0xLTEtODY3MDk_fa1cd089-bb1c-4344-a43b-86e28c509439">455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Deferred royalty obligation transaction costs recorded in Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:AccountsPayableDeferredRoyaltyObligationTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtMy0xLTEtODczMDQ_889d9e5f-3a7f-4f94-a585-60f820f11bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:AccountsPayableDeferredRoyaltyObligationTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtNS0xLTEtODcyOTY_a9505dc0-c029-47d4-a091-4c96ebb0ffe9">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes form an integral part of these condensed consolidated interim financial statements (Unaudited)</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Therapeutics SA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Condensed Consolidated Interim Financial Statements (Unaudited) &#8211; in KUSD except for share and per share data</span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_25"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8yNS9mcmFnOjg3Y2Q2ZGNiMGI3MzRmNTNhZGYxMDkyY2Q4ZjI2NzUwL3RleHRyZWdpb246ODdjZDZkY2IwYjczNGY1M2FkZjEwOTJjZDhmMjY3NTBfMjY_1f17b1bb-676f-40c5-bb98-f9e7a58dc705" continuedAt="ib2b35ccf712f4544bc17d478826e8c06" escape="true">Corporate information</ix:nonNumeric>&#160;</span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_28"></div><ix:continuation id="ib2b35ccf712f4544bc17d478826e8c06" continuedAt="i6000e860422c4bc4bcb61101d0f9cb9e"><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADC Therapeutics SA (the &#8220;Company&#8221; or &#8220;ADCT&#8221;) was incorporated on June 6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls <ix:nonFraction unitRef="subsidiary" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="INF" name="adc:NumberOfSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8yOC9mcmFnOmRlYmE4ZmY1OTA3ZTQ0Mzg5OGM4MmZiZTA0Yjc3MDRkL3RleHRyZWdpb246ZGViYThmZjU5MDdlNDQzODk4YzgyZmJlMDRiNzcwNGRfMjQx_3d1089a8-3750-466c-bac3-317f1eb6ddb6">three</ix:nonFraction> wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#8220;ADCT America&#8221;), which was incorporated in Delaware, USA on December 10, 2014, ADC Therapeutics (UK) Ltd (&#8220;ADCT UK&#8221;), which was incorporated in England on December 12, 2014 and ADC Therapeutics (NL) B.V. which was incorporated in the Netherlands on February 25, 2022. The Company and its <ix:nonFraction unitRef="subsidiary" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="INF" name="adc:NumberOfSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8yOC9mcmFnOmRlYmE4ZmY1OTA3ZTQ0Mzg5OGM4MmZiZTA0Yjc3MDRkL3RleHRyZWdpb246ZGViYThmZjU5MDdlNDQzODk4YzgyZmJlMDRiNzcwNGRfNTkx_d9f4d1b5-bded-4c16-baf4-cad4f476ded8">three</ix:nonFraction> subsidiaries form the ADCT Group (the &#8220;Group&#8221;).</span></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is focused on the development and commercialization of antibody drug conjugates (&#8220;ADCs&#8221;), including research, development, human clinical trials, regulatory approval and commercialization. On April 23, 2021, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) and the Company commenced recognizing revenue upon the sale of ZYNLONTA during the second quarter of 2021. ADCs are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill any cancer cell to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.</span></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November&#160;8, 2022.</span></div></ix:continuation><div id="i648c8e1ac91b483eb52eb5061f8475ee_37"></div><ix:continuation id="i6000e860422c4bc4bcb61101d0f9cb9e" continuedAt="i00f7c1764eca4c619675e7695f532bc9"><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Going concern basis</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADCT is a commercial-stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group&#8217;s success may also depend on its ability to:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain a strong patent position and protection;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, gain regulatory approval and commercialize drug products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaborations with partners in the pharmaceutical industry;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire and retain key personnel; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire additional funding to support its operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its incorporation, the Group has primarily funded its growth through capital increases and additional funds provided by research collaborations, license agreements, the issuance of the Company&#8217;s common shares, the issuance of convertible loans, the issuance of term loans and proceeds from a royalty purchase agreement. During the first quarter of 2022 and third quarter of 2022, the Company entered into exclusive license agreements with Mitsubishi Tanabe Pharma Corporation ("MTPC") and Swedish Orphan Biovitrum AB ("Sobi"), respectively, for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan and all territories outside the U.S., greater China, Singapore and Japan, respectively. During the third quarter of 2022, the Company drew down USD <ix:nonFraction unitRef="usd" contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMzg0ODI5MDcwMjEzMA_d5020953-a9e4-4ccc-9386-a5e4e974b235">120.0</ix:nonFraction>&#160;million principal amount of senior secured term loans, entered into an exchange agreement with Deerfield Partners, L.P., and Deerfield Private Design Fund IV, L.P. (collectively, &#8220;Deerfield&#8221;) and sold shares to Owl Rock Opportunistic Master Fund II, L.P. and OR Opportunistic DL (C), L.P. (the "Purchasers") under a share purchase agreement. See note 14, "Senior secured term loan facility and warrants", note 15, "Convertible loans" and note 17, "Equity" for further information. The Group does not have recourse to bank loans. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans, other than, pursuant to the senior secured term loan facility, it must maintain a balance of at least USD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-6" name="adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMTY0Mg_335b1877-ae32-43c5-86bf-da3af7f772c8">60</ix:nonFraction> million in cash and cash equivalents plus any accounts payable that are greater than ninety days old at the end of each quarter.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Group&#8217;s cash and cash equivalents amounted to USD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMTc2Ng_e135e8ef-a8b5-4406-a058-1b554d5786bc">380.9</ix:nonFraction> million (December&#160;31, 2021: USD <ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-5" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMTc4Ng_3c8d0f85-2b95-4bd1-b852-750fef462365">466.5</ix:nonFraction> million).</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Group has sufficient resources to meet its financial obligations for at least the next 12 months from the date of issuance of these unaudited condensed consolidated interim financial statements and, as a result, is presenting these unaudited condensed consolidated interim financial statements of the Group on a going concern basis.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;margin-top:12pt;padding-left:18pt"><span><br/></span></div><ix:continuation id="i00f7c1764eca4c619675e7695f532bc9"><div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">COVID &#8211; 19</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Group continues to monitor the COVID-19 pandemic and its impact to operations. The Group is commercializing ZYNLONTA using hybrid launch plans. The Company continued to see an increase in face-to-face interactions with physicians in the third quarter, which it believes is a key pillar of its continued success in driving the adoption of ZYNLONTA through ongoing dialogs with the healthcare provider community on ZYNLONTA's differentiated product profile. The Group is in close contact with its principal investigators and clinical sites, which are located in jurisdictions affected by the COVID-19 pandemic and is assessing the impact of the COVID-19 pandemic on its clinical trials, expected timelines and costs on an ongoing basis. In response to the spread of COVID-19, the Group has also modified its business practices based on local guidelines. At this time, Group employees are meeting with investigators and site staff in person as allowed by institutions. The Group continues to closely monitor the potential effects of the COVID-19 pandemic on its clinical trials, commercialization efforts and supply chain, and will work closely with its clinical trial sites and principal investigators, contract research organizations, customers and distributors and contract manufacturing partners to mitigate such impact. As the COVID-19 pandemic continues to evolve, the Group believes the impact to its operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration, the impact on the U.S. and global economies, the timing, the availability, and acceptance and effectiveness of vaccines and treatments, particularly against emerging variants of the novel coronavirus, and the scope and effectiveness of national and local governmental responses to the pandemic. Those primary drivers are beyond the Group&#8217;s knowledge and control, and as a result, the ultimate impact of the COVID-19 pandemic on the Group's results of operations, cash flows and financial position for the remainder of 2022 and thereafter cannot be reasonably predicted. However, on the basis of the risk mitigation measures undertaken, the Group has concluded that there is no material uncertainty that may cast a significant doubt upon the Group&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior secured term loan facility and warrants, convertible loan exchange and share purchase</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company, ADCT UK and ADCT America entered into a loan agreement and guaranty (the &#8220;Loan Agreement&#8221;) with certain affiliates and/or funds managed by each of Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, as lenders, and Owl Rock Opportunistic Master Fund I, L.P., as administrative agent and collateral agent, pursuant to which the Company may borrow up to USD <ix:nonFraction unitRef="usd" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="-5" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzEzMg_d9cc1dce-4106-45a7-98d5-e5a1e4ff82c5">175.0</ix:nonFraction>&#160;million principal amount of secured term loans, including (i) an initial tranche of USD <ix:nonFraction unitRef="usd" contextRef="ie29ccfe5e9104ba781990be9d5a74c93_I20220815" decimals="-5" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE0Nw_ad3dfa24-850c-460c-8958-e60acb3ec8ca">120.0</ix:nonFraction>&#160;million principal amount of term loans (the &#8220;First Tranche&#8221;) and (ii) up to two additional tranches (&#8220;Future Tranches&#8221;), each up to USD <ix:nonFraction unitRef="usd" contextRef="i417e476b63a34ff7a49e6530cd7b944c_I20220815" decimals="-5" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE3Nw_bf96bbea-3717-4997-8c06-62f1f3792864">27.5</ix:nonFraction>&#160;million principal amount of term loans that the Company may draw upon before February 15, 2024, subject to satisfaction of certain customary conditions including compliance with the Company&#8217;s other material agreements for the incurrence of such debt. On August 15, 2022, the Company drew down USD <ix:nonFraction unitRef="usd" contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE2Mg_523691ac-1024-48b6-a95b-33802838b945">120.0</ix:nonFraction>&#160;million principal amount of term loans under the Loan Agreement and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9e5a1305a7604d6e87bd11283adef044_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE5Nw_c356b854-8784-4249-a5c9-632f82023928">527,295</ix:nonFraction> common shares, which warrants have an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE5MQ_b28f689c-9bd6-44a5-829c-ed123fccf09f">8.30</ix:nonFraction> per share. See note 14, &#8220;Senior secured term loan facility and warrants&#8221; for further information on this transaction. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:ExchangeOfConvertibleNotesForWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA5NQ_386d6bbb-52b2-46a7-84c2-cd127401e915">115.0</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s senior secured convertible notes for warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA2Mg_04bcbe7b-5f27-4660-936e-13e79f4d10f7">4,412,840</ix:nonFraction> common shares, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i474416e45737460d849fb01685ad11e6_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA3Mw_f300271e-3792-45ae-9d0e-5c80810c57ae">2,390,297</ix:nonFraction> common shares and cash equal to USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:ConvertibleNotesValueConverted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzExMA_ec59f2b5-be86-4934-be54-7d7d5be1aee4">117.3</ix:nonFraction>&#160;million. The warrants consist of warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA4NA_a384a831-e090-49dd-b90a-3a6a5433cdbc">2,631,578</ix:nonFraction> common shares at an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="i7754055a3c2b48f1973108a8654c2f44_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzEyNQ_b2361d0a-c1b7-450b-9529-6aff4adf2df3">24.70</ix:nonFraction> per share and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIwNg_0a829778-ba3c-4543-a0ca-6a554d1bc8af">1,781,262</ix:nonFraction> common shares at an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIxNw_ccdaac7f-6ee3-419b-81ae-d443116a086a">28.07</ix:nonFraction> per share. As a result of the exchange agreement, the Company recognized a loss on extinguishment of USD <ix:nonFraction unitRef="usd" contextRef="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930" decimals="-5" sign="-" name="adc:GainsLossOnExtinguishmentOfBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMTA5OTUxMTYzMzg3Ng_3d0c17a1-e3a2-4118-8dee-e500459b2618">42.1</ix:nonFraction> million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans,&#8221; note 16, &#8220;Deerfield warrants&#8221; and note 17 &#8220;Equity&#8221; for further information on this transaction. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into a share purchase agreement with the Purchasers, pursuant to which, on September 6, 2022, the Company issued and sold to the Purchasers an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIyNA_2465515d-0a6a-4398-a2c3-c325dc9c2707">733,568</ix:nonFraction> common shares at USD <ix:nonFraction unitRef="usdPerShare" contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815" decimals="2" name="adc:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIzMw_f2d80cc7-6796-49dc-bec7-4add247f70ef">8.52</ix:nonFraction> per share for USD <ix:nonFraction unitRef="usd" contextRef="ia6c9b855c1f247cdae6ad0bac21a2df8_D20220815-20220815" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIzOQ_4bd758a3-117c-4312-bd0e-cc1c9dcdd4a3">6.1</ix:nonFraction>&#160;million in net cash proceeds. See note 17, &#8220;Equity&#8221; for further information on this transaction.</span></div></ix:continuation><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_43"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMw_001548a4-dd13-4c74-b28e-0088604495a4" continuedAt="i2597f8326a8c4df8bdd189788a31c5f8" escape="true">Basis of preparation</ix:nonNumeric></span></div><ix:continuation id="i2597f8326a8c4df8bdd189788a31c5f8" continuedAt="i5d62f24f615f4d26add7f90ca7567cf0"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:StatementOfIFRSCompliance" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxNA_34d991b4-1001-4c0a-94a3-cfd58de96926" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Statement of Compliance</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements as of and for the three and nine months ended September&#160;30, 2022 have been prepared in accordance with International Accounting Standard 34&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;IAS 34&#8221;) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxNQ_a6b7684a-6e47-4321-98e3-d4b8c8a5c065" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Functional and reporting currency</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements are presented in United States Dollars (&#8220;USD&#8221; or &#8220;$&#8221;), which is the Company&#8217;s functional currency and the Group&#8217;s reporting currency.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMA_b71d0939-b914-4773-b8c2-510053d3ff68" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company, ADCT UK, has a functional currency of the British Pound (&#8220;GBP&#8221;). The following exchange rates have been used for the translation of the financial statements of ADCT UK:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.805%"><tr><td style="width:1.0%"></td><td style="width:80.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USD / GBP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Closing rate, GBP 1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerGBP" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="5" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfMy0xLTEtMS04NjcwOQ_09d529e8-0c02-47ab-87be-03e5cbc3e1d8">1.11348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerGBP" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="5" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfMy0zLTEtMS04NjcwOQ_ca5fe848-5f82-4c1a-a325-c606509c20da">1.34593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Weighted average exchange rate, GBP 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerGBP" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="5" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfNC0xLTEtMS04NjcwOQ_ac2b901e-5395-4fa8-894b-4747c87c7f0f">1.18746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerGBP" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="5" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfNC0zLTEtMS04NjcwOQ_9cba1711-9cfd-41d8-a673-bbe853b5bee1">1.39209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;padding-left:18pt"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i5d62f24f615f4d26add7f90ca7567cf0"><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Basis of Consolidation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements incorporate the financial statements of the Company and entities controlled by the Company which are the same as those contained in the audited consolidated financial statements as of and for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMQ_569b03e5-95cd-4796-a29c-0eb41268a53f" continuedAt="i2f4f555a5e524150842c2411e72b4992" escape="true"><div style="margin-bottom:0.1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Use of estimates and judgements</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are based on management&#8217;s knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">As a result of increases in interest rates, the Company assessed the impact of utilizing a higher discount rate, <ix:nonFraction unitRef="number" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="3" name="adc:PensionObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMjA2MQ_3feedbdb-017d-4560-84fb-e5519024b199">2.0</ix:nonFraction>%, in its most recent pension obligation actuarial valuation performed as of December 31, 2021. The use of a higher discount rate resulted in a decrease of KUSD <ix:nonFraction unitRef="usd" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="-5" sign="-" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMjIyMw_d12cc556-5277-43d9-9d5d-249cae7edc29">3.6</ix:nonFraction>&#160;million to its Defined benefit pension liabilities with a corresponding offset to Other comprehensive loss which was recorded during the second quarter of 2022. The reduction in its Defined benefit pension liability was capped at the fair value of the Company&#8217;s pension plan assets. The Company expects to perform its annual actuarial valuation in conjunction with its fiscal year ending December 31, 2022.</span></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i2f4f555a5e524150842c2411e72b4992">In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December 31, 2021. There have been no material changes to the significant accounting policies other than those described in note 3, "Significant accounting policies". In addition, significant judgements were required in determining the fair value of the Company&#8217;s warrant obligations as set out in note 14 &#8220;Senior secured term loan facility and warrants&#8221; and note 16 &#8221;Deerfield warrants,&#8221; including the selection of the valuation methodology to use, as well as determining the underlying valuation assumptions.</ix:continuation> </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMg_2bc5371b-efb9-4554-9e32-3ba0bf086855" escape="true"><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Other income (expense)</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to December 31, 2021, individual components of Non-operating (expense) income were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#8220;Non-operating (expense) income&#8221; for further information.</span></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share Subscription Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-months ended September 30, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i77985cac7eeb4add951edd6bccf0d37e_I20220930" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzg0ODI5MDcwMzMwMg_be9d11de-c33c-437d-ae04-a8c04a88fbc2">3,123,865</ix:nonFraction> common shares to ADCT America pursuant to a share subscription agreement and immediately repurchased these shares as treasury shares at par value. As described above, the Company subsequently issued <ix:nonFraction unitRef="usd" contextRef="i196dad762149431fa1779f78c8388406_D20220701-20220930" decimals="0" name="ifrs-full:SaleOrIssueOfTreasuryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzg0ODI5MDcwMzMxMw_c4302352-0457-4ca3-8087-0991a4b48431">733,568</ix:nonFraction> treasury shares to the Purchasers, in accordance with the share purchase agreement and <ix:nonFraction unitRef="usd" contextRef="i914b59538ffb4aff97128d35a7aec14f_D20220701-20220930" decimals="0" name="ifrs-full:SaleOrIssueOfTreasuryShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzg0ODI5MDcwMzMyMg_2fffbe29-1b88-44d9-863b-70192eca4636">2,390,297</ix:nonFraction> treasury shares to Deerfield in accordance with the exchange agreement entered into on August 15, 2022. See note 17, &#8220;Equity&#8221; for further information.</span></div></ix:continuation><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_49"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfNDE3Mw_f4698a45-214a-4437-86b7-6091eecb64a8" continuedAt="ie4fa1c3a32f84e1cb369527f8c11dd1e" escape="true">Significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="ie4fa1c3a32f84e1cb369527f8c11dd1e" continuedAt="ic823a768011547beaf62818a6c816ad1"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies applied by the Company in these unaudited condensed consolidated interim financial statements are the same as those applied by the Company in its audited consolidated financial statements as of and for the year ended December&#160;31, 2021 and have been applied consistently to all periods presented in these unaudited condensed consolidated interim financial statements, except for the following:</span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg2MQ_b0572e10-6f1a-4af0-aa5e-138abcbc0195" continuedAt="ia4485b8349fc4089ae2170b49bb80077" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Arrangements</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Furthermore, on July 8, 2022, the Company entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. In previous years, the Company had generated revenue from the sale of its product candidates and service revenues from a license and collaboration arrangement. See note 5 &#8220;License Revenue&#8221; for further information on the MTPC and Sobi arrangement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenues from license fees for intellectual property (IP) either at a point in time or over time. The Company must make an assessment as to whether such a license represents a right-to-use the IP (at a point in time) or a right to access the IP (over time). The Company recognizes revenue for a right-to-use license immediately if the licensee can begin to use and benefit from the IP upon commencement of the license term and the Company has no further obligations in the context of the IP. A license is considered a right to access the IP when the Company undertakes activities during the license term that may significantly affect the IP, which directly exposes the customer to any positive or negative effects arising from such activities. These activities do not result in the immediate transfer of a good or service to the customer. As such, revenues from the right to access the IP are recognized over time. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into agreements with multiple performance obligations. Performance obligations are identified and separated when the other party can benefit from the license on its own or together with other resources that are readily available, and the license is separately identifiable from other goods or services in the contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices for out-license arrangements may include fixed up-front amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development and regulatory milestones because the ultimate outcomes are binary in nature. Variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price when sold separately or estimated stand-alone selling price on the basis of comparable transactions with other customers when such goods or services are not sold separately. The residual approach is the method used to estimate a stand-alone selling price when the selling price for a good or service is highly variable or uncertain.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction prices, sales milestones and royalties attributable to licenses are excluded from the variable consideration guidance and recognized at the later of when the subsequent sales transaction occurs, or the satisfaction or partial satisfaction of the performance obligation to which some or all of the royalty has been allocated.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior secured term loan facility</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, ADCT UK and ADCT America entered into a USD <ix:nonFraction unitRef="usd" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="-5" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMzg0ODI5MDcyMjYwNg_3bbb3c15-effe-4b56-98d3-815dbcd218e6">175.0</ix:nonFraction>&#160;million Loan Agreement on August 15, 2022, pursuant to which the counterparty agreed to extend secured term loans to the Company in disbursements as follows: (i) a First Tranche and (ii) Future Tranches. See note 14, &#8220;Senior secured term loan facility and warrants.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the First Tranche </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company drew down the First Tranche of the senior secured term loans in the amount of USD 120.0 million and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. These senior secured term loans have been </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="ic823a768011547beaf62818a6c816ad1" continuedAt="ib9dd343e4ef8423689d5f8a5141ec161"><ix:continuation id="ia4485b8349fc4089ae2170b49bb80077" continuedAt="i77ccdfa9c2e84dcba7195cd02dfab737"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized as a hybrid financial instrument and accounted for as two separate components: (i) a warrant obligation and (ii) a loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)  The warrant obligation is presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value using a Black-Scholes pricing model and is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii) The</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior secured term loan&#8217;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the warrant obligation. The loan is subsequently measured at its amortized cost using an effective interest rate ("EIR") in accordance with IFRS 9. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. The revised EIR will be used prospectively with no income or expense recorded in the period of interest rate change. The loan is presented as a financial liability in the unaudited condensed consolidated interim balance sheet.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses and fees payable upon the issuance of the First Tranche of senior secured term loans were allocated pro rata to the above two components. The share of expenses allocated to the warrant obligation were charged directly to the unaudited condensed consolidated interim statement of operations, while the share of expenses allocated to the residual senior secured term loans was deducted from the loan and included in the calculation of the EIR.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the Future Tranches </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i77ccdfa9c2e84dcba7195cd02dfab737">The Company has no obligation to draw down the Future Tranches of the senior secured term loans. Therefore, the Company will account for the Future Tranches when drawn upon as a liability and subsequently measure the liability at amortized cost in accordance with IFRS 9. Transaction costs associated with the Future Tranches will be deducted from the loan.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Deerfield Warrants</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg2NA_2874c5cb-15b1-42b1-b514-28af6c58fe44">4,412,840</ix:nonFraction> common shares. The agreement consists of warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg4Ng_4b775825-7f70-4cfc-8b87-010512707a55">2,631,578</ix:nonFraction> common shares at an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="i7754055a3c2b48f1973108a8654c2f44_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1MjkwNA_bd6dd00d-37d4-422d-b468-0cc924f6110e">24.70</ix:nonFraction> per share and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg3NQ_0b90fc6d-964e-4b08-a6a3-aff005250305">1,781,262</ix:nonFraction> common shares at an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg5Nw_a7d1021c-4b1b-45a9-9b1b-79cca5072dad">28.07</ix:nonFraction> per share.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrants have been recognized as a warrant obligation and presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value and was determined to approximate the fair value of the existing embedded conversion option features immediately prior to the consummation of the Exchange Agreement. The liability is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. See note 16, &#8220;Deerfield Warrants.&#8221;</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Employee Benefits - 2022 Employee Stock Purchase Plan </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company adopted the 2022 Employee Stock Purchase Plan (&#8220;2022 ESPP&#8221;), which was approved by shareholders at the Company&#8217;s 2022 Annual General Meeting. The Company will account for the 2022 ESPP similar to the Company&#8217;s other share plans. The 2022 ESPP allows eligible employees to purchase designated shares of the Company's common shares at a discount, over a series of offering periods through accumulated payroll deductions. The Company will offer the ESPP to employees twice a year with each having a six-month offering period. The first offering period will generally be from January 1st through June 30th and the second offering period will be from July 1st through December 31st. The grant date is the first day of each offering period.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="ib9dd343e4ef8423689d5f8a5141ec161"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of purchase rights granted under the 2022 ESPP is recognized as an employee share-based compensation expense with a corresponding increase in other reserves. The total amount to be expensed is determined by reference to the fair value of the purchase rights granted. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total expense is recognized over the offering period, which is the period over which all of the specified vesting conditions are to be satisfied. Participants that voluntarily withdrawal from the plan are accounted for as a cancellation and total share-based compensation recorded in the period in which the participant withdrawals. Terminations are accounted for as forfeitures and any share-based compensation expense reversed in the period the participant terminates. Accumulated payroll deductions are recorded within Accrued expenses in other current liabilities in the unaudited condensed consolidated interim balance sheet until shares are purchased by the participant at the end of the offering period. See note 18, &#8220;Share-based compensation&#8221; for further information.</span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg2Mg_8dbde3b9-219a-4ef6-8125-d6b93e1c8da7" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New and amended IFRS standards</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2022, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, are not listed here.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81Mi9mcmFnOjg1ZTI1NTg2NmI3OTQxMzI5M2EyZDg1ZGMzMjQ1Yjk1L3RleHRyZWdpb246ODVlMjU1ODY2Yjc5NDEzMjkzYTJkODVkYzMyNDViOTVfNDUzOA_f8237557-fae0-4e45-84aa-90d89d5be3d9" continuedAt="i8fd70e06e4b1411aa0624de2c4498b04" escape="true">Financial risk management&#160;</ix:nonNumeric></span></div><ix:continuation id="i8fd70e06e4b1411aa0624de2c4498b04"><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Financial risk factors</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s activities are exposed to a variety of financial risks: market risk (including changes in the Company&#8217;s share price, exposure to fluctuation in currency exchange rates and exposure to interest rate movements), credit risk and liquidity risk.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group&#8217;s consolidated financial statements as of December&#160;31, 2021. In relation to the royalty purchase agreement with entities managed by Healthcare Royalty Management, LLC ("HCR"), the Company is obligated to pay interest in the form of royalties in connection with certain net sales and licensing revenue. As the EIR on the deferred royalty obligation does not depend on market performance, the exposure to interest rate and market risk is deemed low. See note 19, &#8220;Deferred royalty obligation&#8221; for further information. In regards to the senior secured term loans, the interest rate is variable and dependent upon market factors. The Company will update the EIR at the end of each reporting period for changes in the rate. See note 14, "Senior secured term loan facility and warrants" for further information. A hypothetical 100 basis point increase (decrease) in the interest rate as of September 30, 2022 would have increased (decreased) the effective interest expense associated with the Company's senior secured term loan facility by KUSD <ix:nonFraction unitRef="usd" contextRef="iac01c43c0d9347968cf7c0f6d6589b05_I20220930" decimals="-3" name="adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81Mi9mcmFnOjg1ZTI1NTg2NmI3OTQxMzI5M2EyZDg1ZGMzMjQ1Yjk1L3RleHRyZWdpb246ODVlMjU1ODY2Yjc5NDEzMjkzYTJkODVkYzMyNDViOTVfMTA5OTUxMTYzNzkwMQ_a1e1eac4-2978-439f-beb7-a34d261ec449">272</ix:nonFraction> and (KUSD <ix:nonFraction unitRef="usd" contextRef="iac01c43c0d9347968cf7c0f6d6589b05_I20220930" decimals="-3" name="adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81Mi9mcmFnOjg1ZTI1NTg2NmI3OTQxMzI5M2EyZDg1ZGMzMjQ1Yjk1L3RleHRyZWdpb246ODVlMjU1ODY2Yjc5NDEzMjkzYTJkODVkYzMyNDViOTVfMTA5OTUxMTYzNzkwNg_a8260d27-c22e-47a4-898e-2e243843fe62">273</ix:nonFraction>), respectively. There have been no other material changes in financial risk management since year-end.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Fair value estimation</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities:</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">Cash and cash equivalents</span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12.53pt">Trade accounts receivable</span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12.53pt">Trade accounts payable</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September&#160;30, 2022, there were no significant changes in the business or economic circumstances that affected the fair value of the Group&#8217;s financial assets and financial liabilities.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values must be estimated at the end of each quarter with regard to the senior secured term loan warrant obligation and the Deerfield warrants. The approach to valuation follows the grant date fair value principle, and the key input factors are described for the senior secured term loan facility warrant obligation in note 14, "Senior secured term loan facility and warrants" and for the Deerfield warrants in note 16, "Deerfield warrants". Commonly accepted pricing models (Black-Scholes) have been used to calculate the fair values. The valuation of the senior secured term loan facility warrant obligation and Deerfield warrants are classified as pertaining to Level 2 of the valuation hierarchy. The convertible loan derivatives previously were classified as pertaining to Level 3 of the valuation hierarchy and were extinguished on August 15, 2022. See note 15, "Convertible loans" for further information. The Company no longer has any inputs pertaining to level 3 of the valuation hierarchy set out below.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The different levels of the valuation hierarchy have been defined as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (for example, as prices) or indirectly (for example, derived from prices);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Level 3: inputs for the asset or liability that are not based on observable market data.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between the respective levels during the period.</span></div></ix:continuation><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfRevenueExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzgzOA_803e3922-7b5c-46b0-918d-84233e4ebaea" continuedAt="i2f7c539a16e5419c879bcc5a4662c4ee" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="i2f7c539a16e5419c879bcc5a4662c4ee" continuedAt="i920f360599de4b9584faead1d6edcc31"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product revenue</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, the Company received FDA accelerated regulatory and marketing approval for ZYNLONTA and launched in the U.S. shortly thereafter. To date, the Company&#8217;s only source of product revenue, which commenced during May 2021, has been sales of ZYNLONTA in the U.S. Product revenues, net were KUSD <ix:nonFraction unitRef="usd" contextRef="ibf907986f9804ac79096e6421bac5248_D20220701-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzUz_b789e6c1-b047-48c8-8996-a32b5f5e2158">21,321</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="i3c7edac15bd64992b9404d86947ee31e_D20220101-20220930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzY1_00f42a76-6801-4bb5-9c40-353dbe0724c8">55,110</ix:nonFraction> for the three and nine months ended September&#160;30, 2022, respectively. Product revenues, net were KUSD <ix:nonFraction unitRef="usd" contextRef="ia10551f99c2f4f2cba09a2c4825b83fb_D20210701-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfNDQy_83c7c907-f77c-4e52-bf7b-715dfedc34e8">13,147</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="i0adb4408d5b64d2eb32d81b113d64564_D20210101-20210930" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfNTQ5NzU1ODE3NzY2_3e6591cb-beb5-4459-8caa-eabb1a167ef9">16,907</ix:nonFraction> for the three and nine months ended September&#160;30, 2021, respectively. The Company records its best estimate of gross-to-net ("GTN") sales adjustments to which customers are likely to be entitled. </span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzgzOQ_a8d39557-539e-4c6d-9fc1-5eddf4c89a01" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s accruals related to the GTN sales adjustments for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:44.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic28832b49da3403a8b557a594e965059_I20220630" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy0yLTEtMS04NjcwOQ_f520c0d1-54d2-4966-8e83-7e256b4c8e24">3,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8a916c5c42b145e7ab29ea4d88cb1cff_I20210630" decimals="-3" name="adc:GTNSalesAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy00LTEtMS04NjcwOQ_099c85c2-da96-4a52-af4a-5d251be20ca0">730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy02LTEtMS04NjcwOQ_31787f1a-d344-4cae-acb7-869005dd7d6a">2,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy04LTEtMS04NjcwOQ_48af29de-3194-4b01-883c-ac6c40dd3133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GTN sales adjustments for current year sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="adc:GTNSalesAdjustmentProvision" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC0yLTEtMS04NjcwOQ_c93ccfe9-628e-4a8c-88cf-21a2e43d6da3">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="adc:GTNSalesAdjustmentProvision" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC00LTEtMS04NjcwOQ_e33178ff-02c9-4193-9d23-9109ec6eb4e7">2,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:GTNSalesAdjustmentProvision" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC02LTEtMS04NjcwOQ_d30ffee4-4463-4ab1-8a0d-f294a301b582">10,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:GTNSalesAdjustmentProvision" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC04LTEtMS04NjcwOQ_8ad095a4-4f4d-441d-9420-6c4186d2c289">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GTN sales adjustments for prior year sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:GTNSalesAdjustmentProvisionPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS0yLTEtMS04NjcwOQ_282c3772-7c7b-4204-b601-0d0104bcbcc7">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="adc:GTNSalesAdjustmentProvisionPriorPeriodSales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS00LTEtMS04NjcwOQ_f30a8752-84d8-4b2a-a502-e2b18cc972dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:GTNSalesAdjustmentProvisionPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS02LTEtMS04NjcwOQ_c8c8b012-203d-465d-86e4-8a3ed9ec0f43">358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:GTNSalesAdjustmentProvisionPriorPeriodSales" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS04LTEtMS04NjcwOQ_e6d48ea6-b096-427a-89c4-93bd536ec683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Credits, payments and reclassifications to Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:GTNSalesAdjustmentCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi0yLTEtMS04NjcwOQ_50547dac-dc7d-4458-9fab-a9086a3dd1df">3,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="adc:GTNSalesAdjustmentCreditsAndPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi00LTEtMS04NjcwOQ_20c17a3d-d29c-464c-b467-42c357ea7940">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:GTNSalesAdjustmentCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi02LTEtMS04NjcwOQ_2766fd0c-5a9a-4d0f-b897-fcff359e108b">9,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="adc:GTNSalesAdjustmentCreditsAndPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi04LTEtMS04NjcwOQ_ea8665bf-323a-43d4-82b8-ea43da895fe8">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Ending balance as of September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy0yLTEtMS04NjcwOQ_d4f65220-c5dd-41fc-a970-87b7261caa9d">3,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy00LTEtMS04NjcwOQ_099655e7-3faf-46a3-8832-9dc4b5bba739">2,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy02LTEtMS04NjcwOQ_91da36ad-f434-4188-8fe7-e5f87bd37430">3,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy04LTEtMS04NjcwOQ_23009dfb-d2bc-4d33-8bb3-e1a06b88c676">2,727</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzg0MA_b71c32ac-d3ce-49d5-a0d9-c3f17e6da590" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company&#8217;s unaudited condensed consolidated interim balance sheet as of September&#160;30, 2022 and December&#160;31, 2021. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:TradeAndOtherCurrentReceivablesSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMS0yLTEtMS04NjcwOQ_cf619242-3195-476e-9b23-4526b050cbaa">1,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:TradeAndOtherCurrentReceivablesSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMS00LTEtMS04NjcwOQ_b864a75c-5578-4b5d-9c29-2d0cfe741c67">1,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMi0yLTEtMS04NjcwOQ_4d0ad6da-18ef-43d5-9bf8-6eabd10a695b">1,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMi00LTEtMS04NjcwOQ_4c73fc6f-8e30-434b-b09b-b7a7f59f6025">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMy0yLTEtMS04NjcwOQ_637b8b8b-369c-453c-a541-559796f638bf">3,293</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:GTNSalesAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMy00LTEtMS04NjcwOQ_f9c7af5b-0b25-4d27-bc1d-3f94c10857eb">2,590</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Accounts receivable</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s inventory is no longer held on consignment by the Company&#8217;s third-party logistics and distribution provider and as a result of receiving a permanent J-code for ZYNLONTA, the Company&#8217;s payment terms currently range from 30 days to 90 days. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">License revenue</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Under the terms of the agreement, the Company received an upfront payment of USD <ix:nonFraction unitRef="usd" contextRef="ib75271c7003f455ea3762473084eeb29_D20220118-20220118" decimals="-6" name="adc:ProceedsFromLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTUxMQ_b896d4a0-3d94-4119-8315-1fc7557973e9">30</ix:nonFraction>&#160;million and may receive up to an additional USD <ix:nonFraction unitRef="usd" contextRef="ib75271c7003f455ea3762473084eeb29_D20220118-20220118" decimals="-6" name="adc:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTU1NA_c869a3f9-949e-4239-8f56-1f8171e0e02a">205</ix:nonFraction>&#160;million in milestones if certain development and commercial events are achieved. The Company will also be entitled to receive royalties ranging in percentage from the high teens to the low twenties based on net sales of ZYNLONTA in Japan. MTPC will conduct clinical studies of ZYNLONTA in Japan and will have the right to participate in any global clinical studies by bearing a portion of the study costs. In addition, the Company will supply ZYNLONTA to MTPC for its drug development and commercialization under a supply agreement. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, the Company entered into exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. Under the terms of the agreement, the Company received an upfront payment of USD <ix:nonFraction unitRef="usd" contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731" decimals="-6" name="adc:ProceedsFromLicenseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTAyNg_56da93b3-3367-417c-b8b0-a0ed95c5fcff">55</ix:nonFraction>&#160;million and is eligible to receive up to USD <ix:nonFraction unitRef="usd" contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731" decimals="-5" name="adc:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTA1MA_0b37a5ef-a19c-4e54-98a8-38c48f6f263b">382.5</ix:nonFraction>&#160;million in regulatory and net sales-based milestones, including USD <ix:nonFraction unitRef="usd" contextRef="i49f1b9c6855e4deba1fc15d4e267a2c3_D20220101-20220131" decimals="-6" name="adc:LicenseAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTAzOA_cd8ee883-768b-41ae-a506-f2f021c9afe9">50</ix:nonFraction>&#160;million upon approval of a Marketing Authorisation Application by the European Commission for ZYNLONTA in third-line DLBCL. The Company will also receive royalties ranging in percentage from the mid-teens to the mid-twenties based on net sales of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i920f360599de4b9584faead1d6edcc31" continuedAt="ib30c6fdddb194dc79e72178d6d9c5866"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product in Sobi&#8217;s licensed territories, subject to certain adjustments. Sobi will also contribute <ix:nonFraction unitRef="number" contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731" decimals="3" name="adc:LicenseAgreementPercentOfClinicalTrialCostsPaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzg0ODI5MDcxNDUxNw_0e63d672-b21e-4b73-8e7b-69e4ab2dd17c">25</ix:nonFraction> percent of clinical trial costs for select global ZYNLONTA trials, up to a cap of USD <ix:nonFraction unitRef="usd" contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731" decimals="-6" name="adc:LicenseAgreementCappedContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTA2NQ_324452d1-e679-4f30-8706-ef3c7bcbfc4f">10</ix:nonFraction>&#160;million per year. In addition, the Company has agreed to supply product to Sobi for its drug development and commercialization under a supply agreement which will be entered into.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MTPC and Sobi license arrangements are accounted for separately. Each agreement includes a license and a performance obligation to supply product. The license and supply obligations are accounted for as separate performance obligations as they are considered distinct because MTPC and Sobi can benefit from the licenses on their own or together with other resources that are readily available, and the licenses are separately identifiable from other goods or services in the contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed significant development work which resulted in FDA approval of ZYNLONTA in the U.S. for the treatment of relapsed or refractory DLBCL. As a result, the up-front license fees for both MTPC and Sobi are recognized immediately at the time of license execution, as MTPC and Sobi can use and benefit from the IP and the Company has no further performance obligation with respect to the IP upon commencement of the license terms. </span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib30c6fdddb194dc79e72178d6d9c5866">Although contingent development milestone amounts are assessed each period for the likelihood of achievement, they are typically constrained and recognized when the uncertainty is subsequently resolved for the full amount of the milestone and will be classified as license revenue. Sales milestones and royalties are recognized when the subsequent sales occur and classified as license revenue.</ix:continuation> </span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_61"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82MS9mcmFnOjVlNTI3OGMyODA5YzQ5OGI5OTdiZTEzMGIyN2UyNmRmL3RleHRyZWdpb246NWU1Mjc4YzI4MDljNDk4Yjk5N2JlMTMwYjI3ZTI2ZGZfMjg1_bda31e76-05f3-45c6-be0b-41d7f05681b8" continuedAt="i9fa19e51f2fd4f96977a844b1a695f18" escape="true">Segment information</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9fa19e51f2fd4f96977a844b1a695f18">The Company is managed and operated as <ix:nonFraction unitRef="segment" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="INF" name="adc:NumberOfBusinessSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82MS9mcmFnOjVlNTI3OGMyODA5YzQ5OGI5OTdiZTEzMGIyN2UyNmRmL3RleHRyZWdpb246NWU1Mjc4YzI4MDljNDk4Yjk5N2JlMTMwYjI3ZTI2ZGZfNjQ_ec91275d-002d-49a0-b1a6-c94b8b35f81b">one</ix:nonFraction> business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as <ix:nonFraction unitRef="segment" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="INF" name="adc:NumberOfBusinessSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82MS9mcmFnOjVlNTI3OGMyODA5YzQ5OGI5OTdiZTEzMGIyN2UyNmRmL3RleHRyZWdpb246NWU1Mjc4YzI4MDljNDk4Yjk5N2JlMTMwYjI3ZTI2ZGZfMjY1_ec91275d-002d-49a0-b1a6-c94b8b35f81b">one</ix:nonFraction> operating segment.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_67"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMjI5NA_f3575309-8ffa-4a93-9844-d1d8f1d23c08" continuedAt="i6e3bef852294410f9395c7fbf950ef99" escape="true">Operating expense</ix:nonNumeric></span></div><ix:continuation id="i6e3bef852294410f9395c7fbf950ef99" continuedAt="i48d4e30730d54f04b4a720c5082f9cf1"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMjI5Mw_5930ef88-eb22-477a-889a-7a82bd8cb7c2" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the unaudited condensed consolidated interim statement of operations classification of the Company's total operating expense:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">Cost of product sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi0xLTEtMS04NjcwOQ_f01f878b-ffd7-437c-8196-4b0e0c37c69e">1,295</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:CostOfSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi0zLTEtMS04NjcwOQ_1c3ca29f-af4c-456d-a574-4345f127d0ed">502</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi01LTEtMS04NjcwOQ_648d9d3f-0ca4-4f37-8df5-30472cb83342">4,090</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:CostOfSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi03LTEtMS04NjcwOQ_7b913f92-48fe-41e8-bc67-d1f80582bb2e">623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">External costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS0xLTEtMS04NjcwOQ_39253689-8b65-4e92-b772-0c333bb5b9b6">24,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS0zLTEtMS04NjcwOQ_20a191ab-22ad-4443-a438-45437f9110e9">20,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS01LTEtMS04NjcwOQ_64fef6d2-6151-4fbb-b196-d145365b6d7b">83,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS03LTEtMS04NjcwOQ_14ff698d-f25e-4523-9500-9ccd0a9b7bc0">66,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Employee expense&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi0xLTEtMS04NjcwOQ_96a68d28-ff1c-45f2-bf1f-5e14607885e0">17,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0531f2c694374cb1b481540b22706efe_D20210701-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi0zLTEtMS04NjcwOQ_44e53623-7882-4ef8-951c-ce6d4d8c197c">16,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi01LTEtMS04NjcwOQ_e12f09a5-fb5b-4479-a100-ee4f68e23369">55,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi03LTEtMS04NjcwOQ_154d17c6-7dda-4a81-a881-0d12be56e73e">49,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy0xLTEtMS04NjcwOQ_6495bd24-6fb7-43aa-a88e-9ab16765cefe">41,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy0zLTEtMS04NjcwOQ_126746a4-e700-4bdd-beab-4d946b77963c">36,805</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy01LTEtMS04NjcwOQ_2aab5ad7-3129-497a-8084-390b1240c58d">139,165</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy03LTEtMS04NjcwOQ_be67834f-f78c-43e5-a905-773f5450a991">115,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">S&amp;M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtMS0xLTEtODY3MDk_1499598f-4cf5-4f28-ab12-ec147a37fc27">8,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtMy0xLTEtODY3MDk_129ba382-b0f2-4c8a-8b60-f228ad2b5c1a">7,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtNS0xLTEtODY3MDk_3237c410-2eae-4893-af62-65ce79249148">26,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtNy0xLTEtODY3MDk_595bd49d-6bf4-4135-8b9f-714470e88f71">18,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee expense&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtMS0xLTEtODY3MDk_7c4f3db2-dff3-4752-9028-09a190f7ebcd">8,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0531f2c694374cb1b481540b22706efe_D20210701-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtMy0xLTEtODY3MDk_62ca871a-dfaf-448b-ae10-cf4ee2fc0934">9,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtNS0xLTEtODY3MDk_dea1fe0e-e903-42e5-9297-f4db4e5d84e1">26,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtNy0xLTEtODY3MDk_f6ba2d47-9fb9-47be-a9cb-ebafc7584e7f">27,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">S&amp;M expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItMS0xLTEtODY3MDk_f4cc78a9-ebda-4210-b81d-7c19307592ad">16,847</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItMy0xLTEtODY3MDk_7268cdf5-e40d-4e95-a239-c38626e635d1">17,045</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItNS0xLTEtODY3MDk_f8a03e45-c40e-450b-b88b-4dbd92abc6ec">52,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:SalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItNy0xLTEtODY3MDk_090215b0-f782-4ae7-adc9-8eb32e0feb85">46,177</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">G&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtMS0xLTEtODY3MDk_70258d49-8476-4080-bd47-5503805fe230">5,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtMy0xLTEtODY3MDk_21783956-d439-4539-8baa-a3e3377f0920">4,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtNS0xLTEtODY3MDk_26e82753-0cde-446b-b34b-149b28ef0d08">18,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtNy0xLTEtODY3MDk_51226808-bec0-4aa6-b859-f52577b17876">15,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtMS0xLTEtODY3MDk_f702d16f-0aa3-4f59-81f6-c281e8016f2e">14,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0531f2c694374cb1b481540b22706efe_D20210701-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtMy0xLTEtODY3MDk_12866360-abff-4313-bcac-7d37bb10970b">11,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtNS0xLTEtODY3MDk_eeaca74f-4775-47c9-b5e1-69067c295b55">38,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtNy0xLTEtODY3MDk_2b45d480-0ae5-4c14-bb7a-7fd9ddc49ea7">38,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">G&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctMS0xLTEtODY3MDk_cfc3e9bb-9164-482b-9d4b-7d7464f196ac">19,617</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctMy0xLTEtODY3MDk_02fec8fa-dfe7-4a22-94d7-db3b59644915">16,587</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctNS0xLTEtODY3MDk_07a19b6a-1175-4a69-b87a-bdb0f2f647c4">56,868</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctNy0xLTEtODY3MDk_c033e798-9c46-4a3f-a918-b4ac09af6a7f">53,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total operating expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtMS0xLTEtODY3MDk_149250d1-749d-404b-b08a-7c7a3548a5ba">79,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtMy0xLTEtODY3MDk_e5146acd-5333-4327-b455-643a3b2f882e">70,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtNS0xLTEtODY3MDk_0db4136d-3384-4f4e-8573-8082b3ef42d0">252,999</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtNy0xLTEtODY3MDk_6040df27-f296-4771-afa4-46fd9df73cad">215,846</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes depreciation expense</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes share-based compensation expense</span></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes depreciation expense for Property, plant and equipment for the three and nine months ended September&#160;30, 2022. All other depreciation expense was not material for the three and nine months ended September&#160;30, 2022. All depreciation expense was not material for the three and nine months ended September&#160;30, 2021.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The increase in Cost of product sales in the three and nine months ended September&#160;30, 2022, was primarily associated with USD <ix:nonFraction unitRef="usd" contextRef="ie05957f8cf6440c0b15060319d7b1f2a_D20220701-20220930" decimals="-5" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjc3OA_1ee076e9-6614-4fcc-8b13-e1a32869a714">0.8</ix:nonFraction>&#160;million and USD <ix:nonFraction unitRef="usd" contextRef="i9c36d77e8cc54708a0792a5def59ba80_D20220101-20220930" decimals="-5" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjc5MQ_c5d41fd2-80e4-4e6a-a39a-6947aa2df4d5">2.5</ix:nonFraction>&#160;million of impairment charges, respectively. The USD <ix:nonFraction unitRef="usd" contextRef="ie05957f8cf6440c0b15060319d7b1f2a_D20220701-20220930" decimals="-5" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgwNA_3bf131e0-54ad-4838-9d7b-fbf12ded15fa">0.8</ix:nonFraction>&#160;million of impairment charges was recorded during both the three months and nine months ended September 30, 2022 and was associated with inventory manufactured using the Company's existing process at a new facility that did not meet the Company's specifications. Additionally, impairment charges of USD <ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-5" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgxNw_d1a7ae88-9b08-45f0-89a2-6b7d59e2e36b">1.7</ix:nonFraction>&#160;million was recorded during the nine months ended September 30, 2022 and related to the manufacturing of antibodies that did not meet the Company's specifications. In addition, Cost of product sales during the nine months ended September&#160;30, 2022 increased due to a full nine months of sales activity in 2022 as compared to the same period in 2021 due to the commencement of ZYNLONTA sales in May 2021.</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">As a result of FDA approval of ZYNLONTA in April 2021, the Company reversed KUSD <ix:nonFraction unitRef="usd" contextRef="i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgzMA_747ead8c-2a90-49cd-ba8f-08c23ce2a479">7,049</ix:nonFraction> of previously recorded impairment charges during the nine months ended September 30, 2021, relating to inventory costs incurred for the manufacture of product prior to FDA approval. R&amp;D external costs increased primarily as a result of higher chemistry, manufacturing and controls ("CMC") expense due to manufacturing activities to support the ADCT-212 program during the three and nine months ended September 30, 2022 as well as our continued clinical trials to expand the potential market opportunities for ZYNLONTA in earlier lines of therapy, advance Cami to support a BLA submission and build our pipeline. Employee expense increased for the nine months ended September 30, 2022 primarily due to higher contract labor expenses, wages and benefits and share-based compensation expense.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in S&amp;M expenses in the three months ended September&#160;30, 2022 was primarily due to lower employee expense due to lower share-based compensation expense. External costs increased for the three months ended September 30, 2022 primarily as a result of higher expenses relating to the commercial launch of ZYNLONTA. The increase in S&amp;M expenses in the nine months ended September&#160;30, 2022 was primarily due to increased professional expenses relating to the commercial launch of ZYNLONTA. This increase during the nine months ended September 30, 2022 was partially offset by lower employee expenses primarily due to lower share-based compensation expense. </span></div></ix:continuation><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i48d4e30730d54f04b4a720c5082f9cf1">The increase in G&amp;A expenses in the three months ended September&#160;30, 2022 was primarily due to higher employee expenses primarily related to USD <ix:nonFraction unitRef="usd" contextRef="i589e24d9d8e0409fb5e40f80435eaa18_D20220101-20220930" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgzNw_da6f52e3-f79b-4c69-a595-7b2dec922dba">1.3</ix:nonFraction>&#160;million of executive compensation associated with the CEO transition and higher share-based compensation expense. External costs for the three months ended September 30, 2022 was primarily due to higher professional expenses. The increase in G&amp;A expenses in the nine months ended September 30, 2022 was primarily due to higher professional fees, including the fees associated with the license agreement entered into with MTPC. Employee expense for the nine months ended September&#160;30, 2022 remained virtually flat at USD <ix:nonFraction unitRef="usd" contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjkyNw_d2dd54f1-1909-40d0-992a-490f746e4c83">38.3</ix:nonFraction>&#160;million primarily as a result of lower share-based compensation expense offset by higher wages and benefits including USD <ix:nonFraction unitRef="usd" contextRef="i589e24d9d8e0409fb5e40f80435eaa18_D20220101-20220930" decimals="-5" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjg1MA_eb749dae-033f-4c8d-921e-5979fbf3dee5">1.3</ix:nonFraction>&#160;million of executive compensation associated with the CEO transition.</ix:continuation></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_70"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMjMxNA_0cc86bb1-24bf-448f-ac2b-31ff55acd24c" continuedAt="ide2dc577baa5483aa0c97efc211a6a5b" escape="true">Non-operating (expense) income</ix:nonNumeric></span></div><ix:continuation id="ide2dc577baa5483aa0c97efc211a6a5b" continuedAt="i9cbd8021c3a84f5f872513778c530109"><div style="margin-bottom:0.1pt;padding-left:18pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMjMxNQ_d0f04dfb-3e29-4146-a241-2e267f69ae86" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:33.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.881%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible loans, derivatives, change in fair value (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi00LTEtMS04NjcwOQ_b9c17c8d-09ff-4190-b666-2eecbc651430">4,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi02LTEtMS04NjcwOQ_4f49ec46-2645-4196-a9b4-9eccbed455fa">6,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi04LTEtMS04NjcwOQ_3caddf01-9198-4c30-bbd8-ba313406a347">25,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi0xMC0xLTEtODY3MDk_494a5496-1151-47eb-8c82-16f36acce80b">16,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible loans, derivatives, transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="adc:BorrowingsDeferredFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy00LTEtMS0xMDI3MzE_4472dec2-bde9-4324-b3b8-741f14980810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="adc:BorrowingsDeferredFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy02LTEtMS0xMDI3MzE_c6d81548-67ed-4fe1-85d0-f58ecf475603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:BorrowingsDeferredFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy04LTEtMS0xMDI3MzE_1ee343a8-0b4e-450e-bf94-4f13de00f1f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="adc:BorrowingsDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy0xMC0xLTEtMTAyNzI5_df781226-d842-4307-af77-42861bc04e13">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:GainsLossOnExtinguishmentOfBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC00LTEtMS05MzE0OQ_7b535a31-a86c-4822-a8de-43032d3c8a92">42,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="adc:GainsLossOnExtinguishmentOfBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC02LTEtMS0xMDI3MzE_b1507ba5-c726-499d-81d9-f62beeca16b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:GainsLossOnExtinguishmentOfBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC04LTEtMS05MzE2OA_e096f12b-b6dd-40bb-90d7-225087bbaaba">42,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:GainsLossOnExtinguishmentOfBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC0xMC0xLTEtMTAyNzMx_948ee2b1-82f8-46af-aeb4-8d39b0479906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deerfield warrant obligation, change in fair value income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1269616118a045b48128c0d3db3063c8_D20220701-20220930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS00LTEtMS05NjcwNw_1726621d-f265-49ca-bfa6-1d91d90a24b3">9,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2f5e11a889cb4519ad08ba38236480fd_D20210701-20210930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS02LTEtMS05NjcwNw_30edaf2f-65a7-42af-80dd-8be95d003e90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS04LTEtMS05NjcwNw_e7a9b90a-5833-4039-bfef-d24bbe40a786">9,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i158d2be3e937431ea999c2367040412b_D20210101-20210930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS0xMC0xLTEtOTY3MDc_2f2ab8d6-d8bd-4843-8f8f-2d6501141701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:WarrantObligationsTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi00LTEtMS0xMDI3MTk_6de486e3-9fe1-44c3-b9a9-95aa49cd60e2">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="adc:WarrantObligationsTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi02LTEtMS0xMDI3MzE_c8bb43f3-67f8-4edf-b6c5-87f271ee37cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:WarrantObligationsTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi04LTEtMS0xMDI3Mjc_519e6fa6-6caf-406e-80a2-a7cae15389fa">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:WarrantObligationsTransactionCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi0xMC0xLTEtMTAyNzMx_7478efad-5091-4557-866e-f1cf34ab570d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, change in fair value income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia84b491c52c74ac69be308c96ea954a1_D20220701-20220930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS00LTEtMS05MzIwNg_9827825a-5531-4596-8596-5f045ae10557">2,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ife2c56e209614e089bacd12b15145e97_D20210701-20210930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi02LTEtMS05NjY2MA_26539283-66ac-444d-8708-8aea8070d2cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ibcfcf3a44f2c4765be8da06698d39b1c_D20220101-20220930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS04LTEtMS05MzI1MQ_90baa370-d401-48a5-994b-f68f16fea3e2">2,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ifa06a2e32fd743d8a7b60007f9ae048d_D20210101-20210930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi0xMC0xLTEtOTY2NjA_5a991655-b746-41a8-a477-cf3748d68d65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share of results with joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC00LTEtMS04NjcwOQ_43a332d5-8552-4923-a669-6e0725fa7ab1">2,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC02LTEtMS04NjcwOQ_bba98efe-a301-4bc0-a29a-880874de8400">2,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC04LTEtMS04NjcwOQ_808f1e75-ba00-4c2b-b6a6-842d6e230d31">6,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC0xMC0xLTEtODY3MDk_0ff9a205-1967-4903-98e3-849100d1a9e3">3,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences (loss) gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS00LTEtMS04NjcwOQ_d29daedd-6ee9-464f-bf09-525733a09440">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS02LTEtMS04NjcwOQ_de66d476-73ce-494a-9a61-c4ef81815975">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS04LTEtMS04NjcwOQ_87eab164-0070-4556-ba84-550d23db41d1">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS0xMC0xLTEtODY3MDk_3d52065e-2b7a-46d5-841d-2d57034e99d7">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="adc:TaxEffectOfResearchAndDevelopmentTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi00LTEtMS04NjcwOQ_02616aee-c99b-458b-8382-fc779f99dae6">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="adc:TaxEffectOfResearchAndDevelopmentTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi02LTEtMS04NjcwOQ_49de9302-ff4f-4e1d-a56c-02c2911c1128">203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:TaxEffectOfResearchAndDevelopmentTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi04LTEtMS04NjcwOQ_cec83d15-d1c3-414c-a282-154f0395a57a">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:TaxEffectOfResearchAndDevelopmentTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi0xMC0xLTEtODY3MDk_b2e9c16d-81f4-4d35-ba3c-8d72c687f84e">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-operating income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="adc:NonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy00LTEtMS04NjcwOQ_707b6ac0-e1d5-4237-8966-b5ce469ef86f">37,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="adc:NonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy02LTEtMS04NjcwOQ_15d9d7e2-a9c6-448f-8574-4d777017ef58">9,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:NonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy04LTEtMS04NjcwOQ_0516b2e7-a8b6-4fdb-a75f-85de04ba828a">10,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="adc:NonOperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy0xMC0xLTEtODY3MDk_f80eb88d-3b49-449d-a9c5-6ebaee4ba311">12,560</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Convertible loans, derivatives, change in fair value (expense) income</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in derivative fair values are explained in note 15, &#8220;Convertible loans&#8221;. Pursuant to the Facility Agreement with Deerfield, the Company drew down the Deerfield First Tranche of the convertible loans amounting to USD <ix:nonFraction unitRef="usd" contextRef="id5e033a22ecb478bb31362e9dd46dcbe_I20200519" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMzIz_af0ad6cc-179d-4032-a7fd-824b5e42096d">65</ix:nonFraction>&#160;million on May 19, 2020. Additionally, in connection with the FDA approval of ZYNLONTA, the Company drew down the Deerfield Second Tranche of convertible loans amounting to USD <ix:nonFraction unitRef="usd" contextRef="idd6e0c7ae1fc42dabeef85f1e367666d_I20200424" decimals="-5" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfNDg1_a1cc33e6-955f-45df-9e07-5f52df04e4b8">50</ix:nonFraction>&#160;million on May 17, 2021. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Convertible loans, derivatives, transaction costs</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction costs associated with the embedded derivatives associated with the draw-down of the second tranche of the convertible loans on April 23, 2021 were charged directly to the unaudited condensed consolidated interim statement of operations.</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss on debt extinguishment</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement, the Company recognized a loss on extinguishment, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans.&#8221; for further information on this transaction. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deerfield warrant obligation, change in fair value income</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMTA5OTUxMTYzNTczNA_44bba8ab-b627-45ed-b1be-f777bd24dec9">4,412,840</ix:nonFraction> common shares. The Deerfield warrant obligation has been recorded at its initial fair value and is remeasured to fair value on a quarterly basis. Changes in fair value of the Deerfield warrant obligation are explained in note 16, "Deerfield warrants".</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior secured term loan facility, warrants, transaction costs</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction costs associated with the warrants in connection with the August 15, 2022 Loan Agreement were charged directly to the unaudited condensed consolidated interim statement of operations. See note 14, "Senior secured term loan facility and warrants", for further information on this transaction.</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, change in fair value income</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the First Tranche of the senior secured term loan and warrants as one hybrid financial instrument, with the USD <ix:nonFraction unitRef="usd" contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMzg0ODI5MDcwNTMwOA_9bd22298-4c04-4c16-a3b6-e4dbc319e13f">120</ix:nonFraction>&#160;million proceeds separated into two components: a warrant obligation and a loan. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i9cbd8021c3a84f5f872513778c530109"><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrant obligation has been recorded at its initial fair value and is remeasured to fair value on a quarterly basis. Changes in fair value of the warrant obligation are explained in note 14, "Senior secured term loan facility and warrants".</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of results with joint venture</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the formation of Overland ADCT BioPharma in December 2020, the Company recorded its proportionate share of Overland ADCT BioPharma&#8217;s net loss. See note 12, &#8220;Interest in joint venture&#8221;. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange differences (loss) gain</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also included in non-operating (expense) income are favorable or unfavorable Exchange differences. The Company is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs. Exchange differences represent gain or (loss) based on favorable or unfavorable changes in foreign currencies. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">R&amp;D tax credit (expense)</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes as income (expense) amounts received and receivable by its subsidiary, ADCT UK, under the United Kingdom&#8217;s R&amp;D Expenditure Credit scheme (&#8220;UK R&amp;D Credit Scheme&#8221;). The grants represent 12% of eligible expenditure. The claims are payable through the tax system, as a refund of corporation tax or of other taxes, including income tax and social security payments deducted at source from qualifying (research) employees&#8217; payroll and VAT. The relevant amounts have been therefore presented net in the balance sheet. As the credit is independent of ADCT UK&#8217;s taxable profit, is clearly designed to incentivize companies to invest in R&amp;D activities and is itself taxable income, the Group has recognized the income as government grants within non-operating (expense) income and not as a credit to income tax expense.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84Mi9mcmFnOjA1YTU0OWU1MmU3MTQ2NGE4MTlhZTI1YmU5OWI4YzA4L3RleHRyZWdpb246MDVhNTQ5ZTUyZTcxNDY0YTgxOWFlMjViZTk5YjhjMDhfNDA1_b543601d-63cf-4ce8-975a-31a981a04b45" continuedAt="i3489963fc1ac4756be82a574876e6a09" escape="true">Cash and cash equivalents</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3489963fc1ac4756be82a574876e6a09">Pursuant to the Loan Agreement entered into on August 15, 2022 (see note 14, &#8220;Senior secured term loan facility and warrants&#8221;), the Company is subject to a covenant that requires it to maintain a balance at the end of each quarter of at least USD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-6" name="adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84Mi9mcmFnOjA1YTU0OWU1MmU3MTQ2NGE4MTlhZTI1YmU5OWI4YzA4L3RleHRyZWdpb246MDVhNTQ5ZTUyZTcxNDY0YTgxOWFlMjViZTk5YjhjMDhfNDA2_c307e039-29d4-48af-9820-86eef06e51e8">60</ix:nonFraction>&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the date of the original invoice.</ix:continuation> </span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_85"></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTE3NQ_13167e76-5032-4c65-90d6-3582ae922f4c" continuedAt="ib1701075958842cdbcebdaedf4f9cc8a" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ib1701075958842cdbcebdaedf4f9cc8a" continuedAt="ibebf4d8160f04ba3a4bb0f777a0fe1f1"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTE3NA_3dfa1f86-6a70-49a5-a447-842d63502dae" continuedAt="ie278a97267b1470ba167c2d59dfc99c7" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:51.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMi0yLTEtMS04NjcwOQ_aa575a82-8a88-480b-a507-ab1ffd92f252">15,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMi00LTEtMS04NjcwOQ_94d31c2c-18d6-4f0e-b5f2-e57e3cf58ada">10,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Finished goods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:FinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMy0yLTEtMS04NjcwOQ_53b5d812-e64e-4129-aa60-6544b0d0a592">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:FinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMy00LTEtMS04NjcwOQ_fc5a55af-6565-4538-952a-be5c7081868d">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:InventoriesTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfNC0yLTEtMS04NjcwOQ_d9f50485-4f00-4cbb-b29e-90ccbc8555dc">15,745</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:InventoriesTotal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfNC00LTEtMS04NjcwOQ_1e621d19-90b9-4296-9caf-eb0ef95e58ce">11,122</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ie278a97267b1470ba167c2d59dfc99c7" continuedAt="i18f8a62d65c14fe7b3f46c44b039fbae">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18f8a62d65c14fe7b3f46c44b039fbae"> Subsequent to December&#160;31, 2021, the Company's inventory is no longer held on consignment by the third-party logistics and distribution provider. Finished goods includes KUSD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:CurrentFinishedGoodsHeldOnConsignment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMjM3_05de1bc9-b236-49bf-8339-522b8588f533">3</ix:nonFraction> relating to ZYNLONTA held on consignment by the Company&#8217;s third-party logistics and distribution provider as of December&#160;31, 2021.</ix:continuation> </span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibebf4d8160f04ba3a4bb0f777a0fe1f1">For the nine months ended September 30, 2021, the Company recognized a gain from reversal of previously recorded impairment charges of KUSD <ix:nonFraction unitRef="usd" contextRef="i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfNDc2_978ccd51-705a-4ef2-90df-1400db539819">7,049</ix:nonFraction> as a result of receiving FDA approval of ZYNLONTA in April 2021. The reversal of previously recorded impairment charges is based on the existence of inventory on hand and estimated demand, as well as expiration dating. For the nine months ended September&#160;30, 2022, the Company designated certain capitalized pre-approval ZYNLONTA inventory for R&amp;D use and recorded a charge to R&amp;D expenses, which was partially offset by a reversal of previously recorded impairment charges. The Company recorded an expense to R&amp;D in the Company&#8217;s unaudited condensed consolidated interim statement of operations for the three and nine months ended September&#160;30, 2022, of nil and KUSD <ix:nonFraction unitRef="usd" contextRef="i6f345e8135d943ddb82dfb8c7d312b08_D20220701-20220930" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTA5OTUxMTYyOTUzMA_6d1d0e55-6056-432a-ae16-31ca9b5ff9eb"><ix:nonFraction unitRef="usd" contextRef="i52142027ddf44c8eab013214816b70f1_D20220101-20220930" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTA5OTUxMTYyOTUzMA_a49df772-3003-4b0c-bfaa-7635afe4ed7b">75</ix:nonFraction></ix:nonFraction> respectively.</ix:continuation> </span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_88"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMzM3NA_bfd9af89-552d-4e8b-9611-4bb2165036d5" continuedAt="ia3ef2cf5c4f24cc886d309c4b57f653f" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="ia3ef2cf5c4f24cc886d309c4b57f653f" continuedAt="i2ca70a7c311f4b9390458c5b5a390b16"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses classified as definite-lived intangible assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. The Company classifies its licenses relating to product candidates for which regulatory approval has not been received as indefinite-lived intangible assets and did not recognize amortization expense relating to these licenses. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal development costs are classified as indefinite-lived intangible assets and are expected to be capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. The Company began to capitalize internal development costs for </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i2ca70a7c311f4b9390458c5b5a390b16" continuedAt="ia0c7588330f4409f979e601b26ff497b"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYNLONTA as an internally generated intangible asset upon the FDA approval in the U.S. and if certain recognition criteria were met. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company capitalized the following license fees paid or accrued to third parties as intangible assets: </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Milestone Payments</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An amount of KUSD <ix:nonFraction unitRef="usd" contextRef="i6898024e6a424206b1716d13c24b930b_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMTMxMQ_e3c26561-9735-436d-8457-36d60b128be4">500</ix:nonFraction> paid upon the dosing of a specific number of patients in the first in-human clinical study related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> </span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">An amount of KUSD <ix:nonFraction unitRef="usd" contextRef="i6510f05326e840eb9346f0cb3062ac1e_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMTYzNA_e91032e9-0c48-4e60-866a-7ce121d80054">195</ix:nonFraction> paid upon the successful completion of in-vivo efficacy studies related to a license with a third party to use their specific binding proteins in the development, manufacturing and commercialization of products. The amount was capitalized as an indefinite-lived intangible asset.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company capitalized the following as intangible assets:</span></div><div style="margin-bottom:0.1pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Milestone Payments</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD <ix:nonFraction unitRef="usd" contextRef="ieea878441dfa4efc8a9b70801ddadd56_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMjA2Mw_b738d9c5-6450-4b9e-a18a-06fcd198aedd">1,050</ix:nonFraction> paid upon the successful completion of a pre-clinical toxicology study and IND submission related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD <ix:nonFraction unitRef="usd" contextRef="i74f1e1d5ebdb414f9b5247864591ca9c_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMjM4NQ_897bf47d-a410-43b2-b268-4b2ab8c7da7e">600</ix:nonFraction> paid upon final regulatory approval of ZYNLONTA related to a license agreement with a third party to use their technology to research, develop, manufacture and commercialize products. The amount was capitalized as a definite-lived intangible asset and will be amortized over its estimated useful life of <ix:nonNumeric contextRef="i766d2e3cc1bf4d91a572ee7391121b0e_D20210101-20210930" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMjY5Mg_6f5df45e-6b79-4ff0-839c-115052720aee">14</ix:nonNumeric> years based on the expected patent life, which includes an extension period that the Company believes is highly probable of being granted. This estimated useful life does not include additional patent protection that may be granted under applications filed but not yet approved other than the extension period discussed above.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">License Payments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD 400 relating to a license agreement with a third party to use their proprietary conjugation technology to research, develop, manufacture and commercialize products. The amount was capitalized as an indefinite-lived intangible asset. </span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD <ix:nonFraction unitRef="usd" contextRef="i9cd70bd278774a99b8e19ac8da87c400_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMzA1Mw_801aa461-bf34-4be6-8b32-66c079399de6">250</ix:nonFraction> paid relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset.</span></div></ix:continuation><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="ia0c7588330f4409f979e601b26ff497b"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The table <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMzM3NQ_d02ef384-b0a9-4099-b245-48ff3b0f8ba3" continuedAt="i67e36b0eec714da5acf2216fb80d76bb" escape="true">below provides a rollforward of the Company&#8217;s intangible assets as of September&#160;30, 2022 and 2021.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"><ix:continuation id="i67e36b0eec714da5acf2216fb80d76bb" continuedAt="ic047ed0cdbc142a792cf768e49c7579e"> </ix:continuation></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><ix:continuation id="ic047ed0cdbc142a792cf768e49c7579e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:37.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Indefinite lived</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Definite lived</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Licenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Internal development costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Licenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie3831a84c41e469fa75f28c8e4d66842_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi0xLTEtMS04NjcwOQ_6df7a681-49c2-4b30-8273-3b1dd6ff4458">12,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib0af6d42a54a4ea29ac6d823b1489254_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi0zLTEtMS04NjcwOQ_fa177e9b-785c-419b-a1bc-ec68e2658532">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id9911d0f78184a2082a9741569f80af9_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi01LTEtMS04NjcwOQ_c1bd2559-206d-40a6-ad18-e7cc94152df9">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2f8c5ec28bf64c13b28d322cc15764ef_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi03LTEtMS04NjcwOQ_9463c10a-eb4f-43d4-bf13-924db48be861">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf2aa78bd37e48d8afb1437f35585633_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi05LTEtMS04NjcwOQ_c3b35428-a958-4a07-ac44-b660137343a1">14,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i090393068e7e4ce2a9bf4269cb47d7aa_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy0xLTEtMS04NjcwOQ_018e2b1a-7cb6-4fc8-a486-ab9b7fd29f26">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id5fe126a6d63476e9d69e3a8dd0f33b0_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy0zLTEtMS04NjcwOQ_2229ffee-07f0-42ba-853a-7cf00b86e484">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie56be2cd7a6c41c7bcd4c44c05784db9_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy01LTEtMS04NjcwOQ_a5d3901b-6e07-4e7c-9f2b-b0cecb5a4542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i576b3e5ad10f4c98a00d3c16839a707c_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy03LTEtMS04NjcwOQ_59abae2d-bbce-4213-a712-c399662d7634">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy05LTEtMS04NjcwOQ_ca4a9065-2ae8-4c18-b707-ffabb4fe3848">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i090393068e7e4ce2a9bf4269cb47d7aa_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS0xLTEtMS04NjcwOQ_136dfc83-96e5-4ff5-82d5-2d94a39dc949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id5fe126a6d63476e9d69e3a8dd0f33b0_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS0zLTEtMS04NjcwOQ_6b2c67df-3214-4efc-b444-597c30a15a0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie56be2cd7a6c41c7bcd4c44c05784db9_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS01LTEtMS04NjcwOQ_cb2ed10f-228a-4ce3-8431-74406ccb1879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i576b3e5ad10f4c98a00d3c16839a707c_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS03LTEtMS04NjcwOQ_1825f932-ffdb-4dbe-aa46-66b6c8807ca8">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS05LTEtMS04NjcwOQ_e81e8a95-c1b2-4ceb-b49a-7f0b1bf18c66">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i06c1a842a7a74eb19e9e9fb576dfa486_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi0xLTEtMS04NjcwOQ_072b7165-9514-4358-b7cd-beeb13a9182d">13,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0735d735202d4e8fa9fe0243e3d57875_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi0zLTEtMS04NjcwOQ_5f934586-ee42-4bec-bbd0-9a4bd5ed6ebf">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i03ecc9946c714265bbb8a89418c63c01_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi01LTEtMS04NjcwOQ_cc6a8b1a-e1fe-458a-af87-e023bfcbee9e">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6bd5f9550f6048c28bee5f1bfdd5d74d_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi03LTEtMS04NjcwOQ_092171a8-3752-4f2d-88e9-40a209ca8d28">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i15b225beffa44b3d87f67b9e69f699fa_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi05LTEtMS04NjcwOQ_f66b0d6c-0ecc-4f7b-9c82-886b9ae2fad9">15,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i8151bd1bc2a04b71adee09c08447999a_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS0xLTEtMS04NjcwOQ_b4017615-0688-47d5-9854-aafc50e0a5f3">1,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1b0a40aaa46242f9b8c656439b48a32c_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS0zLTEtMS04NjcwOQ_2475ec33-6a94-4cc1-80c3-09f24bf5b47e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id6029eb697ae4501b1bce9cb044843bd_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS01LTEtMS04NjcwOQ_e94199d6-343e-4b61-b5be-f37bacd06896">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ide8f1760047640c38a5d3005f9bc6157_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS03LTEtMS04NjcwOQ_11040e23-c05c-4b16-accf-befef1ba271a">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id32707d201834dc793295ca00533da1c_I20211231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS05LTEtMS04NjcwOQ_4a8a6647-329b-4550-a4e3-1712ada49b99">1,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amortization charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5c4fdcd15f36441b91d6a6497571a82b_D20220101-20220930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtMS0xLTEtODY3MDk_236abee1-538a-459d-bdf4-45ed72554956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i69b42fc0ddec473598e886ec0f5e3c9b_D20220101-20220930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtMy0xLTEtODY3MDk_6d27c612-36e4-4f2a-a405-e3b30b761e77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0bd15bcdf0a64b5898e159fda31b9d99_D20220101-20220930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtNS0xLTEtODY3MDk_fa75c7bd-fee8-4e53-b104-14067ed7d259">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i85b68b5b42e242f1985aa0054fda3aaa_D20220101-20220930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtNy0xLTEtODY3MDk_ac46f4ee-dcf4-44b5-98c9-f82c642dfd6a">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtOS0xLTEtODY3MDk_fb0e4d1e-88a5-430a-8cc4-8b703fde8397">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5c4fdcd15f36441b91d6a6497571a82b_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtMS0xLTEtODY3MDk_ad03b7df-82b8-493b-b76e-18ed10e14ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0bd15bcdf0a64b5898e159fda31b9d99_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtNS0xLTEtODY3MDk_6c9a3d9a-2238-47a1-9d8f-bdeae923d9bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i85b68b5b42e242f1985aa0054fda3aaa_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtNy0xLTEtODY3MDk_479b8352-8002-4f09-855d-7f40d0ab4adf">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtOS0xLTEtODY3MDk_772b43d1-4b24-4fef-ba91-1eec72b2691f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3ffc2c26d6241199c0010549c56f460_I20220930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItMS0xLTEtODY3MDk_b5c28669-cf80-4700-b57f-eb739de11671">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5cb5c39e47594c269f24f5e7a5544869_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItMy0xLTEtODY3MDk_d3fea46b-1cc2-4eb1-8161-2cafcf566ccf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i83b175bbb0a9439e8c3c4647daa448dc_I20220930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItNS0xLTEtODY3MDk_2cab843b-4bf5-4b8c-bb4d-6a8f34544409">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i1870dc5d8b164d9ebd63b4021e920cd6_I20220930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItNy0xLTEtODY3MDk_49d0c68b-b8bb-4947-8964-c6ba840c6c63">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i9da30f3755c743e08b48e072dc09209d_I20220930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItOS0xLTEtODY3MDk_1c86f9ec-911a-4873-a3c6-ab0f5c28f77e">1,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net book amount as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i06eae1c2401f49908e95968065439f57_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtMS0xLTEtODY3MDk_57919932-2acc-4afd-8abf-fbe4f86b841f">12,611</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i23ac58a635804353bcd123924428ff13_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtMy0xLTEtODY3MDk_6e880307-7bde-4198-b118-9caa05dee46b">954</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2f3dddcfe8e2427c8d4ff2eee0c6350f_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtNS0xLTEtODY3MDk_85e7a4b1-88ca-47a5-b47a-a1446ff6051c">946</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i668c47e9660643d9a0bc7afaf9b7bc1a_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtNy0xLTEtODY3MDk_13c5fbc8-1027-4464-8911-5a3b62ab3656">87</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtOS0xLTEtODY3MDk_5f5b4974-b432-429f-b329-4de8cd975ce9">14,598</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2e692aa8462f4f09aaf7e7b3b896724f_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctMS0xLTEtODY3MDk_1eb0576d-9914-4284-b8ed-6a15d9696515">11,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id2450f8f780347a6b493d4432cbc51da_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctMy0xLTEtODY3MDk_e3b607e9-bf1d-44d8-ad49-b2628d31353e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7e3cf7b0b5824c3fbf851545e1194289_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctNS0xLTEtODY3MDk_52a116c0-2e9d-49fd-ad32-c94efd0eb16d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8bc4fa9f79eb4710ae4034d037363f25_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctNy0xLTEtODY3MDk_4dd0827a-e9f4-4372-b890-96f86dd8d10b">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i35cab614c8934a419edc6f7cccb644a3_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctOS0xLTEtODY3MDk_77ff1318-a02b-41e2-a422-be4260f25081">11,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i335db87da9ad4f00b7b7b94870fddfb6_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtMS0xLTEtODY3MDk_1036fdb8-9609-4e73-8ad2-663443f84d8f">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ibe0468c473d542f88ffed8e8f6fa3499_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtMy0xLTEtODY3MDk_1b98e491-b4fa-43fc-9f79-e8259cbfa922">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1fae3e626a164280b7a488b6bde2fb6b_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtNS0xLTEtODY3MDk_5d7c16c4-f0a2-4449-adb9-60de91a38f10">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i50390a1027184daa809325bb39041f9e_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtNy0xLTEtODY3MDk_543cfcdc-5e23-47ce-bd98-a17cc2a7030e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtOS0xLTEtODY3MDk_ebfb9a51-97a0-4798-8a24-69a181d69255">3,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Transfers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i335db87da9ad4f00b7b7b94870fddfb6_D20210101-20210930" decimals="-3" sign="-" name="adc:TransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktMS0xLTEtODY3MDk_fea3a548-7420-4792-98ec-1fde105d274f">452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ibe0468c473d542f88ffed8e8f6fa3499_D20210101-20210930" decimals="-3" name="adc:TransfersIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktMy0xLTEtODY3MDk_3b6b454e-91ad-4ae7-ad88-8a47d780320b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1fae3e626a164280b7a488b6bde2fb6b_D20210101-20210930" decimals="-3" name="adc:TransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktNS0xLTEtODY3MDk_03bb2c07-1dac-49e1-90a8-79558648b01c">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i50390a1027184daa809325bb39041f9e_D20210101-20210930" decimals="-3" sign="-" name="adc:TransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktNy0xLTEtODY3MDk_786108c0-0326-4122-9db3-7a093f59fef0">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930" decimals="-3" sign="-" name="adc:TransfersIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktOS0xLTEtODY3MDk_0e7e2b68-c0b8-4717-a768-9f9ee0e86884">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7bfcb651885a4be4a64db35b2e3b0dfe_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtMS0xLTEtODY3MDk_8167d9ed-16aa-4b7f-94c6-fe38a8e4d1da">12,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i334c4a99388b47a7ab36175bbe1622f3_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtMy0xLTEtODY3MDk_997cf641-7522-43d3-a85b-6898f60cac5b">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ifde88f7e0bcd430389cd38d465e25601_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtNS0xLTEtODY3MDk_65b10a0b-2db5-46a3-a844-f3c658d8b028">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i18ce56a8c03a4b7889fd8e92506bdba4_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtNy0xLTEtODY3MDk_21ae7837-ddec-45de-ab69-b8042a9b06af">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i244793ab5a7249738bab95a309aaad60_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtOS0xLTEtODY3MDk_d97b8eb3-0413-44ee-994e-b1ea259835b6">14,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i8d06ca9dbb9943bf87caccfc0bdd279c_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtMS0xLTEtODY3MDk_5d74f029-4332-428c-ad5d-a95a7ccb5248">1,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if0dfcc8b323e454089332943aea91f52_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtMy0xLTEtODY3MDk_c1e6e2b7-2514-4998-887c-687d87d3c2ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0721e1ef08f74225930b348ccc978392_I20201231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtNS0xLTEtODY3MDk_96cdb53d-15b3-4b4c-a472-a23091b61911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3456ecf300704b57b6adcd05b7963d67_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtNy0xLTEtODY3MDk_c19efa4f-b639-479f-b0df-65bc39046911">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i792cccf378ee4050923e53f4a38c7136_I20201231" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtOS0xLTEtODY3MDk_044bb523-a502-48a3-8e4c-5fc1e14dacd9">1,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amortization charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i68593cdfc71c4bbd922f69c3283cf601_D20210101-20210930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtMS0xLTEtODY3MDk_f5425c50-246f-41f8-808e-968034b5e162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i31cbfc1404b44ac995974a2da34c1713_D20210101-20210930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtMy0xLTEtODY3MDk_4c4de9cc-47a7-4371-a543-0b6e591d3aad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ia197fa03b4e0485c894377210f9a37ae_D20210101-20210930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtNS0xLTEtODY3MDk_275bd3dc-5c5d-4cac-9def-1db31590194e">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if7a6a0f0a03341b7a23b2a47027ce477_D20210101-20210930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtNy0xLTEtODY3MDk_d90921b2-f977-4e71-9a41-69d904af8da8">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtOS0xLTEtODY3MDk_d4677b7b-708d-45de-8f15-28a87be3d58b">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ia441c664cd094fa08cfec8c6325f59c0_I20210930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtMS0xLTEtODY3MDk_dbad6b77-e845-4aa2-ba96-87146cf14151">1,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3f566215e8c446edbf6ba6023c4a6697_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtMy0xLTEtODY3MDk_5915a1f7-c552-4a6a-a0d6-0974aa6e822a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i1fe02702964a4fedba3bbd1c9e2ed7a0_I20210930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtNS0xLTEtODY3MDk_ee05c889-a53a-4ab1-9dc6-3cf2112fd13f">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i93a88ce2c37e481c91710d8d7e711e27_I20210930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtNy0xLTEtODY3MDk_32b4070c-3066-4761-8ecc-475a54d3f636">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i6a7ddc9b4e1e4c0f82705cfe7c527db7_I20210930" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtOS0xLTEtODY3MDk_fd47c10d-4480-49e5-91bc-163fa08a2dc1">1,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net book amount as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i328297d89f3241aa834368d0776dfb39_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtMS0xLTEtODY3MDk_1cab2364-5ec1-47ad-ad99-8a9246c0fbc2">11,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i37ad95fb7fdc49e69f2db1a90d8872e9_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtMy0xLTEtODY3MDk_94e70ad2-e00e-44d1-8ead-4168b5bb9776">926</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib728077ca1d24854ad85579c7c79d6de_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtNS0xLTEtODY3MDk_83c7b094-bda9-4678-b590-91e0a5359c3e">1,021</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i72ecf67eda5b4214b2a1b3dec7c45988_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtNy0xLTEtODY3MDk_db1402a9-3ff2-41d9-8af2-3c8a97f4be3a">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtOS0xLTEtODY3MDk_9e54d551-9ebe-4ab1-940d-b89568f6ccd7">13,316</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="padding-left:18pt"><span><br/></span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_91"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Interest in joint venture                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfJointVenturesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMjU4OQ_401b8b2c-0c97-4d57-866c-640f0bfce456" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the Company announced the formation of a new joint venture company, Overland ADCT BioPharma, with Overland Pharmaceuticals (&#8220;Overland&#8221;), a fully integrated biopharmaceutical company backed by Hillhouse Capital. Overland ADCT BioPharma will develop and commercialize <ix:nonFraction unitRef="product" contextRef="i228965fb30b84e8ebf7eb20761e08272_D20201214-20201214" decimals="INF" name="adc:NumberOfProductsDevelopedAndCommercializedInJointVenture" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMTI4Nw_d4c472be-7c42-40e7-ad38-754187b0edf5">one</ix:nonFraction> of the Company&#8217;s ADC products, ZYNLONTA, and <ix:nonFraction unitRef="product" contextRef="i228965fb30b84e8ebf7eb20761e08272_D20201214-20201214" decimals="INF" name="adc:NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMTMzNQ_8aefb112-7219-4573-8e38-0a1e320b6580">three</ix:nonFraction> of the Company&#8217;s ADC product candidates, ADCT-601, ADCT-602 and ADCT-901, in greater China and Singapore. <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMjU5MA_566c155c-deeb-4c54-aa8b-914348afcbd1" continuedAt="ifeb1f8ba63674eabbcbed608c047e2c6" escape="true">The table below provides a rollforward of the Company&#8217;s interest in Overland ADCT BioPharma as of September&#160;30, 2022 and 2021, respectively. </ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"><ix:continuation id="ifeb1f8ba63674eabbcbed608c047e2c6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:75.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Interest in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfMi0yLTEtMS04NjcwOQ_8f06f9b9-4151-41d5-9efc-33f440e754fc">41,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930" decimals="-3" sign="-" name="adc:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfNC0yLTEtMS04NjcwOQ_d4807d5e-d866-4eec-80e9-552a1649e737">6,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf7428455ece4b7882dc15984214fcea_I20220930" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfNS0yLTEtMS04NjcwOQ_7cafaee5-4604-4969-aa44-af8784c67af5">34,687</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8a6d95c9c71c445896f3f224ee1f25ef_I20201231" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfNy0yLTEtMS04NjcwOQ_3e2180d4-86e5-46bd-84e2-3ac9fb0b7725">47,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930" decimals="-3" sign="-" name="adc:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfOC0yLTEtMS04NjcwOQ_0b6d6851-d481-4754-b018-17f057b4d247">3,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic66b9b3ea6b24e6596d461fd96900933_I20210930" decimals="-3" name="ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfOS0yLTEtMS04NjcwOQ_9be44222-de83-4709-a167-bb9abef7a561">44,002</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the deferred gain of USD <ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-5" name="adc:DeferredGainOnInvestmentInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMTYwNQ_c864cab4-f6ff-42ff-9290-fd8072b61a8f">23.5</ix:nonFraction>&#160;million arising from the Company&#8217;s contribution for its equity investment in the joint venture remained unchanged from December&#160;31, 2021. The Company&#8217;s carrying value of its investment in a joint venture increases or decreases in relation to the Company&#8217;s proportionate share of comprehensive income or loss of the joint venture. When the Company&#8217;s share of losses of a joint venture exceeds the Company&#8217;s interest in that joint venture less the carrying value of the deferred gain described above, the Company ceases to recognize its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the joint venture. </span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMjU5MQ_89a37c26-0426-406b-977f-92cae85deee1" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company&#8217;s share of those amounts. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:27.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.289%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Summarized Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf7428455ece4b7882dc15984214fcea_I20220930" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMi0yLTEtMS04NjcwOQ_ccea867f-216a-4e02-b8ee-dd2fe4de9ce1">24,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMi00LTEtMS04NjcwOQ_f8a5bdf6-1e61-4957-9883-990326850eb4">39,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf7428455ece4b7882dc15984214fcea_I20220930" decimals="-3" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMy0yLTEtMS04NjcwOQ_32ba743e-d2b9-4afa-86e7-978ab351b4ff">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231" decimals="-3" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMy00LTEtMS04NjcwOQ_5c5a5ba1-8797-4ab1-a843-5da80544b258">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf7428455ece4b7882dc15984214fcea_I20220930" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNC0yLTEtMS04NjcwOQ_54d05d6c-733c-441f-a510-408573de3a89">48,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNC00LTEtMS04NjcwOQ_c7ee41a2-e294-42da-be0e-20eb1a56ebb1">48,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf7428455ece4b7882dc15984214fcea_I20220930" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNS0yLTEtMS04NjcwOQ_03a8af56-1cb2-4cfb-9dbc-1d44178f65ad">3,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNS00LTEtMS04NjcwOQ_4d536e70-77c5-4e77-b5ed-3cc0afc28470">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf7428455ece4b7882dc15984214fcea_I20220930" decimals="-3" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNi0yLTEtMS04NjcwOQ_e29f933f-bfb1-4313-a260-9aeb2e07ec52">69,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231" decimals="-3" name="ifrs-full:NetAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNi00LTEtMS04NjcwOQ_1c53fad6-8a13-4135-9bcb-3c76cd07874d">84,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Summarized Statement of Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i42d1c8d670234c8ea810b1ad8b5d520f_D20220701-20220930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtMi0xLTEtODY3MDk_f5f20928-66e5-46b5-8e3d-b90277c38b0f">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id388d0fa6213478cba6b2c29801561e0_D20210701-20210930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtNC0xLTEtODY3MDk_29a7f2d2-8377-453e-9647-6b950cf77b82">4,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtNi0xLTEtODY3MDk_65001abb-027f-4ef5-9c6b-f909e842f454">14,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtOC0xLTEtODY3MDk_aace4afe-af2b-4402-867b-4d9bffca4d72">8,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i42d1c8d670234c8ea810b1ad8b5d520f_D20220701-20220930" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItMi0xLTEtODY3MDk_d4684778-52e6-4cbb-966b-d0a1a4f136d6">4,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id388d0fa6213478cba6b2c29801561e0_D20210701-20210930" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItNC0xLTEtODY3MDk_b0f4235b-aaf4-4b2a-8720-14fbfb1f281d">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItNi0xLTEtODY3MDk_714575d9-b24b-4265-83cf-9e77e91f27e2">13,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930" decimals="-3" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItOC0xLTEtODY3MDk_45db5859-9339-4311-8511-4a0c8fe15ef2">7,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_94"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfLeasesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfODA2_adf72658-96ae-4672-95de-b8bcd78c36ae" continuedAt="i7722adcb0d6e4ebfa40e1e2e303fd023" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i7722adcb0d6e4ebfa40e1e2e303fd023" continuedAt="iabc8da2838e14cc7a9bd06ebc189eb48"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company's right-of-use assets as of September&#160;30, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfODA3_ae9df0f4-fddc-44f2-8203-2de94abd8e31" continuedAt="id19da94e4a6441cabbf4da07659d10c4" escape="true"><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:60.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Properties (Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2b56cf9b484847d5ab3c287aa7060a0e_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMy0yLTEtMS04NjcwOQ_b9ef76e4-3e0f-4b82-befd-0d667ee00931">9,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i9b4ebc1ad16249d59d9a2b9574c68a62_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMy00LTEtMS04NjcwOQ_363079fc-6562-41ca-87ad-2ecb0bfea79d">134</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf2aa78bd37e48d8afb1437f35585633_I20211231" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMy02LTEtMS04NjcwOQ_c03ae7d7-2df2-40fd-9587-1f1f5af52449">9,139</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib0cfdd333541408ba83d32b7e1c51e80_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNC0yLTEtMS04NjcwOQ_f4db451d-f2d6-48ed-910a-945980404ced">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6a4d6ad6c402432badd52332e50082ba_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNC00LTEtMS04NjcwOQ_a68118b2-11c4-4b15-ade9-ad2b3583cbce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNC02LTEtMS04NjcwOQ_8969a864-19ee-4d9f-aaf7-1ddc331dad0a">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ib0cfdd333541408ba83d32b7e1c51e80_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNi0yLTEtMS04NjcwOQ_e4a8c681-7715-4a21-b1ca-22185b501134">911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6a4d6ad6c402432badd52332e50082ba_D20220101-20220930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNi00LTEtMS04NjcwOQ_b9fd30af-34fe-40ef-a8b5-5cd8d78722ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNi02LTEtMS04NjcwOQ_f10aec1e-80f2-4397-8de6-a226ac269eed">911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ifc44f11da71445b9bd1dd055c47f9f73_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNy0yLTEtMS04NjcwOQ_baaf2d2b-6a4f-4a3f-ae69-3636e05b8150">9,328</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3ef43b851dc04cf9825b1deb88d8f139_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNy00LTEtMS04NjcwOQ_0c6b3dc5-4112-48b0-ae42-6dd8bcd8f334">134</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i15b225beffa44b3d87f67b9e69f699fa_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNy02LTEtMS04NjcwOQ_2a50f0e4-d5b2-47a2-8983-7e72c43a7c13">9,462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i161a5506dfed4a31a2fb1ac7f5c47782_I20211231" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTAtMi0xLTEtODY3MDk_befeec10-985a-4416-9092-c7c26a2749e9">1,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="iaada04dc38054738b85ebb285ca09c21_I20211231" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTAtNC0xLTEtODY3MDk_38e6ec5b-902d-440d-ade2-8f6fa2df7c8e">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id32707d201834dc793295ca00533da1c_I20211231" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTAtNi0xLTEtODY3MDk_f8719053-f4c9-4fd8-a88b-20331b3d696f">1,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i5477a4b1928548ebbe20d629b66b14ce_D20220101-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTEtMi0xLTEtODY3MDk_4bb9a029-2f97-47c3-b4ea-72aabb1f6da2">871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i2d3ba12574b44bb38c8be7706e8aac18_D20220101-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTEtNC0xLTEtODY3MDk_5c7421a2-fd16-4e6b-a364-b75a1acf7345">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTEtNi0xLTEtODY3MDk_54bde6d3-e108-4365-b068-0cfc23bf8a40">896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5477a4b1928548ebbe20d629b66b14ce_D20220101-20220930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTMtMi0xLTEtODY3MDk_6c41b383-94b0-4a02-a91d-e69a1acf9935">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2d3ba12574b44bb38c8be7706e8aac18_D20220101-20220930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTMtNC0xLTEtODY3MDk_efa95572-7ef3-4bc3-9a04-fc68648ade5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTMtNi0xLTEtODY3MDk_3361ff7d-d6d1-47dd-8b80-2f4a45c5828e">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i8b0b55146cdb49e48b45bad254647bc6_I20220930" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTQtMi0xLTEtODY3MDk_067cda98-20b7-485f-9edb-94420fdf651d">2,679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i9e763260b1f442488b72bf74a7c49c11_I20220930" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTQtNC0xLTEtODY3MDk_d1b2f34e-6723-47d4-8fc1-95c5f9038fcf">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i9da30f3755c743e08b48e072dc09209d_I20220930" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTQtNi0xLTEtODY3MDk_ea2c9855-79fd-4ccd-b5e4-524d3930912d">2,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i834b4d3caeae4e77b67d0f0dc2d552e9_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTYtMi0xLTEtODY3MDk_c3bd9f35-7cd6-4294-936e-5d483ab015f1">6,649</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i638129f1bcc5425ba52dd51ffd7e9490_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTYtNC0xLTEtODY3MDk_1625f35a-afdb-4a5f-9d10-64413cc019b2">59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTYtNi0xLTEtODY3MDk_c4e52e3c-54a0-4d64-82a7-1cba9d4c77c8">6,708</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i401425c5856840c4a0bb4fd8fb8835ae_I20201231" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTktMi0xLTEtODY3MDk_6755eb13-3b81-4174-b2ea-08eb8e22089c">5,324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2efd49a30baa4077ae95107fcc999447_I20201231" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTktNC0xLTEtODY3MDk_c898901b-1c16-4ec5-957c-4da6a5711477">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i35cab614c8934a419edc6f7cccb644a3_I20201231" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTktNi0xLTEtODY3MDk_571d4e4d-6259-4a4c-8a29-5f8b65c200e4">5,402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjAtMi0xLTEtODY3MDk_2f9c67de-3eec-4b97-975c-05d606285b63">5,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjAtNC0xLTEtODY3MDk_ffc4c2da-f4d3-41cb-afc6-d3c00e9c5af3">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjAtNi0xLTEtODY3MDk_13541016-3895-47a6-9902-c0222cf1274e">5,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease termination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjEtMi0xLTEtODY3MDk_3d4c34aa-a798-4b64-baaa-bde602b5f858">864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjEtNC0xLTEtODY3MDk_24984894-dd08-4a3b-a453-86d99b28eb8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjEtNi0xLTEtODY3MDk_9108807c-c74f-441e-92f5-38aa61f494dd">864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjItMi0xLTEtODY3MDk_eb730c46-75d9-4ca7-a4f4-8e924a44a823">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjItNC0xLTEtODY3MDk_02e28b5d-529e-4c61-8419-b8b89299c1ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjItNi0xLTEtODY3MDk_b0b66b74-d43a-4aa4-aca4-5b5f9969907a">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5abfbc2b76094ac5a51ad5a1de5beced_I20210930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjMtMi0xLTEtODY3MDk_36a19f92-2cbe-46f6-962c-162c945a25c4">9,990</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i135ebd8bed6a4537b47040a2f4e822d3_I20210930" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjMtNC0xLTEtODY3MDk_77dcedef-9316-4adf-863d-4db810a46fac">134</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i244793ab5a7249738bab95a309aaad60_I20210930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjMtNi0xLTEtODY3MDk_29fb9e47-ae46-4170-a609-01dae409b268">10,124</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ie2ff798d025b459fa18da647bcec866b_I20201231" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjYtMi0xLTEtODY3MDk_83d22c77-6ecd-40fd-ab4f-87b716beda0b">2,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i15cd499c06e344418b49e009c7d8d193_I20201231" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjYtNC0xLTEtODY3MDk_980a855c-355a-4271-944f-27a7d6be14b1">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i792cccf378ee4050923e53f4a38c7136_I20201231" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjYtNi0xLTEtODY3MDk_4927eaf6-551a-41c4-a2df-75f635dbb13e">2,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjctMi0xLTEtODY3MDk_aff88388-cf9c-4a9c-89a2-5932ad9d3c6b">1,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjctNC0xLTEtODY3MDk_785f0def-80ce-43cf-9617-c1cef3657282">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjctNi0xLTEtODY3MDk_498ba012-74e9-4724-a447-de7891bbbb9c">1,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease termination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjgtMi0xLTEtODY3MDk_ae97f8b0-546d-412f-a382-15ca994859a0">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjgtNC0xLTEtODY3MDk_86e89964-7703-44b5-a70f-807ce9e83cf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjgtNi0xLTEtODY3MDk_ea180631-b773-4b13-b453-12c32b597f9c">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjktMi0xLTEtODY3MDk_822434cb-00d3-4178-9385-d46d2dac3206">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjktNC0xLTEtODY3MDk_a5a29130-41b2-46bf-acaa-ad70e4fc23df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjktNi0xLTEtODY3MDk_024f47b1-a94e-48be-9448-c107119aad79">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i80cd1d5cda1f4e74862567135c82703e_I20210930" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzAtMi0xLTEtODY3MDk_24a32a7e-c6f8-4ce0-9814-42094c638c0d">2,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id5a94dcf4e4844cf92a3de1535f49f1e_I20210930" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzAtNC0xLTEtODY3MDk_be6b6243-31c9-42bd-bcd2-67a8e09d2f6e">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i6a7ddc9b4e1e4c0f82705cfe7c527db7_I20210930" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzAtNi0xLTEtODY3MDk_a5270402-fabb-4727-b683-1a7bf167d13a">2,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i81b5c8e6664d477fa65cefde7362ee81_I20210930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzItMi0xLTEtODY3MDk_444398ac-246d-4711-8f7c-34c66301e20b">7,448</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ibce8feac9624457fae2210499d43d84a_I20210930" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzItNC0xLTEtODY3MDk_10269c85-4ae8-4b88-a0b5-a7ca8036b7e4">92</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzItNi0xLTEtODY3MDk_456299af-5ef8-4184-8b8b-a81f7ca959d6">7,540</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the third quarter of 2022, the Company extended the term of its existing lease related to its U.S. corporate offices in New Jersey for an additional two years commencing on December 1, 2022, including an extension option for three additional years. The Company is reasonably certain it will exercise the extension option and therefore has accounted for the lease using a five-year lease term.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:continuation id="id19da94e4a6441cabbf4da07659d10c4">During the first quarter of 2021, the Company entered into a new lease agreement with a ten-year term commencing in January 2021 for space in the iHub building on the Imperial University college campus in White City, West London. The primary function of the new facility, which consists of approximately <ix:nonFraction unitRef="sqm" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="0" name="adc:LeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfNDI1_2cf3b579-8532-48d2-a1f7-f3a21dc56492">1,100</ix:nonFraction> square meters, is R&amp;D.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets have been charged to the following categories in the unaudited condensed consolidated interim statement of operations. Depreciation expense for S&amp;M expenses was not material for any of the periods presented. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:43.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie83b9d46aa9540e49e84d64af9846e39_D20220701-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi0yLTEtMS04NjcwOQ_d1cb8ced-e5df-4b1e-b57c-8f62a3499acf">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i66e6d9b588aa47d19ad6aad08a538bf5_D20210701-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi00LTEtMS04NjcwOQ_12874089-216e-45dc-abcd-e5d3023d20a9">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia8b0181426584e10a750977ea6280fb4_D20220101-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi02LTEtMS04NjcwOQ_0fca1bfc-edbb-4694-9513-9be40c25f6d5">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5a67346f88234740b156f2c58bfbebe1_D20210101-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi04LTEtMS04NjcwOQ_dbe9b895-e416-42af-857a-1e23f9a87455">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1961636ee14e4def8d8cc7b2018774e3_D20220701-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC0yLTEtMS04NjcwOQ_b1231824-9dc7-4203-98c3-d01a90f2e79c">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5672677502cf4414a866c09aa425cb21_D20210701-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC00LTEtMS04NjcwOQ_3a758f04-7147-4dcc-a206-430058a4218e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i06457785463e407c8483fbe337aa3902_D20220101-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC02LTEtMS04NjcwOQ_cccab1b9-d78e-45b0-88e0-f6ab0781d7bf">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3c884b0bc284c6388a42f8607e2d444_D20210101-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC04LTEtMS04NjcwOQ_b7f5c64f-19f4-440e-a138-661b5dfb149e">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS0yLTEtMS04NjcwOQ_34339a17-b984-43b5-b587-5fc8f2c64ead">290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS00LTEtMS04NjcwOQ_3018eac9-4bd4-45f7-9d00-97c17210f97f">395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS02LTEtMS04NjcwOQ_adb8b910-7ff6-4762-9a01-7d73a09cedab">896</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS04LTEtMS04NjcwOQ_639686b3-471b-44b3-b823-557501741156">1,194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="iabc8da2838e14cc7a9bd06ebc189eb48"><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company's lease liabilities as of September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfODEw_152fb02b-5964-4a17-80b0-a37b0a13d483" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:60.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Properties (Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i28da2485dc9a4fa783f820e72033822c_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMi0yLTEtMS04NjcwOQ_91e6ec73-eae8-4bd9-bc44-1bc8d4918b7f">7,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ic61fb64598ff4cd0ad1e2271aed1a821_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMi00LTEtMS04NjcwOQ_737d209e-ed3d-4ec2-a99f-cc9efa8bf298">125</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMi02LTEtMS04NjcwOQ_2d19b0f9-c76f-4787-9cb8-4fb3b213932d">8,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930" decimals="-3" name="adc:AdditionsToLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMy0yLTEtMS04NjcwOQ_6c0473fe-2e38-4fca-9e4d-f631c6e8e1ae">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930" decimals="-3" name="adc:AdditionsToLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMy00LTEtMS04NjcwOQ_b598c9c2-39e7-4262-9c00-c08c5ccb8093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:AdditionsToLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMy02LTEtMS04NjcwOQ_df587481-f516-455f-acca-b7fb480f6b52">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflow (including interest)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNS0yLTEtMS04NjcwOQ_a0a2b4ee-054d-4008-810d-b49977ee16c4">901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNS00LTEtMS04NjcwOQ_eca4b5c3-9d83-4ab8-a4a9-028db62f8e3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNS02LTEtMS04NjcwOQ_54d8e271-36ef-4884-95c8-4322182b3f44">901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNi0yLTEtMS04NjcwOQ_11e5e838-f342-405b-b958-41029daecbe8">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNi00LTEtMS04NjcwOQ_85b06ce8-282e-4aab-9dd6-44a03fb519a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNi02LTEtMS04NjcwOQ_c6c39554-6bc5-4d84-8791-e8d96d71d3be">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNy0yLTEtMS04NjcwOQ_55a7725a-a00d-4bf7-86a7-00a6b8a84eca">978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNy00LTEtMS04NjcwOQ_1beead2d-d9a7-49b8-8fc2-4f14488dc054">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNy02LTEtMS04NjcwOQ_ee8cbb4a-01ca-493c-a638-fff440358f5c">1,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfOC0yLTEtMS04NjcwOQ_c4130d8f-3be1-4391-9c45-b631bb9be97c">7,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfOC00LTEtMS04NjcwOQ_ff385293-3197-4278-babf-53e5e570798e">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfOC02LTEtMS04NjcwOQ_8a672d9c-a1d5-4e93-836e-1ab1e1680738">7,457</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6b3f2601891941a49171d77873081724_I20201231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTAtMi0xLTEtODY3MDk_1c669556-d5f6-4d9e-811e-a51fff83b3f6">3,402</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1fee265512e746a9a555451fac8020e8_I20201231" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTAtNC0xLTEtODY3MDk_ceae1942-70b3-4d21-91b4-0eee23b94149">65</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTAtNi0xLTEtODY3MDk_6384b7ee-93c7-407f-a5d6-64607d4b4717">3,467</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ied99ac8b277c4b408fb02863f8dffb5e_D20220101-20220630" decimals="-3" name="adc:AdditionsToLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTEtMi0xLTEtODY3MDk_cb02cd46-ceda-4578-a2f2-34c1e61009ac">5,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5b95a2cc92564802b7a6cf3d8824d376_D20220101-20220630" decimals="-3" name="adc:AdditionsToLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTEtNC0xLTEtODY3MDk_3b3a8225-c7f2-4340-96ad-4e0951fd425c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630" decimals="-3" name="adc:AdditionsToLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTEtNi0xLTEtODY3MDk_ad89a19d-58b1-4d21-b584-e8ed5803a224">5,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflow (including interest)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="icada6f229ced49ecacd2e102988715eb_D20210101-20210930" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTMtMi0xLTEtODY3MDk_fb664841-8a72-485f-b9c7-eca04191e381">892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTMtNC0xLTEtODY3MDk_816fb1a5-087f-41e7-a309-49763fafb846">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTMtNi0xLTEtODY3MDk_0c9bbf09-41a9-4bd9-b907-ee5fe85783d2">916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="icada6f229ced49ecacd2e102988715eb_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTQtMi0xLTEtODY3MDk_9d97f3c2-9964-4bc6-b3b0-576d9e5d33d1">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTQtNC0xLTEtODY3MDk_96779f06-dd31-4311-8580-5edf148eff7a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTQtNi0xLTEtODY3MDk_59fa691b-b3f2-4854-b26e-880e5b547e2d">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="icada6f229ced49ecacd2e102988715eb_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTUtMi0xLTEtODY3MDk_2c1c59dd-7dcf-4a70-ad6e-f03738e8fbb6">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTUtNC0xLTEtODY3MDk_82dea3e3-e8de-4475-9bbb-3398a50e8ab3">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTUtNi0xLTEtODY3MDk_8c4bf92c-533a-43b8-bdf4-d2f4387e2410">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTYtMi0xLTEtODY3MDk_e2acf936-d41e-4008-a561-a813c9ae942c">8,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i80fc52680e63461a82201650861575d2_I20210930" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTYtNC0xLTEtODY3MDk_f94ddd94-a976-44b6-a916-2511a87b2b06">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTYtNi0xLTEtODY3MDk_8b8201bc-293a-4393-9534-1e6a19c5b336">8,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTktMi0xLTEtODY3MDk_3ed53a03-ab25-4460-9161-a74d97425419">801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTktNC0xLTEtODY3MDk_56ae546b-8f42-4b9c-80ae-3bdbc78bfda7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTktNi0xLTEtODY3MDk_a5a185b9-fa4a-4e88-9f6c-df5f5a851a36">835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjAtMi0xLTEtODY3MDk_9a96da47-4033-49e8-afbc-952c7399195d">6,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjAtNC0xLTEtODY3MDk_48ae2708-bf0b-4105-9c4d-4b748b895b7f">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjAtNi0xLTEtODY3MDk_09687efc-bc29-4ac8-82e7-23e40138e621">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjEtMi0xLTEtODY3MDk_25de58ea-b021-4656-ad39-ede999b72f87">7,397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjEtNC0xLTEtODY3MDk_336fba6e-a0ab-4ef2-b610-707911812b98">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjEtNi0xLTEtODY3MDk_9b105154-76ce-4eb3-afbf-73214ce35777">7,457</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjQtMi0xLTEtODY3MDk_1301f873-1b21-45aa-9232-03c42af3fabd">981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i80fc52680e63461a82201650861575d2_I20210930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjQtNC0xLTEtODY3MDk_ec372ac0-4512-41f2-9a58-0f44b62d2cce">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjQtNi0xLTEtODY3MDk_5abd3b05-91e5-41b3-9df4-72b66c0dd99b">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjUtMi0xLTEtODY3MDk_c4e1cb1c-c81f-4317-9584-00c555a9b454">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i80fc52680e63461a82201650861575d2_I20210930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjUtNC0xLTEtODY3MDk_fcf2c61f-9df4-470f-a0ce-943e1ba5275e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjUtNi0xLTEtODY3MDk_e90693bd-593e-4023-9392-f20e35388d6e">7,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjYtMi0xLTEtODY3MDk_5f779ffb-1dbc-4748-85b9-3433e7b94098">8,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i80fc52680e63461a82201650861575d2_I20210930" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjYtNC0xLTEtODY3MDk_dbee3d5c-39ea-4f60-b24c-e991419da1d1">89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjYtNi0xLTEtODY3MDk_4278df63-30b5-456a-9f0e-04635e371dd6">8,195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfDebtSecuritiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTUwMzk_ae9f0242-1f66-4d8d-b4e3-6bb11c9da6c4" continuedAt="i9b0e21e865804499a8d7b9e84bba1a90" escape="true">Senior secured term loan facility and warrants</ix:nonNumeric></span></div><ix:continuation id="i9b0e21e865804499a8d7b9e84bba1a90" continuedAt="i221cbc536b5d45859f8aa7cfe79d391e"><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company, ADCT UK and ADCT America entered into the Loan Agreement, pursuant to which the Company may borrow up to USD <ix:nonFraction unitRef="usd" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="-5" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQwMA_ae50cacc-2020-40b4-99fe-151d696359ea">175.0</ix:nonFraction>&#160;million principal amount of secured term loans, including (i) a First Tranche and (ii) Future Tranches. On August 15, 2022, the Company drew down USD <ix:nonFraction unitRef="usd" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQxNQ_f6c81123-7838-42b0-9620-575c90900a63">120.0</ix:nonFraction>&#160;million principal amount of term loans under the Loan Agreement. The secured term loans are scheduled to mature on August 15, 2029 and accrue interest at an annual rate of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secured overnight financing rate (SOFR) plus <ix:nonFraction unitRef="number" contextRef="ib0f3a3c6371f4c089828c4cce5d73dd3_I20220815" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMwMg_1f3e9233-bd4c-41dc-8f9d-14f4960839f6">7.50</ix:nonFraction>% per annum (with respect to SOFR loans) or a base rate plus <ix:nonFraction unitRef="number" contextRef="ie6f2ae527c2944308bb08da4da7ab273_I20220815" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMwOQ_b96b797b-c402-475a-ba7d-427d7b1c46bc">6.50</ix:nonFraction>% per annum (with respect to alternative base rate ("ABR") loans) for the first five years of the term loans, and thereafter, at an annual rate of SOFR plus <ix:nonFraction unitRef="number" contextRef="ie4435c71c4fa4639bb03f664766ee514_I20220815" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMxNg_a5ab7a61-4251-4bb7-83ef-b3ee47c5b650">9.25</ix:nonFraction>% (with respect to SOFR loans) or a base rate plus <ix:nonFraction unitRef="number" contextRef="i35e15f9b287246acba0bdc6c93bd00b7_I20220815" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMyMw_06c5cd4c-1092-495b-8a07-012fe5c3fd45">8.25</ix:nonFraction>% (with respect to ABR loans), in each case subject to a <ix:nonFraction unitRef="number" contextRef="iaf3da50e0c50456c822d82239d1251be_I20220815" decimals="3" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMzMA_19f68fc6-3974-4ccd-9ab0-09317046b815">1.00</ix:nonFraction>% per annum SOFR floor. The Company has the option to elect for the loans to be either a SOFR loan or ABR loan. The Company has elected the First Tranche of the secured term loan to be a SOFR loan. Interest is paid on the last business day of each quarter.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is obligated to pay certain exit fees upon certain prepayments and repayments of the principal amount of the term loans in an amount ranging from <ix:nonFraction unitRef="number" contextRef="if31c404deeed4a629f5368280fa99dd7_D20220101-20220930" decimals="3" name="adc:BorrowingsFacilitiesExitFeePercentage" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDk0Ng_8f85ae70-958b-4834-9878-de84aa1cf56e">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i98de5d1ddb2243a1b01f6acc1c57c72e_D20220101-20220930" decimals="3" name="adc:BorrowingsFacilitiesExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM1MQ_0e15c1f0-a21e-484f-a45f-7ea3637820b9">4.0</ix:nonFraction>% of the amount of the loan so paid. In addition, The Company has the right to prepay the term loans at any time subject to certain prepayment premiums applicable until the August 15, 2026. The Loan Agreement also contains certain prepayment provisions, including mandatory prepayments from the proceeds from certain asset sales, casualty events and from issuances or incurrences of debt, which may also be subject to prepayment premiums if made on or prior to August 15, 2026. The obligations under the Loan Agreement are secured by substantially all of the Company's assets and those of certain of the Company's subsidiaries and are guaranteed initially by the Company's subsidiaries in the US and the UK. The Loan Agreement contains customary covenants, including a covenant to maintain a balance at the end of each quarter of at least USD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-5" name="adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMzNw_179e730a-434b-4f27-aec9-06135fbb8b5e">60.0</ix:nonFraction>&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the original invoice therefore, and negative covenants including limitations on indebtedness, liens, fundamental changes, asset sales, investments, dividends and other restricted payments and other matters customarily restricted in such agreements. The Loan Agreement also contains customary events of default, after which the term loan may become due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults (including creation of any liens other than those that are expressly permitted), bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the Company and its subsidiaries and change in control.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company also issued to the lenders under the Loan Agreement warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9e5a1305a7604d6e87bd11283adef044_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM1Nw_214d94f2-a83e-4a1b-a3a1-54069456c106">527,295</ix:nonFraction> common shares, which warrants have an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM2Ng_517fe607-a614-427b-b714-43cbd045a9d5">8.30</ix:nonFraction> per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to August 15, 2032. The warrants contain customary anti-dilution adjustments and will entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for First Tranche of senior secured term loan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the First Tranche of the senior secured term loans and the warrants described above</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hybrid financial instrument, with the USD <ix:nonFraction unitRef="usd" contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM3Mg_11c23fe1-9b0d-4119-a31d-9c0dae7a3459">120.0</ix:nonFraction>&#160;million draw down separated into two components</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a warrant obligation and a loan. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligation, using the Black-Scholes option-pricing model. <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQyOQ_2b39a4e4-a359-44c4-bbb9-ba087de56fbe" continuedAt="i24f5f722e19e4448a563baa2e959aa84" escape="true">The warrant obligation has been recorded at an initial fair value of USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:WarrantObligationFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM4Nw_2bb64b84-8b3d-45b2-af6e-db7d96499b1c">4.0</ix:nonFraction>&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:</ix:nonNumeric></span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i221cbc536b5d45859f8aa7cfe79d391e" continuedAt="ic693fa79a19144f191ce0b81f52d970c"><div style="padding-left:18pt;text-align:justify"><ix:continuation id="i24f5f722e19e4448a563baa2e959aa84" continuedAt="id237f74c683c42d299defaa47b741090"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:80.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i77b99ef7cc0b4e7ab11c5073c019b286_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfMi0xLTEtMS0xMDMwMjQ_74a52c6f-11be-4155-b14e-a514ea1c5fc0">8.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i31f57aba65894b669b8fadd39cc8a133_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfMy0xLTEtMS0xMDMwMjQ_23249f69-9661-4d04-856a-30733b8973b9">10.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i89faf473a32b42bd935a511f8ee7a191_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNC0xLTEtMS0xMDMwMjQ_00d94064-3f3b-41c8-9236-c082015154d1">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="iff9bc94da04d47ae9a9b849234ad3c6e_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNS0xLTEtMS0xMDMwMjQ_61eda9ef-1d1f-4db6-b1da-e6e0a0095c27">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="icb8358f51a2445159e899b48be721e8d_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNi0xLTEtMS0xMDMwMjQ_b847ed58-da70-4100-a984-6af565e2c5ae">60</ix:nonFraction> months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i9091a412696c4780b52173364c99f1bd_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNy0xLTEtMS0xMDMwMjQ_9ba0674a-ef2e-4942-8a59-5b74981a38ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i0d4e15e2a100434397a55b4e43e929c3_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfOC0xLTEtMS0xMDMwMjQ_91cd84d7-c655-4cab-9011-b64b23ec2b51">7.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan&#8217;s initial fair value was recorded at USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:BorrowingsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQzMQ_7615f518-b2c4-4f74-b99c-300eda53f675">116.0</ix:nonFraction>&#160;million on August 15, 2022, representing the residual amount of the USD <ix:nonFraction unitRef="usd" contextRef="iea17a01e38b140129bf22b46808b9404_I20220815" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ1OQ_6dd9ffb5-9a90-467c-92ad-b962b0caa0d9">120.0</ix:nonFraction>&#160;million draw down, after separating out the initial fair value of USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:WarrantObligationFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ0Ng_f06831c5-b9da-4a8d-a889-f17ee573ca8d">4.0</ix:nonFraction>&#160;million of the warrant obligation. The loan is subsequently measured at its amortized cost. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ3Mw_c98ca6c4-9cff-42c6-81b2-99a50569d7f4" continuedAt="i4a4dcc19b7074c0098d37ee857b83490" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:38.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">in KUSD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Warrant obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Loan Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonFraction unitRef="usd" contextRef="id0d75589019241a5b049c49c03ebd9c4_I20220930" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMS0yLTEtMS0xMDMwMTQ_08405a7d-3462-416b-b957-224a1fbc3b09">3,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonFraction unitRef="usd" contextRef="ieed9dd529b364aa5a0dfd1de03035963_I20220930" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMS00LTEtMS0xMDMwMTY_cca17efb-ee03-4ee9-b81d-0b3238665c3c">116,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonFraction unitRef="usd" contextRef="idda45a536b784d9a83b51c5690223542_I20220930" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMS02LTEtMS0xMDMwMTg_260a6d15-a7f7-4203-a70c-a64db269114b">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(<ix:nonFraction unitRef="usd" contextRef="i9df49cf53777407aaff962bcab6cbb00_I20220930" decimals="-3" name="ifrs-full:Borrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMi0yLTEtMS0xMDMwMTQ_57722ae6-841d-4bff-991e-0f316a2e1240">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(<ix:nonFraction unitRef="usd" contextRef="ida5b2446ccaa4c5c85766d73baef671b_I20220930" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMi00LTEtMS0xMDMwMTY_59314fb8-e547-4b70-9cbe-4bd0d95b6b19">7,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(<ix:nonFraction unitRef="usd" contextRef="id9114014f71e4e669763623118aa0ba8_I20220930" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMi02LTEtMS0xMDMwMTg_eb05e36a-1ec7-4f29-b307-ccae33e33fae">7,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Carrying value of loan at issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"><ix:nonFraction unitRef="usd" contextRef="i0581d534bc684ee0bee89a6945a375ad_I20220930" decimals="-3" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMy00LTEtMS0xMDMwMTY_f9325eaa-edac-4644-bbd4-cc6c065adee8">108,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oak Tree and Owl Rock Warrant Obligations</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company recognized income of KUSD <ix:nonFraction unitRef="usd" contextRef="ibcfcf3a44f2c4765be8da06698d39b1c_D20220101-20220930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfNTQ5NzU1ODY3NzIy_90baa370-d401-48a5-994b-f68f16fea3e2">2,543</ix:nonFraction> as a result of changes in the fair value of the warrant obligations from the issuance date of August 15, 2022. The fair value of the warrant obligations as of September 30, 2022 was KUSD <ix:nonFraction unitRef="usd" contextRef="i328f49717bbc4a43869005d9a11ccde6_I20220930" decimals="-3" name="adc:WarrantObligationFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfNTQ5NzU1ODY3NzMy_921da4cf-38ed-4a34-b775-7bff8bf72b58">1,414</ix:nonFraction>. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period, which was recorded directly to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="id237f74c683c42d299defaa47b741090" continuedAt="i70fb4ac0a93a406c9227534b6609ab48"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:80.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i552db3596e754dcaac31cd578b8a44be_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfMi0xLTEtMS0xMDMwMjE_7a51bcf8-0545-400a-95bf-4168e4a0c7d4">8.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i4d4202329f3c4f6f8e9950a5e0783159_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfMy0xLTEtMS0xMDMwMjE_f2be3425-7e46-410f-b084-62b9f1cdc3ec">4.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i63733b9453004d72806e33eea5e62eb1_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNC0xLTEtMS0xMDMwMjE_2c086aff-2f3c-4e26-856d-d15f4545643d">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="ia734cd26f3504a1883266d439ca95b0d_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNS0xLTEtMS0xMDMwMjE_d0e7aa91-fe0f-4a40-bfdc-109a936dd9bb">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="ic29dc84c1b3c4a498fd95b9388f8e481_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNi0xLTEtMS0xMDMwMjE_e27135ad-ed09-4454-9ebb-3e805070880b">58.5</ix:nonFraction> months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i07af9d83010848bb8b52ef3ad5f34f34_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNy0xLTEtMS0xMDMwMjE_d15f2fa6-2ce3-495f-b8f8-923f87d7e0c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i03d2b5b155c54c47aefdb36bca46343a_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfOC0xLTEtMS0xMDMwMjE_9e2e3c8c-a8c1-4c99-bd0a-14cf266e6e1e">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Term Loan</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As illustrated in the table above, the transaction costs of the residual loan (net of the fair value of warrant obligations) were deducted from the loan to determine the deemed net present value as of August 15, 2022 of all future cash outflows associated with the loan. The implied EIR that would be needed to increase the book value of the loan to cover all future expected outflows, taking into account the deduction of transaction costs from the initial loan balance, and based on a 360-</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="ic693fa79a19144f191ce0b81f52d970c" continuedAt="if73bc6062b694a858f3c3d2e3821edc7"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day year for a SOFR loan, was computed at inception at <ix:nonFraction unitRef="number" contextRef="if1d37dac85a149669ce03adcbf4ccc8e_I20220815" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ3Ng_cb860f0f-fe5a-4987-88d8-a46b4231b085">14.99</ix:nonFraction>%. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. For the three and nine months ended September 30, 2022, the Company recorded interest expense on the senior secured term loan in the amount of KUSD <ix:nonFraction unitRef="usd" contextRef="icf3fa17cff6e42feb53051b533840f31_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTY0OTI2NzQ5NTU2OQ_3e9b10d5-8fce-4b36-8bad-5806cfe2f55b"><ix:nonFraction unitRef="usd" contextRef="i13ee928b02464d82ab56ff3cd45a2c59_D20220701-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTY0OTI2NzQ5NTU2OQ_e12003c9-9009-4125-b2db-01863aef8b36">1,933</ix:nonFraction></ix:nonFraction> which was recorded in Financial expense in the unaudited condensed consolidated interim statement of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount at which the senior secured term loan is presented as a liability in the unaudited condensed consolidated interim balance sheet represents the net present value of all future cash outflows associated with the loan discounted at the EIR. The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability in the unaudited condensed consolidated interim balance sheet. The carrying value of the senior secured term loan was USD <ix:nonFraction unitRef="usd" contextRef="ibd2e5e5704574aebbaa2380a7fde3845_I20220930" decimals="-5" name="ifrs-full:Borrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfNTQ5NzU1ODY3NzUx_4dcf7a87-bf6e-4a5a-8ade-72f4b7c35efc">109.2</ix:nonFraction> million as of September 30, 2022, of which USD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-5" name="adc:ShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDkyNg_3ac63800-0e77-413b-9126-2ac5be13f0c2">12.5</ix:nonFraction> million and USD <ix:nonFraction unitRef="usd" contextRef="ibd2e5e5704574aebbaa2380a7fde3845_I20220930" decimals="-5" name="ifrs-full:LongtermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDkzNA_b742eae0-138c-41dc-a033-4e73f6a933df">96.7</ix:nonFraction> million represented the short-term and long-term portion of the liability, respectively. </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_362"></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:continuation id="if73bc6062b694a858f3c3d2e3821edc7" continuedAt="ib25b59d45b48435a9d5eaa2a7878ba50">Convertible loans</ix:continuation></span></div><ix:continuation id="ib25b59d45b48435a9d5eaa2a7878ba50" continuedAt="i7b36add201aa4bb3a2c1ce1a73c0e189"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Company entered into a USD <ix:nonFraction unitRef="usd" contextRef="i0957db7bd16a421a88aa3e02e84a59f4_I20200424" decimals="-6" name="adc:BorrowingFacilitiesMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY3OTY_6c976752-5871-4137-b0be-68a9810b6609">115</ix:nonFraction>&#160;million Facility Agreement with Deerfield, pursuant to which Deerfield extended a tranche of USD <ix:nonFraction unitRef="usd" contextRef="i1dba557902d64fd2b341f02674834b60_I20200424" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4MDk_f6d9f261-a1e6-4ba9-9072-5dea30843112">65</ix:nonFraction>&#160;million of convertible loans on May 19, 2020 upon completion of the Company&#8217;s initial public offering (the &#8220;Deerfield First Tranche&#8221;) and a tranche of USD <ix:nonFraction unitRef="usd" contextRef="idd6e0c7ae1fc42dabeef85f1e367666d_I20200424" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4MjE_1fc2e4fc-a3eb-4121-ae7b-854884ed36ac">50</ix:nonFraction>&#160;million of convertible loans on May 17, 2021 after the receipt of regulatory approval for ZYNLONTA (the &#8220;Deerfield Second Tranche&#8221;). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:ExchangeOfConvertibleNotesForWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4NzA_ca6f3733-7206-4dc1-b2bd-8f220533a15f">115.0</ix:nonFraction>&#160;million aggregate principal amount of the Company's senior secured convertible notes for warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4MzM_60e3a638-6976-45f8-8ce9-f019ce523ec3">4,412,840</ix:nonFraction> common shares, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i474416e45737460d849fb01685ad11e6_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4NTk_8be2e7ca-9519-4b84-9f1c-e6a3cdd54224">2,390,297</ix:nonFraction> common shares and cash equal to USD <ix:nonFraction unitRef="usd" contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815" decimals="-5" name="adc:ConvertibleNotesValueConverted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4NDQ_ff28ac57-a4d9-43e7-bdcb-45743ee767bc">117.3</ix:nonFraction>&#160;million. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement on August 15, 2022, the Company recognized a loss on extinguishment of USD <ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-5" sign="-" name="adc:GainsLossOnExtinguishmentOfBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzcxMzY_fbcf9fa8-6b8c-4524-b575-f21401792c7c">42.1</ix:nonFraction> million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Embedded conversion option derivatives</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the exchange, the Company accounted for the Facility agreement as a loan and embedded conversion option features. The embedded conversion option derivative was marked-to-market while the loan was measured at its amortized cost on a quarterly basis.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4ODQ_259ad9ee-3228-44a8-9a51-b5684c31153d" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in fair value income (expense) and profit or loss activity of the embedded conversion option derivatives during the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:44.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i4282540cb4d245d89cd058fd40102cd0_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtMi0xLTEtMTAyOTk0_f604b7c8-aadd-4a22-a1a1-fae4ad7d231e">2,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i4c1c3f7a35f3450ca62c6907d078e8e2_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtNC0xLTEtMTAzMDAw_101e2217-9fa3-4f87-a29c-d38584270305">3,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if1a8de23046f4460ad2c010b046624fc_D20220101-20220930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtNi0xLTEtMTAzMDAy_33a3cf71-bc2f-413d-8647-538aa10d82b1">15,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i424298b8a03c4c6291deae71a0a00390_D20210101-20210930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtOC0xLTEtMTAzMDA0_7d803a0e-847c-4106-b21f-52b43b1aa050">16,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - prior to FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8541b30e628240598a82d1a6e8ece81c_D20220701-20220930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtMi0xLTEtMTAyOTk0_f9010412-b3cd-4537-9808-4cf601992aea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i510177f707e04303ad7498a272eb89fe_D20210701-20210930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtNC0xLTEtMTAzMDAw_ebf395f8-6c78-42b9-b4eb-4026f66b6a97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i5bfbbc2c610147c3a34fba908fd852ec_D20220101-20220930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtNi0xLTEtMTAzMDAy_0da66489-830e-4a5b-96c9-a4d33d859730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i47d31600d9f0428d8b62b78002cda536_D20210101-20210930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtOC0xLTEtMTAzMDA0_012ec193-2074-4a9a-9286-6adf0adfd09f">3,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - after FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i78bbf9c8e62844d986598b81c243a4e8_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtMi0xLTEtMTAyOTk0_e6bb35f5-8146-4124-a8a9-b73eacca89b7">1,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i30f2235b8f984b71a72137b6c9c711ed_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtNC0xLTEtMTAzMDAw_2700c87a-0648-485a-96a0-827a3abf3ecf">3,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="iff0912cb42094f0b8c2cf9d89bea012a_D20220101-20220930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtNi0xLTEtMTAzMDAy_8ec4eaea-712a-49ce-bc56-7b7d7843c948">10,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i52bdc445f4e04e91a6b705a99bc90fa5_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtOC0xLTEtMTAzMDA0_2e70afa2-d24b-42b7-9044-d12471302435">4,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctMi0xLTEtMTAyOTk0_33781565-64a9-447c-af9b-dd6c5a7b401d">4,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctNC0xLTEtMTAzMDAw_030ccde9-c3f5-4cd1-acf5-0c2cb98ba3cc">6,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctNi0xLTEtMTAzMDAy_4e78083b-cb02-44f0-ac98-b7edba819deb">25,650</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctOC0xLTEtMTAzMDA0_725779d7-677f-4122-946c-e96d5fc94b74">16,279</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value expense recognized during the three and nine months ended September 30, 2022 represents the change in fair value up until the point of exchange on August 15, 2022.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the changes in fair value, the Company recorded a gain of KUSD <ix:nonFraction unitRef="usd" contextRef="i025881af419e4a3192fb9cf499462a5f_D20210101-20210930" decimals="-3" name="ifrs-full:GainsOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzcxMTk_aa6e8652-b08b-4e7a-84d0-26980741ce9e">1,816</ix:nonFraction> during the nine months ended September 30, 2021 with the receipt of the USD <ix:nonFraction unitRef="usd" contextRef="iff062fd0475a492786d931f7f5c45f6e_I20210930" decimals="-6" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzcxMDc_9cd18f0c-a6df-4def-bcc1-91fdf6fb5bd2">50</ix:nonFraction>&#160;million subsequent disbursement, the establishment of the embedded derivative and residual loan associated with the subsequent disbursement and elimination of the derivative immediately prior to FDA approval of ZYNLONTA.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases (decreases) in fair values of the embedded derivatives are primarily due to increases (decreases) in the fair value of the underlying shares during the respective periods. These amounts were charged directly to the unaudited </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i7b36add201aa4bb3a2c1ce1a73c0e189"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated interim statements of operations. See note 8, &#8220;Non-operating (expense) income&#8221; for further information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative associated with the Deerfield First Tranche was KUSD <ix:nonFraction unitRef="usd" contextRef="i82d563da995d45569288f830e5149dfb_I20220815" decimals="-3" name="ifrs-full:CreditDerivativeFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4OTU_ab7049bd-b360-48dd-b90c-e34f33df5003">7,670</ix:nonFraction> at the time of exchange on August 15, 2022 and KUSD <ix:nonFraction unitRef="usd" contextRef="i2b7c1b8716664d0c8a84d93d75702409_I20211231" decimals="0" name="ifrs-full:CreditDerivativeFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4ODc_3b182a37-0523-42f4-9c27-5aa1a7d4fab2">23,226</ix:nonFraction> on December 31, 2021. The fair value of the embedded derivative associated with the Deerfield Second Tranche was KUSD <ix:nonFraction unitRef="usd" contextRef="i0a3bdac45860479dabcb75dfdd6867f4_I20220815" decimals="-3" name="ifrs-full:CreditDerivativeFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY5MDI_7e4630c3-d719-472a-8e57-1c8fe364342b">4,627</ix:nonFraction> at the time of exchange on August 15, 2022 and KUSD <ix:nonFraction unitRef="usd" contextRef="i97aa7f5a5df243008d7ef0e4a3eb306e_I20211231" decimals="0" name="ifrs-full:CreditDerivativeFairValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY5MDk_da53f6b1-49e3-48d0-a22e-5c066d01edd0">14,721</ix:nonFraction> as of December 31, 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield First Tranche and Deerfield Second Tranche of the embedded conversion option derivatives, which is based on the mean of values derived from application of the Hull and Goldman Sachs convertible bond pricing models. <ix:continuation id="i70fb4ac0a93a406c9227534b6609ab48" continuedAt="ief117518a2954c27aceb136518c4061e">Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:</ix:continuation></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="ief117518a2954c27aceb136518c4061e"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield First Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:59.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price at <ix:nonFraction unitRef="number" contextRef="if1a8de23046f4460ad2c010b046624fc_D20220101-20220930" decimals="2" name="adc:BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMC0xLTEtOTM3MjMvdGV4dHJlZ2lvbjplOWMxNjNiMzM5ZTU0OTM0YTE1MTU4NzY2M2ZhNDI5Y18yMg_07bcc5d6-2985-4d8f-af9c-29e880c9238d">130</ix:nonFraction>% of the IPO price of <ix:nonFraction unitRef="usdPerShare" contextRef="ic3d81122c2c840e4b693968f8c508748_D20200519-20200519" decimals="INF" name="adc:OfferingPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMC0xLTEtOTM3MjMvdGV4dHJlZ2lvbjplOWMxNjNiMzM5ZTU0OTM0YTE1MTU4NzY2M2ZhNDI5Y180NQ_71e7d73d-b0f3-4860-a38c-7efb66422384">19.00</ix:nonFraction>, in USD</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i710642318daa4f7daf7095ef7f4be22a_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMS0xLTEtMTAyODU3_36d5541d-a10b-40bc-b020-5948bce548b8">24.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="id466e5c2487a4ac1b5b6504272a8f609_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMy0xLTEtMTAyODU3_55708dec-2cf5-4597-ac96-197ed18716c0">24.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="iac273354477741cf86e47def8ffcd7a1_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzMtMS0xLTEtMTAyODU3_be87a916-ba5a-4f2f-a555-071d19dffae6">67.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99f4af969dd2458582b9d874b88cbbf4_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzMtMy0xLTEtMTAyODU3_9912e479-dd34-40c1-9b13-72f4d636147d">67.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8931b5a8351240ac87b0246c2abe8dd9_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzQtMS0xLTEtMTAyODU3_f4c93a22-7769-413b-90a3-df30af8d6fa9">10.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d8669ba09764fbb9a618a4a6edae470_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzQtMy0xLTEtMTAyODU3_1cdd4fb3-2d23-4169-8edb-65f7af1a87a7">20.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="ic9928a9264d740c89377de3cdebcd1e5_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzUtMS0xLTEtMTAyODU3_040cf785-0dfa-4136-aea1-a1664b32cd16">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i7c66eb70f2894de98ed215565f60df64_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzUtMy0xLTEtMTAyODU3_00d763d3-1c6c-42e4-8e68-8070f9c88006">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i9de9014907024e3189eac77111a06a63_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzYtMS0xLTEtMTAyODU3_5686cadd-625e-4ea4-a604-89ae941cc0a9">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i45da12590d9f4047b6bd3403ac33f3c7_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzYtMy0xLTEtMTAyODU3_5419cd98-83aa-4a69-b604-bce4142a56f6">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="period" contextRef="i3ef057b084c9401b842b0fe5bdd4e853_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzctMS0xLTEtMTAyODU3_00217663-ec2c-447d-8ee3-3ffb144a696f">32.5</ix:nonFraction> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="period" contextRef="i3f8646e19d5e4d45b7ef56c2360fcbc8_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzctMy0xLTEtMTAyODU3_b2aa0f4b-67af-4cba-8940-02773c989f70">40</ix:nonFraction> months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i86670cf410ee493e8877ad4c966d0671_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzgtMS0xLTEtMTAyODU3_8ebef965-002b-4e98-96a4-98fda59f33f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i2b3ec2e705764730bd7acdc7796976e0_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzgtMy0xLTEtMTAyODU3_8319557e-df8c-4dd5-ac5a-8185592f99b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="ib148dbac37274e269a90f2f14e60f877_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzktMS0xLTEtMTAyODU3_7eb16de3-d751-4980-b612-2745100f724f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i090c3d455bb74e6281428f2f07643108_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzktMy0xLTEtMTAyODU3_027446b4-6786-4b7b-86fb-4eb61899659c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i4f702cd53b354e9881252bcbf57c2f1c_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzEwLTEtMS0xLTEwMjg1Nw_2e342264-08f7-457e-a5b3-e5cda609ab27">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="ic8afbb48cf2d48cfbd405ff609f28cc4_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzEwLTMtMS0xLTEwMjg1Nw_1bc947dc-762c-4fe2-aeb9-b320f9088fe1">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Second Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:54.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56eace5f28ad4674b7f788baea9f47e8_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzItMi0xLTEtMTAyODU5_cf9d877f-f879-4b74-8392-99a21546ceb8">28.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i63e9f713f46b436eb737b72a7e01713b_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzItNC0xLTEtMTAyODU5_69db7540-eeef-4693-a91b-90e45a8fab45">28.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibffd8b0c78d841a5a370b35fad8ace99_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzMtMi0xLTEtMTAyODU5_601df330-3f1d-486c-827d-73a35d3deb59">77.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03318851c1c0465f8efb9f6dbe913d26_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzMtNC0xLTEtMTAyODU5_f8ca0186-b8d6-48b2-8865-a9b47332732a">77.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ef20d84bc4a4f9589901030b1ae9dde_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzQtMi0xLTEtMTAyODU5_054c54e6-43a9-4910-9ed9-6348fd69da2e">10.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20780f1e715242878284103f33e5a95b_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzQtNC0xLTEtMTAyODU5_cc9df8e3-af72-42eb-95d4-d5a09a9eab2b">20.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i0d107c4c0c244c4986cf5e94e684cfa3_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzUtMi0xLTEtMTAyODU5_d7a0cb58-c7cc-41a6-b30b-b1fee732f2df">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i1b8a345318c14c5cb9e3dd2c0e1b53e6_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzUtNC0xLTEtMTAyODU5_195fa227-c2df-4276-b083-4c73d3ff24de">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i7cc325fcfe32426097e9538a2b3302b5_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzYtMi0xLTEtMTAyODU5_4cf2da01-d72e-401f-b5e5-a091d2620841">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i7b376657412246a595f43060ab7c5581_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzYtNC0xLTEtMTAyODU5_2dbc372d-68d5-4c49-8f48-a8285a51ffda">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="period" contextRef="i379eff6d11204554bf233766e8da501f_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzctMi0xLTEtMTAyODU5_3119714d-5f57-435b-a35d-5441a6378c1d">32.5</ix:nonFraction> months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="period" contextRef="ia13a616afebd445f954de55db94ff515_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzctNC0xLTEtMTAyODU5_cfc6dda5-6465-40d1-8554-ba2a0a06dc8b">40</ix:nonFraction> months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i7c15e42527ff44a3a5c93c9c96208bcf_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzgtMi0xLTEtMTAyODU5_c81614b5-1afa-40cf-9c54-5272cdc054a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i19368979b8a145d5a6a63e3b0d6e8636_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzgtNC0xLTEtMTAyODU5_da8a18a2-affa-4c32-95d7-ac84c5a80ee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="ic268075c47794e01a968504730a874e2_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzktMi0xLTEtMTAyODU5_64e89cd6-63b0-4d99-856a-1f340bf2743d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i35e5cd27137b4e10b214c3577489cc0c_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzktNC0xLTEtMTAyODU5_31d0117c-7125-4c92-ad58-7d970ee843bb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="ia5c4b1a0cc67448cbc5473e914944c11_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzEwLTItMS0xLTEwMjg1OQ_303ca624-0944-4620-82a5-cf9ea8ae8631">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="ic4621be8061f40f29a22f85bd1a3ce97_I20211231" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzEwLTQtMS0xLTEwMjg1OQ_a45104a7-ea70-431b-898d-d206457cfa7d">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Residual convertible loan</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="i4a4dcc19b7074c0098d37ee857b83490" continuedAt="i1555dc66c34f44449d2b2d4c6e11fc0f"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:44.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.768%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3bb83ca124504d81bae6bd67b59bdcad_D20220701-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtMi0xLTEtMTAzMDA2_08b6bfd8-a741-447a-b9c8-8980a2e8e3ab">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i8696a50af25a4d5698814222277a2b26_D20210701-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtNC0xLTEtMTAzMDA4_36bd452a-d4a7-44f2-8f83-c9f3e96ddecb">2,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i71dfb6d248ff4198a8951d34e0f3e61b_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtNi0xLTEtMTAzMDEw_b858f470-7e31-4c6f-9557-6894f690af31">5,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i9f2027858cad46a39efcfcb65c359818_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtOC0xLTEtMTAzMDEy_d9f33fc6-6609-44e6-924a-e31e42f4ba40">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i0eb58365b3f6457d8705fd6e8d0e13d4_D20220701-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtMi0xLTEtMTAzMDA2_15d8e4b1-a316-4f88-91ae-73ce40938c46">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ie7aa01b4ce9b4ddf9ea12f4230135446_D20210701-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtNC0xLTEtMTAzMDA4_dd6b77a7-81a0-4b69-b6e2-7370c4e548a0">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ica385bd851294fa8a39c826b2ecb7376_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtNi0xLTEtMTAzMDEw_88d8688a-5e16-4ba2-a21b-d523815c5f81">2,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="iad41e5db92cf4b05819e5ee0b2c622f0_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtOC0xLTEtMTAzMDEy_8b0e6a85-d527-42a7-a304-c2e3bcfd35a7">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i785f01a211a243bda6e912eb3ec1e0a2_D20220701-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtMi0xLTEtMTAzMDA2_5db50011-e17d-4373-9e9d-ee95862e2072">1,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="ib977e7d27b6240c08c35a9a983b92e2b_D20210701-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtNC0xLTEtMTAzMDA4_10fbf0c8-6e6b-4b8a-ab2d-068fdf0caef7">2,961</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i22eebd39c0444c7a8b3ec579b6376df0_D20220101-20220930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtNi0xLTEtMTAzMDEw_0c8ce6af-8cf4-44a2-a796-fe698fd7a466">7,684</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id5dfc30cca8047389598bb92059469df_D20210101-20210930" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtOC0xLTEtMTAzMDEy_e5f4153c-1b89-4805-b61e-bf7b02d785e6">7,393</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_368"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfWarrantsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNjU_b03925a8-8aa2-4563-8622-6f07028f9ea1" continuedAt="i58beb137287e449a8565f8e6810bc9f0" escape="true">Deerfield warrants</ix:nonNumeric></span></div><ix:continuation id="i58beb137287e449a8565f8e6810bc9f0"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMjI_d685211e-59bd-4bc6-90b5-9af4ac6bc440">4,412,840</ix:nonFraction> common shares. The warrants consist of warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMzM_00c58b73-adeb-476c-b40a-ec09badc62ae">2,631,578</ix:nonFraction> common shares at an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="i7754055a3c2b48f1973108a8654c2f44_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMDQ_d5673c0c-dbd7-46b3-a3d8-1c4c169fe209">24.70</ix:nonFraction> per share and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMTE_2c65e2bd-d4ea-44b5-a3bb-bca05e453b56">1,781,262</ix:nonFraction> common shares at an exercise price of USD <ix:nonFraction unitRef="usdPerShare" contextRef="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815" decimals="2" name="adc:WarrantsSharesConvertedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNDQ_20464735-f538-451e-8169-ae993135e7e1">28.07</ix:nonFraction> per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder, at any time on or prior to May 19, 2025. The warrants contain customary anti-dilution adjustments and entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. Each holder also may require the Company to repurchase the warrants for their Black Scholes-based fair value in connection with certain transformative transactions or change of control of the Company that occur prior to their expiration.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the warrants are reflective of the terms of the embedded conversion option features of the Deerfield Facility Agreement prior to the Exchange Agreement. As a result, the fair value of the warrants was determined to approximate the fair value of the existing embedded conversion option features immediately prior to the consummation of the Exchange Agreement. As such, the warrant obligation was recorded at an initial fair value of KUSD <ix:nonFraction unitRef="usd" contextRef="i6ecc2b598dba46c28662f729e6defde9_I20220815" decimals="-3" name="adc:WarrantObligationFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNTE_5d12856d-cccd-4b5b-96ba-55de46a90f84">12,297</ix:nonFraction> on August 15, 2022. Subsequent to issuance, the warrant obligation will be remeasured to fair value on a quarterly basis. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company recognized income of KUSD <ix:nonFraction unitRef="usd" contextRef="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930" decimals="-3" name="adc:GainsLossOnChangeInFairValueWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzU0OTc1NTgxOTMwOA_e7a9b90a-5833-4039-bfef-d24bbe40a786">9,418</ix:nonFraction> as a result of changes in the fair value of the warrant obligation. The fair value of the warrant obligation as of September 30, 2022 was KUSD <ix:nonFraction unitRef="usd" contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930" decimals="-3" name="adc:WarrantObligationFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzU0OTc1NTgxOTEzMQ_a2a605bc-1259-4443-a090-9ab5a7af5015">2,879</ix:nonFraction>. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period. These amounts were recorded to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield warrant obligation, using the Black-Scholes option-pricing model. <ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNjQ_119280b9-f124-47ae-aeb5-5eb86b4f680a" continuedAt="ia0236995cd2e4d24a2dfd738bd81e984" escape="true">Key inputs for the valuation of the warrant obligation as of September 30, 2022 were as follows:</ix:nonNumeric></span></div><div style="padding-left:18pt;text-align:justify"><ix:continuation id="ia0236995cd2e4d24a2dfd738bd81e984"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:80.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia26abd4a41954e9e9346a99a9f049985_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzItMS0xLTEtMTAzNDczL3RleHRyZWdpb246N2UyY2MwN2YzMGI5NDRkMWFlNjU5ODU2ZDQxOWQ3Y2ZfMTA5OTUxMTYyNzgwMA_587da360-bb8b-4b21-9c97-ce62e5c7d13e">24.70</ix:nonFraction> and <ix:nonFraction unitRef="usdPerShare" contextRef="ieca945cdabd9410cbc9c13e7257adfb4_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzItMS0xLTEtMTAzNDczL3RleHRyZWdpb246N2UyY2MwN2YzMGI5NDRkMWFlNjU5ODU2ZDQxOWQ3Y2ZfMTA5OTUxMTYyNzgxMA_b91a893b-d674-4a1c-8a56-ede81288b23d">28.07</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i596a372cc69b47f19dc090d174f662f3_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzMtMS0xLTEtMTAzNDcz_c3ac645c-1ff8-4a0e-a9e2-96211938f1c7">4.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b3bb514320f434fb2c8f0bbf4378a14_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzQtMS0xLTEtMTAzNDcz_9cd3e0a8-0467-4d7f-b7a3-7f5917e0d78c">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i164cd50484d545a2af9114f0c1debbd9_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzUtMS0xLTEtMTAzNDcz_9c2a5a19-c699-4933-99ac-4cea8841dbc9">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i8f02e5be548f4f8dbc48b21e80389512_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzYtMS0xLTEtMTAzNDcz_bd738c74-5754-46d5-a14c-88ada9d242f8">31.7</ix:nonFraction> months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="period" contextRef="i7a71734534bd4767beb6925c131abf14_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzctMS0xLTEtMTAzNDcz_45bd2e6b-1ddf-49e0-8c5a-31b601c06156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i5908e3933d294f34ad3a587158cb41e9_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzgtMS0xLTEtMTAzNjE1L3RleHRyZWdpb246MDViMDZiNzgzZWM0NDVlNWE0MGFmODcyY2Y5YzExYTNfMTA5OTUxMTYyNzc5Nw_63ffcea2-02e8-411b-86bd-9b772c1b2f14">0.69</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i079987d8ff4843f5aa3402f23485ad3e_I20220930" decimals="INF" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzgtMS0xLTEtMTAzNjE1L3RleHRyZWdpb246MDViMDZiNzgzZWM0NDVlNWE0MGFmODcyY2Y5YzExYTNfMTA5OTUxMTYyNzgwNA_a77af946-2272-4c85-9931-d1d4e8e14540">0.60</ix:nonFraction></span></div></td></tr></table></ix:continuation></div></ix:continuation><div id="i648c8e1ac91b483eb52eb5061f8475ee_374"></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzM4NDgyOTA2OTkwMDM_428ea27c-7fab-458b-adf0-a3d837f046db" continuedAt="i85b95362c73c409daca93b8b7eb92a3b" escape="true">Equity</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85b95362c73c409daca93b8b7eb92a3b" continuedAt="i9910d03437744422a224bd59d978e2d6">On August 15, 2022, the Company entered into a share purchase agreement with the Purchasers, pursuant to which, on September 6, 2022, the Company issued and sold to the purchasers an aggregate of <ix:nonFraction unitRef="shares" contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1MTE_632e2bba-0d97-47f6-9a3c-7c136fd390dd">733,568</ix:nonFraction> common shares at USD <ix:nonFraction unitRef="usdPerShare" contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815" decimals="2" name="adc:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1MjA_946ddf21-fcea-4ef6-b525-d95f47abe1f0">8.52</ix:nonFraction> per share. The shares were issued from the Company&#8217;s treasury shares at par value, which arose from the Share Subscription Agreement. See note 2, &#8220;Basis of Preparation." The transaction was recorded as a USD <ix:nonFraction unitRef="usd" contextRef="ia6c9b855c1f247cdae6ad0bac21a2df8_D20220815-20220815" decimals="-5" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzM4NDgyOTA2OTg5OTE_15fc2076-35ee-4f93-a707-797fde694107">6.1</ix:nonFraction>&#160;million net increase to share premium for the issuance of the common shares, net of transaction costs accrued and paid, and an increase in cash and cash equivalents.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9910d03437744422a224bd59d978e2d6">The Company also recorded a USD <ix:nonFraction unitRef="usd" contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930" decimals="-5" name="adc:IssueOfEquityThroughExchangeAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1MjY_73fdc0f3-c463-4c6a-9a1f-67b417d4f02d">19.6</ix:nonFraction>&#160;million non-cash net increase to share premium for the issuance of the <ix:nonFraction unitRef="shares" contextRef="i474416e45737460d849fb01685ad11e6_D20220815-20220815" decimals="INF" name="adc:ConvertibleNotesSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1NDA_6457350e-e5ef-4c2d-85ce-fc669099ddc6">2,390,297</ix:nonFraction> common shares to Deerfield in connection with the exchange of the senior secured convertible notes. The shares were issued from the Company&#8217;s treasury shares at par value, which arose from the Share Subscription Agreement. See note 15, &#8220;Convertible loans&#8221; and note 2, &#8220;Basis of Preparation&#8221; for further information on this transaction and Share Subscription Agreement, respectively.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzM_f43fc059-a316-4257-b1bb-59b2165b529e" continuedAt="i6131a1bb4e154a5299d5868891108154" escape="true">Share-based compensation</ix:nonNumeric></span></div><ix:continuation id="i6131a1bb4e154a5299d5868891108154" continuedAt="i8cc64772a70d4075a054be36f3a4f853"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Incentive Plan 2019</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company adopted the Equity Incentive Plan 2019. Under the Equity Incentive Plan 2019, the Company may at its discretion grant to plan participants, such as directors, certain employees and service providers, awards in the form of restricted shares and restricted share units (&#8220;RSUs&#8221;), share options, share appreciation rights, performance awards and other share-based awards. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="i676dd5e5964f478cb2a4ee69ccbedc9c_I20191130" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzQ4MA_516f6046-3a28-4556-99c4-332f65107711">13,820,000</ix:nonFraction> common shares for future issuance under the Equity Incentive Plan 2019 (including share-based equity awards granted to date less awards forfeited). As of September&#160;30, 2022, the Company has <ix:nonFraction unitRef="shares" contextRef="i2afee1f6b2004f1493e2dcbd25a219d0_I20220930" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzY1Nw_af4d2898-713e-464a-97b1-03779d4a02bc">1,349,944</ix:nonFraction> common shares available for the future issuance of share-based equity awards. On March 7, 2022, the Company issued its annual equity award, which was approved by the Compensation Committee of the Board of Directors and consisted of <ix:nonFraction unitRef="shares" contextRef="i2d4b84bf34674d74a74743921df55fbc_D20210322-20210322" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4Xzg5Mg_6ed5de76-df6b-44c9-847a-c3d05e80a016">1,867,076</ix:nonFraction> share options and <ix:nonFraction unitRef="shares" contextRef="i554dfdb979b34373ae4b5733abf1276e_D20210322-20210322" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzkxMw_53abf8fa-e067-4b1a-86f3-c8274321fcfb">570,340</ix:nonFraction> RSUs. On May 11, 2022, the Company issued a special retention award to select employees, which was approved by the Compensation Committee of the Board of Directors and consisted of <ix:nonFraction unitRef="shares" contextRef="i99eeeb04107b4ce58f0f4c3600598f48_D20220511-20220511" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzEwOTc_076a5591-512d-47e3-9aaa-ba3e4f54ed52">1,298,700</ix:nonFraction> RSU's. As of September&#160;30, 2022, the Company has only granted share options, RSUs and performance awards under the Equity Incentive Plan 2019.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the cumulative amount recorded as an increase to Other Reserves within equity in the unaudited condensed consolidated interim balance sheet of the Equity Incentive Plan 2019 was KUSD <ix:nonFraction unitRef="usd" contextRef="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE0MjA_0b05eb0a-0aa2-40cb-b935-d077a3bc9481">137,759</ix:nonFraction>. An amount of KUSD <ix:nonFraction unitRef="usd" contextRef="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE0NDI_4f385df0-b8b2-4e0a-9a90-f2806c084fab">512</ix:nonFraction> was withheld for tax charges during the three months ended March 31, 2022. There were no amounts withheld for tax charges during both the three months ended September 30, 2022 and June 30, 2022. The amount of expense for all awards recognized for services received during the three and nine months ended September&#160;30, 2022 were KUSD <ix:nonFraction unitRef="shares" contextRef="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE2OTI_2fb6ab2a-ab15-42d3-a6c9-68a92c56eafc">14,565</ix:nonFraction> and KUSD <ix:nonFraction unitRef="shares" contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE3MDQ_7288592d-c396-4687-92b7-655b5acd88d3">42,293</ix:nonFraction>, respectively, and for the three and nine months ended September&#160;30, 2021 were KUSD <ix:nonFraction unitRef="shares" contextRef="i42b2f8cecf45438c8f21adf9eec38ecf_D20210701-20210930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE3NjM_2584bfac-9379-4ff5-8944-2da7a18f28bd">14,798</ix:nonFraction> and KUSD <ix:nonFraction unitRef="shares" contextRef="i03009233bf004bb08cea9b8dc88563c8_D20210101-20210930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE3NzU_4691d6b7-96e1-4161-a04f-3dce06696a8e">47,016</ix:nonFraction>, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Options</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity Incentive Plan 2019, the Company may grant share options to its directors, certain employees and service providers working for the benefit of the Company at the time. The exercise price per share option is set by the Company at the fair market value of the underlying common shares on the date of grant, as determined by the Company, which is generally the closing share price of the Company&#8217;s common shares traded on the NYSE. The awards generally vest <ix:nonFraction unitRef="number" contextRef="idfe39b129e824b348d51d6de645307b0_D20220101-20220930" decimals="INF" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_4535d92c-cafc-4cdf-bee7-0ebc2717c5d5"><ix:nonFraction unitRef="number" contextRef="i6a10848ed433473dacbefea93eb427b0_D20220101-20220930" decimals="INF" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_884233ce-5627-4454-b9ca-29470ea7e27d"><ix:nonFraction unitRef="number" contextRef="i2713424043c64085a64de9bf55b5640e_D20220101-20220930" decimals="INF" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_fc085a33-79d3-438c-83f8-1838a624ee54"><ix:nonFraction unitRef="number" contextRef="i52a52dd4005c426b875e0cc78e2afab5_D20220101-20220930" decimals="INF" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_fe9b7f10-24c1-4586-9ddf-6e9e2743b781">25</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent <ix:nonNumeric contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIzOTY_ff418baf-4d49-4b87-b662-c4c91a6da840">three years</ix:nonNumeric>. The contractual term of each share option award granted is <ix:nonNumeric contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930" name="adc:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzI0NTk_a20cccf6-fa0e-4316-8c57-a265fdc28b8c">ten years</ix:nonNumeric>. Under the grant, the options may be settled only in common shares of the Company. Therefore, the grants of share options under the Equity Incentive Plan 2019 have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company&#8217;s unaudited condensed consolidated interim statement of operations and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim balance sheet.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recognized for services received during the three and nine months ended September&#160;30, 2022 was KUSD <ix:nonFraction unitRef="usd" contextRef="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMxNDg_ca5b84ed-f294-486a-b54b-a340757660a3">8,193</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMxNjA_d8125196-6ba7-4e53-bd3e-fd0f8c3da484">27,158</ix:nonFraction>, respectively. The expense recognized for services received during the three and nine months ended September&#160;30, 2021 was KUSD <ix:nonFraction unitRef="usd" contextRef="i42b2f8cecf45438c8f21adf9eec38ecf_D20210701-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMyNjI_ae6cbec9-a394-4dcb-b646-6547f4fe9f4f">12,105</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="i03009233bf004bb08cea9b8dc88563c8_D20210101-20210930" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMyNzQ_bb5a33f7-d1fb-431e-bbc1-c19b8e3b9012">40,112</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzQ_4b405c5b-e1f9-461a-8d40-6e6027435371" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the share option awards outstanding as of September&#160;30, 2022:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:53.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Average strike price per share in USD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Number of awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted average remaining life<br/>in years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzEtMS0xLTEtODY3MDk_c4bdcd2f-c704-4c95-9e4d-cf83106d1dbc">27.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzEtMy0xLTEtODY3MDk_ec713a04-285d-4175-a851-18151d364793">6,640,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzEtNS0xLTEtODY3MDk_5759370c-8f5a-4040-a416-e18844eb9a09">8.70</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzItMS0xLTEtODY3MDk_24d8805e-0f8c-46f0-9b7c-ec61898214f4">12.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzItMy0xLTEtODY3MDk_aa98b97d-56a9-4917-af4a-e12ca344bd56">3,937,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:WeightedAverageRemainingContractualLifeOfGrantedShareOptions" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzItNS0xLTEtODY3MDk_6f1eef89-5014-4261-ba7d-4d5296de16c8">9.39</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzMtMS0xLTEtODY3MDk_5c6c93bf-fc7b-4710-acde-b6924e861119">26.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="shares" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzMtMy0xLTEtODY3MDk_86c45467-ca14-49a7-ab4b-2d39cdfbb7ee">820,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzYtMS0xLTEtODY3MDk_f577c67b-d0a5-45d6-a2c4-ab5e84caea02">21.23</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzYtMy0xLTEtODY3MDk_5ee6ba91-0cb9-4852-91ca-19775d64a9ab">9,757,225</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzYtNS0xLTEtODY3MDk_8698aa6c-2d7e-45d4-b42f-bc3f61870e1f">8.39</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards outstanding as of September&#160;30, 2022 and December&#160;31, 2021, expire through 2032 and 2031, respectively. The options granted during 2022 include the Company&#8217;s annual equity award discussed above. The grant-date fair value of the options relating to the annual equity awards was USD <ix:nonFraction unitRef="usdPerShare" contextRef="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930" decimals="2" name="adc:WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM2MDM_d6a201c3-9cf7-4fd0-ac03-6359973aec3e">8.85</ix:nonFraction> per share. As of September&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i9d76a10a56a3493d8f750d9aff98a946_I20220930" decimals="INF" name="adc:NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM2Mjc_9312f0c6-04da-4e16-ba4a-d99a9c99756e">3,457,420</ix:nonFraction> awards are vested and exercisable out of the total outstanding awards of <ix:nonFraction unitRef="shares" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM3MDM_5ee6ba91-0cb9-4852-91ca-19775d64a9ab">9,757,225</ix:nonFraction> common shares. The weighted average strike price and weighted average remaining life for vested and exercisable awards is USD <ix:nonFraction unitRef="usdPerShare" contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930" decimals="2" name="adc:WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM4MzI_c738929d-a821-45d2-9cf6-65b4f392f79b">25.67</ix:nonFraction> and <ix:nonNumeric contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930" name="adc:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM4Mzk_b3f58118-d73c-46d8-b40a-65cf47e69f10">7.44</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i8cc64772a70d4075a054be36f3a4f853" continuedAt="i24011a0d29a540e9bcfb542fc8632ba3"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted were determined on the date of the grant using the Black-Scholes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option-pricing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> model. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company used an independent valuation firm to assist in calculating the fair value of the award grants per participant. </span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzU_fb3ed550-3e22-4479-bc40-9db3ca8d1440" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three and nine months ended September&#160;30, 2022 were determined on the date of the grant using the following assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:51.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price, in USD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxMGIzYzhiMWRhOWI0MDZlYjU5MzA0MjQ5ZTAzZDBiMV80_f71f1dae-113a-4365-8510-14e1946286f8">4.83</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxMGIzYzhiMWRhOWI0MDZlYjU5MzA0MjQ5ZTAzZDBiMV85_609eaf8f-744c-4bde-97e9-024af5e65ba4">8.54</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNDVkYmRiOTU1NTY0YzgyOTc3NDU4NWY0MjhkZDViNF80_b05725cb-c291-4404-893e-711522bd38eb">4.83</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNDVkYmRiOTU1NTY0YzgyOTc3NDU4NWY0MjhkZDViNF85_8f054c58-6e99-4e34-90dd-7a954a74da04">19.69</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Strike price, in USD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5ZmQ5OTM3ZjJjYmY0ZmJkYTk3NDI2NTE2M2NjOGExN180_8731e318-a80f-45f2-bfcd-a3351647fef0">4.83</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5ZmQ5OTM3ZjJjYmY0ZmJkYTk3NDI2NTE2M2NjOGExN185_bc8a8ee4-e600-4a5b-9602-f2a14ac8b572">8.54</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNGVlM2E4YzVhYWM0MzYwOGRkMzFlNTAwZGEyMmE3MV80_e10a611a-ecee-45d5-a6ab-f8e764f44428">4.83</ix:nonFraction> - <ix:nonFraction unitRef="usdPerShare" contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNGVlM2E4YzVhYWM0MzYwOGRkMzFlNTAwZGEyMmE3MV85_9da53f11-5a6c-4b8c-a605-be4f825b31ef">19.69</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxZmI3Zjk2NTNhYzg0MzFiOGY4OTJiMDU0ZjVmODU5OF81_c147cc4b-26e4-433b-bc11-088a8b97b90d">70</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxZmI3Zjk2NTNhYzg0MzFiOGY4OTJiMDU0ZjVmODU5OF8xMQ_f66b7e27-1741-43fa-ac62-6faeedf09971">80</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo4Njg2NmZkOTEzMTA0OTc1YTM2NTM3YzQ5ZDgzODA5M180_35a0cd50-e5a6-4c23-b4f0-bdaf872ee751">70</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930" decimals="2" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo4Njg2NmZkOTEzMTA0OTc1YTM2NTM3YzQ5ZDgzODA5M18xMA_99cdd41e-d2c1-4e70-95ee-356bbca82c8b">80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Award life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzUtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjo3ZjM0OTYwMWQ4OTc0MWM3YTlkN2ZhNjRmMDgzZGJjY180_bc440aa4-cfe3-47e7-8ac7-50c3f4d6ef1b">6.08</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930" decimals="INF" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzUtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo0ZWMyNWEzY2VjMGI0ZmQ2YTEyYjEzMTBjY2NiMDBkY180_3a08cbd2-d492-47a0-9a0b-dfb43f7df410">6.08</ix:nonFraction> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:ExpectedDividendShareOptionsGranted" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzYtMS0xLTEtODY3MDk_a3438c21-ae0b-47ff-b54c-8821629e1923">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ExpectedDividendShareOptionsGranted" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzYtMy0xLTEtODY3MDk_493ebf11-56a3-445a-a8ea-e7346e6ffd27">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoyMjUzM2IyODVkMDE0NDI2ODc3MDg3MTBiYmRhNDNmZl80_bb31a8bb-d1d6-4092-9893-a55c3cbd05a0">2.61</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoyMjUzM2IyODVkMDE0NDI2ODc3MDg3MTBiYmRhNDNmZl85_2ff4b5be-8d2c-4aa2-b923-2c06307a73e6">3.77</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="number" contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5NGY4Nzc4YmM0YTI0ZjNiYWMxYzI4MTljYjg1NTc1MV80_ccf86189-b783-42a9-93bd-451c319fae63">1.46</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5NGY4Nzc4YmM0YTI0ZjNiYWMxYzI4MTljYjg1NTc1MV85_70c767b3-b6c6-4cee-849b-6ddd7b993cde">3.77</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility was based on the Company&#8217;s historical volatility and selected volatility determined by median values observed among other comparable public companies. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The award life is based on the time interval between the date of grant and the date during the <ix:nonNumeric contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" name="adc:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMjg_e044905d-b08a-4b0d-8a77-30d11d46ddc2">ten-year</ix:nonNumeric> life after which, when making the grant, the Company expected on average that participants would exercise their options.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity Incentive Plan 2019, the Company may grant RSUs to its directors, certain employees and service providers working for the benefit of the Company at the time. The awards generally vest annually over a period of <ix:nonNumeric contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzQ4OTE_1e627cfe-7da1-446f-8ffa-82e86f494d4a">three years</ix:nonNumeric> commencing on the first anniversary of the date of grant. The special retention awards discussed above vest <ix:nonFraction unitRef="number" contextRef="i45a1053498d5476e8f8d62e1e4575acb_D20220101-20220930" decimals="3" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzUwMDI_1fc229c5-9885-4c8f-8be2-be1545c41f28">50</ix:nonFraction>% and the remainder at the <ix:nonNumeric contextRef="ie78f96aef8b8454a82071adaaa117569_D20220101-20220930" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMjk_f7a2156b-08cf-4425-8ea8-2c65b235e972">six-month</ix:nonNumeric> and <ix:nonNumeric contextRef="ib9d5fe10351e4449b949a8a8feb2c71d_D20220101-20220930" name="adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzUwNDM_01bb6ce8-1deb-4f08-a7ca-cd121bcaf2e0">one year</ix:nonNumeric> anniversaries, respectively, of the grant date. The RSUs may be settled only in common shares of the Company. Therefore, the grants of RSUs under the Equity Incentive Plan 2019 have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company&#8217;s unaudited condensed consolidated interim statement of operations and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim balance sheet.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recognized for services received during the three and nine months ended September&#160;30, 2022 was KUSD <ix:nonFraction unitRef="shares" contextRef="i3a0283334e204aed9dac9cea1dfc698a_D20220701-20220930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU3Njc_13e0ba7d-83a9-4c83-95f8-6d38ae2bf88c">6,372</ix:nonFraction> and KUSD <ix:nonFraction unitRef="shares" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU3Nzk_7402fcad-fb88-4672-9fb7-e4be6e7f9bc4">15,135</ix:nonFraction>, respectively. The expense recognized for services received during the three and nine months ended September&#160;30, 2021 was KUSD <ix:nonFraction unitRef="shares" contextRef="ib1e58e63d94a49548e999adc4a660174_D20210701-20210930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU4ODE_e28d4222-493c-4c78-8128-daf464f161c9">2,693</ix:nonFraction> and KUSD <ix:nonFraction unitRef="shares" contextRef="ic8b357e6573a4bd4b45f578e3c65b1e4_D20210101-20210930" decimals="INF" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU4OTM_a16b7678-8900-4f86-b08c-b9c742966746">6,904</ix:nonFraction>, respectively.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzE_ccf25ea9-3af5-45a4-90f2-db1288df7323" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:71.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Number of awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i1eb06d614e3447ffb6c90235d957a286_I20211231" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzEtMS0xLTEtODY3MDk_6948de5b-f4e0-4202-9286-20cf59d734e7">663,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1eb06d614e3447ffb6c90235d957a286_I20211231" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzEtMy0xLTEtODY3MDk_c98c99f0-bcef-4951-acf7-80bf0b9c7c39">30.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzItMS0xLTEtODY3MDk_89efa2e7-4d75-4ca2-8331-b5e902e78b81">2,129,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzItMy0xLTEtODY3MDk_1057e6b2-4d0a-4844-8fd8-617169c9dd63">9.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="shares" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzMtMS0xLTEtODY3MDk_53de8327-de09-488e-b13f-6715188b2980">344,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzMtMy0xLTEtODY3MDk_8df990bd-e826-4a5b-b9fd-7ab3b92121f1">30.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="shares" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzQtMS0xLTEtODY3MDk_0eab69c9-bf89-4382-bec2-04b5b64eeca4">135,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzQtMy0xLTEtODY3MDk_0d328e83-0f80-40d6-b7c3-2101a4ce66d0">21.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i05e1cf39bbc742f2bcd482dcd9e52fff_I20220930" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzUtMS0xLTEtODY3MDk_15d9a726-a15d-4864-88c0-4197dfd3396f">2,313,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usdPerShare" contextRef="i05e1cf39bbc742f2bcd482dcd9e52fff_I20220930" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzUtMy0xLTEtODY3MDk_8e3e5289-0e27-4f94-804d-cf354b4be946">11.71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs granted during 2022 include the annual equity award and special retention award discussed above, which had grant date fair values of USD <ix:nonFraction unitRef="usdPerShare" contextRef="i6744fd46428b46519b3f53dabe6cec74_D20220101-20220930" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYwNTc_04576190-9583-4004-b3b4-c5132a574474">14.00</ix:nonFraction> and USD <ix:nonFraction unitRef="usdPerShare" contextRef="i45a1053498d5476e8f8d62e1e4575acb_D20220101-20220930" decimals="2" name="adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYwNjQ_52828aff-99b3-4f66-affc-5cae7afbd904">6.93</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><ix:continuation id="i24011a0d29a540e9bcfb542fc8632ba3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share-based Compensation Reserves</span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzI_920556d3-685b-40b1-ba78-efa968dc8884" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement in the Share-based Compensation Reserves (included in Other reserves within equity) is as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - Share Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i4af9ebeb2297423eb394125254b4a972_D20220701-20220930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtMS0xLTEtODY3MDk_a0a2c19e-b015-4e6b-b503-6b81dab24bc4">8,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id3811cf7e2644eda9263cf885c93077f_D20210701-20210930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtMy0xLTEtODY3MDk_69155556-c2c9-4229-9396-24596595f41c">12,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i98d5c21d03c745b5a671f6735837b959_D20220101-20220930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtNS0xLTEtODY3MDk_d5fb3f16-68cd-4629-a304-2b1b0d29f9d4">27,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i23f74715d84641a0818c9605970c3d58_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtNy0xLTEtODY3MDk_0c72a740-cc11-46cf-82fb-5c23cb22a73b">40,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i6cefde464eaa45adbdc8ce7283826a3b_D20220701-20220930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtMS0xLTEtODY3MDk_bdf31e77-5644-4493-b3ae-16f6de893b48">6,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3425d423d7cb4ed7841d8808eb8b91ee_D20210701-20210930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtMy0xLTEtODY3MDk_94b4c444-d8dc-487d-89a0-8b9de054ab2d">2,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if85a6bc595a6484baa94ff58c1ba727d_D20220101-20220930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtNS0xLTEtODY3MDk_64749b91-45f2-4341-8498-bf43283a6933">15,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7bcf43c8d3a64ab28d95b0e02490e5a6_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtNy0xLTEtODY3MDk_4b0c2fb9-d5b9-474e-ae4c-878928e59d91">6,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tax and social charge deductions - Incentive Plan 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if6b8e02492be4003ab27ad39ebc0924a_D20220701-20220930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtMS0xLTEtODY3MDk_874a5b2a-e519-4632-97e5-4d34b7719c71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3528d529fe714216bcf41e3b8f352130_D20210701-20210930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtMy0xLTEtODY3MDk_c8ed9486-460b-4ca0-95ee-bbdefd2797b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930" decimals="-3" sign="-" name="adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtNS0xLTEtODY3MDk_4f385df0-b8b2-4e0a-9a90-f2806c084fab">512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="idab02ef85658428ead895ef5a19a0884_D20210101-20210930" decimals="-3" name="adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtNy0xLTEtODY3MDk_97178e96-17f5-4821-b0dc-b51bf410b6dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctMS0xLTEtODY3MDk_2c4710b6-a7bb-4e7c-a567-b205cebe13e3">14,565</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctMy0xLTEtODY3MDk_58fb4cff-fbeb-438a-b89a-04a9f003d8d0">14,798</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctNS0xLTEtODY3MDk_28b4aa33-83f7-410a-90d3-8651144a6869">41,781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctNy0xLTEtODY3MDk_32624cd9-ba68-4dd3-8cee-fd87202c0a2c">47,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2022 Employee Stock Purchase Plan</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company adopted the 2022 ESPP, which was approved by shareholders at the Company's 2022 Annual General Meeting. The Company has <ix:nonFraction unitRef="shares" contextRef="ic28832b49da3403a8b557a594e965059_I20220630" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzEwOTk1MTE2NDgyMTU_69e88421-e21a-4502-bca5-3892530cc0a3">782,700</ix:nonFraction> common shares reserved and available for the future issuance. The number of shares available for grant and issuance under the 2022 ESPP will increase on January 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each of the first ten calendar years during the term of the 2022 ESPP by the number of shares equal to 1% of the shares outstanding as of the immediately preceding December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or lesser number as may be determined by the Board. The aggregate number of shares that may be issued under the 2022 ESPP Plan is equal to 1% of the ordinary share capital of the Company. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 ESPP allows eligible employees to purchase designated shares of the Company's common shares at a discount, over a series of offering periods through accumulated payroll deductions. No offering period may be longer than 27 months. The purchase price for shares purchased under the 2022 ESPP during any given purchase period will be 85% of the lesser of the market price of the Company&#8217;s common shares on (i) the offering date or (ii) the purchase date.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date of the initial offering period was July 18, 2022, and that offering period will end on December 31, 2022.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense related to purchase rights granted pursuant to its 2022 ESPP on a straight-line basis over the requisite service period, which is generally a six-month period. The fair value of the purchase rights granted were determined on the date of the grant using the Black-Scholes option-pricing model. The Company used an independent valuation firm to assist in calculating the fair value of the purchase rights. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense for services received during the three and nine months ended September 30, 2022 was not material to the overall financial statements. As of September 30, 2022, the Company recorded a liability of KUSD <ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:AccruedShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU0OTc1NTgzMTQ0Nw_7c7a17e6-5149-4f89-bf74-9a0fcf0ca9d5">220</ix:nonFraction> related to the accumulated payroll deductions, which are refundable to employees who withdraw from the ESPP. This amount is included within Accrued expenses in other current liabilities in the unaudited condensed consolidated interim balance sheet.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_109"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="adc:DeferredRoyaltyObligationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzQyMzM_e30dc284-55c9-43e9-9089-2909cb6909c7" continuedAt="i51b19bcb35634de48710dc08dd1425f0" escape="true">Deferred royalty obligation</ix:nonNumeric></span></div><ix:continuation id="i51b19bcb35634de48710dc08dd1425f0" continuedAt="i91fae1ceed474026a12ca61f0da38eb0"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2021, the Company entered into a royalty purchase agreement with HCR for up to USD <ix:nonFraction unitRef="usd" contextRef="ie7216894bf0e483e85c7a8417528b234_I20210825" decimals="INF" name="adc:RoyaltyPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzEzMA_63a9a39f-cb81-4305-8eb0-027214a796a4">325.0</ix:nonFraction>&#160;million of which the Company received gross proceeds of USD <ix:nonFraction unitRef="usd" contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630" decimals="-5" name="adc:ProceedsFromRoyaltyPurchaseAgreementGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzE4NQ_43509ef7-e43e-40b3-ae32-b76f478b091a">225.0</ix:nonFraction>&#160;million during 2021 and is eligible to receive an additional USD <ix:nonFraction unitRef="usd" contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630" decimals="-5" name="adc:RoyaltyPurchaseAdditionalProceedsEligibility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzI0NQ_441bf515-6170-4b07-ac1a-568c254c85b2">100.0</ix:nonFraction>&#160;million upon the occurrence of certain commercial milestones.</span></div><ix:continuation id="i1555dc66c34f44449d2b2d4c6e11fc0f"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s debt obligation relating to the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:78.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:DeferredRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEtMi0xLTEtODY3MDk_7db9e915-49f9-4582-a2b3-0ea27b5e8a87">225,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:RoyaltyObligationPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzItMi0xLTEtODY3MDk_617d0e77-ff78-4971-ba4f-361a2fa0234c">5,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:RoyaltyObligationInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzMtMi0xLTEtODY3MDk_b550023d-c962-4f6a-8a2b-a4773e594029">17,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: cumulative catch-up adjustment, Financial income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="adc:RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzQtMi0xLTEtODY3MDk_1e33e419-23c6-4610-9e68-ae752d85ee65">16,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i002154ec55ee4138b998ace2483bb162_I20220930" decimals="-3" name="adc:DeferredRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzUtMi0xLTEtODY3MDk_f62ca834-f229-42ef-b403-65d4f18ea4b3">221,144</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231" decimals="-3" name="adc:DeferredRoyaltyObligation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzctMi0xLTEtODY3MDk_815449ff-4ba4-4a09-8991-dd92dcdf7b59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Proceeds from the sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="-3" name="adc:ProceedsFromRoyaltyPurchaseAgreementGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzgtMi0xLTEtODY3MDk_a655c510-d65a-4b3d-97d9-3a8523a664c1">225,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="-3" name="adc:RoyaltyObligationTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzktMi0xLTEtODY3MDk_1200662c-2228-4024-aeb2-fe2e338bbbeb">6,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="-3" name="adc:RoyaltyObligationPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEwLTItMS0xLTg2NzA5_15b74da6-1959-4f66-b1fb-e978c6d43e05">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="-3" name="adc:RoyaltyObligationInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzExLTItMS0xLTg2NzA5_9036c0f4-9377-4e0b-89fd-0e82d66e5a06">6,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: cumulative catch-up adjustment, Financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331" decimals="-3" name="adc:RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEyLTItMS0xLTg2NzA5_6fe2c3eb-a4ce-401c-acd7-bf354d924ac6">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231" decimals="-3" name="adc:DeferredRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEzLTItMS0xLTg2NzA5_3570b782-43b3-4193-bc23-8ebac5235816">225,477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a liability relating to the initial gross proceeds received less transaction costs. The Company will record additional liabilities upon the receipt of eligible amounts when such contingent events occur. To determine the accretion of the liability related to the deferred royalty obligation, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payment to HCR based on the Company's revenue projections. Based on the Company's initial revenue projections, the Company used an independent valuation firm to assist in determining the total amount of future royalty payments and estimated timing of such payment to HCR using an option pricing Monte Carlo simulation model. The amount ultimately received by the Company will be accreted to the total amount of the royalty payments necessary to extinguish the Company&#8217;s obligation under the agreement, which will be recorded as interest expense over the life of the royalty purchase agreement. The estimate of this total interest expense resulted in an EIR of <ix:nonFraction unitRef="number" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="3" name="adc:RoyaltyPurchaseAgreementEffectiveInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzE1MjI_b2cf8ec7-e5b3-47a5-90f4-67684e3e6ae3">10</ix:nonFraction>%. As royalty payments are made to HCR, the balance of the debt obligation will be effectively repaid over the life of the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's periodic review, the exact amount and timing of repayment is likely to be different each reporting period as compared to those estimated based on the Company's initial revenue projections. A significant increase or decrease in actual net sales of ZYNLONTA compared to the Company&#8217;s revenue projections, and regulatory approval and commercialization of Cami, as well as ZYNLONTA in other indications as well as licensing revenue could change the royalty rate and royalty cap due to HCR, which could materially impact the debt obligation as well as interest expense associated with the royalty purchase agreement. Also, the Company&#8217;s total obligation to HCR can vary depending on the achievement of the sales milestones as well as the timing of a change in control event. The Company will periodically assess the expected payments to HCR based on its underlying revenue projections and to the extent the amount or timing of such payments is materially different than its initial estimates it will record a cumulative catch-up adjustment. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's 2022 strategic planning decisions including updated development plans, the Company updated the valuation model during the first quarter of 2022, which resulted in a cumulative catch-up adjustment of KUSD 18,288 recorded as Financial income within the unaudited condensed consolidated interim statement of operations for the three months ended March 31, 2022. The Company updated the valuation model in the second quarter of 2022 for revised revenue forecasts, which had the effect of reducing the Company&#8217;s deferred royalty obligation, as well as including upfront and downstream milestone payments related to the Sobi exclusive license agreement, which had the effect of increasing the Company&#8217;s deferred royalty obligation. As a result of the updated valuation model in the second quarter of 2022, the Company recorded a non-material cumulative catch-up adjustment recorded as Financial expense within the unaudited condensed consolidated interim statement of operations for the three months ended June 30, 2022. In the third quarter of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i91fae1ceed474026a12ca61f0da38eb0">2022, the Company updated the valuation model for actual net sales reported in the third quarter 2022, as well as refined the estimated timing of receipt for the downstream milestone payments related to the Sobi exclusive license agreement, which had the effect of increasing the Company&#8217;s deferred royalty obligation. As a result of the updated valuation model used in the third quarter of 2022, the Company recorded a KUSD 2,175 cumulative catch-up adjustment as Financial expense within the unaudited condensed consolidated interim statement of operations for the three months ended September 30, 2022. Under the cumulative catch-up method, the EIR is not revised when actual or estimated net sales differ from those estimated as of the inception of the debt obligation. Instead, the carrying amount of the debt obligation is adjusted to an amount equal to the present value of the estimated remaining future payments, discounted by using the original EIR, 10%, as of the date on which the estimate changes.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzMwOTk_6d466294-6f45-4959-907c-7b4e1ea30ff3" continuedAt="i7a8d23b66ea84312a74b94fd98c75bae" escape="true">Related parties</ix:nonNumeric></span></div><ix:continuation id="i7a8d23b66ea84312a74b94fd98c75bae"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.T. Holdings II S&#224;rl (&#8220;AT Holdings II&#8221;) is a shareholder in the Company. AT Holdings II is in turn ultimately wholly owned by Auven Therapeutics Holdings, L.P. (&#8220;ATH&#8221;), a limited partnership registered in the British Virgin Islands. ATH&#8217;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#8220;ATM&#8221;). As a result, ATH is considered a related party.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s contribution and equity interest in Overland ADCT BioPharma, certain of the Company&#8217;s employees serve on its board of directors. As a result, Overland ADCT BioPharma is considered a related party.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services provided by the Company to related parties</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides registered office and other simple administrative services to <ix:nonFraction unitRef="subsidiary" contextRef="i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930" decimals="INF" name="adc:NumberOfSubsidiariesProvideServicesTo" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzk3OQ_3d1e29c2-2ac4-48d5-8dcc-d5c6ebe422d5">three</ix:nonFraction> subsidiaries of ATH. The amounts invoiced for the three and nine months ended September&#160;30, 2022 and recovered through G&amp;A expenses, amounted to <ix:nonFraction unitRef="usd" contextRef="if51de663eeeb43a9905288c2f5ec4bed_D20220701-20220930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzEwOTk_734ccb14-5829-48be-bee8-de15f1535b9d">nil</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzExMTE_985c2276-3a48-4121-9752-b73686730cad">1</ix:nonFraction>, respectively (three and nine months ended September&#160;30, 2021: KUSD <ix:nonFraction unitRef="usd" contextRef="i08246b7245ce401f95f5c264b9f4aa66_D20210701-20210930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzExNTQ_1430311c-d040-489b-b392-ace7019a3b62">1</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="icf7164681d554945ae3e0bb0a2aba4a1_D20210101-20210930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzExNjY_a786339d-da5d-4b5b-b1c4-afb9a4563450">3</ix:nonFraction>, respectively).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As contemplated by the license agreement with Overland ADCT BioPharma, Overland ADCT BioPharma has elected to participate in certain of the Company&#8217;s global clinical trials, in exchange for which it reimburses the Company for a portion of the cost of those trials. Overland ADCT BioPharma also reimburses the Company for certain expenses in connection with technology transfer and assistance of clinical personnel. During the three and nine months ended September&#160;30, 2022, the Company incurred KUSD <ix:nonFraction unitRef="usd" contextRef="i12b130040d7a4b73bd260af53f216810_D20220701-20220930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE2NTc_d0f9959a-04cf-4092-9dda-d6837af822cf">818</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="i519cc478c39244318ef4ce155c0494b8_D20220101-20220930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE2Njk_e2ffd5ca-a218-4d25-a015-23b296aa4ce6">2,014</ix:nonFraction>, respectively, of clinical trial and service costs to be reimbursed by Overland ADCT BioPharma, which is recorded as a reduction of R&amp;D expenses in the Company&#8217;s unaudited condensed consolidated interim statement of operations (three and nine months ended September&#160;30, 2021: KUSD <ix:nonFraction unitRef="usd" contextRef="i16371fe343804f21aa8c01b295fcfe36_D20210101-20210930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE5MjU_5dd47327-6d12-47e2-9e38-f80b906b2467"><ix:nonFraction unitRef="usd" contextRef="i048e0b2056c24818a8680d84acca00a4_D20210701-20210930" decimals="-3" name="adc:ServicesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE5MjU_e62bffe9-ce2d-4a20-b4cf-d5f4e23f12a9">812</ix:nonFraction></ix:nonFraction> and KUSD 1,602, respectively).</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In addition, the Company entered into a supply agreement with Overland ADCT BioPharma whereby the Company provides Overland ADCT BioPharma clinical supply for use in trials and supply for early access programs. For the three and nine months ended September&#160;30, 2022, KUSD 5 and KUSD <ix:nonFraction unitRef="usd" contextRef="i519cc478c39244318ef4ce155c0494b8_D20220101-20220930" decimals="-3" name="adc:SuppliesProvidedRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzIxNDQ_6739a502-2c44-4f84-abd6-ff8020a56eab">45</ix:nonFraction>, respectively, of supply was provided to Overland ADCT BioPharma which is recorded as a reduction of R&amp;D expenses in the Company&#8217;s unaudited condensed consolidated interim statement of operations. There were no such sales to Overland ADCT BioPharma during the three and nine months ended September&#160;30, 2021. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Related party balances</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a related party receivable balance with Overland ADCT BioPharma of KUSD <ix:nonFraction unitRef="usd" contextRef="icaa43634d02840d5a9bcbd7fa627fe61_I20220930" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzI1NDc_009dcc85-4281-4131-8ee6-2e86de54ac2a">1,695</ix:nonFraction> and KUSD <ix:nonFraction unitRef="usd" contextRef="i65354fc22fe5421c886bb333bb47840b_I20211231" decimals="-3" name="ifrs-full:AmountsReceivableRelatedPartyTransactions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzI1NTk_9dd5fe9d-0968-4850-afa1-6543b4d54abd">789</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively. There were no trade accounts payable with related parties as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Key management compensation</span></div><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzMxMDA_13cf3f95-21ba-4463-bf80-fffdcf63602c" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation of key management is shown below:</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Salaries and other short-term employee costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItMS0xLTEtODY3MDk_4f25b41b-a20e-41f9-bbc9-e163145374f3">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItMy0xLTEtODY3MDk_52110144-cfde-4442-92d6-77a4f31677b7">2,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItNS0xLTEtODY3MDk_204ceb5b-6f4a-4070-9cd1-6b8fad61b616">6,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItNy0xLTEtODY3MDk_70e41af9-b8ba-405e-a087-a0dfdab91ec2">6,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pension costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtMS0xLTEtODY3MDk_a432c1de-d62a-406c-9762-f1aa090d943f">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtMy0xLTEtODY3MDk_d2486791-59b8-4871-be74-6fdb27356f39">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtNS0xLTEtODY3MDk_56b552da-110c-46e5-9f29-4e80e0ca2340">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtNy0xLTEtODY3MDk_41777c39-65f8-434d-8410-e7479a4a0c30">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtMS0xLTEtODY3MDk_ce8f1be8-9db5-44b6-af00-fb5fff2946b3">8,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtMy0xLTEtODY3MDk_6c7f3af5-5580-4be8-8a9e-9a7f21aa47c6">6,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtNS0xLTEtODY3MDk_14855c52-4568-4344-9bf0-811a3c88047d">20,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtNy0xLTEtODY3MDk_1c924639-44e0-428c-abf9-2dbaab8d0ef0">20,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtMS0xLTEtODY3MDk_434c1262-619f-407c-9c65-1a2b9dd10357">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtMy0xLTEtODY3MDk_7a4f4890-dbdd-41a3-ae75-0c2a0956c1e1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtNS0xLTEtODY3MDk_5abe314a-f53a-4c16-b27d-a72d825e8bf0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtNy0xLTEtODY3MDk_02766f06-6cb8-4b42-99e5-0688b731d985">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtMS0xLTEtODY3MDk_b5165a83-ebcf-4d9a-a776-ecd1fb9b25e8">10,242</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtMy0xLTEtODY3MDk_01ed1b26-b04c-4f5a-af56-2c92855a06c5">8,837</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtNS0xLTEtODY3MDk_ea366019-3ea3-44fe-87f9-711ebdc1fd4c">27,119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtNy0xLTEtODY3MDk_299aa75f-3268-4ebf-ac43-01ed1972f42f">26,921</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">During the second quarter of 2022, there was an organizational realignment of certain key management as a result of the appointment of the Company's new CEO. The key management compensation for the three and nine months ended September&#160;30, 2022 reflects the new management structure, while the comparable prior periods have not been recast to conform to the current structure.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i648c8e1ac91b483eb52eb5061f8475ee_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90ZXh0cmVnaW9uOjhmZWU3YmViZTllZDRkNmRiOTNiYzhkYWVmNjI2ZDc3XzQ3NA_a372bca9-9c0d-435a-9419-c95d68c21a31" continuedAt="ic135ec6c8261461b8c79754342138b3e" escape="true">Loss per share</ix:nonNumeric></span></div><ix:continuation id="ic135ec6c8261461b8c79754342138b3e"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:EarningsPerShareExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90ZXh0cmVnaW9uOjhmZWU3YmViZTllZDRkNmRiOTNiYzhkYWVmNjI2ZDc3XzQ3NQ_6cc524ea-b65f-44f4-8196-f7efa51abcb7" continuedAt="ic544123a13fc4a0abaa0d1cd42c3065d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Loss attributable to owners</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItMS0xLTEtODY3MDk_aceabf18-25f6-4d7a-8321-068a1b0c4253">50,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItMy0xLTEtODY3MDk_719480c4-06e0-4109-8368-3cfa4c23ab26">71,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItNS0xLTEtODY3MDk_d386fa8a-5876-4351-9aa9-4c74af34722e"><ix:nonFraction unitRef="usd" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItNS0xLTEtODY3MDk_ee5cd402-d090-4597-9a44-59d05b277822">131,643</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(<ix:nonFraction unitRef="usd" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItNy0xLTEtODY3MDk_b0efb59d-1cda-42b6-9592-fdee8833b040">195,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtMS0xLTEtODY3MDk_51e977ff-887b-4e19-ab74-077923343a82">78,372,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtMy0xLTEtODY3MDk_218fa4ec-78b1-46c8-9064-92704087d2d7">76,739,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtNS0xLTEtODY3MDk_ebaf38f4-3fc8-48c4-9c53-9dcb07ae5232">77,374,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtNy0xLTEtODY3MDk_6c574fe2-017a-4085-b572-1a93997718a4">76,730,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMS0xLTEtODY3MDk_0fcc2a70-3201-41dc-a472-5e7425ed45a8"><ix:nonFraction unitRef="usdPerShare" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMS0xLTEtODY3MDk_fb9dc6a4-a2e7-4ae0-a3bb-0e5905e6be29">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMy0xLTEtODY3MDk_d4d4db6e-0493-4116-a086-fe0c6e95a6c1"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMy0xLTEtODY3MDk_f45b51ae-799c-49ad-bb16-a7e107c90f5d">0.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNS0xLTEtODY3MDk_12b11a32-c463-49d9-9ae0-1e7e39a6e632"><ix:nonFraction unitRef="usdPerShare" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNS0xLTEtODY3MDk_60ff3eb9-5872-471b-9371-859f1cd3c0dc">1.70</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNy0xLTEtODY3MDk_6ceca30d-b33b-4252-80ca-f7aec43bd2c3"><ix:nonFraction unitRef="usdPerShare" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNy0xLTEtODY3MDk_ddc6fbdc-eba1-474f-8493-cad0a4ef682e">2.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022 and 2021, basic and diluted loss per share are calculated on the weighted average number of shares issued and outstanding and exclude shares to be issued under the Equity Incentive Plan 2019, as the effect of including those shares would be anti-dilutive.</span></div><ix:continuation id="ic544123a13fc4a0abaa0d1cd42c3065d"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because the effect of including them would be anti-dilutive were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.694%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - Share Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="ic02e5a8396a24328a44c3c3ca993fbf8_D20220701-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtMS0xLTEtODY3MDk_3baf50d6-2010-4516-9706-4723e24899ef">9,725,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="iae551281e83e4030b20c9779e840a6db_D20210701-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtMy0xLTEtODY3MDk_d55dd54f-3b2f-401e-93d7-0c6707ebf550">6,326,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="if17b1e60018b4848b0cc478a5439fcbe_D20220101-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtNS0xLTEtODY3MDk_7f6ae5ec-e3c7-478f-8c1c-451175df55dc">8,625,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="icef2d3daf96e4c52ba4ccd1c33c624a6_D20210101-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtNy0xLTEtODY3MDk_ca2f7676-50af-4c06-916c-2de54daf5415">5,759,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i42e1e606ace84d21a6ec9a6aee9fd665_D20220701-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtMS0xLTEtODY3MDk_aed51bfb-80fe-4c31-b8da-93b23eeded5a">2,473,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="idb44ceb2a6a84f44b55476a168ce4fa4_D20210701-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtMy0xLTEtODY3MDk_e3f2bc1f-9bde-4dd0-9490-08b70b129bd4">594,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i5eb0fcfe2e954886a15fb411a8e3ec9a_D20220101-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtNS0xLTEtODY3MDk_426ef5a4-c2b1-425c-a8f1-02d7f65397fd">1,731,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="iff327b0f65fe4fce9a6d78995be93ca9_D20210101-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtNy0xLTEtODY3MDk_466cb110-3f23-49b2-9959-82b760bb557b">451,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conversion of the principal amount of convertible loans into the Company&#8217;s common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i5ccd7f1b706c4d9f8b0853b7bb915ab8_D20220701-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtMS0xLTEtODY3MDk_3ffb8b82-43a2-4e8a-acbf-ecef0157464a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i9715b3a7f0dc46af8427382e8c4b913b_D20210701-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtMy0xLTEtODY3MDk_ac47867e-5273-4762-af45-42faef34daaa">4,412,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i9ccb7c3256654c6bab2e6cdeb30d200f_D20220101-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtNS0xLTEtODY3MDk_0f3d8d4a-cea1-4cbf-8b45-22c482a805ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="ia12624d220a540beba94b39cc8891315_D20210101-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtNy0xLTEtODY3MDk_6e6d9884-ea53-4656-b0f5-0426c0727067">3,682,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Outstanding warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i367482dece7c4a8a868d61236759bb2a_D20220701-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMS0xLTEtOTQ0OTU_6520c3f5-f8fb-494d-9fe4-656ffbf56332">2,470,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i68337702bbe542648d3b07bc46ecffc9_D20210701-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMy0xLTEtOTQ0OTU_7188fb2f-f2e1-4823-9487-a34c39f05b14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i6ed07caeea2c4158a84e9c7fe843387a_D20220101-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNS0xLTEtOTQ0OTU_6fe5f04b-2c88-4624-97ee-f25d78d8ba5b">832,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i2c3724a1c9b64111a1170ea671562e28_D20210101-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNy0xLTEtOTQ0OTU_5de643f5-670d-40cc-b46d-21cfb979f5a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMS0xLTEtODY3MDk_b481df0f-ca6b-4f96-88fa-9cdbb6bc88b7">14,668,591</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMy0xLTEtODY3MDk_3c879f12-ceef-413b-9d10-bfea31fe06ad">11,334,313</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNS0xLTEtODY3MDk_fee522e6-c35c-4f89-9010-a5c30ce45327">11,189,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonFraction unitRef="shares" contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930" decimals="0" name="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNy0xLTEtODY3MDk_a93e6e7e-db61-4592-881c-807d95a115a2">9,893,089</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 ESPP share activity was not presented as the effects were not material.</span></div></ix:continuation><div id="i648c8e1ac91b483eb52eb5061f8475ee_121"></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMjEvZnJhZzpjMDg5NDk1ZDMyMDc0NzE5YTlkOWE2YzEwMTcxNGQ5Mi90ZXh0cmVnaW9uOmMwODk0OTVkMzIwNzQ3MTlhOWQ5YTZjMTAxNzE0ZDkyXzEzMzE_bf3546c6-a762-4d1d-a8d7-b8bda350f6c2" continuedAt="i8243029c86d945d5b3a5fcf9905e4de8" escape="true">Events after the reporting date</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><ix:continuation id="i8243029c86d945d5b3a5fcf9905e4de8"><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company has evaluated its subsequent events through November&#160;8, 2022, the date the financial statements were available to be issued, and has concluded that there are no subsequent events requiring disclosure in these unaudited condensed consolidated interim financial statements, other than those described below.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company held a pre-BLA meeting in September 2022 and a Type C meeting with the FDA in late October. During the Type C meeting, the FDA provided strong guidance that, for it to consider an accelerated approval path, a randomized confirmatory Phase 3 study must be well underway and ideally fully enrolled at the time of any BLA filing for Cami.  As a result, the Company will not file the BLA for Cami next year, as it estimates that it would take at least two years to fully enroll a randomized confirmatory Phase 3 study. The Company is engaged with the FDA in an ongoing and constructive dialogue regarding their guidance and the potential regulatory path forward, including the design and timing of the required confirmatory Phase 3 study. At this time, the Company is pausing any material investments in the Hodgkin lymphoma program.  The Company will evaluate its options for Cami with a disciplined and strategic approach to resource allocation.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company discontinued enrollment in the Phase 1b clinical trial of Cami in combination with pembrolizumab for the treatment of solid tumors. The combination was an immune-based approach and intended to enhance the benefit of PD1. While the Company observed signals of immunomodulatory activity, the clinical data were not compelling enough to move forward. The Company recognizes the considerable effort required to fully pursue the opportunity and intend to consider strategic alternatives including a partner for the future development of the program. As this combination was an immunotherapy approach and different from the Company's other solid tumor programs, the Company does not see any read through to its other programs, which it continues to advance.</span></div></ix:continuation><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>adct-20220930x6kex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic91deae69852495fbb6af4f04f832965_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div style="margin-bottom:0.1pt;text-align:right"><font><br></font></div><div id="ic91deae69852495fbb6af4f04f832965_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div id="ic91deae69852495fbb6af4f04f832965_7"></div><div style="margin-bottom:0.1pt;margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. You should read this discussion and analysis in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, as of and for the three and nine months ended September&#160;30, 2022 included as Exhibit 99.1 to the Report on Form 6-K to which this discussion and analysis is included as Exhibit 99.2. You should also read this discussion and analysis in conjunction with our audited consolidated financial statements, including the notes thereto, included in our Annual Report on Form 20-F for the year ended December&#160;31, 2021.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated interim financial statements were prepared in accordance with International Accounting Standard 34,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our audited consolidated financial statements were prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (&#8220;IFRS&#8221;). None of our financial statements were prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The terms &#8220;dollar,&#8221; &#8220;USD&#8221; or &#8220;$&#8221; refer to U.S. dollars and the term &#8220;Swiss franc&#8221; and &#8220;CHF&#8221; refer to the legal currency of Switzerland, unless otherwise indicated. We have made rounding adjustments to some of the figures included in this discussion. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context otherwise requires, all references in this discussion and analysis to &#8220;ADC Therapeutics&#8221; or &#8220;ADCT,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221; or similar terms refer to ADC Therapeutics SA and its consolidated subsidiaries.</font></div><div id="ic91deae69852495fbb6af4f04f832965_10"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a commercial-stage biotechnology company improving the lives of cancer patients with our next-generation, targeted antibody drug conjugates (&#8220;ADCs&#8221;) for patients with hematologic malignancies and solid tumors. We develop our ADCs by applying our decades of experience in this field and using both next-generation pyrrolobenzodiazepine (&#8220;PBD&#8221;) technology to which we have proprietary rights for our targets as well as other validated and novel payloads. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">By leveraging our R&#38;D strengths, our disciplined approach to target selection and our preclinical and clinical development strategy, we have created a diverse and balanced portfolio and research pipeline. Our hematology franchise comprises one approved product (ZYNLONTA, formerly known as loncastuximab tesirine or Lonca) and two clinical-stage product candidates, camidanlumab tesirine (&#8220;Cami&#8221; and previously known as ADCT-301) and ADCT-602. Our solid tumor franchise comprises two clinical-stage product candidates, ADCT-601 (mipasetamab uzoptirine) and ADCT-901, and two preclinical product candidates, ADCT-701 and ADCT-212. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our flagship product, ZYNLONTA, received accelerated approval from the FDA on April 23, 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) not otherwise specified, DLBCL arising from low-grade lymphoma, and also high-grade B-cell lymphoma. The broad patient population included in the label is a key point of differentiation for ZYNLONTA. In a pivotal Phase 2 clinical trial for the treatment of relapsed or refractory DLBCL, ZYNLONTA demonstrated significant clinical activity across a broad population of heavily pre-treated patients, achieving a 48.3% overall response rate (&#8220;ORR&#8221;) and a 24.8% complete response rate (&#8220;CRR&#8221;), while maintaining a manageable tolerability profile. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients with high-grade B-cell lymphoma and patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double&#47;triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. In the most recent data cut as of March 1, 2021, patients who received ZYNLONTA had a median duration of response (&#8220;DoR&#8221;) of 13.4 months for all responders, and the median DoR was not reached for patients with a complete response. We believe that ZYNLONTA has a current addressable patient population of approximately 6,000 patients in the United States, and our experienced commercial organization is unlocking this market opportunity by engaging physicians regarding ZYNLONTA&#8217;s differentiated product profile. Shortly after approval, ZYNLONTA was added to the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines) with a Category 2A recommendation for third-line-plus DLBCL patients, which reflects the broad label and the differentiated profile of ZYNLONTA. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To further expand the market opportunity for ZYNLONTA and maximize its commercial potential, we are conducting LOTIS-5, a confirmatory Phase 3 clinical trial of ZYNLONTA in combination with rituximab that, if successful, we believe </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">will serve as the basis for a supplemental BLA (&#8220;sBLA&#8221;) for ZYNLONTA for the treatment of relapsed or refractory DLBCL in second-line transplant-ineligible patients. As of February 28, 2022, in the safety lead-in part of the clinical trial, data from 20 patients showed a 75.0% ORR and 40.0% CRR and we did not observe any safety events materially different from those observed in prior clinical trials. We are now enrolling the randomized phase of the trial. In addition, we have initiated LOTIS-9, a Phase 2 clinical trial of ZYNLONTA in combination with rituximab in previously untreated unfit or frail patients with DLBCL who are not eligible for R-CHOP. Finally, we have also initiated LOTIS-7, a Phase 1b clinical trial of ZYNLONTA in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first patient in this clinical trial has been dosed with ZYNLONTA in combination with polatuzumab vedotin.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are committed to providing global access to ZYNLONTA to patients who may benefit from treatment. We entered an exclusive license agreement with Swedish Orphan Biovitrum AB (&#8220;Sobi&#8221;) for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Europe and all other jurisdictions outside of the U.S., Japan, greater China and Singapore. In Europe, the European Medicines Agency&#8217;s (&#8220;EMA&#8217;s&#8221;) Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) adopted a positive opinion recommending the marketing authorization of ZYNLONTA for the treatment of relapsed or refractory DLBCL. We expect the European Commission marketing authorization decision by the fourth quarter of 2022, the timing of which may be affected by Sobi's pending appeal of the Committee for Orphan Medicinal Products&#8217; preliminary recommendation to not uphold ZYNLONTA's previously granted orphan drug designation. In September 2021, ADC Therapeutics announced that the European Commission had granted orphan designation to loncastuximab tesirine which was subject to review at time of marketing authorization.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In Japan, we entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (&#8220;MTPC&#8221;) for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications. In China, our joint venture with Overland Pharmaceuticals, Overland ADCT BioPharma (CY) Limited, is continuing to advance the development of ZYNLONTA and has completed enrollment in a pivotal Phase 2 clinical trial of single-agent ZYNLONTA for the treatment of relapsed or refractory DLBCL in China. This local pivotal study mirrors our ongoing global pivotal Phase 2 clinical trial of ZYNLONTA and its results are intended to support the potential registration of ZYNLONTA in China. In addition, the first patient has been dosed in China as part of our LOTIS-5 confirmatory Phase 3 clinical trial. </font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next clinical-stage product candidate, Cami, has demonstrated significant clinical activity across a broad population of heavily pre-treated patients with Hodgkin Lymphoma (&#8220;HL&#8221;), while maintaining a tolerability profile that we believe is manageable. We are evaluating Cami in a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory HL. Patients had a median of six lines of prior systemic therapy. As of November 1, 2021, interim data from 117 patients showed a 70.1% ORR and a 33.3% CRR and a tolerability profile that we believe is manageable. Patients who received Cami had a median DoR of 13.7 months for all responders, and a median DoR of 14.5 months for patients with a complete response.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held a pre-BLA meeting in September 2022 and a Type C meeting with the FDA in late October. During the Type C meeting, the FDA provided strong guidance that, for it to consider an accelerated approval path, a randomized confirmatory Phase 3 study must be well underway and ideally fully enrolled at the time of any BLA filing for Cami.  As a result, we will not file the BLA for Cami next year, as we estimate that it would take at least two years to fully enroll a randomized confirmatory Phase 3 study. We are engaged with the FDA in an ongoing and constructive dialogue regarding their guidance and the potential regulatory path forward, including the design and timing of the required confirmatory Phase 3 study. At this time, we are pausing any material investments in the Hodgkin lymphoma program. We will evaluate our options for Cami with a disciplined and strategic approach to resource allocation.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADCT-901 is a novel, first-in-class candidate targeting KAAG-1 for the treatment of patients with advanced solid tumors. The Phase 1 trial is currently in dose escalation. We are conducting a Phase 1b trial for ADCT-601 (mipasetamab uzoptirine), targeting AXL, as a single agent and in combination with gemcitabine in patients with sarcoma and other selected advanced solid tumors. Finally, we are completing IND enabling work for our ADCT-701 (targeting DLK-1) and ADCT-212 (PSMA) programs.  </font></div><div id="ic91deae69852495fbb6af4f04f832965_13"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, we believe its impact to our operations, operating results, cash flows, liquidity and financial condition will be primarily driven by its severity and duration, its impact on the U.S. and global economies and the timing, the availability, acceptance and effectiveness of vaccines and treatments, particularly against emerging variants of the novel coronavirus, and the scope and effectiveness of national and local governmental responses to the pandemic. Those primary drivers are beyond our knowledge and control, and as a result, the ultimate impact of the COVID-19 pandemic on our results of operations, cash flows and financial position for the remainder of 2022 and thereafter cannot be reasonably predicted. We are conducting our operations in compliance with official guidance and containment measures related to the pandemic, and we are working proactively with our partners and other stakeholders to take steps to mitigate any negative </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact of the COVID-19 pandemic on our operations. Our employees are meeting with investigators and site staff in person as allowed by institutions.   </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Programs&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor the potential effect of the COVID-19 pandemic on our clinical trials, as well as the supply of our product candidates and will work closely with our clinical trial sites, contract research organizations and contract manufacturing partners to mitigate any such impact. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change.</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial Launch of ZYNLONTA&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our launch plans for ZYNLONTA specifically to mitigate to the best of our ability the impact of the ongoing COVID-19 pandemic. Our Commercial and Medical Affairs teams prepared for a hybrid launch. Face-to-face interactions with physicians are a key pillar of our continued success in driving the adoption of ZYNLONTA through ongoing dialogs with the healthcare provider community on ZYNLONTA's differentiated product profile. Access to physicians continued to improve in the third quarter. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Transactions</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, pursuant to an exchange agreement with Deerfield Partners, L.P., and Deerfield Private Design Fund IV, L.P. (collectively, &#8220;Deerfield&#8221;), Deerfield exchanged USD 115.0 million aggregate principal amount of our senior secured convertible notes for warrants to purchase an aggregate of 4,412,840 common shares, an aggregate of 2,390,297 common shares and cash equal to USD 117.3 million. The warrants consist of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to May 19, 2025. The warrants contain customary anti-dilution adjustments and entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, we drew down USD 120.0 million aggregate principal amount of secured term loans pursuant to a loan agreement and guaranty (the &#34;Loan Agreement&#34;) with certain affiliates and&#47;or funds managed by each of Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, as lenders, and Owl Rock Opportunistic Master Fund I, L.P., as administrative agent and collateral agent. We may draw up to two additional tranches, each up to USD 27.5 million principal amount of term loans before February 15, 2024, subject to satisfaction of certain customary conditions including compliance with our other material agreements for the incurrence of such debt. The secured term loans are scheduled to mature on August 15, 2029 and accrue interest at an annual rate of secured overnight financing rate (&#34;SOFR&#34;) plus 7.50% per annum (with respect to SOFR loans) or a base rate plus 6.50% per annum with respect to alternative base rate (&#34;ABR&#34;) loans for the first five years of the term loans, and thereafter, at an annual rate of SOFR plus 9.25% (with respect to SOFR loans) or a base rate plus 8.25% (with respect to ABR loans), in each case subject to a 1.00% per annum SOFR floor. We are obligated to pay certain exit fees upon certain prepayments and repayments of the principal amount of the term loans. In addition, we have the right to prepay the term loans at any time subject to certain prepayment premiums applicable until the August 15, 2026. The Loan Agreement also contains certain prepayment provisions, including mandatory prepayments from the proceeds from certain asset sales, casualty events and from issuances or incurrences of debt, which may also be subject to prepayment premiums if made on or prior to August 15, 2026. The obligations under the Loan Agreement are secured by substantially all of our assets and those of certain of our subsidiaries and are guaranteed initially by our subsidiaries in the United States and the United Kingdom. The Loan Agreement contains customary covenants, including a covenant to maintain qualified cash of at least USD 60.0 million plus an amount equal to any accounts payable that remain unpaid more than ninety days after the date of the original invoice therefor, and negative covenants including limitations on indebtedness, liens, fundamental changes, asset sales, investments, dividends and other restricted payments and other matters customarily restricted in such agreements. The Loan Agreement also contains customary events of default, after which the term loan may become due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults (including creation of any liens other than those that are expressly permitted), bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the Company and its subsidiaries and change in control. In connection with the loan agreement and guarantee, we issued to the lenders warrants to purchase an aggregate of 527,295 common shares. The warrants have an exercise price of USD 8.30 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to August 15, 2032. The warrants contain customary anti-dilution adjustments and will entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, we entered into a share purchase agreement with Owl Rock Opportunistic Master Fund II, L.P. and OR Opportunistic DL (C), L.P., pursuant to which, on September 6, 2022, we issued and sold to the purchasers an aggregate of 733,568 common shares at USD 8.52 per share for USD 6.1 million in net cash proceeds.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Clinical Program Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ZYNLONTA</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">LOTIS-5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 28, 2022, we announced the results of the safety run-in from LOTIS-5, a Phase 3 confirmatory clinical trial evaluating ZYNLONTA in combination with rituximab in patients with relapsed or refractory DLBCL who are ineligible for autologous stem cell transplant. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 20 patients in the safety run&#8208;in were a median age of 74.5 years (range 35&#8208;93) and received a median of 1 prior line of therapy (range 1&#8208;6). As of the February 28, 2022, data cutoff&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The overall response rate by central review was 15&#47;20 (75%). A total of 8&#47;20 (40%) and 7&#47;20 (35%) patients attained complete response and partial response, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The most common all&#8208;grade TEAEs, regardless of the relationship to the study treatment, were rash (5 25%), fatigue (4 20%), and increased gammaglutamyltransferase (4 20%). The most common grade &#8805;3 TEAEs were increased gammaglutamyltransferase (3 15%), increased alanine aminotransferase (2 10%), and neutropenia (2 10%). </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In part 2 of the trial, approximately 330 patients will be randomized 1&#58;1 to receive Lonca&#8208;R or rituximab&#8208;gemcitabine&#8208;oxaliplatin (R&#8208;GemOx).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cami</font></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We held a pre-BLA meeting in September 2022 and a Type C meeting with the FDA in late October. During the Type C meeting, the FDA provided strong guidance that, for it to consider an accelerated approval path, a randomized confirmatory Phase 3 study must be well underway and ideally fully enrolled at the time of any BLA filing for Cami.  As a result, we will not file the BLA for Cami next year, as we estimate that it would take at least two years to fully enroll a randomized confirmatory Phase 3 study. We are engaged with the FDA in an ongoing and constructive dialogue regarding their guidance and the potential regulatory path forward, including the design and timing of the required confirmatory Phase 3 study. At this time, we are pausing any material investments in the Hodgkin lymphoma program. We will evaluate our options for Cami with a disciplined and strategic approach to resource allocation.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We discontinued enrollment in the Phase 1b clinical trial of Cami in combination with pembrolizumab for the treatment of solid tumors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The combination was an immune-based approach and intended to enhance the benefit of PD1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we observed signals of immunomodulatory activity, the clinical data were not compelling enough to move forward. We recognize the considerable effort required to fully pursue the opportunity and intend to consider strategic alternatives including a partner for the future development of the program.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As this combination was an immunotherapy approach and different from our other solid tumor programs, we do not see any read through to our other programs, which we continue to advance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ADCT-602</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 3, 2022 we announced an abstract submitted by MD Anderson for ADCT-602 that will be presented in an oral presentation at ASH in December 2022.  The initial Phase 1 data show encouraging clinical activity.  Additional details will be disclosed at the ASH congress. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Corporate Updates </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 1, 2022, Peter Graham was appointed the Company&#8217;s Chief Legal Officer. Mr. Graham is a senior legal executive with over 25 years of legal, compliance and executive management experience in biotechnology, pharmaceutical and medical device companies. From 2010 until its sale to Halozyme Therapeutics, Inc. in 2022, Mr. Graham served as Executive Vice President, General Counsel, Chief Compliance Officer, Human Resources and Secretary of Antares Pharma, Inc., a commercial-stage specialty pharmaceutical and combination product company. Previously, he served as Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources at Delcath Systems, Inc., a company with commercial operations in Europe focused on cancers of the liver. Earlier, Mr. Graham held leadership roles at ACIST Medical Systems, Inc., E-Z-EM, Inc., and AngioDynamics, Inc. Mr. Graham received his J.D. from Yeshiva University's Benjamin N. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cardozo School of Law and his B.A. in Political Science from the University of Wisconsin-Madison. There are no family relationships between Mr. Graham and any of our directors or executive officers.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 1, 2022, Kristen Harrington-Smith was appointed the Company's Chief Commercial Officer. Ms. Harrington-Smith is a seasoned leader with over 20 years of experience in the pharmaceutical industry. Most recently, she has served as Chief Commercial Officer of Immunogen where she has been responsible for building the commercial organization and preparing for the launch of its first commercial product. Prior to that, she served as Vice President and Head, US Hematology at Novartis Pharmaceuticals, where she led the teams responsible for a portfolio of therapies in both malignant and non-malignant hematologic diseases including diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. In previous roles of increasing seniority at Novartis, Ms. Harrington-Smith was Vice President and Head, US CAR-T, responsible for the commercial launch of Kymriah&#174;, the first CAR-T cell therapy for both DLBCL and acute lymphoblastic leukemia, building the management, sales, marketing, and market access teams, and supporting the launch of Gilenya&#174; for the treatment of multiple sclerosis. Ms. Harrington-Smith received an MBA from the Kenan-Flagler Business School at the University of North Carolina and a BA from Williams College. There are no family relationships between Ms. Harrington-Smith and any of our directors or executive officers.</font></div><div id="ic91deae69852495fbb6af4f04f832965_16"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2022 and 2021</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Product revenues, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21,321&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,147&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">License revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76,321&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,147&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">63,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,295)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(502)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(793)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(41,676)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(36,805)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,871)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling and marketing expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(16,847)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(17,045)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(19,617)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(16,587)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3,030)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(79,435)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(70,939)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8,496)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3,114)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(57,792)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54,678&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">273&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">257&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(11,356)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,265)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7,091)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(37,122)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9,363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(27,759)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total other expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(48,205)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(13,612)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(34,593)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Loss before taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51,319)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(71,404)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20,085</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax benefit (expense) </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">711&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(145)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">856&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(50,608)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(71,549)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20,941</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to December 31, 2021, individual components of Non-operating expense were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#8220;Non-operating (expense) income&#8221; to the unaudited condensed consolidated interim financial statements for further information.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Notable items other than revenue from product sales and license revenue impacting the results of operations for the three months ended September&#160;30, 2022 and 2021 included&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">P&#38;L Classification</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Impairment of assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">767&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">767&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustment of Facility Agreement derivatives</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,660&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,943&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,283)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss on extinguishment</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustment of senior secured term loans warrant obligation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustment of Deerfield warrant obligation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating income </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,418&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,418&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share of Overland ADCT BioPharma net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,210&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(80)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective interest on the first and second tranche convertible loans</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,536&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,961&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,425)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective interest on senior secured term loan facility</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumulative catch-up adjustment of deferred royalty obligation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accretion expense of deferred royalty obligation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,423&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenue</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, we received accelerated approval from the FDA for ZYNLONTA for the treatment of relapsed or refractory DLBCL and launched in the U.S. shortly thereafter. To date, our only source of product revenue, which commenced during May 2021, has been from sales of ZYNLONTA. Product revenues, net increased to USD 21.3 million for the three months ended September&#160;30, 2022 from USD 13.1 million for the three months ended September&#160;30, 2021, an increase of USD 8.2 million primarily due to higher sales volumes related to ZYNLONTA. Our revenue may fluctuate from period to period based on a number of factors including, but not limited to, patient demand, as well as the timing, dose and duration of patient therapy and customers&#8217; buying patterns, including their building of inventory and gross-to-net deductions.</font></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July 2022, we entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. Under the terms of the agreement, the Company received an upfront payment of USD 55 million, which was recorded as license revenue within the unaudited condensed consolidated interim statement of operations. See note 5, &#34;Revenue recognition&#34; to the unaudited condensed consolidated interim financial statements for further information.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of sales</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales increased to USD 1.3 million for the three months ended September&#160;30, 2022 from USD 0.5 million for the three months ended September&#160;30, 2021, an increase of USD 0.8 million primarily related to impairment charges associated with inventory manufactured using the Company's existing process at a new facility that did not meet our specifications. The specification issues did not, and are not expected to, impact the company&#8217;s ability to supply commercial product. Cost of product sales primarily consisted of direct and indirect costs relating to the manufacture of ZYNLONTA from third-party providers of manufacturing, distribution and logistics services, intangible asset amortization expense, impairment charges and royalties paid to a collaboration partner based on net product sales of ZYNLONTA.    </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">R&#38;D expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&#38;D expenses for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">External costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24,363&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,041&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,322&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,313&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,764&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">549&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">41,676</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">36,805</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">4,871</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes depreciation expense</font></div><div style="margin-top:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes share-based compensation expense</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased to USD</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.7 million for the three months ended September&#160;30, 2022 from USD 36.8 million for the three months ended September&#160;30, 2021, an increase of USD 4.9 million, or 13.2%. External costs increased primarily as a result of higher chemistry, manufacturing and controls (&#34;CMC&#34;) expense due to manufacturing activities to support the ADCT-212 program, advance Cami to support a BLA submission and build our pipeline. Employee expense increased primarily due to higher contract labor expenses. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&#38;D expenses for our major development programs for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ZYNLONTA</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(274)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cami</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,579&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-602</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">293&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">539&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(246)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-601</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,659&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,574&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(915)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-901</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,250&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,897&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(647)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-212</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,493&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,325&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preclinical product candidates and research pipeline</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,513&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,742&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(229)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not allocated to specific programs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,680&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,388&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">292&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,309&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,311&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">R&#38;D expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">41,676</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">36,805</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,871</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to June 30, 2022, share-based compensation expense was allocated to the major development programs and preclinical product candidates and research pipeline. Prior to September 30, 2022, ADCT-212 was included in the Preclinical product candidates and research pipeline. Prior periods have been recast to conform to the current period presentation.</font></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&#38;D expenses for our major development programs will fluctuate from period to period primarily due to the nature and timing associated with the various lifecycle stages of each program, including but not limited to early R&#38;D activities&#59; manufacturing of clinical drug product&#59; clinical trial activity&#59; costs associated with the regulatory approval process&#59; and manufacturing costs associated with commercialization activities prior to the receipt of regulatory approval.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&#38;D expenses related to Cami was primarily due to higher CMC expenses as various development activities to support a BLA submission and ongoing clinical trial activity occurred during the three months ended September&#160;30, 2022. This increase was partially offset by a decrease in clinical trial activity of the pivotal Phase 2 trial for HL.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&#38;D expenses related to ADCT-601 was primarily related to lower CMC expenses partially offset by higher clinical expenses.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&#38;D expenses related to ADCT-901 was primarily due to lower CMC and clinical expenses.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&#38;D expenses related to ADCT-212 was primarily due to higher manufacturing expenses related to IND-enabling work during the three months ended September&#160;30, 2022.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">S&#38;M expenses</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our S&#38;M expenses for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">External costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> 1</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,236&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,973&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">263&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> 2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,072&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(461)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">S&#38;M expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16,847</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">17,045</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(198)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:2pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes depreciation expense for Property, plant and equipment for the three months ended September&#160;30, 2022. All other depreciation expense was not material for the three months ended September&#160;30, 2022. All depreciation expense was not material for the three months ended September&#160;30, 2021.</font></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes share-based compensation expense.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our S&#38;M expenses decreased to USD 16.8 million for the three months ended September&#160;30, 2022 from USD 17.0 million for the three months ended September&#160;30, 2021, a decrease of USD 0.2 million, or 1.2% primarily due to lower employee expense due to lower share-based compensation expense. External costs increased for the three months ended September 30, 2022 primarily as a result of higher expenses relating to the commercial launch of ZYNLONTA.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">G&#38;A expenses</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our G&#38;A expenses for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">External costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,020&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,599&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">421&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,597&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,988&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,609&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">G&#38;A expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">19,617</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,587</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,030</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes depreciation expense</font></div><div style="margin-top:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes share-based compensation expense</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses increased to USD 19.6 million for the three months ended September&#160;30, 2022 from USD 16.6 million for the three months ended September&#160;30, 2021, an increase of USD 3.0 million, or 18.3%. Employee expense for the three months ended September&#160;30, 2022 increased to USD 14.6 million primarily related to USD 1.3 million of executive compensation associated with the CEO transition and higher share-based compensation expense. External costs for the three months ended September 30, 2022 was primarily due to higher professional expenses. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other income (expense)</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other income for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Financial income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">273&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">257&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Financial expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(11,356)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,265)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7,091)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Non-operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(37,122)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9,363)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(27,759)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total other expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(48,205)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(13,612)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(34,593)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial income</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial income for the three months ended September&#160;30, 2022 was KUSD 273 as compared to KUSD 16 for the three months ended September&#160;30, 2021 due to higher yields received on our cash deposits.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial expense</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial expense increased to USD 11.4 million for the three months ended September&#160;30, 2022 from USD 4.3 million for the three months ended September&#160;30, 2021. The increase was primarily due to interest expense related to the accretion of our deferred royalty obligation with HCR. The deferred royalty obligation with HCR was entered into during August 2021. Our accounting of these expenses is explained in note 19, &#8220;Deferred royalty obligation&#8221; to the unaudited condensed consolidated interim financial statements. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating expense</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible loans, derivatives, change in fair value (expense) income</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in convertible loans, derivatives, change in fair value was an expense of USD 4.7 million and USD 6.9 million for the three months ended September&#160;30, 2022 and 2021, respectively. Pursuant to the Facility Agreement with Deerfield, we drew down the first and second tranches of the convertible loans amounting to USD 65.0 million and USD 50.0 million on May 19, 2020 and May 17, 2021, respectively.  The increases in fair values of the embedded derivatives are primarily due to increases in </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of the underlying shares during the respective periods. Our accounting for these changes in our derivative fair values is explained in note 15, &#8220;Convertible loans&#8221; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss on debt extinguishment</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement, the Company recognized a loss on extinguishment of USD 42.1 million for the three months ended September 30, 2022, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans,&#8221; note 16, &#8220;Deerfield warrants&#8221; and note 17 &#8220;Equity&#8221; for further information on this transaction. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior secured term loans and warrants</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the first tranche of the senior secured term loan and warrants as one hybrid financial instrument, with the USD 120.0 million proceeds separated into two components&#58; a warrant obligation and a loan. The warrant obligation has been recorded at its initial fair value at the time the agreement was entered into on August 15, 2022 and is remeasured to fair value on a quarterly basis. The income of USD 2.5 million as a result of changes in the warrant obligation for the three months ended September&#160;30, 2022 was primarily due to the decrease in fair value of the underlying shares since August 15, 2022. Our accounting for these changes in the fair value of our warrant obligation is explained in note 14, &#34;Senior secured term loan facility and warrants&#34; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deerfield warrant obligation, change in fair value income</font></div><div style="margin-bottom:0.1pt;margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to Deerfield to purchase an aggregate of 4,412,840 common shares. The Deerfield warrants obligation has been recorded at its initial fair value at the time the agreement was entered into on August 15, 2022 and is remeasured to fair value on a quarterly basis. The income of USD 9.4 million as a result of changes in the warrants obligation for the three months September 30, 2022 was primarily due to the decrease in fair value of the underlying shares since August 15, 2022. Changes in fair value of the Deerfield warrants obligation are explained in note 16, &#34;Deerfield warrants&#34; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share of Results with Joint Venture</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded our proportionate share of Overland ADCT BioPharma&#8217;s net loss of USD 2.1 million and USD 2.2 million for the three months ended September&#160;30, 2022 and 2021, respectively. See note 12, &#8220;Interest in joint venture&#8221; within the notes to the unaudited condensed consolidated interim financial statements for further details. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income tax expense</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded an income tax benefit of KUSD 711 and income tax expense of KUSD 145 for the three months ended September&#160;30, 2022 and 2021, respectively. The income tax benefit is significantly less than the loss before taxes effected at the blended statutory rate due to the fact that the Company does not recognize current or deferred income taxes in connection with its Swiss operations. The Company does not expect to be able to realize the benefit of its tax loss carryforwards for Swiss corporate income tax purposes, and, therefore, we have not recognized deferred tax assets in our financial statements. Further, the Company does not generate or pay current income taxes in Switzerland. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax benefit recorded during the three months ended September 30, 2022 is driven by its U.S. operations. Generally, current income tax is recorded primarily due to our internal arrangements to reimburse our foreign subsidiaries in the U.S. and the United Kingdom for the services they render to our parent company in Switzerland. Commercial sales in the U.S. also contributed to the current period income tax expense. Ultimately, the net profit at each subsidiary is subject to local income tax.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating future taxable income, management develops assumptions including the amount of future net revenue and pre-tax operating income and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates we are using to manage the underlying business. Management notes that its projections of future taxable profits rely on currently enacted law and are subject to revision if the U.S. legislates new tax law. As such, changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. We record the effect of a tax rate or law change on our deferred tax assets and liabilities in the period of enactment. Future tax rate or law changes could have a material effect on our financial condition, results of operations or cash flows.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10</font></div></div></div><div id="ic91deae69852495fbb6af4f04f832965_19"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:0.1pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2022 and 2021</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Product revenues, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55,110&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,907&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">38,203&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">License revenue</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">140,110&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,907&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">123,203&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4,090)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(623)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,467)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(139,165)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(115,510)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(23,655)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Selling and marketing expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(52,876)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(46,177)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,699)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(56,868)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(53,536)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,332)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating expense</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(252,999)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(215,846)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(37,153)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(112,889)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(198,939)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">86,050&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income (expense)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,597&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">46&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,551&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(29,374)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(8,820)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(20,554)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating (expense) income </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(10,805)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,560&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(23,365)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total other (expense) income</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(21,582)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,786&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(25,368)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss before taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(134,471)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(195,153)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">60,682&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Income tax benefit (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,828&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(492)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(131,643)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(195,645)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">64,002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to December 31, 2021, individual components of Non-operating (expense) income were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#8220;Non-operating (expense) income&#8221; to the unaudited condensed consolidated interim financial statements for further information.</font></div><div style="margin-top:7pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Notable items other than revenue from product sales and license revenue impacting the results of operations for the nine months ended September&#160;30, 2022 and 2021 included&#58;</font></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">P&#38;L Classification</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Impairment of assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost of product sales</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,629&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,629&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&#38;D expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,097&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,230&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S&#38;M expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,585&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,529)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">G&#38;A expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22,611&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27,035&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4,424)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustment of Facility Agreement derivatives</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,279&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,371&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss on extinguishment</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustment of senior secured term loan warrant obligation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,543&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,543&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value adjustment of Deerfield warrant obligation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share of Overland ADCT BioPharma net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,549&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,906&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,643&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective interest on first and second tranche convertible loans</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,684&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,393&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">291&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective interest senior secured term loan facility</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,933&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,933&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumulative catch-up adjustment of deferred royalty obligation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cumulative catch-up adjustment of deferred royalty obligation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,255&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,255&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accretion expense of deferred royalty obligation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16,110&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue</font></div><div style="margin-top:7pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product revenues</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, we received accelerated approval from the FDA for ZYNLONTA for the treatment of relapsed or refractory DLBCL and launched in the U.S. shortly thereafter. To date, the Company&#8217;s only source of product revenue, which commenced during May 2021, has been from sales of ZYNLONTA. Product revenues, net increased to USD 55.1 million for the nine months ended September&#160;30, 2022, from USD 16.9 million for the nine months ended September&#160;30, 2021, an increase of USD 38.2 million, due to a full nine months of sales activity in 2022. Our revenue may fluctuate from period to period based on a number of factors including, but not limited to, patient demand, as well as the timing, dose and duration of patient therapy and customers&#8217; buying patterns, including their building of inventory and gross-to-net deductions.</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, we entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Under the terms of the agreement, we received an upfront payment of USD 30.0 million. During July 2022, we entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. Under the terms of the agreement, the Company received an upfront payment of USD 55.0 million. Both of these items were recorded as license revenue within the unaudited condensed consolidated interim statement of operations. See note 5, &#34;Revenue recognition&#34; to the unaudited condensed consolidated interim financial statements for further information.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of sales</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales increased to USD 4.1 million for the nine months ended September&#160;30, 2022 from USD 0.6 million for the nine months ended September&#160;30, 2021, an increase of USD 3.5 million primarily associated with USD 2.5 million of impairment charges, of which USD 1.7 million related to the manufacturing of antibodies that did not meet our specifications. In addition, an increase of USD 0.8 million was associated with inventory manufactured using the Company's existing process at a new facility that did not meet our specifications. The specification issues did not, and are not expected to, impact the company&#8217;s ability to supply commercial product. In addition, cost of product sales increased due to a full nine months of sales activity in 2022 as compared to the comparable period in 2021 due to the commencement of ZYNLONTA sales in May 2021. Cost of product sales primarily consisted of direct and indirect costs relating to the manufacture of ZYNLONTA from third-party providers of manufacturing, distribution and logistics services, intangible asset amortization expense, impairment charges and royalties paid to a collaboration partner based on net product sales of ZYNLONTA.   </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&#38;D expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&#38;D expenses for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">External costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83,706&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66,330&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,376&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55,459&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,279&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">R&#38;D expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">139,165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">115,510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">23,655</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes depreciation expense</font></div><div style="margin-top:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes share-based compensation expense</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our R&#38;D expenses increased to USD 139.2 million for the nine months ended September&#160;30, 2022 from USD 115.5 million for the nine months ended September&#160;30, 2021, an increase of USD 23.7 million, or 20.5%. As a result of FDA approval of ZYNLONTA in April 2021, the Company reversed KUSD 7,049 of previously recorded impairment charges during the nine months ended September&#160;30, 2021, relating to inventory costs incurred for the manufacture of product prior to FDA approval. External costs increased primarily as a result of higher chemistry, manufacturing and controls (&#34;CMC&#34;) expense due to manufacturing activities to support the ADCT-212 program, as well as our continued clinical trials to expand the potential market opportunities for ZYNLONTA in earlier lines of therapy, advance Cami to support a BLA submission and build our pipeline. Employee expense increased primarily due to higher contract labor, wages and benefits and share-based compensation expense. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our R&#38;D expenses for our major development programs for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> 1 </font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ZYNLONTA</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56,065&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50,979&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,086&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cami</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23,396&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,561&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-602</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">871&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(459)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-601</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,903&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,802)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-901</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,939&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,794&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,855)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADCT-212</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,040&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">555&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,485&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Preclinical product candidates and research pipeline</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,424&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Not allocated to specific programs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8,671&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,031&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,640&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Share-based compensation </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,097&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,867&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,230&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">R&#38;D expenses</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">139,165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">115,510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">23,655</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to June 30, 2022, share-based compensation expense was allocated to the major development programs and preclinical product candidates and research pipeline. Prior to September 30, 2022, ADCT-212 was included in the Preclinical product candidates and research pipeline. Prior periods have been recast to conform to the current period presentation.</font></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&#38;D expenses for our major development programs will fluctuate from period to period primarily due to the nature and timing associated with the various lifecycle stages of each program, including but not limited to early R&#38;D activities&#59; manufacturing of clinical drug product&#59; clinical trial activity&#59; costs associated with the regulatory approval process&#59; and manufacturing costs associated with commercialization activities prior to the receipt of regulatory approval.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of FDA approval of ZYNLONTA in April 2021, the Company reversed KUSD 7,049 of previously recorded impairment charges during the nine months ended September&#160;30, 2021, relating to inventory costs incurred for the manufacture of product prior to FDA approval. R&#38;D expenses related to ZYNLONTA increased due to the undertaking of clinical trials to expand the potential market opportunities for ZYNLONTA in earlier lines of therapy, which was partially offset by lower CMC expenses due to the absence of pre-launch commercial supply activities that were performed during the nine months ended September&#160;30, 2021. </font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&#38;D expenses related to Cami was primarily due to higher personnel costs and CMC expenses as various development activities to support a BLA submission and ongoing clinical trial activity occurred during the nine months ended September&#160;30, 2022. This increase was partially offset by a decrease in clinical trial activity of the pivotal Phase 2 trial for HL.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&#38;D expenses related to ADCT-601 was primarily due to lower CMC expenses partially offset by higher clinical expenses.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in R&#38;D expenses related to ADCT-901 was primarily due to lower CMC and preclinical expenses incurred in the nine months ended September 30, 2021.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in R&#38;D expenses related to ADCT-212 was primarily due to higher manufacturing expenses related to IND-enabling work during the nine months ended September&#160;30, 2022.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">S&#38;M expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our S&#38;M expenses for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">External costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26,406&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,989&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,417&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26,470&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27,188&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(718)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">S&#38;M expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">52,876</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">46,177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,699</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:2pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes depreciation expense for Property, plant and equipment for the nine months ended September&#160;30, 2022. All other depreciation expense was not material for the nine months ended September&#160;30, 2022. All depreciation expense was not material for the nine months ended September&#160;30, 2021.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="margin-top:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes share-based compensation expense.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our S&#38;M expenses increased to USD 52.9 million for the nine months ended September&#160;30, 2022 from USD 46.2 million for the nine months ended September&#160;30, 2021, an increase of USD 6.7 million, or 14.5%. The increase was primarily due to increased professional expenses relating to the commercial launch of ZYNLONTA. This increase during the nine months ended September 30, 2022 was partially offset by lower employee expenses primarily due to lower share-based compensation expense.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">G&#38;A expenses</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">External costs </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,539&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,204&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,335&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employee expense </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,332&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">G&#38;A expenses</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">56,868</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">53,536</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">3,332</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes depreciation expense</font></div><div style="margin-top:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes share-based compensation expense</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses increased to USD 56.9 million for the nine months ended September&#160;30, 2022 from USD 53.5 million for the nine months ended September&#160;30, 2021, an increase of USD 3.3 million, or 6.2%. External costs increased primarily due to higher professional fees, including the fees associated with the license agreement entered into with MTPC. Employee expense for the nine months ended September&#160;30, 2022 remained virtually flat at USD 38.3 million primarily as a result of lower share-based compensation expense offset by higher wages and benefits, including USD 1.3 million of executive compensation associated with the CEO transition.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other income (expense)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other income and expense for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">in KUSD</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income (expense) </font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,597&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,551&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(29,374)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(8,820)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(20,554)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-operating (expense) income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(10,805)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,560&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(23,365)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total other (expense) income</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(21,582)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,786</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(25,368)</font></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial income</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial income increased to KUSD 18,597 for the nine months ended September&#160;30, 2022 from KUSD 46 for the nine months ended September&#160;30, 2021. The increase was primarily related to the cumulative catch-up adjustment associated with the deferred royalty obligation with HCR based on the Company's 2022 strategic planning decisions including updated development plans and updated valuation model during the first quarter of 2022. See note 19, &#8220;Deferred royalty obligation&#8221; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial expense</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial expense increased to USD 29.4 million for the nine months ended September&#160;30, 2022 from USD 8.8 million for the nine months ended September&#160;30, 2021. The increase was primarily due to interest expense related to the accretion of our deferred royalty obligation with HCR and senior secured term loans, calculated at their respective implied effective interest rate, as well as a USD 2.2 million cumulative catch-up adjustment related to our deferred royalty obligation. The deferred royalty obligation with HCR was entered into during August 2021 and the senior secured term loan facility was entered into during August 2022. Our accounting of these expenses is explained in note 19, &#8220;Deferred royalty obligation&#8221;, note 14, &#34;Senior secured term loan facility and warrants&#34; and note 15, &#8220;Convertible loans&#8221; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating (expense) income</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible loans, derivatives, change in fair value income (expense)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in convertible loans, derivatives, change in fair value was income of USD 25.7 million and USD 16.3 million for the nine months ended September&#160;30, 2022 and 2021, respectively. Pursuant to the Facility Agreement with Deerfield, we drew down the first and second tranches of the convertible loans amounting to USD 65.0 million and USD 50.0 million on May 19, 2020 and May 17, 2021, respectively. The decreases in fair values of the embedded derivatives are primarily due to decreases in the fair value of the underlying shares during the respective periods. Our accounting for these changes in derivative fair values is explained in note 15, &#8220;Convertible loans&#8221; to the unaudited condensed consolidated interim financial statements. </font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss on debt extinguishment</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement, the Company recognized a loss on extinguishment of USD 42.1 million for the nine months ended September 30, 2022, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans,&#8221; note 16, &#8220;Deerfield warrants&#8221; and note 17 &#8220;Equity&#8221; for further information on this transaction. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior secured term loans and warrants</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the first tranche of the senior secured term loan and warrants as one hybrid financial instrument, with the USD 120.0 million proceeds separated into two components&#58; a warrant obligation and a loan. The warrant obligation has been recorded at its initial fair value at the time the agreement was entered into on August 15, 2022 and is remeasured to fair value on a quarterly basis. The income of USD 2.5 million as a result of changes in the warrant obligation for the nine months ended September&#160;30, 2022 was primarily due to the decrease in fair value of the underlying shares since August 15, 2022. Our accounting for these changes in the fair value of our warrant obligation is explained in note 14, &#34;Senior secured term loan facility and warrants&#34; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deerfield warrant obligation, change in fair value income</font></div><div style="margin-bottom:0.1pt;margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to Deerfield to purchase an aggregate of 4,412,840 common shares. The Deerfield warrant obligation has been recorded at its initial fair value at the time the agreement was entered into on August 15, 2022 and is remeasured to fair value on a quarterly basis. The income of USD 9.4 million as a result of changes in the warrant obligation for the three months September 30, 2022 was primarily due to the decrease in fair value of the underlying shares since August 15, 2022. Changes in fair value of the Deerfield warrant obligation are explained in note 16, &#34;Deerfield warrants&#34; to the unaudited condensed consolidated interim financial statements.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share of Results with Joint Venture</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded our proportionate share of Overland ADCT BioPharma&#8217;s net loss of USD 6.5 million and USD 3.9 million for the nine months ended September&#160;30, 2022 and 2021, respectively. Our share of ADCT BioPharma's net loss increased due to higher clinical trial activity at ADCT BioPharma. See note 12, &#8220;Interest in joint venture&#8221; within the notes to the unaudited condensed consolidated interim financial statements for further details. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income tax expense</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recorded an income tax benefit of KUSD 2,828 and income tax expense of KUSD 492 for the nine months ended September 30, 2022 and 2021, respectively. On the basis of our projections of future taxable income, we recognized KUSD 7,550 of a deferred income tax benefit related to temporary differences associated with our U.S. subsidiary during the nine months ended September 30, 2022. The net income tax benefit recorded is primarily the result of a current income tax benefit derived in the U.S. from its foreign-derived intangible income deduction. This benefit reduces our effective rate from the statutory rate of 21% in the U.S. We did not recognize any deferred tax assets in connection with our U.S. operations prior to December 31, 2021. Our current income tax expense was KUSD 4,722 and KUSD 492 for the nine months ended September 30, 2022 and 2021, respectively, and is primarily due to our internal arrangements to reimburse our foreign subsidiaries in the U.S. and the United Kingdom for the services they render to our parent company in Switzerland. Commercial sales in the U.S. also contributed to the current period income tax expense. Ultimately, the net profit at each subsidiary is subject to local income tax.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating future taxable income, management develops assumptions including the amount of future net revenue and pre-tax operating income and the implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of future taxable income and are consistent with the plans and estimates we are using to manage the underlying business. Management notes that its projections of future taxable profits rely on currently enacted law and are subject to revision if the U.S. legislates new tax law. As such, changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. We record the effect of a tax rate or law change on our deferred tax assets and liabilities in the period of enactment. Future tax rate or law changes could have a material effect on our financial condition, results of operations or cash flows.</font></div><div id="ic91deae69852495fbb6af4f04f832965_22"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses. To date, we have financed our operations primarily through equity financings, including our initial public offering and follow-on offering, convertible debt and senior secure term loan financings and additional funds provided by collaborations and royalty financings. As of September&#160;30, 2022, we had cash and cash equivalents of USD 380.9 million. We have an at-the-market (&#8220;ATM&#8221;) offering program, pursuant to which we may sell our common shares with an aggregate offering price of up to USD 200.0 million. There have been no shares sold under the ATM program to date. In addition, under the Loan Agreement, we may draw up to two additional tranches, each up to USD 27.5 million principal amount of term loans before February 15, 2024, subject to satisfaction of certain customary conditions including compliance with our other material agreements for the incurrence of such debt. We plan to continue to fund our operating needs through our existing cash and cash equivalents, revenues from the sale of ZYNLONTA, potential milestone and royalty payments under our licensing agreements and additional equity financings, debt financings and&#47;or other forms of financing, as well as funds provided by collaborations. We are also continuously engaged in discussions to establish value-maximizing strategic collaborations, business combinations, acquisitions, licensing opportunities or similar strategies for clinical development and commercialization of ZYNLONTA and&#47;or our product candidates.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be, R&#38;D expenses, S&#38;M expenses, compensation and related expenses, interest and principal payments on debt obligations and other operating expenses. We expect to incur substantial expenses in connection with the advancement of clinical trials, including pivotal and confirmatory clinical trials, regulatory submissions for our products, product candidates and research pipeline, and the commercialization of ZYNLONTA. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses, as well as the timing of collecting receivables from the sale of ZYNLONTA and paying royalties related to our deferred royalty obligation.</font></div><div style="margin-bottom:0.1pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17</font></div></div></div><div id="ic91deae69852495fbb6af4f04f832965_34"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2022 and 2021</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</font></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net cash (used in) provided by&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(84,697)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(171,747)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">87,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,391)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(5,843)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,452&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,855&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">268,612&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(266,757)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(85,233)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">91,022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(176,255)</font></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net cash used in operating activities</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities decreased to USD 84.7 million for the nine months ended September&#160;30, 2022 from USD 171.7 million for the nine months ended September&#160;30, 2021, a decrease of USD 87.1 million, or 50.7%. The decrease was primarily due to the receipt of the USD 30 million upfront payment from MTPC, the receipt of the USD 55 million upfront payment from Sobi and increases in the cash received from the sale of ZYNLONTA partially offset by increased cash expenditures in the period related to operating expenses in advancing development of our pipeline and the continued commercialization of ZYNLONTA.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net cash used in investing activities</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities decreased to USD 2.4 million for the nine months ended September&#160;30, 2022 from USD 5.8 million for the nine months ended September&#160;30, 2021, a decrease of USD 3.5 million, or 59.1%. The decrease was primarily due to lower capital expenditures and lower intangible asset acquisitions during the nine months ended September&#160;30, 2022. See note 11, &#8220;Intangible assets&#8221; to the unaudited condensed consolidated interim financial statements for further information.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Net cash provided by financing activities</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was USD 1.9 million for the nine months ended September&#160;30, 2022 compared to USD 268.6 million for the nine months ended September&#160;30, 2021. For the nine months ended September 30, 2022, we drew down USD 120.0 million principal amount of term loans under the Loan Agreement prior to transaction costs paid of USD 5.5 million during the three months ended September 30, 2022. In addition, we received USD 6.1 million of proceeds, net of transaction costs paid during the three months ended September 30, 2022, from the issuance of shares under the share purchase agreement. Additionally, we exchanged our senior secured convertible notes pursuant to the exchange agreement with Deerfield, resulting in USD 118.1 million (including exit fees and transaction costs) being used. See note 14, &#34;Senior secured term loan facility and warrants&#34;, note 15, &#34;Convertible loans&#34;, note 16, &#34;Deerfield warrants&#34; and note 17, &#34;Equity&#34; to the unaudited condensed consolidated interim financial statements for further information. During the nine months ended September 30, 2021, the Company received net proceeds of USD 219.3 million from the sale and purchase agreement associated with our deferred royalty obligation with HCR and receipt of the second tranche of convertible loans under the Facility Agreement of USD 49.6 million. </font></div><div id="ic91deae69852495fbb6af4f04f832965_37"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Capital Requirements</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had cash and cash equivalents of USD 380.9 million. Based on our current business plan, we believe that our existing cash and cash equivalents, forecasted revenue from ZYNLONTA, receipt of forecasted royalty and milestone payments under our license agreements and royalty purchase agreement with HCR will enable us to fund our operating expenses and capital expenditure requirements into early 2025. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, which are outlined in our Annual Report on Form 20-F for the year ended December&#160;31, 2021 and our subsequent filings with the SEC, as well as actual versus forecast demand for ZYNLONTA and amounts that we receive under our license and collaboration agreements. In addition, we may seek to raise additional capital through debt and equity financings, license agreements and other arrangements and combinations thereof that we believe are in our best interest.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18</font></div></div></div><div id="ic91deae69852495fbb6af4f04f832965_43"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and during the periods presented, we did not have, and we do not currently have, any off-balance sheet arrangements. </font></div><div id="ic91deae69852495fbb6af4f04f832965_46"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, there were no significant changes to our quantitative and qualitative disclosures about market risk from those described in the section in our Annual Report on Form 20-F for the year ended December&#160;31, 2021 titled &#8220;Item 11. Quantitative and Qualitative Disclosures About Market Risk&#8221; with the exception of a hypothetical 100 basis point increase (decrease) in our interest rate as of September&#160;30, 2022. A hypothetical 100 basis point increase (decrease) in the interest rate as of September 30, 2022 would have increased (decreased) the effective interest associated with our senior secured term loan facility by KUSD 272 and (KUSD 273), respectively. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not believe that inflation had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition or results of operations.</font></div><div id="ic91deae69852495fbb6af4f04f832965_49"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December 31, 2021. There have been no material changes to the significant accounting policies other than those described in note 3, &#34;Significant accounting policies&#34;. In addition, significant judgements were required in determining the fair value of our warrant obligations as set out in note 14 &#8220;Senior secured term loan facility and warrants&#8221; and note 16 &#8221;Deerfield warrants,&#8221; including the selection of the valuation methodology to use, as well as determining the underlying valuation assumptions. </font></div><div id="ic91deae69852495fbb6af4f04f832965_52"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See note 3, &#8220;Significant accounting policies&#8221;, to our unaudited condensed consolidated interim financial statements for a description of recent accounting pronouncements applicable to our unaudited condensed consolidated interim financial statements.</font></div><div id="ic91deae69852495fbb6af4f04f832965_55"></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this discussion, including statements regarding our future results of operations and financial position, business and commercial strategy, potential market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in this discussion can be identified by the use of forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;will&#8221; and &#8220;potential,&#8221; among others.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements appear in a number of places in this discussion and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section in our Annual Report on Form 20-F for the period ended December&#160;31, 2021 titled &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; and in our subsequent filings with the SEC. These forward-looking statements include, among others&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">our expectations regarding revenues derived from sales of ZYNLONTA&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commencement, timing, progress and results of our R&#38;D programs, preclinical studies and clinical trials&#59;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of investigational new drug application (&#8220;IND&#8221;), BLA, sBLA, marketing authorization application (&#8220;MAA&#8221;) and other regulatory submissions with the FDA, the European Medicines Agency (&#8220;EMA&#8221;) or comparable regulatory authorities in other jurisdictions&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proposed development pathway for ZYNLONTA and Cami, and our other product candidates, and the acceptability of the results of clinical trials for regulatory approval by the FDA, EMA or comparable regulatory authorities in other jurisdictions&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assumptions relating to the identification of serious adverse, undesirable or unacceptable side effects related to our products and product candidates&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approval for our product and product candidates&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plan for the commercialization of ZYNLONTA and, if approved, for Cami&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacture and supply of our products and product candidates&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the size of the patient populations amenable to treatment with our products and, if approved, product candidates, as well as the treatment landscape of the indications that we are targeting with our products and product candidates&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assumptions relating to the rate and degree of market acceptance of ZYNLONTA and any other approved products&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of ZYNLONTA and any other approved products&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop additional product candidates&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the development of and projections relating to our competitors or our industry&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of our expenses, revenues, capital requirements, cash runway and need for or ability to obtain additional financing&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital when needed in order to continue our R&#38;D programs or commercialization efforts&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and successfully enter into strategic collaborations or licensing opportunities in the future, and our assumptions regarding any potential revenue that we may generate under current or future collaborations or licensing arrangements&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, protect and enforce intellectual property protection for our products and product candidates, and the scope of such protection&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of third parties&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the COVID-19 pandemic&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of the current conflict between Russia and Ukraine, including resulting sanctions and changes in commodities prices, on our business and industry and the financial markets&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the impact of inflation and other market risks&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain qualified key management and technical personnel&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the effectiveness of our internal controls over financial reporting&#59; and </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the time during which we will be a foreign private issuer.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements speak only as of the date of this discussion and are subject to a number of risks, uncertainties and assumptions described under the section in our Annual Report on Form 20-F for the year ended December&#160;31, 2021 entitled &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; and in our subsequent filings with the SEC. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</font></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this discussion, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>adct-20220930ex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3d04cf63106b45cfa57590bafd017db9_1"></div><div style="min-height:127.44pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Exhibit 99.3</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">                                                                                    </font><img alt="image_4.jpg" src="image_4.jpg" style="height:93px;margin-bottom:5pt;vertical-align:text-bottom;width:166px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">ADC Therapeutics Reports Third Quarter 2022 Financial Results <br>and Provides Business Updates</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">ZYNLONTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> (loncastuximab tesirine-lpyl) net sales of $21.3 million  </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">in the third quarter of 2022 (+23% vs.2Q 2022)</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Cash runway expected into early 2025</font></div><div style="text-align:center;text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Company to host conference call today at 8&#58;30 a.m. EST </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Lausanne, Switzerland, November 8, 2022</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#8211; ADC Therapeutics SA (NYSE&#58; ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided business updates.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;In the third quarter, we made good progress executing our strategy. We are pleased with the strong ZYNLONTA&#174; performance as the new initiatives we started in the second and third quarters of the year begin to gain traction,&#8221; said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. &#8220;We are encouraged by the initial results of LOTIS-5 in earlier lines of diffuse large B-cell lymphoma with ZYNLONTA and rituximab. We continue to prioritize and develop our pipeline and maintain our cash runway into early 2025.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Recent Highlights and Developments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ZYNLONTA (loncastuximab tesirine-lpyl)</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">ZYNLONTA generated net sales of $21.3 million in the third quarter of 2022, representing 23% growth over the second quarter of 2022.  This was driven by a renewed focus on customer-facing execution and the new initiatives put in place in the second and third quarters of 2022 targeting physicians, community practices and networks, and patients and caregivers.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Initial safety run&#8208;in results of 20 patients from the LOTIS-5 Phase 3 trial of ZYNLONTA in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) were presented at the Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), demonstrating an overall response rate of 75%, a complete response rate of 40% and no safety events materially different from those observed in prior clinical trials. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.53pt">The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the marketing authorization of ZYNLONTA (loncastuximab tesirine) for the treatment of relapsed or refractory DLBCL. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Cami (camidanlumab tesirine) </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">The Cami pivotal phase 2 data in relapsed or refractory Hodgkin lymphoma (HL) were presented in an encore presentation at SOHO 2022, demonstrating an overall response rate of 70% and a complete response rate of 33% with previously reported safety profile. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">The Company held a pre-Biologics License Application (BLA) meeting in September 2022 and a Type C meeting with the U.S. Food and Drug Administration (FDA) in late October. During the Type C meeting, the FDA provided strong guidance that, for it to consider an accelerated approval path, a randomized confirmatory Phase 3 study must be well underway and ideally fully enrolled at the time of any BLA filing for Cami.  As a result, the Company will not submit the BLA for Cami next year, as it is estimated that it would take at least two years to fully enroll a randomized confirmatory Phase 3 study. The Company is engaged with the FDA in an ongoing and constructive dialogue regarding their guidance and the potential regulatory path forward. At this time, the Company is pausing any material investments in the HL program </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and will evaluate options for Cami in HL with a disciplined and strategic approach to resource allocation.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.53pt">The Phase 1b study of Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were not compelling enough for the Company to move forward on its own, so the current trial will not proceed.  The Company recognizes the considerable effort required to fully pursue this opportunity may be better suited for a partner with immuno-oncology development expertise.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Pipeline</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">ADCT-602 (targeting CD22)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; Initial data showing encouraging clinical activity from the Phase 1&#47;2 study of ADCT-602 for patients with relapsed or refractory acute lymphoblastic leukemia has been released in an American Society of Hematology (ASH) abstract by the University of Texas MD Anderson Cancer Center. Additional data will be disclosed in an oral presentation at the 64th ASH Annual Meeting.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">ADCT-901 (targeting KAAG1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; Dose escalation in the Phase 1 trial is proceeding. The Company expects to have an indication of the safety and tolerability, as well as any early signals of antitumor activity, in 2023.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:12.53pt">ADCT-601 (targeting AXL)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#58; The Phase 1b trial is ongoing. The study includes a monotherapy arm including patients with AXL gene amplification and a combination arm with gemcitabine in patients with sarcoma.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Corporate Update</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">The Company announced a $175 million senior secured term loan from Owl Rock, a division of Blue Owl Capital, Inc., and Oaktree Capital Management, L.P. and settlement of existing senior secured convertible notes with Deerfield. The Company also entered into a share purchase agreement with Owl Rock for an investment of $6.25 million.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Kristen Harrington-Smith has been appointed the Company&#8217;s new Chief Commercial Officer, effective November 17, 2022. Ms. Harrington-Smith is a seasoned leader with over 20 years of experience in the pharmaceutical industry. Most recently, she has served as Chief Commercial Officer of Immunogen. She has also served as Vice President and Head, US Hematology and Vice President and Head, US CAR-T at Novartis Pharmaceuticals.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Peter Graham was appointed the Company&#8217;s Chief Legal Officer, effective November 1, 2022. Mr. Graham is a senior legal executive with over 25 years of legal, transactional and executive management experience in biotechnology, pharmaceutical and medical device companies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Upcoming Expected Milestones</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ZYNLONTA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Receive a regulatory decision from the European Commission for third-line DLBCL in 4Q 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Pipeline</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADCT-901 (targeting KAAG1)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Preliminary results of safety and tumor response for the Phase 1 dose-escalation trial in multiple solid tumors in 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADCT-602 (targeting CD-22)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">University of Texas MD Anderson Cancer Center to present oral presentation of Phase 1&#47;2 data at ASH Annual Meeting in 4Q 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADCT-212 (targeting PSMA)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Progress toward IND filing and initiation of Phase 1 trial in 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADCT-701 (targeting DLK-1)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Progress toward IND filing and initiation of Phase 1 trial in 2023</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Third Quarter Financial Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cash and Cash Equivalents</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Cash and cash equivalents were $380.9 million as of September 30, 2022, compared to $376.8 million as of June 30, 2022. Based on the Company&#8217;s business plan and expected milestones from Sobi and Healthcare Royalty Partners, the cash runway extends into early 2025. Potential near-term milestone payments from those agreements include a $50 million milestone from Sobi upon European regulatory approval of ZYNLONTA in third-line DLBCL and a $75 million milestone from our Healthcare Royalty Partners agreement for the first EU Commercial sale. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Product revenue (net) was $21.3 million for the quarter, compared to $13.1 million for the same quarter in 2021. Net revenues are for U.S. sales of ZYNLONTA.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">License Revenue</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">License revenue was $55.0 million for the current quarter. During July 2022, the Company entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. Under the terms of the agreement, the Company received an upfront payment of $55.0 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of product sales</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Cost of product sales was $1.3 million for the quarter, compared to $0.5 million for the same quarter in 2021, an increase of $0.8 million primarily related to impairment charges for product intermediates not meeting the Company&#8217;s specifications. The specification issues did not, and are not expected to, impact the Company&#8217;s ability to supply commercial product. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Research and Development (R&#38;D) Expenses</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">R&#38;D expenses were $41.7 million for the quarter ended September 30, 2022, compared to $36.8 million for the same quarter in 2021.&#160;R&#38;D expenses increased as a result of continued investments in the pipeline. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%"><br>Selling and Marketing (S&#38;M) Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S&#38;M expenses were $</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.8 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended September 30, 2022, compared to $17.0 million for the same quarter in 2021. The decrease in S&#38;M expenses is related to lower share-based compensation partly offset by higher expenses relating to the ongoing commercial launch of ZYNLONTA. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">G&#38;A Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">G&#38;A expenses were $19.6 million for the quarter ended September 30, 2022, compared to $16.6 million for the same quarter in 2021.  G&#38;A expenses increased primarily due to costs associated with the recent CEO transition as well as higher share-based compensation and professional expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Net Loss and Adjusted Net Loss</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net loss was $50.6 million, or a net loss of $0.65 per basic and diluted share, for the quarter ended September 30, 2022. This compares to a net loss of $71.5 million, or a net loss of $0.93 per basic and diluted share, for the same quarter in 2021. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Adjusted net income was $10.3 million, or an adjusted net income of $0.13 per basic and diluted share, for the quarter ended September 30, 2022. This compares to an adjusted net loss of $45.6 million, or an adjusted net loss of $0.59 per basic and diluted share, for the same quarter in 2021. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The decrease in net loss and adjusted net loss for the quarter ended September 30, 2022, as compared to the same period in 2021, was primarily due to higher product and license revenue, partially offset by the increase in cost of product sales, R&#38;D and G&#38;A expenses. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, net loss decreased for the third quarter of 2022 as a result of income and lower charges arising from changes in the fair value of our warrant obligations and derivatives, respectively. These benefits were partially offset by the loss on extinguishment of our convertible loans and derivatives and higher interest and cumulative catch-up expense associated with the deferred royalty obligation with Healthcare Royalty Partners.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Details</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2022 financial results and provide a company update today at 8&#58;30 a.m. Eastern Time. To access the conference call, please register</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> here.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time.  A live webcast of the call will be available under &#8220;Events and Presentations&#8221; in the Investors section of the ADC Therapeutics website at</font><font style="color:#0e32e1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> ir.adctherapeutics.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The archived webcast will be available for 30 days following the call.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About ZYNLONTA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> (loncastuximab tesirine-lpyl)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA&#174; is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r&#47;r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double&#47;triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval based on overall response rate and continued </font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">About ADC Therapeutics</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics (NYSE&#58; ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics&#8217; CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ADC Therapeutics is based in Lausanne (Biop&#244;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;adctherapeutics.com&#47;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and follow the Company on </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Twitter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> and </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LinkedIn</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ZYNLONTA&#174; is a registered trademark of ADC Therapeutics SA.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Use of Non-IFRS Financial Measures</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to financial information prepared in accordance with IFRS, this document also contains certain non-IFRS financial measures based on management&#8217;s view of performance including&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted net loss and income</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Adjusted net loss and income per share</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Management uses such measures internally when monitoring and evaluating our operational performance, generating future operating plans and making strategic decisions regarding the allocation of capital. We believe that these adjusted financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and facilitate operating performance comparability across both past and future reporting periods. These non-IFRS measures have limitations as financial measures and should be considered in addition to, and not in isolation or as a substitute for, the information prepared in accordance with IFRS. When preparing these supplemental non-IFRS measures, management typically excludes certain IFRS items that management does not believe are indicative of our ongoing operating performance. Furthermore, management does not consider these IFRS items to be normal, recurring cash operating expenses&#59; however, these items may not meet the IFRS definition of unusual or non-recurring items. Since non-IFRS financial measures do not have standardized definitions and meanings, they may differ from the non-IFRS financial measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other IFRS financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:127.44pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The following items are excluded from adjusted net loss and adjusted net loss per share&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Shared-Based Compensation Expense&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> We exclude share-based compensation expense from our adjusted financial measures because share-based compensation expense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Share-based compensation expense has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Certain Other Items&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We exclude certain other significant items that we believe do not represent the performance of our business, from our adjusted financial measures. Such items are evaluated by management on an individual basis based on both quantitative and qualitative aspects of their nature. While not all-inclusive, examples of certain other significant items excluded from our adjusted financial measures would be&#58; changes in the fair value of derivatives and warrant obligations and the effective interest expense associated with the Facility Agreement with Deerfield and the senior secured term loan facility, loss on extinguishment, transaction costs associated with debt or equity issuances that are expenses pursuant to IFRS, and the effective interest expense and a cumulative catch-up adjustment associated with the deferred royalty obligation under the royalty purchase agreement with HealthCare Royalty Partners.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">See the attached Reconciliation of IFRS Measures to Non-IFRS Measures for explanations of the amounts excluded and included to arrive at the non-IFRS financial measures.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business and commercialization strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</font></div><div><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i3d04cf63106b45cfa57590bafd017db9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Statement of Operations (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in KUSD except for per share data)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,321&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,147&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,110&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,907&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,321</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140,110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,907</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,090)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,676)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,805)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,165)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115,510)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,847)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,045)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,876)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,177)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,617)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,587)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,868)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,536)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,435)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,939)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(252,999)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,846)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,114)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,792)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,889)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198,939)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,597&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial expense</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,356)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,265)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,374)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,820)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating (expense) income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,122)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,805)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,560&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,205)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,612)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,582)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,786&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(51,319)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71,404)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(134,471)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(195,153)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense) </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50,608)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71,549)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131,643)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(195,645)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Owners of the parent</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,608)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,549)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,643)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,645)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.70)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.55)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i3d04cf63106b45cfa57590bafd017db9_7"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Interim Balance Sheet (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in KUSD)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">466,544&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,218&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,745&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,243&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,298&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">438,099</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">525,182</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,169&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,066&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,708&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,598&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,582&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest in joint venture</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,687&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,236&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,599&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,049&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">93,660</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92,790</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531,759</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">617,972</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS' EQUITY&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,611&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,080&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,658&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, short-term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current income tax payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,754&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loans, short-term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,469&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible loans, short-term</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,575&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87,573</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73,935</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior secured term loans, long- term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,731&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible loans, long-term</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87,153&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible loans, derivatives</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,947&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant obligations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred royalty obligation, long-term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,218&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,664&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred gain of joint venture</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,539&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,539&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, long-term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,622&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defined benefit pension liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,652&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">339,403</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">377,949</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">426,976</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">451,884</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity attributable to owners of the parent</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share capital</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,699&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,445&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share premium</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,007,510&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981,827&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury shares</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other reserves</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,045&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,646&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(842)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated losses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,056,528)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(924,885)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total equity attributable to owners of the parent</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">104,783</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">166,088</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531,759</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">617,972</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i3d04cf63106b45cfa57590bafd017db9_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ADC Therapeutics SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of IFRS Measures to Non-IFRS Measures (Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(in KUSD except for share and per share data)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"></td><td style="width:47.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">in KUSD (except for share and per share data)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50,608)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(71,549)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(131,643)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(195,645)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (i)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,565&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,798&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,293&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,016&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible loans, derivatives, change in fair value expense (income) (ii)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,943&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,650)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,279)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible loans, second tranche, derivatives, transaction costs (iii)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment (iv)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured term loans, warrants, change in fair value income (ii)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,543)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,543)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest expense on convertible loans (v)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,961&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,684&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,393&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deerfield warrants obligation, change in fair value income (ii)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,418)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,418)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured term loan facility, warrants, transaction costs (iii)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective interest expense on senior secured term loan facility (v)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation interest expense (vi)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,356&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation cumulative catch-up adjustment expense (income) (vi)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,113)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted net income (loss)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,328</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(45,601)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(73,742)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(156,121)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.70)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.55)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustment to net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net income (loss) per share, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.95)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.03)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,372,680&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,739,770&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,374,388&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,730,117&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="i3d04cf63106b45cfa57590bafd017db9_13"></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted, including any market and other performance conditions, and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. See note 18, &#8220;Share-based compensation&#8221; to the unaudited condensed consolidated interim financial statements. These accounting entries have no cash impact.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.8pt">Change in the fair value of the convertible loan derivatives, senior secured term loan facility warrants and the Deerfield warrant obligation results from the valuation at the end of each accounting period. See note 14, &#8220;Senior secured term loan facility and warrants&#8221;, note 15 &#8220;Convertible Loans&#8221; and note 16, &#8220;Deerfield warrants&#8221; to the unaudited condensed consolidated interim financial statements. There are several inputs to these valuations, but those most likely to result in significant changes to the valuations are changes in the value of the underlying instrument (i.e., changes in the price of our common shares) and changes in expected volatility in that price. These accounting entries have no cash impact. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:21.03pt">The transaction costs allocated to the convertible loan second tranche derivative as well as the senior secured term loan facility warrant obligation represent actual costs. We do not believe that these costs reflect the performance of our ongoing business.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:21.57pt">As a result of the exchange agreement entered into on August 15, 2022, the Company recognized a loss on extinguishment which primarily consists of the difference between the aggregate principal amount and carrying amount of the convertible loans and exit fee as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans&#8221; to the unaudited condensed consolidated interim financial statements. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Effective interest expense on convertible loans and senior secured term loans relates to the increase in the value of our loans in accordance with the effective interest method. See note 14, &#8220;Senior secured term loan facility and warrants&#8221; and note 15, &#8220;Convertible loans&#8221; to the unaudited condensed consolidated interim financial statements.   </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt">Deferred royalty obligation interest expense relates to the accretion expense on our deferred royalty obligation pursuant to the royalty purchase agreement with HCR and cumulative catch-up adjustment expense relates to changes in the expected payments to HCR based on a periodic assessment of our underlying revenue projections. See note 19, &#8220;Deferred royalty obligation&#8221; to the unaudited condensed consolidated interim financial statements. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><div id="i3d04cf63106b45cfa57590bafd017db9_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">CONTACTS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investors</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br>Eugenia Litz</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">ADC Therapeutics</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Eugenia.Litz&#64;adctherapeutics.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">+44 7879 627205</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Amanda Loshbaugh<br>ADC Therapeutics</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">amanda.loshbaugh&#64;adctherapeutics.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">+1 917-288-7023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Media </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"><br>Mary Ann Ondish<br>ADC Therapeutics <br></font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">maryann.ondish&#64;adctherapeutics.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">+1 914-552-4625</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>adc-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adc="http://adctherapeutics.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://adctherapeutics.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adc-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://adctherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedInterimStatementofOperations" roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations">
        <link:definition>0000002 - Statement - Condensed Consolidated Interim Statement of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedInterimStatementofComprehensiveLoss" roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss">
        <link:definition>0000003 - Statement - Condensed Consolidated Interim Statement of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedInterimBalanceSheet" roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet">
        <link:definition>0000004 - Statement - Condensed Consolidated Interim Balance Sheet</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedInterimStatementofChangesinEquity" roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity">
        <link:definition>0000005 - Statement - Condensed Consolidated Interim Statement of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedInterimStatementofCashFlows" roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Interim Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Corporateinformation" roleURI="http://adctherapeutics.com/role/Corporateinformation">
        <link:definition>0000007 - Disclosure - Corporate information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpreparation" roleURI="http://adctherapeutics.com/role/Basisofpreparation">
        <link:definition>0000008 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantaccountingpolicies" roleURI="http://adctherapeutics.com/role/Significantaccountingpolicies">
        <link:definition>0000009 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Financialriskmanagement" roleURI="http://adctherapeutics.com/role/Financialriskmanagement">
        <link:definition>0000010 - Disclosure - Financial risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Productrevenuesnet" roleURI="http://adctherapeutics.com/role/Productrevenuesnet">
        <link:definition>0000011 - Disclosure - Product revenues, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segmentinformation" roleURI="http://adctherapeutics.com/role/Segmentinformation">
        <link:definition>0000012 - Disclosure - Segment information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Operatingexpense" roleURI="http://adctherapeutics.com/role/Operatingexpense">
        <link:definition>0000013 - Disclosure - Operating expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Cashandcashequivalents" roleURI="http://adctherapeutics.com/role/Cashandcashequivalents">
        <link:definition>0000014 - Disclosure - Cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://adctherapeutics.com/role/Inventories">
        <link:definition>0000015 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://adctherapeutics.com/role/Intangibleassets">
        <link:definition>0000016 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Nonoperatingincome" roleURI="http://adctherapeutics.com/role/Nonoperatingincome">
        <link:definition>0000017 - Disclosure - Non-operating income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Interestinjointventure" roleURI="http://adctherapeutics.com/role/Interestinjointventure">
        <link:definition>0000018 - Disclosure - Interest in joint venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://adctherapeutics.com/role/Leases">
        <link:definition>0000019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Seniorsecuredtermloanfacilityandwarrants" roleURI="http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants">
        <link:definition>0000020 - Disclosure - Senior secured term loan facility and warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Convertibleloans" roleURI="http://adctherapeutics.com/role/Convertibleloans">
        <link:definition>0000021 - Disclosure - Convertible loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeerfieldWarrants" roleURI="http://adctherapeutics.com/role/DeerfieldWarrants">
        <link:definition>0000022 - Disclosure - Deerfield Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Sharebasedcompensation" roleURI="http://adctherapeutics.com/role/Sharebasedcompensation">
        <link:definition>0000023 - Disclosure - Share-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedparties" roleURI="http://adctherapeutics.com/role/Relatedparties">
        <link:definition>0000024 - Disclosure - Related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Losspershare" roleURI="http://adctherapeutics.com/role/Losspershare">
        <link:definition>0000025 - Disclosure - Loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Eventsafterthereportingdate" roleURI="http://adctherapeutics.com/role/Eventsafterthereportingdate">
        <link:definition>0000026 - Disclosure - Events after the reporting date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Deferredroyaltyobligation" roleURI="http://adctherapeutics.com/role/Deferredroyaltyobligation">
        <link:definition>0000027 - Disclosure - Deferred royalty obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://adctherapeutics.com/role/Equity">
        <link:definition>0000028 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesPolicies" roleURI="http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies">
        <link:definition>0000029 - Disclosure - Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationTables" roleURI="http://adctherapeutics.com/role/BasisofpreparationTables">
        <link:definition>0000030 - Disclosure - Basis of preparation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductrevenuesnetTables" roleURI="http://adctherapeutics.com/role/ProductrevenuesnetTables">
        <link:definition>0000031 - Disclosure - Product revenues, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpenseTables" roleURI="http://adctherapeutics.com/role/OperatingexpenseTables">
        <link:definition>0000032 - Disclosure - Operating expense (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://adctherapeutics.com/role/InventoriesTables">
        <link:definition>0000033 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://adctherapeutics.com/role/IntangibleassetsTables">
        <link:definition>0000034 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonoperatingincomeTables" roleURI="http://adctherapeutics.com/role/NonoperatingincomeTables">
        <link:definition>0000035 - Disclosure - Non-operating income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestinjointventureTables" roleURI="http://adctherapeutics.com/role/InterestinjointventureTables">
        <link:definition>0000036 - Disclosure - Interest in joint venture (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://adctherapeutics.com/role/LeasesTables">
        <link:definition>0000037 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorsecuredtermloanfacilityandwarrantsTables" roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables">
        <link:definition>0000038 - Disclosure - Senior secured term loan facility and warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleloansTables" roleURI="http://adctherapeutics.com/role/ConvertibleloansTables">
        <link:definition>0000039 - Disclosure - Convertible loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeerfieldWarrantsTables" roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsTables">
        <link:definition>0000040 - Disclosure - Deerfield Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationTables" roleURI="http://adctherapeutics.com/role/SharebasedcompensationTables">
        <link:definition>0000041 - Disclosure - Share-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesTables" roleURI="http://adctherapeutics.com/role/RelatedpartiesTables">
        <link:definition>0000042 - Disclosure - Related parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareTables" roleURI="http://adctherapeutics.com/role/LosspershareTables">
        <link:definition>0000043 - Disclosure - Loss per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CorporateinformationDetails" roleURI="http://adctherapeutics.com/role/CorporateinformationDetails">
        <link:definition>0000044 - Disclosure - Corporate information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationScheduleofForeigncurrencyexchangerateDetails" roleURI="http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails">
        <link:definition>0000045 - Disclosure - Basis of preparation - Schedule of Foreign currency exchange rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpreparationAdditionalinformationDetails" roleURI="http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails">
        <link:definition>0000046 - Disclosure - Basis of preparation - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesDetails" roleURI="http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails">
        <link:definition>0000047 - Disclosure - Significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialriskmanagementDetails" roleURI="http://adctherapeutics.com/role/FinancialriskmanagementDetails">
        <link:definition>0000048 - Disclosure - Financial risk management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductrevenuesnetDetails" roleURI="http://adctherapeutics.com/role/ProductrevenuesnetDetails">
        <link:definition>0000049 - Disclosure - Product revenues, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductrevenuesnetNarrativeDetails" roleURI="http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails">
        <link:definition>0000050 - Disclosure - Product revenues, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentinformationDetails" roleURI="http://adctherapeutics.com/role/SegmentinformationDetails">
        <link:definition>0000051 - Disclosure - Segment information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpenseScheduleofExpensesbyNatureDetails" roleURI="http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails">
        <link:definition>0000052 - Disclosure - Operating expense - Schedule of Expenses by Nature (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingexpenseNarrativeDetails" roleURI="http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails">
        <link:definition>0000053 - Disclosure - Operating expense - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandcashequivalentsDetails" roleURI="http://adctherapeutics.com/role/CashandcashequivalentsDetails">
        <link:definition>0000054 - Disclosure - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://adctherapeutics.com/role/InventoriesDetails">
        <link:definition>0000055 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://adctherapeutics.com/role/InventoriesNarrativeDetails">
        <link:definition>0000056 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsRollforwardofIntangibleAssetsDetails" roleURI="http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails">
        <link:definition>0000057 - Disclosure - Intangible assets - Rollforward of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsNarrativeDetails" roleURI="http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails">
        <link:definition>0000058 - Disclosure - Intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonoperatingincomeScheduleofOtherIncomeExpenseDetails" roleURI="http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails">
        <link:definition>0000059 - Disclosure - Non-operating income - Schedule of Other Income (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NonoperatingincomeNarrativeDetails" roleURI="http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails">
        <link:definition>0000060 - Disclosure - Non-operating income - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestinjointventureNarrativeDetails" roleURI="http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails">
        <link:definition>0000061 - Disclosure - Interest in joint venture - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestinjointventureScheduleofmovementininterestinjointventureDetails" roleURI="http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails">
        <link:definition>0000062 - Disclosure - Interest in joint venture - Schedule of movement in interest in joint venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InterestinjointventureSummaryoffinancialinformationinjointventureDetails" roleURI="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails">
        <link:definition>0000063 - Disclosure - Interest in joint venture - Summary of financial information in joint venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://adctherapeutics.com/role/LeasesNarrativeDetails">
        <link:definition>0000064 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofUseAssetsandAccumulatedDepreciationDetails" roleURI="http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails">
        <link:definition>0000065 - Disclosure - Leases - Right-of-Use Assets and Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofUseAssetDepreciationDetails" roleURI="http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails">
        <link:definition>0000066 - Disclosure - Leases - Right-of-Use Asset Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesDetails" roleURI="http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails">
        <link:definition>0000067 - Disclosure - Leases - Schedule of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails">
        <link:definition>0000068 - Disclosure - Senior secured term loan facility and warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails">
        <link:definition>0000069 - Disclosure - Senior secured term loan facility and warrants - Valuation of Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails">
        <link:definition>0000070 - Disclosure - Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleloansNarrativeDetails" roleURI="http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails">
        <link:definition>0000071 - Disclosure - Convertible loans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleloansValuationofDerivativeDetails" roleURI="http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails">
        <link:definition>0000072 - Disclosure - Convertible loans - Valuation of Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleloansInterestExpenseDetails" roleURI="http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails">
        <link:definition>0000073 - Disclosure - Convertible loans - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleloansChangeinFairValueDetails" roleURI="http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails">
        <link:definition>0000074 - Disclosure - Convertible loans - Change in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeerfieldWarrantsNarrativeDetails" roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails">
        <link:definition>0000075 - Disclosure - Deerfield Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeerfieldWarrantsScheduleofValuationInputsDetails" roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails">
        <link:definition>0000076 - Disclosure - Deerfield Warrants - Schedule of Valuation Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationNarrativeDetails" roleURI="http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails">
        <link:definition>0000077 - Disclosure - Share-based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails">
        <link:definition>0000078 - Disclosure - Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" roleURI="http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails">
        <link:definition>0000079 - Disclosure - Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails">
        <link:definition>0000080 - Disclosure - Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails">
        <link:definition>0000081 - Disclosure - Share-based compensation - Schedule of Share-based Compensation Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesNarrativeDetails" roleURI="http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails">
        <link:definition>0000082 - Disclosure - Related parties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartiesScheduleofKeyManagementCompensationDetails" roleURI="http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails">
        <link:definition>0000083 - Disclosure - Related parties - Schedule of Key Management Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareDetails" roleURI="http://adctherapeutics.com/role/LosspershareDetails">
        <link:definition>0000084 - Disclosure - Loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" roleURI="http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails">
        <link:definition>0000085 - Disclosure - Loss per share -Schedule of Potentially Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EventsafterthereportingdateDetails" roleURI="http://adctherapeutics.com/role/EventsafterthereportingdateDetails">
        <link:definition>0000086 - Disclosure - Events after the reporting date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredroyaltyobligationDetails" roleURI="http://adctherapeutics.com/role/DeferredroyaltyobligationDetails">
        <link:definition>0000087 - Disclosure - Deferred royalty obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://adctherapeutics.com/role/EquityDetails">
        <link:definition>0000088 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="adc_CurrentFinishedGoodsHeldOnConsignment" abstract="false" name="CurrentFinishedGoodsHeldOnConsignment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_NonOperatingIncomeExpense" abstract="false" name="NonOperatingIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_TrancheOneMember" abstract="true" name="TrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementAxis" abstract="true" name="RoyaltyPurchaseAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_DividendYieldMember" abstract="true" name="DividendYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adc_ApplicationApprovalMember" abstract="true" name="ApplicationApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IssueOfEquityThroughExchangeAgreement" abstract="false" name="IssueOfEquityThroughExchangeAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ProceedsFromLicenseAgreement" abstract="false" name="ProceedsFromLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_A2022ESPPMember" abstract="true" name="A2022ESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_TrancheFourMember" abstract="true" name="TrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_TaxEffectOfResearchAndDevelopmentTaxCredits" abstract="false" name="TaxEffectOfResearchAndDevelopmentTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" abstract="true" name="InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" abstract="true" name="CorporateInformationAndStatementOfIFRSComplianceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_PlanNameDomain" abstract="true" name="PlanNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_BorrowingsImpliedEffectiveInterestRate" abstract="false" name="BorrowingsImpliedEffectiveInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_ConsolidatedStatementOfFinancialPositionLineItems" abstract="true" name="ConsolidatedStatementOfFinancialPositionLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_ShareIssueRelatedCostThroughFollowOnOffering" abstract="false" name="ShareIssueRelatedCostThroughFollowOnOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_LicenseRevenueMember" abstract="true" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" abstract="true" name="SuccessfulCompletionOfInVivoEfficacyStudiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ConsolidatedStatementOfFinancialPositionTable" abstract="true" name="ConsolidatedStatementOfFinancialPositionTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_DeferredRoyaltyObligationNoncurrent" abstract="false" name="DeferredRoyaltyObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" abstract="false" name="WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" abstract="false" name="InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" abstract="false" name="ShareBasedPaymentArrangementSharesIssuedTaxWithheld" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ProceedsFromRoyaltyPurchaseAgreementGross" abstract="false" name="ProceedsFromRoyaltyPurchaseAgreementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" abstract="true" name="FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_A2019EquityIncentivePlanShareOptionsMember" abstract="true" name="A2019EquityIncentivePlanShareOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" abstract="true" name="DisclosureOfDetailedInformationAboutExpensesByNatureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_PaymentTypeDomain" abstract="true" name="PaymentTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" abstract="false" name="DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" abstract="false" name="FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementTermsDomain" abstract="true" name="RoyaltyPurchaseAgreementTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_LoanAgreementFutureTranchesMember" abstract="true" name="LoanAgreementFutureTranchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ExchangeAgreementMember" abstract="true" name="ExchangeAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_LicensesDefiniteLivedMember" abstract="true" name="LicensesDefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_VestingPeriodMember" abstract="true" name="VestingPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" abstract="true" name="FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_BorrowingsDeferredFinancingCosts" abstract="false" name="BorrowingsDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_A2019EquityIncentivePlanMember" abstract="true" name="A2019EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_RelatedPartyAbstract" abstract="true" name="RelatedPartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" abstract="false" name="LicenseAgreementPercentOfClinicalTrialCostsPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" abstract="true" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_TrancheThreeMember" abstract="true" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_IncreaseDecreaseInReserveOfShareBasedPayments" abstract="false" name="IncreaseDecreaseInReserveOfShareBasedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ImpliedBondYieldMember" abstract="true" name="ImpliedBondYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_AccruedShareBasedCompensation" abstract="false" name="AccruedShareBasedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ProceedsFromRoyaltyPurchaseAgreementNet" abstract="false" name="ProceedsFromRoyaltyPurchaseAgreementNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_SupplementalCashFlowInformationAbstract" abstract="true" name="SupplementalCashFlowInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" abstract="true" name="InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_LicenseAgreementCappedContribution" abstract="false" name="LicenseAgreementCappedContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_NumberOfSubsidiariesProvideServicesTo" abstract="false" name="NumberOfSubsidiariesProvideServicesTo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adc_DeferredRoyaltyObligation" abstract="false" name="DeferredRoyaltyObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" abstract="false" name="WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_NetCarryingAmountMember" abstract="true" name="NetCarryingAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_VestingPeriodAxis" abstract="true" name="VestingPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_SuppliesProvidedRelatedPartyTransactions" abstract="false" name="SuppliesProvidedRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" abstract="false" name="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" abstract="false" name="RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" abstract="false" name="NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adc_WarrantsSharesConvertedExercisePrice" abstract="false" name="WarrantsSharesConvertedExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementTerminationPeriod" abstract="false" name="RoyaltyPurchaseAgreementTerminationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="adc_RoyaltyObligationInterest" abstract="false" name="RoyaltyObligationInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" abstract="true" name="WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" abstract="true" name="LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IncentivePlan2014Member" abstract="true" name="IncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" abstract="false" name="AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" abstract="true" name="AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" abstract="true" name="LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_GTNSalesAdjustment" abstract="false" name="GTNSalesAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RecoveryRateMember" abstract="true" name="RecoveryRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WarrantsTrancheOnePriceOneMember" abstract="true" name="WarrantsTrancheOnePriceOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IssueOfEquityThroughOverAllotmentOption" abstract="false" name="IssueOfEquityThroughOverAllotmentOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_IssueOfEquityThroughFollowOnOffering" abstract="false" name="IssueOfEquityThroughFollowOnOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ExecutiveCompensationMember" abstract="true" name="ExecutiveCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_CapitalExpendituresIncurredButNotYetPaid" abstract="false" name="CapitalExpendituresIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_OfferingPricePerShare" abstract="false" name="OfferingPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_ConversionPeriodTwoMember" abstract="true" name="ConversionPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementBuyoutAmount" abstract="false" name="RoyaltyPurchaseAgreementBuyoutAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_ExternalCostsMember" abstract="true" name="ExternalCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WarrantsTrancheOnePriceTwoMember" abstract="true" name="WarrantsTrancheOnePriceTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IssueOfEquityThroughCapitalizationOfReserves" abstract="false" name="IssueOfEquityThroughCapitalizationOfReserves" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ConvertibleLoansContingentlyIssuableSharesMember" abstract="true" name="ConvertibleLoansContingentlyIssuableSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WarrantsTrancheAxis" abstract="true" name="WarrantsTrancheAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_RoyaltyObligationTransactionCosts" abstract="false" name="RoyaltyObligationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_AuvenTherapeuticsHoldingsLPMember" abstract="true" name="AuvenTherapeuticsHoldingsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IssuanceOfShares" abstract="false" name="IssuanceOfShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_GTNSalesAdjustmentProvisionPriorPeriodSales" abstract="false" name="GTNSalesAdjustmentProvisionPriorPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_PlanNameMember" abstract="true" name="PlanNameMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" abstract="false" name="RoyaltyPurchaseAgreementPaymentPercentOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_BorrowingsFacilitiesExitFeePercentage" abstract="false" name="BorrowingsFacilitiesExitFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_InventoryDomain" abstract="true" name="InventoryDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ManufacturingOfAntibodiesMember" abstract="true" name="ManufacturingOfAntibodiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_BorrowingPeriodDomain" abstract="true" name="BorrowingPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ForcedConversionPriceMember" abstract="true" name="ForcedConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ShortTermBorrowings" abstract="false" name="ShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_AmountsDueFromRelatedParties" abstract="false" name="AmountsDueFromRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ResearchAndDevelopmentExpenseMember" abstract="true" name="ResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_TransfersIntangibleAssetsOtherThanGoodwill" abstract="false" name="TransfersIntangibleAssetsOtherThanGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_LoanAgreementFirstTrancheMember" abstract="true" name="LoanAgreementFirstTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAdditionalProceedsEligibility" abstract="false" name="RoyaltyPurchaseAdditionalProceedsEligibility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_ExpectedVolatilityMember" abstract="true" name="ExpectedVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ExpensesByNatureMember" abstract="true" name="ExpensesByNatureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SharePriceMember" abstract="true" name="SharePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" abstract="false" name="BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ExchangeOfConvertibleNotesForWarrants" abstract="false" name="ExchangeOfConvertibleNotesForWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" abstract="false" name="ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" abstract="false" name="IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_OtherNonOperatingIncomeExpense" abstract="false" name="OtherNonOperatingIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_WorldwideMember" abstract="true" name="WorldwideMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ZYNLONTAForRDMember" abstract="true" name="ZYNLONTAForRDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ProductRevenueNetMember" abstract="true" name="ProductRevenueNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" abstract="false" name="AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_GTNSalesAdjustmentProvision" abstract="false" name="GTNSalesAdjustmentProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_GeneralAndAdministrativeExpenseMember" abstract="true" name="GeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" abstract="false" name="RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_MilestonePaymentMember" abstract="true" name="MilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" abstract="false" name="CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyObligationPayments" abstract="false" name="RoyaltyObligationPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_BorrowingsFairValue" abstract="false" name="BorrowingsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ThirdInvestmentAmountMember" abstract="true" name="ThirdInvestmentAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" abstract="false" name="ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_BaseRateMember" abstract="true" name="BaseRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" abstract="false" name="AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_IncomeStatementLocationDomain" abstract="true" name="IncomeStatementLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SecondInvestmentAmountMember" abstract="true" name="SecondInvestmentAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementTermsAxis" abstract="true" name="RoyaltyPurchaseAgreementTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards" abstract="false" name="IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" abstract="false" name="RoyaltyPurchaseAgreementBuyoutPercentPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_ExpensesByNatureDomain" abstract="true" name="ExpensesByNatureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_CamiMember" abstract="true" name="CamiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_GTNSalesAdjustmentCreditsAndPayments" abstract="false" name="GTNSalesAdjustmentCreditsAndPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" abstract="true" name="RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" abstract="true" name="FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_BorrowingNumberOfComponents" abstract="false" name="BorrowingNumberOfComponents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adc_DisclosureOfWarrantsTextBlock" abstract="false" name="DisclosureOfWarrantsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_AdditionsToLeaseLiabilities" abstract="false" name="AdditionsToLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_IssueOfEquityThroughInitialPublicOffering" abstract="false" name="IssueOfEquityThroughInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_AnnualEquityAwardMember" abstract="true" name="AnnualEquityAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_OutsideOfTheUnitedStatesAndEuropeMember" abstract="true" name="OutsideOfTheUnitedStatesAndEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_NumberOfBusinessSegments" abstract="false" name="NumberOfBusinessSegments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adc_InventoryAxis" abstract="true" name="InventoryAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_ZYNLONTAMember" abstract="true" name="ZYNLONTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_ShareSubscriptionAgreementMember" abstract="true" name="ShareSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_BorrowingsConversionPeriodOneMember" abstract="true" name="BorrowingsConversionPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WarrantObligationFairValue" abstract="false" name="WarrantObligationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_BorrowingsConversionPeriodAxis" abstract="true" name="BorrowingsConversionPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="adc_SpecialRetentionAwardMember" abstract="true" name="SpecialRetentionAwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_OutstandingWarrantsMember" abstract="true" name="OutstandingWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_A2019EquityIncentivePlanRSUsMember" abstract="true" name="A2019EquityIncentivePlanRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" abstract="false" name="RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_WarrantsTrancheOneMember" abstract="true" name="WarrantsTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" abstract="false" name="ShareBasedPaymentArrangementSharesTransferredToParticipants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" abstract="false" name="SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_AfterFirstFiveYearsMember" abstract="true" name="AfterFirstFiveYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationExpenseOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_BorrowingConversionPeriodDomain" abstract="true" name="BorrowingConversionPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ExpensesByNatureAxis" abstract="true" name="ExpensesByNatureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_InitialPublicOfferingMember" abstract="true" name="InitialPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" abstract="false" name="IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RestrictedShareUnitsRSUMember" abstract="true" name="RestrictedShareUnitsRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" abstract="false" name="DisclosureOfInventoryInformationExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_ExpectedTermMember" abstract="true" name="ExpectedTermMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" abstract="false" name="SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_DeerfieldWarrantsMember" abstract="true" name="DeerfieldWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes" abstract="false" name="IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" abstract="false" name="RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="adc_BlackScholesValueMember" abstract="true" name="BlackScholesValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyObligationExpectedFutureTransactionCosts" abstract="false" name="RoyaltyObligationExpectedFutureTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementEffectiveInterestRate" abstract="false" name="RoyaltyPurchaseAgreementEffectiveInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" abstract="true" name="RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IncomeStatementLocationAxis" abstract="true" name="IncomeStatementLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_LicensesIndefiniteLivedMember" abstract="true" name="LicensesIndefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_GainsLossOnExtinguishmentOfBorrowings" abstract="false" name="GainsLossOnExtinguishmentOfBorrowings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RiskFreeInterestRateMember" abstract="true" name="RiskFreeInterestRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" abstract="false" name="RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_DeferredFinancingCostsMember" abstract="true" name="DeferredFinancingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SeniorSecuredTermLoansMember" abstract="true" name="SeniorSecuredTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ConvertibleNotesSharesConverted" abstract="false" name="ConvertibleNotesSharesConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="adc_IntangibleAssetsAbstract" abstract="true" name="IntangibleAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_LicenseToAcquireAnAntibodyZYNLONTAMember" abstract="true" name="LicenseToAcquireAnAntibodyZYNLONTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" abstract="true" name="InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_EmployeeExpensesMember" abstract="true" name="EmployeeExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_OakTreeAndOwlRockWarrantObligationsMember" abstract="true" name="OakTreeAndOwlRockWarrantObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_OtherNonOperatingIncome" abstract="false" name="OtherNonOperatingIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_TradeAndOtherCurrentReceivablesSalesAdjustment" abstract="false" name="TradeAndOtherCurrentReceivablesSalesAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_InterestsInOtherEntitiesAbstract" abstract="true" name="InterestsInOtherEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_BorrowingPeriodAxis" abstract="true" name="BorrowingPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" abstract="true" name="FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_PurchasersMember" abstract="true" name="PurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DeferredRoyaltyObligationTextBlock" abstract="false" name="DeferredRoyaltyObligationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_SeniorSecuredTermLoanFacilityTrancheOneMember" abstract="true" name="SeniorSecuredTermLoanFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" abstract="false" name="ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_WarrantObligationsTransactionCosts" abstract="false" name="WarrantObligationsTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_LeaseArea" abstract="false" name="LeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" abstract="false" name="SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ConvertibleLoansExchange" abstract="false" name="ConvertibleLoansExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_BorrowingFacilitiesMaximumBorrowingCapacity" abstract="false" name="BorrowingFacilitiesMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_FirstInvestmentAmountMember" abstract="true" name="FirstInvestmentAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_LicenseAgreementMember" abstract="true" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DosingOfSpecificNumberOfPatientsMember" abstract="true" name="DosingOfSpecificNumberOfPatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_TrancheTwoMember" abstract="true" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SeniorSecuredTermLoanFacilityMember" abstract="true" name="SeniorSecuredTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_NumberOfSubsidiaries" abstract="false" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adc_EventsAfterReportingPeriodAbstract" abstract="true" name="EventsAfterReportingPeriodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" abstract="false" name="SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" abstract="false" name="DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_ExercisePriceMember" abstract="true" name="ExercisePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_LoanAgreementMember" abstract="true" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" abstract="false" name="AccountsPayableDeferredRoyaltyObligationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_LicenseAgreementMilestonePayments" abstract="false" name="LicenseAgreementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" abstract="false" name="RoyaltyPurchaseAgreementRoyaltyRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_PaymentsMadeUnderRoyaltyFinancingTransactions" abstract="false" name="PaymentsMadeUnderRoyaltyFinancingTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_WarrantsTrancheTwoMember" abstract="true" name="WarrantsTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WarrantsTrancheDomain" abstract="true" name="WarrantsTrancheDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_SaleOfStockPricePerShare" abstract="false" name="SaleOfStockPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_InternalDevelopmentCostsMember" abstract="true" name="InternalDevelopmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" abstract="false" name="RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_OverlandADCTBioPharmaCYLimitedMember" abstract="true" name="OverlandADCTBioPharmaCYLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_PaymentForRentDeposits" abstract="false" name="PaymentForRentDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" abstract="false" name="IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ConvertibleLoansMember" abstract="true" name="ConvertibleLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" abstract="false" name="WeightedAverageRemainingContractualLifeOfGrantedShareOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="adc_ServicesProvidedRelatedPartyTransactions" abstract="false" name="ServicesProvidedRelatedPartyTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" abstract="false" name="BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_RevenueFromContractsWithCustomersAbstract" abstract="true" name="RevenueFromContractsWithCustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_LeasesAbstract" abstract="true" name="LeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="adc_PensionObligationDiscountRate" abstract="false" name="PensionObligationDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_PaymentTypeAxis" abstract="true" name="PaymentTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementRoyaltyCap" abstract="false" name="RoyaltyPurchaseAgreementRoyaltyCap" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_PlanNameAxis" abstract="true" name="PlanNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" abstract="false" name="WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_FirstFiveYearsMember" abstract="true" name="FirstFiveYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_ResidualLoanMember" abstract="true" name="ResidualLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementDomain" abstract="true" name="RoyaltyPurchaseAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_IssueOfEquityThroughPurchaseAgreement" abstract="false" name="IssueOfEquityThroughPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_OtherIncomeExpenseAbstract" abstract="true" name="OtherIncomeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" abstract="false" name="NumberOfProductsDevelopedAndCommercializedInJointVenture" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="adc_DeferredRoyaltyObligationAbstract" abstract="true" name="DeferredRoyaltyObligationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" abstract="false" name="RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="adc_ConvertibleNotesValueConverted" abstract="false" name="ConvertibleNotesValueConverted" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_SharePurchasePlan2016Member" abstract="true" name="SharePurchasePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_EmployeeStockOptionMember" abstract="true" name="EmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" abstract="false" name="WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_OperatingSegmentsAbstract" abstract="true" name="OperatingSegmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_InventoryAbstract" abstract="true" name="InventoryAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" abstract="false" name="WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="adc_DeferredGainOnInvestmentInJointVenture" abstract="false" name="DeferredGainOnInvestmentInJointVenture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_FacilityAgreementWithDeerfieldPartnersLPMember" abstract="true" name="FacilityAgreementWithDeerfieldPartnersLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_RestrictedStockUnitsMember" abstract="true" name="RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_RoyaltyPurchaseAgreement" abstract="false" name="RoyaltyPurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_ShareBasedPaymentArrangementsAbstract" abstract="true" name="ShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="adc_LicensePaymentMember" abstract="true" name="LicensePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="adc_GainsLossOnChangeInFairValueWarrants" abstract="false" name="GainsLossOnChangeInFairValueWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" abstract="false" name="IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>adc-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofOperations"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_003d9dbc-054f-424c-9e84-a10ac958ee79" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_014afa54-ef5b-4c3e-adc4-081506234b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_003d9dbc-054f-424c-9e84-a10ac958ee79" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_014afa54-ef5b-4c3e-adc4-081506234b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_c73b3e66-34bf-488c-87d6-523737be15c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_003d9dbc-054f-424c-9e84-a10ac958ee79" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_c73b3e66-34bf-488c-87d6-523737be15c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_52ca367b-c9c7-4aa6-b048-05cc9ad621ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_003d9dbc-054f-424c-9e84-a10ac958ee79" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_52ca367b-c9c7-4aa6-b048-05cc9ad621ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_863f1297-5a70-4400-9208-758ec6303357" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_003d9dbc-054f-424c-9e84-a10ac958ee79" xlink:to="loc_ifrs-full_CostOfSales_863f1297-5a70-4400-9208-758ec6303357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_edab613a-ed36-433a-a77a-f7b7241a0c7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_f73f75c1-99aa-4b19-9985-28174106ddb8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_edab613a-ed36-433a-a77a-f7b7241a0c7c" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_f73f75c1-99aa-4b19-9985-28174106ddb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_892488d2-c9d4-4429-bea8-924d9cee967b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_edab613a-ed36-433a-a77a-f7b7241a0c7c" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_892488d2-c9d4-4429-bea8-924d9cee967b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_101c45ed-c05f-4873-9da0-94855b223c39" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_1fd463ea-8b52-49de-8b71-7d1e71dbc5b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_101c45ed-c05f-4873-9da0-94855b223c39" xlink:to="loc_ifrs-full_OperatingExpense_1fd463ea-8b52-49de-8b71-7d1e71dbc5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_fdbac25a-a3a0-47bc-9fd2-c03f9ec08899" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_101c45ed-c05f-4873-9da0-94855b223c39" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_fdbac25a-a3a0-47bc-9fd2-c03f9ec08899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncomeExpense_7cced29c-6edd-43bb-89f3-1dd4f141585c" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncome_e9ef4cca-349a-4295-8381-93b348e43d66" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_adc_OtherNonOperatingIncomeExpense_7cced29c-6edd-43bb-89f3-1dd4f141585c" xlink:to="loc_adc_OtherNonOperatingIncome_e9ef4cca-349a-4295-8381-93b348e43d66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_7b814957-122f-449f-8d6c-6014b1925c55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_adc_OtherNonOperatingIncomeExpense_7cced29c-6edd-43bb-89f3-1dd4f141585c" xlink:to="loc_ifrs-full_FinanceIncome_7b814957-122f-449f-8d6c-6014b1925c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_c8bb93a4-0897-422e-92bd-55fbb9487be7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_adc_OtherNonOperatingIncomeExpense_7cced29c-6edd-43bb-89f3-1dd4f141585c" xlink:to="loc_ifrs-full_FinanceCosts_c8bb93a4-0897-422e-92bd-55fbb9487be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_b688b0b3-50bf-4604-bf8f-3b87ab33fafd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_300edc09-3072-4693-870c-830f476d9a8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b688b0b3-50bf-4604-bf8f-3b87ab33fafd" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_300edc09-3072-4693-870c-830f476d9a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncomeExpense_ac90125c-6041-4b2e-956e-bc0c0bad2745" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b688b0b3-50bf-4604-bf8f-3b87ab33fafd" xlink:to="loc_adc_OtherNonOperatingIncomeExpense_ac90125c-6041-4b2e-956e-bc0c0bad2745" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_b528f0ce-4352-4600-b07b-f4c2dc4a94e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_f4177788-4df2-4f34-80fe-bed386d19cce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_b528f0ce-4352-4600-b07b-f4c2dc4a94e8" xlink:to="loc_ifrs-full_ComprehensiveIncome_f4177788-4df2-4f34-80fe-bed386d19cce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_3ce5bc34-a4be-41d2-ab19-906d2b055122" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_121502e6-92ba-49a3-be79-07959060c181" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_3ce5bc34-a4be-41d2-ab19-906d2b055122" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_121502e6-92ba-49a3-be79-07959060c181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_500ed862-7092-4eb2-9609-ea9b98613694" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_973d20f6-c766-43bd-bf50-0f5fda6441b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_500ed862-7092-4eb2-9609-ea9b98613694" xlink:to="loc_ifrs-full_ProfitLoss_973d20f6-c766-43bd-bf50-0f5fda6441b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_41fa0176-85ce-4f38-b69c-0cd8524a922e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_500ed862-7092-4eb2-9609-ea9b98613694" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_41fa0176-85ce-4f38-b69c-0cd8524a922e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_a9d72af9-f011-4556-8b6c-0871b92271de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ae97815e-efef-4ea0-8056-39e2d3222e20" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_a9d72af9-f011-4556-8b6c-0871b92271de" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ae97815e-efef-4ea0-8056-39e2d3222e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_7593cf76-7ca5-42c1-8d81-9e98f1092da9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a73e9e0f-6a88-4665-b749-4e12b5cbd3c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_7593cf76-7ca5-42c1-8d81-9e98f1092da9" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a73e9e0f-6a88-4665-b749-4e12b5cbd3c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_93e648f7-c079-4aa4-b2ef-e48919144f0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_7593cf76-7ca5-42c1-8d81-9e98f1092da9" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_93e648f7-c079-4aa4-b2ef-e48919144f0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimBalanceSheet"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_4cb47868-fd86-4e95-b407-ca31c9e96fca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:to="loc_ifrs-full_IssuedCapital_4cb47868-fd86-4e95-b407-ca31c9e96fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_92e3da34-cb14-4648-8189-8d25c77f62fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:to="loc_ifrs-full_SharePremium_92e3da34-cb14-4648-8189-8d25c77f62fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_cd9d50f3-b2d6-4066-9caa-b77c3caa2b6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:to="loc_ifrs-full_TreasuryShares_cd9d50f3-b2d6-4066-9caa-b77c3caa2b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_043195ab-2ad4-40b5-a0d2-6d1dc69a338d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:to="loc_ifrs-full_OtherReserves_043195ab-2ad4-40b5-a0d2-6d1dc69a338d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_38156270-deb8-4fd8-b419-f9e28c2297ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_38156270-deb8-4fd8-b419-f9e28c2297ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_8f96b8ed-407a-495c-b532-9784761dc98a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_83450017-7f61-46e2-9ae1-048c7d775137" xlink:to="loc_ifrs-full_RetainedEarnings_8f96b8ed-407a-495c-b532-9784761dc98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_63e1ecb2-beff-4545-85a4-c8c0a40571e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_b1ca9a73-d388-4c1d-902b-407bd0f358c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63e1ecb2-beff-4545-85a4-c8c0a40571e9" xlink:to="loc_ifrs-full_Inventories_b1ca9a73-d388-4c1d-902b-407bd0f358c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_f7577954-2b1e-486e-bedb-8eeb167565f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63e1ecb2-beff-4545-85a4-c8c0a40571e9" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_f7577954-2b1e-486e-bedb-8eeb167565f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_ab006e0c-3d8c-4c05-a316-c0bc8bd316c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63e1ecb2-beff-4545-85a4-c8c0a40571e9" xlink:to="loc_ifrs-full_CashAndCashEquivalents_ab006e0c-3d8c-4c05-a316-c0bc8bd316c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_48088207-bb73-47e7-a6a8-3c8dc8dfd0d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63e1ecb2-beff-4545-85a4-c8c0a40571e9" xlink:to="loc_ifrs-full_OtherCurrentAssets_48088207-bb73-47e7-a6a8-3c8dc8dfd0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_213a50a4-17a7-4da4-b9e2-136e4c4df54d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_2fc61f1b-3b88-4c26-bad4-28ae8477af35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_213a50a4-17a7-4da4-b9e2-136e4c4df54d" xlink:to="loc_ifrs-full_CurrentLiabilities_2fc61f1b-3b88-4c26-bad4-28ae8477af35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_c388694c-3c69-4703-baec-b168cd081ac1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_213a50a4-17a7-4da4-b9e2-136e4c4df54d" xlink:to="loc_ifrs-full_NoncurrentLiabilities_c388694c-3c69-4703-baec-b168cd081ac1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_fabbbf45-86a2-4a1a-bcc1-23fb85ed34bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_fabbbf45-86a2-4a1a-bcc1-23fb85ed34bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_a4c4a5db-c51a-49d3-97a8-ae331d8761ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:to="loc_ifrs-full_RightofuseAssets_a4c4a5db-c51a-49d3-97a8-ae331d8761ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_4fa2357b-236f-4ad0-b11a-0cd97369d96f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_4fa2357b-236f-4ad0-b11a-0cd97369d96f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_eb47a721-40c8-4217-b42f-b8da43c49a7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_eb47a721-40c8-4217-b42f-b8da43c49a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_a19a93c3-d8af-4c48-a6e2-499ab1646b59" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_a19a93c3-d8af-4c48-a6e2-499ab1646b59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_3bae5d89-d62f-4923-ae28-6d9044fb7451" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_ffb33f99-d44e-4c73-bd53-900248002e93" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_3bae5d89-d62f-4923-ae28-6d9044fb7451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_05ea0456-ae72-4a74-be4b-26ab63cb5dc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_8549379c-d697-479b-b410-cea972f74606" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_05ea0456-ae72-4a74-be4b-26ab63cb5dc4" xlink:to="loc_ifrs-full_Liabilities_8549379c-d697-479b-b410-cea972f74606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f8ff5e0e-35a3-41ec-977b-89bad2c99bf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_05ea0456-ae72-4a74-be4b-26ab63cb5dc4" xlink:to="loc_ifrs-full_Equity_f8ff5e0e-35a3-41ec-977b-89bad2c99bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_67f2c9bd-0931-4c13-932f-25bb07d3b47e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_67f2c9bd-0931-4c13-932f-25bb07d3b47e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_8ce4ea98-bf97-4d7b-996b-321e28cee32d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_8ce4ea98-bf97-4d7b-996b-321e28cee32d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_3f33273c-a82e-437f-9bcf-50aaca72d19d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_ifrs-full_LongtermBorrowings_3f33273c-a82e-437f-9bcf-50aaca72d19d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f77aef8f-4eb4-4c7b-a677-2a817ade43c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_f77aef8f-4eb4-4c7b-a677-2a817ade43c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_b0b88ecd-bdff-4397-9d8f-43aaf7145518" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_b0b88ecd-bdff-4397-9d8f-43aaf7145518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentWarrantLiability_2d1d1840-280e-4512-b471-37ac13f9fe8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_ifrs-full_NoncurrentWarrantLiability_2d1d1840-280e-4512-b471-37ac13f9fe8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationNoncurrent_988e03c1-910f-40fb-8ed6-1b57121d2227" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_64f0ca41-00e9-43bf-a333-35a409318835" xlink:to="loc_adc_DeferredRoyaltyObligationNoncurrent_988e03c1-910f-40fb-8ed6-1b57121d2227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_2607c4fa-9c4a-4339-91a8-c07cd7dff825" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_16b1fd29-75c3-4e81-b928-4fb1f0ae99ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_2607c4fa-9c4a-4339-91a8-c07cd7dff825" xlink:to="loc_ifrs-full_CurrentAssets_16b1fd29-75c3-4e81-b928-4fb1f0ae99ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_b0d2f10c-a21b-47b2-b567-a0b5fda98f05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_2607c4fa-9c4a-4339-91a8-c07cd7dff825" xlink:to="loc_ifrs-full_NoncurrentAssets_b0d2f10c-a21b-47b2-b567-a0b5fda98f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_668b346b-7889-4738-b7a4-76d64ac9c1bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_668b346b-7889-4738-b7a4-76d64ac9c1bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_2226647b-8779-4e59-969c-fab210681b6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_2226647b-8779-4e59-969c-fab210681b6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_7c655d0b-1b8a-40e3-8058-76d7156b603d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_7c655d0b-1b8a-40e3-8058-76d7156b603d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_3e6c6f11-5781-4516-9917-6730bfb62186" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_3e6c6f11-5781-4516-9917-6730bfb62186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_91486a26-bfdc-48cc-abae-9532307d34c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_91486a26-bfdc-48cc-abae-9532307d34c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShortTermBorrowings_07e9ad82-08c7-40d9-ac5e-7ae920d2df98" xlink:href="adc-20220930.xsd#adc_ShortTermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_c340b80e-e2b1-4749-9b3c-8325a0c50afa" xlink:to="loc_adc_ShortTermBorrowings_07e9ad82-08c7-40d9-ac5e-7ae920d2df98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofChangesinEquity"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_a1631a30-ead6-4109-b9d9-673265c2edfb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_8ecb1225-75c0-40ef-8ef0-84c046aeab7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_a1631a30-ead6-4109-b9d9-673265c2edfb" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_8ecb1225-75c0-40ef-8ef0-84c046aeab7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_89f78520-f8a9-46d1-a2bb-4a9ce983dbbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_a1631a30-ead6-4109-b9d9-673265c2edfb" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_89f78520-f8a9-46d1-a2bb-4a9ce983dbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes_97794ab3-6a73-4270-9f5b-bc822509e34c" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes_97794ab3-6a73-4270-9f5b-bc822509e34c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_334d435e-05dd-4774-897f-6d2e0ab43bfb" xlink:href="adc-20220930.xsd#adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_334d435e-05dd-4774-897f-6d2e0ab43bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughInitialPublicOffering_be86783c-98d3-4720-a93c-20f2c9c50944" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughInitialPublicOffering"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_IssueOfEquityThroughInitialPublicOffering_be86783c-98d3-4720-a93c-20f2c9c50944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughCapitalizationOfReserves_c127311f-f249-4b84-a141-c37629aeea82" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughCapitalizationOfReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_IssueOfEquityThroughCapitalizationOfReserves_c127311f-f249-4b84-a141-c37629aeea82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards_f40ebf9a-8ade-4b23-aed9-9023cf3a433a" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards_f40ebf9a-8ade-4b23-aed9-9023cf3a433a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughFollowOnOffering_e5a794de-7c95-4669-bde1-50def0b22d21" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughFollowOnOffering"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_IssueOfEquityThroughFollowOnOffering_e5a794de-7c95-4669-bde1-50def0b22d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareIssueRelatedCostThroughFollowOnOffering_8d89f47e-257d-4e2f-853d-f2ffdb51dfc8" xlink:href="adc-20220930.xsd#adc_ShareIssueRelatedCostThroughFollowOnOffering"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_ShareIssueRelatedCostThroughFollowOnOffering_8d89f47e-257d-4e2f-853d-f2ffdb51dfc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughOverAllotmentOption_ac9a45a2-d251-4213-980d-1e83f513bc71" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughOverAllotmentOption"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_adc_IssueOfEquityThroughOverAllotmentOption_ac9a45a2-d251-4213-980d-1e83f513bc71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_af861276-1679-4590-9769-21fd78308cbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_af861276-1679-4590-9769-21fd78308cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_9741cc32-d77d-470f-bee4-794d5bce5619" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_9741cc32-d77d-470f-bee4-794d5bce5619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_6c8078b5-3335-4c30-a656-545427fd8252" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_3d98119b-e6f8-4d48-842e-aa6658e9ee9b" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_6c8078b5-3335-4c30-a656-545427fd8252" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9ca74e48-43b4-4506-b553-125e1dee03eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_76ec2b8f-5769-40c4-a30f-5d88adc30ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9ca74e48-43b4-4506-b553-125e1dee03eb" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_76ec2b8f-5769-40c4-a30f-5d88adc30ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_7674830a-0f8c-40dd-b4f3-57c5d5e9bf05" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9ca74e48-43b4-4506-b553-125e1dee03eb" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_7674830a-0f8c-40dd-b4f3-57c5d5e9bf05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentForRentDeposits_65dadfc1-99aa-4756-b80e-825bdd9f0fb2" xlink:href="adc-20220930.xsd#adc_PaymentForRentDeposits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_9ca74e48-43b4-4506-b553-125e1dee03eb" xlink:to="loc_adc_PaymentForRentDeposits_65dadfc1-99aa-4756-b80e-825bdd9f0fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3aa476c2-b4a1-42e6-9a2e-4c47e1037a3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_3aa476c2-b4a1-42e6-9a2e-4c47e1037a3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_8d9750cc-fcad-460f-be36-7276fc83eabf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_8d9750cc-fcad-460f-be36-7276fc83eabf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_97049d3f-4615-4ceb-98fb-0b463e7ab3b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_97049d3f-4615-4ceb-98fb-0b463e7ab3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_9e04ad27-a5cd-42ce-bf5d-2adcc9d150a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_9e04ad27-a5cd-42ce-bf5d-2adcc9d150a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_96f88834-8f3f-4f5b-af14-6fb29ea70ac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_96f88834-8f3f-4f5b-af14-6fb29ea70ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_ab0e018b-2819-4007-8796-bf0bde791e45" xlink:href="adc-20220930.xsd#adc_PaymentsMadeUnderRoyaltyFinancingTransactions"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_90d79483-9489-4254-b9f9-045a1f9ae797" xlink:to="loc_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_ab0e018b-2819-4007-8796-bf0bde791e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_ace01a8a-c7b9-4783-89fd-18ed2410edf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_772ffc24-208f-41f9-b471-209de049f8a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_ace01a8a-c7b9-4783-89fd-18ed2410edf4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_772ffc24-208f-41f9-b471-209de049f8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_25d9540e-28a3-4009-aa5a-e58c84082a6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_ace01a8a-c7b9-4783-89fd-18ed2410edf4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_25d9540e-28a3-4009-aa5a-e58c84082a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_0158f890-d1e9-420c-9f63-df968b4c5c70" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_ace01a8a-c7b9-4783-89fd-18ed2410edf4" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_0158f890-d1e9-420c-9f63-df968b4c5c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_66acf1ce-e83f-45bf-abbb-b97f31c31bce" xlink:href="adc-20220930.xsd#adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_66acf1ce-e83f-45bf-abbb-b97f31c31bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638bd871-797e-4b2c-8306-aa1e8a110b92" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638bd871-797e-4b2c-8306-aa1e8a110b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_3ab19e4d-047b-440e-8d59-792d04619a9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_3ab19e4d-047b-440e-8d59-792d04619a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_a87ba87a-8e0d-4c51-83d2-ba6967061165" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_a87ba87a-8e0d-4c51-83d2-ba6967061165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_0b094f1c-c368-4689-952e-fd6c84cd0c3c" xlink:href="adc-20220930.xsd#adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_0b094f1c-c368-4689-952e-fd6c84cd0c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_26369a41-f04c-4ad5-b8d6-c456a1defa8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_26369a41-f04c-4ad5-b8d6-c456a1defa8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_104ea218-035d-4764-934e-2bb3924790dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_104ea218-035d-4764-934e-2bb3924790dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense_109abed0-7229-41ac-9bb2-404046c3d25d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense_109abed0-7229-41ac-9bb2-404046c3d25d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_ccd3f01b-b839-4a8e-b5a9-c154a17f334f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_ccd3f01b-b839-4a8e-b5a9-c154a17f334f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_7a621e68-1283-44cc-9ebb-41439f781ca6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_7a621e68-1283-44cc-9ebb-41439f781ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_2ae52244-4530-4637-89a7-4eb9daa6e27f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_ProfitLoss_2ae52244-4530-4637-89a7-4eb9daa6e27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_56f3d7ed-f641-4991-acab-8a40b6a7351c" xlink:href="adc-20220930.xsd#adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_56f3d7ed-f641-4991-acab-8a40b6a7351c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_e783cf7d-929d-42dd-a69a-b6e46afc5bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_e783cf7d-929d-42dd-a69a-b6e46afc5bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings_6526bd59-6f70-4648-851a-ab94e460963e" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_adc_GainsLossOnExtinguishmentOfBorrowings_6526bd59-6f70-4648-851a-ab94e460963e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_c78849c6-e15a-466b-bd12-622eedba8ad7" xlink:href="adc-20220930.xsd#adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_c78849c6-e15a-466b-bd12-622eedba8ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_fb3610bc-75fd-4b61-a696-64f482f180ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_33432fdc-be10-4bd8-9809-ffe62ca18f40" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_fb3610bc-75fd-4b61-a696-64f482f180ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_8aba5fa5-0613-4848-87ea-b56aba011499" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_8aba5fa5-0613-4848-87ea-b56aba011499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_4113d120-1ec0-446c-bab7-1790aa4e15ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_4113d120-1ec0-446c-bab7-1790aa4e15ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_e6a25ec8-adb5-43cf-8541-03cdefc9143d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_e6a25ec8-adb5-43cf-8541-03cdefc9143d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_4c921afe-93b1-4cdd-bfbf-8777dcb71b84" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_4c921afe-93b1-4cdd-bfbf-8777dcb71b84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_1d2f1fe6-274c-4c71-9d5c-2418125b1f14" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_1d2f1fe6-274c-4c71-9d5c-2418125b1f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_a6121dde-327b-4d74-a66c-48e578917b26" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_a6121dde-327b-4d74-a66c-48e578917b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_8e8c2400-e42a-41f0-af26-e772fdd60f0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_2c340676-d40b-4050-882f-1a353248ae91" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_8e8c2400-e42a-41f0-af26-e772fdd60f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_1a09f422-4627-4fe8-92d1-8702065db56d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_1a09f422-4627-4fe8-92d1-8702065db56d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansExchange_00f5272f-b469-4746-9d5a-d026026d2e48" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansExchange"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_adc_ConvertibleLoansExchange_00f5272f-b469-4746-9d5a-d026026d2e48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_ed705369-bdbf-47c5-81e6-747cc7c2a160" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_ed705369-bdbf-47c5-81e6-747cc7c2a160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_e7efe5cd-44b1-47c3-875e-49d3f34fb4cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_e7efe5cd-44b1-47c3-875e-49d3f34fb4cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1d1cc981-a7e1-4268-867e-a89ae97e211d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1d1cc981-a7e1-4268-867e-a89ae97e211d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_42cb6126-1a70-4a72-a133-d9fe6c83bbf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_42cb6126-1a70-4a72-a133-d9fe6c83bbf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_793fe517-58a8-4106-88dd-672f117decc3" xlink:href="adc-20220930.xsd#adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_ba83eef3-650b-43a6-b0bb-a2ca02c7ff14" xlink:to="loc_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_793fe517-58a8-4106-88dd-672f117decc3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoriesTotal_7bbb690f-60e7-48ee-a0c7-2acb66907ad9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_2f668c58-6fb7-47ad-bbae-ec03f53db8ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InventoriesTotal_7bbb690f-60e7-48ee-a0c7-2acb66907ad9" xlink:to="loc_ifrs-full_RawMaterials_2f668c58-6fb7-47ad-bbae-ec03f53db8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_b29c9ef8-4c54-4628-a751-cb033c027484" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InventoriesTotal_7bbb690f-60e7-48ee-a0c7-2acb66907ad9" xlink:to="loc_ifrs-full_FinishedGoods_b29c9ef8-4c54-4628-a751-cb033c027484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_73e7245d-bc4f-4e0a-8d81-d65b0e5bc973" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WorkInProgress"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_InventoriesTotal_7bbb690f-60e7-48ee-a0c7-2acb66907ad9" xlink:to="loc_ifrs-full_WorkInProgress_73e7245d-bc4f-4e0a-8d81-d65b0e5bc973" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureSummaryoffinancialinformationinjointventureDetails"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_610df824-a1ac-4e6d-81f5-25211839ace0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_679bae8f-4b35-4edc-b60f-630e686686cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities_610df824-a1ac-4e6d-81f5-25211839ace0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_679bae8f-4b35-4edc-b60f-630e686686cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3fb85dbb-eb0e-46bd-8320-67eb7584d6b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities_610df824-a1ac-4e6d-81f5-25211839ace0" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3fb85dbb-eb0e-46bd-8320-67eb7584d6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_834262a0-da68-4da4-a484-8640e1f7da3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities_610df824-a1ac-4e6d-81f5-25211839ace0" xlink:to="loc_ifrs-full_Liabilities_834262a0-da68-4da4-a484-8640e1f7da3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_fccee54a-c8a6-4004-a003-9db1a299b8c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NetAssetsLiabilities_610df824-a1ac-4e6d-81f5-25211839ace0" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_fccee54a-c8a6-4004-a003-9db1a299b8c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#RelatedpartiesScheduleofKeyManagementCompensationDetails"/>
  <link:calculationLink xlink:role="http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_2d81dbc8-8b66-4845-b3f3-aa0f14b94d93" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_bb4be2b1-7a57-407e-9640-3830f0092912" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_2d81dbc8-8b66-4845-b3f3-aa0f14b94d93" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_bb4be2b1-7a57-407e-9640-3830f0092912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a95eb4ad-38d3-428b-a7b9-0bbfb1d6ce78" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_2d81dbc8-8b66-4845-b3f3-aa0f14b94d93" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a95eb4ad-38d3-428b-a7b9-0bbfb1d6ce78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7fde7b7c-4456-492a-9965-b73332e1f649" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_2d81dbc8-8b66-4845-b3f3-aa0f14b94d93" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7fde7b7c-4456-492a-9965-b73332e1f649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_8fce06ce-f36b-4714-aa98-7ad5c16906d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_2d81dbc8-8b66-4845-b3f3-aa0f14b94d93" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_8fce06ce-f36b-4714-aa98-7ad5c16906d3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>adc-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofOperations"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" xlink:type="extended" id="i6a757c9622b9443c9fa1c60480c48e3b_CondensedConsolidatedInterimStatementofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_fa84f612-25b5-4869-bade-f6c411f34841" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_fa84f612-25b5-4869-bade-f6c411f34841" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_8907851c-0dce-4dde-85ea-00c3e4a6e3b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_CostOfSales_8907851c-0dce-4dde-85ea-00c3e4a6e3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_2e1bf753-d2c2-4407-8f6a-46498ed3a44b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_2e1bf753-d2c2-4407-8f6a-46498ed3a44b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_b2bc9c3b-df51-44e1-b58d-9f10298586a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_b2bc9c3b-df51-44e1-b58d-9f10298586a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_7b8cc2fb-1bbc-4282-b04a-bcead97b7342" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_7b8cc2fb-1bbc-4282-b04a-bcead97b7342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_b12978ff-5510-4ef4-95e0-85c0f375c42b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_OperatingExpense_b12978ff-5510-4ef4-95e0-85c0f375c42b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_8235f2b6-c52c-476e-aead-7386f9288ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_8235f2b6-c52c-476e-aead-7386f9288ef9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:href="adc-20220930.xsd#adc_OtherIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_a4e27c9b-1ac9-4ff7-b03e-9b905b34bd88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_ifrs-full_FinanceIncome_a4e27c9b-1ac9-4ff7-b03e-9b905b34bd88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_8a145d4a-6f0c-423f-92ce-af1681b4d7e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_ifrs-full_FinanceCosts_8a145d4a-6f0c-423f-92ce-af1681b4d7e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncome_166a959d-a8d9-489e-a955-5d2a4cdc0c0b" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_adc_OtherNonOperatingIncome_166a959d-a8d9-489e-a955-5d2a4cdc0c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncomeExpense_bf333c2b-8189-4f77-a0ff-1a1921c9a5fc" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_adc_OtherNonOperatingIncomeExpense_bf333c2b-8189-4f77-a0ff-1a1921c9a5fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_3265a0ab-8b64-4728-bb32-82c49c3cb96c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_3265a0ab-8b64-4728-bb32-82c49c3cb96c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_9d7f3769-1cdf-42f1-a08b-933ac919465f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_9d7f3769-1cdf-42f1-a08b-933ac919465f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_78caab85-e1d8-44fd-8a3c-94dc21db4409" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLoss_78caab85-e1d8-44fd-8a3c-94dc21db4409" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_3eafff15-3a45-4974-b592-07f272e18d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLossAttributableToAbstract_3eafff15-3a45-4974-b592-07f272e18d99" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_93d25858-6c72-4e2f-8910-ad81d8322ebb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_3eafff15-3a45-4974-b592-07f272e18d99" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_93d25858-6c72-4e2f-8910-ad81d8322ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_4f763261-9306-436a-9e61-186f16c9fcc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_4f763261-9306-436a-9e61-186f16c9fcc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_4e5b0a4a-1bea-4b3a-8fa5-4af1297d7424" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_4e5b0a4a-1bea-4b3a-8fa5-4af1297d7424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:to="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2e221880-5390-414f-aac4-725c39c2905e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:to="loc_srt_ProductsAndServicesDomain_2e221880-5390-414f-aac4-725c39c2905e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:to="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProductRevenueNetMember_a451a96e-32dd-43e8-b25b-e93b847c4a2e" xlink:href="adc-20220930.xsd#adc_ProductRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:to="loc_adc_ProductRevenueNetMember_a451a96e-32dd-43e8-b25b-e93b847c4a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseRevenueMember_8c2b0106-6523-4535-b3f2-537340b9c9c7" xlink:href="adc-20220930.xsd#adc_LicenseRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:to="loc_adc_LicenseRevenueMember_8c2b0106-6523-4535-b3f2-537340b9c9c7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimBalanceSheet"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" xlink:type="extended" id="i19ef40a4afe8418f83d1f99406f361bc_CondensedConsolidatedInterimBalanceSheet">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:href="adc-20220930.xsd#adc_ConsolidatedStatementOfFinancialPositionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:to="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_afcbca74-aa64-4c16-8391-6a84f3db1ca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_afcbca74-aa64-4c16-8391-6a84f3db1ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_225b3359-51ae-45aa-837e-32813329b99d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_225b3359-51ae-45aa-837e-32813329b99d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_cca239d6-d01f-40ea-a7c4-f3ec6d4f1c0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_Inventories_cca239d6-d01f-40ea-a7c4-f3ec6d4f1c0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_66b2be21-9a3b-45e3-a564-2f9753118615" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_OtherCurrentAssets_66b2be21-9a3b-45e3-a564-2f9753118615" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_657092dc-9d75-439e-b8c8-579b94f16a54" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_CurrentAssets_657092dc-9d75-439e-b8c8-579b94f16a54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_ca857ec4-f74d-49c6-bb8c-ca6ed4482c90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_ca857ec4-f74d-49c6-bb8c-ca6ed4482c90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_ad3fd79e-b287-483b-85e2-a526a2fa88e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_RightofuseAssets_ad3fd79e-b287-483b-85e2-a526a2fa88e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_92a2de36-93e8-476d-94b0-5bd3fd08b263" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_92a2de36-93e8-476d-94b0-5bd3fd08b263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_3b5876a4-46e8-412c-9fa0-b9a3919893bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_3b5876a4-46e8-412c-9fa0-b9a3919893bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_bec5b1fb-f7ad-4dd9-bad5-7c82deddf31f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_bec5b1fb-f7ad-4dd9-bad5-7c82deddf31f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_76b69c5e-8b0c-4596-bf3f-c72c584a23b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_76b69c5e-8b0c-4596-bf3f-c72c584a23b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_ee005cfa-131a-4719-8239-1dc00e1ec294" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_NoncurrentAssets_ee005cfa-131a-4719-8239-1dc00e1ec294" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_65e4c286-5cb3-4c70-ad45-95b66854d970" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:to="loc_ifrs-full_Assets_65e4c286-5cb3-4c70-ad45-95b66854d970" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_a06aa45b-c220-4572-8089-0c7280ceacbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_a06aa45b-c220-4572-8089-0c7280ceacbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0ad31fab-7032-4770-965e-4b000e39fd9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0ad31fab-7032-4770-965e-4b000e39fd9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_85005234-01f4-499f-b900-808268236850" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_85005234-01f4-499f-b900-808268236850" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_3c50ae8b-86e7-4b7f-95f3-b5908adc56f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_3c50ae8b-86e7-4b7f-95f3-b5908adc56f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShortTermBorrowings_eab6a967-d4cb-4091-9756-e7ecaa4ace46" xlink:href="adc-20220930.xsd#adc_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_adc_ShortTermBorrowings_eab6a967-d4cb-4091-9756-e7ecaa4ace46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_6c48e0e3-58aa-40d0-8e87-e33c4557c657" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_6c48e0e3-58aa-40d0-8e87-e33c4557c657" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_65c9db0a-b174-4e7b-b2cf-4943fa1da2e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentLiabilities_65c9db0a-b174-4e7b-b2cf-4943fa1da2e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_c802e936-1b83-46dd-94a8-f0ce0052d1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_LongtermBorrowings_c802e936-1b83-46dd-94a8-f0ce0052d1be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_150f9918-b1f5-4535-8d2b-4415fba56000" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_150f9918-b1f5-4535-8d2b-4415fba56000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentWarrantLiability_5c666e2d-2ddc-4225-a03c-9446c1cc583f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentWarrantLiability_5c666e2d-2ddc-4225-a03c-9446c1cc583f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationNoncurrent_c0671c7c-e449-4c1d-81a6-a5e364b81708" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_adc_DeferredRoyaltyObligationNoncurrent_c0671c7c-e449-4c1d-81a6-a5e364b81708" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_9da2d434-01b3-492c-861f-c2d1344cd8dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_9da2d434-01b3-492c-861f-c2d1344cd8dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_207f2094-b80b-4d7e-90e0-6f90c80fb690" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_207f2094-b80b-4d7e-90e0-6f90c80fb690" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_a8d46486-9727-45ce-a7ec-76679899872e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_a8d46486-9727-45ce-a7ec-76679899872e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_f1a55176-1436-416f-af6e-fd2b7d0ace2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentLiabilities_f1a55176-1436-416f-af6e-fd2b7d0ace2f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_218e8e22-d62d-4eaf-989c-019b7ec3dec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_Liabilities_218e8e22-d62d-4eaf-989c-019b7ec3dec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_c9097c83-5045-4d6c-8f4d-9a776a09aad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_IssuedCapital_c9097c83-5045-4d6c-8f4d-9a776a09aad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_f557c7be-4f69-477a-8bc4-2ea474382414" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_SharePremium_f557c7be-4f69-477a-8bc4-2ea474382414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_6c005e77-d5b7-41c5-b167-5442ebd0c1cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_TreasuryShares_6c005e77-d5b7-41c5-b167-5442ebd0c1cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_a5f4e3aa-45a4-4410-b4dc-fc30512d21d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_OtherReserves_a5f4e3aa-45a4-4410-b4dc-fc30512d21d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_4dff10f6-da4a-4c4e-becc-fbbe3b5d8087" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_4dff10f6-da4a-4c4e-becc-fbbe3b5d8087" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_69cdfe51-adce-4501-85f6-0e50d0d1d04a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_RetainedEarnings_69cdfe51-adce-4501-85f6-0e50d0d1d04a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f9bb0bcb-399a-4b5a-b582-361063c39a6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_Equity_f9bb0bcb-399a-4b5a-b582-361063c39a6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_17a64e50-ba56-48ef-aac9-a71e368f0486" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_EquityAndLiabilities_17a64e50-ba56-48ef-aac9-a71e368f0486" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:href="adc-20220930.xsd#adc_ConsolidatedStatementOfFinancialPositionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:to="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4a6ee0d4-0952-44cd-abd8-d81856181e62_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4a6ee0d4-0952-44cd-abd8-d81856181e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:to="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoansMember_b267c3a2-f9ca-4a12-a18d-25c6d43d74fc" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:to="loc_adc_SeniorSecuredTermLoansMember_b267c3a2-f9ca-4a12-a18d-25c6d43d74fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansMember_7e6496e1-3a47-4178-8a40-da70620f725f" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:to="loc_adc_ConvertibleLoansMember_7e6496e1-3a47-4178-8a40-da70620f725f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofChangesinEquity"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" xlink:type="extended" id="if160566981d641f8a2da3345f1a09252_CondensedConsolidatedInterimStatementofChangesinEquity">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0dacefe8-6ed3-49e7-b4eb-0fc197dae84a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_Equity_0dacefe8-6ed3-49e7-b4eb-0fc197dae84a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_b9faba70-53d1-4e7a-bf37-2b3ce1c5df2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_ProfitLoss_b9faba70-53d1-4e7a-bf37-2b3ce1c5df2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_2719f1f2-6484-421a-9d62-f902827fb0c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_2719f1f2-6484-421a-9d62-f902827fb0c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47cf482f-63d2-49c4-9af4-9904323c47c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47cf482f-63d2-49c4-9af4-9904323c47c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_6c7e5d92-8749-4f50-a5de-eea50fff48c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_6c7e5d92-8749-4f50-a5de-eea50fff48c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ba500442-c53d-416b-b398-c22536e9911e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_ComprehensiveIncome_ba500442-c53d-416b-b398-c22536e9911e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_aeb2f36e-6451-46f0-976c-856c4cc9b4e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_aeb2f36e-6451-46f0-976c-856c4cc9b4e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughExchangeAgreement_add34a5e-acfd-4a79-a92a-a0681db589cf" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_adc_IssueOfEquityThroughExchangeAgreement_add34a5e-acfd-4a79-a92a-a0681db589cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughPurchaseAgreement_40d64160-9360-4eab-b416-e69d02361703" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_adc_IssueOfEquityThroughPurchaseAgreement_40d64160-9360-4eab-b416-e69d02361703" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_b1bad8f7-cae2-4454-8ce3-92ce835d0566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_b1bad8f7-cae2-4454-8ce3-92ce835d0566" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_82d2ead5-73ee-484c-8631-5e436f616f7b" xlink:href="adc-20220930.xsd#adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_82d2ead5-73ee-484c-8631-5e436f616f7b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_ace6152d-9153-49c5-841f-c3f682c69977" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_ace6152d-9153-49c5-841f-c3f682c69977" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_51967bbe-45ae-45da-8c28-325cc0c8236c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_51967bbe-45ae-45da-8c28-325cc0c8236c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d3117020-52bd-47e2-ac92-5f4f28249dc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_8fb44bff-44e0-4563-990a-75b4b3c4bd13_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:to="loc_ifrs-full_EquityMember_8fb44bff-44e0-4563-990a-75b4b3c4bd13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:to="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_122a7ca0-b22f-49eb-8fc5-f66e77cc190b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_IssuedCapitalMember_122a7ca0-b22f-49eb-8fc5-f66e77cc190b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a0d64d59-7aa9-4942-9ce1-6082956f4bdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_SharePremiumMember_a0d64d59-7aa9-4942-9ce1-6082956f4bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_9bc0255e-2686-497e-84f1-83fdf8b7f13d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_OtherReservesMember_9bc0255e-2686-497e-84f1-83fdf8b7f13d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_76f644f7-2553-4abc-86e5-da948c0b8081" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_TreasurySharesMember_76f644f7-2553-4abc-86e5-da948c0b8081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_e5097a01-795a-4748-b5eb-e17bf6c91d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_e5097a01-795a-4748-b5eb-e17bf6c91d44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_c67f663a-ee55-48da-ad1a-d89853e44902" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_RetainedEarningsMember_c67f663a-ee55-48da-ad1a-d89853e44902" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CorporateinformationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#CorporateinformationDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/CorporateinformationDetails" xlink:type="extended" id="i664ac2564a53401a9c1a28617d501092_CorporateinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfSubsidiaries_da7cca32-20cb-4018-845e-8b677e4e5870" xlink:href="adc-20220930.xsd#adc_NumberOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_NumberOfSubsidiaries_da7cca32-20cb-4018-845e-8b677e4e5870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_348c7676-4c89-43c7-9b75-e5e2aa04ca7d" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_348c7676-4c89-43c7-9b75-e5e2aa04ca7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_54094f45-4aa7-4d02-8706-93908fc2ffe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_CashAndCashEquivalents_54094f45-4aa7-4d02-8706-93908fc2ffe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_ee39ca79-82a1-4c2c-962c-d5e17f24655b" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_ee39ca79-82a1-4c2c-962c-d5e17f24655b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_302ca143-2893-44ff-a27a-e5c2af2d4f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_Borrowings_302ca143-2893-44ff-a27a-e5c2af2d4f83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeOfConvertibleNotesForWarrants_4a98d0eb-c83f-4b26-8862-a9fd392c5215" xlink:href="adc-20220930.xsd#adc_ExchangeOfConvertibleNotesForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_ExchangeOfConvertibleNotesForWarrants_4a98d0eb-c83f-4b26-8862-a9fd392c5215" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_ab8eae14-335a-4bd2-aaee-a57956a3a157" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_ConvertibleNotesSharesConverted_ab8eae14-335a-4bd2-aaee-a57956a3a157" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesValueConverted_d27ca174-e821-49dd-b699-c7d1483e5e92" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesValueConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_ConvertibleNotesValueConverted_d27ca174-e821-49dd-b699-c7d1483e5e92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice_fcaa4163-a7bc-4637-a532-5d898c1edeaf" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_WarrantsSharesConvertedExercisePrice_fcaa4163-a7bc-4637-a532-5d898c1edeaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_0c5f2d1b-a046-4469-8492-24713c7f7822" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_NumberOfSharesIssued_0c5f2d1b-a046-4469-8492-24713c7f7822" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockPricePerShare_230b532c-1860-4d7d-9341-8126031dcfd6" xlink:href="adc-20220930.xsd#adc_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_SaleOfStockPricePerShare_230b532c-1860-4d7d-9341-8126031dcfd6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_bb8645b1-72a1-4efd-841c-383e540ef1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_bb8645b1-72a1-4efd-841c-383e540ef1fd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_90ad1dcb-5283-4088-a161-82fdeafdc1ba_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:to="loc_ifrs-full_BorrowingsByNameMember_90ad1dcb-5283-4088-a161-82fdeafdc1ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:to="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_524a7bec-af40-404e-add8-3738e9f1a84e" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_524a7bec-af40-404e-add8-3738e9f1a84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember_4048f6f9-645c-4cd0-9283-375f90fc1843" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_LoanAgreementMember_4048f6f9-645c-4cd0-9283-375f90fc1843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementFirstTrancheMember_1ab6c592-ad66-4cd2-ab9d-55060058331d" xlink:href="adc-20220930.xsd#adc_LoanAgreementFirstTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_LoanAgreementFirstTrancheMember_1ab6c592-ad66-4cd2-ab9d-55060058331d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementFutureTranchesMember_ed60145f-cefd-4dc2-8f5a-1cd4a955e0f6" xlink:href="adc-20220930.xsd#adc_LoanAgreementFutureTranchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_LoanAgreementFutureTranchesMember_ed60145f-cefd-4dc2-8f5a-1cd4a955e0f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_8e39a759-08a5-4007-9188-824e51ce641f_default" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:to="loc_adc_WarrantsTrancheDomain_8e39a759-08a5-4007-9188-824e51ce641f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:to="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_9a33824e-a7d5-4c62-9c32-3a4d77cb6807" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheOneMember_9a33824e-a7d5-4c62-9c32-3a4d77cb6807" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember_5f9126b8-aca8-4383-b102-46a8408d5f3b" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheTwoMember_5f9126b8-aca8-4383-b102-46a8408d5f3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember_665f419e-34d2-4aeb-b559-a31dea4c9ac4" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheOnePriceOneMember_665f419e-34d2-4aeb-b559-a31dea4c9ac4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember_9c250299-d437-47d9-9d61-da1531360ad6" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheOnePriceTwoMember_9c250299-d437-47d9-9d61-da1531360ad6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3_default" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:to="loc_adc_SaleOfStockDomain_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_a78287c5-ec7b-481b-b739-501be55aa53a" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:to="loc_adc_SaleOfStockDomain_a78287c5-ec7b-481b-b739-501be55aa53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PurchasersMember_4094762b-d91f-4192-8ade-81447eabc1db" xlink:href="adc-20220930.xsd#adc_PurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_SaleOfStockDomain_a78287c5-ec7b-481b-b739-501be55aa53a" xlink:to="loc_adc_PurchasersMember_4094762b-d91f-4192-8ade-81447eabc1db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#BasisofpreparationAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" xlink:type="extended" id="i5c960c620a004a58976dbf1af4c3074b_BasisofpreparationAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PensionObligationDiscountRate_eb0b96dc-4e0d-41f5-a3ed-cb979bfa10bc" xlink:href="adc-20220930.xsd#adc_PensionObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_adc_PensionObligationDiscountRate_eb0b96dc-4e0d-41f5-a3ed-cb979bfa10bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_ffaf0b8e-604e-49f4-a997-7ac439ac6859" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_NumberOfSharesIssued_ffaf0b8e-604e-49f4-a997-7ac439ac6859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_df945085-d720-41a4-a7a3-57dfa72000f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_df945085-d720-41a4-a7a3-57dfa72000f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SaleOrIssueOfTreasuryShares_6c13e0d1-312b-4109-83ae-c1dc6f46518b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_SaleOrIssueOfTreasuryShares_6c13e0d1-312b-4109-83ae-c1dc6f46518b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:to="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_c6e31c08-738c-4e4e-b69d-a08d4f4ce865_default" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:to="loc_adc_SaleOfStockDomain_c6e31c08-738c-4e4e-b69d-a08d4f4ce865_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:to="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareSubscriptionAgreementMember_3a4837d7-a97e-4e92-8f99-d41ce3016b97" xlink:href="adc-20220930.xsd#adc_ShareSubscriptionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:to="loc_adc_ShareSubscriptionAgreementMember_3a4837d7-a97e-4e92-8f99-d41ce3016b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeAgreementMember_445f0b46-1b3a-49a8-b310-c7b3dfe696df" xlink:href="adc-20220930.xsd#adc_ExchangeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:to="loc_adc_ExchangeAgreementMember_445f0b46-1b3a-49a8-b310-c7b3dfe696df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SignificantaccountingpoliciesDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" xlink:type="extended" id="if4c12036a3ac419785aa10d3ee18102e_SignificantaccountingpoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_c586beaf-d084-4777-904d-9e9bc34fb93a" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_c586beaf-d084-4777-904d-9e9bc34fb93a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_7aeb00b8-4865-41d3-ba37-06405002fb6d" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:to="loc_adc_ConvertibleNotesSharesConverted_7aeb00b8-4865-41d3-ba37-06405002fb6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:to="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_039b483d-50b7-4d5b-a566-d58d09466b64_default" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:to="loc_adc_WarrantsTrancheDomain_039b483d-50b7-4d5b-a566-d58d09466b64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:to="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_96e74b25-aec3-45d1-aa8c-75cc2b8458bf" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:to="loc_adc_WarrantsTrancheOneMember_96e74b25-aec3-45d1-aa8c-75cc2b8458bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember_0c9b9ccd-efac-41d8-a5ec-1fb9b8f34682" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:to="loc_adc_WarrantsTrancheOnePriceOneMember_0c9b9ccd-efac-41d8-a5ec-1fb9b8f34682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember_27a50ab0-c988-45f2-b8a8-03cfbfb9d4ec" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:to="loc_adc_WarrantsTrancheOnePriceTwoMember_27a50ab0-c988-45f2-b8a8-03cfbfb9d4ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/FinancialriskmanagementDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#FinancialriskmanagementDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/FinancialriskmanagementDetails" xlink:type="extended" id="ia6400a8bf90342a99b18af5436aa1587_FinancialriskmanagementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_e1752b8a-b9ea-45d2-80a6-0312cb06137d" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:to="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_e1752b8a-b9ea-45d2-80a6-0312cb06137d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_7a9c7418-ef12-4fce-ada3-5e72ab80925e" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:to="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_7a9c7418-ef12-4fce-ada3-5e72ab80925e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_76ab4624-f812-4341-b309-92a07547f846_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:to="loc_ifrs-full_TypesOfRisksMember_76ab4624-f812-4341-b309-92a07547f846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_5824c0ac-988d-4a06-b689-9a3ab1f03235" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:to="loc_ifrs-full_TypesOfRisksMember_5824c0ac-988d-4a06-b689-9a3ab1f03235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_fa59ee68-bea7-4ee4-a3cc-e2e31fdd1442" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_5824c0ac-988d-4a06-b689-9a3ab1f03235" xlink:to="loc_ifrs-full_InterestRateRiskMember_fa59ee68-bea7-4ee4-a3cc-e2e31fdd1442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_994e90fe-ee4a-499a-bb82-8de07d0d7c30_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:to="loc_ifrs-full_BorrowingsByNameMember_994e90fe-ee4a-499a-bb82-8de07d0d7c30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_622cdacb-e59a-4e9a-b2de-f565034aa912" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:to="loc_ifrs-full_BorrowingsByNameMember_622cdacb-e59a-4e9a-b2de-f565034aa912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember_8c2a12b8-fe87-44f7-93c7-677481efd42a" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_622cdacb-e59a-4e9a-b2de-f565034aa912" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityMember_8c2a12b8-fe87-44f7-93c7-677481efd42a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ProductrevenuesnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" xlink:type="extended" id="i7cfe5aa32e154de38601a48b1572f010_ProductrevenuesnetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMilestonePayments_1982157e-a1df-496e-9250-83f1fffbb245" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_LicenseAgreementMilestonePayments_1982157e-a1df-496e-9250-83f1fffbb245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromLicenseAgreement_6fc16db5-2ed9-45bd-b915-6bad9a62af1e" xlink:href="adc-20220930.xsd#adc_ProceedsFromLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_ProceedsFromLicenseAgreement_6fc16db5-2ed9-45bd-b915-6bad9a62af1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementCappedContribution_0bd8cd5d-6135-4f4d-991e-a5e8e393ff26" xlink:href="adc-20220930.xsd#adc_LicenseAgreementCappedContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_LicenseAgreementCappedContribution_0bd8cd5d-6135-4f4d-991e-a5e8e393ff26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_0cd1112b-71c0-4693-8c68-ad586fe0045c" xlink:href="adc-20220930.xsd#adc_LicenseAgreementPercentOfClinicalTrialCostsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_0cd1112b-71c0-4693-8c68-ad586fe0045c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e2faf527-6649-4908-8b86-a393d8fc6cc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e2faf527-6649-4908-8b86-a393d8fc6cc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e2faf527-6649-4908-8b86-a393d8fc6cc1" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_c0854245-153d-4077-8548-7c363a2d4673_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:to="loc_ifrs-full_NonadjustingEventsMember_c0854245-153d-4077-8548-7c363a2d4673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:to="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMember_a509327c-3968-43ae-9eb5-e5dce470ff2f" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:to="loc_adc_LicenseAgreementMember_a509327c-3968-43ae-9eb5-e5dce470ff2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ApplicationApprovalMember_1dea3e9d-e5ea-4e5b-8e7d-e6ef52bfebe9" xlink:href="adc-20220930.xsd#adc_ApplicationApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:to="loc_adc_ApplicationApprovalMember_1dea3e9d-e5ea-4e5b-8e7d-e6ef52bfebe9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#OperatingexpenseScheduleofExpensesbyNatureDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" xlink:type="extended" id="i403cc9cfec3c40a88aaa55c4751c73a2_OperatingexpenseScheduleofExpensesbyNatureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_bcc77951-c9be-4254-89d0-3cfc919863dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_CostOfSales_bcc77951-c9be-4254-89d0-3cfc919863dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_d39a4bbb-d0a4-4ea3-b6e0-a592ae3f2b97" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_d39a4bbb-d0a4-4ea3-b6e0-a592ae3f2b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_b9426ccd-235b-4ed0-9db8-7205cf268e4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_b9426ccd-235b-4ed0-9db8-7205cf268e4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_498fc3eb-8aa5-4784-adcd-1d42a3017197" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_498fc3eb-8aa5-4784-adcd-1d42a3017197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_d1648955-2b05-433b-9407-fb719663a90e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_OperatingExpense_d1648955-2b05-433b-9407-fb719663a90e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:to="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain_40462b81-9b4e-4411-966d-36ae7f184525_default" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:to="loc_adc_ExpensesByNatureDomain_40462b81-9b4e-4411-966d-36ae7f184525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain_bf575cc6-3548-44eb-82d8-311392b55d2f" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:to="loc_adc_ExpensesByNatureDomain_bf575cc6-3548-44eb-82d8-311392b55d2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_ExpensesByNatureDomain_bf575cc6-3548-44eb-82d8-311392b55d2f" xlink:to="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExternalCostsMember_b634c0b4-e34e-4cef-af95-35773e72efb3" xlink:href="adc-20220930.xsd#adc_ExternalCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:to="loc_adc_ExternalCostsMember_b634c0b4-e34e-4cef-af95-35773e72efb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeExpensesMember_7cc06c7f-e5d9-4247-9de0-cb254bf85681" xlink:href="adc-20220930.xsd#adc_EmployeeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:to="loc_adc_EmployeeExpensesMember_7cc06c7f-e5d9-4247-9de0-cb254bf85681" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#OperatingexpenseNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" xlink:type="extended" id="i69f5200aa6414516be86a02e30805853_OperatingexpenseNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_9d80e976-a4af-49a3-bb86-31474b0a6048" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_9d80e976-a4af-49a3-bb86-31474b0a6048" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_ba6d7b6c-190c-4c28-9017-21e4528e4320" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_ba6d7b6c-190c-4c28-9017-21e4528e4320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_a05c0efb-2669-456a-add9-320a3159cb0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_a05c0efb-2669-456a-add9-320a3159cb0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:href="adc-20220930.xsd#adc_InventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:to="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a_default" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:to="loc_adc_InventoryDomain_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain_d9ee5dc1-99d3-4e0b-888c-d4e38387b45b" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:to="loc_adc_InventoryDomain_d9ee5dc1-99d3-4e0b-888c-d4e38387b45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ManufacturingOfAntibodiesMember_8a33fafb-d8df-4a40-b6fc-3d8c0f995ea9" xlink:href="adc-20220930.xsd#adc_ManufacturingOfAntibodiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InventoryDomain_d9ee5dc1-99d3-4e0b-888c-d4e38387b45b" xlink:to="loc_adc_ManufacturingOfAntibodiesMember_8a33fafb-d8df-4a40-b6fc-3d8c0f995ea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:to="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca_default" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:to="loc_adc_ExpensesByNatureDomain_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain_c7a5b610-bdbe-40e3-b1d0-3a0bc56442a1" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:to="loc_adc_ExpensesByNatureDomain_c7a5b610-bdbe-40e3-b1d0-3a0bc56442a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExecutiveCompensationMember_7a49b0a7-c240-4165-a5de-6a1e9915af26" xlink:href="adc-20220930.xsd#adc_ExecutiveCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_ExpensesByNatureDomain_c7a5b610-bdbe-40e3-b1d0-3a0bc56442a1" xlink:to="loc_adc_ExecutiveCompensationMember_7a49b0a7-c240-4165-a5de-6a1e9915af26" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="if624e77e19f540a0b68538adc665c709_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_85c3875c-f2d8-4bdd-a55c-960fb5fe0894" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_e7484698-623a-46ea-8af2-c611f3f0407b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_85c3875c-f2d8-4bdd-a55c-960fb5fe0894" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_e7484698-623a-46ea-8af2-c611f3f0407b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_85c3875c-f2d8-4bdd-a55c-960fb5fe0894" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:href="adc-20220930.xsd#adc_InventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:to="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain_452c1d2a-5a01-4a81-ad5d-042f06de7f8b_default" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:to="loc_adc_InventoryDomain_452c1d2a-5a01-4a81-ad5d-042f06de7f8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain_ad34c77c-487f-4404-86a8-9c339b583e07" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:to="loc_adc_InventoryDomain_ad34c77c-487f-4404-86a8-9c339b583e07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAForRDMember_b430c0ab-553d-4e72-86e6-0abdfe89adfc" xlink:href="adc-20220930.xsd#adc_ZYNLONTAForRDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InventoryDomain_ad34c77c-487f-4404-86a8-9c339b583e07" xlink:to="loc_adc_ZYNLONTAForRDMember_b430c0ab-553d-4e72-86e6-0abdfe89adfc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#IntangibleassetsRollforwardofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" xlink:type="extended" id="i8129645b2e9745a1b587989a6177ce02_IntangibleassetsRollforwardofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fc9ef611-eb05-4a8a-bc50-229b75943fe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fc9ef611-eb05-4a8a-bc50-229b75943fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_938fd94b-ef0c-49d0-8b28-dc88c1aefccc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_938fd94b-ef0c-49d0-8b28-dc88c1aefccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TransfersIntangibleAssetsOtherThanGoodwill_709dae8e-5675-47a4-a652-c583dcd08782" xlink:href="adc-20220930.xsd#adc_TransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_adc_TransfersIntangibleAssetsOtherThanGoodwill_709dae8e-5675-47a4-a652-c583dcd08782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_42f01a2c-4e91-4461-a85e-4ecceddfa996" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_42f01a2c-4e91-4461-a85e-4ecceddfa996" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_9349a21e-2ef7-4cab-b421-8c28c8baace3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_9349a21e-2ef7-4cab-b421-8c28c8baace3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_85ece1d3-75e3-4266-97bd-f882c8fb489f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_993ba20c-aa2b-49bf-af34-c685c0061c8d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_993ba20c-aa2b-49bf-af34-c685c0061c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensesIndefiniteLivedMember_9ae1e193-6eef-4cd9-9d1c-5a131c5fea1d" xlink:href="adc-20220930.xsd#adc_LicensesIndefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_adc_LicensesIndefiniteLivedMember_9ae1e193-6eef-4cd9-9d1c-5a131c5fea1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InternalDevelopmentCostsMember_de3e626e-7083-4796-8687-845f89bd82c8" xlink:href="adc-20220930.xsd#adc_InternalDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_adc_InternalDevelopmentCostsMember_de3e626e-7083-4796-8687-845f89bd82c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensesDefiniteLivedMember_7fa1aee9-1e2c-411a-b02c-12ccd3e0e605" xlink:href="adc-20220930.xsd#adc_LicensesDefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_adc_LicensesDefiniteLivedMember_7fa1aee9-1e2c-411a-b02c-12ccd3e0e605" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_f2c5df44-be0c-4b80-9fd9-25cfd917bbb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_ifrs-full_ComputerSoftwareMember_f2c5df44-be0c-4b80-9fd9-25cfd917bbb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_dbc2cbc3-3fec-4eb3-bfda-d2c80daa12a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_ifrs-full_LicencesMember_dbc2cbc3-3fec-4eb3-bfda-d2c80daa12a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_fb7fcbb9-d216-4869-96d8-ca4a2ca36029_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:to="loc_ifrs-full_CarryingAmountMember_fb7fcbb9-d216-4869-96d8-ca4a2ca36029_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:to="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_d7ae5a06-5477-4ec2-a979-97c56a00fd72" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_d7ae5a06-5477-4ec2-a979-97c56a00fd72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_7429bbd4-b7c6-485a-9448-a32b934f986d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_7429bbd4-b7c6-485a-9448-a32b934f986d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#IntangibleassetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended" id="ie8547aaf7760452885c07e0b55ba9c40_IntangibleassetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_ebea633a-d802-4b89-9ff0-cd74bbed5e18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_ebea633a-d802-4b89-9ff0-cd74bbed5e18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8b2cfdd2-0cbd-4db7-824f-9b741b51a6c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8b2cfdd2-0cbd-4db7-824f-9b741b51a6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_945d05e6-1435-4267-a491-dd08f9b038eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_945d05e6-1435-4267-a491-dd08f9b038eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a3da8065-9877-43a3-937b-6a8ebb5ccc1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4163f4cf-5d7f-4844-8cb1-381d02e09380_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4163f4cf-5d7f-4844-8cb1-381d02e09380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DosingOfSpecificNumberOfPatientsMember_18523979-63be-4406-8dc9-5debd107791d" xlink:href="adc-20220930.xsd#adc_DosingOfSpecificNumberOfPatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_DosingOfSpecificNumberOfPatientsMember_18523979-63be-4406-8dc9-5debd107791d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_b33fe019-fa8e-4a16-ba0c-23f042ef1731" xlink:href="adc-20220930.xsd#adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_b33fe019-fa8e-4a16-ba0c-23f042ef1731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_7b52eb2a-22fb-471d-9434-52eb123da4f6" xlink:href="adc-20220930.xsd#adc_LicenseToAcquireAnAntibodyZYNLONTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_7b52eb2a-22fb-471d-9434-52eb123da4f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAMember_a4b1369b-8723-4278-98b2-57ba44633d61" xlink:href="adc-20220930.xsd#adc_ZYNLONTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_ZYNLONTAMember_a4b1369b-8723-4278-98b2-57ba44633d61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_2c49a81d-d7eb-4a7d-820a-3ed654f13069" xlink:href="adc-20220930.xsd#adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_2c49a81d-d7eb-4a7d-820a-3ed654f13069" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_9035dc8e-c3d8-4282-96b3-19be8ee961b4" xlink:href="adc-20220930.xsd#adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_9035dc8e-c3d8-4282-96b3-19be8ee961b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:href="adc-20220930.xsd#adc_PaymentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:to="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeDomain_db0dd79a-6330-4b63-9b18-1e8f7727863e_default" xlink:href="adc-20220930.xsd#adc_PaymentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:to="loc_adc_PaymentTypeDomain_db0dd79a-6330-4b63-9b18-1e8f7727863e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:href="adc-20220930.xsd#adc_PaymentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:to="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_MilestonePaymentMember_1f4fc7db-c2a7-46d5-b224-daa94c10a50e" xlink:href="adc-20220930.xsd#adc_MilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:to="loc_adc_MilestonePaymentMember_1f4fc7db-c2a7-46d5-b224-daa94c10a50e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensePaymentMember_b7c238ee-2e47-40bf-b17d-a09155027fdf" xlink:href="adc-20220930.xsd#adc_LicensePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:to="loc_adc_LicensePaymentMember_b7c238ee-2e47-40bf-b17d-a09155027fdf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#NonoperatingincomeScheduleofOtherIncomeExpenseDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" xlink:type="extended" id="id5bb34b2a9bd48fc80bf4254aea08c53_NonoperatingincomeScheduleofOtherIncomeExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26c90221-740f-4ced-8c03-9467c046d0f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26c90221-740f-4ced-8c03-9467c046d0f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsDeferredFinancingCosts_0d240b66-156f-4369-a7bb-21403e3fbb71" xlink:href="adc-20220930.xsd#adc_BorrowingsDeferredFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_BorrowingsDeferredFinancingCosts_0d240b66-156f-4369-a7bb-21403e3fbb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings_bd9c7f99-6b7d-4007-aa3f-948209abc81b" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_GainsLossOnExtinguishmentOfBorrowings_bd9c7f99-6b7d-4007-aa3f-948209abc81b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnChangeInFairValueWarrants_b62d7d06-2f9b-4a3f-a771-8e381b272f41" xlink:href="adc-20220930.xsd#adc_GainsLossOnChangeInFairValueWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_GainsLossOnChangeInFairValueWarrants_b62d7d06-2f9b-4a3f-a771-8e381b272f41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationsTransactionCosts_7c914fb1-d899-4962-add1-a644bf3e5c0e" xlink:href="adc-20220930.xsd#adc_WarrantObligationsTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_WarrantObligationsTransactionCosts_7c914fb1-d899-4962-add1-a644bf3e5c0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_7b88c4bf-a0c7-4ad7-babd-604a322e4a86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_7b88c4bf-a0c7-4ad7-babd-604a322e4a86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ba67d1c0-19da-419d-ac79-9af0dabc1902" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ba67d1c0-19da-419d-ac79-9af0dabc1902" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_534356cf-a350-4f0d-b20a-0685bba311c7" xlink:href="adc-20220930.xsd#adc_TaxEffectOfResearchAndDevelopmentTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_534356cf-a350-4f0d-b20a-0685bba311c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NonOperatingIncomeExpense_a1dc08d1-8f8d-4b2f-adfa-58f8931a04d2" xlink:href="adc-20220930.xsd#adc_NonOperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_NonOperatingIncomeExpense_a1dc08d1-8f8d-4b2f-adfa-58f8931a04d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_cee883cb-c4ec-4a82-b470-c0fc7c16a81d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:to="loc_ifrs-full_BorrowingsByNameMember_cee883cb-c4ec-4a82-b470-c0fc7c16a81d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_a44a3858-77c0-4858-b9b4-bfb5d8bd7312" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_a44a3858-77c0-4858-b9b4-bfb5d8bd7312" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember_6684632f-4586-4ed4-ae25-749e83340531" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityMember_6684632f-4586-4ed4-ae25-749e83340531" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#NonoperatingincomeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails" xlink:type="extended" id="i401a94d686d64d41914bcf20a170021d_NonoperatingincomeNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_0c110a17-857c-4a3b-861d-b4aa323bf187" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_ifrs-full_Borrowings_0c110a17-857c-4a3b-861d-b4aa323bf187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_19e4c348-e4d2-48e4-a9a7-3d5c3d0c4eb7" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_19e4c348-e4d2-48e4-a9a7-3d5c3d0c4eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_7b5c7e89-71a9-4806-a621-b4b13099c510" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_adc_ConvertibleNotesSharesConverted_7b5c7e89-71a9-4806-a621-b4b13099c510" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_d97897be-8eee-494f-80c6-18fc75790fc3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:to="loc_ifrs-full_BorrowingsByNameMember_d97897be-8eee-494f-80c6-18fc75790fc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:to="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_cb8f0896-b5d3-47cf-9fd2-c0af196b8729" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_cb8f0896-b5d3-47cf-9fd2-c0af196b8729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_a614c719-a295-499b-a6ac-c339f910c73f" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_a614c719-a295-499b-a6ac-c339f910c73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_0096cc09-d523-4bd4-ac57-848bf06607c5" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_0096cc09-d523-4bd4-ac57-848bf06607c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:to="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_5b09e5be-31c7-422f-990c-b0eb50e45c2f_default" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:to="loc_adc_WarrantsTrancheDomain_5b09e5be-31c7-422f-990c-b0eb50e45c2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_b3c9152e-dbb9-417b-acf2-ea743288e85e" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:to="loc_adc_WarrantsTrancheDomain_b3c9152e-dbb9-417b-acf2-ea743288e85e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_2aa8f350-2ed2-4caa-8187-c185230fca1b" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_b3c9152e-dbb9-417b-acf2-ea743288e85e" xlink:to="loc_adc_WarrantsTrancheOneMember_2aa8f350-2ed2-4caa-8187-c185230fca1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" xlink:type="extended" id="i9009c938515245fe97b0746b178ef6ba_InterestinjointventureNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_74d66f20-8955-407e-8057-fcec439d060b" xlink:href="adc-20220930.xsd#adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_74d66f20-8955-407e-8057-fcec439d060b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_dc8d736a-5651-426f-b3b2-8bbf79ad5525" xlink:href="adc-20220930.xsd#adc_NumberOfProductsDevelopedAndCommercializedInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_dc8d736a-5651-426f-b3b2-8bbf79ad5525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredGainOnInvestmentInJointVenture_60cd646d-11b2-4132-9043-0323ba80f4d8" xlink:href="adc-20220930.xsd#adc_DeferredGainOnInvestmentInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_adc_DeferredGainOnInvestmentInJointVenture_60cd646d-11b2-4132-9043-0323ba80f4d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:to="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_520e4f1a-90ba-4577-b522-7bed5969f8ea_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_520e4f1a-90ba-4577-b522-7bed5969f8ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_c4ffdec5-664f-45a3-bc60-727a0cd79f51" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_c4ffdec5-664f-45a3-bc60-727a0cd79f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_40b4f5f0-064c-4b2b-a324-a266e4643fdd" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_c4ffdec5-664f-45a3-bc60-727a0cd79f51" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_40b4f5f0-064c-4b2b-a324-a266e4643fdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureScheduleofmovementininterestinjointventureDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" xlink:type="extended" id="i7b73ed712c264e499ddeaf054362a613_InterestinjointventureScheduleofmovementininterestinjointventureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_62bb25c2-ea59-4235-8229-89ee7ede52d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_62bb25c2-ea59-4235-8229-89ee7ede52d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_c287a7aa-4c66-482b-8801-f7edf575977b" xlink:href="adc-20220930.xsd#adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:to="loc_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_c287a7aa-4c66-482b-8801-f7edf575977b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_aa8cc002-3dae-40e0-a150-de4e3ac2818e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:to="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_ecf7b88d-7d19-4029-b3af-b9598d653608_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_ecf7b88d-7d19-4029-b3af-b9598d653608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_90c381b7-7ab6-497b-bcab-a344f4758c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_90c381b7-7ab6-497b-bcab-a344f4758c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_01cfba3b-c61d-4184-8ea0-32fde1d20029" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_90c381b7-7ab6-497b-bcab-a344f4758c7a" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_01cfba3b-c61d-4184-8ea0-32fde1d20029" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureSummaryoffinancialinformationinjointventureDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" xlink:type="extended" id="icddfc15f8cbf4ff3a1e1e172a4f8ecf2_InterestinjointventureSummaryoffinancialinformationinjointventureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6e7e710e-108d-41ba-b9cf-4b1cf70ff8d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6e7e710e-108d-41ba-b9cf-4b1cf70ff8d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_4d5e998a-51e7-4d95-bb85-f1e3f649902d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_4d5e998a-51e7-4d95-bb85-f1e3f649902d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d73bde9f-a46b-4e3b-b57d-70a74c8540dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d73bde9f-a46b-4e3b-b57d-70a74c8540dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_67d21dd9-ce00-4e13-9532-fc1ad80afde7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_Liabilities_67d21dd9-ce00-4e13-9532-fc1ad80afde7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_db8763ac-3349-4a64-b8cb-f127fd2faaac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_NetAssetsLiabilities_db8763ac-3349-4a64-b8cb-f127fd2faaac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_4f3290d4-0dde-4fc5-9876-a197fb8f73d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_OperatingExpense_4f3290d4-0dde-4fc5-9876-a197fb8f73d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9d359f3a-23c6-449e-af05-2bb3bfe5f5e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_ProfitLoss_9d359f3a-23c6-449e-af05-2bb3bfe5f5e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_1aab52ba-0417-4a2b-9729-7b141ea49e04" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_1aab52ba-0417-4a2b-9729-7b141ea49e04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_1aab52ba-0417-4a2b-9729-7b141ea49e04" xlink:to="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_aa85b437-2c60-4414-9555-9cf6e2a76d33_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_aa85b437-2c60-4414-9555-9cf6e2a76d33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_0e013cfd-fe3c-4a08-afb9-9694434a61ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_0e013cfd-fe3c-4a08-afb9-9694434a61ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_1ea25946-6264-4a08-9829-61f29b828464" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_0e013cfd-fe3c-4a08-afb9-9694434a61ba" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_1ea25946-6264-4a08-9829-61f29b828464" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesRightofUseAssetsandAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" xlink:type="extended" id="i6dff7fb9cec44f26a7131fceafc8173c_LeasesRightofUseAssetsandAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_ce58eeda-2319-4411-b640-9a6539392b4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_RightofuseAssets_ce58eeda-2319-4411-b640-9a6539392b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_e093869f-a72c-41b8-beed-0734b2c2b8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_e093869f-a72c-41b8-beed-0734b2c2b8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_94628050-1185-41f1-94ba-af2323b93f48" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_94628050-1185-41f1-94ba-af2323b93f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_c0d8629c-e990-4f60-9d74-7e1fac2a9564" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_c0d8629c-e990-4f60-9d74-7e1fac2a9564" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_3df6208d-e199-48b8-859d-21ad09383708" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_3df6208d-e199-48b8-859d-21ad09383708" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_8b2a9dfb-240f-44b3-aa7a-f1d327d3255c" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_93fc1c76-de43-42af-8177-042393e34810" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_6ffa13d2-87d6-4377-9778-24c9f0013a2c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_6ffa13d2-87d6-4377-9778-24c9f0013a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_c394e700-67f4-4ad8-b644-fa86483e08fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:to="loc_ifrs-full_BuildingsMember_c394e700-67f4-4ad8-b644-fa86483e08fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_36b6877e-8bb5-4fd3-8075-a9d81b912863" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:to="loc_ifrs-full_VehiclesMember_36b6877e-8bb5-4fd3-8075-a9d81b912863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_bf018239-f9e2-4b3b-93c7-199ce29d0cbf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:to="loc_ifrs-full_CarryingAmountMember_bf018239-f9e2-4b3b-93c7-199ce29d0cbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:to="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_eb566c32-3857-45e7-b627-ccaa33596834" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_eb566c32-3857-45e7-b627-ccaa33596834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_55f463eb-e849-402d-8405-4ee5278d1b84" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_55f463eb-e849-402d-8405-4ee5278d1b84" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesRightofUseAssetDepreciationDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" xlink:type="extended" id="i634272627aea4391917c04a127ee8561_LeasesRightofUseAssetDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_b0561b77-8c03-4f41-9b56-9e1726c8ff76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_edaeed14-28cd-43a5-a4ed-09ae213ffb8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_b0561b77-8c03-4f41-9b56-9e1726c8ff76" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_edaeed14-28cd-43a5-a4ed-09ae213ffb8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_b0561b77-8c03-4f41-9b56-9e1726c8ff76" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:to="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationDomain_87e6b4e0-9dbe-4b43-af54-bf4d781c7193_default" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:to="loc_adc_IncomeStatementLocationDomain_87e6b4e0-9dbe-4b43-af54-bf4d781c7193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:to="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResearchAndDevelopmentExpenseMember_73e999bc-ff3b-47a5-8f58-e45743558c47" xlink:href="adc-20220930.xsd#adc_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:to="loc_adc_ResearchAndDevelopmentExpenseMember_73e999bc-ff3b-47a5-8f58-e45743558c47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GeneralAndAdministrativeExpenseMember_2ae67ff6-1cd0-4999-9788-b25bc2f9ad51" xlink:href="adc-20220930.xsd#adc_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:to="loc_adc_GeneralAndAdministrativeExpenseMember_2ae67ff6-1cd0-4999-9788-b25bc2f9ad51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesScheduleofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" xlink:type="extended" id="i07c8af40bd804854ac7c2131b2c26e37_LeasesScheduleofLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:href="adc-20220930.xsd#adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_b0682afa-bef6-40d0-90bc-0f26d0bc8b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_LeaseLiabilities_b0682afa-bef6-40d0-90bc-0f26d0bc8b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdditionsToLeaseLiabilities_1bd13380-0795-4c40-af96-4bbaa6d5ce80" xlink:href="adc-20220930.xsd#adc_AdditionsToLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_AdditionsToLeaseLiabilities_1bd13380-0795-4c40-af96-4bbaa6d5ce80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_48e36480-4020-42a4-957e-50a504fb94b3" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_48e36480-4020-42a4-957e-50a504fb94b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_23195504-878b-4113-8cd1-5aaa9421e76d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_CashOutflowForLeases_23195504-878b-4113-8cd1-5aaa9421e76d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0c6496f3-f704-4f13-823b-88aa303b02ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0c6496f3-f704-4f13-823b-88aa303b02ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_55b4d443-afb7-4f19-8b49-3c08109accbb" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_55b4d443-afb7-4f19-8b49-3c08109accbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_353c4361-080a-4472-b82c-650fca987ac8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_04e53e1b-79ae-49a8-8ab4-fe187fd83b4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_04e53e1b-79ae-49a8-8ab4-fe187fd83b4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_673df831-755d-402b-a08e-92be6ce44cef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_673df831-755d-402b-a08e-92be6ce44cef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_f1adfc75-ef9c-4468-b674-de074cc6a505_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:to="loc_ifrs-full_LiabilitiesMember_f1adfc75-ef9c-4468-b674-de074cc6a505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:to="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_da102f65-cc9b-481f-a70e-d5897f3bb58d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:to="loc_ifrs-full_BuildingsMember_da102f65-cc9b-481f-a70e-d5897f3bb58d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_09b5683a-f98e-4864-8a23-308d39fca362" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:to="loc_ifrs-full_VehiclesMember_09b5683a-f98e-4864-8a23-308d39fca362" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" xlink:type="extended" id="iab0e84a8e09e4ed1ba1768eeb180edfb_SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_90bc1da8-2304-4e17-858c-561429a3731d" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_90bc1da8-2304-4e17-858c-561429a3731d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_41ca0de8-d1d3-402b-bcf2-ffefa728f520" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_Borrowings_41ca0de8-d1d3-402b-bcf2-ffefa728f520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_4c814f85-bfb8-477b-a190-a00ce8b3f013" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_BorrowingsInterestRate_4c814f85-bfb8-477b-a190-a00ce8b3f013" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFacilitiesExitFeePercentage_682496e0-1510-4812-b6ae-d45afe6da6ff" xlink:href="adc-20220930.xsd#adc_BorrowingsFacilitiesExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsFacilitiesExitFeePercentage_682496e0-1510-4812-b6ae-d45afe6da6ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_55adc4ba-f1b6-4205-8cca-4afc07de97cf" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_55adc4ba-f1b6-4205-8cca-4afc07de97cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_60ae8055-4f59-4d3f-b1dc-3a12f82e05c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_60ae8055-4f59-4d3f-b1dc-3a12f82e05c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_75b3620d-0685-4f79-a842-b534407c3e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_75b3620d-0685-4f79-a842-b534407c3e12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_525820d6-3aaf-4d6c-b8ed-1548a70619ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_525820d6-3aaf-4d6c-b8ed-1548a70619ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsImpliedEffectiveInterestRate_5e67adbd-24b2-4ca1-aef7-2856bae5e6ce" xlink:href="adc-20220930.xsd#adc_BorrowingsImpliedEffectiveInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsImpliedEffectiveInterestRate_5e67adbd-24b2-4ca1-aef7-2856bae5e6ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_1b71b16e-0deb-4df5-a4ba-8db66cf64ee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LoansReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_LoansReceived_1b71b16e-0deb-4df5-a4ba-8db66cf64ee9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_54c940c0-edf8-478c-953a-0e2a615468be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_54c940c0-edf8-478c-953a-0e2a615468be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_e8fa45bf-0af5-4428-9667-b5393496723a" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_e8fa45bf-0af5-4428-9667-b5393496723a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f079a4c7-4736-40a3-98e8-bc70b1f050fc" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f079a4c7-4736-40a3-98e8-bc70b1f050fc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_f84608e6-600c-44da-9fcb-a5c177842394" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_f84608e6-600c-44da-9fcb-a5c177842394" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_1df1f7cc-5f96-4f1a-86c5-eacfe8f8d57b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_1df1f7cc-5f96-4f1a-86c5-eacfe8f8d57b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_c503dfe5-4d34-43be-830b-dc3b478d1d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_c503dfe5-4d34-43be-830b-dc3b478d1d91" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_b5686bb7-3ff9-4fb9-be80-05f896f1b3b9" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_ConvertibleNotesSharesConverted_b5686bb7-3ff9-4fb9-be80-05f896f1b3b9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice_95a5b69b-f065-4d92-94d4-584c60389edf" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_WarrantsSharesConvertedExercisePrice_95a5b69b-f065-4d92-94d4-584c60389edf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationFairValue_a829c1bc-61b9-4c75-873b-f86a7a083047" xlink:href="adc-20220930.xsd#adc_WarrantObligationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_WarrantObligationFairValue_a829c1bc-61b9-4c75-873b-f86a7a083047" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFairValue_24e1826b-5c2c-4882-b8bc-e643ddcbb50a" xlink:href="adc-20220930.xsd#adc_BorrowingsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsFairValue_24e1826b-5c2c-4882-b8bc-e643ddcbb50a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_85e96825-2b8a-440e-b8f5-78fbc413b0de_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:to="loc_ifrs-full_BorrowingsByNameMember_85e96825-2b8a-440e-b8f5-78fbc413b0de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:to="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_6d24ed85-9eea-4b8b-adcf-8201ca08597e" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_6d24ed85-9eea-4b8b-adcf-8201ca08597e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_84ec9e12-37d7-4ea1-97c4-19c70389949e" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_84ec9e12-37d7-4ea1-97c4-19c70389949e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_c2613f71-615f-465c-8c3a-bb5744c3f3c4" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_c2613f71-615f-465c-8c3a-bb5744c3f3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember_df9d1014-3806-4871-9080-fbf929be6a3a" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_LoanAgreementMember_df9d1014-3806-4871-9080-fbf929be6a3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember_da18abba-ea1b-4490-a598-92cf03adf295" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityMember_da18abba-ea1b-4490-a598-92cf03adf295" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_c257974a-b2d5-42b0-af98-fb77b7e0227d" xlink:href="adc-20220930.xsd#adc_OakTreeAndOwlRockWarrantObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_c257974a-b2d5-42b0-af98-fb77b7e0227d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:to="loc_srt_RangeMember_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:to="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16ccb890-27ee-44e3-b881-b5f4c600d6d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:to="loc_srt_MinimumMember_16ccb890-27ee-44e3-b881-b5f4c600d6d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e00aeb4-03bd-4ef3-9c29-74415bf6de02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:to="loc_srt_MaximumMember_1e00aeb4-03bd-4ef3-9c29-74415bf6de02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_7c4b186f-f420-48a9-b810-45632ccfaabf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:to="loc_ifrs-full_RangesMember_7c4b186f-f420-48a9-b810-45632ccfaabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_af08675a-6458-4f8a-9bb7-373a5743032b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:to="loc_ifrs-full_RangesMember_af08675a-6458-4f8a-9bb7-373a5743032b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_155b9bc8-5d5a-4f6d-b103-8d4fbe9f7553" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_af08675a-6458-4f8a-9bb7-373a5743032b" xlink:to="loc_ifrs-full_TopOfRangeMember_155b9bc8-5d5a-4f6d-b103-8d4fbe9f7553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain_cea08a0b-392e-4276-8006-d99276c76121_default" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:to="loc_adc_BorrowingConversionPeriodDomain_cea08a0b-392e-4276-8006-d99276c76121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:to="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodOneMember_206788e3-59ea-4b9c-910b-1da7bc47c60a" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:to="loc_adc_BorrowingsConversionPeriodOneMember_206788e3-59ea-4b9c-910b-1da7bc47c60a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConversionPeriodTwoMember_4d7d57a0-7d61-4f82-bca5-3662716ac6c4" xlink:href="adc-20220930.xsd#adc_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:to="loc_adc_ConversionPeriodTwoMember_4d7d57a0-7d61-4f82-bca5-3662716ac6c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_d2ea7911-32e8-4f0f-b948-fcfb52984086_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:to="loc_ifrs-full_LiabilitiesMember_d2ea7911-32e8-4f0f-b948-fcfb52984086_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:to="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_4416ee6f-8785-4436-952f-df798d525742" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:to="loc_adc_ResidualLoanMember_4416ee6f-8785-4436-952f-df798d525742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_0b6df30b-9884-4e56-b82b-1677e6b5a61f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:to="loc_ifrs-full_DerivativesMember_0b6df30b-9884-4e56-b82b-1677e6b5a61f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" xlink:type="extended" id="i71718a963db746c5b8f05561177c3631_SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b7dff7aa-74ae-4d1c-8ba2-a12504e1518f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_140e5ee3-4cdc-4e26-8b84-aed906baa26a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b7dff7aa-74ae-4d1c-8ba2-a12504e1518f" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_140e5ee3-4cdc-4e26-8b84-aed906baa26a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b7dff7aa-74ae-4d1c-8ba2-a12504e1518f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_b057dd83-0478-4c08-a45f-abfd6eea8ec4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:to="loc_ifrs-full_UnobservableInputsMember_b057dd83-0478-4c08-a45f-abfd6eea8ec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:to="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WrittenPutOptionsMember_d9caa011-2fdb-458f-b0a1-c64f2dbcdf9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WrittenPutOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_ifrs-full_WrittenPutOptionsMember_d9caa011-2fdb-458f-b0a1-c64f2dbcdf9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember_9ac1561d-e50a-4f2d-a939-e0db09f561c1" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_SharePriceMember_9ac1561d-e50a-4f2d-a939-e0db09f561c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember_7c851947-c5d0-4561-9223-25d57bf8349f" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_RiskFreeInterestRateMember_7c851947-c5d0-4561-9223-25d57bf8349f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember_256ca636-d63e-4b05-91ef-a1ab1754e2d4" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_ExpectedVolatilityMember_256ca636-d63e-4b05-91ef-a1ab1754e2d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember_16b9432f-66fa-401c-b3b3-60829c369e31" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_ExpectedTermMember_16b9432f-66fa-401c-b3b3-60829c369e31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DividendYieldMember_6f42305a-622a-4904-9795-ac4a84de2320" xlink:href="adc-20220930.xsd#adc_DividendYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_DividendYieldMember_6f42305a-622a-4904-9795-ac4a84de2320" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BlackScholesValueMember_d347aeda-23df-44a2-b247-e3ce0d7a926f" xlink:href="adc-20220930.xsd#adc_BlackScholesValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_BlackScholesValueMember_d347aeda-23df-44a2-b247-e3ce0d7a926f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_615b3635-7f30-4dcc-986b-ec40798d3b9a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:to="loc_ifrs-full_LiabilitiesMember_615b3635-7f30-4dcc-986b-ec40798d3b9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_43eb673a-3359-4643-82ab-75605e3805aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:to="loc_ifrs-full_LiabilitiesMember_43eb673a-3359-4643-82ab-75605e3805aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_24507e42-258f-49cd-976e-2daca4cc3724" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_43eb673a-3359-4643-82ab-75605e3805aa" xlink:to="loc_ifrs-full_DerivativesMember_24507e42-258f-49cd-976e-2daca4cc3724" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_685d772f-8284-4770-82f3-3e50e04c46ee_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:to="loc_ifrs-full_BorrowingsByNameMember_685d772f-8284-4770-82f3-3e50e04c46ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:to="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_9b34bcec-b640-4e52-9676-2aa16125cb97" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_9b34bcec-b640-4e52-9676-2aa16125cb97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_934dbc89-1ad3-41c2-b79e-2271f7abfe65" xlink:href="adc-20220930.xsd#adc_OakTreeAndOwlRockWarrantObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:to="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_934dbc89-1ad3-41c2-b79e-2271f7abfe65" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" xlink:type="extended" id="i0f30515e664b40fea61448e8b109f906_SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8167700c-27b0-4d49-b72d-8543306af5a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_048ba8a4-101f-4098-a5bf-466df86f1372" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8167700c-27b0-4d49-b72d-8543306af5a4" xlink:to="loc_ifrs-full_Borrowings_048ba8a4-101f-4098-a5bf-466df86f1372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8167700c-27b0-4d49-b72d-8543306af5a4" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1611fb14-4ec6-4c27-835a-ad3ba455a613_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1611fb14-4ec6-4c27-835a-ad3ba455a613_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_9450ea19-817f-4bf0-9fae-1696b562b428" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:to="loc_ifrs-full_BorrowingsByNameMember_9450ea19-817f-4bf0-9fae-1696b562b428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_1d329ad5-3d88-47a0-9ce3-f616d05a9579" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9450ea19-817f-4bf0-9fae-1696b562b428" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_1d329ad5-3d88-47a0-9ce3-f616d05a9579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_fde9a86a-8011-43a7-97f2-fd7f3187ecb2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:to="loc_ifrs-full_CarryingAmountMember_fde9a86a-8011-43a7-97f2-fd7f3187ecb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:to="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_b0f65dd1-82b5-4dec-af39-bf3512e16c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_b0f65dd1-82b5-4dec-af39-bf3512e16c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredFinancingCostsMember_d898902a-4c17-4e56-ac58-bd465ebb9aaa" xlink:href="adc-20220930.xsd#adc_DeferredFinancingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:to="loc_adc_DeferredFinancingCostsMember_d898902a-4c17-4e56-ac58-bd465ebb9aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NetCarryingAmountMember_5fa63e21-2d5d-470f-a7c6-4547f838bcfc" xlink:href="adc-20220930.xsd#adc_NetCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:to="loc_adc_NetCarryingAmountMember_5fa63e21-2d5d-470f-a7c6-4547f838bcfc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_b84fe025-007e-41ae-b578-ad64e8360d89_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:to="loc_ifrs-full_LiabilitiesMember_b84fe025-007e-41ae-b578-ad64e8360d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:to="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_ae25da7d-c002-42fa-828a-1345588e71c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:to="loc_ifrs-full_DerivativesMember_ae25da7d-c002-42fa-828a-1345588e71c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_117ed8b0-c72c-4261-8c1b-ceebb710bea2" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:to="loc_adc_ResidualLoanMember_117ed8b0-c72c-4261-8c1b-ceebb710bea2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" xlink:type="extended" id="i855ac3dd0bbf4f9699c0bc8875094c71_ConvertibleloansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_4fa73d54-aa02-435d-9c39-cfd461fb0d5b" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_4fa73d54-aa02-435d-9c39-cfd461fb0d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingNumberOfComponents_fa5d127a-af0a-40c8-8c8d-00c53289c10b" xlink:href="adc-20220930.xsd#adc_BorrowingNumberOfComponents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingNumberOfComponents_fa5d127a-af0a-40c8-8c8d-00c53289c10b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4aa547e6-29e4-45a8-b7b6-8f7e9f0870f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_Borrowings_4aa547e6-29e4-45a8-b7b6-8f7e9f0870f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_fb4b6402-1245-4dfc-8829-db3c85e8bf57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_BorrowingsInterestRate_fb4b6402-1245-4dfc-8829-db3c85e8bf57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFacilitiesExitFeePercentage_6e020822-7f91-43bb-b60c-9ce4a8458302" xlink:href="adc-20220930.xsd#adc_BorrowingsFacilitiesExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingsFacilitiesExitFeePercentage_6e020822-7f91-43bb-b60c-9ce4a8458302" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_eeb06750-f17b-48a2-a2ba-41023ea5c0ab" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_eeb06750-f17b-48a2-a2ba-41023ea5c0ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_8bb0b695-0165-47f2-89e4-56102d25665c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_8bb0b695-0165-47f2-89e4-56102d25665c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_bbb7b326-000d-49e0-8fac-1cae3022eb3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_bbb7b326-000d-49e0-8fac-1cae3022eb3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_3fd411df-1427-4a32-bc2c-4bf6b011298d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_3fd411df-1427-4a32-bc2c-4bf6b011298d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsImpliedEffectiveInterestRate_6a810129-4881-464e-ad2d-3793a8b176d1" xlink:href="adc-20220930.xsd#adc_BorrowingsImpliedEffectiveInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingsImpliedEffectiveInterestRate_6a810129-4881-464e-ad2d-3793a8b176d1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_7c9ee540-89f1-43bc-8306-15f54d27f315" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LoansReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_LoansReceived_7c9ee540-89f1-43bc-8306-15f54d27f315" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_028d7b27-84c4-49b6-b174-906fad1ace70" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_028d7b27-84c4-49b6-b174-906fad1ace70" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_14cea341-1ac9-4e9e-9ec1-9d2f2d4922c2" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_14cea341-1ac9-4e9e-9ec1-9d2f2d4922c2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f8e2bb29-c337-439c-afcb-7f32b7a2de77" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f8e2bb29-c337-439c-afcb-7f32b7a2de77" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_a209d80e-f86f-4f16-95c2-27206055e9f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_a209d80e-f86f-4f16-95c2-27206055e9f8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_8dc6da60-9fdc-478d-b8aa-68b003f447fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_8dc6da60-9fdc-478d-b8aa-68b003f447fc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_8dc89e60-7a84-4c0a-bb1a-f247c0943e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_8dc89e60-7a84-4c0a-bb1a-f247c0943e7b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditDerivativeFairValue_2e49f819-b02b-4d8b-8cb7-a46e7d44406f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditDerivativeFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_CreditDerivativeFairValue_2e49f819-b02b-4d8b-8cb7-a46e7d44406f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_fe2e4cca-5c43-4299-bb0c-f4c52ad9850d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_fe2e4cca-5c43-4299-bb0c-f4c52ad9850d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeOfConvertibleNotesForWarrants_5304da4e-1575-4c93-ab78-0e797a946268" xlink:href="adc-20220930.xsd#adc_ExchangeOfConvertibleNotesForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_ExchangeOfConvertibleNotesForWarrants_5304da4e-1575-4c93-ab78-0e797a946268" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_c8dab84e-0f59-4170-8905-4e7053daf967" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_ConvertibleNotesSharesConverted_c8dab84e-0f59-4170-8905-4e7053daf967" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesValueConverted_e929d133-ed71-4498-89fc-95d3508fb32c" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesValueConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_ConvertibleNotesValueConverted_e929d133-ed71-4498-89fc-95d3508fb32c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:to="loc_ifrs-full_BorrowingsByNameMember_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:to="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_761ec969-ed96-4652-84d0-fedd5c0a9c1b" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_761ec969-ed96-4652-84d0-fedd5c0a9c1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e5a10776-5c5c-496f-918a-f701c806522c" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e5a10776-5c5c-496f-918a-f701c806522c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember_b6a02062-6fab-4da6-864e-8f38ac2a3258" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:to="loc_adc_LoanAgreementMember_b6a02062-6fab-4da6-864e-8f38ac2a3258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoansMember_e54bf726-2fb9-41d4-a564-eed093dd31c3" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:to="loc_adc_SeniorSecuredTermLoansMember_e54bf726-2fb9-41d4-a564-eed093dd31c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_46d4c987-876b-4912-8ea9-9fc8bcbfd710_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:to="loc_ifrs-full_RangesMember_46d4c987-876b-4912-8ea9-9fc8bcbfd710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_94b5b1d6-b128-4abb-8b02-5a9cc0319fe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:to="loc_ifrs-full_RangesMember_94b5b1d6-b128-4abb-8b02-5a9cc0319fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_4e2283eb-4df4-406f-aeba-2e920aee85c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_94b5b1d6-b128-4abb-8b02-5a9cc0319fe6" xlink:to="loc_ifrs-full_TopOfRangeMember_4e2283eb-4df4-406f-aeba-2e920aee85c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain_f97db78f-6f48-40e9-b12c-326c0092cb74_default" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:to="loc_adc_BorrowingConversionPeriodDomain_f97db78f-6f48-40e9-b12c-326c0092cb74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:to="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodOneMember_56468b7b-28bf-4352-849f-0ac70f9a39a2" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:to="loc_adc_BorrowingsConversionPeriodOneMember_56468b7b-28bf-4352-849f-0ac70f9a39a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConversionPeriodTwoMember_6b7e4b8d-2190-4852-aa94-e3079858175b" xlink:href="adc-20220930.xsd#adc_ConversionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:to="loc_adc_ConversionPeriodTwoMember_6b7e4b8d-2190-4852-aa94-e3079858175b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_d3ed77a8-c3ab-4bcb-a578-26598961da92_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:to="loc_ifrs-full_LiabilitiesMember_d3ed77a8-c3ab-4bcb-a578-26598961da92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:to="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_58d843c1-aad4-4e80-883b-97cd4cd4cf63" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:to="loc_adc_ResidualLoanMember_58d843c1-aad4-4e80-883b-97cd4cd4cf63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_51fb7feb-612b-447b-bc2a-181d217fbc6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:to="loc_ifrs-full_DerivativesMember_51fb7feb-612b-447b-bc2a-181d217fbc6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_11ba8b78-e44a-42a5-898b-fd0bc8677571_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:to="loc_ifrs-full_InterestRateTypesMember_11ba8b78-e44a-42a5-898b-fd0bc8677571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:to="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SecuredOvernightFinancingRateSOFRMember_66968624-a51b-4cdc-99de-86cd7ed4afc3" xlink:href="adc-20220930.xsd#adc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:to="loc_adc_SecuredOvernightFinancingRateSOFRMember_66968624-a51b-4cdc-99de-86cd7ed4afc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BaseRateMember_9fc32253-a6d8-4a8f-9b5d-f88a9de1da04" xlink:href="adc-20220930.xsd#adc_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:to="loc_adc_BaseRateMember_9fc32253-a6d8-4a8f-9b5d-f88a9de1da04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodDomain_0749df62-7d8f-485f-a90b-6461f82674f5_default" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:to="loc_adc_BorrowingPeriodDomain_0749df62-7d8f-485f-a90b-6461f82674f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:to="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FirstFiveYearsMember_cce15e30-d29a-4c0b-802a-24a892d4b27a" xlink:href="adc-20220930.xsd#adc_FirstFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:to="loc_adc_FirstFiveYearsMember_cce15e30-d29a-4c0b-802a-24a892d4b27a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AfterFirstFiveYearsMember_a5836cf6-520e-4a6b-87df-bad58991722f" xlink:href="adc-20220930.xsd#adc_AfterFirstFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:to="loc_adc_AfterFirstFiveYearsMember_a5836cf6-520e-4a6b-87df-bad58991722f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:to="loc_srt_RangeMember_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:to="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_067895ea-052a-48b9-a38d-e0eded06f9af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:to="loc_srt_MinimumMember_067895ea-052a-48b9-a38d-e0eded06f9af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7aac6cbe-bf81-4818-b57b-1995c0789e10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:to="loc_srt_MaximumMember_7aac6cbe-bf81-4818-b57b-1995c0789e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_aaa397a4-4db6-4704-bcd3-61756e4e25fa_default" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:to="loc_adc_WarrantsTrancheDomain_aaa397a4-4db6-4704-bcd3-61756e4e25fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:to="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_eba939bb-809a-488d-baef-17e30ae13ef3" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:to="loc_adc_WarrantsTrancheOneMember_eba939bb-809a-488d-baef-17e30ae13ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember_9a7721d0-9096-4645-aae9-5a6c67102e26" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:to="loc_adc_WarrantsTrancheTwoMember_9a7721d0-9096-4645-aae9-5a6c67102e26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansValuationofDerivativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" xlink:type="extended" id="i664f0812c09a4644b25cc62815c692a9_ConvertibleloansValuationofDerivativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_7ac84d87-90ee-4bc8-960a-4d391c34dbdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_7ac84d87-90ee-4bc8-960a-4d391c34dbdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_ff9ecb55-5e8c-4c9e-a08a-fef51444b170" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_ff9ecb55-5e8c-4c9e-a08a-fef51444b170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OfferingPricePerShare_bb33f352-1238-40cc-9f57-d48d043ccfff" xlink:href="adc-20220930.xsd#adc_OfferingPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_adc_OfferingPricePerShare_bb33f352-1238-40cc-9f57-d48d043ccfff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_c4911a3c-d973-4bd5-bd13-38d7701b61a0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:to="loc_ifrs-full_UnobservableInputsMember_c4911a3c-d973-4bd5-bd13-38d7701b61a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:to="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WrittenPutOptionsMember_62563619-7954-4ddc-b295-cfd073255ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WrittenPutOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_ifrs-full_WrittenPutOptionsMember_62563619-7954-4ddc-b295-cfd073255ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ForcedConversionPriceMember_22fe1a58-d61d-434f-bea1-203c7ac60007" xlink:href="adc-20220930.xsd#adc_ForcedConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ForcedConversionPriceMember_22fe1a58-d61d-434f-bea1-203c7ac60007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember_3d6728e7-4bc7-4ed1-a3a4-4af21834fc1c" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_SharePriceMember_3d6728e7-4bc7-4ed1-a3a4-4af21834fc1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember_be1ae4a1-4981-4432-8421-aa87c76193af" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_RiskFreeInterestRateMember_be1ae4a1-4981-4432-8421-aa87c76193af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember_f5972e97-8480-42cc-9dd2-2fa65dc121aa" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ExpectedVolatilityMember_f5972e97-8480-42cc-9dd2-2fa65dc121aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember_08608e5a-ce45-4328-9f90-7d1512f4274d" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ExpectedTermMember_08608e5a-ce45-4328-9f90-7d1512f4274d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DividendYieldMember_f2f59232-3692-4968-8dcc-eb4dfe5d9501" xlink:href="adc-20220930.xsd#adc_DividendYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_DividendYieldMember_f2f59232-3692-4968-8dcc-eb4dfe5d9501" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RecoveryRateMember_87129b16-8a54-450f-8cbe-5effa61accad" xlink:href="adc-20220930.xsd#adc_RecoveryRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_RecoveryRateMember_87129b16-8a54-450f-8cbe-5effa61accad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ImpliedBondYieldMember_178cc40a-71ee-4533-8f2a-bfb076fea1ce" xlink:href="adc-20220930.xsd#adc_ImpliedBondYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ImpliedBondYieldMember_178cc40a-71ee-4533-8f2a-bfb076fea1ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_2deffb87-f6bb-45e1-8ce4-a3a234fa8970_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:to="loc_ifrs-full_LiabilitiesMember_2deffb87-f6bb-45e1-8ce4-a3a234fa8970_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_22fa7ab9-9d79-460e-90f6-568acbdbdd56" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:to="loc_ifrs-full_LiabilitiesMember_22fa7ab9-9d79-460e-90f6-568acbdbdd56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_072c25e5-64bd-4977-ad5b-0ca8c8e13d62" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_22fa7ab9-9d79-460e-90f6-568acbdbdd56" xlink:to="loc_ifrs-full_DerivativesMember_072c25e5-64bd-4977-ad5b-0ca8c8e13d62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:to="loc_ifrs-full_BorrowingsByNameMember_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_b2197c70-8078-4971-b42d-bea05398ae4c" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_b2197c70-8078-4971-b42d-bea05398ae4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_776cf1f4-7bc7-4d24-811b-8977fb426a66" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_776cf1f4-7bc7-4d24-811b-8977fb426a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_c8f6059e-0540-4629-afa6-7d63e3816c4c_default" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:to="loc_adc_SaleOfStockDomain_c8f6059e-0540-4629-afa6-7d63e3816c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_156e2c75-0fd4-4696-a0e0-07220a712433" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:to="loc_adc_SaleOfStockDomain_156e2c75-0fd4-4696-a0e0-07220a712433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InitialPublicOfferingMember_f319d9ff-f0fb-45f1-a06c-975e70475faa" xlink:href="adc-20220930.xsd#adc_InitialPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_SaleOfStockDomain_156e2c75-0fd4-4696-a0e0-07220a712433" xlink:to="loc_adc_InitialPublicOfferingMember_f319d9ff-f0fb-45f1-a06c-975e70475faa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails" xlink:type="extended" id="i67d02813ea694aa4afea159c97d0c60f_ConvertibleloansInterestExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8863bf85-c639-4ba2-b4c4-dfe3dcbbe31c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_938323e2-d783-4c62-8413-212dbc1e818d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8863bf85-c639-4ba2-b4c4-dfe3dcbbe31c" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_938323e2-d783-4c62-8413-212dbc1e818d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8863bf85-c639-4ba2-b4c4-dfe3dcbbe31c" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_4a10338a-1588-4811-9c00-cbcbfc887c1e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:to="loc_ifrs-full_BorrowingsByNameMember_4a10338a-1588-4811-9c00-cbcbfc887c1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:to="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_82515c01-bfa6-4b8c-848a-57a55f7e5060" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_82515c01-bfa6-4b8c-848a-57a55f7e5060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e625a5e1-46b8-4862-a7bc-679bf6af3893" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e625a5e1-46b8-4862-a7bc-679bf6af3893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_4d417402-170e-4be3-9b08-f3ca6f892507_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:to="loc_ifrs-full_LiabilitiesMember_4d417402-170e-4be3-9b08-f3ca6f892507_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_10ae347f-bbaf-4194-a8f2-a22769cdad1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:to="loc_ifrs-full_LiabilitiesMember_10ae347f-bbaf-4194-a8f2-a22769cdad1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_b05ca98d-3b6b-4e28-b2c1-1fc41ea6b8f9" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_10ae347f-bbaf-4194-a8f2-a22769cdad1f" xlink:to="loc_adc_ResidualLoanMember_b05ca98d-3b6b-4e28-b2c1-1fc41ea6b8f9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansChangeinFairValueDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails" xlink:type="extended" id="i531bd49c741b4e90b8b7f68fc5dfa8d2_ConvertibleloansChangeinFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_de23eb3c-7226-440f-ab4c-3aad3547bb0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_717e7541-f6a8-4ce0-8076-f0fe88fd093a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_de23eb3c-7226-440f-ab4c-3aad3547bb0b" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_717e7541-f6a8-4ce0-8076-f0fe88fd093a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_de23eb3c-7226-440f-ab4c-3aad3547bb0b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_d96b4ceb-f531-4445-891d-0f08194d3220_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:to="loc_ifrs-full_BorrowingsByNameMember_d96b4ceb-f531-4445-891d-0f08194d3220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:to="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_eb8ca75b-852a-4eaa-ae34-9b1ed16d3acc" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_eb8ca75b-852a-4eaa-ae34-9b1ed16d3acc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_048b3666-6a6a-4cc2-ae7e-e41960779d62" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_048b3666-6a6a-4cc2-ae7e-e41960779d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_efc7b00d-8f7c-4d57-aa12-4ad440a10ab1" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_efc7b00d-8f7c-4d57-aa12-4ad440a10ab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_8565e421-86fe-4067-bd5a-004660372264" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_8565e421-86fe-4067-bd5a-004660372264" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#DeerfieldWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails" xlink:type="extended" id="i23ffc22c0dc4464494c7780cddcffc54_DeerfieldWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_945f8188-0077-45e1-86ea-d278ba71c15a" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_ConvertibleNotesSharesConverted_945f8188-0077-45e1-86ea-d278ba71c15a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice_c072e155-56ef-429d-83c8-62f38e4d56a5" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_WarrantsSharesConvertedExercisePrice_c072e155-56ef-429d-83c8-62f38e4d56a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnChangeInFairValueWarrants_3382539d-3f6f-42b7-abd8-ba8c306e72e4" xlink:href="adc-20220930.xsd#adc_GainsLossOnChangeInFairValueWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_GainsLossOnChangeInFairValueWarrants_3382539d-3f6f-42b7-abd8-ba8c306e72e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationFairValue_fc7e8730-fe08-4e4d-9f54-6d2a94163687" xlink:href="adc-20220930.xsd#adc_WarrantObligationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_WarrantObligationFairValue_fc7e8730-fe08-4e4d-9f54-6d2a94163687" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:to="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a_default" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:to="loc_adc_WarrantsTrancheDomain_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:to="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_ba0ebc31-1095-4d67-a300-26c6b6108c50" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:to="loc_adc_WarrantsTrancheOneMember_ba0ebc31-1095-4d67-a300-26c6b6108c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember_d8ae02b0-9159-4b94-9861-d0a88e2db233" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:to="loc_adc_WarrantsTrancheOnePriceOneMember_d8ae02b0-9159-4b94-9861-d0a88e2db233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember_2205bf36-5127-4b7f-a0af-c828d2bb39b9" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:to="loc_adc_WarrantsTrancheOnePriceTwoMember_2205bf36-5127-4b7f-a0af-c828d2bb39b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2da285ad-b985-44ef-94a9-9f6c9b610b9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2da285ad-b985-44ef-94a9-9f6c9b610b9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_89097b8d-982d-47f8-92a1-b83410bb640d" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2da285ad-b985-44ef-94a9-9f6c9b610b9a" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_89097b8d-982d-47f8-92a1-b83410bb640d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#DeerfieldWarrantsScheduleofValuationInputsDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" xlink:type="extended" id="i531357c1826d4922a8acbdf82b03492e_DeerfieldWarrantsScheduleofValuationInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0456a668-a665-4e08-8040-307375b66543" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_43df7d0c-adcf-4301-80e9-a1ce51556372" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0456a668-a665-4e08-8040-307375b66543" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_43df7d0c-adcf-4301-80e9-a1ce51556372" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0456a668-a665-4e08-8040-307375b66543" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_25e61a96-a7c1-47c9-a1a4-65b9a5d65778_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:to="loc_ifrs-full_BorrowingsByNameMember_25e61a96-a7c1-47c9-a1a4-65b9a5d65778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2eca988e-53b4-4595-b69e-be402246a11f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2eca988e-53b4-4595-b69e-be402246a11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeerfieldWarrantsMember_c0404671-75dc-4453-b78e-e2bdf54ca2f1" xlink:href="adc-20220930.xsd#adc_DeerfieldWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2eca988e-53b4-4595-b69e-be402246a11f" xlink:to="loc_adc_DeerfieldWarrantsMember_c0404671-75dc-4453-b78e-e2bdf54ca2f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_5a7210cf-4581-4519-90f6-147426489fa7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:to="loc_ifrs-full_LiabilitiesMember_5a7210cf-4581-4519-90f6-147426489fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_07596e8a-c887-4094-bda9-e02d25410c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:to="loc_ifrs-full_LiabilitiesMember_07596e8a-c887-4094-bda9-e02d25410c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_297377e0-77f6-457c-94a0-9a6300986366" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_07596e8a-c887-4094-bda9-e02d25410c62" xlink:to="loc_ifrs-full_DerivativesMember_297377e0-77f6-457c-94a0-9a6300986366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_059c819f-3520-4165-89e9-15a04d129864_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:to="loc_ifrs-full_UnobservableInputsMember_059c819f-3520-4165-89e9-15a04d129864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:to="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExercisePriceMember_10ef316f-d606-4295-aaf4-d55a9cc79eff" xlink:href="adc-20220930.xsd#adc_ExercisePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ExercisePriceMember_10ef316f-d606-4295-aaf4-d55a9cc79eff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ForcedConversionPriceMember_e426c10d-aedd-4877-855b-c662230995cc" xlink:href="adc-20220930.xsd#adc_ForcedConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ForcedConversionPriceMember_e426c10d-aedd-4877-855b-c662230995cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember_153d04ea-4a7f-4503-bef0-1e711d5203cb" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_SharePriceMember_153d04ea-4a7f-4503-bef0-1e711d5203cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember_5d97ee2a-68a5-4cd1-90f5-c77dd33212e7" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_RiskFreeInterestRateMember_5d97ee2a-68a5-4cd1-90f5-c77dd33212e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember_94a4f536-1cae-4109-bdfb-e31523a1dc24" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ExpectedVolatilityMember_94a4f536-1cae-4109-bdfb-e31523a1dc24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember_2222996c-190b-46e9-97e0-0a410fc59a36" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ExpectedTermMember_2222996c-190b-46e9-97e0-0a410fc59a36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BlackScholesValueMember_e93cfa43-81ac-4fc1-9988-7a9763f0ea7d" xlink:href="adc-20220930.xsd#adc_BlackScholesValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_BlackScholesValueMember_e93cfa43-81ac-4fc1-9988-7a9763f0ea7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:to="loc_srt_RangeMember_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:to="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_358b5811-ac5e-4748-a58f-2c901a2f1115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:to="loc_srt_MinimumMember_358b5811-ac5e-4748-a58f-2c901a2f1115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca5d92c8-c47c-49c8-83cf-711e9cc5cd43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:to="loc_srt_MaximumMember_ca5d92c8-c47c-49c8-83cf-711e9cc5cd43" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended" id="idaaf3769bc484271aa040207780152a9_SharebasedcompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a73267b8-86d6-46d4-9c50-87fb0844ae36" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a73267b8-86d6-46d4-9c50-87fb0844ae36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_01b30664-1fa8-4b9a-bed8-fde6b8dbc886" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_01b30664-1fa8-4b9a-bed8-fde6b8dbc886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_072f0fdc-fe80-495a-845f-cea54394543a" xlink:href="adc-20220930.xsd#adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_072f0fdc-fe80-495a-845f-cea54394543a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_82f75ad5-d9ae-413b-a4af-65e01614d590" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_82f75ad5-d9ae-413b-a4af-65e01614d590" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_136b755b-ceec-4b08-bc15-9b20c73513a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_136b755b-ceec-4b08-bc15-9b20c73513a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_16543d4c-c034-4ed3-ade3-b6ed95888514" xlink:href="adc-20220930.xsd#adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_16543d4c-c034-4ed3-ade3-b6ed95888514" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_611018b3-321b-45bd-9878-fc3ee174c747" xlink:href="adc-20220930.xsd#adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_611018b3-321b-45bd-9878-fc3ee174c747" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6f6cf00-a866-49d2-8f8f-eb6c162a73a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6f6cf00-a866-49d2-8f8f-eb6c162a73a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_31069e9b-8a45-4e07-bc41-d024aa297a27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_31069e9b-8a45-4e07-bc41-d024aa297a27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_4d00125b-ee8a-4407-8598-592a8e2b3a9e" xlink:href="adc-20220930.xsd#adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_4d00125b-ee8a-4407-8598-592a8e2b3a9e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_77238fdb-9cb5-475d-bfd4-59ca3218e030" xlink:href="adc-20220930.xsd#adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_77238fdb-9cb5-475d-bfd4-59ca3218e030" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_0089c745-c32e-4390-8f9d-f80ea7610d43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_0089c745-c32e-4390-8f9d-f80ea7610d43" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_2fb4902d-0762-4462-aacb-f4111e981203" xlink:href="adc-20220930.xsd#adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_2fb4902d-0762-4462-aacb-f4111e981203" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_52ded2cd-b196-44ae-9f3c-2a1c38408bec" xlink:href="adc-20220930.xsd#adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_52ded2cd-b196-44ae-9f3c-2a1c38408bec" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_49f52a0c-d6cc-4ead-9596-375e12cc9e84" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementSharesTransferredToParticipants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_49f52a0c-d6cc-4ead-9596-375e12cc9e84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_1a1b83f8-4a91-427e-bfa2-4c6fab5e047d" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_1a1b83f8-4a91-427e-bfa2-4c6fab5e047d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_7cf2b54e-3bfa-41cc-a4eb-27a340667896" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_7cf2b54e-3bfa-41cc-a4eb-27a340667896" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccruedShareBasedCompensation_15f5c83a-064b-4b2d-8d14-731ab0e1cdec" xlink:href="adc-20220930.xsd#adc_AccruedShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_AccruedShareBasedCompensation_15f5c83a-064b-4b2d-8d14-731ab0e1cdec" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:href="adc-20220930.xsd#adc_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember_6e56d94e-ab04-44ce-8a80-574ed132d08c_default" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:to="loc_adc_PlanNameMember_6e56d94e-ab04-44ce-8a80-574ed132d08c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:to="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePurchasePlan2016Member_1c439a28-21fc-4859-bf5d-6a54330fbd76" xlink:href="adc-20220930.xsd#adc_SharePurchasePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_SharePurchasePlan2016Member_1c439a28-21fc-4859-bf5d-6a54330fbd76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncentivePlan2014Member_7d88e839-6712-4f69-ae1d-c40de31ea868" xlink:href="adc-20220930.xsd#adc_IncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_IncentivePlan2014Member_7d88e839-6712-4f69-ae1d-c40de31ea868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanMember_6bfa9ac2-38f5-4a48-b38f-b7baaadddf7c" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_A2019EquityIncentivePlanMember_6bfa9ac2-38f5-4a48-b38f-b7baaadddf7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AnnualEquityAwardMember_d2a70130-00d8-4419-8751-ebc757c6cbe5" xlink:href="adc-20220930.xsd#adc_AnnualEquityAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_AnnualEquityAwardMember_d2a70130-00d8-4419-8751-ebc757c6cbe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SpecialRetentionAwardMember_e6f9e1f7-9091-4c2d-8f67-58ebfba75868" xlink:href="adc-20220930.xsd#adc_SpecialRetentionAwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_SpecialRetentionAwardMember_e6f9e1f7-9091-4c2d-8f67-58ebfba75868" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_ff4191d5-9c82-412c-ba74-28124db3855e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_ff4191d5-9c82-412c-ba74-28124db3855e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeStockOptionMember_2e86c0a8-3b80-4cd5-a5c1-fa51bda2d960" xlink:href="adc-20220930.xsd#adc_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:to="loc_adc_EmployeeStockOptionMember_2e86c0a8-3b80-4cd5-a5c1-fa51bda2d960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedShareUnitsRSUMember_c5e8342d-e3ad-4c14-a76a-4687bd271353" xlink:href="adc-20220930.xsd#adc_RestrictedShareUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:to="loc_adc_RestrictedShareUnitsRSUMember_c5e8342d-e3ad-4c14-a76a-4687bd271353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedStockUnitsMember_8ad43229-1144-44dc-92eb-7f9a4b23fae2" xlink:href="adc-20220930.xsd#adc_RestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:to="loc_adc_RestrictedStockUnitsMember_8ad43229-1144-44dc-92eb-7f9a4b23fae2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:href="adc-20220930.xsd#adc_VestingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodMember_1f6101b9-1102-413d-b563-63a1d6f5cc5a_default" xlink:href="adc-20220930.xsd#adc_VestingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:to="loc_adc_VestingPeriodMember_1f6101b9-1102-413d-b563-63a1d6f5cc5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:href="adc-20220930.xsd#adc_VestingPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:to="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheOneMember_e5fc4a00-e801-49c4-bc97-a5604197f748" xlink:href="adc-20220930.xsd#adc_TrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheOneMember_e5fc4a00-e801-49c4-bc97-a5604197f748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheTwoMember_da0191d3-6e26-490a-9231-8fb498e09459" xlink:href="adc-20220930.xsd#adc_TrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheTwoMember_da0191d3-6e26-490a-9231-8fb498e09459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheThreeMember_0648f6e6-c39b-4091-bd42-da7efccf8c54" xlink:href="adc-20220930.xsd#adc_TrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheThreeMember_0648f6e6-c39b-4091-bd42-da7efccf8c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheFourMember_20b91194-d498-4ce3-aa27-a886dce3dcf5" xlink:href="adc-20220930.xsd#adc_TrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheFourMember_20b91194-d498-4ce3-aa27-a886dce3dcf5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" xlink:type="extended" id="i86d0b712aa7c43b492028165d230481c_SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_842799ce-ac8f-437c-beef-843112c2174b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_842799ce-ac8f-437c-beef-843112c2174b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b741b9c8-a158-4475-ad55-d021e1e4b7df" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b741b9c8-a158-4475-ad55-d021e1e4b7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_702ac60c-616d-4264-9491-b8d7936505b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_702ac60c-616d-4264-9491-b8d7936505b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_63aae7f8-b631-4bab-b5e4-2f43bba8a65b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_63aae7f8-b631-4bab-b5e4-2f43bba8a65b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendShareOptionsGranted_212ae71a-812e-4811-adf4-7b19f6c9a3c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_ExpectedDividendShareOptionsGranted_212ae71a-812e-4811-adf4-7b19f6c9a3c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1d4fc3df-05e7-48ea-bd7b-1e9fb79a923c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1d4fc3df-05e7-48ea-bd7b-1e9fb79a923c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:to="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:to="loc_ifrs-full_RangesMember_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:to="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f48b1c6-afbf-4570-9abf-c09d89da2860" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:to="loc_srt_MinimumMember_2f48b1c6-afbf-4570-9abf-c09d89da2860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_748438f3-8f1f-4dd8-8ab6-959f6f094ad7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:to="loc_srt_MaximumMember_748438f3-8f1f-4dd8-8ab6-959f6f094ad7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" xlink:type="extended" id="i79aa793955be4de1b2ca7bf8badcbad8_SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b3035aa0-f30e-495c-b89b-2f4f8318d053" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b3035aa0-f30e-495c-b89b-2f4f8318d053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_dcc95ea0-d8c6-40f5-9fe8-8dc3889e3881" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_dcc95ea0-d8c6-40f5-9fe8-8dc3889e3881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_aefd2911-c0c4-4d9c-8d0a-f84eba86bbde" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_aefd2911-c0c4-4d9c-8d0a-f84eba86bbde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e77b3813-481c-4de8-8aec-13641815b20f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e77b3813-481c-4de8-8aec-13641815b20f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b66d70b8-3bd5-47e7-9117-3d700be266e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_d91f95c5-b55d-407b-9942-6307a77fb9d0" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_d91f95c5-b55d-407b-9942-6307a77fb9d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_c91b25ec-437d-41c0-b096-123b172cf19d" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_c91b25ec-437d-41c0-b096-123b172cf19d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_34789788-0321-46a2-8792-a25a11d349e4" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_34789788-0321-46a2-8792-a25a11d349e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_a10776dd-d19e-4dd7-ac9c-d5b0132bcfdf" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_a10776dd-d19e-4dd7-ac9c-d5b0132bcfdf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_8144c1d2-a8ec-40fb-bb71-1499467beebf" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c8df2e20-f93f-4ac8-83b9-ad305661991c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c8df2e20-f93f-4ac8-83b9-ad305661991c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c8df2e20-f93f-4ac8-83b9-ad305661991c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_df09014d-76cc-4555-b368-3dab7bb0fbd7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_df09014d-76cc-4555-b368-3dab7bb0fbd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f9a266e5-345e-41b7-8e69-82f610e67e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f9a266e5-345e-41b7-8e69-82f610e67e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedShareUnitsRSUMember_34c374e8-1c7c-4499-8c5f-8296d1d539b0" xlink:href="adc-20220930.xsd#adc_RestrictedShareUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_f9a266e5-345e-41b7-8e69-82f610e67e7b" xlink:to="loc_adc_RestrictedShareUnitsRSUMember_34c374e8-1c7c-4499-8c5f-8296d1d539b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" xlink:type="extended" id="ie9e0cd403b774a328482a770c615f1b2_SharebasedcompensationScheduleofSharebasedCompensationReserveDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseInReserveOfShareBasedPayments_e4ea7d82-99f1-4c5b-9ab9-f5e081a41ba8" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseInReserveOfShareBasedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_adc_IncreaseDecreaseInReserveOfShareBasedPayments_e4ea7d82-99f1-4c5b-9ab9-f5e081a41ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_d39a00fd-2906-41da-b93c-4e47f371a025" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_d39a00fd-2906-41da-b93c-4e47f371a025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_628eab3a-b906-49fa-8cd2-30c18b29a640" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_628eab3a-b906-49fa-8cd2-30c18b29a640" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:href="adc-20220930.xsd#adc_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:to="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember_0b62ea35-0825-44a8-aff7-7a75271e7c25_default" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:to="loc_adc_PlanNameMember_0b62ea35-0825-44a8-aff7-7a75271e7c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:to="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncentivePlan2014Member_07833807-b0a6-476c-bfa3-676b75994b92" xlink:href="adc-20220930.xsd#adc_IncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:to="loc_adc_IncentivePlan2014Member_07833807-b0a6-476c-bfa3-676b75994b92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePurchasePlan2016Member_93015d91-2164-48e2-a56c-97f9e2c657a1" xlink:href="adc-20220930.xsd#adc_SharePurchasePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:to="loc_adc_SharePurchasePlan2016Member_93015d91-2164-48e2-a56c-97f9e2c657a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanMember_e32c9995-011f-434a-977a-5cdc020517f7" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:to="loc_adc_A2019EquityIncentivePlanMember_e32c9995-011f-434a-977a-5cdc020517f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameDomain_0942c36a-c996-4553-81eb-f2a94c37dd96" xlink:href="adc-20220930.xsd#adc_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:to="loc_adc_PlanNameDomain_0942c36a-c996-4553-81eb-f2a94c37dd96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_cdf19c80-e69a-4e76-a9f3-f7e098033f55_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_cdf19c80-e69a-4e76-a9f3-f7e098033f55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeStockOptionMember_ae935cc4-736c-4a17-8fe2-1a9d2c5a9b9b" xlink:href="adc-20220930.xsd#adc_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:to="loc_adc_EmployeeStockOptionMember_ae935cc4-736c-4a17-8fe2-1a9d2c5a9b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedStockUnitsMember_81de1a93-dce9-45f9-996b-3395f513ac3e" xlink:href="adc-20220930.xsd#adc_RestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:to="loc_adc_RestrictedStockUnitsMember_81de1a93-dce9-45f9-996b-3395f513ac3e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#RelatedpartiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" xlink:type="extended" id="i07fc0713111745e68555a1b94b885212_RelatedpartiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfSubsidiariesProvideServicesTo_851bac48-eca6-4f19-8a7c-5727af939866" xlink:href="adc-20220930.xsd#adc_NumberOfSubsidiariesProvideServicesTo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_NumberOfSubsidiariesProvideServicesTo_851bac48-eca6-4f19-8a7c-5727af939866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ServicesProvidedRelatedPartyTransactions_c7fd7d48-c2b9-4b65-b6ab-2ec701665552" xlink:href="adc-20220930.xsd#adc_ServicesProvidedRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_ServicesProvidedRelatedPartyTransactions_c7fd7d48-c2b9-4b65-b6ab-2ec701665552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AmountsDueFromRelatedParties_13686bef-917e-4c5d-979a-779e55d5fc6e" xlink:href="adc-20220930.xsd#adc_AmountsDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_AmountsDueFromRelatedParties_13686bef-917e-4c5d-979a-779e55d5fc6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SuppliesProvidedRelatedPartyTransactions_fee68448-c1e3-41ac-92b8-10baecb2fdd1" xlink:href="adc-20220930.xsd#adc_SuppliesProvidedRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_SuppliesProvidedRelatedPartyTransactions_fee68448-c1e3-41ac-92b8-10baecb2fdd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_5c5d5af6-6414-4d13-9295-a58ac57b8c57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_5c5d5af6-6414-4d13-9295-a58ac57b8c57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_83d4fd7f-b6ed-466d-ba94-411dddc0041e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_83d4fd7f-b6ed-466d-ba94-411dddc0041e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_02780cc2-e02b-4576-ada5-7a1612ba3fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_02780cc2-e02b-4576-ada5-7a1612ba3fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_02780cc2-e02b-4576-ada5-7a1612ba3fac" xlink:to="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AuvenTherapeuticsHoldingsLPMember_2d579fc5-3e4b-46b6-8d32-2e7e15916b6d" xlink:href="adc-20220930.xsd#adc_AuvenTherapeuticsHoldingsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:to="loc_adc_AuvenTherapeuticsHoldingsLPMember_2d579fc5-3e4b-46b6-8d32-2e7e15916b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_ee719930-2786-42f6-89d9-dd9d70c442b6" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_ee719930-2786-42f6-89d9-dd9d70c442b6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" id="ib5d354fe71d948f0bafef4c2074107a9_LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_6d077d2c-0f5d-43b9-bbd2-0329154d053b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_32ac4f35-e891-40b5-8023-e6aea35f7588" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_6d077d2c-0f5d-43b9-bbd2-0329154d053b" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_32ac4f35-e891-40b5-8023-e6aea35f7588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_6d077d2c-0f5d-43b9-bbd2-0329154d053b" xlink:to="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_a7b7d750-b1aa-4286-8159-8cbe341dc17b_default" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_a7b7d750-b1aa-4286-8159-8cbe341dc17b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_d95a5ecd-b585-4765-aeb0-b5fb50c163b6" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_d95a5ecd-b585-4765-aeb0-b5fb50c163b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_d95a5ecd-b585-4765-aeb0-b5fb50c163b6" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanShareOptionsMember_a0a7f308-d3e5-45c9-836a-1c5899924202" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_A2019EquityIncentivePlanShareOptionsMember_a0a7f308-d3e5-45c9-836a-1c5899924202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanRSUsMember_09a5e9fd-b129-4073-80f5-4cc32ab5efa0" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_A2019EquityIncentivePlanRSUsMember_09a5e9fd-b129-4073-80f5-4cc32ab5efa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2022ESPPMember_499ab9bb-417b-4a33-af12-f756fab6d603" xlink:href="adc-20220930.xsd#adc_A2022ESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_A2022ESPPMember_499ab9bb-417b-4a33-af12-f756fab6d603" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansContingentlyIssuableSharesMember_e226d9d0-78ad-48a0-be51-ceaee81b4a90" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansContingentlyIssuableSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_ConvertibleLoansContingentlyIssuableSharesMember_e226d9d0-78ad-48a0-be51-ceaee81b4a90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OutstandingWarrantsMember_3ffebb64-f926-4b61-affd-b0b3164b84be" xlink:href="adc-20220930.xsd#adc_OutstandingWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_OutstandingWarrantsMember_3ffebb64-f926-4b61-affd-b0b3164b84be" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/EventsafterthereportingdateDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#EventsafterthereportingdateDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/EventsafterthereportingdateDetails" xlink:type="extended" id="if9ba296ef6934955a98a8b373c2c3cc3_EventsafterthereportingdateDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromLicenseAgreement_84966fb7-4166-4585-938a-7d098044ec30" xlink:href="adc-20220930.xsd#adc_ProceedsFromLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_ProceedsFromLicenseAgreement_84966fb7-4166-4585-938a-7d098044ec30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMilestonePayments_44f097c8-1a11-41b8-8f8d-b1e3276c9313" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_LicenseAgreementMilestonePayments_44f097c8-1a11-41b8-8f8d-b1e3276c9313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_370c0755-4262-437d-8c28-324ad3af1b8a" xlink:href="adc-20220930.xsd#adc_LicenseAgreementPercentOfClinicalTrialCostsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_370c0755-4262-437d-8c28-324ad3af1b8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementCappedContribution_2b71a098-cc1f-4e41-a9bd-4486287166fb" xlink:href="adc-20220930.xsd#adc_LicenseAgreementCappedContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_LicenseAgreementCappedContribution_2b71a098-cc1f-4e41-a9bd-4486287166fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_c66d8fde-5658-42f4-ab0f-940499da9d60_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:to="loc_ifrs-full_NonadjustingEventsMember_c66d8fde-5658-42f4-ab0f-940499da9d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:to="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMember_ecb422dd-97a1-4460-9cd0-386370140d7d" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:to="loc_adc_LicenseAgreementMember_ecb422dd-97a1-4460-9cd0-386370140d7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ApplicationApprovalMember_548b847a-3fae-4216-9f27-41b13a3b830d" xlink:href="adc-20220930.xsd#adc_ApplicationApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:to="loc_adc_ApplicationApprovalMember_548b847a-3fae-4216-9f27-41b13a3b830d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#DeferredroyaltyobligationDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" xlink:type="extended" id="i1f94abeaa6fc45ff9d06242a9469db19_DeferredroyaltyobligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreement_1ccd22d1-5466-4c88-9830-413458fbf3c6" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreement_1ccd22d1-5466-4c88-9830-413458fbf3c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromRoyaltyPurchaseAgreementGross_0d50b6c5-4cde-414c-967a-0c8aa561c4ea" xlink:href="adc-20220930.xsd#adc_ProceedsFromRoyaltyPurchaseAgreementGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_ProceedsFromRoyaltyPurchaseAgreementGross_0d50b6c5-4cde-414c-967a-0c8aa561c4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationTransactionCosts_fc43852d-6169-4a0f-9321-c9e721d19bc5" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationTransactionCosts_fc43852d-6169-4a0f-9321-c9e721d19bc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationInterest_8e4872c8-8c56-4e3a-8d35-6a0962d50db6" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationInterest_8e4872c8-8c56-4e3a-8d35-6a0962d50db6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAdditionalProceedsEligibility_1413af04-c416-4f09-8061-81de1259c090" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAdditionalProceedsEligibility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAdditionalProceedsEligibility_1413af04-c416-4f09-8061-81de1259c090" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_163a61d7-520c-40ba-a377-11e17c803d8d" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_163a61d7-520c-40ba-a377-11e17c803d8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_405eee1a-b8a1-4bda-8698-223be4781097" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_405eee1a-b8a1-4bda-8698-223be4781097" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_8fdc58d1-0c4d-49e6-8590-36a77e554e5d" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_8fdc58d1-0c4d-49e6-8590-36a77e554e5d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_53eb8215-2ab7-444b-b5f6-17b23f3398b2" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_53eb8215-2ab7-444b-b5f6-17b23f3398b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_9be53c07-5000-46c9-8f0e-78b50d97ce36" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_9be53c07-5000-46c9-8f0e-78b50d97ce36" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCap_207c2e19-573f-4e3e-a0b0-e365f956c2c5" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCap"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyCap_207c2e19-573f-4e3e-a0b0-e365f956c2c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_a413ed38-0c03-4f51-bb7d-9e9424cc3352" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_a413ed38-0c03-4f51-bb7d-9e9424cc3352" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligation_b453bfb6-0160-43ed-8f0b-6625126954ce" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_DeferredRoyaltyObligation_b453bfb6-0160-43ed-8f0b-6625126954ce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationExpectedFutureTransactionCosts_1321c58e-9ff4-434a-bb78-36228c6c9dda" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationExpectedFutureTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationExpectedFutureTransactionCosts_1321c58e-9ff4-434a-bb78-36228c6c9dda" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromRoyaltyPurchaseAgreementNet_e7e1078d-d260-4745-b93d-f63ffe8845bf" xlink:href="adc-20220930.xsd#adc_ProceedsFromRoyaltyPurchaseAgreementNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_ProceedsFromRoyaltyPurchaseAgreementNet_e7e1078d-d260-4745-b93d-f63ffe8845bf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_42d09db9-df8d-45ce-adb6-f0dec9a3c607" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementEffectiveInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_42d09db9-df8d-45ce-adb6-f0dec9a3c607" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTerminationPeriod_324bfa29-9871-48dd-ad90-1035197f6d64" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTerminationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementTerminationPeriod_324bfa29-9871-48dd-ad90-1035197f6d64" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_95101b9b-0123-4806-8b9f-fa69c480ea6d" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_95101b9b-0123-4806-8b9f-fa69c480ea6d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutAmount_6979add8-b803-4c28-b9cb-e461b5daa1e5" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementBuyoutAmount_6979add8-b803-4c28-b9cb-e461b5daa1e5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_dba7cf8d-96f9-46e2-a651-9b7a669fa4ac" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_dba7cf8d-96f9-46e2-a651-9b7a669fa4ac" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_c457f789-a0e8-43ef-ad15-fadba290df76" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutPercentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_c457f789-a0e8-43ef-ad15-fadba290df76" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationPayments_a45d69b5-7d3d-43bb-af98-d765e07467ff" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationPayments_a45d69b5-7d3d-43bb-af98-d765e07467ff" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_53ec6e2b-c806-4638-9e66-8d22e25f7ad3" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_53ec6e2b-c806-4638-9e66-8d22e25f7ad3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementDomain_e91f18be-f6e3-4b77-83ac-9ae36c6a4687_default" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:to="loc_adc_RoyaltyPurchaseAgreementDomain_e91f18be-f6e3-4b77-83ac-9ae36c6a4687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:to="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FirstInvestmentAmountMember_8412a3e6-2203-49e9-ab9e-e843c5992985" xlink:href="adc-20220930.xsd#adc_FirstInvestmentAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:to="loc_adc_FirstInvestmentAmountMember_8412a3e6-2203-49e9-ab9e-e843c5992985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SecondInvestmentAmountMember_736a7397-7529-4a1d-b94e-878822344a46" xlink:href="adc-20220930.xsd#adc_SecondInvestmentAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:to="loc_adc_SecondInvestmentAmountMember_736a7397-7529-4a1d-b94e-878822344a46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ThirdInvestmentAmountMember_14b23fb2-1b26-442c-adfb-1b44f6f40744" xlink:href="adc-20220930.xsd#adc_ThirdInvestmentAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:to="loc_adc_ThirdInvestmentAmountMember_14b23fb2-1b26-442c-adfb-1b44f6f40744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:to="loc_srt_SegmentGeographicalDomain_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:to="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_87198bae-ad61-4aaa-8511-e496c98e3a69" xlink:href="adc-20220930.xsd#adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:to="loc_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_87198bae-ad61-4aaa-8511-e496c98e3a69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WorldwideMember_8eb24f53-2795-473e-8788-a59b8af3373e" xlink:href="adc-20220930.xsd#adc_WorldwideMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:to="loc_adc_WorldwideMember_8eb24f53-2795-473e-8788-a59b8af3373e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OutsideOfTheUnitedStatesAndEuropeMember_c282a307-d7e3-4086-8d98-d86c5e94f72b" xlink:href="adc-20220930.xsd#adc_OutsideOfTheUnitedStatesAndEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:to="loc_adc_OutsideOfTheUnitedStatesAndEuropeMember_c282a307-d7e3-4086-8d98-d86c5e94f72b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b757d92-05a0-4dd3-b41c-f533f3137458_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:to="loc_srt_ProductsAndServicesDomain_4b757d92-05a0-4dd3-b41c-f533f3137458_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:to="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAMember_4149a260-e106-4434-bada-48c3bc5abcb8" xlink:href="adc-20220930.xsd#adc_ZYNLONTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:to="loc_adc_ZYNLONTAMember_4149a260-e106-4434-bada-48c3bc5abcb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CamiMember_df5a6c46-f35e-43c8-8323-804d2ba72cc6" xlink:href="adc-20220930.xsd#adc_CamiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:to="loc_adc_CamiMember_df5a6c46-f35e-43c8-8323-804d2ba72cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsDomain_78a4e0ce-f5bb-475b-9982-c0d09e455f57_default" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:to="loc_adc_RoyaltyPurchaseAgreementTermsDomain_78a4e0ce-f5bb-475b-9982-c0d09e455f57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:to="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_c69407c5-231d-4779-9d33-a888b95c9ddd" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_c69407c5-231d-4779-9d33-a888b95c9ddd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_8974bbb4-da8d-4e18-9f1d-6da3a000f338" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_8974bbb4-da8d-4e18-9f1d-6da3a000f338" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/EquityDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#EquityDetails"/>
  <link:definitionLink xlink:role="http://adctherapeutics.com/role/EquityDetails" xlink:type="extended" id="i02b1b4b1546a48839959498259c84cfd_EquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughExchangeAgreement_d87e58f0-b38b-4621-a388-0f85e1c3c825" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughExchangeAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_IssueOfEquityThroughExchangeAgreement_d87e58f0-b38b-4621-a388-0f85e1c3c825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings_3422bb4d-8637-496c-b148-78f7010e668b" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_GainsLossOnExtinguishmentOfBorrowings_3422bb4d-8637-496c-b148-78f7010e668b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_56d102f2-58de-4cf1-9eff-221c92e49596" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_ifrs-full_NumberOfSharesIssued_56d102f2-58de-4cf1-9eff-221c92e49596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockPricePerShare_e2eb4a90-f5bd-446b-9d50-8ca01bfc8f9e" xlink:href="adc-20220930.xsd#adc_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_SaleOfStockPricePerShare_e2eb4a90-f5bd-446b-9d50-8ca01bfc8f9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_9ee9bceb-aa4a-4b10-8292-ef94ea0e6619" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_9ee9bceb-aa4a-4b10-8292-ef94ea0e6619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_15949195-e2e2-4d53-8e2f-bdce382cb09e" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_ConvertibleNotesSharesConverted_15949195-e2e2-4d53-8e2f-bdce382cb09e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_9bae4137-0d8a-42a1-a67a-8b18b9619b3e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:to="loc_ifrs-full_EquityMember_9bae4137-0d8a-42a1-a67a-8b18b9619b3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_00343e67-ce7f-433d-9334-cc2b526bec67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:to="loc_ifrs-full_EquityMember_00343e67-ce7f-433d-9334-cc2b526bec67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_27410f71-07dd-4064-abd7-f0f67b51cb40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_00343e67-ce7f-433d-9334-cc2b526bec67" xlink:to="loc_ifrs-full_SharePremiumMember_27410f71-07dd-4064-abd7-f0f67b51cb40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_00f4269a-40f3-4222-8351-43adebd76c44_default" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:to="loc_adc_SaleOfStockDomain_00f4269a-40f3-4222-8351-43adebd76c44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_42a1991c-6da7-423c-ad00-3ea1c6436834" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:to="loc_adc_SaleOfStockDomain_42a1991c-6da7-423c-ad00-3ea1c6436834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PurchasersMember_8b24f65f-896f-4404-a009-dadd51fab882" xlink:href="adc-20220930.xsd#adc_PurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_SaleOfStockDomain_42a1991c-6da7-423c-ad00-3ea1c6436834" xlink:to="loc_adc_PurchasersMember_8b24f65f-896f-4404-a009-dadd51fab882" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_9c80532b-4327-46ed-a852-79d61e8974d7_default" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:to="loc_adc_WarrantsTrancheDomain_9c80532b-4327-46ed-a852-79d61e8974d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_063e19cc-9f5c-4eee-a598-e24c18a9e9f7" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:to="loc_adc_WarrantsTrancheDomain_063e19cc-9f5c-4eee-a598-e24c18a9e9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember_3b55dfab-2172-4f21-917f-e8070c940d12" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_adc_WarrantsTrancheDomain_063e19cc-9f5c-4eee-a598-e24c18a9e9f7" xlink:to="loc_adc_WarrantsTrancheTwoMember_3b55dfab-2172-4f21-917f-e8070c940d12" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>adc-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_9c635204-8e69-44e8-a683-0d3599da2bbd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_b147e11a-13e5-4976-8723-4aed949abda2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in income taxes</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncomeTaxExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="lab_ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_37931c6f-68d0-47b6-845b-c0c885535570_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New and amended IFRS standards</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PlanNameAxis_9614f69c-c555-4dc6-b06d-7034a7d05d01_terseLabel_en-US" xlink:label="lab_adc_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_adc_PlanNameAxis_label_en-US" xlink:label="lab_adc_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_adc_PlanNameAxis_documentation_en-US" xlink:label="lab_adc_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameAxis" xlink:href="adc-20220930.xsd#adc_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PlanNameAxis" xlink:to="lab_adc_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CreditDerivativeFairValue_49579a27-87f6-468d-b63e-32ea27f48d74_terseLabel_en-US" xlink:label="lab_ifrs-full_CreditDerivativeFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit derivative, fair value</link:label>
    <link:label id="lab_ifrs-full_CreditDerivativeFairValue_label_en-US" xlink:label="lab_ifrs-full_CreditDerivativeFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit derivative, fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditDerivativeFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditDerivativeFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CreditDerivativeFairValue" xlink:to="lab_ifrs-full_CreditDerivativeFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ResearchAndDevelopmentExpenseMember_3192f4a8-06bc-4605-bfe3-38d7ef3914ec_terseLabel_en-US" xlink:label="lab_adc_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D expense</link:label>
    <link:label id="lab_adc_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_adc_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense [Member]</link:label>
    <link:label id="lab_adc_ResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_adc_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResearchAndDevelopmentExpenseMember" xlink:href="adc-20220930.xsd#adc_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ResearchAndDevelopmentExpenseMember" xlink:to="lab_adc_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_902f55c7-b9f0-4938-b540-a3ab9a3dd443_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_477cc980-0395-4fc0-a23f-c3df8fb074e7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_9826c76d-4778-43be-8484-a579ceb6e5e9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans, derivatives, decrease in fair value</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock_f1452e40-cf42-48c3-a8db-76d2d196cdaf_terseLabel_en-US" xlink:label="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Foreign currency exchange rate</link:label>
    <link:label id="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock_label_en-US" xlink:label="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Foreign Currency Exchange Rate Explanatory [Table Text Block]</link:label>
    <link:label id="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Detailed Information About Foreign Currency Exchange Rate Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" xlink:href="adc-20220930.xsd#adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" xlink:to="lab_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasuryShares_c9412d92-51a4-48cf-9dc8-ece8fcf94a22_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:label id="lab_ifrs-full_TreasuryShares_label_en-US" xlink:label="lab_ifrs-full_TreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasuryShares" xlink:to="lab_ifrs-full_TreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_539c37c6-b994-4c90-86ee-4c33cdca175e_terseLabel_en-US" xlink:label="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_label_en-US" xlink:label="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-Based Payment Arrangement</link:label>
    <link:label id="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term Of Options Granted For Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:href="adc-20220930.xsd#adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:to="lab_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_671fdc46-de8f-4d6b-add5-bf7a4e231d38_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, Granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OfferingPricePerShare_70c4c712-bea6-41b5-b4bf-4a2808f96a66_terseLabel_en-US" xlink:label="lab_adc_OfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in USD per share)</link:label>
    <link:label id="lab_adc_OfferingPricePerShare_label_en-US" xlink:label="lab_adc_OfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Price Per Share</link:label>
    <link:label id="lab_adc_OfferingPricePerShare_documentation_en-US" xlink:label="lab_adc_OfferingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OfferingPricePerShare" xlink:href="adc-20220930.xsd#adc_OfferingPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OfferingPricePerShare" xlink:to="lab_adc_OfferingPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForAmortisationExpense_93488bf4-7a83-4ba2-b952-8e6696f8b8e1_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTermsAxis_3756d312-bbb4-494b-8089-dddfdb8e4990_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Terms [Axis]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTermsAxis_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Terms [Axis]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTermsAxis_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsAxis" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsAxis" xlink:to="lab_adc_RoyaltyPurchaseAgreementTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_7100879b-3c36-4fc5-8565-2fe60ae67fea_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_46319980-01ce-40ad-a7e4-717bf3f086a0_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_9d2bff62-0af3-42d5-a37e-e31bb75bd613_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for purchase of intangible assets</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of intangible assets, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_e0f45a92-e9d5-44ca-b482-7c7a751631c3_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of results in joint venture</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_d7e1f01b-7d55-4486-bf1a-07f27edae7be_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of results with joint venture</link:label>
    <link:label id="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of profit (loss) of joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_cd24252e-94ed-45a0-9f17-9d57cbcc6d08_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated losses</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsImpliedEffectiveInterestRate_046b0275-cb92-4e7b-b627-3e55e04d39a0_terseLabel_en-US" xlink:label="lab_adc_BorrowingsImpliedEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implied effective interest rate</link:label>
    <link:label id="lab_adc_BorrowingsImpliedEffectiveInterestRate_label_en-US" xlink:label="lab_adc_BorrowingsImpliedEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Implied Effective Interest Rate</link:label>
    <link:label id="lab_adc_BorrowingsImpliedEffectiveInterestRate_documentation_en-US" xlink:label="lab_adc_BorrowingsImpliedEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Implied Effective Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsImpliedEffectiveInterestRate" xlink:href="adc-20220930.xsd#adc_BorrowingsImpliedEffectiveInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsImpliedEffectiveInterestRate" xlink:to="lab_adc_BorrowingsImpliedEffectiveInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock_a8bcbf80-e7ac-42eb-8072-c5e7b54a25fa_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other income (expense)</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Other Income (Expense) Explanatory [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Other Income (Expense) Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsTrancheOneMember_5f622945-8642-4199-99d9-540639e151f2_terseLabel_en-US" xlink:label="lab_adc_WarrantsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One</link:label>
    <link:label id="lab_adc_WarrantsTrancheOneMember_label_en-US" xlink:label="lab_adc_WarrantsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One [Member]</link:label>
    <link:label id="lab_adc_WarrantsTrancheOneMember_documentation_en-US" xlink:label="lab_adc_WarrantsTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsTrancheOneMember" xlink:to="lab_adc_WarrantsTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_808440c3-715d-49e2-96fd-5a7e2de1d459_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, granted (in USD per share)</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_label_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_documentation_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" xlink:to="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_11682566-d2d5-4972-8fe4-e5ad960d6cf5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantObligationFairValue_c5ec94f8-0452-4b69-ba1c-d751afa38aa6_terseLabel_en-US" xlink:label="lab_adc_WarrantObligationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Obligation, Fair Value</link:label>
    <link:label id="lab_adc_WarrantObligationFairValue_label_en-US" xlink:label="lab_adc_WarrantObligationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Obligation, Fair Value</link:label>
    <link:label id="lab_adc_WarrantObligationFairValue_documentation_en-US" xlink:label="lab_adc_WarrantObligationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Obligation, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationFairValue" xlink:href="adc-20220930.xsd#adc_WarrantObligationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantObligationFairValue" xlink:to="lab_adc_WarrantObligationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_73d0efbc-7d21-48e3-bfeb-1b226f1ab486_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0902c076-b42e-42a6-8e9e-8f3047a0fcbf_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesLineItems_eea34d21-e2f2-4129-a710-ee27235fb25c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint ventures [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint ventures [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConvertibleLoansExchange_8e86b4e3-32f8-48e3-a2d1-05c351cfcb2c_negatedTerseLabel_en-US" xlink:label="lab_adc_ConvertibleLoansExchange" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans exchange</link:label>
    <link:label id="lab_adc_ConvertibleLoansExchange_label_en-US" xlink:label="lab_adc_ConvertibleLoansExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans Exchange</link:label>
    <link:label id="lab_adc_ConvertibleLoansExchange_documentation_en-US" xlink:label="lab_adc_ConvertibleLoansExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansExchange" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConvertibleLoansExchange" xlink:to="lab_adc_ConvertibleLoansExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_087062b6-2498-4f2a-8445-5fae388f6863_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_3dafdbbf-77ad-435a-846c-c0245a77bfd6_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_a4a30657-4496-4cb8-83ff-9a7aa94b37ba_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in other current assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExpensesByNatureAxis_7fa41b8f-3cd5-4cd4-9af8-35f61efb020f_terseLabel_en-US" xlink:label="lab_adc_ExpensesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature [Axis]</link:label>
    <link:label id="lab_adc_ExpensesByNatureAxis_label_en-US" xlink:label="lab_adc_ExpensesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature [Axis]</link:label>
    <link:label id="lab_adc_ExpensesByNatureAxis_documentation_en-US" xlink:label="lab_adc_ExpensesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureAxis" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExpensesByNatureAxis" xlink:to="lab_adc_ExpensesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_d493cb40-10ba-499f-875b-27899fc8d1b7_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation charge</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_39088428-8493-4466-bf5a-e7ad5e2ebd9c_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_26bd82f2-e5da-4bb6-8cb7-54e2a4744ca2_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_907db098-1d6d-4526-a214-cf1af4d6eab1_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IssueOfEquityThroughPurchaseAgreement_774fa97c-8f87-487c-91c7-34740d487173_terseLabel_en-US" xlink:label="lab_adc_IssueOfEquityThroughPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares, share purchase agreement, net of transaction costs</link:label>
    <link:label id="lab_adc_IssueOfEquityThroughPurchaseAgreement_label_en-US" xlink:label="lab_adc_IssueOfEquityThroughPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity Through Purchase Agreement</link:label>
    <link:label id="lab_adc_IssueOfEquityThroughPurchaseAgreement_documentation_en-US" xlink:label="lab_adc_IssueOfEquityThroughPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity Through Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughPurchaseAgreement" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IssueOfEquityThroughPurchaseAgreement" xlink:to="lab_adc_IssueOfEquityThroughPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RelatedPartiesMember_fe683a5a-d4d6-4e3e-945a-43a9e960ab7d_terseLabel_en-US" xlink:label="lab_ifrs-full_RelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ifrs-full_RelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_RelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RelatedPartiesMember" xlink:to="lab_ifrs-full_RelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_47029b5a-d1be-4d8d-a07b-f65f846250d9_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_6ca3ac1e-fe12-4d5c-9957-acd702219a9c_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsMember_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsMember" xlink:to="lab_ifrs-full_UnobservableInputsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_2393c2cb-0690-4b7a-8db4-6a8072433c46_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_ded60a0e-8209-4454-bd1d-67a2b5464b99_terseLabel_en-US" xlink:label="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion percentage</link:label>
    <link:label id="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_label_en-US" xlink:label="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price</link:label>
    <link:label id="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_documentation_en-US" xlink:label="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" xlink:to="lab_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AdditionsToLeaseLiabilities_879a8847-1eff-4815-96b2-7d366aadc0fa_terseLabel_en-US" xlink:label="lab_adc_AdditionsToLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_adc_AdditionsToLeaseLiabilities_label_en-US" xlink:label="lab_adc_AdditionsToLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions To Lease Liabilities</link:label>
    <link:label id="lab_adc_AdditionsToLeaseLiabilities_documentation_en-US" xlink:label="lab_adc_AdditionsToLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions To Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdditionsToLeaseLiabilities" xlink:href="adc-20220930.xsd#adc_AdditionsToLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AdditionsToLeaseLiabilities" xlink:to="lab_adc_AdditionsToLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_d0fbe274-aaf6-43ff-867e-e71b43270aa1_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from equity issuance, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_a521fea3-ce2d-4167-93c9-7d6b30c9c8ba_terseLabel_en-US" xlink:label="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and vestings of RSUs</link:label>
    <link:label id="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_label_en-US" xlink:label="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option</link:label>
    <link:label id="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_documentation_en-US" xlink:label="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" xlink:href="adc-20220930.xsd#adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" xlink:to="lab_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_aebe2b02-953a-4ad1-9a6f-6104b091c3c9_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_2c093084-2705-44b6-9d34-15939bb3f1e9_negatedLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, vested (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_2bad54bc-7c9a-4253-8fbf-24d0f367316c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_74786f68-cb53-4184-bf76-12c322741019_terseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SaleOrIssueOfTreasuryShares_adb70651-1678-4fe7-baaa-37539f4597f2_terseLabel_en-US" xlink:label="lab_ifrs-full_SaleOrIssueOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale or issue of treasury shares</link:label>
    <link:label id="lab_ifrs-full_SaleOrIssueOfTreasuryShares_label_en-US" xlink:label="lab_ifrs-full_SaleOrIssueOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale or issue of treasury shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SaleOrIssueOfTreasuryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="lab_ifrs-full_SaleOrIssueOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_85d0c04a-0ef3-4b82-9cc6-3db39fc7eb59_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible loans, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RawMaterials_df053a18-42ac-448b-97c0-30db7a344dc6_terseLabel_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current raw materials</link:label>
    <link:label id="lab_ifrs-full_RawMaterials_label_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current raw materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterials" xlink:to="lab_ifrs-full_RawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_8ccf52c0-2b59-400f-848d-8f115a0e0b78_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TrancheTwoMember_7191aa11-6b38-4a30-bf53-d4cfec67750b_terseLabel_en-US" xlink:label="lab_adc_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_adc_TrancheTwoMember_label_en-US" xlink:label="lab_adc_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two [Member]</link:label>
    <link:label id="lab_adc_TrancheTwoMember_documentation_en-US" xlink:label="lab_adc_TrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheTwoMember" xlink:href="adc-20220930.xsd#adc_TrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TrancheTwoMember" xlink:to="lab_adc_TrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExchangeAgreementMember_a1648c7d-c8d0-42c4-b864-c3b7d7988abc_terseLabel_en-US" xlink:label="lab_adc_ExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement</link:label>
    <link:label id="lab_adc_ExchangeAgreementMember_label_en-US" xlink:label="lab_adc_ExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement [Member]</link:label>
    <link:label id="lab_adc_ExchangeAgreementMember_documentation_en-US" xlink:label="lab_adc_ExchangeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeAgreementMember" xlink:href="adc-20220930.xsd#adc_ExchangeAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExchangeAgreementMember" xlink:to="lab_adc_ExchangeAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsSharesConvertedExercisePrice_ad5ceee3-261f-428d-837e-8bfe85671026_terseLabel_en-US" xlink:label="lab_adc_WarrantsSharesConvertedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares Converted, Exercise Price</link:label>
    <link:label id="lab_adc_WarrantsSharesConvertedExercisePrice_label_en-US" xlink:label="lab_adc_WarrantsSharesConvertedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares Converted, Exercise Price</link:label>
    <link:label id="lab_adc_WarrantsSharesConvertedExercisePrice_documentation_en-US" xlink:label="lab_adc_WarrantsSharesConvertedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares Converted, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsSharesConvertedExercisePrice" xlink:to="lab_adc_WarrantsSharesConvertedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExpectedTermMember_774d8a48-afff-4798-83e3-9ef4dea11848_terseLabel_en-US" xlink:label="lab_adc_ExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Term</link:label>
    <link:label id="lab_adc_ExpectedTermMember_label_en-US" xlink:label="lab_adc_ExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Term [Member]</link:label>
    <link:label id="lab_adc_ExpectedTermMember_documentation_en-US" xlink:label="lab_adc_ExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExpectedTermMember" xlink:to="lab_adc_ExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetDeferredTaxAssets_7ba91b16-d268-47e5-8a3c-d466e79f21b0_terseLabel_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_NetDeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_NetDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetDeferredTaxAssets" xlink:to="lab_ifrs-full_NetDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_cd617efd-81a0-4c0d-ad98-60188758503a_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for joint ventures [member]</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForJointVenturesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for joint ventures [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember" xlink:to="lab_ifrs-full_EntitysTotalForJointVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConvertibleNotesSharesConverted_dfec32d0-fd1a-4f0c-9c8d-3591f443c127_terseLabel_en-US" xlink:label="lab_adc_ConvertibleNotesSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Shares Converted</link:label>
    <link:label id="lab_adc_ConvertibleNotesSharesConverted_label_en-US" xlink:label="lab_adc_ConvertibleNotesSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Shares Converted</link:label>
    <link:label id="lab_adc_ConvertibleNotesSharesConverted_documentation_en-US" xlink:label="lab_adc_ConvertibleNotesSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConvertibleNotesSharesConverted" xlink:to="lab_adc_ConvertibleNotesSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_64e06a21-7635-427f-aca5-d2a9b19e065b_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromCurrentBorrowings_8c4533f0-e9d6-4c94-b271-96e0c21f2905_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from senior secured term loans, net of transaction costs</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromCurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromCurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromCurrentBorrowings" xlink:to="lab_ifrs-full_ProceedsFromCurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativesMember_c95577da-1641-46c5-84ee-ce03d7fcb14b_terseLabel_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_ifrs-full_DerivativesMember_48e6909b-5451-4070-a50a-418698c6832c_verboseLabel_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_ifrs-full_DerivativesMember_label_en-US" xlink:label="lab_ifrs-full_DerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativesMember" xlink:to="lab_ifrs-full_DerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_432700e9-56a1-409d-a180-9c6d976511ab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events after the reporting date</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_3cb6676b-ccb3-4b0c-9161-9f9f91ab7662_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss before working capital changes</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_8e11680c-208d-4a27-934e-010c13a33c46_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Rate Percent</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Rate Percent</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Rate Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" xlink:to="lab_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_EventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_adc_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events After Reporting Period [Abstract]</link:label>
    <link:label id="lab_adc_EventsAfterReportingPeriodAbstract_documentation_en-US" xlink:label="lab_adc_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Events After Reporting Period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EventsAfterReportingPeriodAbstract" xlink:href="adc-20220930.xsd#adc_EventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_EventsAfterReportingPeriodAbstract" xlink:to="lab_adc_EventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsFacilitiesExitFeePercentage_471e79f4-84b2-498d-a382-73ce18ebd7ef_terseLabel_en-US" xlink:label="lab_adc_BorrowingsFacilitiesExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee</link:label>
    <link:label id="lab_adc_BorrowingsFacilitiesExitFeePercentage_label_en-US" xlink:label="lab_adc_BorrowingsFacilitiesExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Facilities, Exit Fee, Percentage</link:label>
    <link:label id="lab_adc_BorrowingsFacilitiesExitFeePercentage_documentation_en-US" xlink:label="lab_adc_BorrowingsFacilitiesExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Facilities, Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFacilitiesExitFeePercentage" xlink:href="adc-20220930.xsd#adc_BorrowingsFacilitiesExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsFacilitiesExitFeePercentage" xlink:to="lab_adc_BorrowingsFacilitiesExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount_271d6772-bb55-4125-aa46-5523922b7d69_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Amount</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Amount</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutAmount" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementBuyoutAmount" xlink:to="lab_adc_RoyaltyPurchaseAgreementBuyoutAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_4b039e9d-ce74-4297-99b8-0f8cad4ceb32_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key inputs for valuations</link:label>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputLiabilities_label_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable input, liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="lab_ifrs-full_SignificantUnobservableInputLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_85740a87-823f-460b-868e-592e80edd1f2_terseLabel_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_AverageForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_AverageForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AverageForeignExchangeRate" xlink:to="lab_ifrs-full_AverageForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_f20ccc7d-0ee4-4b66-a092-d8c6577139dc_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average strike price in USD per share, Expired (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_204fe5b2-9fa6-4fa8-94ff-b82aae3a64a7_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total items that will not be reclassified to profit and loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will not be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_deccb8c2-2271-43f1-913f-e54dee7f428f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Option and Convertible Loan</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsTrancheOnePriceTwoMember_b0375f0a-1e5c-4e02-a0d7-b8fa5decf732_terseLabel_en-US" xlink:label="lab_adc_WarrantsTrancheOnePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One, Price Two</link:label>
    <link:label id="lab_adc_WarrantsTrancheOnePriceTwoMember_label_en-US" xlink:label="lab_adc_WarrantsTrancheOnePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One, Price Two [Member]</link:label>
    <link:label id="lab_adc_WarrantsTrancheOnePriceTwoMember_documentation_en-US" xlink:label="lab_adc_WarrantsTrancheOnePriceTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One, Price Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsTrancheOnePriceTwoMember" xlink:to="lab_adc_WarrantsTrancheOnePriceTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock_1e6c06fd-5254-4943-869d-368db181dcb2_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Reserve</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingNumberOfComponents_4d93accd-9996-4872-8345-a59b0ad164e9_terseLabel_en-US" xlink:label="lab_adc_BorrowingNumberOfComponents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of borrowing components</link:label>
    <link:label id="lab_adc_BorrowingNumberOfComponents_label_en-US" xlink:label="lab_adc_BorrowingNumberOfComponents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Number Of Components</link:label>
    <link:label id="lab_adc_BorrowingNumberOfComponents_documentation_en-US" xlink:label="lab_adc_BorrowingNumberOfComponents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing, Number Of Components</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingNumberOfComponents" xlink:href="adc-20220930.xsd#adc_BorrowingNumberOfComponents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingNumberOfComponents" xlink:to="lab_adc_BorrowingNumberOfComponents" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseAgreementCappedContribution_e4d0435b-d919-4228-bab4-ee7b2fb32263_terseLabel_en-US" xlink:label="lab_adc_LicenseAgreementCappedContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Capped Contribution</link:label>
    <link:label id="lab_adc_LicenseAgreementCappedContribution_label_en-US" xlink:label="lab_adc_LicenseAgreementCappedContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Capped Contribution</link:label>
    <link:label id="lab_adc_LicenseAgreementCappedContribution_documentation_en-US" xlink:label="lab_adc_LicenseAgreementCappedContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Capped Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementCappedContribution" xlink:href="adc-20220930.xsd#adc_LicenseAgreementCappedContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseAgreementCappedContribution" xlink:to="lab_adc_LicenseAgreementCappedContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_1d14558f-92fc-41c2-8039-133223b97b9e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Functional and reporting currency</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_405384ab-e3fe-421d-ba8d-42894dea2e1f_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans, long-term</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExchangeOfConvertibleNotesForWarrants_b7aad212-b5f3-4cf7-8464-b3dfe1daf709_terseLabel_en-US" xlink:label="lab_adc_ExchangeOfConvertibleNotesForWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Of Convertible Notes For Warrants</link:label>
    <link:label id="lab_adc_ExchangeOfConvertibleNotesForWarrants_label_en-US" xlink:label="lab_adc_ExchangeOfConvertibleNotesForWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Of Convertible Notes For Warrants</link:label>
    <link:label id="lab_adc_ExchangeOfConvertibleNotesForWarrants_documentation_en-US" xlink:label="lab_adc_ExchangeOfConvertibleNotesForWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Of Convertible Notes For Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeOfConvertibleNotesForWarrants" xlink:href="adc-20220930.xsd#adc_ExchangeOfConvertibleNotesForWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExchangeOfConvertibleNotesForWarrants" xlink:to="lab_adc_ExchangeOfConvertibleNotesForWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_4673be33-e9c5-49fb-9d65-2edb8c918974_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_93bf7e60-7777-4d5c-a3ae-e049a4d58bcd_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expense</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_37091c2f-2408-4a7f-b7c1-2d2182d6ce9b_terseLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_7262c50d-a34b-4365-85a3-ad52046b46dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9d5adcef-a7b8-49c1-8acd-7a3de9c5f87b_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LoansReceived_6d207365-0796-47d4-9eca-a717aff029d9_terseLabel_en-US" xlink:label="lab_ifrs-full_LoansReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans received</link:label>
    <link:label id="lab_ifrs-full_LoansReceived_label_en-US" xlink:label="lab_ifrs-full_LoansReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LoansReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LoansReceived" xlink:to="lab_ifrs-full_LoansReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncomeStatementLocationAxis_a18a6d61-b580-49ea-ad7e-9c21483ba3ad_terseLabel_en-US" xlink:label="lab_adc_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_adc_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_adc_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_adc_IncomeStatementLocationAxis_documentation_en-US" xlink:label="lab_adc_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationAxis" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncomeStatementLocationAxis" xlink:to="lab_adc_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_e8d3c0dc-1df4-41b1-bc36-e33a12cae779_terseLabel_en-US" xlink:label="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products developed and commercialized in joint venture</link:label>
    <link:label id="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_label_en-US" xlink:label="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products Developed And Commercialized In Joint Venture</link:label>
    <link:label id="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_documentation_en-US" xlink:label="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Products Developed And Commercialized In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" xlink:href="adc-20220930.xsd#adc_NumberOfProductsDevelopedAndCommercializedInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" xlink:to="lab_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GainsLossOnExtinguishmentOfBorrowings_e1070750-0edc-4fcc-8ce2-1f1514be7739_terseLabel_en-US" xlink:label="lab_adc_GainsLossOnExtinguishmentOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment</link:label>
    <link:label id="lab_adc_GainsLossOnExtinguishmentOfBorrowings_label_en-US" xlink:label="lab_adc_GainsLossOnExtinguishmentOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Loss) On Extinguishment Of Borrowings</link:label>
    <link:label id="lab_adc_GainsLossOnExtinguishmentOfBorrowings_documentation_en-US" xlink:label="lab_adc_GainsLossOnExtinguishmentOfBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Loss) On Extinguishment Of Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GainsLossOnExtinguishmentOfBorrowings" xlink:to="lab_adc_GainsLossOnExtinguishmentOfBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_a7cec1af-ec99-4494-bbd5-18113a621ab7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_87b554fd-0bb2-48ac-adce-7d155cdd605b_terseLabel_en-US" xlink:label="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from deferred royalty transaction, net of transaction costs</link:label>
    <link:label id="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_label_en-US" xlink:label="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs</link:label>
    <link:label id="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_documentation_en-US" xlink:label="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" xlink:href="adc-20220930.xsd#adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" xlink:to="lab_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareTable_0e367df2-1b95-40a6-8d51-e8b48634c059_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [table]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareTable_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareTable" xlink:to="lab_ifrs-full_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InventoryAxis_f7463444-9674-46e6-9ece-060dce1f9043_terseLabel_en-US" xlink:label="lab_adc_InventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_adc_InventoryAxis_label_en-US" xlink:label="lab_adc_InventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_adc_InventoryAxis_documentation_en-US" xlink:label="lab_adc_InventoryAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAxis" xlink:href="adc-20220930.xsd#adc_InventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InventoryAxis" xlink:to="lab_adc_InventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_e5793b0e-3bc4-4156-a0bf-0bcee4d5f989_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_ab10e5bc-4b01-43f9-9764-84e2752bc569_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_83cf09db-bf9b-46ed-a6f6-21cfbbb2ed0c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap_4fbfa702-2720-4a20-b1b9-72e8b63ef1fb_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCap" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCap"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementRoyaltyCap" xlink:to="lab_adc_RoyaltyPurchaseAgreementRoyaltyCap" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock_0d2093d3-da1f-4c09-803d-1fa174abb20d_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Inventory Information Explanatory</link:label>
    <link:label id="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Inventory Information Explanatory [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Inventory Information Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" xlink:to="lab_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1a32788a-0c8c-4426-ae7e-4338af6557eb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_de051919-db94-42d0-b116-da4f010476cd_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareBasedPaymentArrangementsAbstract_f79edac0-b870-4221-8b25-0d1d9aacbf8a_terseLabel_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_adc_ShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_adc_ShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementsAbstract" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract" xlink:to="lab_adc_ShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NonOperatingIncomeExpense_451176e5-4324-4ead-974b-6ef503e647e4_terseLabel_en-US" xlink:label="lab_adc_NonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense)</link:label>
    <link:label id="lab_adc_NonOperatingIncomeExpense_label_en-US" xlink:label="lab_adc_NonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Operating Income (Expense)</link:label>
    <link:label id="lab_adc_NonOperatingIncomeExpense_documentation_en-US" xlink:label="lab_adc_NonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NonOperatingIncomeExpense" xlink:href="adc-20220930.xsd#adc_NonOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NonOperatingIncomeExpense" xlink:to="lab_adc_NonOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_677c2925-8872-46dc-b1cc-215521a894db_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_d7afc7af-e389-4996-8d2f-c46c6d92cb4e_terseLabel_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Issued, Tax Withheld</link:label>
    <link:label id="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_label_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Issued, Tax Withheld</link:label>
    <link:label id="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_documentation_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Issued, Tax Withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" xlink:to="lab_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_a126a218-579e-4e6e-9815-18252860a7fa_terseLabel_en-US" xlink:label="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in estimated probability of derivative</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_label_en-US" xlink:label="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Percent</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_documentation_en-US" xlink:label="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" xlink:to="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_d3701af3-92d3-4085-bae8-e1393ec26e21_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current prepayments and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock_c10aab1a-0f01-4824-9463-574b9e700891_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income</link:label>
    <link:label id="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Non-Operating Income, Explanatory [Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Other Non-Operating Income, Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" xlink:to="lab_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_4f93acef-929d-40d8-87f8-3b5cc0236f1b_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_4e5e5c23-420d-4c52-8dc0-8513ea05ed85_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aaf87b46-654c-4f58-8e97-94461a65030f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_49bdcd84-349f-4c39-ad1b-f9c5c561bd7c_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" xlink:to="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyObligationPayments_a4ad9c07-f4d9-4773-aff1-4dd02acb206a_terseLabel_en-US" xlink:label="lab_adc_RoyaltyObligationPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Payments</link:label>
    <link:label id="lab_adc_RoyaltyObligationPayments_label_en-US" xlink:label="lab_adc_RoyaltyObligationPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Payments</link:label>
    <link:label id="lab_adc_RoyaltyObligationPayments_documentation_en-US" xlink:label="lab_adc_RoyaltyObligationPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationPayments" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyObligationPayments" xlink:to="lab_adc_RoyaltyObligationPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_A2019EquityIncentivePlanShareOptionsMember_0c0632f4-1861-4d4d-a87c-24f8e90c0fc0_terseLabel_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2019 - Share Options</link:label>
    <link:label id="lab_adc_A2019EquityIncentivePlanShareOptionsMember_label_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan - Share Options [Member]</link:label>
    <link:label id="lab_adc_A2019EquityIncentivePlanShareOptionsMember_documentation_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan - Share Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanShareOptionsMember" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_A2019EquityIncentivePlanShareOptionsMember" xlink:to="lab_adc_A2019EquityIncentivePlanShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_cd04c1ca-5c57-4782-b3c5-11d7afe977b5_terseLabel_en-US" xlink:label="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, increase on derivative values</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_label_en-US" xlink:label="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_documentation_en-US" xlink:label="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" xlink:to="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_df4c31ba-5f95-4f2d-8581-47c50f83e30f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SharePurchasePlan2016Member_6b128a82-d0e0-4558-aa4e-14c499eeb48d_terseLabel_en-US" xlink:label="lab_adc_SharePurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Plan 2016 [Member]</link:label>
    <link:label id="lab_adc_SharePurchasePlan2016Member_label_en-US" xlink:label="lab_adc_SharePurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Plan 2016 [Member]</link:label>
    <link:label id="lab_adc_SharePurchasePlan2016Member_documentation_en-US" xlink:label="lab_adc_SharePurchasePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Plan 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePurchasePlan2016Member" xlink:href="adc-20220930.xsd#adc_SharePurchasePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SharePurchasePlan2016Member" xlink:to="lab_adc_SharePurchasePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_8fac63d0-ab34-4a8d-ae56-8f0f87cc15ad_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_a611250b-c676-47ed-bfe8-befa07715981_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_76145df8-47be-4dd6-b841-500bb7bbf416_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_bc4a3d38-b458-44b0-8eba-70b3aad34c84_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap, Period Of Payment</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap, Period Of Payment</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap, Period Of Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" xlink:to="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SharePriceMember_456e8d45-bd53-4de1-ae96-718d5f05b4a7_terseLabel_en-US" xlink:label="lab_adc_SharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price (in USD per share)</link:label>
    <link:label id="lab_adc_SharePriceMember_label_en-US" xlink:label="lab_adc_SharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price [Member]</link:label>
    <link:label id="lab_adc_SharePriceMember_documentation_en-US" xlink:label="lab_adc_SharePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SharePriceMember" xlink:to="lab_adc_SharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_9659cf3d-93e6-4c3f-b635-406b3f073d63_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseAgreementMember_b859fb51-26e8-4848-b925-ea41c81975aa_terseLabel_en-US" xlink:label="lab_adc_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_adc_LicenseAgreementMember_label_en-US" xlink:label="lab_adc_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Member]</link:label>
    <link:label id="lab_adc_LicenseAgreementMember_documentation_en-US" xlink:label="lab_adc_LicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMember" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseAgreementMember" xlink:to="lab_adc_LicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RiskFreeInterestRateMember_6e105d61-ea8b-499e-89af-aa1ef50c2beb_terseLabel_en-US" xlink:label="lab_adc_RiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free, Interest Rate</link:label>
    <link:label id="lab_adc_RiskFreeInterestRateMember_label_en-US" xlink:label="lab_adc_RiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free, Interest Rate [Member]</link:label>
    <link:label id="lab_adc_RiskFreeInterestRateMember_documentation_en-US" xlink:label="lab_adc_RiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RiskFreeInterestRateMember" xlink:to="lab_adc_RiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConvertibleNotesValueConverted_e2804b68-e1ee-4a15-b6af-538376d39aa5_terseLabel_en-US" xlink:label="lab_adc_ConvertibleNotesValueConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Value Converted</link:label>
    <link:label id="lab_adc_ConvertibleNotesValueConverted_label_en-US" xlink:label="lab_adc_ConvertibleNotesValueConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Value Converted</link:label>
    <link:label id="lab_adc_ConvertibleNotesValueConverted_documentation_en-US" xlink:label="lab_adc_ConvertibleNotesValueConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes, Value Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesValueConverted" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesValueConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConvertibleNotesValueConverted" xlink:to="lab_adc_ConvertibleNotesValueConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityTable_7b670b3b-c87b-40b4-97e2-9ce2d3d579db_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reserves within equity [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reserves within equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:to="lab_ifrs-full_DisclosureOfReservesWithinEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross_cc8c11bd-afc4-4ada-97f2-42c975e7834c_terseLabel_en-US" xlink:label="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement, Gross</link:label>
    <link:label id="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross_label_en-US" xlink:label="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement, Gross</link:label>
    <link:label id="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross_documentation_en-US" xlink:label="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromRoyaltyPurchaseAgreementGross" xlink:href="adc-20220930.xsd#adc_ProceedsFromRoyaltyPurchaseAgreementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ProceedsFromRoyaltyPurchaseAgreementGross" xlink:to="lab_adc_ProceedsFromRoyaltyPurchaseAgreementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_734ec19a-3920-47bb-b0f9-d64e242305be_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [member]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsMember" xlink:to="lab_ifrs-full_ClassesOfAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsFairValue_bbb8089a-4e44-4716-8190-76802fe4c48d_terseLabel_en-US" xlink:label="lab_adc_BorrowingsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Fair Value</link:label>
    <link:label id="lab_adc_BorrowingsFairValue_label_en-US" xlink:label="lab_adc_BorrowingsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Fair Value</link:label>
    <link:label id="lab_adc_BorrowingsFairValue_documentation_en-US" xlink:label="lab_adc_BorrowingsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFairValue" xlink:href="adc-20220930.xsd#adc_BorrowingsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsFairValue" xlink:to="lab_adc_BorrowingsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsTrancheAxis_9d254947-dff2-4125-a23d-a4d405ee5610_terseLabel_en-US" xlink:label="lab_adc_WarrantsTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche [Axis]</link:label>
    <link:label id="lab_adc_WarrantsTrancheAxis_label_en-US" xlink:label="lab_adc_WarrantsTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche [Axis]</link:label>
    <link:label id="lab_adc_WarrantsTrancheAxis_documentation_en-US" xlink:label="lab_adc_WarrantsTrancheAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsTrancheAxis" xlink:to="lab_adc_WarrantsTrancheAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_ebc9f4ab-31a0-4d5b-8164-8743bd3f4883_terseLabel_en-US" xlink:label="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</link:label>
    <link:label id="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_label_en-US" xlink:label="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</link:label>
    <link:label id="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_documentation_en-US" xlink:label="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:href="adc-20220930.xsd#adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:to="lab_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e1feab72-643f-4134-8d7c-34dc3f09c8b6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_79566693-a483-4ede-bfe5-bea338db445a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other liabilities and other payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_25818640-570d-4305-8bef-4d10998767cf_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit pension liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_label_en-US" xlink:label="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current net defined benefit liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:to="lab_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_eab53b9f-14ba-4adb-a08b-6771a93f006c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, Forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_c41e2a8c-9624-4fa7-b8cf-70cffee24511_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in other current assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExternalCostsMember_8dcc3738-8e5f-49d5-85c4-69b471178e32_terseLabel_en-US" xlink:label="lab_adc_ExternalCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External costs</link:label>
    <link:label id="lab_adc_ExternalCostsMember_label_en-US" xlink:label="lab_adc_ExternalCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Costs [Member]</link:label>
    <link:label id="lab_adc_ExternalCostsMember_documentation_en-US" xlink:label="lab_adc_ExternalCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExternalCostsMember" xlink:href="adc-20220930.xsd#adc_ExternalCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExternalCostsMember" xlink:to="lab_adc_ExternalCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_ed689e9d-96d0-435f-9e16-34223739c8f1_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received</link:label>
    <link:label id="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ZYNLONTAMember_cabef61f-1870-459a-a619-a9091637304b_terseLabel_en-US" xlink:label="lab_adc_ZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYNLONTA</link:label>
    <link:label id="lab_adc_ZYNLONTAMember_label_en-US" xlink:label="lab_adc_ZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYNLONTA [Member]</link:label>
    <link:label id="lab_adc_ZYNLONTAMember_documentation_en-US" xlink:label="lab_adc_ZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYNLONTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAMember" xlink:href="adc-20220930.xsd#adc_ZYNLONTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ZYNLONTAMember" xlink:to="lab_adc_ZYNLONTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_a0bf751e-00b8-47f2-9db9-d5e4e37c11d4_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ThirdInvestmentAmountMember_a4ee88d1-c5e5-4a84-a633-cb5684e4797e_terseLabel_en-US" xlink:label="lab_adc_ThirdInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Investment Amount</link:label>
    <link:label id="lab_adc_ThirdInvestmentAmountMember_label_en-US" xlink:label="lab_adc_ThirdInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Investment Amount [Member]</link:label>
    <link:label id="lab_adc_ThirdInvestmentAmountMember_documentation_en-US" xlink:label="lab_adc_ThirdInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Investment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ThirdInvestmentAmountMember" xlink:href="adc-20220930.xsd#adc_ThirdInvestmentAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ThirdInvestmentAmountMember" xlink:to="lab_adc_ThirdInvestmentAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TreasurySharesMember_8dcf9a31-4414-4c8f-ad4e-a96bf020273b_terseLabel_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_ifrs-full_TreasurySharesMember_label_en-US" xlink:label="lab_ifrs-full_TreasurySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TreasurySharesMember" xlink:to="lab_ifrs-full_TreasurySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PaymentTypeAxis_1432fc34-2e96-48d5-8fb5-7eb7341337c2_terseLabel_en-US" xlink:label="lab_adc_PaymentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Axis]</link:label>
    <link:label id="lab_adc_PaymentTypeAxis_label_en-US" xlink:label="lab_adc_PaymentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Axis]</link:label>
    <link:label id="lab_adc_PaymentTypeAxis_documentation_en-US" xlink:label="lab_adc_PaymentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeAxis" xlink:href="adc-20220930.xsd#adc_PaymentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PaymentTypeAxis" xlink:to="lab_adc_PaymentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_2a9b6099-37b8-4c4b-9911-d44890ddd3e4_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WrittenPutOptionsMember_c915c5b9-c252-4a94-b4c9-1a1288edce92_terseLabel_en-US" xlink:label="lab_ifrs-full_WrittenPutOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written put options (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WrittenPutOptionsMember_label_en-US" xlink:label="lab_ifrs-full_WrittenPutOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written put options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WrittenPutOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WrittenPutOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WrittenPutOptionsMember" xlink:to="lab_ifrs-full_WrittenPutOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_aa615e21-395b-4330-8efe-c7b3a664b9e2_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, beginning of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9247cbca-4df2-4432-9a13-7720104daaa7_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, end of period (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_e88af278-6de9-49a3-8304-b2537765bbc5_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quantitative information about lease liabilities</link:label>
    <link:label id="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:to="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_e77a41ab-58d1-4274-949c-cd8e96ea92f9_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on change in fair value of derivatives</link:label>
    <link:label id="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_1f41fe73-e3ee-4526-85de-c783a786fcbb_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_278c877c-0e34-4ad2-98ca-8ccd0c52bb14_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of preparation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2f5b3c62-c226-4446-ade2-6aa239eee38c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_b0dab3a8-7f53-4a14-a263-8ebcd0f86568_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_a1ed05d2-438a-490a-a84d-5b51b92ba588_negatedTerseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" xlink:to="lab_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GTNSalesAdjustment_abdaba14-5c39-4df7-947f-7e7ef6a87e5c_terseLabel_en-US" xlink:label="lab_adc_GTNSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales adjustment, beginning balance</link:label>
    <link:label id="lab_adc_GTNSalesAdjustment_9046d0a5-a346-4417-8d66-07ed51e9f0b3_periodEndLabel_en-US" xlink:label="lab_adc_GTNSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales adjustment, ending balance</link:label>
    <link:label id="lab_adc_GTNSalesAdjustment_label_en-US" xlink:label="lab_adc_GTNSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment</link:label>
    <link:label id="lab_adc_GTNSalesAdjustment_documentation_en-US" xlink:label="lab_adc_GTNSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustment" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GTNSalesAdjustment" xlink:to="lab_adc_GTNSalesAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember_20374f1a-c930-4850-b1d5-3c4aa0a9c8ef_terseLabel_en-US" xlink:label="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of the principal amount of convertible loans into the Company&#8217;s common shares</link:label>
    <link:label id="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember_label_en-US" xlink:label="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans, Contingently Issuable Shares [Member]</link:label>
    <link:label id="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember_documentation_en-US" xlink:label="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans, Contingently Issuable Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansContingentlyIssuableSharesMember" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansContingentlyIssuableSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConvertibleLoansContingentlyIssuableSharesMember" xlink:to="lab_adc_ConvertibleLoansContingentlyIssuableSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_fafce724-88f5-441c-82e6-590403f287d0_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease obligations</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_65966a59-681c-4bf2-be7b-c27559fad3d9_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_VestingPeriodAxis_82bceeef-9cc8-4111-b2cd-afe3dfac3331_terseLabel_en-US" xlink:label="lab_adc_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_adc_VestingPeriodAxis_label_en-US" xlink:label="lab_adc_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Axis]</link:label>
    <link:label id="lab_adc_VestingPeriodAxis_documentation_en-US" xlink:label="lab_adc_VestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodAxis" xlink:href="adc-20220930.xsd#adc_VestingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_VestingPeriodAxis" xlink:to="lab_adc_VestingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_099129dc-2e00-45d6-aedc-8da3ecfdc280_terseLabel_en-US" xlink:label="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Research And Development Tax Credits</link:label>
    <link:label id="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_label_en-US" xlink:label="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Research And Development Tax Credits</link:label>
    <link:label id="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_documentation_en-US" xlink:label="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Effect Of Research And Development Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TaxEffectOfResearchAndDevelopmentTaxCredits" xlink:href="adc-20220930.xsd#adc_TaxEffectOfResearchAndDevelopmentTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TaxEffectOfResearchAndDevelopmentTaxCredits" xlink:to="lab_adc_TaxEffectOfResearchAndDevelopmentTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_3fa8507f-1643-4c86-b2c1-02c7706e3396_terseLabel_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_label_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Axis]</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_documentation_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" xlink:to="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_d0642357-3174-4197-afd1-e31c23fe383c_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, long-term</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_960abd59-7a6d-4667-b016-6dbc42738548_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_000856d7-0de3-480b-aef0-6dd692bc7951_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from reversal of inventory impairment charges</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" xlink:to="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_296e8cdd-705b-4bc0-9409-501e833f7f48_negatedTerseLabel_en-US" xlink:label="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid under royalty financing transaction</link:label>
    <link:label id="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_label_en-US" xlink:label="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made Under Royalty Financing Transactions</link:label>
    <link:label id="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_documentation_en-US" xlink:label="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Made Under Royalty Financing Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentsMadeUnderRoyaltyFinancingTransactions" xlink:href="adc-20220930.xsd#adc_PaymentsMadeUnderRoyaltyFinancingTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PaymentsMadeUnderRoyaltyFinancingTransactions" xlink:to="lab_adc_PaymentsMadeUnderRoyaltyFinancingTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_bcfb1965-3388-42b9-91b2-8163cda904ab_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans, short-term</link:label>
    <link:label id="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_label_en-US" xlink:label="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowings and current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="lab_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ImpliedBondYieldMember_1a814ac4-abac-4125-ad89-c2f0bb908b3d_terseLabel_en-US" xlink:label="lab_adc_ImpliedBondYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implied Bond Yield [Member]</link:label>
    <link:label id="lab_adc_ImpliedBondYieldMember_label_en-US" xlink:label="lab_adc_ImpliedBondYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implied Bond Yield [Member]</link:label>
    <link:label id="lab_adc_ImpliedBondYieldMember_documentation_en-US" xlink:label="lab_adc_ImpliedBondYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implied Bond Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ImpliedBondYieldMember" xlink:href="adc-20220930.xsd#adc_ImpliedBondYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ImpliedBondYieldMember" xlink:to="lab_adc_ImpliedBondYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_ced6dccb-6e10-45e6-9d73-54bfcaaf07f0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_86a37f87-788c-43bc-8837-606dd54b7551_terseLabel_en-US" xlink:label="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense from share-based payment transactions with employees</link:label>
    <link:label id="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_label_en-US" xlink:label="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions</link:label>
    <link:label id="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_documentation_en-US" xlink:label="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" xlink:to="lab_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OtherIncomeExpenseAbstract_fdf2dc49-ac58-40b1-8e3b-6f23b33c9dbb_terseLabel_en-US" xlink:label="lab_adc_OtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_adc_OtherIncomeExpenseAbstract_label_en-US" xlink:label="lab_adc_OtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense) [Abstract]</link:label>
    <link:label id="lab_adc_OtherIncomeExpenseAbstract_documentation_en-US" xlink:label="lab_adc_OtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherIncomeExpenseAbstract" xlink:href="adc-20220930.xsd#adc_OtherIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OtherIncomeExpenseAbstract" xlink:to="lab_adc_OtherIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_bc61a32c-3b40-4564-81a7-57b7a8b94893_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and other short-term employee costs</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingPeriodDomain_2fb8019c-9148-4be0-a9a5-d7656b5b3549_terseLabel_en-US" xlink:label="lab_adc_BorrowingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Period [Domain]</link:label>
    <link:label id="lab_adc_BorrowingPeriodDomain_label_en-US" xlink:label="lab_adc_BorrowingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Period [Domain]</link:label>
    <link:label id="lab_adc_BorrowingPeriodDomain_documentation_en-US" xlink:label="lab_adc_BorrowingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodDomain" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingPeriodDomain" xlink:to="lab_adc_BorrowingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_586745cc-ea9d-445b-adcd-f057f11fd335_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RevenueFromContractsWithCustomersAbstract_label_en-US" xlink:label="lab_adc_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers [Abstract]</link:label>
    <link:label id="lab_adc_RevenueFromContractsWithCustomersAbstract_documentation_en-US" xlink:label="lab_adc_RevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RevenueFromContractsWithCustomersAbstract" xlink:href="adc-20220930.xsd#adc_RevenueFromContractsWithCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract" xlink:to="lab_adc_RevenueFromContractsWithCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_A2019EquityIncentivePlanMember_976c4991-199f-4564-ad4b-fcd1be2b905a_terseLabel_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_adc_A2019EquityIncentivePlanMember_label_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_adc_A2019EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanMember" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_A2019EquityIncentivePlanMember" xlink:to="lab_adc_A2019EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_c00d55ba-5fdd-4707-bb10-87ff73169926_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_26fb2d3d-4da0-42ec-8557-0546ea6a6b3d_terseLabel_en-US" xlink:label="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_label_en-US" xlink:label="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:label id="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_documentation_en-US" xlink:label="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:href="adc-20220930.xsd#adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:to="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_b3b01d77-b4fe-4c25-b3a6-9c8179b463c3_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate risk</link:label>
    <link:label id="lab_ifrs-full_InterestRateRiskMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateRiskMember" xlink:to="lab_ifrs-full_InterestRateRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_aca55d78-3203-44c8-ab7a-e8384d7380ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedIncomeStatementsCaptionsLineItems_164acdc5-62d0-4b0a-8016-ed1715540cd9_terseLabel_en-US" xlink:label="lab_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedIncomeStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementDomain_5d0cf38f-a427-4ee2-838c-081411a31146_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement [Domain]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementDomain_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement [Domain]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementDomain_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementDomain" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain" xlink:to="lab_adc_RoyaltyPurchaseAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConvertibleLoansMember_993993a3-408a-4308-afc1-faaff8a10147_terseLabel_en-US" xlink:label="lab_adc_ConvertibleLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans</link:label>
    <link:label id="lab_adc_ConvertibleLoansMember_label_en-US" xlink:label="lab_adc_ConvertibleLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans [Member]</link:label>
    <link:label id="lab_adc_ConvertibleLoansMember_documentation_en-US" xlink:label="lab_adc_ConvertibleLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansMember" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConvertibleLoansMember" xlink:to="lab_adc_ConvertibleLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d50746f5-110d-41e6-adb8-0917de75d41a_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation differences</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_04d100ed-f698-44d7-8a6a-1c2af061afbb_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_382af29a-2201-4936-9cfd-97135472e1e5_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsConversionPeriodAxis_a132e3a6-4a2b-4b43-9dcd-5f107bb7caf0_terseLabel_en-US" xlink:label="lab_adc_BorrowingsConversionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Conversion Period [Axis]</link:label>
    <link:label id="lab_adc_BorrowingsConversionPeriodAxis_label_en-US" xlink:label="lab_adc_BorrowingsConversionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Conversion Period [Axis]</link:label>
    <link:label id="lab_adc_BorrowingsConversionPeriodAxis_documentation_en-US" xlink:label="lab_adc_BorrowingsConversionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Conversion Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodAxis" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsConversionPeriodAxis" xlink:to="lab_adc_BorrowingsConversionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_2d4d66f8-2a6a-4821-8e2f-93223c24d483_terseLabel_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:label id="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions_label_en-US" xlink:label="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts receivable, related party transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:to="lab_ifrs-full_AmountsReceivableRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GTNSalesAdjustmentCreditsAndPayments_ec2b986d-2c10-4e70-9e7c-1b371d74a337_terseLabel_en-US" xlink:label="lab_adc_GTNSalesAdjustmentCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Credits And Payments</link:label>
    <link:label id="lab_adc_GTNSalesAdjustmentCreditsAndPayments_label_en-US" xlink:label="lab_adc_GTNSalesAdjustmentCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Credits And Payments</link:label>
    <link:label id="lab_adc_GTNSalesAdjustmentCreditsAndPayments_documentation_en-US" xlink:label="lab_adc_GTNSalesAdjustmentCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Credits And Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustmentCreditsAndPayments" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustmentCreditsAndPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GTNSalesAdjustmentCreditsAndPayments" xlink:to="lab_adc_GTNSalesAdjustmentCreditsAndPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c71d66ac-3881-49b2-a478-55e1aa8bf1d3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SaleOfStockAxis_c45afb6d-ecd5-4f71-a36c-b24aa0a099b8_terseLabel_en-US" xlink:label="lab_adc_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_adc_SaleOfStockAxis_label_en-US" xlink:label="lab_adc_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_adc_SaleOfStockAxis_documentation_en-US" xlink:label="lab_adc_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SaleOfStockAxis" xlink:to="lab_adc_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_4b946304-f3e7-4bb5-ae11-2660f1ceab5a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow (including interest)</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_41d248d0-758b-4b3b-8ed5-cd0537734f87_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of valuation inputs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems_beb8a0ae-eb1e-4b25-93b4-32b09aafb746_terseLabel_en-US" xlink:label="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statement of Financial Position [Line Items]</link:label>
    <link:label id="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems_label_en-US" xlink:label="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statement of Financial Position [Line Items]</link:label>
    <link:label id="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems_documentation_en-US" xlink:label="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statement of Financial Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems" xlink:href="adc-20220930.xsd#adc_ConsolidatedStatementOfFinancialPositionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems" xlink:to="lab_adc_ConsolidatedStatementOfFinancialPositionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_96e53d40-19ec-4772-8681-d2c7996d7020_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_48a0c50e-fce0-4aac-b635-567080c0390a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_4166f3a1-86c5-4683-b94b-b4fad4c0535a_terseLabel_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred gain of joint venture</link:label>
    <link:label id="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_label_en-US" xlink:label="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities incurred in relation to interests in joint ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:to="lab_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_4e616c5c-5c91-42d2-9ec9-d441afde7417_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of exchange differences on translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_23b52eb7-180d-48c4-bcfa-a9dbdf013eac_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total items that may be reclassified to profit and loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InitialPublicOfferingMember_e6f3ee98-4704-4614-b7b8-aac90c128b7e_terseLabel_en-US" xlink:label="lab_adc_InitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_adc_InitialPublicOfferingMember_label_en-US" xlink:label="lab_adc_InitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Member]</link:label>
    <link:label id="lab_adc_InitialPublicOfferingMember_documentation_en-US" xlink:label="lab_adc_InitialPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InitialPublicOfferingMember" xlink:href="adc-20220930.xsd#adc_InitialPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InitialPublicOfferingMember" xlink:to="lab_adc_InitialPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesExplanatory_29aa68a3-4734-49ef-b4b9-7ee69e863678_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint ventures [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_8c18bd89-a4d1-4d5d-b807-455a9fb161d7_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, short-term</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_1bfad6e9-8b10-4a40-8d5e-8a9404b8aaa5_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PensionObligationDiscountRate_b5ebf04e-b624-4068-a02f-ef30f6d2829e_terseLabel_en-US" xlink:label="lab_adc_PensionObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Obligation, Discount Rate</link:label>
    <link:label id="lab_adc_PensionObligationDiscountRate_label_en-US" xlink:label="lab_adc_PensionObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Obligation, Discount Rate</link:label>
    <link:label id="lab_adc_PensionObligationDiscountRate_documentation_en-US" xlink:label="lab_adc_PensionObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PensionObligationDiscountRate" xlink:href="adc-20220930.xsd#adc_PensionObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PensionObligationDiscountRate" xlink:to="lab_adc_PensionObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_8bb589fa-0f0b-4c63-812d-a24aea87a0e6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_15fbaabc-089f-4d2e-8b03-fe619cab558e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_JointVenturesAxis_3ca0d483-421e-4ace-b40a-fab479917031_terseLabel_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:label id="lab_ifrs-full_JointVenturesAxis_label_en-US" xlink:label="lab_ifrs-full_JointVenturesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint ventures [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_JointVenturesAxis" xlink:to="lab_ifrs-full_JointVenturesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_c0efb324-5ac3-4086-afc2-03d6815971dd_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_9e727913-5c52-4b26-a086-a02eda41db75_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average strike price in USD per share, Exercised (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_b2a81aae-7c9f-407b-abc7-111ab75e414c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Equity Instruments Outstanding</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_f2421ece-ca13-404d-9df1-b3c2160ea720_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_050ee4fb-d2f2-4dc9-bcf9-c751292038cb_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average strike price, vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:href="adc-20220930.xsd#adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:to="lab_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OtherNonOperatingIncomeExpense_57914c24-7a34-46b6-93a9-daffc1b8cad1_totalLabel_en-US" xlink:label="lab_adc_OtherNonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income</link:label>
    <link:label id="lab_adc_OtherNonOperatingIncomeExpense_label_en-US" xlink:label="lab_adc_OtherNonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Operating Income (Expense)</link:label>
    <link:label id="lab_adc_OtherNonOperatingIncomeExpense_documentation_en-US" xlink:label="lab_adc_OtherNonOperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Operating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncomeExpense" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OtherNonOperatingIncomeExpense" xlink:to="lab_adc_OtherNonOperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_407513dd-0d1e-4780-9e81-fee1516de750_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility_d8f4de03-895a-4018-a12a-6be23c57c29c_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Additional Proceeds Eligibility</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Additional Proceeds Eligibility</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Additional Proceeds Eligibility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAdditionalProceedsEligibility" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAdditionalProceedsEligibility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAdditionalProceedsEligibility" xlink:to="lab_adc_RoyaltyPurchaseAdditionalProceedsEligibility" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3970f608-ce31-436c-bda7-4a9633011572_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_83416a7c-3804-4477-ba9e-62176f2f4f4a_terseLabel_en-US" xlink:label="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Acquire An Antibody, ZYNLONTA</link:label>
    <link:label id="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_label_en-US" xlink:label="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Acquire An Antibody, ZYNLONTA [Member]</link:label>
    <link:label id="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_documentation_en-US" xlink:label="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Acquire An Antibody, ZYNLONTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToAcquireAnAntibodyZYNLONTAMember" xlink:href="adc-20220930.xsd#adc_LicenseToAcquireAnAntibodyZYNLONTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseToAcquireAnAntibodyZYNLONTAMember" xlink:to="lab_adc_LicenseToAcquireAnAntibodyZYNLONTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinishedGoods_c3ccd2d4-42ff-4d86-aed2-57faee26c626_terseLabel_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finished goods</link:label>
    <link:label id="lab_ifrs-full_FinishedGoods_label_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finished goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicensesIndefiniteLivedMember_89d8071d-ba0e-4bc6-94c0-d60432e27b19_terseLabel_en-US" xlink:label="lab_adc_LicensesIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_adc_LicensesIndefiniteLivedMember_label_en-US" xlink:label="lab_adc_LicensesIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses, Indefinite-Lived [Member]</link:label>
    <link:label id="lab_adc_LicensesIndefiniteLivedMember_documentation_en-US" xlink:label="lab_adc_LicensesIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses, Indefinite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensesIndefiniteLivedMember" xlink:href="adc-20220930.xsd#adc_LicensesIndefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicensesIndefiniteLivedMember" xlink:to="lab_adc_LicensesIndefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncomeStatementLocationDomain_21655d79-52df-4f15-834b-2153a96616d5_terseLabel_en-US" xlink:label="lab_adc_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Member]</link:label>
    <link:label id="lab_adc_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_adc_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_adc_IncomeStatementLocationDomain_documentation_en-US" xlink:label="lab_adc_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationDomain" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncomeStatementLocationDomain" xlink:to="lab_adc_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_4c2a3ec7-6d74-4a7a-a227-823a793f0c29_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FirstInvestmentAmountMember_c5af5759-7daa-436b-bac3-f452f2f23798_terseLabel_en-US" xlink:label="lab_adc_FirstInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Investment Amount</link:label>
    <link:label id="lab_adc_FirstInvestmentAmountMember_label_en-US" xlink:label="lab_adc_FirstInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Investment Amount [Member]</link:label>
    <link:label id="lab_adc_FirstInvestmentAmountMember_documentation_en-US" xlink:label="lab_adc_FirstInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Investment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FirstInvestmentAmountMember" xlink:href="adc-20220930.xsd#adc_FirstInvestmentAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FirstInvestmentAmountMember" xlink:to="lab_adc_FirstInvestmentAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_f50aee1c-17be-4ad0-a0e8-3922abcdb06f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_0f0eb945-870e-49a4-8c98-3e09b1ab8d00_terseLabel_en-US" xlink:label="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea)</link:label>
    <link:label id="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_label_en-US" xlink:label="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea) [Member]</link:label>
    <link:label id="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_documentation_en-US" xlink:label="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" xlink:href="adc-20220930.xsd#adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" xlink:to="lab_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_b6f3aa86-08d9-4b65-be92-9af2d29a8d55_terseLabel_en-US" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss</link:label>
    <link:label id="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of impairment loss recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_b12f7aff-9b1a-4f10-a227-1eef17ef9f71_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature [Table]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature [Table]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_4f71d903-c190-4ae6-bd84-b1fb4056ae1b_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total transactions with owners</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through transactions with owners, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_f738dabf-3094-4254-81ff-538328c62b60_terseLabel_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_label_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_documentation_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" xlink:to="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_f39ad405-47aa-41f8-90fe-b73d1bdc0bff_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_b4156e60-11d9-4a6d-a75c-ff2d9df52cc3_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales_85c512cc-16bb-42c1-9f6e-3bd679c517b1_terseLabel_en-US" xlink:label="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Provision, Prior Period Sales</link:label>
    <link:label id="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales_label_en-US" xlink:label="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Provision, Prior Period Sales</link:label>
    <link:label id="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales_documentation_en-US" xlink:label="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Provision, Prior Period Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustmentProvisionPriorPeriodSales" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustmentProvisionPriorPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GTNSalesAdjustmentProvisionPriorPeriodSales" xlink:to="lab_adc_GTNSalesAdjustmentProvisionPriorPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_c9bb961b-a25c-4017-910f-75be07973a24_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GainsLossOnChangeInFairValueWarrants_08c83c0d-e4cd-457d-8a56-a19fa51351c5_terseLabel_en-US" xlink:label="lab_adc_GainsLossOnChangeInFairValueWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield warrant obligation, change in fair value income</link:label>
    <link:label id="lab_adc_GainsLossOnChangeInFairValueWarrants_label_en-US" xlink:label="lab_adc_GainsLossOnChangeInFairValueWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Loss) On Change In Fair Value, Warrants</link:label>
    <link:label id="lab_adc_GainsLossOnChangeInFairValueWarrants_documentation_en-US" xlink:label="lab_adc_GainsLossOnChangeInFairValueWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Loss) On Change In Fair Value, Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnChangeInFairValueWarrants" xlink:href="adc-20220930.xsd#adc_GainsLossOnChangeInFairValueWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GainsLossOnChangeInFairValueWarrants" xlink:to="lab_adc_GainsLossOnChangeInFairValueWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedIncomeStatementTable_c95a4495-b690-4ccd-82e9-787528e9c0e5_terseLabel_en-US" xlink:label="lab_srt_CondensedIncomeStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedIncomeStatementTable_label_en-US" xlink:label="lab_srt_CondensedIncomeStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedIncomeStatementTable" xlink:to="lab_srt_CondensedIncomeStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingPeriodAxis_aea027a2-d971-4f1d-908d-7ff6d0478071_terseLabel_en-US" xlink:label="lab_adc_BorrowingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Period [Axis]</link:label>
    <link:label id="lab_adc_BorrowingPeriodAxis_label_en-US" xlink:label="lab_adc_BorrowingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Period [Axis]</link:label>
    <link:label id="lab_adc_BorrowingPeriodAxis_documentation_en-US" xlink:label="lab_adc_BorrowingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodAxis" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingPeriodAxis" xlink:to="lab_adc_BorrowingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ManufacturingOfAntibodiesMember_1c4f660a-d381-4d78-afa2-10a351e757d1_terseLabel_en-US" xlink:label="lab_adc_ManufacturingOfAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Of Antibodies</link:label>
    <link:label id="lab_adc_ManufacturingOfAntibodiesMember_label_en-US" xlink:label="lab_adc_ManufacturingOfAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Of Antibodies [Member]</link:label>
    <link:label id="lab_adc_ManufacturingOfAntibodiesMember_documentation_en-US" xlink:label="lab_adc_ManufacturingOfAntibodiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Of Antibodies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ManufacturingOfAntibodiesMember" xlink:href="adc-20220930.xsd#adc_ManufacturingOfAntibodiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ManufacturingOfAntibodiesMember" xlink:to="lab_adc_ManufacturingOfAntibodiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_fe892b66-0e65-44eb-9735-56c684b979f7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key Management Compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_c9599c82-aeb2-4580-8e2f-354b0171bbaf_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_85b50b7a-6fa6-4275-a3ac-e24e69935c4b_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_25f7cc4c-d6ff-41f7-8e6f-9694c0205e64_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Owners of the parent</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_3972400a-9eb3-4864-86e5-55a0290a336b_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining life, vested and exercisable</link:label>
    <link:label id="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_label_en-US" xlink:label="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Outstanding Share Options</link:label>
    <link:label id="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_documentation_en-US" xlink:label="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Outstanding Share Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:href="adc-20220930.xsd#adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:to="lab_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_38c15582-4c1b-4aa4-9743-391856a52242_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesAuthorised" xlink:to="lab_ifrs-full_NumberOfSharesAuthorised" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AfterFirstFiveYearsMember_8a12d944-f3a2-4395-8fba-04dbb1d5234f_terseLabel_en-US" xlink:label="lab_adc_AfterFirstFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After First Five Years</link:label>
    <link:label id="lab_adc_AfterFirstFiveYearsMember_label_en-US" xlink:label="lab_adc_AfterFirstFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After First Five Years [Member]</link:label>
    <link:label id="lab_adc_AfterFirstFiveYearsMember_documentation_en-US" xlink:label="lab_adc_AfterFirstFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After First Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AfterFirstFiveYearsMember" xlink:href="adc-20220930.xsd#adc_AfterFirstFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AfterFirstFiveYearsMember" xlink:to="lab_adc_AfterFirstFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExpectedVolatilityMember_3ea0f894-4b9e-4115-8b22-a4bc727f455e_terseLabel_en-US" xlink:label="lab_adc_ExpectedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility</link:label>
    <link:label id="lab_adc_ExpectedVolatilityMember_label_en-US" xlink:label="lab_adc_ExpectedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility [Member]</link:label>
    <link:label id="lab_adc_ExpectedVolatilityMember_documentation_en-US" xlink:label="lab_adc_ExpectedVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExpectedVolatilityMember" xlink:to="lab_adc_ExpectedVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_5286a5d3-33df-4273-bbf5-33f373f2f4ac_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_230aa7fa-a9a4-4976-b5a7-0223b5ac09cf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_d2ae0e6c-a0a3-4563-8d26-f8b8b1c7f951_terseLabel_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_label_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Member]</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_documentation_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" xlink:to="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConsolidatedStatementOfFinancialPositionTable_69ef3aae-b184-4f3b-806e-682cf78134a7_terseLabel_en-US" xlink:label="lab_adc_ConsolidatedStatementOfFinancialPositionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statement of Financial Position [Table]</link:label>
    <link:label id="lab_adc_ConsolidatedStatementOfFinancialPositionTable_label_en-US" xlink:label="lab_adc_ConsolidatedStatementOfFinancialPositionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statement of Financial Position [Table]</link:label>
    <link:label id="lab_adc_ConsolidatedStatementOfFinancialPositionTable_documentation_en-US" xlink:label="lab_adc_ConsolidatedStatementOfFinancialPositionTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statement of Financial Position [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConsolidatedStatementOfFinancialPositionTable" xlink:href="adc-20220930.xsd#adc_ConsolidatedStatementOfFinancialPositionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionTable" xlink:to="lab_adc_ConsolidatedStatementOfFinancialPositionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeferredRoyaltyObligationTextBlock_cc13eb62-bcc6-4e11-bf09-d75aa5bc21e4_terseLabel_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalty obligation</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligationTextBlock_label_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation [Text Block]</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligationTextBlock_documentation_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationTextBlock" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeferredRoyaltyObligationTextBlock" xlink:to="lab_adc_DeferredRoyaltyObligationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c4fe3862-5e09-4e20-b009-36034005309b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3058d878-a461-4011-91db-fbd6b2bcf2e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_d510316e-6a13-4f7a-a740-c8b226341ee5_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_28b1bb76-ba70-41d6-8869-933a419884a4_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, High-Single-Digit Percentage Rate</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, High-Single-Digit Percentage Rate</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, High-Single-Digit Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" xlink:to="lab_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SpecialRetentionAwardMember_47c27e4a-7cd9-469b-93b3-a9a8153dc4de_terseLabel_en-US" xlink:label="lab_adc_SpecialRetentionAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Retention Award</link:label>
    <link:label id="lab_adc_SpecialRetentionAwardMember_label_en-US" xlink:label="lab_adc_SpecialRetentionAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Retention Award [Member]</link:label>
    <link:label id="lab_adc_SpecialRetentionAwardMember_documentation_en-US" xlink:label="lab_adc_SpecialRetentionAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Retention Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SpecialRetentionAwardMember" xlink:href="adc-20220930.xsd#adc_SpecialRetentionAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SpecialRetentionAwardMember" xlink:to="lab_adc_SpecialRetentionAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_c2ab6356-2e8f-4630-86b0-41bd98594776_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax payable</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilitiesCurrent_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax liabilities, current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="lab_ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_4c393263-a49c-401c-867c-3ca53151b2ca_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_d08ddd36-20f3-49d5-8895-afc305e21163_terseLabel_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Transferred To Participants</link:label>
    <link:label id="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_label_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Transferred To Participants</link:label>
    <link:label id="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_documentation_en-US" xlink:label="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Transferred To Participants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementSharesTransferredToParticipants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" xlink:to="lab_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_56229f76-21ec-4399-a0fc-e164fe79439f_terseLabel_en-US" xlink:label="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2)</link:label>
    <link:label id="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_label_en-US" xlink:label="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2) [Member]</link:label>
    <link:label id="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_documentation_en-US" xlink:label="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" xlink:href="adc-20220930.xsd#adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" xlink:to="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_cc34870a-f387-48c6-b23c-22a869cc80a0_terseLabel_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche One</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_label_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche One [Member]</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_documentation_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" xlink:to="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeferredFinancingCostsMember_24c78b42-b6a7-44b4-b5fa-69d598e58129_terseLabel_en-US" xlink:label="lab_adc_DeferredFinancingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_adc_DeferredFinancingCostsMember_label_en-US" xlink:label="lab_adc_DeferredFinancingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs [Member]</link:label>
    <link:label id="lab_adc_DeferredFinancingCostsMember_documentation_en-US" xlink:label="lab_adc_DeferredFinancingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredFinancingCostsMember" xlink:href="adc-20220930.xsd#adc_DeferredFinancingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeferredFinancingCostsMember" xlink:to="lab_adc_DeferredFinancingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_1f972761-b377-4b41-8d3d-5609c6189504_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeferredRoyaltyObligationAbstract_label_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation [Abstract]</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligationAbstract_documentation_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationAbstract" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeferredRoyaltyObligationAbstract" xlink:to="lab_adc_DeferredRoyaltyObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementAxis_0134c3ac-7d8a-4ec9-bd6a-2933e0931bbe_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement [Axis]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementAxis_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement [Axis]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementAxis_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementAxis" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementAxis" xlink:to="lab_adc_RoyaltyPurchaseAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e84cc9cc-b9fd-4366-805b-f2bbc2cd06bd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember_54e138f5-cd6b-4020-9b86-a719e0ed1418_terseLabel_en-US" xlink:label="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of The United States And Europe</link:label>
    <link:label id="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember_label_en-US" xlink:label="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of The United States And Europe [Member]</link:label>
    <link:label id="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember_documentation_en-US" xlink:label="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of The United States And Europe</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OutsideOfTheUnitedStatesAndEuropeMember" xlink:href="adc-20220930.xsd#adc_OutsideOfTheUnitedStatesAndEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OutsideOfTheUnitedStatesAndEuropeMember" xlink:to="lab_adc_OutsideOfTheUnitedStatesAndEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_8ed41ca1-196d-4381-83d2-a84654533b98_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NumberOfBusinessSegments_dec18942-30d1-47ac-90b3-775f4b92e80b_terseLabel_en-US" xlink:label="lab_adc_NumberOfBusinessSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_adc_NumberOfBusinessSegments_label_en-US" xlink:label="lab_adc_NumberOfBusinessSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Segments</link:label>
    <link:label id="lab_adc_NumberOfBusinessSegments_documentation_en-US" xlink:label="lab_adc_NumberOfBusinessSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfBusinessSegments" xlink:href="adc-20220930.xsd#adc_NumberOfBusinessSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NumberOfBusinessSegments" xlink:to="lab_adc_NumberOfBusinessSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ResidualLoanMember_ceb8c1c1-5a30-4dbb-9a28-34c02fab45fe_terseLabel_en-US" xlink:label="lab_adc_ResidualLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residual Loan</link:label>
    <link:label id="lab_adc_ResidualLoanMember_label_en-US" xlink:label="lab_adc_ResidualLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residual Loan [Member]</link:label>
    <link:label id="lab_adc_ResidualLoanMember_documentation_en-US" xlink:label="lab_adc_ResidualLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residual Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ResidualLoanMember" xlink:to="lab_adc_ResidualLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_978a9efb-47cc-4074-bc65-1180e1294b2a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_65bc596a-7d52-41d8-bd70-7977765e7e80_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_4eb5948e-b5f7-4a13-8fca-b1457ec942c8_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SuppliesProvidedRelatedPartyTransactions_fb3a1349-2f9b-4a16-a187-22ecee9505ef_terseLabel_en-US" xlink:label="lab_adc_SuppliesProvidedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Provided, Related Party Transactions</link:label>
    <link:label id="lab_adc_SuppliesProvidedRelatedPartyTransactions_label_en-US" xlink:label="lab_adc_SuppliesProvidedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Provided, Related Party Transactions</link:label>
    <link:label id="lab_adc_SuppliesProvidedRelatedPartyTransactions_documentation_en-US" xlink:label="lab_adc_SuppliesProvidedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Provided, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SuppliesProvidedRelatedPartyTransactions" xlink:href="adc-20220930.xsd#adc_SuppliesProvidedRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SuppliesProvidedRelatedPartyTransactions" xlink:to="lab_adc_SuppliesProvidedRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsTrancheOnePriceOneMember_31f48e2a-49e7-4621-8916-a666d592eb40_terseLabel_en-US" xlink:label="lab_adc_WarrantsTrancheOnePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One, Price One</link:label>
    <link:label id="lab_adc_WarrantsTrancheOnePriceOneMember_label_en-US" xlink:label="lab_adc_WarrantsTrancheOnePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One, Price One [Member]</link:label>
    <link:label id="lab_adc_WarrantsTrancheOnePriceOneMember_documentation_en-US" xlink:label="lab_adc_WarrantsTrancheOnePriceOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche One, Price One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsTrancheOnePriceOneMember" xlink:to="lab_adc_WarrantsTrancheOnePriceOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember_21bfd882-b4a6-4f4a-b59f-e7c45e8ec26d_terseLabel_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement with Deerfield Partners, L.P.</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember_label_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement with Deerfield Partners, L.P. [Member]</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember_documentation_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement with Deerfield Partners, L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember" xlink:to="lab_adc_FacilityAgreementWithDeerfieldPartnersLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PaymentTypeDomain_683c39bd-dd78-40cb-8dc2-fe9101924edc_terseLabel_en-US" xlink:label="lab_adc_PaymentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Domain]</link:label>
    <link:label id="lab_adc_PaymentTypeDomain_label_en-US" xlink:label="lab_adc_PaymentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Domain]</link:label>
    <link:label id="lab_adc_PaymentTypeDomain_documentation_en-US" xlink:label="lab_adc_PaymentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeDomain" xlink:href="adc-20220930.xsd#adc_PaymentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PaymentTypeDomain" xlink:to="lab_adc_PaymentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory_79c7d206-00ab-45cd-b645-57536fe976e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial information in join venture</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of summarised financial information of joint venture accounted for using equity method to carrying amount of interest in joint venture [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_677df8a3-2d8f-4b66-a766-0671a5896704_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature [Line Items]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature [Line Items]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_c216ab6c-4ff1-4c6e-a1af-05e23fb03779_terseLabel_en-US" xlink:label="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA</link:label>
    <link:label id="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_label_en-US" xlink:label="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA [Member]</link:label>
    <link:label id="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_documentation_en-US" xlink:label="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" xlink:href="adc-20220930.xsd#adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" xlink:to="lab_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PlanNameDomain_60a76ec4-d0b5-4cc9-9e8b-411e23e8a896_terseLabel_en-US" xlink:label="lab_adc_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_adc_PlanNameDomain_label_en-US" xlink:label="lab_adc_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_adc_PlanNameDomain_documentation_en-US" xlink:label="lab_adc_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameDomain" xlink:href="adc-20220930.xsd#adc_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PlanNameDomain" xlink:to="lab_adc_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_20758336-daf6-4a67-80cd-fa11e9d2de91_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Owners of the parent</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment_bb585d8a-1509-42dd-9a09-b212188b1b72_terseLabel_en-US" xlink:label="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment_label_en-US" xlink:label="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued Expenses And Other Current Liabilities, Sales Adjustment</link:label>
    <link:label id="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment_documentation_en-US" xlink:label="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Accrued Expenses And Other Current Liabilities, Sales Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" xlink:href="adc-20220930.xsd#adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" xlink:to="lab_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_db652ea2-71a7-4bb3-9bcc-3f5d043948ba_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_ba6c97d2-0498-4abd-b92e-746bb0ccfdf6_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for non-monetary items:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToAbstract_c3c46837-1534-446e-ba00-b78dd2921830_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to:</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss), attributable to [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract" xlink:to="lab_ifrs-full_ProfitLossAttributableToAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions_94ce1b45-b974-4c75-b3bd-3acf4fcb8d8d_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of granted share options</link:label>
    <link:label id="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions_label_en-US" xlink:label="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Granted Share Options</link:label>
    <link:label id="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions_documentation_en-US" xlink:label="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Granted Share Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" xlink:href="adc-20220930.xsd#adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" xlink:to="lab_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsConversionPeriodOneMember_dcdf8973-e6ba-4a2d-af76-565d07fa1688_terseLabel_en-US" xlink:label="lab_adc_BorrowingsConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion period one</link:label>
    <link:label id="lab_adc_BorrowingsConversionPeriodOneMember_label_en-US" xlink:label="lab_adc_BorrowingsConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Conversion Period One [Member]</link:label>
    <link:label id="lab_adc_BorrowingsConversionPeriodOneMember_documentation_en-US" xlink:label="lab_adc_BorrowingsConversionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings Conversion Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodOneMember" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsConversionPeriodOneMember" xlink:to="lab_adc_BorrowingsConversionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_70e3168b-a11b-46f3-9b9c-c8c1ee64a61a_terseLabel_en-US" xlink:label="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in defined benefit pension liability</link:label>
    <link:label id="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_label_en-US" xlink:label="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability</link:label>
    <link:label id="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_documentation_en-US" xlink:label="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" xlink:href="adc-20220930.xsd#adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" xlink:to="lab_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_01c2ce6b-e118-4fc9-9e47-55d4a8d1e4c6_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems_5ce56d23-a49d-4d57-8aee-ce6eaab01361_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reserves within equity [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reserves within equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:to="lab_ifrs-full_DisclosureOfReservesWithinEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LoanAgreementMember_eab89898-74b7-430c-bdc6-59a68f40667c_terseLabel_en-US" xlink:label="lab_adc_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_adc_LoanAgreementMember_label_en-US" xlink:label="lab_adc_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement [Member]</link:label>
    <link:label id="lab_adc_LoanAgreementMember_documentation_en-US" xlink:label="lab_adc_LoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LoanAgreementMember" xlink:to="lab_adc_LoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_d471dae1-c702-4d26-af64-4489f75ef102_totalLabel_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets</link:label>
    <link:label id="lab_ifrs-full_NetAssetsLiabilities_label_en-US" xlink:label="lab_ifrs-full_NetAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets (liabilities)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NetAssetsLiabilities" xlink:to="lab_ifrs-full_NetAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_95c77270-334b-4e1f-b21b-87388adce62b_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_da9a9525-b1da-445f-b884-b062f63b1404_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_49c7b626-6d0d-4d9d-8698-951d5805e5f9_terseLabel_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for related parties</link:label>
    <link:label id="lab_ifrs-full_EntitysTotalForRelatedPartiesMember_label_en-US" xlink:label="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="lab_ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_8d7bef91-d189-4f64-af4a-dce108afc35b_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_cf887873-1ec5-4f71-9b26-62d629c601da_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_b04e892a-9f61-4cc0-98f7-eeeae99d88e7_terseLabel_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_label_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</link:label>
    <link:label id="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_documentation_en-US" xlink:label="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:to="lab_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_fb83ca50-92d5-42c1-bd2d-eb79bd32f00d_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_840c48b7-abf7-4d56-b384-663fe57986b4_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity attributable to owners of the parent</link:label>
    <link:label id="lab_ifrs-full_Equity_7ac7ff5c-f814-4f93-936d-18f1d4e40432_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_0feef688-0f19-46b9-83f4-211c095f40d2_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_265f9af0-74c3-4aa6-8b72-7f82c38409a6_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash (used in) provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IssuanceOfShares_211c1d12-c71d-4399-9100-a50c254c4e1a_terseLabel_en-US" xlink:label="lab_adc_IssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares, Deerfield exchange agreement</link:label>
    <link:label id="lab_adc_IssuanceOfShares_label_en-US" xlink:label="lab_adc_IssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Shares</link:label>
    <link:label id="lab_adc_IssuanceOfShares_documentation_en-US" xlink:label="lab_adc_IssuanceOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssuanceOfShares" xlink:href="adc-20220930.xsd#adc_IssuanceOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IssuanceOfShares" xlink:to="lab_adc_IssuanceOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock_e7b5ea46-8c87-47bb-bb18-9d4fd3218571_terseLabel_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates and judgements</link:label>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" xlink:href="adc-20220930.xsd#adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" xlink:to="lab_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity_43dff38e-37ab-44ee-b8b8-158ce5087ee5_terseLabel_en-US" xlink:label="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, maximum borrowing capacity</link:label>
    <link:label id="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity_label_en-US" xlink:label="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Facilities, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Facilities, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity" xlink:to="lab_adc_BorrowingFacilitiesMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_79e68453-c8ec-41fd-883c-003131751d93_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfInterestRatesAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of interest rates [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis" xlink:to="lab_ifrs-full_TypesOfInterestRatesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_6b4a2a5e-eaa8-4c85-b914-b9a99b670075_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_0a51c467-37c9-49d2-a184-16d1d677a510_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsMember_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsMember" xlink:to="lab_ifrs-full_NonadjustingEventsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_c6f2d29b-8c10-4524-a90d-b92c99db158b_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SaleOfStockDomain_c4cb2403-922f-4f2e-add1-fb90fe2e460b_terseLabel_en-US" xlink:label="lab_adc_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_adc_SaleOfStockDomain_label_en-US" xlink:label="lab_adc_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_adc_SaleOfStockDomain_documentation_en-US" xlink:label="lab_adc_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SaleOfStockDomain" xlink:to="lab_adc_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8836e749-0818-42aa-a3e7-84ef4de1835b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_16f7e420-4d73-4c1c-aab0-ec7030cf2662_terseLabel_en-US" xlink:label="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_documentation_en-US" xlink:label="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InventoryAbstract_51ba0c7a-d9d7-403b-b369-432116d74238_terseLabel_en-US" xlink:label="lab_adc_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_adc_InventoryAbstract_label_en-US" xlink:label="lab_adc_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:label id="lab_adc_InventoryAbstract_documentation_en-US" xlink:label="lab_adc_InventoryAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAbstract" xlink:href="adc-20220930.xsd#adc_InventoryAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InventoryAbstract" xlink:to="lab_adc_InventoryAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_249e2da7-155f-4a2b-af72-8d49108482e1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShortTermBorrowings_da5f8a57-5f48-41a1-b317-2262687771f3_terseLabel_en-US" xlink:label="lab_adc_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured term loans, short-term</link:label>
    <link:label id="lab_adc_ShortTermBorrowings_label_en-US" xlink:label="lab_adc_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Borrowings</link:label>
    <link:label id="lab_adc_ShortTermBorrowings_documentation_en-US" xlink:label="lab_adc_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShortTermBorrowings" xlink:href="adc-20220930.xsd#adc_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShortTermBorrowings" xlink:to="lab_adc_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_81913060-362b-49c3-9b7e-5eeb00a837d3_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesTable_e21ea0da-7d62-49e9-af0f-6b9e3bc86e13_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint ventures [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfJointVenturesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfJointVenturesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of joint ventures [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable" xlink:to="lab_ifrs-full_DisclosureOfJointVenturesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_9cba46f2-bd35-43aa-af78-615e131454eb_terseLabel_en-US" xlink:label="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment</link:label>
    <link:label id="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_label_en-US" xlink:label="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment</link:label>
    <link:label id="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_documentation_en-US" xlink:label="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" xlink:to="lab_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeferredRoyaltyObligation_b4fa6063-5552-4aef-9ec2-1bb010ab33a1_terseLabel_en-US" xlink:label="lab_adc_DeferredRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligation_label_en-US" xlink:label="lab_adc_DeferredRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligation_documentation_en-US" xlink:label="lab_adc_DeferredRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligation" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeferredRoyaltyObligation" xlink:to="lab_adc_DeferredRoyaltyObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingConversionPeriodDomain_a170e61e-6017-4288-b9e4-184b0ad3117d_terseLabel_en-US" xlink:label="lab_adc_BorrowingConversionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Conversion Period [Domain]</link:label>
    <link:label id="lab_adc_BorrowingConversionPeriodDomain_label_en-US" xlink:label="lab_adc_BorrowingConversionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Conversion Period [Domain]</link:label>
    <link:label id="lab_adc_BorrowingConversionPeriodDomain_documentation_en-US" xlink:label="lab_adc_BorrowingConversionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing Conversion Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingConversionPeriodDomain" xlink:to="lab_adc_BorrowingConversionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_08fa5586-e5b0-475a-8c6f-b9bd5d9367ba_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss for the period</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_372c9d6f-9655-408b-81e6-69aea4c9367d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss for the period</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_849f3dfd-f912-492f-8a11-d51dcb71bcdc_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AnnualEquityAwardMember_a449ded4-fb1f-4487-a18e-c0107a6d2570_terseLabel_en-US" xlink:label="lab_adc_AnnualEquityAwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Equity Award</link:label>
    <link:label id="lab_adc_AnnualEquityAwardMember_label_en-US" xlink:label="lab_adc_AnnualEquityAwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Equity Award [Member]</link:label>
    <link:label id="lab_adc_AnnualEquityAwardMember_documentation_en-US" xlink:label="lab_adc_AnnualEquityAwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Equity Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AnnualEquityAwardMember" xlink:href="adc-20220930.xsd#adc_AnnualEquityAwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AnnualEquityAwardMember" xlink:to="lab_adc_AnnualEquityAwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_b31ecb97-4a4a-46d5-b15d-0b6b71e0f696_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_2257b7b5-583c-4605-ad22-14a615e845cd_terseLabel_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Modification of lease terms</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_label_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Modification Of Lease Terms, Lease Liabilities</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_documentation_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Modification Of Lease Terms, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" xlink:to="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_c558d1c1-4e31-486a-b568-a6b48312179e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of key inputs used for valuation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_7916ed0c-2718-4beb-8482-c41f9d0555be_terseLabel_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_label_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two [Member]</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_documentation_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" xlink:to="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_8ea11b2f-be19-469f-a2ce-5b9235347dd2_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_label_en-US" xlink:label="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted</link:label>
    <link:label id="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_documentation_en-US" xlink:label="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" xlink:href="adc-20220930.xsd#adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" xlink:to="lab_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicencesMember_ede06c98-c49e-4e23-a222-b8623e97316a_terseLabel_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licences [member]</link:label>
    <link:label id="lab_ifrs-full_LicencesMember_label_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_d0d706b1-fd52-4af2-b704-0da5f13c5343_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments of Assets</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock_968a3e28-5811-4382-b0d0-d34f8ad82903_terseLabel_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Other Income (Expense) Explanatory</link:label>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Other Income (Expense) Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Other Income (Expense) Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" xlink:href="adc-20220930.xsd#adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" xlink:to="lab_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_1c4add63-3e02-4342-ae8b-ddc85213eb73_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related parties</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OperatingSegmentsAbstract_c1c83c2a-3621-4c36-bd94-45e281dd0dd6_terseLabel_en-US" xlink:label="lab_adc_OperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Abstract]</link:label>
    <link:label id="lab_adc_OperatingSegmentsAbstract_label_en-US" xlink:label="lab_adc_OperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Abstract]</link:label>
    <link:label id="lab_adc_OperatingSegmentsAbstract_documentation_en-US" xlink:label="lab_adc_OperatingSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OperatingSegmentsAbstract" xlink:href="adc-20220930.xsd#adc_OperatingSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OperatingSegmentsAbstract" xlink:to="lab_adc_OperatingSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FinancialInstrumentsAbstract_8a6c0ef8-20b9-45e2-af56-f8195a67b228_terseLabel_en-US" xlink:label="lab_adc_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_adc_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_adc_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_adc_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_adc_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FinancialInstrumentsAbstract" xlink:to="lab_adc_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_b818ba1c-ab38-40aa-a31f-33b8fa1e93bc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SecuredOvernightFinancingRateSOFRMember_63ca563f-141c-4e4b-897d-b186017b4cba_terseLabel_en-US" xlink:label="lab_adc_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_adc_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_adc_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_adc_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_adc_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SecuredOvernightFinancingRateSOFRMember" xlink:href="adc-20220930.xsd#adc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_adc_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareSubscriptionAgreementMember_06bd979f-9edf-4068-9de6-3c422293b477_terseLabel_en-US" xlink:label="lab_adc_ShareSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Subscription Agreement</link:label>
    <link:label id="lab_adc_ShareSubscriptionAgreementMember_label_en-US" xlink:label="lab_adc_ShareSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Subscription Agreement [Member]</link:label>
    <link:label id="lab_adc_ShareSubscriptionAgreementMember_documentation_en-US" xlink:label="lab_adc_ShareSubscriptionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Subscription Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareSubscriptionAgreementMember" xlink:href="adc-20220930.xsd#adc_ShareSubscriptionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareSubscriptionAgreementMember" xlink:to="lab_adc_ShareSubscriptionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseAgreementMilestonePayments_a2388562-b397-464d-aba4-33ae4ff80a73_terseLabel_en-US" xlink:label="lab_adc_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:label id="lab_adc_LicenseAgreementMilestonePayments_label_en-US" xlink:label="lab_adc_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:label id="lab_adc_LicenseAgreementMilestonePayments_documentation_en-US" xlink:label="lab_adc_LicenseAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMilestonePayments" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseAgreementMilestonePayments" xlink:to="lab_adc_LicenseAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PlanNameMember_9ade9502-5186-4152-8a44-5fa5b61c7376_terseLabel_en-US" xlink:label="lab_adc_PlanNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_adc_PlanNameMember_label_en-US" xlink:label="lab_adc_PlanNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Member]</link:label>
    <link:label id="lab_adc_PlanNameMember_documentation_en-US" xlink:label="lab_adc_PlanNameMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PlanNameMember" xlink:to="lab_adc_PlanNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_f3067020-0542-4bc9-8aab-4a9103da36c9_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_eda8cb80-fe36-43ca-9cd3-a4acdb3a7bf9_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_9e32798e-4ff4-4b1f-a1f1-94268d360c52_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quantitative information about right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_909f56e6-c47e-4990-9bd4-6fdf6dd14092_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued expenses and other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncentivePlan2014Member_bd8e6482-3769-4831-8506-00f094a56925_terseLabel_en-US" xlink:label="lab_adc_IncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_adc_IncentivePlan2014Member_label_en-US" xlink:label="lab_adc_IncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_adc_IncentivePlan2014Member_documentation_en-US" xlink:label="lab_adc_IncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan 2014</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncentivePlan2014Member" xlink:href="adc-20220930.xsd#adc_IncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncentivePlan2014Member" xlink:to="lab_adc_IncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_24aafe81-4ca4-4933-98ba-838383fb02e4_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LeasesAbstract_label_en-US" xlink:label="lab_adc_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_adc_LeasesAbstract_documentation_en-US" xlink:label="lab_adc_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LeasesAbstract" xlink:to="lab_adc_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2c9239f4-2063-49f8-8f55-f2fe23363bf8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average strike price in USD per share, At beginning of the year (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1ccb7f7c-d989-473b-be4f-53e473872b9e_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average strike price in USD per share, At end of the year (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseRevenueMember_269db1cc-dcd7-43d4-bf00-e1f08f883543_terseLabel_en-US" xlink:label="lab_adc_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_adc_LicenseRevenueMember_label_en-US" xlink:label="lab_adc_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue [Member]</link:label>
    <link:label id="lab_adc_LicenseRevenueMember_documentation_en-US" xlink:label="lab_adc_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseRevenueMember" xlink:href="adc-20220930.xsd#adc_LicenseRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseRevenueMember" xlink:to="lab_adc_LicenseRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_46d3894d-e408-47aa-8007-e7aaf11b19ea_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares outstanding</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock_7dbd4506-8c74-42e2-8651-c10f98d869e2_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_00b23308-c277-4a5e-856e-b953ebe2d9f4_terseLabel_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange difference</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_label_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_documentation_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" xlink:to="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SaleOfStockPricePerShare_93c36f66-e8c4-4c0e-b508-91cb9c65a632_terseLabel_en-US" xlink:label="lab_adc_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Price Per Share</link:label>
    <link:label id="lab_adc_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_adc_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Price Per Share</link:label>
    <link:label id="lab_adc_SaleOfStockPricePerShare_documentation_en-US" xlink:label="lab_adc_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockPricePerShare" xlink:href="adc-20220930.xsd#adc_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SaleOfStockPricePerShare" xlink:to="lab_adc_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LoanAgreementFutureTranchesMember_fa3e18a2-a0b5-4801-92c8-62bfadfbd64e_terseLabel_en-US" xlink:label="lab_adc_LoanAgreementFutureTranchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Tranches</link:label>
    <link:label id="lab_adc_LoanAgreementFutureTranchesMember_label_en-US" xlink:label="lab_adc_LoanAgreementFutureTranchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Tranches [Member]</link:label>
    <link:label id="lab_adc_LoanAgreementFutureTranchesMember_documentation_en-US" xlink:label="lab_adc_LoanAgreementFutureTranchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementFutureTranchesMember" xlink:href="adc-20220930.xsd#adc_LoanAgreementFutureTranchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LoanAgreementFutureTranchesMember" xlink:to="lab_adc_LoanAgreementFutureTranchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_44fbe159-8146-450c-b0ef-8a5a0cd5ec3a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_05151482-ac2b-436f-b56f-256de9ede68c_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:label id="lab_ifrs-full_InterestRateTypesMember_label_en-US" xlink:label="lab_ifrs-full_InterestRateTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate types [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRateTypesMember" xlink:to="lab_ifrs-full_InterestRateTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_fda07d2d-1035-47f7-9f79-390e002f2cd2_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_42b8805a-ac95-412a-ab59-d5948849feed_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_92f2b5d2-5d48-42d7-9d84-084a0d0c73e6_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_07b1dd05-ff16-40d9-bf7f-ac60c61ca990_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_aa807d0c-4b8c-4f66-92d2-87ce789fee15_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_157caeb3-ff14-44f9-9f07-56a33a6cba5a_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OutstandingWarrantsMember_ab56894c-9e9b-442c-bb0a-c9d89f0d33f6_terseLabel_en-US" xlink:label="lab_adc_OutstandingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Warrants</link:label>
    <link:label id="lab_adc_OutstandingWarrantsMember_label_en-US" xlink:label="lab_adc_OutstandingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Warrants [Member]</link:label>
    <link:label id="lab_adc_OutstandingWarrantsMember_documentation_en-US" xlink:label="lab_adc_OutstandingWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OutstandingWarrantsMember" xlink:href="adc-20220930.xsd#adc_OutstandingWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OutstandingWarrantsMember" xlink:to="lab_adc_OutstandingWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_a6e24348-add9-441e-b0e4-eae262f514c7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial risk management</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of financial risk management [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ConversionPeriodTwoMember_1d5f332b-ef87-48b2-a258-5d003886bc81_terseLabel_en-US" xlink:label="lab_adc_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion period two</link:label>
    <link:label id="lab_adc_ConversionPeriodTwoMember_label_en-US" xlink:label="lab_adc_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two [Member]</link:label>
    <link:label id="lab_adc_ConversionPeriodTwoMember_documentation_en-US" xlink:label="lab_adc_ConversionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConversionPeriodTwoMember" xlink:href="adc-20220930.xsd#adc_ConversionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ConversionPeriodTwoMember" xlink:to="lab_adc_ConversionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_ef88f2b3-2e59-45d3-9913-a09a0546cae5_terseLabel_en-US" xlink:label="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Clinical Trial Costs Paid</link:label>
    <link:label id="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_label_en-US" xlink:label="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Clinical Trial Costs Paid</link:label>
    <link:label id="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_documentation_en-US" xlink:label="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percent Of Clinical Trial Costs Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" xlink:href="adc-20220930.xsd#adc_LicenseAgreementPercentOfClinicalTrialCostsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" xlink:to="lab_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsTrancheTwoMember_ce307579-2264-4cf5-a758-2fc7bfe05ed7_terseLabel_en-US" xlink:label="lab_adc_WarrantsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche Two</link:label>
    <link:label id="lab_adc_WarrantsTrancheTwoMember_label_en-US" xlink:label="lab_adc_WarrantsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche Two [Member]</link:label>
    <link:label id="lab_adc_WarrantsTrancheTwoMember_documentation_en-US" xlink:label="lab_adc_WarrantsTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsTrancheTwoMember" xlink:to="lab_adc_WarrantsTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_5020a097-21e2-4c6e-91e2-7baa977d8c85_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_eaa51bc1-1d34-4214-b7b3-571f232c6838_terseLabel_en-US" xlink:label="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, decrease on derivative values</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_label_en-US" xlink:label="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_documentation_en-US" xlink:label="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" xlink:to="lab_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_d6a00a96-ab2a-42a2-8abf-21f3c6aee839_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension costs</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, post-employment benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExercisePriceMember_790d1b3a-5434-4c5e-95a5-ca0902a38d36_terseLabel_en-US" xlink:label="lab_adc_ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_adc_ExercisePriceMember_label_en-US" xlink:label="lab_adc_ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price [Member]</link:label>
    <link:label id="lab_adc_ExercisePriceMember_documentation_en-US" xlink:label="lab_adc_ExercisePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExercisePriceMember" xlink:href="adc-20220930.xsd#adc_ExercisePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExercisePriceMember" xlink:to="lab_adc_ExercisePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_234c8fad-0876-4afb-88a1-2ecb40d6b58a_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RecoveryRateMember_9c159923-1c57-4e7a-b111-33a15d7b7523_terseLabel_en-US" xlink:label="lab_adc_RecoveryRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Rate [Member]</link:label>
    <link:label id="lab_adc_RecoveryRateMember_label_en-US" xlink:label="lab_adc_RecoveryRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Rate [Member]</link:label>
    <link:label id="lab_adc_RecoveryRateMember_documentation_en-US" xlink:label="lab_adc_RecoveryRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RecoveryRateMember" xlink:href="adc-20220930.xsd#adc_RecoveryRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RecoveryRateMember" xlink:to="lab_adc_RecoveryRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_9ec8326b-e7d5-49fb-9d90-54931d8f8ba8_terseLabel_en-US" xlink:label="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of right-of-use assets</link:label>
    <link:label id="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_label_en-US" xlink:label="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation Expense Of Right-Of-Use Assets</link:label>
    <link:label id="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_documentation_en-US" xlink:label="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation Expense Of Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" xlink:href="adc-20220930.xsd#adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" xlink:to="lab_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TrancheFourMember_3790c4ac-f0ee-477b-b45d-acbeab40d0d0_terseLabel_en-US" xlink:label="lab_adc_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four</link:label>
    <link:label id="lab_adc_TrancheFourMember_label_en-US" xlink:label="lab_adc_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four [Member]</link:label>
    <link:label id="lab_adc_TrancheFourMember_documentation_en-US" xlink:label="lab_adc_TrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheFourMember" xlink:href="adc-20220930.xsd#adc_TrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TrancheFourMember" xlink:to="lab_adc_TrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_ec8d28c9-e415-4dc0-836d-0330daa8eb9f_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_bdc4b837-5d0f-4c96-b063-b7a414ceef1b_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Percent, Payment</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Percent, Payment</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Percent, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutPercentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" xlink:to="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BlackScholesValueMember_b281611a-96cc-45bc-9e08-0926f731c25d_terseLabel_en-US" xlink:label="lab_adc_BlackScholesValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Value</link:label>
    <link:label id="lab_adc_BlackScholesValueMember_label_en-US" xlink:label="lab_adc_BlackScholesValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Value [Member]</link:label>
    <link:label id="lab_adc_BlackScholesValueMember_documentation_en-US" xlink:label="lab_adc_BlackScholesValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BlackScholesValueMember" xlink:href="adc-20220930.xsd#adc_BlackScholesValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BlackScholesValueMember" xlink:to="lab_adc_BlackScholesValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory_0b37bd0c-8178-4531-bc1b-4615840b6b75_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of movement in interest in joint venture</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of interests in joint arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AccruedShareBasedCompensation_6cd339f2-8498-4e1c-81a4-6a6be5c517d9_terseLabel_en-US" xlink:label="lab_adc_AccruedShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Share Based Compensation</link:label>
    <link:label id="lab_adc_AccruedShareBasedCompensation_label_en-US" xlink:label="lab_adc_AccruedShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Share Based Compensation</link:label>
    <link:label id="lab_adc_AccruedShareBasedCompensation_documentation_en-US" xlink:label="lab_adc_AccruedShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccruedShareBasedCompensation" xlink:href="adc-20220930.xsd#adc_AccruedShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AccruedShareBasedCompensation" xlink:to="lab_adc_AccruedShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_05082f72-859f-408d-afe0-73589c0ddd2c_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InventoryDomain_1423d465-ef81-4bd7-b466-26084a708f64_terseLabel_en-US" xlink:label="lab_adc_InventoryDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_adc_InventoryDomain_label_en-US" xlink:label="lab_adc_InventoryDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_adc_InventoryDomain_documentation_en-US" xlink:label="lab_adc_InventoryDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InventoryDomain" xlink:to="lab_adc_InventoryDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_80354ba6-5e16-4eee-b90a-dc4edf192697_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Effective Interest Rate</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Effective Interest Rate</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Effective Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementEffectiveInterestRate" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementEffectiveInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementEffectiveInterestRate" xlink:to="lab_adc_RoyaltyPurchaseAgreementEffectiveInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_3b6547aa-f7ac-4868-b6e3-9b90a2c1a1f7_terseLabel_en-US" xlink:label="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards vested and exercisable (in shares)</link:label>
    <link:label id="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:href="adc-20220930.xsd#adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:to="lab_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_e7b725e9-2ff3-4985-bbe3-42a940d0c629_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PaymentForRentDeposits_6271ab05-01cf-4192-a92a-7be63cf1295d_negatedTerseLabel_en-US" xlink:label="lab_adc_PaymentForRentDeposits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for deposits</link:label>
    <link:label id="lab_adc_PaymentForRentDeposits_label_en-US" xlink:label="lab_adc_PaymentForRentDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Rent Deposits</link:label>
    <link:label id="lab_adc_PaymentForRentDeposits_documentation_en-US" xlink:label="lab_adc_PaymentForRentDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Rent Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentForRentDeposits" xlink:href="adc-20220930.xsd#adc_PaymentForRentDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PaymentForRentDeposits" xlink:to="lab_adc_PaymentForRentDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_46031169-e4e8-411b-8fc0-3139cb911d88_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OtherNonOperatingIncome_1c5bded4-081b-4710-b784-d7c549156494_terseLabel_en-US" xlink:label="lab_adc_OtherNonOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating (expense) income</link:label>
    <link:label id="lab_adc_OtherNonOperatingIncome_label_en-US" xlink:label="lab_adc_OtherNonOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Operating Income</link:label>
    <link:label id="lab_adc_OtherNonOperatingIncome_documentation_en-US" xlink:label="lab_adc_OtherNonOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncome" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OtherNonOperatingIncome" xlink:to="lab_adc_OtherNonOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_b5f4f6b8-fb45-4965-a2fa-a0a7b0b10701_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_c8e0dc9f-be2b-4714-84bc-b0a646c756eb_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Percent, Continued Payment</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Percent, Continued Payment</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Buyout Percent, Continued Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" xlink:to="lab_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_98fe2826-0d97-4b16-96ef-be05871bdf44_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_2b761ad2-14a0-43e7-92bc-07b0e3823774_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_fe8f26f3-c175-46bf-95bd-e15ac963a4f4_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in accounts payable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_0c82d488-bfd5-430a-a091-63dcf8a69a3c_negatedTerseLabel_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_label_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_documentation_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" xlink:to="lab_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_c65d70ba-37a4-4be6-b270-af2865a0ffab_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of consolidated entities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of interests in subsidiaries [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_A2022ESPPMember_18bb2fb0-3c2e-4359-b530-eadddb06e2c8_terseLabel_en-US" xlink:label="lab_adc_A2022ESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 ESPP</link:label>
    <link:label id="lab_adc_A2022ESPPMember_label_en-US" xlink:label="lab_adc_A2022ESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 ESPP [Member]</link:label>
    <link:label id="lab_adc_A2022ESPPMember_documentation_en-US" xlink:label="lab_adc_A2022ESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2022ESPPMember" xlink:href="adc-20220930.xsd#adc_A2022ESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_A2022ESPPMember" xlink:to="lab_adc_A2022ESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GeneralAndAdministrativeExpenseMember_14609860-59c4-4742-8378-8f3b3612e178_terseLabel_en-US" xlink:label="lab_adc_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">G&amp;A expense</link:label>
    <link:label id="lab_adc_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_adc_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense [Member]</link:label>
    <link:label id="lab_adc_GeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_adc_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GeneralAndAdministrativeExpenseMember" xlink:href="adc-20220930.xsd#adc_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GeneralAndAdministrativeExpenseMember" xlink:to="lab_adc_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ApplicationApprovalMember_d00e0034-768f-494c-aee9-1709a1458ccf_terseLabel_en-US" xlink:label="lab_adc_ApplicationApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Application Approval</link:label>
    <link:label id="lab_adc_ApplicationApprovalMember_label_en-US" xlink:label="lab_adc_ApplicationApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Application Approval [Member]</link:label>
    <link:label id="lab_adc_ApplicationApprovalMember_documentation_en-US" xlink:label="lab_adc_ApplicationApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Application Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ApplicationApprovalMember" xlink:href="adc-20220930.xsd#adc_ApplicationApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ApplicationApprovalMember" xlink:to="lab_adc_ApplicationApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_CapitalExpendituresIncurredButNotYetPaid_edbe8585-f438-4711-9c0b-eb0b91bccbb9_terseLabel_en-US" xlink:label="lab_adc_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures and intangible asset acquisitions recorded in Accounts payable</link:label>
    <link:label id="lab_adc_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_adc_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures, Incurred But Not Yet Paid</link:label>
    <link:label id="lab_adc_CapitalExpendituresIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_adc_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures, Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CapitalExpendituresIncurredButNotYetPaid" xlink:href="adc-20220930.xsd#adc_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_adc_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTermsDomain_80bc77ac-9b8d-4fff-b4a6-b793f59b1446_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Terms [Domain]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTermsDomain_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Terms [Domain]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTermsDomain_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement Terms [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsDomain" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsDomain" xlink:to="lab_adc_RoyaltyPurchaseAgreementTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareLineItems_4ba2ab7d-f87e-4607-9b15-13626a8a94e9_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [line items]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareLineItems" xlink:to="lab_ifrs-full_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_2ac48257-4859-4959-aae4-e392c400894c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_24908d80-b83f-41c1-b1e7-6cc5b69fe566_terseLabel_en-US" xlink:label="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Facility, Tranche One</link:label>
    <link:label id="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_label_en-US" xlink:label="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:to="lab_adc_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_1df378ec-4872-4f93-849f-8ea3a3688450_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_616e6c11-2dc8-4b34-8b34-5b14594c985f_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_a7ba1ba3-fcfc-4425-8298-367f3af2f717_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of debt instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_207be391-46a5-4d0f-91c0-f7d97137f1a1_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_14b95ecc-cdfe-4b7b-ad8a-66b34a0abada_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_35b643b0-4659-43e1-9231-f5d1de27fb12_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_391e7989-f77f-46e2-a5b1-a773564f64f7_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalties Paid Under Agreement</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalties Paid Under Agreement [Member]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalties Paid Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" xlink:to="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RestrictedShareUnitsRSUMember_5d771f86-67bc-4d66-bb32-ddc72fcb8f6f_terseLabel_en-US" xlink:label="lab_adc_RestrictedShareUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSU)</link:label>
    <link:label id="lab_adc_RestrictedShareUnitsRSUMember_label_en-US" xlink:label="lab_adc_RestrictedShareUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSU) [Member]</link:label>
    <link:label id="lab_adc_RestrictedShareUnitsRSUMember_documentation_en-US" xlink:label="lab_adc_RestrictedShareUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units (RSU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedShareUnitsRSUMember" xlink:href="adc-20220930.xsd#adc_RestrictedShareUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RestrictedShareUnitsRSUMember" xlink:to="lab_adc_RestrictedShareUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_MilestonePaymentMember_1208e31f-b712-4d26-b43a-c5e482c57ceb_terseLabel_en-US" xlink:label="lab_adc_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_adc_MilestonePaymentMember_label_en-US" xlink:label="lab_adc_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Member]</link:label>
    <link:label id="lab_adc_MilestonePaymentMember_documentation_en-US" xlink:label="lab_adc_MilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_MilestonePaymentMember" xlink:href="adc-20220930.xsd#adc_MilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_MilestonePaymentMember" xlink:to="lab_adc_MilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract_ca7f5780-624e-4779-9824-1fd7e190681f_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to:</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_1bfa9457-8f71-41e1-aae7-178cad083f55_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_99a2421a-f39f-42fe-92ca-c0708ac4d9af_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, At beginning of the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_90ba790f-fd61-4380-9281-b04fde9b7f6f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, At end of the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet_b2cfa5e1-da23-49fa-b7cd-c093dc41cf66_terseLabel_en-US" xlink:label="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement, Net</link:label>
    <link:label id="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet_label_en-US" xlink:label="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement, Net</link:label>
    <link:label id="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet_documentation_en-US" xlink:label="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Royalty Purchase Agreement, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromRoyaltyPurchaseAgreementNet" xlink:href="adc-20220930.xsd#adc_ProceedsFromRoyaltyPurchaseAgreementNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ProceedsFromRoyaltyPurchaseAgreementNet" xlink:to="lab_adc_ProceedsFromRoyaltyPurchaseAgreementNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_ccdf1915-2faf-417d-9b0e-e084e623dc0c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in accounts receivable, net</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_b1856486-2db1-43e9-a753-405fdeb3a0fe_terseLabel_en-US" xlink:label="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion Of In-Vivo Efficacy Studies</link:label>
    <link:label id="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_label_en-US" xlink:label="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion Of In-Vivo Efficacy Studies [Member]</link:label>
    <link:label id="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_documentation_en-US" xlink:label="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successful Completion Of In-Vivo Efficacy Studies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" xlink:href="adc-20220930.xsd#adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" xlink:to="lab_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment_c83176fb-b84c-4810-9b20-66cdd1d71171_terseLabel_en-US" xlink:label="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment_label_en-US" xlink:label="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current receivables, Sales Adjustment</link:label>
    <link:label id="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment_documentation_en-US" xlink:label="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current receivables, Sales Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TradeAndOtherCurrentReceivablesSalesAdjustment" xlink:href="adc-20220930.xsd#adc_TradeAndOtherCurrentReceivablesSalesAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TradeAndOtherCurrentReceivablesSalesAdjustment" xlink:to="lab_adc_TradeAndOtherCurrentReceivablesSalesAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IssueOfEquityThroughExchangeAgreement_33a0e592-7f22-4ee4-98a2-6a58a7c2bb61_terseLabel_en-US" xlink:label="lab_adc_IssueOfEquityThroughExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares, Deerfield exchange agreement, net of transaction costs</link:label>
    <link:label id="lab_adc_IssueOfEquityThroughExchangeAgreement_label_en-US" xlink:label="lab_adc_IssueOfEquityThroughExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity Through Exchange Agreement</link:label>
    <link:label id="lab_adc_IssueOfEquityThroughExchangeAgreement_documentation_en-US" xlink:label="lab_adc_IssueOfEquityThroughExchangeAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issue Of Equity Through Exchange Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughExchangeAgreement" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughExchangeAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IssueOfEquityThroughExchangeAgreement" xlink:to="lab_adc_IssueOfEquityThroughExchangeAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ServicesProvidedRelatedPartyTransactions_e5f01bb5-9df5-4744-abd1-dd8a70d12cbd_terseLabel_en-US" xlink:label="lab_adc_ServicesProvidedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services provided to, related party transactions</link:label>
    <link:label id="lab_adc_ServicesProvidedRelatedPartyTransactions_label_en-US" xlink:label="lab_adc_ServicesProvidedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Provided, Related Party Transactions</link:label>
    <link:label id="lab_adc_ServicesProvidedRelatedPartyTransactions_documentation_en-US" xlink:label="lab_adc_ServicesProvidedRelatedPartyTransactions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Provided, Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ServicesProvidedRelatedPartyTransactions" xlink:href="adc-20220930.xsd#adc_ServicesProvidedRelatedPartyTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ServicesProvidedRelatedPartyTransactions" xlink:to="lab_adc_ServicesProvidedRelatedPartyTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NetCarryingAmountMember_144b4044-907c-47f9-9469-20cfae45d956_terseLabel_en-US" xlink:label="lab_adc_NetCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_adc_NetCarryingAmountMember_label_en-US" xlink:label="lab_adc_NetCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount [Member]</link:label>
    <link:label id="lab_adc_NetCarryingAmountMember_documentation_en-US" xlink:label="lab_adc_NetCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NetCarryingAmountMember" xlink:href="adc-20220930.xsd#adc_NetCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NetCarryingAmountMember" xlink:to="lab_adc_NetCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_PurchasersMember_ec8f39b7-5e42-4992-a1ab-d10f3ca65b7f_terseLabel_en-US" xlink:label="lab_adc_PurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasers</link:label>
    <link:label id="lab_adc_PurchasersMember_label_en-US" xlink:label="lab_adc_PurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasers [Member]</link:label>
    <link:label id="lab_adc_PurchasersMember_documentation_en-US" xlink:label="lab_adc_PurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchasers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PurchasersMember" xlink:href="adc-20220930.xsd#adc_PurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_PurchasersMember" xlink:to="lab_adc_PurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExecutiveCompensationMember_510802ca-9efe-4888-aed5-efde23c383f4_terseLabel_en-US" xlink:label="lab_adc_ExecutiveCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Compensation</link:label>
    <link:label id="lab_adc_ExecutiveCompensationMember_label_en-US" xlink:label="lab_adc_ExecutiveCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Compensation [Member]</link:label>
    <link:label id="lab_adc_ExecutiveCompensationMember_documentation_en-US" xlink:label="lab_adc_ExecutiveCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExecutiveCompensationMember" xlink:href="adc-20220930.xsd#adc_ExecutiveCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExecutiveCompensationMember" xlink:to="lab_adc_ExecutiveCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_d5bd81a7-365f-4b39-914e-da2e94fd25cb_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation, other long-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IntangibleAssetsAbstract_c4ed7b72-26d6-4a42-9467-565a3c2ae34a_terseLabel_en-US" xlink:label="lab_adc_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:label id="lab_adc_IntangibleAssetsAbstract_label_en-US" xlink:label="lab_adc_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:label id="lab_adc_IntangibleAssetsAbstract_documentation_en-US" xlink:label="lab_adc_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IntangibleAssetsAbstract" xlink:href="adc-20220930.xsd#adc_IntangibleAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IntangibleAssetsAbstract" xlink:to="lab_adc_IntangibleAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_0e2bb653-b64d-4651-bde4-f920f2dbfc10_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_52ed8670-a141-49bd-8119-feb3888dc7ce_terseLabel_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_label_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval [Member]</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_documentation_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" xlink:to="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_46cdac45-2be6-4ce0-ad00-eca270a75bc4_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial income&#160;</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_478aad2f-e2db-4db0-9b35-b63b5a70a36a_negatedTerseLabel_en-US" xlink:label="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant obligations, decrease in fair value</link:label>
    <link:label id="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_label_en-US" xlink:label="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Gains (Losses) On change In Fair Value Of Warrants</link:label>
    <link:label id="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_documentation_en-US" xlink:label="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Gains (Losses) On change In Fair Value Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" xlink:href="adc-20220930.xsd#adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" xlink:to="lab_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_de8194f5-469c-47f2-9c02-674189296388_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_570e4e62-435e-41d6-9f01-ce9ea7a6611f_terseLabel_en-US" xlink:label="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, minimum quarterly balance</link:label>
    <link:label id="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_label_en-US" xlink:label="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents</link:label>
    <link:label id="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_documentation_en-US" xlink:label="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" xlink:to="lab_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_83a7480b-c660-4124-8f5c-3f8bb7156bad_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_c977390b-d07a-462f-bf88-5e9a3cebb188_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BuildingsMember_58f06544-53a2-4e4c-a779-b2960a01957b_terseLabel_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Properties (Offices)</link:label>
    <link:label id="lab_ifrs-full_BuildingsMember_label_en-US" xlink:label="lab_ifrs-full_BuildingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BuildingsMember" xlink:to="lab_ifrs-full_BuildingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_9628ace6-f6f1-43bf-9209-bca61073c3b3_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing expenses</link:label>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_e0a90a7b-a89f-40cd-845c-eba4e3aa7494_terseLabel_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:label id="lab_ifrs-full_SalesAndMarketingExpense_label_en-US" xlink:label="lab_ifrs-full_SalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SalesAndMarketingExpense" xlink:to="lab_ifrs-full_SalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SecondInvestmentAmountMember_de1142e4-f6f3-4ef3-8377-fc5e4351d21d_terseLabel_en-US" xlink:label="lab_adc_SecondInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Investment Amount</link:label>
    <link:label id="lab_adc_SecondInvestmentAmountMember_label_en-US" xlink:label="lab_adc_SecondInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Investment Amount [Member]</link:label>
    <link:label id="lab_adc_SecondInvestmentAmountMember_documentation_en-US" xlink:label="lab_adc_SecondInvestmentAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Investment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SecondInvestmentAmountMember" xlink:href="adc-20220930.xsd#adc_SecondInvestmentAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SecondInvestmentAmountMember" xlink:to="lab_adc_SecondInvestmentAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NumberOfSubsidiariesProvideServicesTo_dc6b6729-1afd-4843-a705-f1235574f980_terseLabel_en-US" xlink:label="lab_adc_NumberOfSubsidiariesProvideServicesTo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subsidiaries provide services to</link:label>
    <link:label id="lab_adc_NumberOfSubsidiariesProvideServicesTo_label_en-US" xlink:label="lab_adc_NumberOfSubsidiariesProvideServicesTo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Subsidiaries Provide Services To</link:label>
    <link:label id="lab_adc_NumberOfSubsidiariesProvideServicesTo_documentation_en-US" xlink:label="lab_adc_NumberOfSubsidiariesProvideServicesTo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Subsidiaries Provide Services To</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfSubsidiariesProvideServicesTo" xlink:href="adc-20220930.xsd#adc_NumberOfSubsidiariesProvideServicesTo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NumberOfSubsidiariesProvideServicesTo" xlink:to="lab_adc_NumberOfSubsidiariesProvideServicesTo" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_adc_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_adc_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_adc_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="adc-20220930.xsd#adc_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_adc_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_48f992ee-bed2-46a5-aef9-6a39f7043bb8_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_270b7cf3-dbf5-482d-94f8-fccc8be32246_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RestrictedStockUnitsMember_3ae2be5c-6a4c-4d8c-bf3b-f209c01d29df_terseLabel_en-US" xlink:label="lab_adc_RestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_adc_RestrictedStockUnitsMember_label_en-US" xlink:label="lab_adc_RestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
    <link:label id="lab_adc_RestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_adc_RestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedStockUnitsMember" xlink:href="adc-20220930.xsd#adc_RestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RestrictedStockUnitsMember" xlink:to="lab_adc_RestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_4078d779-2a67-4232-9ea6-5028fdaca4b7_terseLabel_en-US" xlink:label="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates developed and commercialized in joint venture</link:label>
    <link:label id="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_label_en-US" xlink:label="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates Developed And Commercialized In Joint Venture</link:label>
    <link:label id="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_documentation_en-US" xlink:label="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates Developed And Commercialized In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" xlink:href="adc-20220930.xsd#adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" xlink:to="lab_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_ea819771-e7f3-4cff-8066-a6f23dd844fd_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_25f8ca5c-4952-4ab5-85dc-f9bf4eaf946c_periodStartLabel_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, beginning balance (in USD per share)</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_d4bd7603-f7a0-44b0-b42f-3d795267acce_periodEndLabel_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, ending balance (in USD per share)</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_label_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_documentation_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:to="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_VehiclesMember_ae593f79-4149-49fb-94e5-8a786478be36_terseLabel_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_ifrs-full_VehiclesMember_label_en-US" xlink:label="lab_ifrs-full_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_VehiclesMember" xlink:to="lab_ifrs-full_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_0888c1be-7736-4e86-aff3-d89c946e5d93_terseLabel_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_label_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval [Member]</link:label>
    <link:label id="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_documentation_en-US" xlink:label="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" xlink:to="lab_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OakTreeAndOwlRockWarrantObligationsMember_08b82555-3f58-40b0-8678-77fe25758e32_terseLabel_en-US" xlink:label="lab_adc_OakTreeAndOwlRockWarrantObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oak Tree And Owl Rock Warrant Obligations</link:label>
    <link:label id="lab_adc_OakTreeAndOwlRockWarrantObligationsMember_label_en-US" xlink:label="lab_adc_OakTreeAndOwlRockWarrantObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oak Tree And Owl Rock Warrant Obligations [Member]</link:label>
    <link:label id="lab_adc_OakTreeAndOwlRockWarrantObligationsMember_documentation_en-US" xlink:label="lab_adc_OakTreeAndOwlRockWarrantObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oak Tree And Owl Rock Warrant Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OakTreeAndOwlRockWarrantObligationsMember" xlink:href="adc-20220930.xsd#adc_OakTreeAndOwlRockWarrantObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OakTreeAndOwlRockWarrantObligationsMember" xlink:to="lab_adc_OakTreeAndOwlRockWarrantObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_b2d814e9-ec71-4659-9c5b-36b3fd7bdceb_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expense</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TrancheThreeMember_a5b9e1a6-8fc7-467f-aebd-bf000170071a_terseLabel_en-US" xlink:label="lab_adc_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_adc_TrancheThreeMember_label_en-US" xlink:label="lab_adc_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three [Member]</link:label>
    <link:label id="lab_adc_TrancheThreeMember_documentation_en-US" xlink:label="lab_adc_TrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheThreeMember" xlink:href="adc-20220930.xsd#adc_TrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TrancheThreeMember" xlink:to="lab_adc_TrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_b8d7307a-d465-4642-b405-50df14681b41_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of borrowings</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments_419ca33c-666c-4721-9c80-59720aa5ae4f_terseLabel_en-US" xlink:label="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in reserve of share-based payments</link:label>
    <link:label id="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments_label_en-US" xlink:label="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Reserve Of Share-Based Payments</link:label>
    <link:label id="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments_documentation_en-US" xlink:label="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Reserve Of Share-Based Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseInReserveOfShareBasedPayments" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseInReserveOfShareBasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncreaseDecreaseInReserveOfShareBasedPayments" xlink:to="lab_adc_IncreaseDecreaseInReserveOfShareBasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_d27d4a29-7b6d-42a2-a22f-7c21e4f51895_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Translation Adjustments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_ffa10f6f-0d47-4313-8b79-f97203c05819_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap, Payment Maximum</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap, Payment Maximum</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalty Cap, Payment Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" xlink:to="lab_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeerfieldWarrantsMember_a364613b-8199-45b7-86a1-1431bced1479_terseLabel_en-US" xlink:label="lab_adc_DeerfieldWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Warrants</link:label>
    <link:label id="lab_adc_DeerfieldWarrantsMember_label_en-US" xlink:label="lab_adc_DeerfieldWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Warrants [Member]</link:label>
    <link:label id="lab_adc_DeerfieldWarrantsMember_documentation_en-US" xlink:label="lab_adc_DeerfieldWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeerfieldWarrantsMember" xlink:href="adc-20220930.xsd#adc_DeerfieldWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeerfieldWarrantsMember" xlink:to="lab_adc_DeerfieldWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InterestsInOtherEntitiesAbstract_label_en-US" xlink:label="lab_adc_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:label id="lab_adc_InterestsInOtherEntitiesAbstract_documentation_en-US" xlink:label="lab_adc_InterestsInOtherEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interests In Other Entities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InterestsInOtherEntitiesAbstract" xlink:href="adc-20220930.xsd#adc_InterestsInOtherEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InterestsInOtherEntitiesAbstract" xlink:to="lab_adc_InterestsInOtherEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_0a9d516d-7407-4c81-9f3f-a81ea23ae74c_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_0d149de8-cc3f-4fcf-ac24-5d2db8d5da8f_terseLabel_en-US" xlink:label="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of property, plant and equipment</link:label>
    <link:label id="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_label_en-US" xlink:label="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation Expense, Property, Plant And Equipment</link:label>
    <link:label id="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments For Depreciation Expense, Property, Plant And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" xlink:href="adc-20220930.xsd#adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" xlink:to="lab_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FirstFiveYearsMember_370debc8-eed3-4a9e-86ef-2474214d27f3_terseLabel_en-US" xlink:label="lab_adc_FirstFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Five Years</link:label>
    <link:label id="lab_adc_FirstFiveYearsMember_label_en-US" xlink:label="lab_adc_FirstFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Five Years [Member]</link:label>
    <link:label id="lab_adc_FirstFiveYearsMember_documentation_en-US" xlink:label="lab_adc_FirstFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FirstFiveYearsMember" xlink:href="adc-20220930.xsd#adc_FirstFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FirstFiveYearsMember" xlink:to="lab_adc_FirstFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_d5235f12-85bc-4494-b0f7-d47acba0c6df_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_615bcb04-0a89-4cb2-bea7-76d2c941e684_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_label_en-US" xlink:label="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_documentation_en-US" xlink:label="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:href="adc-20220930.xsd#adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:to="lab_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_03df56b4-f639-414a-9b0e-40879fc6896a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal portion of lease obligation payments</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract_bf1a0479-e772-4e80-9d2d-4958adc50b4f_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, before tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_48b894d4-2c41-4203-af4d-5eedd9075d56_terseLabel_en-US" xlink:label="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of results in joint venture</link:label>
    <link:label id="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_label_en-US" xlink:label="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results</link:label>
    <link:label id="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_documentation_en-US" xlink:label="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" xlink:href="adc-20220930.xsd#adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" xlink:to="lab_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_8b6a65f3-120d-48d0-8bb1-d7271f7ab9d2_terseLabel_en-US" xlink:label="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_label_en-US" xlink:label="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</link:label>
    <link:label id="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_documentation_en-US" xlink:label="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:href="adc-20220930.xsd#adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:to="lab_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_9f3c1c7a-100e-4684-9c58-edefe17bada7_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Premium</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_014e2d07-320e-4893-8b9f-021f78b52c30_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial expense</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_5980881d-8df5-4f7b-a46f-968bce8bd3aa_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Compliance</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyObligationInterest_c67411ff-96b6-45ce-8fb4-b9889598c0e8_terseLabel_en-US" xlink:label="lab_adc_RoyaltyObligationInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Interest</link:label>
    <link:label id="lab_adc_RoyaltyObligationInterest_label_en-US" xlink:label="lab_adc_RoyaltyObligationInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Interest</link:label>
    <link:label id="lab_adc_RoyaltyObligationInterest_documentation_en-US" xlink:label="lab_adc_RoyaltyObligationInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationInterest" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyObligationInterest" xlink:to="lab_adc_RoyaltyObligationInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantObligationsTransactionCosts_e62c30a9-0795-49ef-b4cf-7ab62811df76_terseLabel_en-US" xlink:label="lab_adc_WarrantObligationsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Obligations, Transaction Costs</link:label>
    <link:label id="lab_adc_WarrantObligationsTransactionCosts_label_en-US" xlink:label="lab_adc_WarrantObligationsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Obligations, Transaction Costs</link:label>
    <link:label id="lab_adc_WarrantObligationsTransactionCosts_documentation_en-US" xlink:label="lab_adc_WarrantObligationsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Obligations, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationsTransactionCosts" xlink:href="adc-20220930.xsd#adc_WarrantObligationsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantObligationsTransactionCosts" xlink:to="lab_adc_WarrantObligationsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_8c0fb8ee-2446-4e1b-b656-07f91b18a87f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill_8d01d831-b95b-462e-81ac-216a8d6488c4_terseLabel_en-US" xlink:label="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers</link:label>
    <link:label id="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers, Intangible Assets Other Than Goodwill</link:label>
    <link:label id="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill_documentation_en-US" xlink:label="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers, Intangible Assets Other Than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TransfersIntangibleAssetsOtherThanGoodwill" xlink:href="adc-20220930.xsd#adc_TransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TransfersIntangibleAssetsOtherThanGoodwill" xlink:to="lab_adc_TransfersIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DividendYieldMember_017c5513-cd5a-4a06-bd9f-c3eb037023ff_terseLabel_en-US" xlink:label="lab_adc_DividendYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield [Member]</link:label>
    <link:label id="lab_adc_DividendYieldMember_label_en-US" xlink:label="lab_adc_DividendYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield [Member]</link:label>
    <link:label id="lab_adc_DividendYieldMember_documentation_en-US" xlink:label="lab_adc_DividendYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Yield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DividendYieldMember" xlink:href="adc-20220930.xsd#adc_DividendYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DividendYieldMember" xlink:to="lab_adc_DividendYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeferredRoyaltyObligationNoncurrent_52db8565-f36f-46c9-a77d-f8a027c591ce_terseLabel_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalty obligation, long-term</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligationNoncurrent_label_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:label id="lab_adc_DeferredRoyaltyObligationNoncurrent_documentation_en-US" xlink:label="lab_adc_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationNoncurrent" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeferredRoyaltyObligationNoncurrent" xlink:to="lab_adc_DeferredRoyaltyObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_459a1b19-6565-4621-a25b-bcbba314b976_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of defined benefit pension liability</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_acdadbb3-eac9-44ca-8815-2c75632e2a95_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average strike price in USD per share, Forfeited (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WorldwideMember_b5237be0-05f0-4241-b792-718455cdcf53_terseLabel_en-US" xlink:label="lab_adc_WorldwideMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide</link:label>
    <link:label id="lab_adc_WorldwideMember_label_en-US" xlink:label="lab_adc_WorldwideMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide [Member]</link:label>
    <link:label id="lab_adc_WorldwideMember_documentation_en-US" xlink:label="lab_adc_WorldwideMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WorldwideMember" xlink:href="adc-20220930.xsd#adc_WorldwideMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WorldwideMember" xlink:to="lab_adc_WorldwideMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod_cc9b3922-dce8-44fd-9d37-442a27094cb1_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Termination Period</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Termination Period</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Termination Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTerminationPeriod" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTerminationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementTerminationPeriod" xlink:to="lab_adc_RoyaltyPurchaseAgreementTerminationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SeniorSecuredTermLoansMember_41da35aa-a643-4868-87fe-6ba4b71b8ae7_terseLabel_en-US" xlink:label="lab_adc_SeniorSecuredTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loans</link:label>
    <link:label id="lab_adc_SeniorSecuredTermLoansMember_label_en-US" xlink:label="lab_adc_SeniorSecuredTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loans [Member]</link:label>
    <link:label id="lab_adc_SeniorSecuredTermLoansMember_documentation_en-US" xlink:label="lab_adc_SeniorSecuredTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoansMember" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SeniorSecuredTermLoansMember" xlink:to="lab_adc_SeniorSecuredTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock_76f4bb59-7c27-4a0b-a33d-0930dc6159a9_terseLabel_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing ("S&amp;M") expenses</link:label>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock_label_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Selling And Marketing Expenses Explanatory [Policy Text Block]</link:label>
    <link:label id="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock_documentation_en-US" xlink:label="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Accounting Policy For Selling And Marketing Expenses Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" xlink:href="adc-20220930.xsd#adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" xlink:to="lab_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_499d8d7f-a538-488d-a604-eddb827f4dc9_terseLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_56d6765e-d517-43fb-a2cc-ff17f25e4daf_periodStartLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_21b0f23a-a4b7-41fa-80a0-979809069713_periodEndLabel_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_label_en-US" xlink:label="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in joint ventures accounted for using equity method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:to="lab_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_409d38d1-4439-4df4-85c9-7ca7393ca376_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_InternalDevelopmentCostsMember_3352f8b8-472e-4f7a-aa79-69520b3a891f_terseLabel_en-US" xlink:label="lab_adc_InternalDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal development costs</link:label>
    <link:label id="lab_adc_InternalDevelopmentCostsMember_label_en-US" xlink:label="lab_adc_InternalDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Development Costs [Member]</link:label>
    <link:label id="lab_adc_InternalDevelopmentCostsMember_documentation_en-US" xlink:label="lab_adc_InternalDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InternalDevelopmentCostsMember" xlink:href="adc-20220930.xsd#adc_InternalDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_InternalDevelopmentCostsMember" xlink:to="lab_adc_InternalDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_68ae3afd-7976-4b54-993d-bef00d510898_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_bd56ae9a-bff5-4248-8881-6b0553c65834_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, Exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_80c966e1-ea91-482e-a03d-720dc26da4d3_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in credit derivative, fair value</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in credit derivative, fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:to="lab_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_261cc75b-cf00-435d-bd70-2e1ab782581f_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_1d2c46c0-b46d-4a18-9ea9-463a5579a315_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_9bb1b38a-f735-45cc-aeb4-44fc40e4900e_terseLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts_b40c2bb7-6a07-4e71-9005-ee502ded6174_terseLabel_en-US" xlink:label="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Expected Future Transaction Costs</link:label>
    <link:label id="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts_label_en-US" xlink:label="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Expected Future Transaction Costs</link:label>
    <link:label id="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts_documentation_en-US" xlink:label="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Expected Future Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationExpectedFutureTransactionCosts" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationExpectedFutureTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyObligationExpectedFutureTransactionCosts" xlink:to="lab_adc_RoyaltyObligationExpectedFutureTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_1e5511ab-ad23-4fea-9346-dcfd2666094b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_18b981af-6780-4ab2-8f0f-d7449c9132fd_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InventoriesTotal_26163fd2-fc40-4568-b196-524e616ac751_totalLabel_en-US" xlink:label="lab_ifrs-full_InventoriesTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_InventoriesTotal_label_en-US" xlink:label="lab_ifrs-full_InventoriesTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoriesTotal" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InventoriesTotal" xlink:to="lab_ifrs-full_InventoriesTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7e39a195-17fb-4100-9b2a-cb313568a1df_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_2648e561-98fd-488d-bb1d-eade79ddc7a5_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_GTNSalesAdjustmentProvision_afe0c292-b6bb-4f11-94bc-b5e6b811d52a_terseLabel_en-US" xlink:label="lab_adc_GTNSalesAdjustmentProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Provision</link:label>
    <link:label id="lab_adc_GTNSalesAdjustmentProvision_label_en-US" xlink:label="lab_adc_GTNSalesAdjustmentProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Provision</link:label>
    <link:label id="lab_adc_GTNSalesAdjustmentProvision_documentation_en-US" xlink:label="lab_adc_GTNSalesAdjustmentProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GTN Sales Adjustment, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustmentProvision" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustmentProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_GTNSalesAdjustmentProvision" xlink:to="lab_adc_GTNSalesAdjustmentProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_fa5aace4-b211-4cd5-89be-0d515f8a1517_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_EmployeeStockOptionMember_a28d4012-683a-4746-8287-4c8c0d2c3223_terseLabel_en-US" xlink:label="lab_adc_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Options</link:label>
    <link:label id="lab_adc_EmployeeStockOptionMember_label_en-US" xlink:label="lab_adc_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:label id="lab_adc_EmployeeStockOptionMember_documentation_en-US" xlink:label="lab_adc_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeStockOptionMember" xlink:href="adc-20220930.xsd#adc_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_EmployeeStockOptionMember" xlink:to="lab_adc_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ZYNLONTAForRDMember_ace6b044-d331-4320-bde5-02c7cd4e7716_terseLabel_en-US" xlink:label="lab_adc_ZYNLONTAForRDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYNLONTA For R&amp;D</link:label>
    <link:label id="lab_adc_ZYNLONTAForRDMember_label_en-US" xlink:label="lab_adc_ZYNLONTAForRDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYNLONTA For R&amp;D [Member]</link:label>
    <link:label id="lab_adc_ZYNLONTAForRDMember_documentation_en-US" xlink:label="lab_adc_ZYNLONTAForRDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYNLONTA For R&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAForRDMember" xlink:href="adc-20220930.xsd#adc_ZYNLONTAForRDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ZYNLONTAForRDMember" xlink:to="lab_adc_ZYNLONTAForRDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_c4b41daf-d018-4c90-86aa-ab4a98fa4b18_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_b9b0ef86-db1d-40c7-84d0-f58caefda8c5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_64bb76a8-3398-46c1-b16a-ad41f2cf2112_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_427b23ed-9a24-4183-bea8-44dd9352da00_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_56658dd4-2df9-454b-ad7a-685153ac57d8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_547822a2-e2e6-4076-b9b3-6d7443509bf9_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value grant date (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_CurrentFinishedGoodsHeldOnConsignment_447d7ee8-e519-46a4-a4ae-b9575f666a09_terseLabel_en-US" xlink:label="lab_adc_CurrentFinishedGoodsHeldOnConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Finished Goods Held On Consignment</link:label>
    <link:label id="lab_adc_CurrentFinishedGoodsHeldOnConsignment_label_en-US" xlink:label="lab_adc_CurrentFinishedGoodsHeldOnConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Finished Goods Held On Consignment</link:label>
    <link:label id="lab_adc_CurrentFinishedGoodsHeldOnConsignment_documentation_en-US" xlink:label="lab_adc_CurrentFinishedGoodsHeldOnConsignment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Finished Goods Held On Consignment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CurrentFinishedGoodsHeldOnConsignment" xlink:href="adc-20220930.xsd#adc_CurrentFinishedGoodsHeldOnConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_CurrentFinishedGoodsHeldOnConsignment" xlink:to="lab_adc_CurrentFinishedGoodsHeldOnConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WorkInProgress_0c618843-7163-45b9-ac01-e78966040156_terseLabel_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current work in progress</link:label>
    <link:label id="lab_ifrs-full_WorkInProgress_label_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current work in progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WorkInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_afb28e61-5d70-4d09-9cb6-51a860aff3c1_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Losses</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExpensesByNatureDomain_db388891-0037-48db-a2d5-9347a5292dda_terseLabel_en-US" xlink:label="lab_adc_ExpensesByNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature [Domain]</link:label>
    <link:label id="lab_adc_ExpensesByNatureDomain_label_en-US" xlink:label="lab_adc_ExpensesByNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature [Domain]</link:label>
    <link:label id="lab_adc_ExpensesByNatureDomain_documentation_en-US" xlink:label="lab_adc_ExpensesByNatureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExpensesByNatureDomain" xlink:to="lab_adc_ExpensesByNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_e1dfea76-5af5-40fb-bbc5-d8cbf7b08a2b_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Percent On Net Sales</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Percent On Net Sales</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Payment Percent On Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" xlink:to="lab_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ProductRevenueNetMember_bd2c4025-d88b-4bf4-bd17-47a2415e274d_terseLabel_en-US" xlink:label="lab_adc_ProductRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues, net</link:label>
    <link:label id="lab_adc_ProductRevenueNetMember_label_en-US" xlink:label="lab_adc_ProductRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net [Member]</link:label>
    <link:label id="lab_adc_ProductRevenueNetMember_documentation_en-US" xlink:label="lab_adc_ProductRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProductRevenueNetMember" xlink:href="adc-20220930.xsd#adc_ProductRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ProductRevenueNetMember" xlink:to="lab_adc_ProductRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_f19ac7f5-9a8c-4f41-aa19-51eb28af3e92_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for purchase of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_97c753f0-0950-41c6-b707-1b3c13e76ff8_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY&#160;</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_5b0a539f-5226-40bd-a690-3d45a35fee47_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SeniorSecuredTermLoanFacilityMember_adacd3a5-29eb-4988-acb8-5786ac18fe3a_terseLabel_en-US" xlink:label="lab_adc_SeniorSecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Facility</link:label>
    <link:label id="lab_adc_SeniorSecuredTermLoanFacilityMember_label_en-US" xlink:label="lab_adc_SeniorSecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Facility [Member]</link:label>
    <link:label id="lab_adc_SeniorSecuredTermLoanFacilityMember_documentation_en-US" xlink:label="lab_adc_SeniorSecuredTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SeniorSecuredTermLoanFacilityMember" xlink:to="lab_adc_SeniorSecuredTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_e89ed755-b51a-4739-981c-0b2585c7f81d_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_A2019EquityIncentivePlanRSUsMember_bdf7e04e-097a-4df5-9447-e105da05e3f9_terseLabel_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2019 - RSUs</link:label>
    <link:label id="lab_adc_A2019EquityIncentivePlanRSUsMember_label_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan - RSUs [Member]</link:label>
    <link:label id="lab_adc_A2019EquityIncentivePlanRSUsMember_documentation_en-US" xlink:label="lab_adc_A2019EquityIncentivePlanRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan - RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanRSUsMember" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_A2019EquityIncentivePlanRSUsMember" xlink:to="lab_adc_A2019EquityIncentivePlanRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_cae84730-21f3-4238-a0b6-a2fa3506d1cb_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_92962b97-4132-4c9a-86e7-5de4b09fa244_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WarrantsTrancheDomain_eee0da40-ec2c-4214-a83e-a36a66a7a942_terseLabel_en-US" xlink:label="lab_adc_WarrantsTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche [Domain]</link:label>
    <link:label id="lab_adc_WarrantsTrancheDomain_label_en-US" xlink:label="lab_adc_WarrantsTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche [Domain]</link:label>
    <link:label id="lab_adc_WarrantsTrancheDomain_documentation_en-US" xlink:label="lab_adc_WarrantsTrancheDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Tranche [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WarrantsTrancheDomain" xlink:to="lab_adc_WarrantsTrancheDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DeferredGainOnInvestmentInJointVenture_1433580e-7744-4d36-b486-d555575e8811_terseLabel_en-US" xlink:label="lab_adc_DeferredGainOnInvestmentInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain On Investment In Joint Venture</link:label>
    <link:label id="lab_adc_DeferredGainOnInvestmentInJointVenture_label_en-US" xlink:label="lab_adc_DeferredGainOnInvestmentInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain On Investment In Joint Venture</link:label>
    <link:label id="lab_adc_DeferredGainOnInvestmentInJointVenture_documentation_en-US" xlink:label="lab_adc_DeferredGainOnInvestmentInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain On Investment In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredGainOnInvestmentInJointVenture" xlink:href="adc-20220930.xsd#adc_DeferredGainOnInvestmentInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DeferredGainOnInvestmentInJointVenture" xlink:to="lab_adc_DeferredGainOnInvestmentInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_96c0d41f-3efc-414e-9727-d0bd7ab9d38d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_5e4236cd-3a07-4386-9825-0b9e1efa64fc_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_78d193f5-5d6e-4d21-8a52-11d45c5201c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumption For Options Granted</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicensesDefiniteLivedMember_5b9a001a-f982-46f7-8a83-780904758a76_terseLabel_en-US" xlink:label="lab_adc_LicensesDefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_adc_LicensesDefiniteLivedMember_label_en-US" xlink:label="lab_adc_LicensesDefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses, Definite-Lived [Member]</link:label>
    <link:label id="lab_adc_LicensesDefiniteLivedMember_documentation_en-US" xlink:label="lab_adc_LicensesDefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses, Definite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensesDefiniteLivedMember" xlink:href="adc-20220930.xsd#adc_LicensesDefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicensesDefiniteLivedMember" xlink:to="lab_adc_LicensesDefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2665a6d2-6d3c-4d89-a32d-a94466e7cec5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b04f8209-b5a6-429e-a97b-a71d76ac82be_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_c37e1e53-4974-4bb1-a6d6-18becf722d00_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_514ee6f0-364b-49f3-9941-a0699261d3ed_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ForcedConversionPriceMember_29db6ce8-4d6c-4fa3-b9ac-fea710e0b5c8_terseLabel_en-US" xlink:label="lab_adc_ForcedConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forced Conversion Price (in USD per share)</link:label>
    <link:label id="lab_adc_ForcedConversionPriceMember_label_en-US" xlink:label="lab_adc_ForcedConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forced Conversion Price [Member]</link:label>
    <link:label id="lab_adc_ForcedConversionPriceMember_documentation_en-US" xlink:label="lab_adc_ForcedConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forced Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ForcedConversionPriceMember" xlink:href="adc-20220930.xsd#adc_ForcedConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ForcedConversionPriceMember" xlink:to="lab_adc_ForcedConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_5291bc6e-fc94-4ee9-9e41-8110b60a56bb_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentAssets" xlink:to="lab_ifrs-full_OtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_4f8bd5b9-0d79-4d40-a583-3a2b94478fb9_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income for the period</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LicensePaymentMember_116121f9-cc48-4187-94b2-659a4f721b25_terseLabel_en-US" xlink:label="lab_adc_LicensePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payment</link:label>
    <link:label id="lab_adc_LicensePaymentMember_label_en-US" xlink:label="lab_adc_LicensePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payment [Member]</link:label>
    <link:label id="lab_adc_LicensePaymentMember_documentation_en-US" xlink:label="lab_adc_LicensePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensePaymentMember" xlink:href="adc-20220930.xsd#adc_LicensePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LicensePaymentMember" xlink:to="lab_adc_LicensePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c5c137f8-863c-4787-ad69-20e3645ebd1e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreement_a9c0ea9c-f564-4f8b-8229-fe976a0ad119_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreement_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreement_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreement" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreement" xlink:to="lab_adc_RoyaltyPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LoanAgreementFirstTrancheMember_12c4b3b5-9e40-4553-bc37-6fd15a646b30_terseLabel_en-US" xlink:label="lab_adc_LoanAgreementFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, First Tranche</link:label>
    <link:label id="lab_adc_LoanAgreementFirstTrancheMember_label_en-US" xlink:label="lab_adc_LoanAgreementFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, First Tranche [Member]</link:label>
    <link:label id="lab_adc_LoanAgreementFirstTrancheMember_documentation_en-US" xlink:label="lab_adc_LoanAgreementFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, First Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementFirstTrancheMember" xlink:href="adc-20220930.xsd#adc_LoanAgreementFirstTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LoanAgreementFirstTrancheMember" xlink:to="lab_adc_LoanAgreementFirstTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_401fb29b-7aad-4934-8df8-c7c5bfe485e4_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameMember_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameMember" xlink:to="lab_ifrs-full_BorrowingsByNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock_38426990-2936-4dcb-9cdb-441050d635bf_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Sales Adjustments Explanatory</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Sales Adjustments Explanatory [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Sales Adjustments Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_851e5f1d-f68d-446b-898a-f7faf4680d03_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_1cd0fc02-3da8-484c-9a4a-8eaf50a88174_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_be155391-f07c-48f2-81ee-5d9b8b0fea87_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfWarrantsTextBlock_91566611-083a-431a-8a6a-ffc2adac4166_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfWarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Warrants</link:label>
    <link:label id="lab_adc_DisclosureOfWarrantsTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfWarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrants [Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfWarrantsTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfWarrantsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfWarrantsTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfWarrantsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfWarrantsTextBlock" xlink:to="lab_adc_DisclosureOfWarrantsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_47a94c39-6cee-435b-8a5e-c37999e86b8a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of defined benefit pension liability</link:label>
    <link:label id="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="lab_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_50b52c15-079f-420a-b440-3af59f991f69_terseLabel_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_label_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit [Member]</link:label>
    <link:label id="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_documentation_en-US" xlink:label="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" xlink:to="lab_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_c8ee8439-b69f-458b-8d39-75c6c68d0aa3_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items that may be reclassified to profit and loss</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="lab_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_65fcb8d0-5489-48a5-800a-5557814fbf7d_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_743940b9-7b2c-4045-be51-5a4b35c07f29_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_834092ab-595d-4767-a48f-56f5b5fc6bb3_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BorrowingsDeferredFinancingCosts_5de48fbd-b96b-4db2-bba7-51bfbc166e03_terseLabel_en-US" xlink:label="lab_adc_BorrowingsDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans, derivatives, transaction costs</link:label>
    <link:label id="lab_adc_BorrowingsDeferredFinancingCosts_label_en-US" xlink:label="lab_adc_BorrowingsDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Deferred Financing Costs</link:label>
    <link:label id="lab_adc_BorrowingsDeferredFinancingCosts_documentation_en-US" xlink:label="lab_adc_BorrowingsDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings, Deferred Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsDeferredFinancingCosts" xlink:href="adc-20220930.xsd#adc_BorrowingsDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BorrowingsDeferredFinancingCosts" xlink:to="lab_adc_BorrowingsDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_LeaseArea_64be105f-497d-448c-a1ef-5cc7e9ffbbea_terseLabel_en-US" xlink:label="lab_adc_LeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease area (in square meters)</link:label>
    <link:label id="lab_adc_LeaseArea_label_en-US" xlink:label="lab_adc_LeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Area</link:label>
    <link:label id="lab_adc_LeaseArea_documentation_en-US" xlink:label="lab_adc_LeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeaseArea" xlink:href="adc-20220930.xsd#adc_LeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_LeaseArea" xlink:to="lab_adc_LeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_a83d185c-667d-4d00-af1c-7fe14a02c461_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RelatedPartyAbstract_label_en-US" xlink:label="lab_adc_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:label id="lab_adc_RelatedPartyAbstract_documentation_en-US" xlink:label="lab_adc_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RelatedPartyAbstract" xlink:href="adc-20220930.xsd#adc_RelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RelatedPartyAbstract" xlink:to="lab_adc_RelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_4ffe624b-9ed6-4757-b288-1696d797c112_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_4b47e17b-935e-425a-901a-28a9694905da_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ExpensesByNatureMember_6f5f8358-3fdd-4ab5-9d59-eae5ef1cb7a5_terseLabel_en-US" xlink:label="lab_adc_ExpensesByNatureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature</link:label>
    <link:label id="lab_adc_ExpensesByNatureMember_label_en-US" xlink:label="lab_adc_ExpensesByNatureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature [Member]</link:label>
    <link:label id="lab_adc_ExpensesByNatureMember_documentation_en-US" xlink:label="lab_adc_ExpensesByNatureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses By Nature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureMember" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ExpensesByNatureMember" xlink:to="lab_adc_ExpensesByNatureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f54f531a-7f0b-4f4f-a552-dbd694bf17d5_terseLabel_en-US" xlink:label="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of change in derivative</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_label_en-US" xlink:label="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Increase (Decrease) In Derivative</link:label>
    <link:label id="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_documentation_en-US" xlink:label="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Increase (Decrease) In Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" xlink:to="lab_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_c6e2d8c0-28dd-41cf-9cb1-bbc3e4e06f58_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_ab5eb2ff-2e0a-424a-ad44-00fd24a50d2e_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of loss per share and potentially dilutive securities</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_EmployeeExpensesMember_0cc0d4d4-98cb-4af6-8d86-5b5df588d080_terseLabel_en-US" xlink:label="lab_adc_EmployeeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee expense</link:label>
    <link:label id="lab_adc_EmployeeExpensesMember_label_en-US" xlink:label="lab_adc_EmployeeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Expenses [Member]</link:label>
    <link:label id="lab_adc_EmployeeExpensesMember_documentation_en-US" xlink:label="lab_adc_EmployeeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeExpensesMember" xlink:href="adc-20220930.xsd#adc_EmployeeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_EmployeeExpensesMember" xlink:to="lab_adc_EmployeeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_9280bc85-5696-4f8d-a4f4-436e55f7eed4_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_e66a955a-6a50-45b3-8f7b-0fc1c28c52a7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares to be held as treasury shares</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) through treasury share transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AuvenTherapeuticsHoldingsLPMember_65a04aa0-14a0-4472-a52b-cf1c61e0d215_terseLabel_en-US" xlink:label="lab_adc_AuvenTherapeuticsHoldingsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auven Therapeutics Holdings, L.P.</link:label>
    <link:label id="lab_adc_AuvenTherapeuticsHoldingsLPMember_label_en-US" xlink:label="lab_adc_AuvenTherapeuticsHoldingsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auven Therapeutics Holdings, L.P. [Member]</link:label>
    <link:label id="lab_adc_AuvenTherapeuticsHoldingsLPMember_documentation_en-US" xlink:label="lab_adc_AuvenTherapeuticsHoldingsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auven Therapeutics Holdings, L.P.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AuvenTherapeuticsHoldingsLPMember" xlink:href="adc-20220930.xsd#adc_AuvenTherapeuticsHoldingsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AuvenTherapeuticsHoldingsLPMember" xlink:to="lab_adc_AuvenTherapeuticsHoldingsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_VestingPeriodMember_efc6d2d5-cce6-416a-a6f4-0618bb3179ce_terseLabel_en-US" xlink:label="lab_adc_VestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period</link:label>
    <link:label id="lab_adc_VestingPeriodMember_label_en-US" xlink:label="lab_adc_VestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period [Member]</link:label>
    <link:label id="lab_adc_VestingPeriodMember_documentation_en-US" xlink:label="lab_adc_VestingPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodMember" xlink:href="adc-20220930.xsd#adc_VestingPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_VestingPeriodMember" xlink:to="lab_adc_VestingPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_422affce-68a9-4c37-8691-66f73d7a222e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AmountsDueFromRelatedParties_f4480d0d-24d1-4120-b1e0-214af58aaef0_terseLabel_en-US" xlink:label="lab_adc_AmountsDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from related parties</link:label>
    <link:label id="lab_adc_AmountsDueFromRelatedParties_label_en-US" xlink:label="lab_adc_AmountsDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due From Related Parties</link:label>
    <link:label id="lab_adc_AmountsDueFromRelatedParties_documentation_en-US" xlink:label="lab_adc_AmountsDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due From Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AmountsDueFromRelatedParties" xlink:href="adc-20220930.xsd#adc_AmountsDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AmountsDueFromRelatedParties" xlink:to="lab_adc_AmountsDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReservesMember_46c07204-487c-4d7a-bc4e-162550f7c198_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReservesMember_label_en-US" xlink:label="lab_ifrs-full_OtherReservesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other reserves [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReservesMember" xlink:to="lab_ifrs-full_OtherReservesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_4fa285bc-4871-4bf7-a2af-533f11df7024_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_078bbf8c-cd68-4177-8903-c852039aac7d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_ade7aa19-3da7-4878-9ca0-ed1e3991462b_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_ed3824f2-7e2d-44e4-8c8e-b1f2e2a49d1b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange differences</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4a346578-1985-4795-a1a5-fc031c9f5ef1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_dee060e8-56e8-4f90-b5aa-85692d53aa18_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, vested (in dollars per share)</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_label_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_documentation_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" xlink:to="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_TrancheOneMember_fe4deea1-ba00-4d9d-9ea9-40aab9abc55f_terseLabel_en-US" xlink:label="lab_adc_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_adc_TrancheOneMember_label_en-US" xlink:label="lab_adc_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One [Member]</link:label>
    <link:label id="lab_adc_TrancheOneMember_documentation_en-US" xlink:label="lab_adc_TrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheOneMember" xlink:href="adc-20220930.xsd#adc_TrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_TrancheOneMember" xlink:to="lab_adc_TrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DosingOfSpecificNumberOfPatientsMember_68639052-f29b-4cac-a6e0-24b3eb4e92fc_terseLabel_en-US" xlink:label="lab_adc_DosingOfSpecificNumberOfPatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dosing Of Specific Number Of Patients</link:label>
    <link:label id="lab_adc_DosingOfSpecificNumberOfPatientsMember_label_en-US" xlink:label="lab_adc_DosingOfSpecificNumberOfPatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dosing Of Specific Number Of Patients [Member]</link:label>
    <link:label id="lab_adc_DosingOfSpecificNumberOfPatientsMember_documentation_en-US" xlink:label="lab_adc_DosingOfSpecificNumberOfPatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dosing Of Specific Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DosingOfSpecificNumberOfPatientsMember" xlink:href="adc-20220930.xsd#adc_DosingOfSpecificNumberOfPatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DosingOfSpecificNumberOfPatientsMember" xlink:to="lab_adc_DosingOfSpecificNumberOfPatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_RoyaltyObligationTransactionCosts_d2f761a0-9282-496a-8c7a-dcd640f5faea_terseLabel_en-US" xlink:label="lab_adc_RoyaltyObligationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Transaction Costs</link:label>
    <link:label id="lab_adc_RoyaltyObligationTransactionCosts_label_en-US" xlink:label="lab_adc_RoyaltyObligationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Transaction Costs</link:label>
    <link:label id="lab_adc_RoyaltyObligationTransactionCosts_documentation_en-US" xlink:label="lab_adc_RoyaltyObligationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationTransactionCosts" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_RoyaltyObligationTransactionCosts" xlink:to="lab_adc_RoyaltyObligationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_752bb3e4-bd81-4f68-94b1-75805d747345_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities_3bb88e71-b8cf-4b4f-b99d-5be5cf2d501c_terseLabel_en-US" xlink:label="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-on transaction costs recorded in Accounts payable and Other current liabilities</link:label>
    <link:label id="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities</link:label>
    <link:label id="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" xlink:href="adc-20220930.xsd#adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" xlink:to="lab_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_62f5bcb2-f660-4d57-bfeb-b513664aed3a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award life</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_f2f65485-ce50-41a2-a91b-706bf141c27f_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_0a2c59de-8892-46f1-bf18-806addfe4945_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_4777902d-25de-4039-80c8-55a584fde5bc_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_6e281d32-a651-4501-8ff7-89af7d63bf5c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendShareOptionsGranted_f0740038-1f5d-48bc-bcb4-4ef0d6f6250c_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_CamiMember_228325a7-0f68-4ab1-9d25-7caf0f8e92da_terseLabel_en-US" xlink:label="lab_adc_CamiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cami</link:label>
    <link:label id="lab_adc_CamiMember_label_en-US" xlink:label="lab_adc_CamiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cami [Member]</link:label>
    <link:label id="lab_adc_CamiMember_documentation_en-US" xlink:label="lab_adc_CamiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cami</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CamiMember" xlink:href="adc-20220930.xsd#adc_CamiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_CamiMember" xlink:to="lab_adc_CamiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_NumberOfSubsidiaries_cea81b2f-7742-48c1-9610-5e88fadeeb38_terseLabel_en-US" xlink:label="lab_adc_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subsidiaries</link:label>
    <link:label id="lab_adc_NumberOfSubsidiaries_label_en-US" xlink:label="lab_adc_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:label id="lab_adc_NumberOfSubsidiaries_documentation_en-US" xlink:label="lab_adc_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfSubsidiaries" xlink:href="adc-20220930.xsd#adc_NumberOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_NumberOfSubsidiaries" xlink:to="lab_adc_NumberOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_a0b3b98c-6521-4416-bf32-cd57202999ae_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible loans, derivatives</link:label>
    <link:label id="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_39b26be0-3510-4e03-b408-4f3f1adfff15_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards, Expired (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_338c8060-f1c7-4b4f-af13-fffc2b207032_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to owners of the parent</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_412f3a0e-8e88-4a81-84fb-5c2520bed40d_terseLabel_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange difference</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_label_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Lease Liabilities</link:label>
    <link:label id="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_documentation_en-US" xlink:label="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Through Net Exchange Differences, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" xlink:to="lab_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_e55029f5-9cfa-4563-a491-8bc26aff82d6_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_ProceedsFromLicenseAgreement_c9fa11d9-5f5f-4dfb-8e0b-8aa01451bdc3_terseLabel_en-US" xlink:label="lab_adc_ProceedsFromLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From License Agreement</link:label>
    <link:label id="lab_adc_ProceedsFromLicenseAgreement_label_en-US" xlink:label="lab_adc_ProceedsFromLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From License Agreement</link:label>
    <link:label id="lab_adc_ProceedsFromLicenseAgreement_documentation_en-US" xlink:label="lab_adc_ProceedsFromLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromLicenseAgreement" xlink:href="adc-20220930.xsd#adc_ProceedsFromLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_ProceedsFromLicenseAgreement" xlink:to="lab_adc_ProceedsFromLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_f3931cfb-fad3-44a1-a697-950f5c4b573f_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price (in USD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average share price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts_74385d03-38f8-47fb-9260-10e1a63de721_terseLabel_en-US" xlink:label="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalty obligation transaction costs recorded in Accounts payable</link:label>
    <link:label id="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts_label_en-US" xlink:label="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Deferred Royalty Obligation Transaction Costs</link:label>
    <link:label id="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts_documentation_en-US" xlink:label="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Deferred Royalty Obligation Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" xlink:href="adc-20220930.xsd#adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" xlink:to="lab_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_SupplementalCashFlowInformationAbstract_da61427d-ac8e-41e8-a239-f454c9857f36_terseLabel_en-US" xlink:label="lab_adc_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Non-Cash Investing Information</link:label>
    <link:label id="lab_adc_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_adc_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_adc_SupplementalCashFlowInformationAbstract_documentation_en-US" xlink:label="lab_adc_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SupplementalCashFlowInformationAbstract" xlink:href="adc-20220930.xsd#adc_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_SupplementalCashFlowInformationAbstract" xlink:to="lab_adc_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_ab8973a6-d39b-4da8-8363-1ba176506737_terseLabel_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, forfeited (in dollars per share)</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_label_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited</link:label>
    <link:label id="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_documentation_en-US" xlink:label="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" xlink:to="lab_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentWarrantLiability_2b97b852-a73f-413c-bfed-3862cc079f30_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant obligations</link:label>
    <link:label id="lab_ifrs-full_NoncurrentWarrantLiability_label_en-US" xlink:label="lab_ifrs-full_NoncurrentWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentWarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentWarrantLiability" xlink:to="lab_ifrs-full_NoncurrentWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_OverlandADCTBioPharmaCYLimitedMember_59f210d1-19de-4346-88b2-eb5dedd9a84b_terseLabel_en-US" xlink:label="lab_adc_OverlandADCTBioPharmaCYLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland ADCT BioPharma</link:label>
    <link:label id="lab_adc_OverlandADCTBioPharmaCYLimitedMember_label_en-US" xlink:label="lab_adc_OverlandADCTBioPharmaCYLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland ADCT BioPharma (CY) Limited [Member]</link:label>
    <link:label id="lab_adc_OverlandADCTBioPharmaCYLimitedMember_documentation_en-US" xlink:label="lab_adc_OverlandADCTBioPharmaCYLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland ADCT BioPharma (CY) Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_OverlandADCTBioPharmaCYLimitedMember" xlink:to="lab_adc_OverlandADCTBioPharmaCYLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_BaseRateMember_33108dc9-b85b-4ab9-94e8-fe72685d9d3b_terseLabel_en-US" xlink:label="lab_adc_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_adc_BaseRateMember_label_en-US" xlink:label="lab_adc_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_adc_BaseRateMember_documentation_en-US" xlink:label="lab_adc_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BaseRateMember" xlink:href="adc-20220930.xsd#adc_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_BaseRateMember" xlink:to="lab_adc_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_d817dfcd-195d-4f55-9d9f-60e9abae2112_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of expenses by nature [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_568dd2a0-5792-47a1-a7c8-a420f657d234_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfRelatedPartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="lab_ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock_cf3a1c03-5efc-4429-bd05-0ab1ebf4df5b_terseLabel_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature Explanatory</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock_label_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature Explanatory [Table Text Block]</link:label>
    <link:label id="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Detailed Information About Expenses By Nature Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" xlink:to="lab_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_01e5be11-eff6-4e19-ab76-5b245ee10238_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Outstanding</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_fcd98331-3405-4b26-9cfc-c4ae713ed37a_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>adc-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6b949c65-610b-498d-9522-9f49538139b0,g:b2608e38-f354-4038-8621-e387852f85e5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://adctherapeutics.com/role/Cover" xlink:type="simple" xlink:href="adc-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_de9f38c1-2915-4e29-9250-55e2fc5c58fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_DocumentType_de9f38c1-2915-4e29-9250-55e2fc5c58fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_58a7a09d-05d0-4637-b523-ca6e859f7ba2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_DocumentPeriodEndDate_58a7a09d-05d0-4637-b523-ca6e859f7ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8075496a-e195-4aac-bc04-eec7c19e4d5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityFileNumber_8075496a-e195-4aac-bc04-eec7c19e4d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_07cca11b-3f34-4ec3-ab57-5e47d03995e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityRegistrantName_07cca11b-3f34-4ec3-ab57-5e47d03995e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8fd1ceef-eb7b-4747-9024-a7dc900cb94a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityAddressAddressLine1_8fd1ceef-eb7b-4747-9024-a7dc900cb94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_56af0291-496a-44d1-92e4-1ee2a42cfb67" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityAddressAddressLine2_56af0291-496a-44d1-92e4-1ee2a42cfb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9a765005-71d4-4bf9-9486-de5d9fdd33bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityAddressPostalZipCode_9a765005-71d4-4bf9-9486-de5d9fdd33bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e14ddb9f-15ca-47aa-bd3e-300c25269095" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityAddressCityOrTown_e14ddb9f-15ca-47aa-bd3e-300c25269095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_e6d93715-fc6d-4faa-bc33-8c47a397bdeb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityAddressCountry_e6d93715-fc6d-4faa-bc33-8c47a397bdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2fc06aef-2f1c-443f-ade2-1a2881e6b68e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_EntityCentralIndexKey_2fc06aef-2f1c-443f-ade2-1a2881e6b68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7e78f640-830c-4486-b3bb-40d1962405e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_CurrentFiscalYearEndDate_7e78f640-830c-4486-b3bb-40d1962405e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d067aae4-2044-4966-9b18-2925d5d1c3dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_AmendmentFlag_d067aae4-2044-4966-9b18-2925d5d1c3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cd9c0b3c-cc52-46b6-99dc-07b0ae8f776d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_DocumentFiscalYearFocus_cd9c0b3c-cc52-46b6-99dc-07b0ae8f776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_92988ade-3256-40bc-b470-e7e8e1f48315" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_47074bad-4d99-467c-a4fa-f0e39e46b3d9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_92988ade-3256-40bc-b470-e7e8e1f48315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofOperations"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_9917f705-2cd0-4ec9-8edb-1309e03796d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_9917f705-2cd0-4ec9-8edb-1309e03796d1" xlink:to="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:to="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2e221880-5390-414f-aac4-725c39c2905e" xlink:to="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProductRevenueNetMember_a451a96e-32dd-43e8-b25b-e93b847c4a2e" xlink:href="adc-20220930.xsd#adc_ProductRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:to="loc_adc_ProductRevenueNetMember_a451a96e-32dd-43e8-b25b-e93b847c4a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseRevenueMember_8c2b0106-6523-4535-b3f2-537340b9c9c7" xlink:href="adc-20220930.xsd#adc_LicenseRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1d74daa8-ec63-4f27-b029-c0087c002044" xlink:to="loc_adc_LicenseRevenueMember_8c2b0106-6523-4535-b3f2-537340b9c9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementTable_c23aa075-8d30-44de-9d49-278fe9f2ae87" xlink:to="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_fa84f612-25b5-4869-bade-f6c411f34841" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_fa84f612-25b5-4869-bade-f6c411f34841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_8907851c-0dce-4dde-85ea-00c3e4a6e3b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_CostOfSales_8907851c-0dce-4dde-85ea-00c3e4a6e3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_2e1bf753-d2c2-4407-8f6a-46498ed3a44b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_2e1bf753-d2c2-4407-8f6a-46498ed3a44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_b2bc9c3b-df51-44e1-b58d-9f10298586a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_b2bc9c3b-df51-44e1-b58d-9f10298586a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_7b8cc2fb-1bbc-4282-b04a-bcead97b7342" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_7b8cc2fb-1bbc-4282-b04a-bcead97b7342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_b12978ff-5510-4ef4-95e0-85c0f375c42b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_OperatingExpense_b12978ff-5510-4ef4-95e0-85c0f375c42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_8235f2b6-c52c-476e-aead-7386f9288ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_8235f2b6-c52c-476e-aead-7386f9288ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:href="adc-20220930.xsd#adc_OtherIncomeExpenseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_a4e27c9b-1ac9-4ff7-b03e-9b905b34bd88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_ifrs-full_FinanceIncome_a4e27c9b-1ac9-4ff7-b03e-9b905b34bd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_8a145d4a-6f0c-423f-92ce-af1681b4d7e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_ifrs-full_FinanceCosts_8a145d4a-6f0c-423f-92ce-af1681b4d7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncome_166a959d-a8d9-489e-a955-5d2a4cdc0c0b" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_adc_OtherNonOperatingIncome_166a959d-a8d9-489e-a955-5d2a4cdc0c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OtherNonOperatingIncomeExpense_bf333c2b-8189-4f77-a0ff-1a1921c9a5fc" xlink:href="adc-20220930.xsd#adc_OtherNonOperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_OtherIncomeExpenseAbstract_fc2c92a7-4f8c-4cfb-9fb1-daa29d5411f9" xlink:to="loc_adc_OtherNonOperatingIncomeExpense_bf333c2b-8189-4f77-a0ff-1a1921c9a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_3265a0ab-8b64-4728-bb32-82c49c3cb96c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_3265a0ab-8b64-4728-bb32-82c49c3cb96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_9d7f3769-1cdf-42f1-a08b-933ac919465f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_9d7f3769-1cdf-42f1-a08b-933ac919465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_78caab85-e1d8-44fd-8a3c-94dc21db4409" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLoss_78caab85-e1d8-44fd-8a3c-94dc21db4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_3eafff15-3a45-4974-b592-07f272e18d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_ProfitLossAttributableToAbstract_3eafff15-3a45-4974-b592-07f272e18d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_93d25858-6c72-4e2f-8910-ad81d8322ebb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_3eafff15-3a45-4974-b592-07f272e18d99" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_93d25858-6c72-4e2f-8910-ad81d8322ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_dd0dff51-3def-46e0-947b-81e01add6646" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_4f763261-9306-436a-9e61-186f16c9fcc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_4f763261-9306-436a-9e61-186f16c9fcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_4e5b0a4a-1bea-4b3a-8fa5-4af1297d7424" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7935f5e8-57e6-47c7-823b-7540c27b3c8e" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_4e5b0a4a-1bea-4b3a-8fa5-4af1297d7424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_c156f75f-5e42-43f6-8701-ef3af484338f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_98297045-d228-4f68-97a6-eaeabb09b95a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c156f75f-5e42-43f6-8701-ef3af484338f" xlink:to="loc_ifrs-full_ProfitLoss_98297045-d228-4f68-97a6-eaeabb09b95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_c156f75f-5e42-43f6-8701-ef3af484338f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract_bba02b30-c89b-4ce4-b057-48143ef546ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract_bba02b30-c89b-4ce4-b057-48143ef546ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_fe8e22cf-2c5a-49b0-9ecc-e83313cd3f6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract_bba02b30-c89b-4ce4-b057-48143ef546ce" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_fe8e22cf-2c5a-49b0-9ecc-e83313cd3f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a89363a2-c236-40f6-bda9-dc21879a76f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract_bba02b30-c89b-4ce4-b057-48143ef546ce" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_a89363a2-c236-40f6-bda9-dc21879a76f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4ce05244-23cd-437f-86b2-f67e9d963f30" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:to="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4ce05244-23cd-437f-86b2-f67e9d963f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_7fa487d2-de89-44b7-8550-87f4fd37d346" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4ce05244-23cd-437f-86b2-f67e9d963f30" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_7fa487d2-de89-44b7-8550-87f4fd37d346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_1b8a6ae4-16cf-44ca-894b-050ab468067e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_4ce05244-23cd-437f-86b2-f67e9d963f30" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_1b8a6ae4-16cf-44ca-894b-050ab468067e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_714b4dff-cda8-48e8-ba9d-8bb20b037477" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_714b4dff-cda8-48e8-ba9d-8bb20b037477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_9d3bc7b7-af19-4752-ab71-735dcffeae37" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:to="loc_ifrs-full_ComprehensiveIncome_9d3bc7b7-af19-4752-ab71-735dcffeae37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_9bf4ee08-3893-41bc-b76b-859ebc409c64" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_7f33fe47-df76-43d7-ae89-ddfc044ed29f" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_9bf4ee08-3893-41bc-b76b-859ebc409c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_931cf79b-e89b-4521-9a3b-ed68a7d9db49" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_9bf4ee08-3893-41bc-b76b-859ebc409c64" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_931cf79b-e89b-4521-9a3b-ed68a7d9db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimBalanceSheet"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_395b4082-3103-47c5-9017-6a1209b88bae" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:href="adc-20220930.xsd#adc_ConsolidatedStatementOfFinancialPositionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_395b4082-3103-47c5-9017-6a1209b88bae" xlink:to="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4a6ee0d4-0952-44cd-abd8-d81856181e62" xlink:to="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoansMember_b267c3a2-f9ca-4a12-a18d-25c6d43d74fc" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:to="loc_adc_SeniorSecuredTermLoansMember_b267c3a2-f9ca-4a12-a18d-25c6d43d74fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansMember_7e6496e1-3a47-4178-8a40-da70620f725f" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_ca4239cd-55e5-47f7-816e-85068c94264e" xlink:to="loc_adc_ConvertibleLoansMember_7e6496e1-3a47-4178-8a40-da70620f725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:href="adc-20220930.xsd#adc_ConsolidatedStatementOfFinancialPositionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionTable_e61e3c46-e993-410a-8710-d4a163dfaa7c" xlink:to="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:to="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_afcbca74-aa64-4c16-8391-6a84f3db1ca9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_afcbca74-aa64-4c16-8391-6a84f3db1ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_225b3359-51ae-45aa-837e-32813329b99d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_225b3359-51ae-45aa-837e-32813329b99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_cca239d6-d01f-40ea-a7c4-f3ec6d4f1c0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_Inventories_cca239d6-d01f-40ea-a7c4-f3ec6d4f1c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_66b2be21-9a3b-45e3-a564-2f9753118615" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_OtherCurrentAssets_66b2be21-9a3b-45e3-a564-2f9753118615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_657092dc-9d75-439e-b8c8-579b94f16a54" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_18bdd838-8168-48b2-b331-a755cf3f79a6" xlink:to="loc_ifrs-full_CurrentAssets_657092dc-9d75-439e-b8c8-579b94f16a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_ca857ec4-f74d-49c6-bb8c-ca6ed4482c90" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_ca857ec4-f74d-49c6-bb8c-ca6ed4482c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_ad3fd79e-b287-483b-85e2-a526a2fa88e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_RightofuseAssets_ad3fd79e-b287-483b-85e2-a526a2fa88e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_92a2de36-93e8-476d-94b0-5bd3fd08b263" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_92a2de36-93e8-476d-94b0-5bd3fd08b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_3b5876a4-46e8-412c-9fa0-b9a3919893bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_3b5876a4-46e8-412c-9fa0-b9a3919893bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetDeferredTaxAssets_bec5b1fb-f7ad-4dd9-bad5-7c82deddf31f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_NetDeferredTaxAssets_bec5b1fb-f7ad-4dd9-bad5-7c82deddf31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentAssets_76b69c5e-8b0c-4596-bf3f-c72c584a23b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_OtherNoncurrentAssets_76b69c5e-8b0c-4596-bf3f-c72c584a23b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_ee005cfa-131a-4719-8239-1dc00e1ec294" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_6e5c757f-0ec4-48b2-9027-ee4e2e8cb181" xlink:to="loc_ifrs-full_NoncurrentAssets_ee005cfa-131a-4719-8239-1dc00e1ec294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_65e4c286-5cb3-4c70-ad45-95b66854d970" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_9fdca542-d49e-4b29-9bed-ea4923c7f62f" xlink:to="loc_ifrs-full_Assets_65e4c286-5cb3-4c70-ad45-95b66854d970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ConsolidatedStatementOfFinancialPositionLineItems_d49c3001-c684-4806-98b0-2787440dbcd7" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_a06aa45b-c220-4572-8089-0c7280ceacbc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_a06aa45b-c220-4572-8089-0c7280ceacbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0ad31fab-7032-4770-965e-4b000e39fd9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_0ad31fab-7032-4770-965e-4b000e39fd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_85005234-01f4-499f-b900-808268236850" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_85005234-01f4-499f-b900-808268236850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_3c50ae8b-86e7-4b7f-95f3-b5908adc56f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentTaxLiabilitiesCurrent_3c50ae8b-86e7-4b7f-95f3-b5908adc56f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShortTermBorrowings_eab6a967-d4cb-4091-9756-e7ecaa4ace46" xlink:href="adc-20220930.xsd#adc_ShortTermBorrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_adc_ShortTermBorrowings_eab6a967-d4cb-4091-9756-e7ecaa4ace46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_6c48e0e3-58aa-40d0-8e87-e33c4557c657" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_6c48e0e3-58aa-40d0-8e87-e33c4557c657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_65c9db0a-b174-4e7b-b2cf-4943fa1da2e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_1de27277-fc1f-4cf5-8e37-df540c75a3c4" xlink:to="loc_ifrs-full_CurrentLiabilities_65c9db0a-b174-4e7b-b2cf-4943fa1da2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_c802e936-1b83-46dd-94a8-f0ce0052d1be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_LongtermBorrowings_c802e936-1b83-46dd-94a8-f0ce0052d1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_150f9918-b1f5-4535-8d2b-4415fba56000" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_150f9918-b1f5-4535-8d2b-4415fba56000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentWarrantLiability_5c666e2d-2ddc-4225-a03c-9446c1cc583f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentWarrantLiability_5c666e2d-2ddc-4225-a03c-9446c1cc583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationNoncurrent_c0671c7c-e449-4c1d-81a6-a5e364b81708" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_adc_DeferredRoyaltyObligationNoncurrent_c0671c7c-e449-4c1d-81a6-a5e364b81708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_9da2d434-01b3-492c-861f-c2d1344cd8dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures_9da2d434-01b3-492c-861f-c2d1344cd8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_207f2094-b80b-4d7e-90e0-6f90c80fb690" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_207f2094-b80b-4d7e-90e0-6f90c80fb690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_a8d46486-9727-45ce-a7ec-76679899872e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan_a8d46486-9727-45ce-a7ec-76679899872e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_f1a55176-1436-416f-af6e-fd2b7d0ace2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a8896089-beeb-48af-9bd9-4c99190c48cb" xlink:to="loc_ifrs-full_NoncurrentLiabilities_f1a55176-1436-416f-af6e-fd2b7d0ace2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_218e8e22-d62d-4eaf-989c-019b7ec3dec2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_Liabilities_218e8e22-d62d-4eaf-989c-019b7ec3dec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_c9097c83-5045-4d6c-8f4d-9a776a09aad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_IssuedCapital_c9097c83-5045-4d6c-8f4d-9a776a09aad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_f557c7be-4f69-477a-8bc4-2ea474382414" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_SharePremium_f557c7be-4f69-477a-8bc4-2ea474382414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasuryShares_6c005e77-d5b7-41c5-b167-5442ebd0c1cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_TreasuryShares_6c005e77-d5b7-41c5-b167-5442ebd0c1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_a5f4e3aa-45a4-4410-b4dc-fc30512d21d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_OtherReserves_a5f4e3aa-45a4-4410-b4dc-fc30512d21d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_4dff10f6-da4a-4c4e-becc-fbbe3b5d8087" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslation_4dff10f6-da4a-4c4e-becc-fbbe3b5d8087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_69cdfe51-adce-4501-85f6-0e50d0d1d04a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_RetainedEarnings_69cdfe51-adce-4501-85f6-0e50d0d1d04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f9bb0bcb-399a-4b5a-b582-361063c39a6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_62d38d1f-7418-455e-8f03-091df971206f" xlink:to="loc_ifrs-full_Equity_f9bb0bcb-399a-4b5a-b582-361063c39a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_17a64e50-ba56-48ef-aac9-a71e368f0486" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_fd3a8606-4bc0-4066-8dd2-9cfb55258c37" xlink:to="loc_ifrs-full_EquityAndLiabilities_17a64e50-ba56-48ef-aac9-a71e368f0486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofChangesinEquity"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_14e58f66-423b-4180-af89-95692d927783" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_14e58f66-423b-4180-af89-95692d927783" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8fb44bff-44e0-4563-990a-75b4b3c4bd13" xlink:to="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_122a7ca0-b22f-49eb-8fc5-f66e77cc190b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_IssuedCapitalMember_122a7ca0-b22f-49eb-8fc5-f66e77cc190b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a0d64d59-7aa9-4942-9ce1-6082956f4bdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_SharePremiumMember_a0d64d59-7aa9-4942-9ce1-6082956f4bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReservesMember_9bc0255e-2686-497e-84f1-83fdf8b7f13d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_OtherReservesMember_9bc0255e-2686-497e-84f1-83fdf8b7f13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TreasurySharesMember_76f644f7-2553-4abc-86e5-da948c0b8081" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_TreasurySharesMember_76f644f7-2553-4abc-86e5-da948c0b8081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_e5097a01-795a-4748-b5eb-e17bf6c91d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_e5097a01-795a-4748-b5eb-e17bf6c91d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_c67f663a-ee55-48da-ad1a-d89853e44902" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5e9ab922-1c01-43d8-9c0b-5e38be83d5ea" xlink:to="loc_ifrs-full_RetainedEarningsMember_c67f663a-ee55-48da-ad1a-d89853e44902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_e0673d90-ad92-4815-bc55-196225138fe1" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_0dacefe8-6ed3-49e7-b4eb-0fc197dae84a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_Equity_0dacefe8-6ed3-49e7-b4eb-0fc197dae84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_b9faba70-53d1-4e7a-bf37-2b3ce1c5df2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_ProfitLoss_b9faba70-53d1-4e7a-bf37-2b3ce1c5df2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_2719f1f2-6484-421a-9d62-f902827fb0c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_2719f1f2-6484-421a-9d62-f902827fb0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47cf482f-63d2-49c4-9af4-9904323c47c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_47cf482f-63d2-49c4-9af4-9904323c47c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_6c7e5d92-8749-4f50-a5de-eea50fff48c1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_6c7e5d92-8749-4f50-a5de-eea50fff48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ba500442-c53d-416b-b398-c22536e9911e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_ComprehensiveIncome_ba500442-c53d-416b-b398-c22536e9911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_aeb2f36e-6451-46f0-976c-856c4cc9b4e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_aeb2f36e-6451-46f0-976c-856c4cc9b4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughExchangeAgreement_add34a5e-acfd-4a79-a92a-a0681db589cf" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughExchangeAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_adc_IssueOfEquityThroughExchangeAgreement_add34a5e-acfd-4a79-a92a-a0681db589cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughPurchaseAgreement_40d64160-9360-4eab-b416-e69d02361703" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughPurchaseAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_adc_IssueOfEquityThroughPurchaseAgreement_40d64160-9360-4eab-b416-e69d02361703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_b1bad8f7-cae2-4454-8ce3-92ce835d0566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_b1bad8f7-cae2-4454-8ce3-92ce835d0566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_82d2ead5-73ee-484c-8631-5e436f616f7b" xlink:href="adc-20220930.xsd#adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption_82d2ead5-73ee-484c-8631-5e436f616f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_ace6152d-9153-49c5-841f-c3f682c69977" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_ace6152d-9153-49c5-841f-c3f682c69977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_51967bbe-45ae-45da-8c28-325cc0c8236c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_51967bbe-45ae-45da-8c28-325cc0c8236c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_d3117020-52bd-47e2-ac92-5f4f28249dc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_b7c300a9-f02a-401c-8919-0db6a81ff636" xlink:to="loc_ifrs-full_Equity_d3117020-52bd-47e2-ac92-5f4f28249dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" xlink:type="simple" xlink:href="adc-20220930.xsd#CondensedConsolidatedInterimStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_825e59f4-53dd-4330-84b3-5d4b871c6293" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_ProfitLoss_825e59f4-53dd-4330-84b3-5d4b871c6293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_9b8051b2-f9f6-44d6-8d11-fc49fb3cd607" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_9b8051b2-f9f6-44d6-8d11-fc49fb3cd607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_36a9219a-6b7d-4854-b02b-bddcd0ce4032" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_36a9219a-6b7d-4854-b02b-bddcd0ce4032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_f8354491-acd6-4732-a61f-2395a2349862" xlink:href="adc-20220930.xsd#adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment_f8354491-acd6-4732-a61f-2395a2349862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense_2858961e-ac5d-4b33-b3e5-d041eb9c1da7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense_2858961e-ac5d-4b33-b3e5-d041eb9c1da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_f140fbfe-1a14-41cd-b3f7-b1842e076671" xlink:href="adc-20220930.xsd#adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets_f140fbfe-1a14-41cd-b3f7-b1842e076671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_4a83a299-3630-4c87-b945-8a80ecd547b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_4a83a299-3630-4c87-b945-8a80ecd547b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_eef549a0-57e9-4a57-853c-7bc7652ef320" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_eef549a0-57e9-4a57-853c-7bc7652ef320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_dde36fc4-69ff-4ac2-9549-2a37689fd5b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_dde36fc4-69ff-4ac2-9549-2a37689fd5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_e641e219-2d0d-4062-b4e2-e1111b4c3377" xlink:href="adc-20220930.xsd#adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability_e641e219-2d0d-4062-b4e2-e1111b4c3377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_b2ddcccd-0395-41f8-be62-52232d2e2233" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_b2ddcccd-0395-41f8-be62-52232d2e2233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_d78c2d7a-daec-465f-b03d-85db72125445" xlink:href="adc-20220930.xsd#adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants_d78c2d7a-daec-465f-b03d-85db72125445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_14b2eda5-f69c-48bc-9f57-9ea9df4cfac3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_14b2eda5-f69c-48bc-9f57-9ea9df4cfac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_ab000411-8137-43d3-889f-61e1ddf1a235" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_ab000411-8137-43d3-889f-61e1ddf1a235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings_69495679-8aaf-43ff-b8a5-312cf23bbfe9" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_adc_GainsLossOnExtinguishmentOfBorrowings_69495679-8aaf-43ff-b8a5-312cf23bbfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_22d205ba-45ea-4bef-bb66-3eef52984be7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_22d205ba-45ea-4bef-bb66-3eef52984be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_35bff2ed-05e1-4aa7-89c2-f9d3ffbfbd5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_b0a7601a-d07f-44dc-b241-b9e934b01aed" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_35bff2ed-05e1-4aa7-89c2-f9d3ffbfbd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_aebbb639-1473-4ab4-8855-c798ea1f7e1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_aebbb639-1473-4ab4-8855-c798ea1f7e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_2414ad46-b3aa-4d15-b0c9-98b488705d9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_2414ad46-b3aa-4d15-b0c9-98b488705d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_21b0c7d9-0e97-46ad-baef-e8b869935c49" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_21b0c7d9-0e97-46ad-baef-e8b869935c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_ee106aca-3a0c-48a3-82fb-45d5080cb337" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_ee106aca-3a0c-48a3-82fb-45d5080cb337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_9b1363be-1a8d-4964-a755-5996131d81d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForIncomeTaxExpense_9b1363be-1a8d-4964-a755-5996131d81d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_af2438aa-bfe8-4b01-8ebe-571a21b3e67c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_af2438aa-bfe8-4b01-8ebe-571a21b3e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_1d2ea951-d698-4c6e-a931-65f83899f1ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_1d2ea951-d698-4c6e-a931-65f83899f1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_4c9d6fb0-a719-4a68-ac63-45165c52fcd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_4c9d6fb0-a719-4a68-ac63-45165c52fcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_7f2d22ad-4259-40b5-8543-0e24657a5c2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_InterestReceivedClassifiedAsOperatingActivities_7f2d22ad-4259-40b5-8543-0e24657a5c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_04dadd29-b011-4fae-8130-84af69c1eb0f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_04dadd29-b011-4fae-8130-84af69c1eb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_d3aeb1ae-f45d-4f6a-bd86-4a006a1511b6" xlink:href="adc-20220930.xsd#adc_PaymentsMadeUnderRoyaltyFinancingTransactions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_adc_PaymentsMadeUnderRoyaltyFinancingTransactions_d3aeb1ae-f45d-4f6a-bd86-4a006a1511b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_6cbda0e7-357e-4a26-8838-432aeb524cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_6cbda0e7-357e-4a26-8838-432aeb524cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_3870776b-58db-4786-b14a-104d87569b1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_a29bef3d-7c92-4c7e-93ef-39170333d6a5" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_3870776b-58db-4786-b14a-104d87569b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4a8a61d2-5d42-45b5-a38b-8e48ccb70afc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4a8a61d2-5d42-45b5-a38b-8e48ccb70afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_203616b6-2dc3-4918-a5e1-6fc5451c07f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4a8a61d2-5d42-45b5-a38b-8e48ccb70afc" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_203616b6-2dc3-4918-a5e1-6fc5451c07f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_303f40d1-891b-4001-9018-ffa8511bd5aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4a8a61d2-5d42-45b5-a38b-8e48ccb70afc" xlink:to="loc_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_303f40d1-891b-4001-9018-ffa8511bd5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentForRentDeposits_60e23011-684c-4213-adef-21ad64f0f770" xlink:href="adc-20220930.xsd#adc_PaymentForRentDeposits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4a8a61d2-5d42-45b5-a38b-8e48ccb70afc" xlink:to="loc_adc_PaymentForRentDeposits_60e23011-684c-4213-adef-21ad64f0f770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_18dfb8d3-a575-4939-bcad-4ee3fc9a047c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4a8a61d2-5d42-45b5-a38b-8e48ccb70afc" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_18dfb8d3-a575-4939-bcad-4ee3fc9a047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_624978bc-78af-45a6-bc61-d3a983dce544" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_624978bc-78af-45a6-bc61-d3a983dce544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_682ac211-6d6c-4fa9-a4c2-0767512e8286" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_682ac211-6d6c-4fa9-a4c2-0767512e8286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansExchange_24ec88d8-6b1a-423b-bcb9-35cac7fb0713" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansExchange"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_adc_ConvertibleLoansExchange_24ec88d8-6b1a-423b-bcb9-35cac7fb0713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_d1724b06-32d1-43b6-b7fb-553149c8e0d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_d1724b06-32d1-43b6-b7fb-553149c8e0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_c3013998-5414-4d69-9244-5435a98ec755" xlink:href="adc-20220930.xsd#adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts_c3013998-5414-4d69-9244-5435a98ec755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_cc918c3e-c988-4fdb-96ea-e452997e0d9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_cc918c3e-c988-4fdb-96ea-e452997e0d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_74a2aa03-02a5-462c-8dbd-efd86a67b6d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_74a2aa03-02a5-462c-8dbd-efd86a67b6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_adc34cd6-1d5b-4383-ad07-c2b3d40a3886" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_1a49fc7d-07d3-4ef3-9bc3-8d0a69861306" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_adc34cd6-1d5b-4383-ad07-c2b3d40a3886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_840e7a37-9f01-46c0-a7e1-ff9ad7349920" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_840e7a37-9f01-46c0-a7e1-ff9ad7349920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1cd5fac5-417c-4093-bc6b-f89a236234fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_1cd5fac5-417c-4093-bc6b-f89a236234fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_006d5075-8349-4447-ba5c-203520b0dc46" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_006d5075-8349-4447-ba5c-203520b0dc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_36d02c57-fa41-44e0-8f98-da0c329dfe54" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_36d02c57-fa41-44e0-8f98-da0c329dfe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SupplementalCashFlowInformationAbstract_cfbd9783-58df-469e-9221-4fe18f0fac53" xlink:href="adc-20220930.xsd#adc_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_5df87a9f-70b6-4c03-8aa1-a6536ec7562c" xlink:to="loc_adc_SupplementalCashFlowInformationAbstract_cfbd9783-58df-469e-9221-4fe18f0fac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssuanceOfShares_df6f2566-be45-4b5a-b7ec-65653eb725c2" xlink:href="adc-20220930.xsd#adc_IssuanceOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SupplementalCashFlowInformationAbstract_cfbd9783-58df-469e-9221-4fe18f0fac53" xlink:to="loc_adc_IssuanceOfShares_df6f2566-be45-4b5a-b7ec-65653eb725c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities_a16de988-5c7f-4f30-89ab-e85e6988c12c" xlink:href="adc-20220930.xsd#adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SupplementalCashFlowInformationAbstract_cfbd9783-58df-469e-9221-4fe18f0fac53" xlink:to="loc_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities_a16de988-5c7f-4f30-89ab-e85e6988c12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CapitalExpendituresIncurredButNotYetPaid_07e72ecb-724c-459d-8639-367bc3e68800" xlink:href="adc-20220930.xsd#adc_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SupplementalCashFlowInformationAbstract_cfbd9783-58df-469e-9221-4fe18f0fac53" xlink:to="loc_adc_CapitalExpendituresIncurredButNotYetPaid_07e72ecb-724c-459d-8639-367bc3e68800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts_9400420b-aee0-463e-b167-9c1417cb8d88" xlink:href="adc-20220930.xsd#adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SupplementalCashFlowInformationAbstract_cfbd9783-58df-469e-9221-4fe18f0fac53" xlink:to="loc_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts_9400420b-aee0-463e-b167-9c1417cb8d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Corporateinformation" xlink:type="simple" xlink:href="adc-20220930.xsd#Corporateinformation"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Corporateinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_220d459e-ebc3-4308-9fc1-1b4e2dec498f" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_08231500-ce94-4cc1-ba4c-64e81f0f2bfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_220d459e-ebc3-4308-9fc1-1b4e2dec498f" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_08231500-ce94-4cc1-ba4c-64e81f0f2bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Basisofpreparation" xlink:type="simple" xlink:href="adc-20220930.xsd#Basisofpreparation"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Basisofpreparation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_5b482fa1-15c1-468c-8b2d-bdd64e4c53e5" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_39f083cc-2796-49cf-8983-24ef4518d929" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_5b482fa1-15c1-468c-8b2d-bdd64e4c53e5" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_39f083cc-2796-49cf-8983-24ef4518d929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Significantaccountingpolicies" xlink:type="simple" xlink:href="adc-20220930.xsd#Significantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Significantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_7fed3166-e163-4c56-9a52-f0fc75c5ec7e" xlink:href="adc-20220930.xsd#adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_71c431e0-1c69-4d78-8679-c8f72646a228" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_7fed3166-e163-4c56-9a52-f0fc75c5ec7e" xlink:to="loc_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_71c431e0-1c69-4d78-8679-c8f72646a228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Financialriskmanagement" xlink:type="simple" xlink:href="adc-20220930.xsd#Financialriskmanagement"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Financialriskmanagement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_eda16100-a9cf-462f-9372-6581bd983654" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_ad7cd84a-ee55-435e-86b4-63233dc9353d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_eda16100-a9cf-462f-9372-6581bd983654" xlink:to="loc_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_ad7cd84a-ee55-435e-86b4-63233dc9353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Productrevenuesnet" xlink:type="simple" xlink:href="adc-20220930.xsd#Productrevenuesnet"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Productrevenuesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RevenueFromContractsWithCustomersAbstract_b9a8934d-fc7b-489c-aa79-4635ddf74093" xlink:href="adc-20220930.xsd#adc_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_9423eaf2-b4ee-4701-b634-bc81b3f6fc5f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_b9a8934d-fc7b-489c-aa79-4635ddf74093" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_9423eaf2-b4ee-4701-b634-bc81b3f6fc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Segmentinformation" xlink:type="simple" xlink:href="adc-20220930.xsd#Segmentinformation"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Segmentinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_OperatingSegmentsAbstract_6318edfc-3171-4830-9892-164c21c2352b" xlink:href="adc-20220930.xsd#adc_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_4ee1b6ae-af0b-4b0d-aeee-389c6ab1f5f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_OperatingSegmentsAbstract_6318edfc-3171-4830-9892-164c21c2352b" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsExplanatory_4ee1b6ae-af0b-4b0d-aeee-389c6ab1f5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Operatingexpense" xlink:type="simple" xlink:href="adc-20220930.xsd#Operatingexpense"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Operatingexpense" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c5f7f108-d6e9-44e4-a377-53bd73ff530c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_16170939-c266-42a1-8554-e00009148124" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c5f7f108-d6e9-44e4-a377-53bd73ff530c" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_16170939-c266-42a1-8554-e00009148124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Cashandcashequivalents" xlink:type="simple" xlink:href="adc-20220930.xsd#Cashandcashequivalents"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Cashandcashequivalents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_4b510d90-e806-492c-9445-30dfc1e08d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_024865cc-f169-481b-9764-cdc79adceb96" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_4b510d90-e806-492c-9445-30dfc1e08d53" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_024865cc-f169-481b-9764-cdc79adceb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="adc-20220930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAbstract_cb796452-7a76-48e0-9321-59b9360cebe8" xlink:href="adc-20220930.xsd#adc_InventoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_3f014703-0f29-4b39-b58f-0f733bdf5e82" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_cb796452-7a76-48e0-9321-59b9360cebe8" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_3f014703-0f29-4b39-b58f-0f733bdf5e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Intangibleassets" xlink:type="simple" xlink:href="adc-20220930.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_IntangibleAssetsAbstract_fbe41d5b-010f-493d-a8fd-9f8edd7ffe7b" xlink:href="adc-20220930.xsd#adc_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_6fda6f8c-cb5e-4604-8b18-1e626993e70c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_IntangibleAssetsAbstract_fbe41d5b-010f-493d-a8fd-9f8edd7ffe7b" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_6fda6f8c-cb5e-4604-8b18-1e626993e70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Nonoperatingincome" xlink:type="simple" xlink:href="adc-20220930.xsd#Nonoperatingincome"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Nonoperatingincome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3fb74800-d919-4500-bb6a-62f8174fedc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock_82da5b7d-5ddc-4285-8689-82efcdb27ffd" xlink:href="adc-20220930.xsd#adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3fb74800-d919-4500-bb6a-62f8174fedc6" xlink:to="loc_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock_82da5b7d-5ddc-4285-8689-82efcdb27ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Interestinjointventure" xlink:type="simple" xlink:href="adc-20220930.xsd#Interestinjointventure"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Interestinjointventure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InterestsInOtherEntitiesAbstract_e0c6dac5-82a7-4324-bd69-882f63cfd35f" xlink:href="adc-20220930.xsd#adc_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesExplanatory_2ab5d6f7-f3f7-41cb-b98b-2afb6465eced" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InterestsInOtherEntitiesAbstract_e0c6dac5-82a7-4324-bd69-882f63cfd35f" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesExplanatory_2ab5d6f7-f3f7-41cb-b98b-2afb6465eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Leases" xlink:type="simple" xlink:href="adc-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract_9935f62d-81f2-44ec-b1e3-58deedbb115d" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_d9836a3f-37ee-44e8-980e-89308becae09" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_9935f62d-81f2-44ec-b1e3-58deedbb115d" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_d9836a3f-37ee-44e8-980e-89308becae09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants" xlink:type="simple" xlink:href="adc-20220930.xsd#Seniorsecuredtermloanfacilityandwarrants"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_b1588ee3-d5f6-4787-a8bd-6e384b30c5a9" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_32e5d2f6-1a3e-40e6-9da6-632023daff8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_b1588ee3-d5f6-4787-a8bd-6e384b30c5a9" xlink:to="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_32e5d2f6-1a3e-40e6-9da6-632023daff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Convertibleloans" xlink:type="simple" xlink:href="adc-20220930.xsd#Convertibleloans"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Convertibleloans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_cf810a96-7046-49c0-a3f9-43915ae786df" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_1680b0df-2425-4a5d-b24e-c35ffaeed65a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_cf810a96-7046-49c0-a3f9-43915ae786df" xlink:to="loc_ifrs-full_DisclosureOfDebtSecuritiesExplanatory_1680b0df-2425-4a5d-b24e-c35ffaeed65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeerfieldWarrants" xlink:type="simple" xlink:href="adc-20220930.xsd#DeerfieldWarrants"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/DeerfieldWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_0d74e124-867a-4ec7-98a5-8970a3c062e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfWarrantsTextBlock_3c20b3aa-4727-4b68-81bf-8309352df991" xlink:href="adc-20220930.xsd#adc_DisclosureOfWarrantsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_0d74e124-867a-4ec7-98a5-8970a3c062e1" xlink:to="loc_adc_DisclosureOfWarrantsTextBlock_3c20b3aa-4727-4b68-81bf-8309352df991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Sharebasedcompensation" xlink:type="simple" xlink:href="adc-20220930.xsd#Sharebasedcompensation"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Sharebasedcompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementsAbstract_bbc6eede-eaf7-4061-be7d-e89ed941ccee" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_fb85fd85-0f32-49b7-b3b5-70d5fffb0d35" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_bbc6eede-eaf7-4061-be7d-e89ed941ccee" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_fb85fd85-0f32-49b7-b3b5-70d5fffb0d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Relatedparties" xlink:type="simple" xlink:href="adc-20220930.xsd#Relatedparties"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Relatedparties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RelatedPartyAbstract_e10a2703-6cc6-44c5-9d9c-3173e32d87d6" xlink:href="adc-20220930.xsd#adc_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_429a2741-95c5-44ca-b21f-7385f8057604" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_e10a2703-6cc6-44c5-9d9c-3173e32d87d6" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_429a2741-95c5-44ca-b21f-7385f8057604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Losspershare" xlink:type="simple" xlink:href="adc-20220930.xsd#Losspershare"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Losspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_7e46fcf3-7ad7-46d5-b331-5e6c4c41faf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_b89789b6-6bd7-4a67-ae30-ba10a7a6fd3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_7e46fcf3-7ad7-46d5-b331-5e6c4c41faf7" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_b89789b6-6bd7-4a67-ae30-ba10a7a6fd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Eventsafterthereportingdate" xlink:type="simple" xlink:href="adc-20220930.xsd#Eventsafterthereportingdate"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Eventsafterthereportingdate" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_d6033385-925a-475f-81a4-a2e1e07bf63e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EventsAfterReportingPeriodAbstract_92005aad-e47d-4692-b69b-e8281c4244dc" xlink:href="adc-20220930.xsd#adc_EventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_b7ac7193-bae4-4784-9ca9-0ef305cc15fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_EventsAfterReportingPeriodAbstract_92005aad-e47d-4692-b69b-e8281c4244dc" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_b7ac7193-bae4-4784-9ca9-0ef305cc15fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Deferredroyaltyobligation" xlink:type="simple" xlink:href="adc-20220930.xsd#Deferredroyaltyobligation"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Deferredroyaltyobligation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationAbstract_77027534-9ca5-4881-90b1-1b0bb230045e" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationTextBlock_28632250-629a-45d0-8007-feea9f5ad1b8" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DeferredRoyaltyObligationAbstract_77027534-9ca5-4881-90b1-1b0bb230045e" xlink:to="loc_adc_DeferredRoyaltyObligationTextBlock_28632250-629a-45d0-8007-feea9f5ad1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_916c97f9-9daa-4e2f-bbba-0dee44453603" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DeferredRoyaltyObligationAbstract_77027534-9ca5-4881-90b1-1b0bb230045e" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_916c97f9-9daa-4e2f-bbba-0dee44453603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/Equity" xlink:type="simple" xlink:href="adc-20220930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareCapitalReservesAndOtherEquityInterestAbstract_69a6c8e3-676a-4135-b846-faf206481043" xlink:href="adc-20220930.xsd#adc_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_45070ac8-8816-4069-9108-4279cabc48f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareCapitalReservesAndOtherEquityInterestAbstract_69a6c8e3-676a-4135-b846-faf206481043" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_45070ac8-8816-4069-9108-4279cabc48f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="adc-20220930.xsd#SignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:href="adc-20220930.xsd#adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_bda5350d-2c1d-490d-9612-255b2e490a1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_bda5350d-2c1d-490d-9612-255b2e490a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_a986723d-b7a3-481f-9ee7-4cc3fadee319" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_a986723d-b7a3-481f-9ee7-4cc3fadee319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock_1628f410-dfe3-4cbc-b04e-7a23dec959f9" xlink:href="adc-20220930.xsd#adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock_1628f410-dfe3-4cbc-b04e-7a23dec959f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock_675e0f6b-2340-4348-a2d4-7fb5cfd43f2b" xlink:href="adc-20220930.xsd#adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock_675e0f6b-2340-4348-a2d4-7fb5cfd43f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock_6f808d74-655f-4134-b888-b44059e5cbac" xlink:href="adc-20220930.xsd#adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock_6f808d74-655f-4134-b888-b44059e5cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_91c2f067-f9ff-4aed-b4f5-02808dce558d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_91c2f067-f9ff-4aed-b4f5-02808dce558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_16251051-4c41-4122-9ceb-0fbc76e4d376" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_16251051-4c41-4122-9ceb-0fbc76e4d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a3494ade-d0b3-41f6-a658-187a246ecb0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_71b79bd1-d49f-4ccb-9ea7-fb72a4475871" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a3494ade-d0b3-41f6-a658-187a246ecb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/BasisofpreparationTables" xlink:type="simple" xlink:href="adc-20220930.xsd#BasisofpreparationTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/BasisofpreparationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_f1619d7c-564e-4718-ac6f-9ffc328ba145" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock_ac2c4e11-31df-4fed-891a-9ca97619591c" xlink:href="adc-20220930.xsd#adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_f1619d7c-564e-4718-ac6f-9ffc328ba145" xlink:to="loc_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock_ac2c4e11-31df-4fed-891a-9ca97619591c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_1c28ef4c-0964-4cc9-9b4a-bf19149bfc57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_f1619d7c-564e-4718-ac6f-9ffc328ba145" xlink:to="loc_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_1c28ef4c-0964-4cc9-9b4a-bf19149bfc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ProductrevenuesnetTables" xlink:type="simple" xlink:href="adc-20220930.xsd#ProductrevenuesnetTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ProductrevenuesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RevenueFromContractsWithCustomersAbstract_cc4f117d-d8b9-4f88-824d-7b9e1e34db8f" xlink:href="adc-20220930.xsd#adc_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock_27d5235a-8bbf-4dca-8094-659ca432044f" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_cc4f117d-d8b9-4f88-824d-7b9e1e34db8f" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock_27d5235a-8bbf-4dca-8094-659ca432044f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock_23e6dc26-b36a-4da0-a6bc-e25db1bcbadc" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_cc4f117d-d8b9-4f88-824d-7b9e1e34db8f" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock_23e6dc26-b36a-4da0-a6bc-e25db1bcbadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/OperatingexpenseTables" xlink:type="simple" xlink:href="adc-20220930.xsd#OperatingexpenseTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/OperatingexpenseTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2d2b7930-7390-4a4c-80e1-a887bd3738d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock_263a09c1-e53b-4c65-957b-f36973a96f24" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_2d2b7930-7390-4a4c-80e1-a887bd3738d3" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock_263a09c1-e53b-4c65-957b-f36973a96f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adc-20220930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAbstract_df481aa5-3054-4ca6-8691-367c0c29ee4e" xlink:href="adc-20220930.xsd#adc_InventoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock_3b8429cb-7acf-40a8-8d69-0f757df3e2f4" xlink:href="adc-20220930.xsd#adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_df481aa5-3054-4ca6-8691-367c0c29ee4e" xlink:to="loc_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock_3b8429cb-7acf-40a8-8d69-0f757df3e2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="adc-20220930.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_IntangibleAssetsAbstract_8f8f9bd4-53fe-47a0-9d2c-95df66f2b820" xlink:href="adc-20220930.xsd#adc_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_aba17f15-9e1e-4364-a663-453f3e569ded" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_IntangibleAssetsAbstract_8f8f9bd4-53fe-47a0-9d2c-95df66f2b820" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory_aba17f15-9e1e-4364-a663-453f3e569ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/NonoperatingincomeTables" xlink:type="simple" xlink:href="adc-20220930.xsd#NonoperatingincomeTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/NonoperatingincomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5bb5f80c-124d-4899-b775-d1b51e4c6ff7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock_e6d53d87-e799-4ce3-8bd2-8606fbd46dce" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5bb5f80c-124d-4899-b775-d1b51e4c6ff7" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock_e6d53d87-e799-4ce3-8bd2-8606fbd46dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureTables" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InterestsInOtherEntitiesAbstract_4b39e0b0-42e1-42af-9a72-ec6b2d849f04" xlink:href="adc-20220930.xsd#adc_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory_eddb2685-7d97-48ff-a386-446df9e37ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InterestsInOtherEntitiesAbstract_4b39e0b0-42e1-42af-9a72-ec6b2d849f04" xlink:to="loc_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory_eddb2685-7d97-48ff-a386-446df9e37ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory_01daeff6-3bcc-4502-8c9a-ffa956561857" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InterestsInOtherEntitiesAbstract_4b39e0b0-42e1-42af-9a72-ec6b2d849f04" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory_01daeff6-3bcc-4502-8c9a-ffa956561857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesTables" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract_b2fb3af3-021f-4162-a918-52c752c746ed" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_096a1fcd-bec3-49cb-9e51-da113998a8c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_b2fb3af3-021f-4162-a918-52c752c746ed" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_096a1fcd-bec3-49cb-9e51-da113998a8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_06467e95-099c-418e-92c6-1cfde2ce1918" xlink:href="adc-20220930.xsd#adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_b2fb3af3-021f-4162-a918-52c752c746ed" xlink:to="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock_06467e95-099c-418e-92c6-1cfde2ce1918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_1cc375bd-2396-499d-ad70-7fafc8482742" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_7c056fbf-b609-44d5-bc18-9aa5d00bfe9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_1cc375bd-2396-499d-ad70-7fafc8482742" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_7c056fbf-b609-44d5-bc18-9aa5d00bfe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_7bfee3a0-1998-4a82-8ec9-9524f7ac4f33" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_1cc375bd-2396-499d-ad70-7fafc8482742" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_7bfee3a0-1998-4a82-8ec9-9524f7ac4f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansTables" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_04b7b411-918a-4468-9306-000c9f80fcc5" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_c49efb14-02e8-4c24-a409-1c3abfc7c8ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_04b7b411-918a-4468-9306-000c9f80fcc5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_c49efb14-02e8-4c24-a409-1c3abfc7c8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_1042758b-9d61-415b-9511-fe25db771cc4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_04b7b411-918a-4468-9306-000c9f80fcc5" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_1042758b-9d61-415b-9511-fe25db771cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_42a025dc-228e-4288-873d-3fc770137f08" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_04b7b411-918a-4468-9306-000c9f80fcc5" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_42a025dc-228e-4288-873d-3fc770137f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsTables" xlink:type="simple" xlink:href="adc-20220930.xsd#DeerfieldWarrantsTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/DeerfieldWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_da9f2442-9550-4d5f-a40c-ab854b30ddd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_38544203-89c8-4796-834a-8fcc8e370fe8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_da9f2442-9550-4d5f-a40c-ab854b30ddd5" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_38544203-89c8-4796-834a-8fcc8e370fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationTables" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementsAbstract_0c03c5ce-6005-4f97-81c7-b0589fd8aa97" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_61a55785-b24a-408f-9b5e-c97ce324dc52" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_0c03c5ce-6005-4f97-81c7-b0589fd8aa97" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_61a55785-b24a-408f-9b5e-c97ce324dc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_6f0129d9-8fe1-4b68-9843-cdff5312ac67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_0c03c5ce-6005-4f97-81c7-b0589fd8aa97" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_6f0129d9-8fe1-4b68-9843-cdff5312ac67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c499e2d3-689d-4f29-8b00-f2d7efd0067f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_0c03c5ce-6005-4f97-81c7-b0589fd8aa97" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c499e2d3-689d-4f29-8b00-f2d7efd0067f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock_d6dd6a68-3508-4798-9a7a-af8ee729618b" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_0c03c5ce-6005-4f97-81c7-b0589fd8aa97" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock_d6dd6a68-3508-4798-9a7a-af8ee729618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/RelatedpartiesTables" xlink:type="simple" xlink:href="adc-20220930.xsd#RelatedpartiesTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/RelatedpartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RelatedPartyAbstract_a1218ed9-4fdb-4a8b-90a7-0f5c01c8c90c" xlink:href="adc-20220930.xsd#adc_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1d097cf9-5d2a-420c-9f6e-53b8ca4c6e49" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_a1218ed9-4fdb-4a8b-90a7-0f5c01c8c90c" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_1d097cf9-5d2a-420c-9f6e-53b8ca4c6e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LosspershareTables" xlink:type="simple" xlink:href="adc-20220930.xsd#LosspershareTables"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_07c043f5-aabf-4fbf-8184-feb9cdfa6bfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_443d6752-3ef6-49a2-8324-9314873e0662" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_07c043f5-aabf-4fbf-8184-feb9cdfa6bfe" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_443d6752-3ef6-49a2-8324-9314873e0662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CorporateinformationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#CorporateinformationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CorporateinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_bb107796-ff27-422a-a0ab-2e1b24a8c1fc" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_bb107796-ff27-422a-a0ab-2e1b24a8c1fc" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_90ad1dcb-5283-4088-a161-82fdeafdc1ba" xlink:to="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_524a7bec-af40-404e-add8-3738e9f1a84e" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_524a7bec-af40-404e-add8-3738e9f1a84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember_4048f6f9-645c-4cd0-9283-375f90fc1843" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_LoanAgreementMember_4048f6f9-645c-4cd0-9283-375f90fc1843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementFirstTrancheMember_1ab6c592-ad66-4cd2-ab9d-55060058331d" xlink:href="adc-20220930.xsd#adc_LoanAgreementFirstTrancheMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_LoanAgreementFirstTrancheMember_1ab6c592-ad66-4cd2-ab9d-55060058331d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementFutureTranchesMember_ed60145f-cefd-4dc2-8f5a-1cd4a955e0f6" xlink:href="adc-20220930.xsd#adc_LoanAgreementFutureTranchesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_20a328cb-dd01-402c-8d5e-543e90fc12e0" xlink:to="loc_adc_LoanAgreementFutureTranchesMember_ed60145f-cefd-4dc2-8f5a-1cd4a955e0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheAxis_8e39a759-08a5-4007-9188-824e51ce641f" xlink:to="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_9a33824e-a7d5-4c62-9c32-3a4d77cb6807" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheOneMember_9a33824e-a7d5-4c62-9c32-3a4d77cb6807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember_5f9126b8-aca8-4383-b102-46a8408d5f3b" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheTwoMember_5f9126b8-aca8-4383-b102-46a8408d5f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember_665f419e-34d2-4aeb-b559-a31dea4c9ac4" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheOnePriceOneMember_665f419e-34d2-4aeb-b559-a31dea4c9ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember_9c250299-d437-47d9-9d61-da1531360ad6" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_2e218d27-bd94-4c43-bb80-248bb22e9db8" xlink:to="loc_adc_WarrantsTrancheOnePriceTwoMember_9c250299-d437-47d9-9d61-da1531360ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_a78287c5-ec7b-481b-b739-501be55aa53a" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockAxis_cb0280ce-a71c-496a-93c6-6b4cc3dfe5d3" xlink:to="loc_adc_SaleOfStockDomain_a78287c5-ec7b-481b-b739-501be55aa53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PurchasersMember_4094762b-d91f-4192-8ade-81447eabc1db" xlink:href="adc-20220930.xsd#adc_PurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockDomain_a78287c5-ec7b-481b-b739-501be55aa53a" xlink:to="loc_adc_PurchasersMember_4094762b-d91f-4192-8ade-81447eabc1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_00c1b93a-27eb-4e6b-bf0e-c8c4e9415e22" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfSubsidiaries_da7cca32-20cb-4018-845e-8b677e4e5870" xlink:href="adc-20220930.xsd#adc_NumberOfSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_NumberOfSubsidiaries_da7cca32-20cb-4018-845e-8b677e4e5870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_348c7676-4c89-43c7-9b75-e5e2aa04ca7d" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_348c7676-4c89-43c7-9b75-e5e2aa04ca7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_54094f45-4aa7-4d02-8706-93908fc2ffe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_CashAndCashEquivalents_54094f45-4aa7-4d02-8706-93908fc2ffe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_ee39ca79-82a1-4c2c-962c-d5e17f24655b" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_ee39ca79-82a1-4c2c-962c-d5e17f24655b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_302ca143-2893-44ff-a27a-e5c2af2d4f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_Borrowings_302ca143-2893-44ff-a27a-e5c2af2d4f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeOfConvertibleNotesForWarrants_4a98d0eb-c83f-4b26-8862-a9fd392c5215" xlink:href="adc-20220930.xsd#adc_ExchangeOfConvertibleNotesForWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_ExchangeOfConvertibleNotesForWarrants_4a98d0eb-c83f-4b26-8862-a9fd392c5215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_ab8eae14-335a-4bd2-aaee-a57956a3a157" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_ConvertibleNotesSharesConverted_ab8eae14-335a-4bd2-aaee-a57956a3a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesValueConverted_d27ca174-e821-49dd-b699-c7d1483e5e92" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesValueConverted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_ConvertibleNotesValueConverted_d27ca174-e821-49dd-b699-c7d1483e5e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice_fcaa4163-a7bc-4637-a532-5d898c1edeaf" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_WarrantsSharesConvertedExercisePrice_fcaa4163-a7bc-4637-a532-5d898c1edeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_0c5f2d1b-a046-4469-8492-24713c7f7822" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_NumberOfSharesIssued_0c5f2d1b-a046-4469-8492-24713c7f7822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockPricePerShare_230b532c-1860-4d7d-9341-8126031dcfd6" xlink:href="adc-20220930.xsd#adc_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_adc_SaleOfStockPricePerShare_230b532c-1860-4d7d-9341-8126031dcfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_bb8645b1-72a1-4efd-841c-383e540ef1fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_83db16b3-8cbe-4201-aad0-c5df362c9c88" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_bb8645b1-72a1-4efd-841c-383e540ef1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#BasisofpreparationScheduleofForeigncurrencyexchangerateDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_5d1ca612-14e3-452e-9de0-e9ae6f88cc43" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_1189aabc-5ebc-4bb1-b6b7-d432897384e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_5d1ca612-14e3-452e-9de0-e9ae6f88cc43" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_1189aabc-5ebc-4bb1-b6b7-d432897384e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AverageForeignExchangeRate_2d3907f3-4713-4c52-b431-a5a3a7b12fcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AverageForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_5d1ca612-14e3-452e-9de0-e9ae6f88cc43" xlink:to="loc_ifrs-full_AverageForeignExchangeRate_2d3907f3-4713-4c52-b431-a5a3a7b12fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#BasisofpreparationAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_88a5bf2f-4ab4-4a4b-a36f-a6ac605db985" xlink:href="adc-20220930.xsd#adc_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract_88a5bf2f-4ab4-4a4b-a36f-a6ac605db985" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:to="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockAxis_c6e31c08-738c-4e4e-b69d-a08d4f4ce865" xlink:to="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareSubscriptionAgreementMember_3a4837d7-a97e-4e92-8f99-d41ce3016b97" xlink:href="adc-20220930.xsd#adc_ShareSubscriptionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:to="loc_adc_ShareSubscriptionAgreementMember_3a4837d7-a97e-4e92-8f99-d41ce3016b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeAgreementMember_445f0b46-1b3a-49a8-b310-c7b3dfe696df" xlink:href="adc-20220930.xsd#adc_ExchangeAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockDomain_bb1458af-6468-437a-9dd2-2ed2ad163dcd" xlink:to="loc_adc_ExchangeAgreementMember_445f0b46-1b3a-49a8-b310-c7b3dfe696df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ecc08e58-2b86-41e1-928d-cf53921287d5" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PensionObligationDiscountRate_eb0b96dc-4e0d-41f5-a3ed-cb979bfa10bc" xlink:href="adc-20220930.xsd#adc_PensionObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_adc_PensionObligationDiscountRate_eb0b96dc-4e0d-41f5-a3ed-cb979bfa10bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_ffaf0b8e-604e-49f4-a997-7ac439ac6859" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_NumberOfSharesIssued_ffaf0b8e-604e-49f4-a997-7ac439ac6859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_df945085-d720-41a4-a7a3-57dfa72000f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_df945085-d720-41a4-a7a3-57dfa72000f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SaleOrIssueOfTreasuryShares_6c13e0d1-312b-4109-83ae-c1dc6f46518b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_e7e9bb05-f0c5-4a31-99b7-cd00a9fb5b1f" xlink:to="loc_ifrs-full_SaleOrIssueOfTreasuryShares_6c13e0d1-312b-4109-83ae-c1dc6f46518b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SignificantaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_ad4d3900-cecc-4340-9917-073f1c92e4ae" xlink:href="adc-20220930.xsd#adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract_ad4d3900-cecc-4340-9917-073f1c92e4ae" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:to="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheAxis_039b483d-50b7-4d5b-a566-d58d09466b64" xlink:to="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_96e74b25-aec3-45d1-aa8c-75cc2b8458bf" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:to="loc_adc_WarrantsTrancheOneMember_96e74b25-aec3-45d1-aa8c-75cc2b8458bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember_0c9b9ccd-efac-41d8-a5ec-1fb9b8f34682" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:to="loc_adc_WarrantsTrancheOnePriceOneMember_0c9b9ccd-efac-41d8-a5ec-1fb9b8f34682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember_27a50ab0-c988-45f2-b8a8-03cfbfb9d4ec" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_9803116c-b973-4f51-a825-c0f18080d170" xlink:to="loc_adc_WarrantsTrancheOnePriceTwoMember_27a50ab0-c988-45f2-b8a8-03cfbfb9d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_7fb39784-c281-4ce6-a3ad-4a9a552a0926" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_c586beaf-d084-4777-904d-9e9bc34fb93a" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_c586beaf-d084-4777-904d-9e9bc34fb93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_7aeb00b8-4865-41d3-ba37-06405002fb6d" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_4a4da4db-c74e-4260-81a6-9f3431662443" xlink:to="loc_adc_ConvertibleNotesSharesConverted_7aeb00b8-4865-41d3-ba37-06405002fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/FinancialriskmanagementDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#FinancialriskmanagementDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/FinancialriskmanagementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_4f5bca00-88da-452d-9923-338a7b2060ab" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_4f5bca00-88da-452d-9923-338a7b2060ab" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:to="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_5824c0ac-988d-4a06-b689-9a3ab1f03235" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_76ab4624-f812-4341-b309-92a07547f846" xlink:to="loc_ifrs-full_TypesOfRisksMember_5824c0ac-988d-4a06-b689-9a3ab1f03235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateRiskMember_fa59ee68-bea7-4ee4-a3cc-e2e31fdd1442" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_5824c0ac-988d-4a06-b689-9a3ab1f03235" xlink:to="loc_ifrs-full_InterestRateRiskMember_fa59ee68-bea7-4ee4-a3cc-e2e31fdd1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_622cdacb-e59a-4e9a-b2de-f565034aa912" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_994e90fe-ee4a-499a-bb82-8de07d0d7c30" xlink:to="loc_ifrs-full_BorrowingsByNameMember_622cdacb-e59a-4e9a-b2de-f565034aa912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember_8c2a12b8-fe87-44f7-93c7-677481efd42a" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_622cdacb-e59a-4e9a-b2de-f565034aa912" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityMember_8c2a12b8-fe87-44f7-93c7-677481efd42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsTable_2be43b3a-6885-49d9-8357-5cbdd632136b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_e1752b8a-b9ea-45d2-80a6-0312cb06137d" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:to="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues_e1752b8a-b9ea-45d2-80a6-0312cb06137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_7a9c7418-ef12-4fce-ada3-5e72ab80925e" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsLineItems_efe35a75-d2bc-4c04-b674-df5fdf0486cd" xlink:to="loc_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues_7a9c7418-ef12-4fce-ada3-5e72ab80925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ProductrevenuesnetDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ProductrevenuesnetDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ProductrevenuesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:href="adc-20220930.xsd#adc_RevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustment_69f62e54-c1e5-4c34-a7bf-1f022afc8815" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_GTNSalesAdjustment_69f62e54-c1e5-4c34-a7bf-1f022afc8815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustmentProvision_0d147385-766a-4243-9c93-b5ad3b31e21d" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustmentProvision"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_GTNSalesAdjustmentProvision_0d147385-766a-4243-9c93-b5ad3b31e21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustmentProvisionPriorPeriodSales_f751b7fd-c1b4-4fb1-8960-ac0aa475f5f9" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustmentProvisionPriorPeriodSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_GTNSalesAdjustmentProvisionPriorPeriodSales_f751b7fd-c1b4-4fb1-8960-ac0aa475f5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustmentCreditsAndPayments_56ec766b-5c04-4da4-852f-44f8d76cbfe5" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustmentCreditsAndPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_GTNSalesAdjustmentCreditsAndPayments_56ec766b-5c04-4da4-852f-44f8d76cbfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GTNSalesAdjustment_fd0f07aa-5fca-4f78-9404-475b09a6f3a4" xlink:href="adc-20220930.xsd#adc_GTNSalesAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_GTNSalesAdjustment_fd0f07aa-5fca-4f78-9404-475b09a6f3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TradeAndOtherCurrentReceivablesSalesAdjustment_0981986f-d9a3-4d91-8ac4-72ad18372c4f" xlink:href="adc-20220930.xsd#adc_TradeAndOtherCurrentReceivablesSalesAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_TradeAndOtherCurrentReceivablesSalesAdjustment_0981986f-d9a3-4d91-8ac4-72ad18372c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment_6f7c647f-7eeb-4b17-b8b2-0c7e19b14a7b" xlink:href="adc-20220930.xsd#adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RevenueFromContractsWithCustomersAbstract_c9809fa3-9cf6-4213-8158-e755d145daf3" xlink:to="loc_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment_6f7c647f-7eeb-4b17-b8b2-0c7e19b14a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ProductrevenuesnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e2faf527-6649-4908-8b86-a393d8fc6cc1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e2faf527-6649-4908-8b86-a393d8fc6cc1" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c0854245-153d-4077-8548-7c363a2d4673" xlink:to="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMember_a509327c-3968-43ae-9eb5-e5dce470ff2f" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:to="loc_adc_LicenseAgreementMember_a509327c-3968-43ae-9eb5-e5dce470ff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ApplicationApprovalMember_1dea3e9d-e5ea-4e5b-8e7d-e6ef52bfebe9" xlink:href="adc-20220930.xsd#adc_ApplicationApprovalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_08cc7f23-8b93-44fa-8f1a-fd2adc72bacb" xlink:to="loc_adc_ApplicationApprovalMember_1dea3e9d-e5ea-4e5b-8e7d-e6ef52bfebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_e2faf527-6649-4908-8b86-a393d8fc6cc1" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMilestonePayments_1982157e-a1df-496e-9250-83f1fffbb245" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_LicenseAgreementMilestonePayments_1982157e-a1df-496e-9250-83f1fffbb245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromLicenseAgreement_6fc16db5-2ed9-45bd-b915-6bad9a62af1e" xlink:href="adc-20220930.xsd#adc_ProceedsFromLicenseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_ProceedsFromLicenseAgreement_6fc16db5-2ed9-45bd-b915-6bad9a62af1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementCappedContribution_0bd8cd5d-6135-4f4d-991e-a5e8e393ff26" xlink:href="adc-20220930.xsd#adc_LicenseAgreementCappedContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_LicenseAgreementCappedContribution_0bd8cd5d-6135-4f4d-991e-a5e8e393ff26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_0cd1112b-71c0-4693-8c68-ad586fe0045c" xlink:href="adc-20220930.xsd#adc_LicenseAgreementPercentOfClinicalTrialCostsPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_2e7ce0af-62a3-446b-b473-bdee88ee6e74" xlink:to="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_0cd1112b-71c0-4693-8c68-ad586fe0045c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SegmentinformationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SegmentinformationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SegmentinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_OperatingSegmentsAbstract_1989ee75-096d-4d6f-97ea-d5bb190d46f4" xlink:href="adc-20220930.xsd#adc_OperatingSegmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfBusinessSegments_e8d5bd7e-704c-42d5-a790-4397fecdb70b" xlink:href="adc-20220930.xsd#adc_NumberOfBusinessSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_OperatingSegmentsAbstract_1989ee75-096d-4d6f-97ea-d5bb190d46f4" xlink:to="loc_adc_NumberOfBusinessSegments_e8d5bd7e-704c-42d5-a790-4397fecdb70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#OperatingexpenseScheduleofExpensesbyNatureDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5f1cdc1e-c7e9-4887-af77-0f666c0b6210" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_5f1cdc1e-c7e9-4887-af77-0f666c0b6210" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:to="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain_bf575cc6-3548-44eb-82d8-311392b55d2f" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ExpensesByNatureAxis_40462b81-9b4e-4411-966d-36ae7f184525" xlink:to="loc_adc_ExpensesByNatureDomain_bf575cc6-3548-44eb-82d8-311392b55d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ExpensesByNatureDomain_bf575cc6-3548-44eb-82d8-311392b55d2f" xlink:to="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExternalCostsMember_b634c0b4-e34e-4cef-af95-35773e72efb3" xlink:href="adc-20220930.xsd#adc_ExternalCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:to="loc_adc_ExternalCostsMember_b634c0b4-e34e-4cef-af95-35773e72efb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeExpensesMember_7cc06c7f-e5d9-4247-9de0-cb254bf85681" xlink:href="adc-20220930.xsd#adc_EmployeeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ExpensesByNatureMember_a99aff6e-afd7-40f1-a2e0-ea3310cbf62b" xlink:to="loc_adc_EmployeeExpensesMember_7cc06c7f-e5d9-4247-9de0-cb254bf85681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_973e31c2-2645-4f1e-a606-8467957f2c94" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_bcc77951-c9be-4254-89d0-3cfc919863dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_CostOfSales_bcc77951-c9be-4254-89d0-3cfc919863dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_d39a4bbb-d0a4-4ea3-b6e0-a592ae3f2b97" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_d39a4bbb-d0a4-4ea3-b6e0-a592ae3f2b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SalesAndMarketingExpense_b9426ccd-235b-4ed0-9db8-7205cf268e4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_SalesAndMarketingExpense_b9426ccd-235b-4ed0-9db8-7205cf268e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_498fc3eb-8aa5-4784-adcd-1d42a3017197" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_498fc3eb-8aa5-4784-adcd-1d42a3017197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_d1648955-2b05-433b-9407-fb719663a90e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_92ee19d4-d28d-4b36-8949-a32add069ba6" xlink:to="loc_ifrs-full_OperatingExpense_d1648955-2b05-433b-9407-fb719663a90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#OperatingexpenseNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_09ffb335-d470-42d5-9ff1-7b1958340af2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_09ffb335-d470-42d5-9ff1-7b1958340af2" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:href="adc-20220930.xsd#adc_InventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:to="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain_d9ee5dc1-99d3-4e0b-888c-d4e38387b45b" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAxis_6e51bd9d-b71e-4490-bdd9-7fa16e884e9a" xlink:to="loc_adc_InventoryDomain_d9ee5dc1-99d3-4e0b-888c-d4e38387b45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ManufacturingOfAntibodiesMember_8a33fafb-d8df-4a40-b6fc-3d8c0f995ea9" xlink:href="adc-20220930.xsd#adc_ManufacturingOfAntibodiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryDomain_d9ee5dc1-99d3-4e0b-888c-d4e38387b45b" xlink:to="loc_adc_ManufacturingOfAntibodiesMember_8a33fafb-d8df-4a40-b6fc-3d8c0f995ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:to="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpensesByNatureDomain_c7a5b610-bdbe-40e3-b1d0-3a0bc56442a1" xlink:href="adc-20220930.xsd#adc_ExpensesByNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ExpensesByNatureAxis_ed0c5378-e16f-4d9f-91d7-a48fc8fc8dca" xlink:to="loc_adc_ExpensesByNatureDomain_c7a5b610-bdbe-40e3-b1d0-3a0bc56442a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExecutiveCompensationMember_7a49b0a7-c240-4165-a5de-6a1e9915af26" xlink:href="adc-20220930.xsd#adc_ExecutiveCompensationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ExpensesByNatureDomain_c7a5b610-bdbe-40e3-b1d0-3a0bc56442a1" xlink:to="loc_adc_ExecutiveCompensationMember_7a49b0a7-c240-4165-a5de-6a1e9915af26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_06c516e3-e1a1-4f9a-8b64-0f10cfb4d556" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_9d80e976-a4af-49a3-bb86-31474b0a6048" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_9d80e976-a4af-49a3-bb86-31474b0a6048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_ba6d7b6c-190c-4c28-9017-21e4528e4320" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_ba6d7b6c-190c-4c28-9017-21e4528e4320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_a05c0efb-2669-456a-add9-320a3159cb0e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_8bd0bdaf-84e8-4676-9d2b-60f61018c513" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_a05c0efb-2669-456a-add9-320a3159cb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/CashandcashequivalentsDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#CashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/CashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_2884aa6e-2d5d-4bd6-930f-95870522335c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_b5f8bb90-2903-4980-a3b4-82e3e3e11018" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_2884aa6e-2d5d-4bd6-930f-95870522335c" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_b5f8bb90-2903-4980-a3b4-82e3e3e11018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:href="adc-20220930.xsd#adc_InventoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_e8d7883b-efe3-4815-9678-8f31bca665d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:to="loc_ifrs-full_RawMaterials_e8d7883b-efe3-4815-9678-8f31bca665d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_2acef072-4d85-4079-b94f-f1b4f3cebf4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WorkInProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:to="loc_ifrs-full_WorkInProgress_2acef072-4d85-4079-b94f-f1b4f3cebf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_733575dd-3568-4efc-80fc-b2c4a4e02795" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:to="loc_ifrs-full_FinishedGoods_733575dd-3568-4efc-80fc-b2c4a4e02795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InventoriesTotal_7e5fa029-8a84-4dbf-b24a-0e56fdcd922d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoriesTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:to="loc_ifrs-full_InventoriesTotal_7e5fa029-8a84-4dbf-b24a-0e56fdcd922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_14a58c4e-1f92-4108-8d37-2b652df6fb81" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:to="loc_ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss_14a58c4e-1f92-4108-8d37-2b652df6fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CurrentFinishedGoodsHeldOnConsignment_51ef1ac9-b763-48c7-acb4-d0c33048e6b9" xlink:href="adc-20220930.xsd#adc_CurrentFinishedGoodsHeldOnConsignment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_ba5544a6-239d-4a96-af8e-9617e6d506a3" xlink:to="loc_adc_CurrentFinishedGoodsHeldOnConsignment_51ef1ac9-b763-48c7-acb4-d0c33048e6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAbstract_c8965ed0-8b92-4caa-a4b1-6b6fb3981da3" xlink:href="adc-20220930.xsd#adc_InventoryAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAbstract_c8965ed0-8b92-4caa-a4b1-6b6fb3981da3" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:href="adc-20220930.xsd#adc_InventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:to="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InventoryDomain_ad34c77c-487f-4404-86a8-9c339b583e07" xlink:href="adc-20220930.xsd#adc_InventoryDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryAxis_452c1d2a-5a01-4a81-ad5d-042f06de7f8b" xlink:to="loc_adc_InventoryDomain_ad34c77c-487f-4404-86a8-9c339b583e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAForRDMember_b430c0ab-553d-4e72-86e6-0abdfe89adfc" xlink:href="adc-20220930.xsd#adc_ZYNLONTAForRDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InventoryDomain_ad34c77c-487f-4404-86a8-9c339b583e07" xlink:to="loc_adc_ZYNLONTAForRDMember_b430c0ab-553d-4e72-86e6-0abdfe89adfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_85c3875c-f2d8-4bdd-a55c-960fb5fe0894" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable_0fc900c5-24ba-4719-b13e-e3d69ca66fad" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_85c3875c-f2d8-4bdd-a55c-960fb5fe0894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_e7484698-623a-46ea-8af2-c611f3f0407b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems_85c3875c-f2d8-4bdd-a55c-960fb5fe0894" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories_e7484698-623a-46ea-8af2-c611f3f0407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#IntangibleassetsRollforwardofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_IntangibleAssetsAbstract_9cc7b3e6-4b5a-4fae-946b-cf57513a9a13" xlink:href="adc-20220930.xsd#adc_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_IntangibleAssetsAbstract_9cc7b3e6-4b5a-4fae-946b-cf57513a9a13" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_993ba20c-aa2b-49bf-af34-c685c0061c8d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensesIndefiniteLivedMember_9ae1e193-6eef-4cd9-9d1c-5a131c5fea1d" xlink:href="adc-20220930.xsd#adc_LicensesIndefiniteLivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_adc_LicensesIndefiniteLivedMember_9ae1e193-6eef-4cd9-9d1c-5a131c5fea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InternalDevelopmentCostsMember_de3e626e-7083-4796-8687-845f89bd82c8" xlink:href="adc-20220930.xsd#adc_InternalDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_adc_InternalDevelopmentCostsMember_de3e626e-7083-4796-8687-845f89bd82c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensesDefiniteLivedMember_7fa1aee9-1e2c-411a-b02c-12ccd3e0e605" xlink:href="adc-20220930.xsd#adc_LicensesDefiniteLivedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_adc_LicensesDefiniteLivedMember_7fa1aee9-1e2c-411a-b02c-12ccd3e0e605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_f2c5df44-be0c-4b80-9fd9-25cfd917bbb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_ifrs-full_ComputerSoftwareMember_f2c5df44-be0c-4b80-9fd9-25cfd917bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_dbc2cbc3-3fec-4eb3-bfda-d2c80daa12a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_fa4e29e6-34d9-458d-a1e6-516261fff244" xlink:to="loc_ifrs-full_LicencesMember_dbc2cbc3-3fec-4eb3-bfda-d2c80daa12a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb7fcbb9-d216-4869-96d8-ca4a2ca36029" xlink:to="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_d7ae5a06-5477-4ec2-a979-97c56a00fd72" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_d7ae5a06-5477-4ec2-a979-97c56a00fd72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_7429bbd4-b7c6-485a-9448-a32b934f986d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_34089e69-4e3a-4014-96dc-11b65e39a935" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_7429bbd4-b7c6-485a-9448-a32b934f986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_f227fe90-63a3-4104-8a60-98959310fd65" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fc9ef611-eb05-4a8a-bc50-229b75943fe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_fc9ef611-eb05-4a8a-bc50-229b75943fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_938fd94b-ef0c-49d0-8b28-dc88c1aefccc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_938fd94b-ef0c-49d0-8b28-dc88c1aefccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TransfersIntangibleAssetsOtherThanGoodwill_709dae8e-5675-47a4-a652-c583dcd08782" xlink:href="adc-20220930.xsd#adc_TransfersIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_adc_TransfersIntangibleAssetsOtherThanGoodwill_709dae8e-5675-47a4-a652-c583dcd08782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_42f01a2c-4e91-4461-a85e-4ecceddfa996" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_42f01a2c-4e91-4461-a85e-4ecceddfa996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_9349a21e-2ef7-4cab-b421-8c28c8baace3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_9349a21e-2ef7-4cab-b421-8c28c8baace3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_85ece1d3-75e3-4266-97bd-f882c8fb489f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_54c4bb70-1329-4496-b5b5-e07e7c83232d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_85ece1d3-75e3-4266-97bd-f882c8fb489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#IntangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_4163f4cf-5d7f-4844-8cb1-381d02e09380" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DosingOfSpecificNumberOfPatientsMember_18523979-63be-4406-8dc9-5debd107791d" xlink:href="adc-20220930.xsd#adc_DosingOfSpecificNumberOfPatientsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_DosingOfSpecificNumberOfPatientsMember_18523979-63be-4406-8dc9-5debd107791d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_b33fe019-fa8e-4a16-ba0c-23f042ef1731" xlink:href="adc-20220930.xsd#adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember_b33fe019-fa8e-4a16-ba0c-23f042ef1731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_7b52eb2a-22fb-471d-9434-52eb123da4f6" xlink:href="adc-20220930.xsd#adc_LicenseToAcquireAnAntibodyZYNLONTAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_LicenseToAcquireAnAntibodyZYNLONTAMember_7b52eb2a-22fb-471d-9434-52eb123da4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAMember_a4b1369b-8723-4278-98b2-57ba44633d61" xlink:href="adc-20220930.xsd#adc_ZYNLONTAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_ZYNLONTAMember_a4b1369b-8723-4278-98b2-57ba44633d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_2c49a81d-d7eb-4a7d-820a-3ed654f13069" xlink:href="adc-20220930.xsd#adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember_2c49a81d-d7eb-4a7d-820a-3ed654f13069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_9035dc8e-c3d8-4282-96b3-19be8ee961b4" xlink:href="adc-20220930.xsd#adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_4ced9514-8e40-4f25-a6f5-81c77e1ad0c6" xlink:to="loc_adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member_9035dc8e-c3d8-4282-96b3-19be8ee961b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:href="adc-20220930.xsd#adc_PaymentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:to="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:href="adc-20220930.xsd#adc_PaymentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PaymentTypeAxis_db0dd79a-6330-4b63-9b18-1e8f7727863e" xlink:to="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_MilestonePaymentMember_1f4fc7db-c2a7-46d5-b224-daa94c10a50e" xlink:href="adc-20220930.xsd#adc_MilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:to="loc_adc_MilestonePaymentMember_1f4fc7db-c2a7-46d5-b224-daa94c10a50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicensePaymentMember_b7c238ee-2e47-40bf-b17d-a09155027fdf" xlink:href="adc-20220930.xsd#adc_LicensePaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PaymentTypeDomain_2f7bb733-8dc3-493d-8159-5e521cd82eec" xlink:to="loc_adc_LicensePaymentMember_b7c238ee-2e47-40bf-b17d-a09155027fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_77cb2d3b-d1da-4c48-8652-44b619d5104d" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_ebea633a-d802-4b89-9ff0-cd74bbed5e18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_ebea633a-d802-4b89-9ff0-cd74bbed5e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8b2cfdd2-0cbd-4db7-824f-9b741b51a6c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_8b2cfdd2-0cbd-4db7-824f-9b741b51a6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_945d05e6-1435-4267-a491-dd08f9b038eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_13cb9907-711d-4314-8a07-e6dbe63320ea" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_945d05e6-1435-4267-a491-dd08f9b038eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a3da8065-9877-43a3-937b-6a8ebb5ccc1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#NonoperatingincomeScheduleofOtherIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e6c0bfeb-92d6-4dad-b290-16f3c5a4c374" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e6c0bfeb-92d6-4dad-b290-16f3c5a4c374" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_cee883cb-c4ec-4a82-b470-c0fc7c16a81d" xlink:to="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_a44a3858-77c0-4858-b9b4-bfb5d8bd7312" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_a44a3858-77c0-4858-b9b4-bfb5d8bd7312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember_6684632f-4586-4ed4-ae25-749e83340531" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_a9df57ca-3014-4b84-8e8f-edb86970cbf8" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityMember_6684632f-4586-4ed4-ae25-749e83340531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_5157dbc9-737e-473c-92f7-6679eb5830e5" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26c90221-740f-4ced-8c03-9467c046d0f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26c90221-740f-4ced-8c03-9467c046d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsDeferredFinancingCosts_0d240b66-156f-4369-a7bb-21403e3fbb71" xlink:href="adc-20220930.xsd#adc_BorrowingsDeferredFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_BorrowingsDeferredFinancingCosts_0d240b66-156f-4369-a7bb-21403e3fbb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings_bd9c7f99-6b7d-4007-aa3f-948209abc81b" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_GainsLossOnExtinguishmentOfBorrowings_bd9c7f99-6b7d-4007-aa3f-948209abc81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnChangeInFairValueWarrants_b62d7d06-2f9b-4a3f-a771-8e381b272f41" xlink:href="adc-20220930.xsd#adc_GainsLossOnChangeInFairValueWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_GainsLossOnChangeInFairValueWarrants_b62d7d06-2f9b-4a3f-a771-8e381b272f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationsTransactionCosts_7c914fb1-d899-4962-add1-a644bf3e5c0e" xlink:href="adc-20220930.xsd#adc_WarrantObligationsTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_WarrantObligationsTransactionCosts_7c914fb1-d899-4962-add1-a644bf3e5c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_7b88c4bf-a0c7-4ad7-babd-604a322e4a86" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod_7b88c4bf-a0c7-4ad7-babd-604a322e4a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ba67d1c0-19da-419d-ac79-9af0dabc1902" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_ba67d1c0-19da-419d-ac79-9af0dabc1902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_534356cf-a350-4f0d-b20a-0685bba311c7" xlink:href="adc-20220930.xsd#adc_TaxEffectOfResearchAndDevelopmentTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_TaxEffectOfResearchAndDevelopmentTaxCredits_534356cf-a350-4f0d-b20a-0685bba311c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NonOperatingIncomeExpense_a1dc08d1-8f8d-4b2f-adfa-58f8931a04d2" xlink:href="adc-20220930.xsd#adc_NonOperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_63f376c0-95ae-451d-b6e7-61e49d8b4c94" xlink:to="loc_adc_NonOperatingIncomeExpense_a1dc08d1-8f8d-4b2f-adfa-58f8931a04d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#NonoperatingincomeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6ee9aaa6-f2ce-489f-a250-d079d4c13d3b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_6ee9aaa6-f2ce-489f-a250-d079d4c13d3b" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_d97897be-8eee-494f-80c6-18fc75790fc3" xlink:to="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_cb8f0896-b5d3-47cf-9fd2-c0af196b8729" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_cb8f0896-b5d3-47cf-9fd2-c0af196b8729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_a614c719-a295-499b-a6ac-c339f910c73f" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_a614c719-a295-499b-a6ac-c339f910c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_0096cc09-d523-4bd4-ac57-848bf06607c5" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_63cb9391-0e38-44ea-8046-f9e87ec0f646" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_0096cc09-d523-4bd4-ac57-848bf06607c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:to="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_b3c9152e-dbb9-417b-acf2-ea743288e85e" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheAxis_5b09e5be-31c7-422f-990c-b0eb50e45c2f" xlink:to="loc_adc_WarrantsTrancheDomain_b3c9152e-dbb9-417b-acf2-ea743288e85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_2aa8f350-2ed2-4caa-8187-c185230fca1b" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_b3c9152e-dbb9-417b-acf2-ea743288e85e" xlink:to="loc_adc_WarrantsTrancheOneMember_2aa8f350-2ed2-4caa-8187-c185230fca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_7e652e37-0842-47ac-8b11-4378565e871d" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_0c110a17-857c-4a3b-861d-b4aa323bf187" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_ifrs-full_Borrowings_0c110a17-857c-4a3b-861d-b4aa323bf187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_19e4c348-e4d2-48e4-a9a7-3d5c3d0c4eb7" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_19e4c348-e4d2-48e4-a9a7-3d5c3d0c4eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_7b5c7e89-71a9-4806-a621-b4b13099c510" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b074a016-ead0-43c6-bb5d-a1d9e59835b1" xlink:to="loc_adc_ConvertibleNotesSharesConverted_7b5c7e89-71a9-4806-a621-b4b13099c510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InterestsInOtherEntitiesAbstract_327a76bd-4289-4ea5-b42f-cb16c48de1bf" xlink:href="adc-20220930.xsd#adc_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InterestsInOtherEntitiesAbstract_327a76bd-4289-4ea5-b42f-cb16c48de1bf" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:to="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_c4ffdec5-664f-45a3-bc60-727a0cd79f51" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_520e4f1a-90ba-4577-b522-7bed5969f8ea" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_c4ffdec5-664f-45a3-bc60-727a0cd79f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_40b4f5f0-064c-4b2b-a324-a266e4643fdd" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_c4ffdec5-664f-45a3-bc60-727a0cd79f51" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_40b4f5f0-064c-4b2b-a324-a266e4643fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_68f48787-8b6f-46e1-b777-8de03ba055c0" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_74d66f20-8955-407e-8057-fcec439d060b" xlink:href="adc-20220930.xsd#adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture_74d66f20-8955-407e-8057-fcec439d060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_dc8d736a-5651-426f-b3b2-8bbf79ad5525" xlink:href="adc-20220930.xsd#adc_NumberOfProductsDevelopedAndCommercializedInJointVenture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture_dc8d736a-5651-426f-b3b2-8bbf79ad5525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredGainOnInvestmentInJointVenture_60cd646d-11b2-4132-9043-0323ba80f4d8" xlink:href="adc-20220930.xsd#adc_DeferredGainOnInvestmentInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_ad2d723a-d233-47cc-9d35-df09db9dfefe" xlink:to="loc_adc_DeferredGainOnInvestmentInJointVenture_60cd646d-11b2-4132-9043-0323ba80f4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureScheduleofmovementininterestinjointventureDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_InterestsInOtherEntitiesAbstract_cff1494a-d698-4741-ad4a-86d777e7e42d" xlink:href="adc-20220930.xsd#adc_InterestsInOtherEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InterestsInOtherEntitiesAbstract_cff1494a-d698-4741-ad4a-86d777e7e42d" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:to="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_90c381b7-7ab6-497b-bcab-a344f4758c7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_ecf7b88d-7d19-4029-b3af-b9598d653608" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_90c381b7-7ab6-497b-bcab-a344f4758c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_01cfba3b-c61d-4184-8ea0-32fde1d20029" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_90c381b7-7ab6-497b-bcab-a344f4758c7a" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_01cfba3b-c61d-4184-8ea0-32fde1d20029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_bf1ca4c2-5800-4374-96c5-283ef8216991" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_62bb25c2-ea59-4235-8229-89ee7ede52d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_62bb25c2-ea59-4235-8229-89ee7ede52d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_c287a7aa-4c66-482b-8801-f7edf575977b" xlink:href="adc-20220930.xsd#adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:to="loc_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults_c287a7aa-4c66-482b-8801-f7edf575977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_aa8cc002-3dae-40e0-a150-de4e3ac2818e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_c0b027b8-b661-48f1-ae15-36707706543e" xlink:to="loc_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod_aa8cc002-3dae-40e0-a150-de4e3ac2818e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#InterestinjointventureSummaryoffinancialinformationinjointventureDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesTable_1aab52ba-0417-4a2b-9729-7b141ea49e04" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_JointVenturesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_1aab52ba-0417-4a2b-9729-7b141ea49e04" xlink:to="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForJointVenturesMember_0e013cfd-fe3c-4a08-afb9-9694434a61ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForJointVenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_JointVenturesAxis_aa85b437-2c60-4414-9555-9cf6e2a76d33" xlink:to="loc_ifrs-full_EntitysTotalForJointVenturesMember_0e013cfd-fe3c-4a08-afb9-9694434a61ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_1ea25946-6264-4a08-9829-61f29b828464" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForJointVenturesMember_0e013cfd-fe3c-4a08-afb9-9694434a61ba" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_1ea25946-6264-4a08-9829-61f29b828464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfJointVenturesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesTable_1aab52ba-0417-4a2b-9729-7b141ea49e04" xlink:to="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6e7e710e-108d-41ba-b9cf-4b1cf70ff8d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6e7e710e-108d-41ba-b9cf-4b1cf70ff8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_4d5e998a-51e7-4d95-bb85-f1e3f649902d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_4d5e998a-51e7-4d95-bb85-f1e3f649902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d73bde9f-a46b-4e3b-b57d-70a74c8540dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d73bde9f-a46b-4e3b-b57d-70a74c8540dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_67d21dd9-ce00-4e13-9532-fc1ad80afde7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_Liabilities_67d21dd9-ce00-4e13-9532-fc1ad80afde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NetAssetsLiabilities_db8763ac-3349-4a64-b8cb-f127fd2faaac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetAssetsLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_NetAssetsLiabilities_db8763ac-3349-4a64-b8cb-f127fd2faaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_4f3290d4-0dde-4fc5-9876-a197fb8f73d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_OperatingExpense_4f3290d4-0dde-4fc5-9876-a197fb8f73d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9d359f3a-23c6-449e-af05-2bb3bfe5f5e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfJointVenturesLineItems_adcd3c41-9215-48cd-81f6-46f54bfe2271" xlink:to="loc_ifrs-full_ProfitLoss_9d359f3a-23c6-449e-af05-2bb3bfe5f5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract_42d51ae9-0f1c-4eaa-a1f7-e789b90cefac" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeaseArea_58a64324-9488-4123-802f-ca15520ca37d" xlink:href="adc-20220930.xsd#adc_LeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_42d51ae9-0f1c-4eaa-a1f7-e789b90cefac" xlink:to="loc_adc_LeaseArea_58a64324-9488-4123-802f-ca15520ca37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesRightofUseAssetsandAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract_1c11505b-6550-4399-a845-f232af0126e6" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_1c11505b-6550-4399-a845-f232af0126e6" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_6ffa13d2-87d6-4377-9778-24c9f0013a2c" xlink:to="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_c394e700-67f4-4ad8-b644-fa86483e08fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:to="loc_ifrs-full_BuildingsMember_c394e700-67f4-4ad8-b644-fa86483e08fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_36b6877e-8bb5-4fd3-8075-a9d81b912863" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsMember_b9eeb8b3-1c09-4361-8cef-e2d4b845a75a" xlink:to="loc_ifrs-full_VehiclesMember_36b6877e-8bb5-4fd3-8075-a9d81b912863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_bf018239-f9e2-4b3b-93c7-199ce29d0cbf" xlink:to="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_eb566c32-3857-45e7-b627-ccaa33596834" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_eb566c32-3857-45e7-b627-ccaa33596834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_55f463eb-e849-402d-8405-4ee5278d1b84" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_d07f2f22-2f98-4954-b521-ba24826dbd6e" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_55f463eb-e849-402d-8405-4ee5278d1b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_6818ce27-b0d5-4065-a59c-87ca56effe55" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_ce58eeda-2319-4411-b640-9a6539392b4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_RightofuseAssets_ce58eeda-2319-4411-b640-9a6539392b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_e093869f-a72c-41b8-beed-0734b2c2b8f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_e093869f-a72c-41b8-beed-0734b2c2b8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_94628050-1185-41f1-94ba-af2323b93f48" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_94628050-1185-41f1-94ba-af2323b93f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_c0d8629c-e990-4f60-9d74-7e1fac2a9564" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_c0d8629c-e990-4f60-9d74-7e1fac2a9564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_3df6208d-e199-48b8-859d-21ad09383708" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets_3df6208d-e199-48b8-859d-21ad09383708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets_8b2a9dfb-240f-44b3-aa7a-f1d327d3255c" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_93fc1c76-de43-42af-8177-042393e34810" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_9f03edd7-7d23-4b5d-a112-7110a4d50138" xlink:to="loc_ifrs-full_RightofuseAssets_93fc1c76-de43-42af-8177-042393e34810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesRightofUseAssetDepreciationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract_b1ab1cac-d901-4e52-bfc0-1565978f4b98" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_b1ab1cac-d901-4e52-bfc0-1565978f4b98" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:to="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:href="adc-20220930.xsd#adc_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_IncomeStatementLocationAxis_87e6b4e0-9dbe-4b43-af54-bf4d781c7193" xlink:to="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResearchAndDevelopmentExpenseMember_73e999bc-ff3b-47a5-8f58-e45743558c47" xlink:href="adc-20220930.xsd#adc_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:to="loc_adc_ResearchAndDevelopmentExpenseMember_73e999bc-ff3b-47a5-8f58-e45743558c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GeneralAndAdministrativeExpenseMember_2ae67ff6-1cd0-4999-9788-b25bc2f9ad51" xlink:href="adc-20220930.xsd#adc_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_IncomeStatementLocationDomain_5647988d-153b-4263-86e0-5fec897b8ce0" xlink:to="loc_adc_GeneralAndAdministrativeExpenseMember_2ae67ff6-1cd0-4999-9788-b25bc2f9ad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_b0561b77-8c03-4f41-9b56-9e1726c8ff76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_caa684e3-381d-4ee1-8f3c-b82ab11e45b8" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_b0561b77-8c03-4f41-9b56-9e1726c8ff76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_edaeed14-28cd-43a5-a4ed-09ae213ffb8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_b0561b77-8c03-4f41-9b56-9e1726c8ff76" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_edaeed14-28cd-43a5-a4ed-09ae213ffb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LeasesScheduleofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_LeasesAbstract_a54a7325-91ac-4254-bde5-8cc07d513890" xlink:href="adc-20220930.xsd#adc_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:href="adc-20220930.xsd#adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_LeasesAbstract_a54a7325-91ac-4254-bde5-8cc07d513890" xlink:to="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f1adfc75-ef9c-4468-b674-de074cc6a505" xlink:to="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BuildingsMember_da102f65-cc9b-481f-a70e-d5897f3bb58d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:to="loc_ifrs-full_BuildingsMember_da102f65-cc9b-481f-a70e-d5897f3bb58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_VehiclesMember_09b5683a-f98e-4864-8a23-308d39fca362" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_VehiclesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_e2e91dd2-2380-4464-aa57-66623d9c80c8" xlink:to="loc_ifrs-full_VehiclesMember_09b5683a-f98e-4864-8a23-308d39fca362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:href="adc-20220930.xsd#adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_6ef77253-74de-4122-ac0d-c3dd49c6e774" xlink:to="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_b0682afa-bef6-40d0-90bc-0f26d0bc8b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_LeaseLiabilities_b0682afa-bef6-40d0-90bc-0f26d0bc8b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AdditionsToLeaseLiabilities_1bd13380-0795-4c40-af96-4bbaa6d5ce80" xlink:href="adc-20220930.xsd#adc_AdditionsToLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_AdditionsToLeaseLiabilities_1bd13380-0795-4c40-af96-4bbaa6d5ce80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_48e36480-4020-42a4-957e-50a504fb94b3" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities_48e36480-4020-42a4-957e-50a504fb94b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_23195504-878b-4113-8cd1-5aaa9421e76d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_CashOutflowForLeases_23195504-878b-4113-8cd1-5aaa9421e76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0c6496f3-f704-4f13-823b-88aa303b02ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_0c6496f3-f704-4f13-823b-88aa303b02ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_55b4d443-afb7-4f19-8b49-3c08109accbb" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities_55b4d443-afb7-4f19-8b49-3c08109accbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_353c4361-080a-4472-b82c-650fca987ac8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_LeaseLiabilities_353c4361-080a-4472-b82c-650fca987ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_04e53e1b-79ae-49a8-8ab4-fe187fd83b4e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_04e53e1b-79ae-49a8-8ab4-fe187fd83b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_673df831-755d-402b-a08e-92be6ce44cef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems_d8ebb482-45fe-4056-b59e-182f50ac44d4" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_673df831-755d-402b-a08e-92be6ce44cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_5e3b977f-9584-4af2-ac53-bf53f5879019" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_5e3b977f-9584-4af2-ac53-bf53f5879019" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_85e96825-2b8a-440e-b8f5-78fbc413b0de" xlink:to="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_6d24ed85-9eea-4b8b-adcf-8201ca08597e" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_6d24ed85-9eea-4b8b-adcf-8201ca08597e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_84ec9e12-37d7-4ea1-97c4-19c70389949e" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ec331e4a-44eb-4104-a2d4-0bf46aa330e0" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_84ec9e12-37d7-4ea1-97c4-19c70389949e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_c2613f71-615f-465c-8c3a-bb5744c3f3c4" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_c2613f71-615f-465c-8c3a-bb5744c3f3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember_df9d1014-3806-4871-9080-fbf929be6a3a" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_LoanAgreementMember_df9d1014-3806-4871-9080-fbf929be6a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityMember_da18abba-ea1b-4490-a598-92cf03adf295" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityMember_da18abba-ea1b-4490-a598-92cf03adf295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_c257974a-b2d5-42b0-af98-fb77b7e0227d" xlink:href="adc-20220930.xsd#adc_OakTreeAndOwlRockWarrantObligationsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_3b0f2516-0c7c-4715-8288-8026305fd08f" xlink:to="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_c257974a-b2d5-42b0-af98-fb77b7e0227d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4cf3ef0a-ee41-4e56-951f-c8f88447fd8c" xlink:to="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_16ccb890-27ee-44e3-b881-b5f4c600d6d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:to="loc_srt_MinimumMember_16ccb890-27ee-44e3-b881-b5f4c600d6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1e00aeb4-03bd-4ef3-9c29-74415bf6de02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24650c76-62f8-41f8-a442-209c002976de" xlink:to="loc_srt_MaximumMember_1e00aeb4-03bd-4ef3-9c29-74415bf6de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_af08675a-6458-4f8a-9bb7-373a5743032b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_7c4b186f-f420-48a9-b810-45632ccfaabf" xlink:to="loc_ifrs-full_RangesMember_af08675a-6458-4f8a-9bb7-373a5743032b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_155b9bc8-5d5a-4f6d-b103-8d4fbe9f7553" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_af08675a-6458-4f8a-9bb7-373a5743032b" xlink:to="loc_ifrs-full_TopOfRangeMember_155b9bc8-5d5a-4f6d-b103-8d4fbe9f7553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingsConversionPeriodAxis_cea08a0b-392e-4276-8006-d99276c76121" xlink:to="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodOneMember_206788e3-59ea-4b9c-910b-1da7bc47c60a" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:to="loc_adc_BorrowingsConversionPeriodOneMember_206788e3-59ea-4b9c-910b-1da7bc47c60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConversionPeriodTwoMember_4d7d57a0-7d61-4f82-bca5-3662716ac6c4" xlink:href="adc-20220930.xsd#adc_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingConversionPeriodDomain_53f1fe94-91ca-4337-ae09-b141c6491b2b" xlink:to="loc_adc_ConversionPeriodTwoMember_4d7d57a0-7d61-4f82-bca5-3662716ac6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d2ea7911-32e8-4f0f-b948-fcfb52984086" xlink:to="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_4416ee6f-8785-4436-952f-df798d525742" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:to="loc_adc_ResidualLoanMember_4416ee6f-8785-4436-952f-df798d525742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_0b6df30b-9884-4e56-b82b-1677e6b5a61f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_5145f5b4-3075-4d7d-89e3-83f2d9f6786b" xlink:to="loc_ifrs-full_DerivativesMember_0b6df30b-9884-4e56-b82b-1677e6b5a61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_cccc2317-ef5e-4dcb-9b3c-1db80dbc8563" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_90bc1da8-2304-4e17-858c-561429a3731d" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_90bc1da8-2304-4e17-858c-561429a3731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_41ca0de8-d1d3-402b-bcf2-ffefa728f520" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_Borrowings_41ca0de8-d1d3-402b-bcf2-ffefa728f520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_4c814f85-bfb8-477b-a190-a00ce8b3f013" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_BorrowingsInterestRate_4c814f85-bfb8-477b-a190-a00ce8b3f013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFacilitiesExitFeePercentage_682496e0-1510-4812-b6ae-d45afe6da6ff" xlink:href="adc-20220930.xsd#adc_BorrowingsFacilitiesExitFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsFacilitiesExitFeePercentage_682496e0-1510-4812-b6ae-d45afe6da6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_55adc4ba-f1b6-4205-8cca-4afc07de97cf" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_55adc4ba-f1b6-4205-8cca-4afc07de97cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_60ae8055-4f59-4d3f-b1dc-3a12f82e05c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_60ae8055-4f59-4d3f-b1dc-3a12f82e05c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_75b3620d-0685-4f79-a842-b534407c3e12" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_75b3620d-0685-4f79-a842-b534407c3e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_525820d6-3aaf-4d6c-b8ed-1548a70619ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_525820d6-3aaf-4d6c-b8ed-1548a70619ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsImpliedEffectiveInterestRate_5e67adbd-24b2-4ca1-aef7-2856bae5e6ce" xlink:href="adc-20220930.xsd#adc_BorrowingsImpliedEffectiveInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsImpliedEffectiveInterestRate_5e67adbd-24b2-4ca1-aef7-2856bae5e6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_1b71b16e-0deb-4df5-a4ba-8db66cf64ee9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LoansReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_LoansReceived_1b71b16e-0deb-4df5-a4ba-8db66cf64ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_54c940c0-edf8-478c-953a-0e2a615468be" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_54c940c0-edf8-478c-953a-0e2a615468be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_e8fa45bf-0af5-4428-9667-b5393496723a" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_e8fa45bf-0af5-4428-9667-b5393496723a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f079a4c7-4736-40a3-98e8-bc70b1f050fc" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f079a4c7-4736-40a3-98e8-bc70b1f050fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_f84608e6-600c-44da-9fcb-a5c177842394" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_f84608e6-600c-44da-9fcb-a5c177842394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_1df1f7cc-5f96-4f1a-86c5-eacfe8f8d57b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_1df1f7cc-5f96-4f1a-86c5-eacfe8f8d57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_c503dfe5-4d34-43be-830b-dc3b478d1d91" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_c503dfe5-4d34-43be-830b-dc3b478d1d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_b5686bb7-3ff9-4fb9-be80-05f896f1b3b9" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_ConvertibleNotesSharesConverted_b5686bb7-3ff9-4fb9-be80-05f896f1b3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice_95a5b69b-f065-4d92-94d4-584c60389edf" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_WarrantsSharesConvertedExercisePrice_95a5b69b-f065-4d92-94d4-584c60389edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationFairValue_a829c1bc-61b9-4c75-873b-f86a7a083047" xlink:href="adc-20220930.xsd#adc_WarrantObligationFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_WarrantObligationFairValue_a829c1bc-61b9-4c75-873b-f86a7a083047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFairValue_24e1826b-5c2c-4882-b8bc-e643ddcbb50a" xlink:href="adc-20220930.xsd#adc_BorrowingsFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0de81d80-a0e2-4ccc-a514-2d80e368feb4" xlink:to="loc_adc_BorrowingsFairValue_24e1826b-5c2c-4882-b8bc-e643ddcbb50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_9c9b8d87-dd40-4aa3-be54-c5fdc28da41f" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_9c9b8d87-dd40-4aa3-be54-c5fdc28da41f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_b057dd83-0478-4c08-a45f-abfd6eea8ec4" xlink:to="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WrittenPutOptionsMember_d9caa011-2fdb-458f-b0a1-c64f2dbcdf9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WrittenPutOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_ifrs-full_WrittenPutOptionsMember_d9caa011-2fdb-458f-b0a1-c64f2dbcdf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember_9ac1561d-e50a-4f2d-a939-e0db09f561c1" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_SharePriceMember_9ac1561d-e50a-4f2d-a939-e0db09f561c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember_7c851947-c5d0-4561-9223-25d57bf8349f" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_RiskFreeInterestRateMember_7c851947-c5d0-4561-9223-25d57bf8349f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember_256ca636-d63e-4b05-91ef-a1ab1754e2d4" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_ExpectedVolatilityMember_256ca636-d63e-4b05-91ef-a1ab1754e2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember_16b9432f-66fa-401c-b3b3-60829c369e31" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_ExpectedTermMember_16b9432f-66fa-401c-b3b3-60829c369e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DividendYieldMember_6f42305a-622a-4904-9795-ac4a84de2320" xlink:href="adc-20220930.xsd#adc_DividendYieldMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_DividendYieldMember_6f42305a-622a-4904-9795-ac4a84de2320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BlackScholesValueMember_d347aeda-23df-44a2-b247-e3ce0d7a926f" xlink:href="adc-20220930.xsd#adc_BlackScholesValueMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_641fdc71-ca69-4e05-9945-c40d90fbce1d" xlink:to="loc_adc_BlackScholesValueMember_d347aeda-23df-44a2-b247-e3ce0d7a926f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_43eb673a-3359-4643-82ab-75605e3805aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_615b3635-7f30-4dcc-986b-ec40798d3b9a" xlink:to="loc_ifrs-full_LiabilitiesMember_43eb673a-3359-4643-82ab-75605e3805aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_24507e42-258f-49cd-976e-2daca4cc3724" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_43eb673a-3359-4643-82ab-75605e3805aa" xlink:to="loc_ifrs-full_DerivativesMember_24507e42-258f-49cd-976e-2daca4cc3724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_685d772f-8284-4770-82f3-3e50e04c46ee" xlink:to="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_9b34bcec-b640-4e52-9676-2aa16125cb97" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_9b34bcec-b640-4e52-9676-2aa16125cb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_934dbc89-1ad3-41c2-b79e-2271f7abfe65" xlink:href="adc-20220930.xsd#adc_OakTreeAndOwlRockWarrantObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_816a0de2-c17f-49fa-a5b1-2ee79ca1b274" xlink:to="loc_adc_OakTreeAndOwlRockWarrantObligationsMember_934dbc89-1ad3-41c2-b79e-2271f7abfe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b7dff7aa-74ae-4d1c-8ba2-a12504e1518f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2142d3d6-9726-408c-9fa8-b1dbc0cd3494" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b7dff7aa-74ae-4d1c-8ba2-a12504e1518f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_140e5ee3-4cdc-4e26-8b84-aed906baa26a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b7dff7aa-74ae-4d1c-8ba2-a12504e1518f" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_140e5ee3-4cdc-4e26-8b84-aed906baa26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_9450ea19-817f-4bf0-9fae-1696b562b428" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_1611fb14-4ec6-4c27-835a-ad3ba455a613" xlink:to="loc_ifrs-full_BorrowingsByNameMember_9450ea19-817f-4bf0-9fae-1696b562b428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_1d329ad5-3d88-47a0-9ce3-f616d05a9579" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoanFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9450ea19-817f-4bf0-9fae-1696b562b428" xlink:to="loc_adc_SeniorSecuredTermLoanFacilityTrancheOneMember_1d329ad5-3d88-47a0-9ce3-f616d05a9579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fde9a86a-8011-43a7-97f2-fd7f3187ecb2" xlink:to="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_b0f65dd1-82b5-4dec-af39-bf3512e16c8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_b0f65dd1-82b5-4dec-af39-bf3512e16c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredFinancingCostsMember_d898902a-4c17-4e56-ac58-bd465ebb9aaa" xlink:href="adc-20220930.xsd#adc_DeferredFinancingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:to="loc_adc_DeferredFinancingCostsMember_d898902a-4c17-4e56-ac58-bd465ebb9aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NetCarryingAmountMember_5fa63e21-2d5d-470f-a7c6-4547f838bcfc" xlink:href="adc-20220930.xsd#adc_NetCarryingAmountMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_ca14eae0-0e0f-4c96-99c6-b6fe0f3c6ee5" xlink:to="loc_adc_NetCarryingAmountMember_5fa63e21-2d5d-470f-a7c6-4547f838bcfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b84fe025-007e-41ae-b578-ad64e8360d89" xlink:to="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_ae25da7d-c002-42fa-828a-1345588e71c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:to="loc_ifrs-full_DerivativesMember_ae25da7d-c002-42fa-828a-1345588e71c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_117ed8b0-c72c-4261-8c1b-ceebb710bea2" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_578c56e9-16e6-4871-ac5b-1bb83daf5629" xlink:to="loc_adc_ResidualLoanMember_117ed8b0-c72c-4261-8c1b-ceebb710bea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8167700c-27b0-4d49-b72d-8543306af5a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2879d3bc-4fd9-401f-8abc-8744e9aa4db6" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8167700c-27b0-4d49-b72d-8543306af5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_048ba8a4-101f-4098-a5bf-466df86f1372" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8167700c-27b0-4d49-b72d-8543306af5a4" xlink:to="loc_ifrs-full_Borrowings_048ba8a4-101f-4098-a5bf-466df86f1372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_348b4227-ee88-4959-93af-23cdaa0abdb4" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_348b4227-ee88-4959-93af-23cdaa0abdb4" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_aebf0eee-24f7-4fd3-8bb6-1711f0b4c465" xlink:to="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_761ec969-ed96-4652-84d0-fedd5c0a9c1b" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_761ec969-ed96-4652-84d0-fedd5c0a9c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e5a10776-5c5c-496f-918a-f701c806522c" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_ab367ebf-83a7-4c0b-84a5-2019f427fa39" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e5a10776-5c5c-496f-918a-f701c806522c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LoanAgreementMember_b6a02062-6fab-4da6-864e-8f38ac2a3258" xlink:href="adc-20220930.xsd#adc_LoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:to="loc_adc_LoanAgreementMember_b6a02062-6fab-4da6-864e-8f38ac2a3258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SeniorSecuredTermLoansMember_e54bf726-2fb9-41d4-a564-eed093dd31c3" xlink:href="adc-20220930.xsd#adc_SeniorSecuredTermLoansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_9a089543-002f-4421-8721-040ed23276a9" xlink:to="loc_adc_SeniorSecuredTermLoansMember_e54bf726-2fb9-41d4-a564-eed093dd31c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_94b5b1d6-b128-4abb-8b02-5a9cc0319fe6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_46d4c987-876b-4912-8ea9-9fc8bcbfd710" xlink:to="loc_ifrs-full_RangesMember_94b5b1d6-b128-4abb-8b02-5a9cc0319fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_4e2283eb-4df4-406f-aeba-2e920aee85c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_94b5b1d6-b128-4abb-8b02-5a9cc0319fe6" xlink:to="loc_ifrs-full_TopOfRangeMember_4e2283eb-4df4-406f-aeba-2e920aee85c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:href="adc-20220930.xsd#adc_BorrowingConversionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingsConversionPeriodAxis_f97db78f-6f48-40e9-b12c-326c0092cb74" xlink:to="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsConversionPeriodOneMember_56468b7b-28bf-4352-849f-0ac70f9a39a2" xlink:href="adc-20220930.xsd#adc_BorrowingsConversionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:to="loc_adc_BorrowingsConversionPeriodOneMember_56468b7b-28bf-4352-849f-0ac70f9a39a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConversionPeriodTwoMember_6b7e4b8d-2190-4852-aa94-e3079858175b" xlink:href="adc-20220930.xsd#adc_ConversionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingConversionPeriodDomain_47ba9913-fea5-4998-a141-615cf8b1d553" xlink:to="loc_adc_ConversionPeriodTwoMember_6b7e4b8d-2190-4852-aa94-e3079858175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d3ed77a8-c3ab-4bcb-a578-26598961da92" xlink:to="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_58d843c1-aad4-4e80-883b-97cd4cd4cf63" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:to="loc_adc_ResidualLoanMember_58d843c1-aad4-4e80-883b-97cd4cd4cf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_51fb7feb-612b-447b-bc2a-181d217fbc6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_48fa5a02-aa0c-4275-8667-9315576bb903" xlink:to="loc_ifrs-full_DerivativesMember_51fb7feb-612b-447b-bc2a-181d217fbc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfInterestRatesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestRateTypesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfInterestRatesAxis_11ba8b78-e44a-42a5-898b-fd0bc8677571" xlink:to="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SecuredOvernightFinancingRateSOFRMember_66968624-a51b-4cdc-99de-86cd7ed4afc3" xlink:href="adc-20220930.xsd#adc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:to="loc_adc_SecuredOvernightFinancingRateSOFRMember_66968624-a51b-4cdc-99de-86cd7ed4afc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BaseRateMember_9fc32253-a6d8-4a8f-9b5d-f88a9de1da04" xlink:href="adc-20220930.xsd#adc_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_InterestRateTypesMember_3beb89b8-6203-4a9b-bae8-ee9253954f20" xlink:to="loc_adc_BaseRateMember_9fc32253-a6d8-4a8f-9b5d-f88a9de1da04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:href="adc-20220930.xsd#adc_BorrowingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingPeriodAxis_0749df62-7d8f-485f-a90b-6461f82674f5" xlink:to="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FirstFiveYearsMember_cce15e30-d29a-4c0b-802a-24a892d4b27a" xlink:href="adc-20220930.xsd#adc_FirstFiveYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:to="loc_adc_FirstFiveYearsMember_cce15e30-d29a-4c0b-802a-24a892d4b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AfterFirstFiveYearsMember_a5836cf6-520e-4a6b-87df-bad58991722f" xlink:href="adc-20220930.xsd#adc_AfterFirstFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_BorrowingPeriodDomain_28f87213-48db-4f49-b3f6-91e70f7bf77f" xlink:to="loc_adc_AfterFirstFiveYearsMember_a5836cf6-520e-4a6b-87df-bad58991722f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1c6b3c7-c6a8-41b6-af5c-ff5e88905842" xlink:to="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_067895ea-052a-48b9-a38d-e0eded06f9af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:to="loc_srt_MinimumMember_067895ea-052a-48b9-a38d-e0eded06f9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7aac6cbe-bf81-4818-b57b-1995c0789e10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_75053855-5c11-4cf0-b525-92af26fb9263" xlink:to="loc_srt_MaximumMember_7aac6cbe-bf81-4818-b57b-1995c0789e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheAxis_aaa397a4-4db6-4704-bcd3-61756e4e25fa" xlink:to="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_eba939bb-809a-488d-baef-17e30ae13ef3" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:to="loc_adc_WarrantsTrancheOneMember_eba939bb-809a-488d-baef-17e30ae13ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember_9a7721d0-9096-4645-aae9-5a6c67102e26" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_569ff936-f948-4e4f-9583-ac680dbab5ee" xlink:to="loc_adc_WarrantsTrancheTwoMember_9a7721d0-9096-4645-aae9-5a6c67102e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_e40b775f-b2c5-403e-89db-084de51fe5a9" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_4fa73d54-aa02-435d-9c39-cfd461fb0d5b" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingFacilitiesMaximumBorrowingCapacity_4fa73d54-aa02-435d-9c39-cfd461fb0d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingNumberOfComponents_fa5d127a-af0a-40c8-8c8d-00c53289c10b" xlink:href="adc-20220930.xsd#adc_BorrowingNumberOfComponents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingNumberOfComponents_fa5d127a-af0a-40c8-8c8d-00c53289c10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_4aa547e6-29e4-45a8-b7b6-8f7e9f0870f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_Borrowings_4aa547e6-29e4-45a8-b7b6-8f7e9f0870f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_fb4b6402-1245-4dfc-8829-db3c85e8bf57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_BorrowingsInterestRate_fb4b6402-1245-4dfc-8829-db3c85e8bf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsFacilitiesExitFeePercentage_6e020822-7f91-43bb-b60c-9ce4a8458302" xlink:href="adc-20220930.xsd#adc_BorrowingsFacilitiesExitFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingsFacilitiesExitFeePercentage_6e020822-7f91-43bb-b60c-9ce4a8458302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_eeb06750-f17b-48a2-a2ba-41023ea5c0ab" xlink:href="adc-20220930.xsd#adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents_eeb06750-f17b-48a2-a2ba-41023ea5c0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_8bb0b695-0165-47f2-89e4-56102d25665c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_8bb0b695-0165-47f2-89e4-56102d25665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_bbb7b326-000d-49e0-8fac-1cae3022eb3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_NoncurrentDerivativeFinancialLiabilities_bbb7b326-000d-49e0-8fac-1cae3022eb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_3fd411df-1427-4a32-bc2c-4bf6b011298d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_3fd411df-1427-4a32-bc2c-4bf6b011298d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingsImpliedEffectiveInterestRate_6a810129-4881-464e-ad2d-3793a8b176d1" xlink:href="adc-20220930.xsd#adc_BorrowingsImpliedEffectiveInterestRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_BorrowingsImpliedEffectiveInterestRate_6a810129-4881-464e-ad2d-3793a8b176d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LoansReceived_7c9ee540-89f1-43bc-8306-15f54d27f315" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LoansReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_LoansReceived_7c9ee540-89f1-43bc-8306-15f54d27f315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_028d7b27-84c4-49b6-b174-906fad1ace70" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_028d7b27-84c4-49b6-b174-906fad1ace70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_14cea341-1ac9-4e9e-9ec1-9d2f2d4922c2" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent_14cea341-1ac9-4e9e-9ec1-9d2f2d4922c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f8e2bb29-c337-439c-afcb-7f32b7a2de77" xlink:href="adc-20220930.xsd#adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative_f8e2bb29-c337-439c-afcb-7f32b7a2de77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromCurrentBorrowings_a209d80e-f86f-4f16-95c2-27206055e9f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromCurrentBorrowings"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_ProceedsFromCurrentBorrowings_a209d80e-f86f-4f16-95c2-27206055e9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_8dc6da60-9fdc-478d-b8aa-68b003f447fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_8dc6da60-9fdc-478d-b8aa-68b003f447fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_8dc89e60-7a84-4c0a-bb1a-f247c0943e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue_8dc89e60-7a84-4c0a-bb1a-f247c0943e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CreditDerivativeFairValue_2e49f819-b02b-4d8b-8cb7-a46e7d44406f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CreditDerivativeFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_CreditDerivativeFairValue_2e49f819-b02b-4d8b-8cb7-a46e7d44406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_fe2e4cca-5c43-4299-bb0c-f4c52ad9850d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_ifrs-full_GainsOnChangeInFairValueOfDerivatives_fe2e4cca-5c43-4299-bb0c-f4c52ad9850d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExchangeOfConvertibleNotesForWarrants_5304da4e-1575-4c93-ab78-0e797a946268" xlink:href="adc-20220930.xsd#adc_ExchangeOfConvertibleNotesForWarrants"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_ExchangeOfConvertibleNotesForWarrants_5304da4e-1575-4c93-ab78-0e797a946268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_c8dab84e-0f59-4170-8905-4e7053daf967" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_ConvertibleNotesSharesConverted_c8dab84e-0f59-4170-8905-4e7053daf967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesValueConverted_e929d133-ed71-4498-89fc-95d3508fb32c" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesValueConverted"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7c758725-6e8e-44ba-9850-95cbf52aaef4" xlink:to="loc_adc_ConvertibleNotesValueConverted_e929d133-ed71-4498-89fc-95d3508fb32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansValuationofDerivativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_60168679-56c3-4db9-acbe-9eba2a5ca265" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_60168679-56c3-4db9-acbe-9eba2a5ca265" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_c4911a3c-d973-4bd5-bd13-38d7701b61a0" xlink:to="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WrittenPutOptionsMember_62563619-7954-4ddc-b295-cfd073255ebf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WrittenPutOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_ifrs-full_WrittenPutOptionsMember_62563619-7954-4ddc-b295-cfd073255ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ForcedConversionPriceMember_22fe1a58-d61d-434f-bea1-203c7ac60007" xlink:href="adc-20220930.xsd#adc_ForcedConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ForcedConversionPriceMember_22fe1a58-d61d-434f-bea1-203c7ac60007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember_3d6728e7-4bc7-4ed1-a3a4-4af21834fc1c" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_SharePriceMember_3d6728e7-4bc7-4ed1-a3a4-4af21834fc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember_be1ae4a1-4981-4432-8421-aa87c76193af" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_RiskFreeInterestRateMember_be1ae4a1-4981-4432-8421-aa87c76193af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember_f5972e97-8480-42cc-9dd2-2fa65dc121aa" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ExpectedVolatilityMember_f5972e97-8480-42cc-9dd2-2fa65dc121aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember_08608e5a-ce45-4328-9f90-7d1512f4274d" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ExpectedTermMember_08608e5a-ce45-4328-9f90-7d1512f4274d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DividendYieldMember_f2f59232-3692-4968-8dcc-eb4dfe5d9501" xlink:href="adc-20220930.xsd#adc_DividendYieldMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_DividendYieldMember_f2f59232-3692-4968-8dcc-eb4dfe5d9501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RecoveryRateMember_87129b16-8a54-450f-8cbe-5effa61accad" xlink:href="adc-20220930.xsd#adc_RecoveryRateMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_RecoveryRateMember_87129b16-8a54-450f-8cbe-5effa61accad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ImpliedBondYieldMember_178cc40a-71ee-4533-8f2a-bfb076fea1ce" xlink:href="adc-20220930.xsd#adc_ImpliedBondYieldMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_cbfd513e-4841-4a11-af40-c71c0ece97ca" xlink:to="loc_adc_ImpliedBondYieldMember_178cc40a-71ee-4533-8f2a-bfb076fea1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_22fa7ab9-9d79-460e-90f6-568acbdbdd56" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_2deffb87-f6bb-45e1-8ce4-a3a234fa8970" xlink:to="loc_ifrs-full_LiabilitiesMember_22fa7ab9-9d79-460e-90f6-568acbdbdd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_072c25e5-64bd-4977-ad5b-0ca8c8e13d62" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_22fa7ab9-9d79-460e-90f6-568acbdbdd56" xlink:to="loc_ifrs-full_DerivativesMember_072c25e5-64bd-4977-ad5b-0ca8c8e13d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_3e0fa10f-d85a-4a28-a408-3f74b65dc5ad" xlink:to="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_b2197c70-8078-4971-b42d-bea05398ae4c" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_b2197c70-8078-4971-b42d-bea05398ae4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_776cf1f4-7bc7-4d24-811b-8977fb426a66" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_1b8af26f-4e7c-4abb-96ca-7ee5382f22e3" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_776cf1f4-7bc7-4d24-811b-8977fb426a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_156e2c75-0fd4-4696-a0e0-07220a712433" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockAxis_c8f6059e-0540-4629-afa6-7d63e3816c4c" xlink:to="loc_adc_SaleOfStockDomain_156e2c75-0fd4-4696-a0e0-07220a712433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InitialPublicOfferingMember_f319d9ff-f0fb-45f1-a06c-975e70475faa" xlink:href="adc-20220930.xsd#adc_InitialPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockDomain_156e2c75-0fd4-4696-a0e0-07220a712433" xlink:to="loc_adc_InitialPublicOfferingMember_f319d9ff-f0fb-45f1-a06c-975e70475faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_b72214d7-1388-4828-9aee-1b5402ff55b6" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_7ac84d87-90ee-4bc8-960a-4d391c34dbdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_7ac84d87-90ee-4bc8-960a-4d391c34dbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_ff9ecb55-5e8c-4c9e-a08a-fef51444b170" xlink:href="adc-20220930.xsd#adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice_ff9ecb55-5e8c-4c9e-a08a-fef51444b170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OfferingPricePerShare_bb33f352-1238-40cc-9f57-d48d043ccfff" xlink:href="adc-20220930.xsd#adc_OfferingPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_7700e3fb-8415-4eee-b7d3-db0849a30c76" xlink:to="loc_adc_OfferingPricePerShare_bb33f352-1238-40cc-9f57-d48d043ccfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_93f1c1a1-8bbe-4079-b529-fb0497c6447d" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_93f1c1a1-8bbe-4079-b529-fb0497c6447d" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_4a10338a-1588-4811-9c00-cbcbfc887c1e" xlink:to="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_82515c01-bfa6-4b8c-848a-57a55f7e5060" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_82515c01-bfa6-4b8c-848a-57a55f7e5060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e625a5e1-46b8-4862-a7bc-679bf6af3893" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_0f2b269c-b0ee-4dc2-8493-289fd734f2d2" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_e625a5e1-46b8-4862-a7bc-679bf6af3893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_10ae347f-bbaf-4194-a8f2-a22769cdad1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_4d417402-170e-4be3-9b08-f3ca6f892507" xlink:to="loc_ifrs-full_LiabilitiesMember_10ae347f-bbaf-4194-a8f2-a22769cdad1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ResidualLoanMember_b05ca98d-3b6b-4e28-b2c1-1fc41ea6b8f9" xlink:href="adc-20220930.xsd#adc_ResidualLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_10ae347f-bbaf-4194-a8f2-a22769cdad1f" xlink:to="loc_adc_ResidualLoanMember_b05ca98d-3b6b-4e28-b2c1-1fc41ea6b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8863bf85-c639-4ba2-b4c4-dfe3dcbbe31c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_26cb6371-4ec5-49d2-a4f2-cb140baf1657" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8863bf85-c639-4ba2-b4c4-dfe3dcbbe31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_938323e2-d783-4c62-8413-212dbc1e818d" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_8863bf85-c639-4ba2-b4c4-dfe3dcbbe31c" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_938323e2-d783-4c62-8413-212dbc1e818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#ConvertibleloansChangeinFairValueDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_FinancialInstrumentsAbstract_4bdbffaa-2dac-4658-a3b4-d23c76316604" xlink:href="adc-20220930.xsd#adc_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_FinancialInstrumentsAbstract_4bdbffaa-2dac-4658-a3b4-d23c76316604" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_d96b4ceb-f531-4445-891d-0f08194d3220" xlink:to="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_eb8ca75b-852a-4eaa-ae34-9b1ed16d3acc" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember_eb8ca75b-852a-4eaa-ae34-9b1ed16d3acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_048b3666-6a6a-4cc2-ae7e-e41960779d62" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember_048b3666-6a6a-4cc2-ae7e-e41960779d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_efc7b00d-8f7c-4d57-aa12-4ad440a10ab1" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember_efc7b00d-8f7c-4d57-aa12-4ad440a10ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_8565e421-86fe-4067-bd5a-004660372264" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_f825421c-c65f-46bb-97e5-413592fd58a5" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember_8565e421-86fe-4067-bd5a-004660372264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_de23eb3c-7226-440f-ab4c-3aad3547bb0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_f4ad6ac4-714f-4d0f-b49a-eeb126a5c498" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_de23eb3c-7226-440f-ab4c-3aad3547bb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_717e7541-f6a8-4ce0-8076-f0fe88fd093a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_de23eb3c-7226-440f-ab4c-3aad3547bb0b" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_717e7541-f6a8-4ce0-8076-f0fe88fd093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#DeerfieldWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_17b8f866-af57-4948-a46a-07ece8c7ac45" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_17b8f866-af57-4948-a46a-07ece8c7ac45" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:to="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheAxis_ec1ff0f2-d780-4c2c-a1bf-c7c94e91307a" xlink:to="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOneMember_ba0ebc31-1095-4d67-a300-26c6b6108c50" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:to="loc_adc_WarrantsTrancheOneMember_ba0ebc31-1095-4d67-a300-26c6b6108c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceOneMember_d8ae02b0-9159-4b94-9861-d0a88e2db233" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:to="loc_adc_WarrantsTrancheOnePriceOneMember_d8ae02b0-9159-4b94-9861-d0a88e2db233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheOnePriceTwoMember_2205bf36-5127-4b7f-a0af-c828d2bb39b9" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheOnePriceTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_f03eeed3-5d0d-4b8b-8802-90065d275f25" xlink:to="loc_adc_WarrantsTrancheOnePriceTwoMember_2205bf36-5127-4b7f-a0af-c828d2bb39b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2da285ad-b985-44ef-94a9-9f6c9b610b9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_a2f6d2e2-5bef-4e61-b30d-f8c325fe1c7c" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2da285ad-b985-44ef-94a9-9f6c9b610b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_89097b8d-982d-47f8-92a1-b83410bb640d" xlink:href="adc-20220930.xsd#adc_FacilityAgreementWithDeerfieldPartnersLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2da285ad-b985-44ef-94a9-9f6c9b610b9a" xlink:to="loc_adc_FacilityAgreementWithDeerfieldPartnersLPMember_89097b8d-982d-47f8-92a1-b83410bb640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_8fc16c3a-aab3-4c4b-8485-defad82f64f3" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_945f8188-0077-45e1-86ea-d278ba71c15a" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_ConvertibleNotesSharesConverted_945f8188-0077-45e1-86ea-d278ba71c15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsSharesConvertedExercisePrice_c072e155-56ef-429d-83c8-62f38e4d56a5" xlink:href="adc-20220930.xsd#adc_WarrantsSharesConvertedExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_WarrantsSharesConvertedExercisePrice_c072e155-56ef-429d-83c8-62f38e4d56a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnChangeInFairValueWarrants_3382539d-3f6f-42b7-abd8-ba8c306e72e4" xlink:href="adc-20220930.xsd#adc_GainsLossOnChangeInFairValueWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_GainsLossOnChangeInFairValueWarrants_3382539d-3f6f-42b7-abd8-ba8c306e72e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantObligationFairValue_fc7e8730-fe08-4e4d-9f54-6d2a94163687" xlink:href="adc-20220930.xsd#adc_WarrantObligationFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_357a462c-bae8-43f6-9ee9-195caf86eb39" xlink:to="loc_adc_WarrantObligationFairValue_fc7e8730-fe08-4e4d-9f54-6d2a94163687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#DeerfieldWarrantsScheduleofValuationInputsDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_62dcdcfb-2f48-4e91-a440-f3bc323c5a1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_62dcdcfb-2f48-4e91-a440-f3bc323c5a1c" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameMember_2eca988e-53b4-4595-b69e-be402246a11f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_25e61a96-a7c1-47c9-a1a4-65b9a5d65778" xlink:to="loc_ifrs-full_BorrowingsByNameMember_2eca988e-53b4-4595-b69e-be402246a11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeerfieldWarrantsMember_c0404671-75dc-4453-b78e-e2bdf54ca2f1" xlink:href="adc-20220930.xsd#adc_DeerfieldWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameMember_2eca988e-53b4-4595-b69e-be402246a11f" xlink:to="loc_adc_DeerfieldWarrantsMember_c0404671-75dc-4453-b78e-e2bdf54ca2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_07596e8a-c887-4094-bda9-e02d25410c62" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_5a7210cf-4581-4519-90f6-147426489fa7" xlink:to="loc_ifrs-full_LiabilitiesMember_07596e8a-c887-4094-bda9-e02d25410c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativesMember_297377e0-77f6-457c-94a0-9a6300986366" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_07596e8a-c887-4094-bda9-e02d25410c62" xlink:to="loc_ifrs-full_DerivativesMember_297377e0-77f6-457c-94a0-9a6300986366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_UnobservableInputsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_059c819f-3520-4165-89e9-15a04d129864" xlink:to="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExercisePriceMember_10ef316f-d606-4295-aaf4-d55a9cc79eff" xlink:href="adc-20220930.xsd#adc_ExercisePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ExercisePriceMember_10ef316f-d606-4295-aaf4-d55a9cc79eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ForcedConversionPriceMember_e426c10d-aedd-4877-855b-c662230995cc" xlink:href="adc-20220930.xsd#adc_ForcedConversionPriceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ForcedConversionPriceMember_e426c10d-aedd-4877-855b-c662230995cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePriceMember_153d04ea-4a7f-4503-bef0-1e711d5203cb" xlink:href="adc-20220930.xsd#adc_SharePriceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_SharePriceMember_153d04ea-4a7f-4503-bef0-1e711d5203cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RiskFreeInterestRateMember_5d97ee2a-68a5-4cd1-90f5-c77dd33212e7" xlink:href="adc-20220930.xsd#adc_RiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_RiskFreeInterestRateMember_5d97ee2a-68a5-4cd1-90f5-c77dd33212e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedVolatilityMember_94a4f536-1cae-4109-bdfb-e31523a1dc24" xlink:href="adc-20220930.xsd#adc_ExpectedVolatilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ExpectedVolatilityMember_94a4f536-1cae-4109-bdfb-e31523a1dc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ExpectedTermMember_2222996c-190b-46e9-97e0-0a410fc59a36" xlink:href="adc-20220930.xsd#adc_ExpectedTermMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_ExpectedTermMember_2222996c-190b-46e9-97e0-0a410fc59a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_BlackScholesValueMember_e93cfa43-81ac-4fc1-9988-7a9763f0ea7d" xlink:href="adc-20220930.xsd#adc_BlackScholesValueMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsMember_48fe01dd-be45-4162-9bac-317a30861426" xlink:to="loc_adc_BlackScholesValueMember_e93cfa43-81ac-4fc1-9988-7a9763f0ea7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dcebb26f-0d42-48e6-922d-f9d1fcd6a77d" xlink:to="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_358b5811-ac5e-4748-a58f-2c901a2f1115" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:to="loc_srt_MinimumMember_358b5811-ac5e-4748-a58f-2c901a2f1115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ca5d92c8-c47c-49c8-83cf-711e9cc5cd43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b690d27a-f6c2-4fa7-93ff-e8fae9f938a9" xlink:to="loc_srt_MaximumMember_ca5d92c8-c47c-49c8-83cf-711e9cc5cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0456a668-a665-4e08-8040-307375b66543" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_5ac31891-530c-41ea-a87f-886c7b571852" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0456a668-a665-4e08-8040-307375b66543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputLiabilities_43df7d0c-adcf-4301-80e9-a1ce51556372" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantUnobservableInputLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_0456a668-a665-4e08-8040-307375b66543" xlink:to="loc_ifrs-full_SignificantUnobservableInputLiabilities_43df7d0c-adcf-4301-80e9-a1ce51556372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementsAbstract_41d9d315-5a50-45cf-b816-1422794f3226" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_41d9d315-5a50-45cf-b816-1422794f3226" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:href="adc-20220930.xsd#adc_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameAxis_6e56d94e-ab04-44ce-8a80-574ed132d08c" xlink:to="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePurchasePlan2016Member_1c439a28-21fc-4859-bf5d-6a54330fbd76" xlink:href="adc-20220930.xsd#adc_SharePurchasePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_SharePurchasePlan2016Member_1c439a28-21fc-4859-bf5d-6a54330fbd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncentivePlan2014Member_7d88e839-6712-4f69-ae1d-c40de31ea868" xlink:href="adc-20220930.xsd#adc_IncentivePlan2014Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_IncentivePlan2014Member_7d88e839-6712-4f69-ae1d-c40de31ea868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanMember_6bfa9ac2-38f5-4a48-b38f-b7baaadddf7c" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_A2019EquityIncentivePlanMember_6bfa9ac2-38f5-4a48-b38f-b7baaadddf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AnnualEquityAwardMember_d2a70130-00d8-4419-8751-ebc757c6cbe5" xlink:href="adc-20220930.xsd#adc_AnnualEquityAwardMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_AnnualEquityAwardMember_d2a70130-00d8-4419-8751-ebc757c6cbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SpecialRetentionAwardMember_e6f9e1f7-9091-4c2d-8f67-58ebfba75868" xlink:href="adc-20220930.xsd#adc_SpecialRetentionAwardMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_1e899ff1-79d6-4d1e-b434-11ad5c4b69e8" xlink:to="loc_adc_SpecialRetentionAwardMember_e6f9e1f7-9091-4c2d-8f67-58ebfba75868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ff4191d5-9c82-412c-ba74-28124db3855e" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeStockOptionMember_2e86c0a8-3b80-4cd5-a5c1-fa51bda2d960" xlink:href="adc-20220930.xsd#adc_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:to="loc_adc_EmployeeStockOptionMember_2e86c0a8-3b80-4cd5-a5c1-fa51bda2d960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedShareUnitsRSUMember_c5e8342d-e3ad-4c14-a76a-4687bd271353" xlink:href="adc-20220930.xsd#adc_RestrictedShareUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:to="loc_adc_RestrictedShareUnitsRSUMember_c5e8342d-e3ad-4c14-a76a-4687bd271353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedStockUnitsMember_8ad43229-1144-44dc-92eb-7f9a4b23fae2" xlink:href="adc-20220930.xsd#adc_RestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_51849380-db93-408e-9911-57946b0e2bef" xlink:to="loc_adc_RestrictedStockUnitsMember_8ad43229-1144-44dc-92eb-7f9a4b23fae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:href="adc-20220930.xsd#adc_VestingPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:href="adc-20220930.xsd#adc_VestingPeriodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_VestingPeriodAxis_1f6101b9-1102-413d-b563-63a1d6f5cc5a" xlink:to="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheOneMember_e5fc4a00-e801-49c4-bc97-a5604197f748" xlink:href="adc-20220930.xsd#adc_TrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheOneMember_e5fc4a00-e801-49c4-bc97-a5604197f748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheTwoMember_da0191d3-6e26-490a-9231-8fb498e09459" xlink:href="adc-20220930.xsd#adc_TrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheTwoMember_da0191d3-6e26-490a-9231-8fb498e09459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheThreeMember_0648f6e6-c39b-4091-bd42-da7efccf8c54" xlink:href="adc-20220930.xsd#adc_TrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheThreeMember_0648f6e6-c39b-4091-bd42-da7efccf8c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_TrancheFourMember_20b91194-d498-4ce3-aa27-a886dce3dcf5" xlink:href="adc-20220930.xsd#adc_TrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_VestingPeriodMember_771a54ff-644b-4b13-9642-a787e3354543" xlink:to="loc_adc_TrancheFourMember_20b91194-d498-4ce3-aa27-a886dce3dcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_d32b88f8-7f06-4a63-8541-515321f7dc4b" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a73267b8-86d6-46d4-9c50-87fb0844ae36" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_a73267b8-86d6-46d4-9c50-87fb0844ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_01b30664-1fa8-4b9a-bed8-fde6b8dbc886" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_01b30664-1fa8-4b9a-bed8-fde6b8dbc886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_072f0fdc-fe80-495a-845f-cea54394543a" xlink:href="adc-20220930.xsd#adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_072f0fdc-fe80-495a-845f-cea54394543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_82f75ad5-d9ae-413b-a4af-65e01614d590" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_82f75ad5-d9ae-413b-a4af-65e01614d590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_136b755b-ceec-4b08-bc15-9b20c73513a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_136b755b-ceec-4b08-bc15-9b20c73513a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_16543d4c-c034-4ed3-ade3-b6ed95888514" xlink:href="adc-20220930.xsd#adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage_16543d4c-c034-4ed3-ade3-b6ed95888514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_611018b3-321b-45bd-9878-fc3ee174c747" xlink:href="adc-20220930.xsd#adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement_611018b3-321b-45bd-9878-fc3ee174c747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6f6cf00-a866-49d2-8f8f-eb6c162a73a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_c6f6cf00-a866-49d2-8f8f-eb6c162a73a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_31069e9b-8a45-4e07-bc41-d024aa297a27" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_31069e9b-8a45-4e07-bc41-d024aa297a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_4d00125b-ee8a-4407-8598-592a8e2b3a9e" xlink:href="adc-20220930.xsd#adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted_4d00125b-ee8a-4407-8598-592a8e2b3a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_77238fdb-9cb5-475d-bfd4-59ca3218e030" xlink:href="adc-20220930.xsd#adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_77238fdb-9cb5-475d-bfd4-59ca3218e030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_0089c745-c32e-4390-8f9d-f80ea7610d43" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_0089c745-c32e-4390-8f9d-f80ea7610d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_2fb4902d-0762-4462-aacb-f4111e981203" xlink:href="adc-20220930.xsd#adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement_2fb4902d-0762-4462-aacb-f4111e981203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_52ded2cd-b196-44ae-9f3c-2a1c38408bec" xlink:href="adc-20220930.xsd#adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_52ded2cd-b196-44ae-9f3c-2a1c38408bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_49f52a0c-d6cc-4ead-9596-375e12cc9e84" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementSharesTransferredToParticipants"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_ShareBasedPaymentArrangementSharesTransferredToParticipants_49f52a0c-d6cc-4ead-9596-375e12cc9e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_1a1b83f8-4a91-427e-bfa2-4c6fab5e047d" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld_1a1b83f8-4a91-427e-bfa2-4c6fab5e047d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_7cf2b54e-3bfa-41cc-a4eb-27a340667896" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_7cf2b54e-3bfa-41cc-a4eb-27a340667896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AccruedShareBasedCompensation_15f5c83a-064b-4b2d-8d14-731ab0e1cdec" xlink:href="adc-20220930.xsd#adc_AccruedShareBasedCompensation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_2b70ca4b-4f8a-43c0-b566-c2fe5765caa5" xlink:to="loc_adc_AccruedShareBasedCompensation_15f5c83a-064b-4b2d-8d14-731ab0e1cdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1a65b9d7-f7a9-44cd-88e1-70e11e1b129c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_1a65b9d7-f7a9-44cd-88e1-70e11e1b129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_756bc5ee-d772-44ff-8b55-9af7ca7cd552" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_756bc5ee-d772-44ff-8b55-9af7ca7cd552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_5eb7be73-6ed5-4614-80b4-0ed558d653d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_5eb7be73-6ed5-4614-80b4-0ed558d653d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_0cafc1ee-8b59-4478-b815-638df7db18a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_0cafc1ee-8b59-4478-b815-638df7db18a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_413448e9-a986-4aad-bba8-e8478d680931" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_413448e9-a986-4aad-bba8-e8478d680931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2bef3c52-7f94-468d-af87-3821f18d7e87" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2bef3c52-7f94-468d-af87-3821f18d7e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_b755e7da-1382-410d-9790-4a64979295d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_b755e7da-1382-410d-9790-4a64979295d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_11cbc110-84cd-4b90-b118-764b9cbcfc18" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_11cbc110-84cd-4b90-b118-764b9cbcfc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3341920b-fd5c-42ae-ae88-353396a963ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3341920b-fd5c-42ae-ae88-353396a963ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_047ca4b5-bfdf-45a9-8466-1f912100dcb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_047ca4b5-bfdf-45a9-8466-1f912100dcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_4d9ab9b9-b68d-4977-99dd-fa3983834c58" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_4d9ab9b9-b68d-4977-99dd-fa3983834c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_6d858389-b5e2-46cf-bb10-f9d873a5323a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_6d858389-b5e2-46cf-bb10-f9d873a5323a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_9f8a0c7c-f834-47eb-8a5a-d0f28227196f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_9f8a0c7c-f834-47eb-8a5a-d0f28227196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions_6e0cf2be-f795-42f9-881b-4c577b1425d4" xlink:href="adc-20220930.xsd#adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_d6d56679-46ee-459d-9432-7484f9615e77" xlink:to="loc_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions_6e0cf2be-f795-42f9-881b-4c577b1425d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareBasedPaymentArrangementsAbstract_83ef8909-3fd4-48d9-b091-9ebd4afac2b0" xlink:href="adc-20220930.xsd#adc_ShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareBasedPaymentArrangementsAbstract_83ef8909-3fd4-48d9-b091-9ebd4afac2b0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:to="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_ac1a18dd-9bbc-4edc-9655-0ca0e760dfe9" xlink:to="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2f48b1c6-afbf-4570-9abf-c09d89da2860" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:to="loc_srt_MinimumMember_2f48b1c6-afbf-4570-9abf-c09d89da2860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_748438f3-8f1f-4dd8-8ab6-959f6f094ad7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_92afb94c-5613-4118-90ec-ead56c90c793" xlink:to="loc_srt_MaximumMember_748438f3-8f1f-4dd8-8ab6-959f6f094ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e18501b0-609e-41bd-9167-1f85219466de" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_842799ce-ac8f-437c-beef-843112c2174b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_842799ce-ac8f-437c-beef-843112c2174b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b741b9c8-a158-4475-ad55-d021e1e4b7df" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_b741b9c8-a158-4475-ad55-d021e1e4b7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_702ac60c-616d-4264-9491-b8d7936505b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_702ac60c-616d-4264-9491-b8d7936505b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_63aae7f8-b631-4bab-b5e4-2f43bba8a65b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_63aae7f8-b631-4bab-b5e4-2f43bba8a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendShareOptionsGranted_212ae71a-812e-4811-adf4-7b19f6c9a3c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpectedDividendShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_ExpectedDividendShareOptionsGranted_212ae71a-812e-4811-adf4-7b19f6c9a3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1d4fc3df-05e7-48ea-bd7b-1e9fb79a923c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_6c4453b9-5d2f-4fd6-a69f-edc93e0cb662" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_1d4fc3df-05e7-48ea-bd7b-1e9fb79a923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c8df2e20-f93f-4ac8-83b9-ad305661991c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c8df2e20-f93f-4ac8-83b9-ad305661991c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_f9a266e5-345e-41b7-8e69-82f610e67e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_df09014d-76cc-4555-b368-3dab7bb0fbd7" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_f9a266e5-345e-41b7-8e69-82f610e67e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedShareUnitsRSUMember_34c374e8-1c7c-4499-8c5f-8296d1d539b0" xlink:href="adc-20220930.xsd#adc_RestrictedShareUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_f9a266e5-345e-41b7-8e69-82f610e67e7b" xlink:to="loc_adc_RestrictedShareUnitsRSUMember_34c374e8-1c7c-4499-8c5f-8296d1d539b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_c8df2e20-f93f-4ac8-83b9-ad305661991c" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b3035aa0-f30e-495c-b89b-2f4f8318d053" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b3035aa0-f30e-495c-b89b-2f4f8318d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_dcc95ea0-d8c6-40f5-9fe8-8dc3889e3881" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_dcc95ea0-d8c6-40f5-9fe8-8dc3889e3881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_aefd2911-c0c4-4d9c-8d0a-f84eba86bbde" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_aefd2911-c0c4-4d9c-8d0a-f84eba86bbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e77b3813-481c-4de8-8aec-13641815b20f" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_e77b3813-481c-4de8-8aec-13641815b20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b66d70b8-3bd5-47e7-9117-3d700be266e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_b66d70b8-3bd5-47e7-9117-3d700be266e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_d91f95c5-b55d-407b-9942-6307a77fb9d0" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_d91f95c5-b55d-407b-9942-6307a77fb9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_c91b25ec-437d-41c0-b096-123b172cf19d" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted_c91b25ec-437d-41c0-b096-123b172cf19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_34789788-0321-46a2-8792-a25a11d349e4" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested_34789788-0321-46a2-8792-a25a11d349e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_a10776dd-d19e-4dd7-ac9c-d5b0132bcfdf" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited_a10776dd-d19e-4dd7-ac9c-d5b0132bcfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_8144c1d2-a8ec-40fb-bb71-1499467beebf" xlink:href="adc-20220930.xsd#adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_4646a26b-171c-4194-aa75-f56a20c2c5f9" xlink:to="loc_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding_8144c1d2-a8ec-40fb-bb71-1499467beebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:href="adc-20220930.xsd#adc_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:to="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:href="adc-20220930.xsd#adc_PlanNameMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:to="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncentivePlan2014Member_07833807-b0a6-476c-bfa3-676b75994b92" xlink:href="adc-20220930.xsd#adc_IncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:to="loc_adc_IncentivePlan2014Member_07833807-b0a6-476c-bfa3-676b75994b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SharePurchasePlan2016Member_93015d91-2164-48e2-a56c-97f9e2c657a1" xlink:href="adc-20220930.xsd#adc_SharePurchasePlan2016Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:to="loc_adc_SharePurchasePlan2016Member_93015d91-2164-48e2-a56c-97f9e2c657a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanMember_e32c9995-011f-434a-977a-5cdc020517f7" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameMember_17704d35-cb73-4b9e-b500-de3b18295d86" xlink:to="loc_adc_A2019EquityIncentivePlanMember_e32c9995-011f-434a-977a-5cdc020517f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PlanNameDomain_0942c36a-c996-4553-81eb-f2a94c37dd96" xlink:href="adc-20220930.xsd#adc_PlanNameDomain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_PlanNameAxis_0b62ea35-0825-44a8-aff7-7a75271e7c25" xlink:to="loc_adc_PlanNameDomain_0942c36a-c996-4553-81eb-f2a94c37dd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cdf19c80-e69a-4e76-a9f3-f7e098033f55" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_EmployeeStockOptionMember_ae935cc4-736c-4a17-8fe2-1a9d2c5a9b9b" xlink:href="adc-20220930.xsd#adc_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:to="loc_adc_EmployeeStockOptionMember_ae935cc4-736c-4a17-8fe2-1a9d2c5a9b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RestrictedStockUnitsMember_81de1a93-dce9-45f9-996b-3395f513ac3e" xlink:href="adc-20220930.xsd#adc_RestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_2c105549-c1cd-4d6f-84ae-dcd51394b166" xlink:to="loc_adc_RestrictedStockUnitsMember_81de1a93-dce9-45f9-996b-3395f513ac3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_e80dd5a6-74e1-460c-a5b4-2d4784904712" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseInReserveOfShareBasedPayments_e4ea7d82-99f1-4c5b-9ab9-f5e081a41ba8" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseInReserveOfShareBasedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_adc_IncreaseDecreaseInReserveOfShareBasedPayments_e4ea7d82-99f1-4c5b-9ab9-f5e081a41ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_d39a00fd-2906-41da-b93c-4e47f371a025" xlink:href="adc-20220930.xsd#adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions_d39a00fd-2906-41da-b93c-4e47f371a025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_628eab3a-b906-49fa-8cd2-30c18b29a640" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_ec44e470-7858-4eec-8657-a9bfacac69ea" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_628eab3a-b906-49fa-8cd2-30c18b29a640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#RelatedpartiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RelatedPartyAbstract_6a8d744f-880f-48e4-b81b-df77223dee71" xlink:href="adc-20220930.xsd#adc_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_6a8d744f-880f-48e4-b81b-df77223dee71" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:to="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_02780cc2-e02b-4576-ada5-7a1612ba3fac" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfRelatedPartiesAxis_83d4fd7f-b6ed-466d-ba94-411dddc0041e" xlink:to="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_02780cc2-e02b-4576-ada5-7a1612ba3fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RelatedPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EntitysTotalForRelatedPartiesMember_02780cc2-e02b-4576-ada5-7a1612ba3fac" xlink:to="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AuvenTherapeuticsHoldingsLPMember_2d579fc5-3e4b-46b6-8d32-2e7e15916b6d" xlink:href="adc-20220930.xsd#adc_AuvenTherapeuticsHoldingsLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:to="loc_adc_AuvenTherapeuticsHoldingsLPMember_2d579fc5-3e4b-46b6-8d32-2e7e15916b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OverlandADCTBioPharmaCYLimitedMember_ee719930-2786-42f6-89d9-dd9d70c442b6" xlink:href="adc-20220930.xsd#adc_OverlandADCTBioPharmaCYLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RelatedPartiesMember_1b6984d0-9be6-47a5-80c3-103f10264ff8" xlink:to="loc_adc_OverlandADCTBioPharmaCYLimitedMember_ee719930-2786-42f6-89d9-dd9d70c442b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_68b720b8-0553-48ea-9944-581297de4398" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_NumberOfSubsidiariesProvideServicesTo_851bac48-eca6-4f19-8a7c-5727af939866" xlink:href="adc-20220930.xsd#adc_NumberOfSubsidiariesProvideServicesTo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_NumberOfSubsidiariesProvideServicesTo_851bac48-eca6-4f19-8a7c-5727af939866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ServicesProvidedRelatedPartyTransactions_c7fd7d48-c2b9-4b65-b6ab-2ec701665552" xlink:href="adc-20220930.xsd#adc_ServicesProvidedRelatedPartyTransactions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_ServicesProvidedRelatedPartyTransactions_c7fd7d48-c2b9-4b65-b6ab-2ec701665552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_AmountsDueFromRelatedParties_13686bef-917e-4c5d-979a-779e55d5fc6e" xlink:href="adc-20220930.xsd#adc_AmountsDueFromRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_AmountsDueFromRelatedParties_13686bef-917e-4c5d-979a-779e55d5fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SuppliesProvidedRelatedPartyTransactions_fee68448-c1e3-41ac-92b8-10baecb2fdd1" xlink:href="adc-20220930.xsd#adc_SuppliesProvidedRelatedPartyTransactions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_adc_SuppliesProvidedRelatedPartyTransactions_fee68448-c1e3-41ac-92b8-10baecb2fdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_5c5d5af6-6414-4d13-9295-a58ac57b8c57" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmountsReceivableRelatedPartyTransactions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_42887c32-8b80-4d59-9a66-387904db98a9" xlink:to="loc_ifrs-full_AmountsReceivableRelatedPartyTransactions_5c5d5af6-6414-4d13-9295-a58ac57b8c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#RelatedpartiesScheduleofKeyManagementCompensationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_RelatedPartyAbstract_de2de0be-da7b-4b00-94ef-2b15c1a4a608" xlink:href="adc-20220930.xsd#adc_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0a95a9f2-19bc-4354-8e16-1d13041e6643" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_de2de0be-da7b-4b00-94ef-2b15c1a4a608" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0a95a9f2-19bc-4354-8e16-1d13041e6643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_3d245122-cc99-4973-8809-9ca611c07f71" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_de2de0be-da7b-4b00-94ef-2b15c1a4a608" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits_3d245122-cc99-4973-8809-9ca611c07f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5020d2ed-e22d-403a-8784-5fef33dd2907" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_de2de0be-da7b-4b00-94ef-2b15c1a4a608" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5020d2ed-e22d-403a-8784-5fef33dd2907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_fef9ae5c-8276-4863-87bb-1cba862d6aaf" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_de2de0be-da7b-4b00-94ef-2b15c1a4a608" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits_fef9ae5c-8276-4863-87bb-1cba862d6aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_1282ceb6-cbe4-4ee5-a918-2570d060845c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RelatedPartyAbstract_de2de0be-da7b-4b00-94ef-2b15c1a4a608" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_1282ceb6-cbe4-4ee5-a918-2570d060845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LosspershareDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LosspershareDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_a1b1d985-a435-45b8-ace0-cf19b7f0ee17" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_a3439c37-f7ef-41cb-84ab-a37a62c34a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a1b1d985-a435-45b8-ace0-cf19b7f0ee17" xlink:to="loc_ifrs-full_ProfitLoss_a3439c37-f7ef-41cb-84ab-a37a62c34a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_0f5309db-a657-450c-b2e0-599cefe3d2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a1b1d985-a435-45b8-ace0-cf19b7f0ee17" xlink:to="loc_ifrs-full_WeightedAverageShares_0f5309db-a657-450c-b2e0-599cefe3d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_542f77af-f436-48ac-af68-b1a4c4b05566" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a1b1d985-a435-45b8-ace0-cf19b7f0ee17" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_542f77af-f436-48ac-af68-b1a4c4b05566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_65ef3b3b-f919-4bd5-8950-0b3b07defe4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a1b1d985-a435-45b8-ace0-cf19b7f0ee17" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_65ef3b3b-f919-4bd5-8950-0b3b07defe4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_899a381d-eab2-4144-a9da-c768cb7b2e22" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_899a381d-eab2-4144-a9da-c768cb7b2e22" xlink:to="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_d95a5ecd-b585-4765-aeb0-b5fb50c163b6" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis_a7b7d750-b1aa-4286-8159-8cbe341dc17b" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_d95a5ecd-b585-4765-aeb0-b5fb50c163b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain_d95a5ecd-b585-4765-aeb0-b5fb50c163b6" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanShareOptionsMember_a0a7f308-d3e5-45c9-836a-1c5899924202" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_A2019EquityIncentivePlanShareOptionsMember_a0a7f308-d3e5-45c9-836a-1c5899924202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2019EquityIncentivePlanRSUsMember_09a5e9fd-b129-4073-80f5-4cc32ab5efa0" xlink:href="adc-20220930.xsd#adc_A2019EquityIncentivePlanRSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_A2019EquityIncentivePlanRSUsMember_09a5e9fd-b129-4073-80f5-4cc32ab5efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_A2022ESPPMember_499ab9bb-417b-4a33-af12-f756fab6d603" xlink:href="adc-20220930.xsd#adc_A2022ESPPMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_A2022ESPPMember_499ab9bb-417b-4a33-af12-f756fab6d603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleLoansContingentlyIssuableSharesMember_e226d9d0-78ad-48a0-be51-ceaee81b4a90" xlink:href="adc-20220930.xsd#adc_ConvertibleLoansContingentlyIssuableSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_ConvertibleLoansContingentlyIssuableSharesMember_e226d9d0-78ad-48a0-be51-ceaee81b4a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OutstandingWarrantsMember_3ffebb64-f926-4b61-affd-b0b3164b84be" xlink:href="adc-20220930.xsd#adc_OutstandingWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember_580d4a60-f59f-4c6e-94af-45df63189597" xlink:to="loc_adc_OutstandingWarrantsMember_3ffebb64-f926-4b61-affd-b0b3164b84be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareLineItems_6d077d2c-0f5d-43b9-bbd2-0329154d053b" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareTable_d927fc47-2b26-49db-8468-9b60d1a222ce" xlink:to="loc_ifrs-full_EarningsPerShareLineItems_6d077d2c-0f5d-43b9-bbd2-0329154d053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_32ac4f35-e891-40b5-8023-e6aea35f7588" xlink:href="adc-20220930.xsd#adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareLineItems_6d077d2c-0f5d-43b9-bbd2-0329154d053b" xlink:to="loc_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare_32ac4f35-e891-40b5-8023-e6aea35f7588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/EventsafterthereportingdateDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#EventsafterthereportingdateDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/EventsafterthereportingdateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_EventsAfterReportingPeriodAbstract_0e1c5b54-8fb9-4fa1-bb67-e9fb340feb13" xlink:href="adc-20220930.xsd#adc_EventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_EventsAfterReportingPeriodAbstract_0e1c5b54-8fb9-4fa1-bb67-e9fb340feb13" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_c66d8fde-5658-42f4-ab0f-940499da9d60" xlink:to="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMember_ecb422dd-97a1-4460-9cd0-386370140d7d" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:to="loc_adc_LicenseAgreementMember_ecb422dd-97a1-4460-9cd0-386370140d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ApplicationApprovalMember_548b847a-3fae-4216-9f27-41b13a3b830d" xlink:href="adc-20220930.xsd#adc_ApplicationApprovalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsMember_f57ad0dc-dc29-4dc0-a739-e1daf7e15bb6" xlink:to="loc_adc_ApplicationApprovalMember_548b847a-3fae-4216-9f27-41b13a3b830d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_3c58c242-7241-4564-9c66-2c347089ff16" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromLicenseAgreement_84966fb7-4166-4585-938a-7d098044ec30" xlink:href="adc-20220930.xsd#adc_ProceedsFromLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_ProceedsFromLicenseAgreement_84966fb7-4166-4585-938a-7d098044ec30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementMilestonePayments_44f097c8-1a11-41b8-8f8d-b1e3276c9313" xlink:href="adc-20220930.xsd#adc_LicenseAgreementMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_LicenseAgreementMilestonePayments_44f097c8-1a11-41b8-8f8d-b1e3276c9313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_370c0755-4262-437d-8c28-324ad3af1b8a" xlink:href="adc-20220930.xsd#adc_LicenseAgreementPercentOfClinicalTrialCostsPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid_370c0755-4262-437d-8c28-324ad3af1b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_LicenseAgreementCappedContribution_2b71a098-cc1f-4e41-a9bd-4486287166fb" xlink:href="adc-20220930.xsd#adc_LicenseAgreementCappedContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_35b08a21-5793-4aea-957c-1fb02489bf3c" xlink:to="loc_adc_LicenseAgreementCappedContribution_2b71a098-cc1f-4e41-a9bd-4486287166fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#DeferredroyaltyobligationDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/DeferredroyaltyobligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligationAbstract_0ecc886d-9f66-41f5-bb94-ca37651e9169" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_DeferredRoyaltyObligationAbstract_0ecc886d-9f66-41f5-bb94-ca37651e9169" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementAxis_e91f18be-f6e3-4b77-83ac-9ae36c6a4687" xlink:to="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_FirstInvestmentAmountMember_8412a3e6-2203-49e9-ab9e-e843c5992985" xlink:href="adc-20220930.xsd#adc_FirstInvestmentAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:to="loc_adc_FirstInvestmentAmountMember_8412a3e6-2203-49e9-ab9e-e843c5992985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SecondInvestmentAmountMember_736a7397-7529-4a1d-b94e-878822344a46" xlink:href="adc-20220930.xsd#adc_SecondInvestmentAmountMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:to="loc_adc_SecondInvestmentAmountMember_736a7397-7529-4a1d-b94e-878822344a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ThirdInvestmentAmountMember_14b23fb2-1b26-442c-adfb-1b44f6f40744" xlink:href="adc-20220930.xsd#adc_ThirdInvestmentAmountMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementDomain_2908ea52-f82a-4b5f-b857-744cc359fb10" xlink:to="loc_adc_ThirdInvestmentAmountMember_14b23fb2-1b26-442c-adfb-1b44f6f40744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6f2ec249-d7a8-41a0-9d96-b4f357ceb8de" xlink:to="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_87198bae-ad61-4aaa-8511-e496c98e3a69" xlink:href="adc-20220930.xsd#adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:to="loc_adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember_87198bae-ad61-4aaa-8511-e496c98e3a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WorldwideMember_8eb24f53-2795-473e-8788-a59b8af3373e" xlink:href="adc-20220930.xsd#adc_WorldwideMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:to="loc_adc_WorldwideMember_8eb24f53-2795-473e-8788-a59b8af3373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_OutsideOfTheUnitedStatesAndEuropeMember_c282a307-d7e3-4086-8d98-d86c5e94f72b" xlink:href="adc-20220930.xsd#adc_OutsideOfTheUnitedStatesAndEuropeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_00238ac5-4373-45b7-9b16-58ea6d3bc2fe" xlink:to="loc_adc_OutsideOfTheUnitedStatesAndEuropeMember_c282a307-d7e3-4086-8d98-d86c5e94f72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4b757d92-05a0-4dd3-b41c-f533f3137458" xlink:to="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ZYNLONTAMember_4149a260-e106-4434-bada-48c3bc5abcb8" xlink:href="adc-20220930.xsd#adc_ZYNLONTAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:to="loc_adc_ZYNLONTAMember_4149a260-e106-4434-bada-48c3bc5abcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_CamiMember_df5a6c46-f35e-43c8-8323-804d2ba72cc6" xlink:href="adc-20220930.xsd#adc_CamiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9beb357b-0123-43b4-8d4a-1b9085328c7f" xlink:to="loc_adc_CamiMember_df5a6c46-f35e-43c8-8323-804d2ba72cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsAxis_78a4e0ce-f5bb-475b-9982-c0d09e455f57" xlink:to="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_c69407c5-231d-4779-9d33-a888b95c9ddd" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember_c69407c5-231d-4779-9d33-a888b95c9ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_8974bbb4-da8d-4e18-9f1d-6da3a000f338" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_RoyaltyPurchaseAgreementTermsDomain_da69005d-f830-4b11-a03e-c679d326d958" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember_8974bbb4-da8d-4e18-9f1d-6da3a000f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_d86e507a-20d8-4f78-9502-e533ae2844d2" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreement_1ccd22d1-5466-4c88-9830-413458fbf3c6" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreement_1ccd22d1-5466-4c88-9830-413458fbf3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromRoyaltyPurchaseAgreementGross_0d50b6c5-4cde-414c-967a-0c8aa561c4ea" xlink:href="adc-20220930.xsd#adc_ProceedsFromRoyaltyPurchaseAgreementGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_ProceedsFromRoyaltyPurchaseAgreementGross_0d50b6c5-4cde-414c-967a-0c8aa561c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationTransactionCosts_fc43852d-6169-4a0f-9321-c9e721d19bc5" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationTransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationTransactionCosts_fc43852d-6169-4a0f-9321-c9e721d19bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationInterest_8e4872c8-8c56-4e3a-8d35-6a0962d50db6" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationInterest_8e4872c8-8c56-4e3a-8d35-6a0962d50db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAdditionalProceedsEligibility_1413af04-c416-4f09-8061-81de1259c090" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAdditionalProceedsEligibility"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAdditionalProceedsEligibility_1413af04-c416-4f09-8061-81de1259c090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_163a61d7-520c-40ba-a377-11e17c803d8d" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales_163a61d7-520c-40ba-a377-11e17c803d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_405eee1a-b8a1-4bda-8698-223be4781097" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses_405eee1a-b8a1-4bda-8698-223be4781097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_8fdc58d1-0c4d-49e6-8590-36a77e554e5d" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests_8fdc58d1-0c4d-49e6-8590-36a77e554e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_53eb8215-2ab7-444b-b5f6-17b23f3398b2" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyRatePercent_53eb8215-2ab7-444b-b5f6-17b23f3398b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_9be53c07-5000-46c9-8f0e-78b50d97ce36" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate_9be53c07-5000-46c9-8f0e-78b50d97ce36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCap_207c2e19-573f-4e3e-a0b0-e365f956c2c5" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCap"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyCap_207c2e19-573f-4e3e-a0b0-e365f956c2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_a413ed38-0c03-4f51-bb7d-9e9424cc3352" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment_a413ed38-0c03-4f51-bb7d-9e9424cc3352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_DeferredRoyaltyObligation_b453bfb6-0160-43ed-8f0b-6625126954ce" xlink:href="adc-20220930.xsd#adc_DeferredRoyaltyObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_DeferredRoyaltyObligation_b453bfb6-0160-43ed-8f0b-6625126954ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationExpectedFutureTransactionCosts_1321c58e-9ff4-434a-bb78-36228c6c9dda" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationExpectedFutureTransactionCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationExpectedFutureTransactionCosts_1321c58e-9ff4-434a-bb78-36228c6c9dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ProceedsFromRoyaltyPurchaseAgreementNet_e7e1078d-d260-4745-b93d-f63ffe8845bf" xlink:href="adc-20220930.xsd#adc_ProceedsFromRoyaltyPurchaseAgreementNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_ProceedsFromRoyaltyPurchaseAgreementNet_e7e1078d-d260-4745-b93d-f63ffe8845bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_42d09db9-df8d-45ce-adb6-f0dec9a3c607" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementEffectiveInterestRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementEffectiveInterestRate_42d09db9-df8d-45ce-adb6-f0dec9a3c607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementTerminationPeriod_324bfa29-9871-48dd-ad90-1035197f6d64" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementTerminationPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementTerminationPeriod_324bfa29-9871-48dd-ad90-1035197f6d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_95101b9b-0123-4806-8b9f-fa69c480ea6d" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum_95101b9b-0123-4806-8b9f-fa69c480ea6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutAmount_6979add8-b803-4c28-b9cb-e461b5daa1e5" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutAmount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementBuyoutAmount_6979add8-b803-4c28-b9cb-e461b5daa1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_dba7cf8d-96f9-46e2-a651-9b7a669fa4ac" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment_dba7cf8d-96f9-46e2-a651-9b7a669fa4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_c457f789-a0e8-43ef-ad15-fadba290df76" xlink:href="adc-20220930.xsd#adc_RoyaltyPurchaseAgreementBuyoutPercentPayment"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyPurchaseAgreementBuyoutPercentPayment_c457f789-a0e8-43ef-ad15-fadba290df76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationPayments_a45d69b5-7d3d-43bb-af98-d765e07467ff" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationPayments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationPayments_a45d69b5-7d3d-43bb-af98-d765e07467ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_53ec6e2b-c806-4638-9e66-8d22e25f7ad3" xlink:href="adc-20220930.xsd#adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_af36fbfc-4c81-4fb2-97fe-0dcdb38f8750" xlink:to="loc_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment_53ec6e2b-c806-4638-9e66-8d22e25f7ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://adctherapeutics.com/role/EquityDetails" xlink:type="simple" xlink:href="adc-20220930.xsd#EquityDetails"/>
  <link:presentationLink xlink:role="http://adctherapeutics.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_adc_ShareCapitalReservesAndOtherEquityInterestAbstract_0ae71c1f-0ef3-4098-92b5-ddd1d73fb289" xlink:href="adc-20220930.xsd#adc_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesWithinEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_ShareCapitalReservesAndOtherEquityInterestAbstract_0ae71c1f-0ef3-4098-92b5-ddd1d73fb289" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_00343e67-ce7f-433d-9334-cc2b526bec67" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_9bae4137-0d8a-42a1-a67a-8b18b9619b3e" xlink:to="loc_ifrs-full_EquityMember_00343e67-ce7f-433d-9334-cc2b526bec67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_27410f71-07dd-4064-abd7-f0f67b51cb40" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_00343e67-ce7f-433d-9334-cc2b526bec67" xlink:to="loc_ifrs-full_SharePremiumMember_27410f71-07dd-4064-abd7-f0f67b51cb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:href="adc-20220930.xsd#adc_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockDomain_42a1991c-6da7-423c-ad00-3ea1c6436834" xlink:href="adc-20220930.xsd#adc_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockAxis_00f4269a-40f3-4222-8351-43adebd76c44" xlink:to="loc_adc_SaleOfStockDomain_42a1991c-6da7-423c-ad00-3ea1c6436834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_PurchasersMember_8b24f65f-896f-4404-a009-dadd51fab882" xlink:href="adc-20220930.xsd#adc_PurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_SaleOfStockDomain_42a1991c-6da7-423c-ad00-3ea1c6436834" xlink:to="loc_adc_PurchasersMember_8b24f65f-896f-4404-a009-dadd51fab882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheDomain_063e19cc-9f5c-4eee-a598-e24c18a9e9f7" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheAxis_9c80532b-4327-46ed-a852-79d61e8974d7" xlink:to="loc_adc_WarrantsTrancheDomain_063e19cc-9f5c-4eee-a598-e24c18a9e9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_WarrantsTrancheTwoMember_3b55dfab-2172-4f21-917f-e8070c940d12" xlink:href="adc-20220930.xsd#adc_WarrantsTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_adc_WarrantsTrancheDomain_063e19cc-9f5c-4eee-a598-e24c18a9e9f7" xlink:to="loc_adc_WarrantsTrancheTwoMember_3b55dfab-2172-4f21-917f-e8070c940d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesWithinEquityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityTable_b65bb35c-5488-4fd3-9831-2cc73c399214" xlink:to="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_IssueOfEquityThroughExchangeAgreement_d87e58f0-b38b-4621-a388-0f85e1c3c825" xlink:href="adc-20220930.xsd#adc_IssueOfEquityThroughExchangeAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_IssueOfEquityThroughExchangeAgreement_d87e58f0-b38b-4621-a388-0f85e1c3c825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_GainsLossOnExtinguishmentOfBorrowings_3422bb4d-8637-496c-b148-78f7010e668b" xlink:href="adc-20220930.xsd#adc_GainsLossOnExtinguishmentOfBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_GainsLossOnExtinguishmentOfBorrowings_3422bb4d-8637-496c-b148-78f7010e668b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_56d102f2-58de-4cf1-9eff-221c92e49596" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_ifrs-full_NumberOfSharesIssued_56d102f2-58de-4cf1-9eff-221c92e49596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_SaleOfStockPricePerShare_e2eb4a90-f5bd-446b-9d50-8ca01bfc8f9e" xlink:href="adc-20220930.xsd#adc_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_SaleOfStockPricePerShare_e2eb4a90-f5bd-446b-9d50-8ca01bfc8f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_9ee9bceb-aa4a-4b10-8292-ef94ea0e6619" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_9ee9bceb-aa4a-4b10-8292-ef94ea0e6619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_adc_ConvertibleNotesSharesConverted_15949195-e2e2-4d53-8e2f-bdce382cb09e" xlink:href="adc-20220930.xsd#adc_ConvertibleNotesSharesConverted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReservesWithinEquityLineItems_4c41926e-70b4-49ae-b765-521327e1968a" xlink:to="loc_adc_ConvertibleNotesSharesConverted_15949195-e2e2-4d53-8e2f-bdce382cb09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_4.jpg
<TEXT>
begin 644 image_4.jpg
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M> R%\\>=,&!K  !($)>O7B?FHVXF.A0=J7-(1YP<-CEX<@KD1/ASBS6P-0
MQ!Q#ST&4LK,8*N]%Y55'&UOX<XX=L#4  ,00:N@!Q>6BY&*9FPKVQ-O<L#4
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MX4?.6Z6BB66"CC50!6RM!?J[;>>AT_Q!VZ+_&<'6FA")Z6;>BN$W%>SASQ8
MK\#6V4?_;<M<U< IL#60)!+;D7HKAF/S,J 0V#K+-+=UWCIJE>@2?>*V!DZ!
MK8$\T>A>NR^&8U=PH!#8.LN,750BBD2KN*V!4V!K($\DNM=NB^$C=E3PYPF
M#V#K;$)$*%I$JY O$_Q!RP%; U?HW[W^SJ:O127;9'_U1?XD ? !;)TU]%^R
M=>NH51YJX!38&K@B&MUKZ6U2L' +* >VSAK$%J)"M$II11U_T-+ UL M^M^;
M2W[/<,PO \J!K;-#X?:CHC^T2G[1%_Q!NP&V!F[1?^UU3O%?13&;!O/+@')@
MZRR@_Y(M/S5P"FP-/*#_G31%,8OIM[R,/S$ ? -;APVQH.;;EO7Q5P.GP-;
M S,KOA$%J55R%AT0]<P%M[(&00!;ATU^T1>B.;2*SQHX!;8&'M#_QEPYR\I%
M/7-!&1P$ 6P=*J3/*FI#JY!^O\\:. 6V!M[0?*Z9X] URN @(&#K\" 6U'S)
M%LFQ,TW\<7L"M@;>*#K=(CI2JXB&9H,R. @(V#H\<N?M%)VA58AB^8/V"FP-
MO%';?D,4I%:Q'[I&&1P$!&P=$OHOV>H_<1U_T#Z K8%G="^&6Z^ZQJ8H(#A@
MZS#0?]NR/NIJX!38&GBFX,0ET9'ZQ&;#\+R22OYD % $;!T&^B_94E@#I\#6
MP#.:SPS/65\I>IIFV\E&_F0 4 1L'3CZ>TMM#9RB_UG#UCJC^38IHJ=I+E^]
MSI\) (J K8-%_R5;-^<N55L#I\#6P \C#S>*CM0GIA/-L'8+! IL'2#-;9VW
MCEHE>D*K%&X_RA^W"F!KX ?-UW'EO'-0M#4&K4&@P-8!,G91B2@)K1*<L6!K
MX ?=AZ[-=C1;?:R>/PT U %;!\7.0Z=%0VB5FW.7UIQOX8];$; U\(G.0]>F
M.YIAI34(%-@Z$"*Q9"N@&C@%M@8^&5S6(&I2DWQGT]><JF\JV,.?  !*@:T#
M@9A U(-6"=I5L#7PB>ZKKC-M/:"XG#\! )0"6ZM'_VW+ JV!4V!KX)/=#>VB
M(_5)3L'GK*TQQ0P$#6RMF&-GFD0QZ):=AT[SQZT:V!KX1/,-P[E%7)AB!H(&
MME9)<UNG_MN6Y<[;R1]W ,#6P#^B(_4)-RU\?_5%_N@!4 ILK9+\HB]$*VB5
MFW.7*KE]M2.P-?"/SA/-.%OSAPZ :F!K9>B_;5F?4&K@%-@:^"?O2).H24W"
M+N+"A' 0 K"U&DB'5?\E6^'4P"FP-?"/SM/"65MC0C@( =A:#42$H@^T2F@U
M< IL#?RC\[1P=LGUP,U'^$,'0#6PM0*"6+(U\.%7'G]TYI3'I[X^>N+"T<]M
M>V'TWOP1>_-'DK0O&D32L?BACK=(!J?R]L.IO$/R2$?AH]WY \EC)UY[8N_+
M3Y.<^,/SU=L65W]21-)464YRY7PM?R;J@*V!?PY>N"IJ4I\8MIY=>HH_= !4
M UO[Q?^V943,XX=,>WW4LVM^^_3>R4\TS!_4OO W[0L?:"]X,)4W2 :F_O?-
M@=33W;;N577:UE35AJW3JDYER6,=2Q_K6)9+<I7FW2%7BWIS<=68AK7YU1^]
M5?WI\J83Y9>KU2P;A:V!$D1'ZA/8&H0);.T7#TNVGGADQIPGGELS;O27^8^U
M+[BO?<&O4OG]_>V__W7'PE]WJ_KUM*U3JDZ'4W6J8ZU U5>7DPQ-944Z*[O3
MN.:YF@\75'^V@OB[L[69/V<)8&N@!-&1^L18<HWE6R $8&M?2#KI?S]8,#XW
M?]GH9[Z<\DC[_)^WS_]%*K_[9?MK,JH>:*;JM*VIJE.VEE1UKKFJ5V:H^NK*
M8:FL2F?UL,[WAEU<,[9N\YR:_>N;OI:=32-Y9;(8V#H2W+._7M2D)H&M09C
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MV98:YX:M@1*T7G+=LYT9?]  ! !L[86=AT[3%G_00W.6C1Q5.?E7;;/N3&=
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MDEJ<A';$:42M>LM-!7N,YZ2O0JV<D+*V!V!K    7J#]<ODDL'RM$-@:
MT!W8&@   - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8
M&@   - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@
M - =V!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@   - =
MV!H   #0'=@:    T!W8&@   - =V!H   #0'=@:    T!W8&@   - =V!H
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<O[4?V#;E_P?75$V.L?%O6@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614026302608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADC Therapeutics SA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Biop&#244;le<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Route de la Corniche 3B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">1066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Epalinges<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001771910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045372336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statement of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue</a></td>
<td class="nump">$ 76,321<span></span>
</td>
<td class="nump">$ 13,147<span></span>
</td>
<td class="nump">$ 140,110<span></span>
</td>
<td class="nump">$ 16,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of product sales</a></td>
<td class="num">(1,295)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="num">(4,090)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(41,676)<span></span>
</td>
<td class="num">(36,805)<span></span>
</td>
<td class="num">(139,165)<span></span>
</td>
<td class="num">(115,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="num">(16,847)<span></span>
</td>
<td class="num">(17,045)<span></span>
</td>
<td class="num">(52,876)<span></span>
</td>
<td class="num">(46,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(19,617)<span></span>
</td>
<td class="num">(16,587)<span></span>
</td>
<td class="num">(56,868)<span></span>
</td>
<td class="num">(53,536)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expense</a></td>
<td class="num">(79,435)<span></span>
</td>
<td class="num">(70,939)<span></span>
</td>
<td class="num">(252,999)<span></span>
</td>
<td class="num">(215,846)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operations</a></td>
<td class="num">(3,114)<span></span>
</td>
<td class="num">(57,792)<span></span>
</td>
<td class="num">(112,889)<span></span>
</td>
<td class="num">(198,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_OtherIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">18,597<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expense</a></td>
<td class="num">(11,356)<span></span>
</td>
<td class="num">(4,265)<span></span>
</td>
<td class="num">(29,374)<span></span>
</td>
<td class="num">(8,820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_OtherNonOperatingIncome', window );">Non-operating (expense) income</a></td>
<td class="num">(37,122)<span></span>
</td>
<td class="num">(9,363)<span></span>
</td>
<td class="num">(10,805)<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_OtherNonOperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(48,205)<span></span>
</td>
<td class="num">(13,612)<span></span>
</td>
<td class="num">(21,582)<span></span>
</td>
<td class="nump">3,786<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before taxes</a></td>
<td class="num">(51,319)<span></span>
</td>
<td class="num">(71,404)<span></span>
</td>
<td class="num">(134,471)<span></span>
</td>
<td class="num">(195,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit (expense)</a></td>
<td class="nump">711<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="num">(492)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (50,608)<span></span>
</td>
<td class="num">(71,549)<span></span>
</td>
<td class="num">$ (131,643)<span></span>
</td>
<td class="num">(195,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Net loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (195,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
<td class="num">$ (2.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
<td class="num">$ (2.55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adc_ProductRevenueNetMember', window );">Product revenues, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue</a></td>
<td class="nump">$ 21,321<span></span>
</td>
<td class="nump">$ 13,147<span></span>
</td>
<td class="nump">$ 55,110<span></span>
</td>
<td class="nump">$ 16,907<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adc_LicenseRevenueMember', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_OtherIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_OtherIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_OtherNonOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Operating Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_OtherNonOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_OtherNonOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Non-Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_OtherNonOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adc_ProductRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adc_ProductRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adc_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adc_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614026338016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statement of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (50,608)<span></span>
</td>
<td class="num">$ (71,549)<span></span>
</td>
<td class="num">$ (131,643)<span></span>
</td>
<td class="num">$ (195,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of defined benefit pension liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Total items that will not be reclassified to profit and loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified to profit and loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation differences</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Total items that may be reclassified to profit and loss</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (loss) income for the period</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">(51,092)<span></span>
</td>
<td class="num">(71,689)<span></span>
</td>
<td class="num">(129,050)<span></span>
</td>
<td class="num">(195,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Total comprehensive loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Owners of the parent</a></td>
<td class="num">$ (51,092)<span></span>
</td>
<td class="num">$ (71,689)<span></span>
</td>
<td class="num">$ (129,050)<span></span>
</td>
<td class="num">$ (195,729)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045447200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Balance Sheet - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 380,860<span></span>
</td>
<td class="nump">$ 466,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">23,251<span></span>
</td>
<td class="nump">30,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">15,745<span></span>
</td>
<td class="nump">11,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">18,243<span></span>
</td>
<td class="nump">17,298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">438,099<span></span>
</td>
<td class="nump">525,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">6,708<span></span>
</td>
<td class="nump">7,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,598<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Interest in joint venture</a></td>
<td class="nump">34,687<span></span>
</td>
<td class="nump">41,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="nump">33,599<span></span>
</td>
<td class="nump">26,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">899<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">93,660<span></span>
</td>
<td class="nump">92,790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">531,759<span></span>
</td>
<td class="nump">617,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable</a></td>
<td class="nump">11,611<span></span>
</td>
<td class="nump">12,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">62,658<span></span>
</td>
<td class="nump">50,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities, short-term</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Current income tax payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShortTermBorrowings', window );">Senior secured term loans, short-term</a></td>
<td class="nump">12,469<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Convertible loans, short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">87,573<span></span>
</td>
<td class="nump">73,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Convertible loans, derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentWarrantLiability', window );">Warrant obligations</a></td>
<td class="nump">4,293<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DeferredRoyaltyObligationNoncurrent', window );">Deferred royalty obligation, long-term</a></td>
<td class="nump">208,218<span></span>
</td>
<td class="nump">218,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures', window );">Deferred gain of joint venture</a></td>
<td class="nump">23,539<span></span>
</td>
<td class="nump">23,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities, long-term</a></td>
<td class="nump">6,622<span></span>
</td>
<td class="nump">6,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan', window );">Defined benefit pension liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">339,403<span></span>
</td>
<td class="nump">377,949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">426,976<span></span>
</td>
<td class="nump">451,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity attributable to owners of the parent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">6,699<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">1,007,510<span></span>
</td>
<td class="nump">981,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury shares</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">148,045<span></span>
</td>
<td class="nump">102,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Cumulative translation adjustments</a></td>
<td class="num">(842)<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated losses</a></td>
<td class="num">(1,056,528)<span></span>
</td>
<td class="num">(924,885)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity attributable to owners of the parent</a></td>
<td class="nump">104,783<span></span>
</td>
<td class="nump">166,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">531,759<span></span>
</td>
<td class="nump">617,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember', window );">Senior Secured Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Convertible loans, long-term</a></td>
<td class="nump">96,731<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_ConvertibleLoansMember', window );">Convertible Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Convertible loans, long-term</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 87,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DeferredRoyaltyObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DeferredRoyaltyObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities incurred in relation to interests in joint ventures. [Refer: Contingent liabilities [member]; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_ConvertibleLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_ConvertibleLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024620976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statement of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th"><div>Share Premium</div></th>
<th class="th"><div>Other Reserves</div></th>
<th class="th"><div>Treasury Shares</div></th>
<th class="th"><div>Cumulative Translation Adjustments</div></th>
<th class="th"><div>Accumulated Losses</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 335,505<span></span>
</td>
<td class="nump">$ 6,314<span></span>
</td>
<td class="nump">$ 981,056<span></span>
</td>
<td class="nump">$ 42,753<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="num">$ (694,859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(195,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (loss) income for the period</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">(195,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(195,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="nump">47,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="nump">47,532<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">47,016<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, ending balance at Sep. 30, 2021</a></td>
<td class="nump">187,308<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">981,570<span></span>
</td>
<td class="nump">89,769<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="num">(890,504)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, beginning balance at Jun. 30, 2021</a></td>
<td class="nump">243,918<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">981,290<span></span>
</td>
<td class="nump">74,971<span></span>
</td>
<td class="num">(134)<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="num">(818,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(71,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (loss) income for the period</a></td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">(71,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(71,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="nump">14,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="nump">15,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">14,798<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, ending balance at Sep. 30, 2021</a></td>
<td class="nump">187,308<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">981,570<span></span>
</td>
<td class="nump">89,769<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="num">(890,504)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">166,088<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">981,827<span></span>
</td>
<td class="nump">102,646<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="num">(924,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(131,643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of defined benefit pension liability</a></td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(1,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (loss) income for the period</a></td>
<td class="nump">2,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">(129,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
<td class="num">(131,643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssueOfEquityThroughExchangeAgreement', window );">Issuance of shares, Deerfield exchange agreement, net of transaction costs</a></td>
<td class="nump">19,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssueOfEquityThroughPurchaseAgreement', window );">Issuance of shares, share purchase agreement, net of transaction costs</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption', window );">Exercise of options and vestings of RSUs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="nump">41,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="nump">67,745<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">25,683<span></span>
</td>
<td class="nump">41,781<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, ending balance at Sep. 30, 2022</a></td>
<td class="nump">104,783<span></span>
</td>
<td class="nump">6,699<span></span>
</td>
<td class="nump">1,007,510<span></span>
</td>
<td class="nump">148,045<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(842)<span></span>
</td>
<td class="num">(1,056,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, beginning balance at Jun. 30, 2022</a></td>
<td class="nump">115,346<span></span>
</td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">981,818<span></span>
</td>
<td class="nump">133,480<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(358)<span></span>
</td>
<td class="num">(1,005,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(50,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive (loss) income for the period</a></td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">(51,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="num">(50,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Issuance of shares to be held as treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssueOfEquityThroughExchangeAgreement', window );">Issuance of shares, Deerfield exchange agreement, net of transaction costs</a></td>
<td class="nump">19,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssueOfEquityThroughPurchaseAgreement', window );">Issuance of shares, share purchase agreement, net of transaction costs</a></td>
<td class="nump">6,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption', window );">Exercise of options and vestings of RSUs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="nump">14,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total transactions with owners</a></td>
<td class="nump">40,529<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">25,692<span></span>
</td>
<td class="nump">14,565<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity, ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 104,783<span></span>
</td>
<td class="nump">$ 6,699<span></span>
</td>
<td class="nump">$ 1,007,510<span></span>
</td>
<td class="nump">$ 148,045<span></span>
</td>
<td class="num">$ (101)<span></span>
</td>
<td class="num">$ (842)<span></span>
</td>
<td class="num">$ (1,056,528)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IssueOfEquityThroughExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity Through Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IssueOfEquityThroughExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IssueOfEquityThroughPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity Through Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IssueOfEquityThroughPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045632720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">$ (131,643)<span></span>
</td>
<td class="num">$ (195,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-monetary items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense</a></td>
<td class="nump">41,781<span></span>
</td>
<td class="nump">47,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Impairments of Assets</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of intangible assets</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="nump">896<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories', window );">Gain from reversal of inventory impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod', window );">Share of results in joint venture</a></td>
<td class="nump">6,549<span></span>
</td>
<td class="nump">3,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Deferred tax asset</a></td>
<td class="num">(7,550)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability', window );">Change in defined benefit pension liability</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives', window );">Convertible loans, derivatives, decrease in fair value</a></td>
<td class="num">(25,650)<span></span>
</td>
<td class="num">(16,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants', window );">Warrant obligations, decrease in fair value</a></td>
<td class="num">(11,961)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Financial income&#160;</a></td>
<td class="num">(18,597)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Financial expense</a></td>
<td class="nump">29,230<span></span>
</td>
<td class="nump">8,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnExtinguishmentOfBorrowings', window );">Loss on extinguishment</a></td>
<td class="num">(42,114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Exchange differences</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Operating loss before working capital changes</a></td>
<td class="num">(71,461)<span></span>
</td>
<td class="num">(157,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease (increase) in accounts receivable, net</a></td>
<td class="nump">6,936<span></span>
</td>
<td class="num">(15,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="num">(6,145)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="nump">489<span></span>
</td>
<td class="num">(3,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease) increase in accounts payable</a></td>
<td class="num">(411)<span></span>
</td>
<td class="nump">5,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Increase in income taxes</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Increase in other liabilities and other payables</a></td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(61,189)<span></span>
</td>
<td class="num">(167,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(6,924)<span></span>
</td>
<td class="num">(3,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease obligations</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PaymentsMadeUnderRoyaltyFinancingTransactions', window );">Interest paid under royalty financing transaction</a></td>
<td class="num">(5,656)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Taxes paid</a></td>
<td class="num">(11,381)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(84,697)<span></span>
</td>
<td class="num">(171,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash used in investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Payment for purchase of property, plant and equipment</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(3,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Payment for purchase of intangible assets</a></td>
<td class="num">(1,708)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PaymentForRentDeposits', window );">Payment for deposits</a></td>
<td class="num">(210)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,391)<span></span>
</td>
<td class="num">(5,843)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash (used in) provided by financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceeds from senior secured term loans, net of transaction costs</a></td>
<td class="nump">114,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from equity issuance, net of transaction costs</a></td>
<td class="nump">6,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleLoansExchange', window );">Convertible loans exchange</a></td>
<td class="num">(118,070)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from convertible loans, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts', window );">Proceeds from deferred royalty transaction, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">219,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal portion of lease obligation payments</a></td>
<td class="num">(757)<span></span>
</td>
<td class="num">(746)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">268,612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(85,233)<span></span>
</td>
<td class="nump">91,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange losses on cash and cash equivalents</a></td>
<td class="num">(451)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">466,544<span></span>
</td>
<td class="nump">439,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">380,860<span></span>
</td>
<td class="nump">530,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Non-Cash Investing Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssuanceOfShares', window );">Issuance of shares, Deerfield exchange agreement</a></td>
<td class="nump">19,834<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities', window );">Follow-on transaction costs recorded in Accounts payable and Other current liabilities</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures and intangible asset acquisitions recorded in Accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts', window );">Deferred royalty obligation transaction costs recorded in Accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Deferred Royalty Obligation Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Depreciation Expense Of Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Depreciation Expense, Property, Plant And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Gains (Losses) On change In Fair Value Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Expenditures, Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleLoansExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Loans Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleLoansExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GainsLossOnExtinguishmentOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Loss) On Extinguishment Of Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GainsLossOnExtinguishmentOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PaymentForRentDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Rent Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PaymentForRentDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PaymentsMadeUnderRoyaltyFinancingTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Made Under Royalty Financing Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PaymentsMadeUnderRoyaltyFinancingTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614049173712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Corporate information</a></td>
<td class="text">Corporate information<div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADC Therapeutics SA (the &#8220;Company&#8221; or &#8220;ADCT&#8221;) was incorporated on June 6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls three wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#8220;ADCT America&#8221;), which was incorporated in Delaware, USA on December 10, 2014, ADC Therapeutics (UK) Ltd (&#8220;ADCT UK&#8221;), which was incorporated in England on December 12, 2014 and ADC Therapeutics (NL) B.V. which was incorporated in the Netherlands on February 25, 2022. The Company and its three subsidiaries form the ADCT Group (the &#8220;Group&#8221;).</span></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group is focused on the development and commercialization of antibody drug conjugates (&#8220;ADCs&#8221;), including research, development, human clinical trials, regulatory approval and commercialization. On April 23, 2021, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;) and the Company commenced recognizing revenue upon the sale of ZYNLONTA during the second quarter of 2021. ADCs are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill any cancer cell to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.</span></div><div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November&#160;8, 2022.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Going concern basis</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADCT is a commercial-stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group&#8217;s success may also depend on its ability to:</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain a strong patent position and protection;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, gain regulatory approval and commercialize drug products;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaborations with partners in the pharmaceutical industry;</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire and retain key personnel; and</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire additional funding to support its operations.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its incorporation, the Group has primarily funded its growth through capital increases and additional funds provided by research collaborations, license agreements, the issuance of the Company&#8217;s common shares, the issuance of convertible loans, the issuance of term loans and proceeds from a royalty purchase agreement. During the first quarter of 2022 and third quarter of 2022, the Company entered into exclusive license agreements with Mitsubishi Tanabe Pharma Corporation ("MTPC") and Swedish Orphan Biovitrum AB ("Sobi"), respectively, for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan and all territories outside the U.S., greater China, Singapore and Japan, respectively. During the third quarter of 2022, the Company drew down USD 120.0&#160;million principal amount of senior secured term loans, entered into an exchange agreement with Deerfield Partners, L.P., and Deerfield Private Design Fund IV, L.P. (collectively, &#8220;Deerfield&#8221;) and sold shares to Owl Rock Opportunistic Master Fund II, L.P. and OR Opportunistic DL (C), L.P. (the "Purchasers") under a share purchase agreement. See note 14, "Senior secured term loan facility and warrants", note 15, "Convertible loans" and note 17, "Equity" for further information. The Group does not have recourse to bank loans. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans, other than, pursuant to the senior secured term loan facility, it must maintain a balance of at least USD 60 million in cash and cash equivalents plus any accounts payable that are greater than ninety days old at the end of each quarter.</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Group&#8217;s cash and cash equivalents amounted to USD 380.9 million (December&#160;31, 2021: USD 466.5 million).</span></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the Group has sufficient resources to meet its financial obligations for at least the next 12 months from the date of issuance of these unaudited condensed consolidated interim financial statements and, as a result, is presenting these unaudited condensed consolidated interim financial statements of the Group on a going concern basis.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">COVID &#8211; 19</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Group continues to monitor the COVID-19 pandemic and its impact to operations. The Group is commercializing ZYNLONTA using hybrid launch plans. The Company continued to see an increase in face-to-face interactions with physicians in the third quarter, which it believes is a key pillar of its continued success in driving the adoption of ZYNLONTA through ongoing dialogs with the healthcare provider community on ZYNLONTA's differentiated product profile. The Group is in close contact with its principal investigators and clinical sites, which are located in jurisdictions affected by the COVID-19 pandemic and is assessing the impact of the COVID-19 pandemic on its clinical trials, expected timelines and costs on an ongoing basis. In response to the spread of COVID-19, the Group has also modified its business practices based on local guidelines. At this time, Group employees are meeting with investigators and site staff in person as allowed by institutions. The Group continues to closely monitor the potential effects of the COVID-19 pandemic on its clinical trials, commercialization efforts and supply chain, and will work closely with its clinical trial sites and principal investigators, contract research organizations, customers and distributors and contract manufacturing partners to mitigate such impact. As the COVID-19 pandemic continues to evolve, the Group believes the impact to its operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration, the impact on the U.S. and global economies, the timing, the availability, and acceptance and effectiveness of vaccines and treatments, particularly against emerging variants of the novel coronavirus, and the scope and effectiveness of national and local governmental responses to the pandemic. Those primary drivers are beyond the Group&#8217;s knowledge and control, and as a result, the ultimate impact of the COVID-19 pandemic on the Group's results of operations, cash flows and financial position for the remainder of 2022 and thereafter cannot be reasonably predicted. However, on the basis of the risk mitigation measures undertaken, the Group has concluded that there is no material uncertainty that may cast a significant doubt upon the Group&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior secured term loan facility and warrants, convertible loan exchange and share purchase</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company, ADCT UK and ADCT America entered into a loan agreement and guaranty (the &#8220;Loan Agreement&#8221;) with certain affiliates and/or funds managed by each of Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, as lenders, and Owl Rock Opportunistic Master Fund I, L.P., as administrative agent and collateral agent, pursuant to which the Company may borrow up to USD 175.0&#160;million principal amount of secured term loans, including (i) an initial tranche of USD 120.0&#160;million principal amount of term loans (the &#8220;First Tranche&#8221;) and (ii) up to two additional tranches (&#8220;Future Tranches&#8221;), each up to USD 27.5&#160;million principal amount of term loans that the Company may draw upon before February 15, 2024, subject to satisfaction of certain customary conditions including compliance with the Company&#8217;s other material agreements for the incurrence of such debt. On August 15, 2022, the Company drew down USD 120.0&#160;million principal amount of term loans under the Loan Agreement and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. See note 14, &#8220;Senior secured term loan facility and warrants&#8221; for further information on this transaction. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD 115.0&#160;million aggregate principal amount of the Company&#8217;s senior secured convertible notes for warrants to purchase an aggregate of 4,412,840 common shares, an aggregate of 2,390,297 common shares and cash equal to USD 117.3&#160;million. The warrants consist of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share. As a result of the exchange agreement, the Company recognized a loss on extinguishment of USD 42.1 million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans,&#8221; note 16, &#8220;Deerfield warrants&#8221; and note 17 &#8220;Equity&#8221; for further information on this transaction. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into a share purchase agreement with the Purchasers, pursuant to which, on September 6, 2022, the Company issued and sold to the Purchasers an aggregate of 733,568 common shares at USD 8.52 per share for USD 6.1&#160;million in net cash proceeds. See note 17, &#8220;Equity&#8221; for further information on this transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614072264368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text">Basis of preparation<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Statement of Compliance</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements as of and for the three and nine months ended September&#160;30, 2022 have been prepared in accordance with International Accounting Standard 34&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;IAS 34&#8221;) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Functional and reporting currency</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements are presented in United States Dollars (&#8220;USD&#8221; or &#8220;$&#8221;), which is the Company&#8217;s functional currency and the Group&#8217;s reporting currency.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company, ADCT UK, has a functional currency of the British Pound (&#8220;GBP&#8221;). The following exchange rates have been used for the translation of the financial statements of ADCT UK:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.805%"><tr><td style="width:1.0%"/><td style="width:80.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USD / GBP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Closing rate, GBP 1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.11348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.34593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Weighted average exchange rate, GBP 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.18746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.39209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Basis of Consolidation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements incorporate the financial statements of the Company and entities controlled by the Company which are the same as those contained in the audited consolidated financial statements as of and for the year ended December&#160;31, 2021. </span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Use of estimates and judgements</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are based on management&#8217;s knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">As a result of increases in interest rates, the Company assessed the impact of utilizing a higher discount rate, 2.0%, in its most recent pension obligation actuarial valuation performed as of December 31, 2021. The use of a higher discount rate resulted in a decrease of KUSD 3.6&#160;million to its Defined benefit pension liabilities with a corresponding offset to Other comprehensive loss which was recorded during the second quarter of 2022. The reduction in its Defined benefit pension liability was capped at the fair value of the Company&#8217;s pension plan assets. The Company expects to perform its annual actuarial valuation in conjunction with its fiscal year ending December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December 31, 2021. There have been no material changes to the significant accounting policies other than those described in note 3, "Significant accounting policies". In addition, significant judgements were required in determining the fair value of the Company&#8217;s warrant obligations as set out in note 14 &#8220;Senior secured term loan facility and warrants&#8221; and note 16 &#8221;Deerfield warrants,&#8221; including the selection of the valuation methodology to use, as well as determining the underlying valuation assumptions. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Other income (expense)</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to December 31, 2021, individual components of Non-operating (expense) income were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#8220;Non-operating (expense) income&#8221; for further information.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share Subscription Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-months ended September 30, 2022, the Company issued 3,123,865 common shares to ADCT America pursuant to a share subscription agreement and immediately repurchased these shares as treasury shares at par value. As described above, the Company subsequently issued 733,568 treasury shares to the Purchasers, in accordance with the share purchase agreement and 2,390,297 treasury shares to Deerfield in accordance with the exchange agreement entered into on August 15, 2022. See note 17, &#8220;Equity&#8221; for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614072264368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract', window );"><strong>Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant accounting policies</a></td>
<td class="text">Significant accounting policies<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies applied by the Company in these unaudited condensed consolidated interim financial statements are the same as those applied by the Company in its audited consolidated financial statements as of and for the year ended December&#160;31, 2021 and have been applied consistently to all periods presented in these unaudited condensed consolidated interim financial statements, except for the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Arrangements</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Furthermore, on July 8, 2022, the Company entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. In previous years, the Company had generated revenue from the sale of its product candidates and service revenues from a license and collaboration arrangement. See note 5 &#8220;License Revenue&#8221; for further information on the MTPC and Sobi arrangement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenues from license fees for intellectual property (IP) either at a point in time or over time. The Company must make an assessment as to whether such a license represents a right-to-use the IP (at a point in time) or a right to access the IP (over time). The Company recognizes revenue for a right-to-use license immediately if the licensee can begin to use and benefit from the IP upon commencement of the license term and the Company has no further obligations in the context of the IP. A license is considered a right to access the IP when the Company undertakes activities during the license term that may significantly affect the IP, which directly exposes the customer to any positive or negative effects arising from such activities. These activities do not result in the immediate transfer of a good or service to the customer. As such, revenues from the right to access the IP are recognized over time. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into agreements with multiple performance obligations. Performance obligations are identified and separated when the other party can benefit from the license on its own or together with other resources that are readily available, and the license is separately identifiable from other goods or services in the contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices for out-license arrangements may include fixed up-front amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development and regulatory milestones because the ultimate outcomes are binary in nature. Variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price when sold separately or estimated stand-alone selling price on the basis of comparable transactions with other customers when such goods or services are not sold separately. The residual approach is the method used to estimate a stand-alone selling price when the selling price for a good or service is highly variable or uncertain.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction prices, sales milestones and royalties attributable to licenses are excluded from the variable consideration guidance and recognized at the later of when the subsequent sales transaction occurs, or the satisfaction or partial satisfaction of the performance obligation to which some or all of the royalty has been allocated.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior secured term loan facility</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, ADCT UK and ADCT America entered into a USD 175.0&#160;million Loan Agreement on August 15, 2022, pursuant to which the counterparty agreed to extend secured term loans to the Company in disbursements as follows: (i) a First Tranche and (ii) Future Tranches. See note 14, &#8220;Senior secured term loan facility and warrants.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the First Tranche </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company drew down the First Tranche of the senior secured term loans in the amount of USD 120.0 million and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. These senior secured term loans have been </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized as a hybrid financial instrument and accounted for as two separate components: (i) a warrant obligation and (ii) a loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)  The warrant obligation is presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value using a Black-Scholes pricing model and is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii) The</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior secured term loan&#8217;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the warrant obligation. The loan is subsequently measured at its amortized cost using an effective interest rate ("EIR") in accordance with IFRS 9. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. The revised EIR will be used prospectively with no income or expense recorded in the period of interest rate change. The loan is presented as a financial liability in the unaudited condensed consolidated interim balance sheet.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses and fees payable upon the issuance of the First Tranche of senior secured term loans were allocated pro rata to the above two components. The share of expenses allocated to the warrant obligation were charged directly to the unaudited condensed consolidated interim statement of operations, while the share of expenses allocated to the residual senior secured term loans was deducted from the loan and included in the calculation of the EIR.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the Future Tranches </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no obligation to draw down the Future Tranches of the senior secured term loans. Therefore, the Company will account for the Future Tranches when drawn upon as a liability and subsequently measure the liability at amortized cost in accordance with IFRS 9. Transaction costs associated with the Future Tranches will be deducted from the loan. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Deerfield Warrants</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The agreement consists of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These warrants have been recognized as a warrant obligation and presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value and was determined to approximate the fair value of the existing embedded conversion option features immediately prior to the consummation of the Exchange Agreement. The liability is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. See note 16, &#8220;Deerfield Warrants.&#8221;</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Employee Benefits - 2022 Employee Stock Purchase Plan </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company adopted the 2022 Employee Stock Purchase Plan (&#8220;2022 ESPP&#8221;), which was approved by shareholders at the Company&#8217;s 2022 Annual General Meeting. The Company will account for the 2022 ESPP similar to the Company&#8217;s other share plans. The 2022 ESPP allows eligible employees to purchase designated shares of the Company's common shares at a discount, over a series of offering periods through accumulated payroll deductions. The Company will offer the ESPP to employees twice a year with each having a six-month offering period. The first offering period will generally be from January 1st through June 30th and the second offering period will be from July 1st through December 31st. The grant date is the first day of each offering period.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of purchase rights granted under the 2022 ESPP is recognized as an employee share-based compensation expense with a corresponding increase in other reserves. The total amount to be expensed is determined by reference to the fair value of the purchase rights granted. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total expense is recognized over the offering period, which is the period over which all of the specified vesting conditions are to be satisfied. Participants that voluntarily withdrawal from the plan are accounted for as a cancellation and total share-based compensation recorded in the period in which the participant withdrawals. Terminations are accounted for as forfeitures and any share-based compensation expense reversed in the period the participant terminates. Accumulated payroll deductions are recorded within Accrued expenses in other current liabilities in the unaudited condensed consolidated interim balance sheet until shares are purchased by the participant at the end of the offering period. See note 18, &#8220;Share-based compensation&#8221; for further information.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New and amended IFRS standards</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2022, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, are not listed here.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614049163520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial risk management<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial risk management</a></td>
<td class="text">Financial risk management&#160;<div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Financial risk factors</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group&#8217;s activities are exposed to a variety of financial risks: market risk (including changes in the Company&#8217;s share price, exposure to fluctuation in currency exchange rates and exposure to interest rate movements), credit risk and liquidity risk.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group&#8217;s consolidated financial statements as of December&#160;31, 2021. In relation to the royalty purchase agreement with entities managed by Healthcare Royalty Management, LLC ("HCR"), the Company is obligated to pay interest in the form of royalties in connection with certain net sales and licensing revenue. As the EIR on the deferred royalty obligation does not depend on market performance, the exposure to interest rate and market risk is deemed low. See note 19, &#8220;Deferred royalty obligation&#8221; for further information. In regards to the senior secured term loans, the interest rate is variable and dependent upon market factors. The Company will update the EIR at the end of each reporting period for changes in the rate. See note 14, "Senior secured term loan facility and warrants" for further information. A hypothetical 100 basis point increase (decrease) in the interest rate as of September 30, 2022 would have increased (decreased) the effective interest expense associated with the Company's senior secured term loan facility by KUSD 272 and (KUSD 273), respectively. There have been no other material changes in financial risk management since year-end.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Fair value estimation</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities:</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">Cash and cash equivalents</span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12.53pt">Trade accounts receivable</span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12.53pt">Trade accounts payable</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September&#160;30, 2022, there were no significant changes in the business or economic circumstances that affected the fair value of the Group&#8217;s financial assets and financial liabilities.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values must be estimated at the end of each quarter with regard to the senior secured term loan warrant obligation and the Deerfield warrants. The approach to valuation follows the grant date fair value principle, and the key input factors are described for the senior secured term loan facility warrant obligation in note 14, "Senior secured term loan facility and warrants" and for the Deerfield warrants in note 16, "Deerfield warrants". Commonly accepted pricing models (Black-Scholes) have been used to calculate the fair values. The valuation of the senior secured term loan facility warrant obligation and Deerfield warrants are classified as pertaining to Level 2 of the valuation hierarchy. The convertible loan derivatives previously were classified as pertaining to Level 3 of the valuation hierarchy and were extinguished on August 15, 2022. See note 15, "Convertible loans" for further information. The Company no longer has any inputs pertaining to level 3 of the valuation hierarchy set out below.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The different levels of the valuation hierarchy have been defined as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (for example, as prices) or indirectly (for example, derived from prices);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Level 3: inputs for the asset or liability that are not based on observable market data.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between the respective levels during the period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044606272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenues, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Product revenue, net</a></td>
<td class="text">Revenue recognition<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product revenue</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 23, 2021, the Company received FDA accelerated regulatory and marketing approval for ZYNLONTA and launched in the U.S. shortly thereafter. To date, the Company&#8217;s only source of product revenue, which commenced during May 2021, has been sales of ZYNLONTA in the U.S. Product revenues, net were KUSD 21,321 and KUSD 55,110 for the three and nine months ended September&#160;30, 2022, respectively. Product revenues, net were KUSD 13,147 and KUSD 16,907 for the three and nine months ended September&#160;30, 2021, respectively. The Company records its best estimate of gross-to-net ("GTN") sales adjustments to which customers are likely to be entitled. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s accruals related to the GTN sales adjustments for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GTN sales adjustments for current year sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GTN sales adjustments for prior year sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Credits, payments and reclassifications to Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(9,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Ending balance as of September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company&#8217;s unaudited condensed consolidated interim balance sheet as of September&#160;30, 2022 and December&#160;31, 2021. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Accounts receivable</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s inventory is no longer held on consignment by the Company&#8217;s third-party logistics and distribution provider and as a result of receiving a permanent J-code for ZYNLONTA, the Company&#8217;s payment terms currently range from 30 days to 90 days. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">License revenue</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Under the terms of the agreement, the Company received an upfront payment of USD 30&#160;million and may receive up to an additional USD 205&#160;million in milestones if certain development and commercial events are achieved. The Company will also be entitled to receive royalties ranging in percentage from the high teens to the low twenties based on net sales of ZYNLONTA in Japan. MTPC will conduct clinical studies of ZYNLONTA in Japan and will have the right to participate in any global clinical studies by bearing a portion of the study costs. In addition, the Company will supply ZYNLONTA to MTPC for its drug development and commercialization under a supply agreement. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, the Company entered into exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. Under the terms of the agreement, the Company received an upfront payment of USD 55&#160;million and is eligible to receive up to USD 382.5&#160;million in regulatory and net sales-based milestones, including USD 50&#160;million upon approval of a Marketing Authorisation Application by the European Commission for ZYNLONTA in third-line DLBCL. The Company will also receive royalties ranging in percentage from the mid-teens to the mid-twenties based on net sales of </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the product in Sobi&#8217;s licensed territories, subject to certain adjustments. Sobi will also contribute 25 percent of clinical trial costs for select global ZYNLONTA trials, up to a cap of USD 10&#160;million per year. In addition, the Company has agreed to supply product to Sobi for its drug development and commercialization under a supply agreement which will be entered into.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MTPC and Sobi license arrangements are accounted for separately. Each agreement includes a license and a performance obligation to supply product. The license and supply obligations are accounted for as separate performance obligations as they are considered distinct because MTPC and Sobi can benefit from the licenses on their own or together with other resources that are readily available, and the licenses are separately identifiable from other goods or services in the contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed significant development work which resulted in FDA approval of ZYNLONTA in the U.S. for the treatment of relapsed or refractory DLBCL. As a result, the up-front license fees for both MTPC and Sobi are recognized immediately at the time of license execution, as MTPC and Sobi can use and benefit from the IP and the Company has no further performance obligation with respect to the IP upon commencement of the license terms. </span></div>Although contingent development milestone amounts are assessed each period for the likelihood of achievement, they are typically constrained and recognized when the uncertainty is subsequently resolved for the full amount of the milestone and will be classified as license revenue. Sales milestones and royalties are recognized when the subsequent sales occur and classified as license revenue.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044681168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_OperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segment information</a></td>
<td class="text">Segment informationThe Company is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_OperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Segments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_OperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044662768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expense<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Operating expense</a></td>
<td class="text">Operating expense<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the unaudited condensed consolidated interim statement of operations classification of the Company's total operating expense:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">Cost of product sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">4,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">External costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">83,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">66,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Employee expense&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">49,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">41,676</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">36,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">139,165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">115,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">S&amp;M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee expense&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">S&amp;M expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">17,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">52,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">46,177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">G&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">38,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">38,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">G&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">19,617</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">56,868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">53,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total operating expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">79,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">70,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">252,999</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">215,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes depreciation expense</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes share-based compensation expense</span></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes depreciation expense for Property, plant and equipment for the three and nine months ended September&#160;30, 2022. All other depreciation expense was not material for the three and nine months ended September&#160;30, 2022. All depreciation expense was not material for the three and nine months ended September&#160;30, 2021.</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The increase in Cost of product sales in the three and nine months ended September&#160;30, 2022, was primarily associated with USD 0.8&#160;million and USD 2.5&#160;million of impairment charges, respectively. The USD 0.8&#160;million of impairment charges was recorded during both the three months and nine months ended September 30, 2022 and was associated with inventory manufactured using the Company's existing process at a new facility that did not meet the Company's specifications. Additionally, impairment charges of USD 1.7&#160;million was recorded during the nine months ended September 30, 2022 and related to the manufacturing of antibodies that did not meet the Company's specifications. In addition, Cost of product sales during the nine months ended September&#160;30, 2022 increased due to a full nine months of sales activity in 2022 as compared to the same period in 2021 due to the commencement of ZYNLONTA sales in May 2021.</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">As a result of FDA approval of ZYNLONTA in April 2021, the Company reversed KUSD 7,049 of previously recorded impairment charges during the nine months ended September 30, 2021, relating to inventory costs incurred for the manufacture of product prior to FDA approval. R&amp;D external costs increased primarily as a result of higher chemistry, manufacturing and controls ("CMC") expense due to manufacturing activities to support the ADCT-212 program during the three and nine months ended September 30, 2022 as well as our continued clinical trials to expand the potential market opportunities for ZYNLONTA in earlier lines of therapy, advance Cami to support a BLA submission and build our pipeline. Employee expense increased for the nine months ended September 30, 2022 primarily due to higher contract labor expenses, wages and benefits and share-based compensation expense.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in S&amp;M expenses in the three months ended September&#160;30, 2022 was primarily due to lower employee expense due to lower share-based compensation expense. External costs increased for the three months ended September 30, 2022 primarily as a result of higher expenses relating to the commercial launch of ZYNLONTA. The increase in S&amp;M expenses in the nine months ended September&#160;30, 2022 was primarily due to increased professional expenses relating to the commercial launch of ZYNLONTA. This increase during the nine months ended September 30, 2022 was partially offset by lower employee expenses primarily due to lower share-based compensation expense. </span></div>The increase in G&amp;A expenses in the three months ended September&#160;30, 2022 was primarily due to higher employee expenses primarily related to USD 1.3&#160;million of executive compensation associated with the CEO transition and higher share-based compensation expense. External costs for the three months ended September 30, 2022 was primarily due to higher professional expenses. The increase in G&amp;A expenses in the nine months ended September 30, 2022 was primarily due to higher professional fees, including the fees associated with the license agreement entered into with MTPC. Employee expense for the nine months ended September&#160;30, 2022 remained virtually flat at USD 38.3&#160;million primarily as a result of lower share-based compensation expense offset by higher wages and benefits including USD 1.3&#160;million of executive compensation associated with the CEO transition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044606272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text">Cash and cash equivalentsPursuant to the Loan Agreement entered into on August 15, 2022 (see note 14, &#8220;Senior secured term loan facility and warrants&#8221;), the Company is subject to a covenant that requires it to maintain a balance at the end of each quarter of at least USD 60&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the date of the original invoice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044746320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Disclosure of inventories [text block]</a></td>
<td class="text">Inventory<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:51.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.865%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Finished goods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">15,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Subsequent to December&#160;31, 2021, the Company's inventory is no longer held on consignment by the third-party logistics and distribution provider. Finished goods includes KUSD 3 relating to ZYNLONTA held on consignment by the Company&#8217;s third-party logistics and distribution provider as of December&#160;31, 2021. </span></div>For the nine months ended September 30, 2021, the Company recognized a gain from reversal of previously recorded impairment charges of KUSD 7,049 as a result of receiving FDA approval of ZYNLONTA in April 2021. The reversal of previously recorded impairment charges is based on the existence of inventory on hand and estimated demand, as well as expiration dating. For the nine months ended September&#160;30, 2022, the Company designated certain capitalized pre-approval ZYNLONTA inventory for R&amp;D use and recorded a charge to R&amp;D expenses, which was partially offset by a reversal of previously recorded impairment charges. The Company recorded an expense to R&amp;D in the Company&#8217;s unaudited condensed consolidated interim statement of operations for the three and nine months ended September&#160;30, 2022, of nil and KUSD 75 respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044594112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Intangible assets</a></td>
<td class="text">Intangible assets<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses classified as definite-lived intangible assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. The Company classifies its licenses relating to product candidates for which regulatory approval has not been received as indefinite-lived intangible assets and did not recognize amortization expense relating to these licenses. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal development costs are classified as indefinite-lived intangible assets and are expected to be capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. The Company began to capitalize internal development costs for </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYNLONTA as an internally generated intangible asset upon the FDA approval in the U.S. and if certain recognition criteria were met. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, the Company capitalized the following license fees paid or accrued to third parties as intangible assets: </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Milestone Payments</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An amount of KUSD 500 paid upon the dosing of a specific number of patients in the first in-human clinical study related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"> </span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt">An amount of KUSD 195 paid upon the successful completion of in-vivo efficacy studies related to a license with a third party to use their specific binding proteins in the development, manufacturing and commercialization of products. The amount was capitalized as an indefinite-lived intangible asset.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company capitalized the following as intangible assets:</span></div><div style="margin-bottom:0.1pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Milestone Payments</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD 1,050 paid upon the successful completion of a pre-clinical toxicology study and IND submission related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD 600 paid upon final regulatory approval of ZYNLONTA related to a license agreement with a third party to use their technology to research, develop, manufacture and commercialize products. The amount was capitalized as a definite-lived intangible asset and will be amortized over its estimated useful life of 14 years based on the expected patent life, which includes an extension period that the Company believes is highly probable of being granted. This estimated useful life does not include additional patent protection that may be granted under applications filed but not yet approved other than the extension period discussed above.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">License Payments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD 400 relating to a license agreement with a third party to use their proprietary conjugation technology to research, develop, manufacture and commercialize products. The amount was capitalized as an indefinite-lived intangible asset. </span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;An amount of KUSD 250 paid relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset.</span></div><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The table below provides a rollforward of the Company&#8217;s intangible assets as of September&#160;30, 2022 and 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Indefinite lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Definite lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Licenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Internal development costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Licenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,680&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amortization charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(169)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,344)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net book amount as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">12,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,598</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Transfers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,392&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amortization charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net book amount as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">926</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">13,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128__IAS38_g118-128_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044791488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-operating income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock', window );">Non-operating income</a></td>
<td class="text">Non-operating (expense) income<div style="margin-bottom:0.1pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:33.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.881%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible loans, derivatives, change in fair value (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4,660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible loans, derivatives, transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(42,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(42,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deerfield warrant obligation, change in fair value income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, change in fair value income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share of results with joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences (loss) gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-operating income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(37,122)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(9,363)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(10,805)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">12,560</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Convertible loans, derivatives, change in fair value (expense) income</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in derivative fair values are explained in note 15, &#8220;Convertible loans&#8221;. Pursuant to the Facility Agreement with Deerfield, the Company drew down the Deerfield First Tranche of the convertible loans amounting to USD 65&#160;million on May 19, 2020. Additionally, in connection with the FDA approval of ZYNLONTA, the Company drew down the Deerfield Second Tranche of convertible loans amounting to USD 50&#160;million on May 17, 2021. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Convertible loans, derivatives, transaction costs</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction costs associated with the embedded derivatives associated with the draw-down of the second tranche of the convertible loans on April 23, 2021 were charged directly to the unaudited condensed consolidated interim statement of operations.</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss on debt extinguishment</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement, the Company recognized a loss on extinguishment, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#8220;Convertible loans.&#8221; for further information on this transaction. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deerfield warrant obligation, change in fair value income</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The Deerfield warrant obligation has been recorded at its initial fair value and is remeasured to fair value on a quarterly basis. Changes in fair value of the Deerfield warrant obligation are explained in note 16, "Deerfield warrants".</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senior secured term loan facility, warrants, transaction costs</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction costs associated with the warrants in connection with the August 15, 2022 Loan Agreement were charged directly to the unaudited condensed consolidated interim statement of operations. See note 14, "Senior secured term loan facility and warrants", for further information on this transaction.</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, change in fair value income</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the First Tranche of the senior secured term loan and warrants as one hybrid financial instrument, with the USD 120&#160;million proceeds separated into two components: a warrant obligation and a loan. The </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrant obligation has been recorded at its initial fair value and is remeasured to fair value on a quarterly basis. Changes in fair value of the warrant obligation are explained in note 14, "Senior secured term loan facility and warrants".</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Share of results with joint venture</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the formation of Overland ADCT BioPharma in December 2020, the Company recorded its proportionate share of Overland ADCT BioPharma&#8217;s net loss. See note 12, &#8220;Interest in joint venture&#8221;. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Exchange differences (loss) gain</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also included in non-operating (expense) income are favorable or unfavorable Exchange differences. The Company is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs. Exchange differences represent gain or (loss) based on favorable or unfavorable changes in foreign currencies. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">R&amp;D tax credit (expense)</span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes as income (expense) amounts received and receivable by its subsidiary, ADCT UK, under the United Kingdom&#8217;s R&amp;D Expenditure Credit scheme (&#8220;UK R&amp;D Credit Scheme&#8221;). The grants represent 12% of eligible expenditure. The claims are payable through the tax system, as a refund of corporation tax or of other taxes, including income tax and social security payments deducted at source from qualifying (research) employees&#8217; payroll and VAT. The relevant amounts have been therefore presented net in the balance sheet. As the credit is independent of ADCT UK&#8217;s taxable profit, is clearly designed to incentivize companies to invest in R&amp;D activities and is itself taxable income, the Group has recognized the income as government grants within non-operating (expense) income and not as a credit to income tax expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Other Non-Operating Income, Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614026302496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest in joint venture<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesExplanatory', window );">Interest in joint venture</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the Company announced the formation of a new joint venture company, Overland ADCT BioPharma, with Overland Pharmaceuticals (&#8220;Overland&#8221;), a fully integrated biopharmaceutical company backed by Hillhouse Capital. Overland ADCT BioPharma will develop and commercialize one of the Company&#8217;s ADC products, ZYNLONTA, and three of the Company&#8217;s ADC product candidates, ADCT-601, ADCT-602 and ADCT-901, in greater China and Singapore. The table below provides a rollforward of the Company&#8217;s interest in Overland ADCT BioPharma as of September&#160;30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:75.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Interest in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">41,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">34,687</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">44,002</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the deferred gain of USD 23.5&#160;million arising from the Company&#8217;s contribution for its equity investment in the joint venture remained unchanged from December&#160;31, 2021. The Company&#8217;s carrying value of its investment in a joint venture increases or decreases in relation to the Company&#8217;s proportionate share of comprehensive income or loss of the joint venture. When the Company&#8217;s share of losses of a joint venture exceeds the Company&#8217;s interest in that joint venture less the carrying value of the deferred gain described above, the Company ceases to recognize its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the joint venture. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company&#8217;s share of those amounts. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Summarized Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">39,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">48,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">48,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">69,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">84,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Summarized Statement of Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of joint ventures. [Refer: Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B4<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B4_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044844752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company's right-of-use assets as of September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:60.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Properties (Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(1,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(1,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(75)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">6,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">6,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">5,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">5,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease termination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">10,124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease termination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,542)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,584)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the third quarter of 2022, the Company extended the term of its existing lease related to its U.S. corporate offices in New Jersey for an additional two years commencing on December 1, 2022, including an extension option for three additional years. The Company is reasonably certain it will exercise the extension option and therefore has accounted for the lease using a five-year lease term.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">During the first quarter of 2021, the Company entered into a new lease agreement with a ten-year term commencing in January 2021 for space in the iHub building on the Imperial University college campus in White City, West London. The primary function of the new facility, which consists of approximately 1,100 square meters, is R&amp;D. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets have been charged to the following categories in the unaudited condensed consolidated interim statement of operations. Depreciation expense for S&amp;M expenses was not material for any of the periods presented. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:43.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G&amp;A expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">395</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">896</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,194</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company's lease liabilities as of September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:60.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Properties (Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflow (including interest)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflow (including interest)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044661536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior secured term loan facility and warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory', window );">Convertible loans</a></td>
<td class="text">Senior secured term loan facility and warrants<div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company, ADCT UK and ADCT America entered into the Loan Agreement, pursuant to which the Company may borrow up to USD 175.0&#160;million principal amount of secured term loans, including (i) a First Tranche and (ii) Future Tranches. On August 15, 2022, the Company drew down USD 120.0&#160;million principal amount of term loans under the Loan Agreement. The secured term loans are scheduled to mature on August 15, 2029 and accrue interest at an annual rate of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secured overnight financing rate (SOFR) plus 7.50% per annum (with respect to SOFR loans) or a base rate plus 6.50% per annum (with respect to alternative base rate ("ABR") loans) for the first five years of the term loans, and thereafter, at an annual rate of SOFR plus 9.25% (with respect to SOFR loans) or a base rate plus 8.25% (with respect to ABR loans), in each case subject to a 1.00% per annum SOFR floor. The Company has the option to elect for the loans to be either a SOFR loan or ABR loan. The Company has elected the First Tranche of the secured term loan to be a SOFR loan. Interest is paid on the last business day of each quarter.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is obligated to pay certain exit fees upon certain prepayments and repayments of the principal amount of the term loans in an amount ranging from zero to 4.0% of the amount of the loan so paid. In addition, The Company has the right to prepay the term loans at any time subject to certain prepayment premiums applicable until the August 15, 2026. The Loan Agreement also contains certain prepayment provisions, including mandatory prepayments from the proceeds from certain asset sales, casualty events and from issuances or incurrences of debt, which may also be subject to prepayment premiums if made on or prior to August 15, 2026. The obligations under the Loan Agreement are secured by substantially all of the Company's assets and those of certain of the Company's subsidiaries and are guaranteed initially by the Company's subsidiaries in the US and the UK. The Loan Agreement contains customary covenants, including a covenant to maintain a balance at the end of each quarter of at least USD 60.0&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the original invoice therefore, and negative covenants including limitations on indebtedness, liens, fundamental changes, asset sales, investments, dividends and other restricted payments and other matters customarily restricted in such agreements. The Loan Agreement also contains customary events of default, after which the term loan may become due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults (including creation of any liens other than those that are expressly permitted), bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the Company and its subsidiaries and change in control.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company also issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to August 15, 2032. The warrants contain customary anti-dilution adjustments and will entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for First Tranche of senior secured term loan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the First Tranche of the senior secured term loans and the warrants described above</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hybrid financial instrument, with the USD 120.0&#160;million draw down separated into two components</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a warrant obligation and a loan. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligation, using the Black-Scholes option-pricing model. The warrant obligation has been recorded at an initial fair value of USD 4.0&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">60 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan&#8217;s initial fair value was recorded at USD 116.0&#160;million on August 15, 2022, representing the residual amount of the USD 120.0&#160;million draw down, after separating out the initial fair value of USD 4.0&#160;million of the warrant obligation. The loan is subsequently measured at its amortized cost. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">in KUSD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Warrant obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Loan Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">3,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">116,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">120,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Carrying value of loan at issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">108,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oak Tree and Owl Rock Warrant Obligations</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company recognized income of KUSD 2,543 as a result of changes in the fair value of the warrant obligations from the issuance date of August 15, 2022. The fair value of the warrant obligations as of September 30, 2022 was KUSD 1,414. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period, which was recorded directly to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58.5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Term Loan</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As illustrated in the table above, the transaction costs of the residual loan (net of the fair value of warrant obligations) were deducted from the loan to determine the deemed net present value as of August 15, 2022 of all future cash outflows associated with the loan. The implied EIR that would be needed to increase the book value of the loan to cover all future expected outflows, taking into account the deduction of transaction costs from the initial loan balance, and based on a 360-</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day year for a SOFR loan, was computed at inception at 14.99%. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. For the three and nine months ended September 30, 2022, the Company recorded interest expense on the senior secured term loan in the amount of KUSD 1,933 which was recorded in Financial expense in the unaudited condensed consolidated interim statement of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount at which the senior secured term loan is presented as a liability in the unaudited condensed consolidated interim balance sheet represents the net present value of all future cash outflows associated with the loan discounted at the EIR. The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability in the unaudited condensed consolidated interim balance sheet. The carrying value of the senior secured term loan was USD 109.2 million as of September 30, 2022, of which USD 12.5 million and USD 96.7 million represented the short-term and long-term portion of the liability, respectively. </span></div>Convertible loans<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Company entered into a USD 115&#160;million Facility Agreement with Deerfield, pursuant to which Deerfield extended a tranche of USD 65&#160;million of convertible loans on May 19, 2020 upon completion of the Company&#8217;s initial public offering (the &#8220;Deerfield First Tranche&#8221;) and a tranche of USD 50&#160;million of convertible loans on May 17, 2021 after the receipt of regulatory approval for ZYNLONTA (the &#8220;Deerfield Second Tranche&#8221;). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD 115.0&#160;million aggregate principal amount of the Company's senior secured convertible notes for warrants to purchase an aggregate of 4,412,840 common shares, an aggregate of 2,390,297 common shares and cash equal to USD 117.3&#160;million. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement on August 15, 2022, the Company recognized a loss on extinguishment of USD 42.1 million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Embedded conversion option derivatives</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the exchange, the Company accounted for the Facility agreement as a loan and embedded conversion option features. The embedded conversion option derivative was marked-to-market while the loan was measured at its amortized cost on a quarterly basis.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in fair value income (expense) and profit or loss activity of the embedded conversion option derivatives during the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,822)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - prior to FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - after FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(4,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(6,943)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">25,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value expense recognized during the three and nine months ended September 30, 2022 represents the change in fair value up until the point of exchange on August 15, 2022.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the changes in fair value, the Company recorded a gain of KUSD 1,816 during the nine months ended September 30, 2021 with the receipt of the USD 50&#160;million subsequent disbursement, the establishment of the embedded derivative and residual loan associated with the subsequent disbursement and elimination of the derivative immediately prior to FDA approval of ZYNLONTA.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases (decreases) in fair values of the embedded derivatives are primarily due to increases (decreases) in the fair value of the underlying shares during the respective periods. These amounts were charged directly to the unaudited </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated interim statements of operations. See note 8, &#8220;Non-operating (expense) income&#8221; for further information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative associated with the Deerfield First Tranche was KUSD 7,670 at the time of exchange on August 15, 2022 and KUSD 23,226 on December 31, 2021. The fair value of the embedded derivative associated with the Deerfield Second Tranche was KUSD 4,627 at the time of exchange on August 15, 2022 and KUSD 14,721 as of December 31, 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield First Tranche and Deerfield Second Tranche of the embedded conversion option derivatives, which is based on the mean of values derived from application of the Hull and Goldman Sachs convertible bond pricing models. Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield First Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:59.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price at 130% of the IPO price of 19.00, in USD</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Second Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Residual convertible loan</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDebtSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044780880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible loans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory', window );">Convertible loans</a></td>
<td class="text">Senior secured term loan facility and warrants<div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company, ADCT UK and ADCT America entered into the Loan Agreement, pursuant to which the Company may borrow up to USD 175.0&#160;million principal amount of secured term loans, including (i) a First Tranche and (ii) Future Tranches. On August 15, 2022, the Company drew down USD 120.0&#160;million principal amount of term loans under the Loan Agreement. The secured term loans are scheduled to mature on August 15, 2029 and accrue interest at an annual rate of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secured overnight financing rate (SOFR) plus 7.50% per annum (with respect to SOFR loans) or a base rate plus 6.50% per annum (with respect to alternative base rate ("ABR") loans) for the first five years of the term loans, and thereafter, at an annual rate of SOFR plus 9.25% (with respect to SOFR loans) or a base rate plus 8.25% (with respect to ABR loans), in each case subject to a 1.00% per annum SOFR floor. The Company has the option to elect for the loans to be either a SOFR loan or ABR loan. The Company has elected the First Tranche of the secured term loan to be a SOFR loan. Interest is paid on the last business day of each quarter.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is obligated to pay certain exit fees upon certain prepayments and repayments of the principal amount of the term loans in an amount ranging from zero to 4.0% of the amount of the loan so paid. In addition, The Company has the right to prepay the term loans at any time subject to certain prepayment premiums applicable until the August 15, 2026. The Loan Agreement also contains certain prepayment provisions, including mandatory prepayments from the proceeds from certain asset sales, casualty events and from issuances or incurrences of debt, which may also be subject to prepayment premiums if made on or prior to August 15, 2026. The obligations under the Loan Agreement are secured by substantially all of the Company's assets and those of certain of the Company's subsidiaries and are guaranteed initially by the Company's subsidiaries in the US and the UK. The Loan Agreement contains customary covenants, including a covenant to maintain a balance at the end of each quarter of at least USD 60.0&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the original invoice therefore, and negative covenants including limitations on indebtedness, liens, fundamental changes, asset sales, investments, dividends and other restricted payments and other matters customarily restricted in such agreements. The Loan Agreement also contains customary events of default, after which the term loan may become due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults (including creation of any liens other than those that are expressly permitted), bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the Company and its subsidiaries and change in control.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company also issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to August 15, 2032. The warrants contain customary anti-dilution adjustments and will entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for First Tranche of senior secured term loan</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the First Tranche of the senior secured term loans and the warrants described above</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hybrid financial instrument, with the USD 120.0&#160;million draw down separated into two components</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a warrant obligation and a loan. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligation, using the Black-Scholes option-pricing model. The warrant obligation has been recorded at an initial fair value of USD 4.0&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">60 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan&#8217;s initial fair value was recorded at USD 116.0&#160;million on August 15, 2022, representing the residual amount of the USD 120.0&#160;million draw down, after separating out the initial fair value of USD 4.0&#160;million of the warrant obligation. The loan is subsequently measured at its amortized cost. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">in KUSD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Warrant obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Loan Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">3,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">116,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">120,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Carrying value of loan at issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">108,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oak Tree and Owl Rock Warrant Obligations</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company recognized income of KUSD 2,543 as a result of changes in the fair value of the warrant obligations from the issuance date of August 15, 2022. The fair value of the warrant obligations as of September 30, 2022 was KUSD 1,414. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period, which was recorded directly to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58.5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Term Loan</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As illustrated in the table above, the transaction costs of the residual loan (net of the fair value of warrant obligations) were deducted from the loan to determine the deemed net present value as of August 15, 2022 of all future cash outflows associated with the loan. The implied EIR that would be needed to increase the book value of the loan to cover all future expected outflows, taking into account the deduction of transaction costs from the initial loan balance, and based on a 360-</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day year for a SOFR loan, was computed at inception at 14.99%. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. For the three and nine months ended September 30, 2022, the Company recorded interest expense on the senior secured term loan in the amount of KUSD 1,933 which was recorded in Financial expense in the unaudited condensed consolidated interim statement of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount at which the senior secured term loan is presented as a liability in the unaudited condensed consolidated interim balance sheet represents the net present value of all future cash outflows associated with the loan discounted at the EIR. The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability in the unaudited condensed consolidated interim balance sheet. The carrying value of the senior secured term loan was USD 109.2 million as of September 30, 2022, of which USD 12.5 million and USD 96.7 million represented the short-term and long-term portion of the liability, respectively. </span></div>Convertible loans<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 24, 2020, the Company entered into a USD 115&#160;million Facility Agreement with Deerfield, pursuant to which Deerfield extended a tranche of USD 65&#160;million of convertible loans on May 19, 2020 upon completion of the Company&#8217;s initial public offering (the &#8220;Deerfield First Tranche&#8221;) and a tranche of USD 50&#160;million of convertible loans on May 17, 2021 after the receipt of regulatory approval for ZYNLONTA (the &#8220;Deerfield Second Tranche&#8221;). </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD 115.0&#160;million aggregate principal amount of the Company's senior secured convertible notes for warrants to purchase an aggregate of 4,412,840 common shares, an aggregate of 2,390,297 common shares and cash equal to USD 117.3&#160;million. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the exchange agreement on August 15, 2022, the Company recognized a loss on extinguishment of USD 42.1 million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Embedded conversion option derivatives</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the exchange, the Company accounted for the Facility agreement as a loan and embedded conversion option features. The embedded conversion option derivative was marked-to-market while the loan was measured at its amortized cost on a quarterly basis.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in fair value income (expense) and profit or loss activity of the embedded conversion option derivatives during the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,822)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - prior to FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - after FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(4,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(6,943)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">25,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value expense recognized during the three and nine months ended September 30, 2022 represents the change in fair value up until the point of exchange on August 15, 2022.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the changes in fair value, the Company recorded a gain of KUSD 1,816 during the nine months ended September 30, 2021 with the receipt of the USD 50&#160;million subsequent disbursement, the establishment of the embedded derivative and residual loan associated with the subsequent disbursement and elimination of the derivative immediately prior to FDA approval of ZYNLONTA.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases (decreases) in fair values of the embedded derivatives are primarily due to increases (decreases) in the fair value of the underlying shares during the respective periods. These amounts were charged directly to the unaudited </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated interim statements of operations. See note 8, &#8220;Non-operating (expense) income&#8221; for further information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative associated with the Deerfield First Tranche was KUSD 7,670 at the time of exchange on August 15, 2022 and KUSD 23,226 on December 31, 2021. The fair value of the embedded derivative associated with the Deerfield Second Tranche was KUSD 4,627 at the time of exchange on August 15, 2022 and KUSD 14,721 as of December 31, 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield First Tranche and Deerfield Second Tranche of the embedded conversion option derivatives, which is based on the mean of values derived from application of the Hull and Goldman Sachs convertible bond pricing models. Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield First Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:59.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price at 130% of the IPO price of 19.00, in USD</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Second Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Residual convertible loan</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDebtSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044688528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deerfield Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfWarrantsTextBlock', window );">Deerfield Warrants</a></td>
<td class="text">Deerfield warrants<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The warrants consist of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder, at any time on or prior to May 19, 2025. The warrants contain customary anti-dilution adjustments and entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. Each holder also may require the Company to repurchase the warrants for their Black Scholes-based fair value in connection with certain transformative transactions or change of control of the Company that occur prior to their expiration.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the warrants are reflective of the terms of the embedded conversion option features of the Deerfield Facility Agreement prior to the Exchange Agreement. As a result, the fair value of the warrants was determined to approximate the fair value of the existing embedded conversion option features immediately prior to the consummation of the Exchange Agreement. As such, the warrant obligation was recorded at an initial fair value of KUSD 12,297 on August 15, 2022. Subsequent to issuance, the warrant obligation will be remeasured to fair value on a quarterly basis. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2022, the Company recognized income of KUSD 9,418 as a result of changes in the fair value of the warrant obligation. The fair value of the warrant obligation as of September 30, 2022 was KUSD 2,879. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period. These amounts were recorded to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield warrant obligation, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligation as of September 30, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70 and 28.07</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31.7 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">0.69 and 0.60</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044856736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareBasedPaymentArrangementsAbstract', window );"><strong>Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based compensation</a></td>
<td class="text">Share-based compensation<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Equity Incentive Plan 2019</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company adopted the Equity Incentive Plan 2019. Under the Equity Incentive Plan 2019, the Company may at its discretion grant to plan participants, such as directors, certain employees and service providers, awards in the form of restricted shares and restricted share units (&#8220;RSUs&#8221;), share options, share appreciation rights, performance awards and other share-based awards. The Company has reserved 13,820,000 common shares for future issuance under the Equity Incentive Plan 2019 (including share-based equity awards granted to date less awards forfeited). As of September&#160;30, 2022, the Company has 1,349,944 common shares available for the future issuance of share-based equity awards. On March 7, 2022, the Company issued its annual equity award, which was approved by the Compensation Committee of the Board of Directors and consisted of 1,867,076 share options and 570,340 RSUs. On May 11, 2022, the Company issued a special retention award to select employees, which was approved by the Compensation Committee of the Board of Directors and consisted of 1,298,700 RSU's. As of September&#160;30, 2022, the Company has only granted share options, RSUs and performance awards under the Equity Incentive Plan 2019.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the cumulative amount recorded as an increase to Other Reserves within equity in the unaudited condensed consolidated interim balance sheet of the Equity Incentive Plan 2019 was KUSD 137,759. An amount of KUSD 512 was withheld for tax charges during the three months ended March 31, 2022. There were no amounts withheld for tax charges during both the three months ended September 30, 2022 and June 30, 2022. The amount of expense for all awards recognized for services received during the three and nine months ended September&#160;30, 2022 were KUSD 14,565 and KUSD 42,293, respectively, and for the three and nine months ended September&#160;30, 2021 were KUSD 14,798 and KUSD 47,016, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Options</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity Incentive Plan 2019, the Company may grant share options to its directors, certain employees and service providers working for the benefit of the Company at the time. The exercise price per share option is set by the Company at the fair market value of the underlying common shares on the date of grant, as determined by the Company, which is generally the closing share price of the Company&#8217;s common shares traded on the NYSE. The awards generally vest 25% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent three years. The contractual term of each share option award granted is ten years. Under the grant, the options may be settled only in common shares of the Company. Therefore, the grants of share options under the Equity Incentive Plan 2019 have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company&#8217;s unaudited condensed consolidated interim statement of operations and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim balance sheet.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recognized for services received during the three and nine months ended September&#160;30, 2022 was KUSD 8,193 and KUSD 27,158, respectively. The expense recognized for services received during the three and nine months ended September&#160;30, 2021 was KUSD 12,105 and KUSD 40,112, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the share option awards outstanding as of September&#160;30, 2022:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:53.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Average strike price per share in USD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Number of awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted average remaining life<br/>in years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,640,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.70</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,937,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9.39</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(820,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">21.23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,757,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8.39</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards outstanding as of September&#160;30, 2022 and December&#160;31, 2021, expire through 2032 and 2031, respectively. The options granted during 2022 include the Company&#8217;s annual equity award discussed above. The grant-date fair value of the options relating to the annual equity awards was USD 8.85 per share. As of September&#160;30, 2022, 3,457,420 awards are vested and exercisable out of the total outstanding awards of 9,757,225 common shares. The weighted average strike price and weighted average remaining life for vested and exercisable awards is USD 25.67 and 7.44 years, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted were determined on the date of the grant using the Black-Scholes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">option-pricing</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> model. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Company used an independent valuation firm to assist in calculating the fair value of the award grants per participant. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three and nine months ended September&#160;30, 2022 were determined on the date of the grant using the following assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:51.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price, in USD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 8.54</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 19.69</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Strike price, in USD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 8.54</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 19.69</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">70% to 80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">70% to 80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Award life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.08</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.08 </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.61% - 3.77%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.46% - 3.77%</span></div></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility was based on the Company&#8217;s historical volatility and selected volatility determined by median values observed among other comparable public companies. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The award life is based on the time interval between the date of grant and the date during the ten-year life after which, when making the grant, the Company expected on average that participants would exercise their options.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RSUs</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Equity Incentive Plan 2019, the Company may grant RSUs to its directors, certain employees and service providers working for the benefit of the Company at the time. The awards generally vest annually over a period of three years commencing on the first anniversary of the date of grant. The special retention awards discussed above vest 50% and the remainder at the six-month and one year anniversaries, respectively, of the grant date. The RSUs may be settled only in common shares of the Company. Therefore, the grants of RSUs under the Equity Incentive Plan 2019 have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company&#8217;s unaudited condensed consolidated interim statement of operations and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim balance sheet.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense recognized for services received during the three and nine months ended September&#160;30, 2022 was KUSD 6,372 and KUSD 15,135, respectively. The expense recognized for services received during the three and nine months ended September&#160;30, 2021 was KUSD 2,693 and KUSD 6,904, respectively.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Number of awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">663,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">30.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,129,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(344,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">30.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(135,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,313,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11.71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSUs granted during 2022 include the annual equity award and special retention award discussed above, which had grant date fair values of USD 14.00 and USD 6.93, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share-based Compensation Reserves</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement in the Share-based Compensation Reserves (included in Other reserves within equity) is as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:39.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - Share Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tax and social charge deductions - Incentive Plan 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,798</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">41,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">47,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2022 Employee Stock Purchase Plan</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company adopted the 2022 ESPP, which was approved by shareholders at the Company's 2022 Annual General Meeting. The Company has 782,700 common shares reserved and available for the future issuance. The number of shares available for grant and issuance under the 2022 ESPP will increase on January 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of each of the first ten calendar years during the term of the 2022 ESPP by the number of shares equal to 1% of the shares outstanding as of the immediately preceding December 31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or lesser number as may be determined by the Board. The aggregate number of shares that may be issued under the 2022 ESPP Plan is equal to 1% of the ordinary share capital of the Company. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 ESPP allows eligible employees to purchase designated shares of the Company's common shares at a discount, over a series of offering periods through accumulated payroll deductions. No offering period may be longer than 27 months. The purchase price for shares purchased under the 2022 ESPP during any given purchase period will be 85% of the lesser of the market price of the Company&#8217;s common shares on (i) the offering date or (ii) the purchase date.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant date of the initial offering period was July 18, 2022, and that offering period will end on December 31, 2022.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes share-based compensation expense related to purchase rights granted pursuant to its 2022 ESPP on a straight-line basis over the requisite service period, which is generally a six-month period. The fair value of the purchase rights granted were determined on the date of the grant using the Black-Scholes option-pricing model. The Company used an independent valuation firm to assist in calculating the fair value of the purchase rights. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expense for services received during the three and nine months ended September 30, 2022 was not material to the overall financial statements. As of September 30, 2022, the Company recorded a liability of KUSD 220 related to the accumulated payroll deductions, which are refundable to employees who withdraw from the ESPP. This amount is included within Accrued expenses in other current liabilities in the unaudited condensed consolidated interim balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044783360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related parties</a></td>
<td class="text">Related parties<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.T. Holdings II S&#224;rl (&#8220;AT Holdings II&#8221;) is a shareholder in the Company. AT Holdings II is in turn ultimately wholly owned by Auven Therapeutics Holdings, L.P. (&#8220;ATH&#8221;), a limited partnership registered in the British Virgin Islands. ATH&#8217;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#8220;ATM&#8221;). As a result, ATH is considered a related party.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s contribution and equity interest in Overland ADCT BioPharma, certain of the Company&#8217;s employees serve on its board of directors. As a result, Overland ADCT BioPharma is considered a related party.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services provided by the Company to related parties</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides registered office and other simple administrative services to three subsidiaries of ATH. The amounts invoiced for the three and nine months ended September&#160;30, 2022 and recovered through G&amp;A expenses, amounted to nil and KUSD 1, respectively (three and nine months ended September&#160;30, 2021: KUSD 1 and KUSD 3, respectively).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As contemplated by the license agreement with Overland ADCT BioPharma, Overland ADCT BioPharma has elected to participate in certain of the Company&#8217;s global clinical trials, in exchange for which it reimburses the Company for a portion of the cost of those trials. Overland ADCT BioPharma also reimburses the Company for certain expenses in connection with technology transfer and assistance of clinical personnel. During the three and nine months ended September&#160;30, 2022, the Company incurred KUSD 818 and KUSD 2,014, respectively, of clinical trial and service costs to be reimbursed by Overland ADCT BioPharma, which is recorded as a reduction of R&amp;D expenses in the Company&#8217;s unaudited condensed consolidated interim statement of operations (three and nine months ended September&#160;30, 2021: KUSD 812 and KUSD 1,602, respectively).</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">In addition, the Company entered into a supply agreement with Overland ADCT BioPharma whereby the Company provides Overland ADCT BioPharma clinical supply for use in trials and supply for early access programs. For the three and nine months ended September&#160;30, 2022, KUSD 5 and KUSD 45, respectively, of supply was provided to Overland ADCT BioPharma which is recorded as a reduction of R&amp;D expenses in the Company&#8217;s unaudited condensed consolidated interim statement of operations. There were no such sales to Overland ADCT BioPharma during the three and nine months ended September&#160;30, 2021. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Related party balances</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a related party receivable balance with Overland ADCT BioPharma of KUSD 1,695 and KUSD 789 as of September&#160;30, 2022 and December&#160;31, 2021, respectively. There were no trade accounts payable with related parties as of September&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Key management compensation</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation of key management is shown below:</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Salaries and other short-term employee costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pension costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">10,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">27,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">26,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">During the second quarter of 2022, there was an organizational realignment of certain key management as a result of the appointment of the Company's new CEO. The key management compensation for the three and nine months ended September&#160;30, 2022 reflects the new management structure, while the comparable prior periods have not been recast to conform to the current structure.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044594112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">Loss per share<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Loss attributable to owners</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(50,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(71,549)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(131,643)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(195,645)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">78,372,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">76,739,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77,374,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">76,730,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(0.65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(0.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(1.70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2.55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2022 and 2021, basic and diluted loss per share are calculated on the weighted average number of shares issued and outstanding and exclude shares to be issued under the Equity Incentive Plan 2019, as the effect of including those shares would be anti-dilutive.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because the effect of including them would be anti-dilutive were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.694%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - Share Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,725,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,326,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,625,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,759,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,473,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">594,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,731,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">451,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conversion of the principal amount of convertible loans into the Company&#8217;s common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,412,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,682,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Outstanding warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,470,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">832,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,668,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,334,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,189,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,893,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 ESPP share activity was not presented as the effects were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044692256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events after the reporting date<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_EventsAfterReportingPeriodAbstract', window );"><strong>Events After Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Events after the reporting date</a></td>
<td class="text">Events after the reporting date<div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company has evaluated its subsequent events through November&#160;8, 2022, the date the financial statements were available to be issued, and has concluded that there are no subsequent events requiring disclosure in these unaudited condensed consolidated interim financial statements, other than those described below.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company held a pre-BLA meeting in September 2022 and a Type C meeting with the FDA in late October. During the Type C meeting, the FDA provided strong guidance that, for it to consider an accelerated approval path, a randomized confirmatory Phase 3 study must be well underway and ideally fully enrolled at the time of any BLA filing for Cami.  As a result, the Company will not file the BLA for Cami next year, as it estimates that it would take at least two years to fully enroll a randomized confirmatory Phase 3 study. The Company is engaged with the FDA in an ongoing and constructive dialogue regarding their guidance and the potential regulatory path forward, including the design and timing of the required confirmatory Phase 3 study. At this time, the Company is pausing any material investments in the Hodgkin lymphoma program.  The Company will evaluate its options for Cami with a disciplined and strategic approach to resource allocation.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The Company discontinued enrollment in the Phase 1b clinical trial of Cami in combination with pembrolizumab for the treatment of solid tumors. The combination was an immune-based approach and intended to enhance the benefit of PD1. While the Company observed signals of immunomodulatory activity, the clinical data were not compelling enough to move forward. The Company recognizes the considerable effort required to fully pursue the opportunity and intend to consider strategic alternatives including a partner for the future development of the program. As this combination was an immunotherapy approach and different from the Company's other solid tumor programs, the Company does not see any read through to its other programs, which it continues to advance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_EventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Events After Reporting Period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_EventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044678512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred royalty obligation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DeferredRoyaltyObligationAbstract', window );"><strong>Deferred Royalty Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DeferredRoyaltyObligationTextBlock', window );">Deferred royalty obligation</a></td>
<td class="text">Deferred royalty obligation<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2021, the Company entered into a royalty purchase agreement with HCR for up to USD 325.0&#160;million of which the Company received gross proceeds of USD 225.0&#160;million during 2021 and is eligible to receive an additional USD 100.0&#160;million upon the occurrence of certain commercial milestones.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s debt obligation relating to the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:78.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: cumulative catch-up adjustment, Financial income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">221,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Proceeds from the sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: cumulative catch-up adjustment, Financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">225,477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a liability relating to the initial gross proceeds received less transaction costs. The Company will record additional liabilities upon the receipt of eligible amounts when such contingent events occur. To determine the accretion of the liability related to the deferred royalty obligation, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payment to HCR based on the Company's revenue projections. Based on the Company's initial revenue projections, the Company used an independent valuation firm to assist in determining the total amount of future royalty payments and estimated timing of such payment to HCR using an option pricing Monte Carlo simulation model. The amount ultimately received by the Company will be accreted to the total amount of the royalty payments necessary to extinguish the Company&#8217;s obligation under the agreement, which will be recorded as interest expense over the life of the royalty purchase agreement. The estimate of this total interest expense resulted in an EIR of 10%. As royalty payments are made to HCR, the balance of the debt obligation will be effectively repaid over the life of the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's periodic review, the exact amount and timing of repayment is likely to be different each reporting period as compared to those estimated based on the Company's initial revenue projections. A significant increase or decrease in actual net sales of ZYNLONTA compared to the Company&#8217;s revenue projections, and regulatory approval and commercialization of Cami, as well as ZYNLONTA in other indications as well as licensing revenue could change the royalty rate and royalty cap due to HCR, which could materially impact the debt obligation as well as interest expense associated with the royalty purchase agreement. Also, the Company&#8217;s total obligation to HCR can vary depending on the achievement of the sales milestones as well as the timing of a change in control event. The Company will periodically assess the expected payments to HCR based on its underlying revenue projections and to the extent the amount or timing of such payments is materially different than its initial estimates it will record a cumulative catch-up adjustment. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's 2022 strategic planning decisions including updated development plans, the Company updated the valuation model during the first quarter of 2022, which resulted in a cumulative catch-up adjustment of KUSD 18,288 recorded as Financial income within the unaudited condensed consolidated interim statement of operations for the three months ended March 31, 2022. The Company updated the valuation model in the second quarter of 2022 for revised revenue forecasts, which had the effect of reducing the Company&#8217;s deferred royalty obligation, as well as including upfront and downstream milestone payments related to the Sobi exclusive license agreement, which had the effect of increasing the Company&#8217;s deferred royalty obligation. As a result of the updated valuation model in the second quarter of 2022, the Company recorded a non-material cumulative catch-up adjustment recorded as Financial expense within the unaudited condensed consolidated interim statement of operations for the three months ended June 30, 2022. In the third quarter of </span></div>2022, the Company updated the valuation model for actual net sales reported in the third quarter 2022, as well as refined the estimated timing of receipt for the downstream milestone payments related to the Sobi exclusive license agreement, which had the effect of increasing the Company&#8217;s deferred royalty obligation. As a result of the updated valuation model used in the third quarter of 2022, the Company recorded a KUSD 2,175 cumulative catch-up adjustment as Financial expense within the unaudited condensed consolidated interim statement of operations for the three months ended September 30, 2022. Under the cumulative catch-up method, the EIR is not revised when actual or estimated net sales differ from those estimated as of the inception of the debt obligation. Instead, the carrying amount of the debt obligation is adjusted to an amount equal to the present value of the estimated remaining future payments, discounted by using the original EIR, 10%, as of the date on which the estimate changes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of borrowings</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">in KUSD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Warrant obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Loan Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">3,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">116,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">120,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Carrying value of loan at issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">108,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s debt obligation relating to the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:78.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: cumulative catch-up adjustment, Financial income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">221,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Proceeds from the sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: cumulative catch-up adjustment, Financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">225,477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DeferredRoyaltyObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DeferredRoyaltyObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DeferredRoyaltyObligationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DeferredRoyaltyObligationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044734400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Equity</a></td>
<td class="text">EquityOn August 15, 2022, the Company entered into a share purchase agreement with the Purchasers, pursuant to which, on September 6, 2022, the Company issued and sold to the purchasers an aggregate of 733,568 common shares at USD 8.52 per share. The shares were issued from the Company&#8217;s treasury shares at par value, which arose from the Share Subscription Agreement. See note 2, &#8220;Basis of Preparation." The transaction was recorded as a USD 6.1&#160;million net increase to share premium for the issuance of the common shares, net of transaction costs accrued and paid, and an increase in cash and cash equivalents.The Company also recorded a USD 19.6&#160;million non-cash net increase to share premium for the issuance of the 2,390,297 common shares to Deerfield in connection with the exchange of the senior secured convertible notes. The shares were issued from the Company&#8217;s treasury shares at par value, which arose from the Share Subscription Agreement. See note 15, &#8220;Convertible loans&#8221; and note 2, &#8220;Basis of Preparation&#8221; for further information on this transaction and Share Subscription Agreement, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045343936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract', window );"><strong>Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">Statement of Compliance</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Statement of Compliance</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements as of and for the three and nine months ended September&#160;30, 2022 have been prepared in accordance with International Accounting Standard 34&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;IAS 34&#8221;) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Functional and reporting currency</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Functional and reporting currency</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated interim financial statements are presented in United States Dollars (&#8220;USD&#8221; or &#8220;$&#8221;), which is the Company&#8217;s functional currency and the Group&#8217;s reporting currency.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock', window );">Use of estimates and judgements</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Use of estimates and judgements</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are based on management&#8217;s knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">As a result of increases in interest rates, the Company assessed the impact of utilizing a higher discount rate, 2.0%, in its most recent pension obligation actuarial valuation performed as of December 31, 2021. The use of a higher discount rate resulted in a decrease of KUSD 3.6&#160;million to its Defined benefit pension liabilities with a corresponding offset to Other comprehensive loss which was recorded during the second quarter of 2022. The reduction in its Defined benefit pension liability was capped at the fair value of the Company&#8217;s pension plan assets. The Company expects to perform its annual actuarial valuation in conjunction with its fiscal year ending December 31, 2022.</span></div>In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December 31, 2021. There have been no material changes to the significant accounting policies other than those described in note 3, "Significant accounting policies". In addition, significant judgements were required in determining the fair value of the Company&#8217;s warrant obligations as set out in note 14 &#8220;Senior secured term loan facility and warrants&#8221; and note 16 &#8221;Deerfield warrants,&#8221; including the selection of the valuation methodology to use, as well as determining the underlying valuation assumptions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock', window );">Description Of Accounting Policy For Other Income (Expense) Explanatory</a></td>
<td class="text"><div style="margin-bottom:0.1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline">Other income (expense)</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to December 31, 2021, individual components of Non-operating (expense) income were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#8220;Non-operating (expense) income&#8221; for further information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Arrangements</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Furthermore, on July 8, 2022, the Company entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. In previous years, the Company had generated revenue from the sale of its product candidates and service revenues from a license and collaboration arrangement. See note 5 &#8220;License Revenue&#8221; for further information on the MTPC and Sobi arrangement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenues from license fees for intellectual property (IP) either at a point in time or over time. The Company must make an assessment as to whether such a license represents a right-to-use the IP (at a point in time) or a right to access the IP (over time). The Company recognizes revenue for a right-to-use license immediately if the licensee can begin to use and benefit from the IP upon commencement of the license term and the Company has no further obligations in the context of the IP. A license is considered a right to access the IP when the Company undertakes activities during the license term that may significantly affect the IP, which directly exposes the customer to any positive or negative effects arising from such activities. These activities do not result in the immediate transfer of a good or service to the customer. As such, revenues from the right to access the IP are recognized over time. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into agreements with multiple performance obligations. Performance obligations are identified and separated when the other party can benefit from the license on its own or together with other resources that are readily available, and the license is separately identifiable from other goods or services in the contract. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction prices for out-license arrangements may include fixed up-front amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development and regulatory milestones because the ultimate outcomes are binary in nature. Variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price when sold separately or estimated stand-alone selling price on the basis of comparable transactions with other customers when such goods or services are not sold separately. The residual approach is the method used to estimate a stand-alone selling price when the selling price for a good or service is highly variable or uncertain.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction prices, sales milestones and royalties attributable to licenses are excluded from the variable consideration guidance and recognized at the later of when the subsequent sales transaction occurs, or the satisfaction or partial satisfaction of the performance obligation to which some or all of the royalty has been allocated.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior secured term loan facility</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, ADCT UK and ADCT America entered into a USD 175.0&#160;million Loan Agreement on August 15, 2022, pursuant to which the counterparty agreed to extend secured term loans to the Company in disbursements as follows: (i) a First Tranche and (ii) Future Tranches. See note 14, &#8220;Senior secured term loan facility and warrants.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the First Tranche </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company drew down the First Tranche of the senior secured term loans in the amount of USD 120.0 million and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. These senior secured term loans have been </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized as a hybrid financial instrument and accounted for as two separate components: (i) a warrant obligation and (ii) a loan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i)  The warrant obligation is presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value using a Black-Scholes pricing model and is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii) The</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">senior secured term loan&#8217;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the warrant obligation. The loan is subsequently measured at its amortized cost using an effective interest rate ("EIR") in accordance with IFRS 9. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. The revised EIR will be used prospectively with no income or expense recorded in the period of interest rate change. The loan is presented as a financial liability in the unaudited condensed consolidated interim balance sheet.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses and fees payable upon the issuance of the First Tranche of senior secured term loans were allocated pro rata to the above two components. The share of expenses allocated to the warrant obligation were charged directly to the unaudited condensed consolidated interim statement of operations, while the share of expenses allocated to the residual senior secured term loans was deducted from the loan and included in the calculation of the EIR.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the Future Tranches </span></div>The Company has no obligation to draw down the Future Tranches of the senior secured term loans. Therefore, the Company will account for the Future Tranches when drawn upon as a liability and subsequently measure the liability at amortized cost in accordance with IFRS 9. Transaction costs associated with the Future Tranches will be deducted from the loan.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New and amended IFRS standards</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New and amended IFRS standards</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2022, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, are not listed here.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Other Income (Expense) Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.
Effective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]
Effective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Effective 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 117<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_117_b&amp;doctype=Standard&amp;forcepdf=true<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614049163520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock', window );">Schedule of Foreign currency exchange rate</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A subsidiary of the Company, ADCT UK, has a functional currency of the British Pound (&#8220;GBP&#8221;). The following exchange rates have been used for the translation of the financial statements of ADCT UK:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.805%"><tr><td style="width:1.0%"/><td style="width:80.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">USD / GBP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Closing rate, GBP 1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.11348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.34593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Weighted average exchange rate, GBP 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.18746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.39209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Information About Foreign Currency Exchange Rate Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614026300544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenues, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock', window );">Disclosure Of Detailed Information About Sales Adjustments Explanatory</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s accruals related to the GTN sales adjustments for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GTN sales adjustments for current year sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">GTN sales adjustments for prior year sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Credits, payments and reclassifications to Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(9,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Ending balance as of September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,727</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock', window );">Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company&#8217;s unaudited condensed consolidated interim balance sheet as of September&#160;30, 2022 and December&#160;31, 2021. </span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:44.138%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.644%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.728%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,590</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Sales Adjustments Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614049038160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock', window );">Disclosure Of Detailed Information About Expenses By Nature Explanatory</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the unaudited condensed consolidated interim statement of operations classification of the Company's total operating expense:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">Cost of product sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,295</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">502</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">4,090</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">External costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">83,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">66,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Employee expense&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">55,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">49,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">41,676</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">36,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">139,165</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">115,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">S&amp;M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee expense&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">S&amp;M expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,847</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">17,045</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">52,876</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">46,177</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline">G&amp;A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External costs&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">18,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">38,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">38,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">G&amp;A expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">19,617</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">56,868</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">53,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total operating expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">79,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">70,939</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">252,999</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">215,846</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes depreciation expense</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes share-based compensation expense</span></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes depreciation expense for Property, plant and equipment for the three and nine months ended September&#160;30, 2022. All other depreciation expense was not material for the three and nine months ended September&#160;30, 2022. All depreciation expense was not material for the three and nine months ended September&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Expenses By Nature Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614026364160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock', window );">Disclosure Of Inventory Information Explanatory</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory as of September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:51.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.865%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Work in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Finished goods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">15,745</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,122</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Subsequent to December&#160;31, 2021, the Company's inventory is no longer held on consignment by the third-party logistics and distribution provider. Finished goods includes KUSD 3 relating to ZYNLONTA held on consignment by the Company&#8217;s third-party logistics and distribution provider as of December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Inventory Information Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044694688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory', window );">Disclosure of reconciliation of changes in intangible assets and goodwill [text block]</a></td>
<td class="text">below provides a rollforward of the Company&#8217;s intangible assets as of September&#160;30, 2022 and 2021. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Indefinite lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Definite lived</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Licenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Internal development costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Licenses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,052&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,680&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amortization charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(106)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(169)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,344)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net book amount as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">12,611</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">946</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,598</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">11,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Transfers</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,392&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">176&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Amortization charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,069)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Net book amount as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">926</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">13,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044594112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-operating income (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock', window );">Schedule of Other income (expense)</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:33.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.881%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible loans, derivatives, change in fair value (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4,660)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible loans, derivatives, transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on debt extinguishment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(42,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(42,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deerfield warrant obligation, change in fair value income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured term loan facility, warrants, change in fair value income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share of results with joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences (loss) gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credit (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-operating income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(37,122)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(9,363)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(10,805)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">12,560</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Income (Expense) Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045362736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest in joint venture (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InterestsInOtherEntitiesAbstract', window );"><strong>Interests In Other Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory', window );">Schedule of movement in interest in joint venture</a></td>
<td class="text">The table below provides a rollforward of the Company&#8217;s interest in Overland ADCT BioPharma as of September&#160;30, 2022 and 2021, respectively. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:75.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Interest in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">41,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(6,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">34,687</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share of results in joint venture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">44,002</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory', window );">Summary of financial information in join venture</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company&#8217;s share of those amounts. </span></div><div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:27.927%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.593%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Summarized Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">39,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">48,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">48,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">69,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">84,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Summarized Statement of Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">14,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">13,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InterestsInOtherEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interests In Other Entities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InterestsInOtherEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interests in joint arrangements. A joint arrangement is an arrangement of which two or more parties have joint control.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 2<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_2_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of the summarised financial information of a joint venture accounted for using the equity method to the carrying amount of the reporting entity's interest in the joint venture. [Refer: Carrying amount [member]; Joint ventures [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B14<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B14_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044828432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of quantitative information about right-of-use assets</a></td>
<td class="text"><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:60.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Properties (Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,328</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,462</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(1,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(1,975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,679)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(75)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,754)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount as of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">6,649</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">59</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">6,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">5,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">5,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease termination</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(864)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">134</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">10,124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease termination</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,542)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2,584)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net book amount as of September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,448</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,540</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the third quarter of 2022, the Company extended the term of its existing lease related to its U.S. corporate offices in New Jersey for an additional two years commencing on December 1, 2022, including an extension option for three additional years. The Company is reasonably certain it will exercise the extension option and therefore has accounted for the lease using a five-year lease term.</span></div>During the first quarter of 2021, the Company entered into a new lease agreement with a ten-year term commencing in January 2021 for space in the iHub building on the Imperial University college campus in White City, West London. The primary function of the new facility, which consists of approximately 1,100 square meters, is R&amp;D.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock', window );">Schedule of quantitative information about lease liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:60.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Properties (Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Vehicles</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflow (including interest)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,402</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">3,467</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash outflow (including interest)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange difference</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">835&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,457</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (short-term)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities (long-term)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,195</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045830624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior secured term loan facility and warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of key inputs used for valuation</a></td>
<td class="text">The warrant obligation has been recorded at an initial fair value of USD 4.0&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">60 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58.5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:<div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield First Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:59.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price at 130% of the IPO price of 19.00, in USD</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Second Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of borrowings</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">in KUSD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Warrant obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Loan Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">3,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">116,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">120,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Carrying value of loan at issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">108,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s debt obligation relating to the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:78.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: cumulative catch-up adjustment, Financial income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">221,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Proceeds from the sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: cumulative catch-up adjustment, Financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">225,477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044691424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Schedule of Derivative Option and Convertible Loan</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in fair value income (expense) and profit or loss activity of the embedded conversion option derivatives during the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(2,822)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,913)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - prior to FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche - after FDA approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(1,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(3,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(4,042)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(4,660)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(6,943)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">25,650</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">16,279</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The fair value expense recognized during the three and nine months ended September 30, 2022 represents the change in fair value up until the point of exchange on August 15, 2022.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the changes in fair value, the Company recorded a gain of KUSD 1,816 during the nine months ended September 30, 2021 with the receipt of the USD 50&#160;million subsequent disbursement, the establishment of the embedded derivative and residual loan associated with the subsequent disbursement and elimination of the derivative immediately prior to FDA approval of ZYNLONTA.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of key inputs used for valuation</a></td>
<td class="text">The warrant obligation has been recorded at an initial fair value of USD 4.0&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">60 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">58.5 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:<div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield First Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:59.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price at 130% of the IPO price of 19.00, in USD</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">67.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deerfield Second Tranche</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:54.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">August 15, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">28.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forced conversion price, in USD </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">10.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">32.5 months</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40 months</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Recovery rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Implied bond yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of borrowings</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:38.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">in KUSD</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">Warrant obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Loan Principal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">3,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">116,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">120,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Transaction costs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(245)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">(7,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">Carrying value of loan at issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%">108,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:44.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield First Tranche </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Deerfield Second Tranche</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">1,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,961</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,684</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">7,393</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides a rollforward of the Company&#8217;s debt obligation relating to the royalty purchase agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:78.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">17,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: cumulative catch-up adjustment, Financial income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">16,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">221,144</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Proceeds from the sale of future royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Less: royalty payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Plus: cumulative catch-up adjustment, Financial expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">225,477</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044804784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deerfield Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory', window );">Schedule of valuation inputs</a></td>
<td class="text">Key inputs for the valuation of the warrant obligation as of September 30, 2022 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:80.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Exercise price in USD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">24.70 and 28.07</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price in USD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected term (months)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">31.7 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Black-Scholes value in USD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">0.69 and 0.60</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Entity's own equity instruments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045616800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareBasedPaymentArrangementsAbstract', window );"><strong>Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Shares Outstanding</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the share option awards outstanding as of September&#160;30, 2022:</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:53.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Average strike price per share in USD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Number of awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted average remaining life<br/>in years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,640,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8.70</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,937,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9.39</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">26.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(820,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">21.23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,757,225</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8.39</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Schedule of Fair Value Assumption For Options Granted</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">values</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the options granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the three and nine months ended September&#160;30, 2022 were determined on the date of the grant using the following assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:51.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share price, in USD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 8.54</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 19.69</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Strike price, in USD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 8.54</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4.83 - 19.69</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">70% to 80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">70% to 80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Award life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.08</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6.08 </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2.61% - 3.77%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1.46% - 3.77%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of Other Equity Instruments Outstanding</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Number of awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Weighted average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">663,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">30.95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,129,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(344,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">30.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(135,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">21.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2,313,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11.71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock', window );">Schedule of Share-based Compensation Reserve</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement in the Share-based Compensation Reserves (included in Other reserves within equity) is as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:39.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - Share Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,193&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">27,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">40,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">15,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Tax and social charge deductions - Incentive Plan 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,798</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">41,781</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">47,016</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044934176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Key Management Compensation</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation of key management is shown below:</span></div><div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Salaries and other short-term employee costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Pension costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">20,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Other compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">10,242</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">8,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">27,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">26,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044784160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of loss per share and potentially dilutive securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.547%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(in KUSD, except per share amounts)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Loss attributable to owners</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(50,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(71,549)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(131,643)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">(195,645)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">78,372,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">76,739,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">77,374,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">76,730,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(0.65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(0.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(1.70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">(2.55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities that were not included in the diluted per share calculations because the effect of including them would be anti-dilutive were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.694%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - Share Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">9,725,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">6,326,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">8,625,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">5,759,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Equity Incentive Plan 2019 - RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,473,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">594,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">1,731,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">451,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Conversion of the principal amount of convertible loans into the Company&#8217;s common shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">4,412,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">3,682,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Outstanding warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">2,470,068&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">832,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">14,668,591</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,334,313</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">11,189,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">9,893,089</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024095152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NumberOfSubsidiaries', window );">Number of subsidiaries | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents', window );">Cash and cash equivalents, minimum quarterly balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,860<span></span>
</td>
<td class="nump">$ 530,194<span></span>
</td>
<td class="nump">$ 466,544<span></span>
</td>
<td class="nump">$ 439,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ExchangeOfConvertibleNotesForWarrants', window );">Exchange Of Convertible Notes For Warrants</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesValueConverted', window );">Convertible Notes, Value Converted</a></td>
<td class="nump">$ 117,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from equity issuance, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,192<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockAxis=adc_PurchasersMember', window );">Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="nump">733,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockPricePerShare', window );">Sale Of Stock, Price Per Share | $ / shares</a></td>
<td class="nump">$ 8.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from equity issuance, net of transaction costs</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember', window );">Warrants, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted | shares</a></td>
<td class="nump">4,412,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember', window );">Warrants, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted | shares</a></td>
<td class="nump">2,390,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember', window );">Warrants, Tranche One, Price One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted | shares</a></td>
<td class="nump">2,631,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsSharesConvertedExercisePrice', window );">Warrants, Shares Converted, Exercise Price | $ / shares</a></td>
<td class="nump">$ 24.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember', window );">Warrants, Tranche One, Price Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted | shares</a></td>
<td class="nump">1,781,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsSharesConvertedExercisePrice', window );">Warrants, Shares Converted, Exercise Price | $ / shares</a></td>
<td class="nump">$ 28.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember', window );">Facility Agreement with Deerfield Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted | shares</a></td>
<td class="nump">527,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsSharesConvertedExercisePrice', window );">Warrants, Shares Converted, Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementFirstTrancheMember', window );">Loan Agreement, First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementFutureTranchesMember', window );">Loan Agreement, Future Tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Facilities, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingFacilitiesMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesValueConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Value Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesValueConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ExchangeOfConvertibleNotesForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange Of Convertible Notes For Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ExchangeOfConvertibleNotesForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsSharesConvertedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Shares Converted, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsSharesConvertedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockAxis=adc_PurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockAxis=adc_PurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementFutureTranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementFutureTranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614025272448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation - Schedule of Foreign currency exchange rate (Details) - $ / &#163;<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate Information And Statement Of IFRS Compliance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing foreign exchange rate</a></td>
<td class="nump">1.11348<span></span>
</td>
<td class="nump">1.34593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average foreign exchange rate</a></td>
<td class="nump">1.18746<span></span>
</td>
<td class="nump">1.39209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Information And Statement Of IFRS Compliance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045741248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PensionObligationDiscountRate', window );">Pension Obligation, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Remeasurement of defined benefit pension liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 3,618,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockAxis=adc_ShareSubscriptionAgreementMember', window );">Share Subscription Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">3,123,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,123,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Sale or issue of treasury shares</a></td>
<td class="nump">$ 733,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockAxis=adc_ExchangeAgreementMember', window );">Exchange Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Sale or issue of treasury shares</a></td>
<td class="nump">$ 2,390,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PensionObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pension Obligation, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PensionObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2022-03-24<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockAxis=adc_ShareSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockAxis=adc_ShareSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockAxis=adc_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockAxis=adc_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024555072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant accounting policies (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 15, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember', window );">Warrants, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">4,412,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember', window );">Warrants, Tranche One, Price One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">2,631,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember', window );">Warrants, Tranche One, Price Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">1,781,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044027520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial risk management (Details) - Interest rate risk - Senior Secured Term Loan Facility<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues', window );">Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, increase on derivative values</a></td>
<td class="nump">$ 272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues', window );">Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, decrease on derivative values</a></td>
<td class="nump">$ 273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045477920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenues, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RevenueFromContractsWithCustomersAbstract', window );"><strong>Revenue From Contracts With Customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GTNSalesAdjustment', window );">Sales adjustment, beginning balance</a></td>
<td class="nump">$ 3,293<span></span>
</td>
<td class="nump">$ 2,727<span></span>
</td>
<td class="nump">$ 3,293<span></span>
</td>
<td class="nump">$ 2,727<span></span>
</td>
<td class="nump">$ 3,464<span></span>
</td>
<td class="nump">$ 2,590<span></span>
</td>
<td class="nump">$ 730<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GTNSalesAdjustmentProvision', window );">GTN Sales Adjustment, Provision</a></td>
<td class="nump">3,706<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">10,403<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GTNSalesAdjustmentProvisionPriorPeriodSales', window );">GTN Sales Adjustment, Provision, Prior Period Sales</a></td>
<td class="num">(253)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(358)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GTNSalesAdjustmentCreditsAndPayments', window );">GTN Sales Adjustment, Credits And Payments</a></td>
<td class="num">(3,624)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(9,342)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GTNSalesAdjustment', window );">Sales adjustment, ending balance</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">$ 2,727<span></span>
</td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">$ 2,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TradeAndOtherCurrentReceivablesSalesAdjustment', window );">Accounts receivable, net</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment', window );">Other current liabilities</a></td>
<td class="nump">$ 1,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Accrued Expenses And Other Current Liabilities, Sales Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GTNSalesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GTN Sales Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GTNSalesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GTNSalesAdjustmentCreditsAndPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GTN Sales Adjustment, Credits And Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GTNSalesAdjustmentCreditsAndPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GTNSalesAdjustmentProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GTN Sales Adjustment, Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GTNSalesAdjustmentProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GTNSalesAdjustmentProvisionPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>GTN Sales Adjustment, Provision, Prior Period Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GTNSalesAdjustmentProvisionPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_TradeAndOtherCurrentReceivablesSalesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other current receivables, Sales Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_TradeAndOtherCurrentReceivablesSalesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045492448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product revenues, net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementMilestonePayments', window );">License Agreement, Milestone Payments</a></td>
<td class="nump">$ 205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ProceedsFromLicenseAgreement', window );">Proceeds From License Agreement</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementMilestonePayments', window );">License Agreement, Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ProceedsFromLicenseAgreement', window );">Proceeds From License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementCappedContribution', window );">License Agreement, Capped Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid', window );">License Agreement, Percent Of Clinical Trial Costs Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_ApplicationApprovalMember', window );">Application Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementMilestonePayments', window );">License Agreement, Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LicenseAgreementCappedContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Capped Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LicenseAgreementCappedContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percent Of Clinical Trial Costs Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LicenseAgreementPercentOfClinicalTrialCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ProceedsFromLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ProceedsFromLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_ApplicationApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_ApplicationApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044784160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_OperatingSegmentsAbstract', window );"><strong>Operating Segments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NumberOfBusinessSegments', window );">Number of business segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NumberOfBusinessSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Segments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NumberOfBusinessSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_OperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Segments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_OperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045274736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expense - Schedule of Expenses by Nature (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of product sales</a></td>
<td class="nump">$ 1,295<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 4,090<span></span>
</td>
<td class="nump">$ 623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">41,676<span></span>
</td>
<td class="nump">36,805<span></span>
</td>
<td class="nump">139,165<span></span>
</td>
<td class="nump">115,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">16,847<span></span>
</td>
<td class="nump">17,045<span></span>
</td>
<td class="nump">52,876<span></span>
</td>
<td class="nump">46,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">19,617<span></span>
</td>
<td class="nump">16,587<span></span>
</td>
<td class="nump">56,868<span></span>
</td>
<td class="nump">53,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expense</a></td>
<td class="nump">79,435<span></span>
</td>
<td class="nump">70,939<span></span>
</td>
<td class="nump">252,999<span></span>
</td>
<td class="nump">215,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ExpensesByNatureAxis=adc_ExternalCostsMember', window );">External costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">24,363<span></span>
</td>
<td class="nump">20,041<span></span>
</td>
<td class="nump">83,706<span></span>
</td>
<td class="nump">66,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">8,236<span></span>
</td>
<td class="nump">7,973<span></span>
</td>
<td class="nump">26,406<span></span>
</td>
<td class="nump">18,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">5,020<span></span>
</td>
<td class="nump">4,599<span></span>
</td>
<td class="nump">18,539<span></span>
</td>
<td class="nump">15,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ExpensesByNatureAxis=adc_EmployeeExpensesMember', window );">Employee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">17,313<span></span>
</td>
<td class="nump">16,764<span></span>
</td>
<td class="nump">55,459<span></span>
</td>
<td class="nump">49,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">8,611<span></span>
</td>
<td class="nump">9,072<span></span>
</td>
<td class="nump">26,470<span></span>
</td>
<td class="nump">27,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 14,597<span></span>
</td>
<td class="nump">$ 11,988<span></span>
</td>
<td class="nump">$ 38,329<span></span>
</td>
<td class="nump">$ 38,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Expenses By Nature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ExpensesByNatureAxis=adc_ExternalCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ExpensesByNatureAxis=adc_ExternalCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ExpensesByNatureAxis=adc_EmployeeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ExpensesByNatureAxis=adc_EmployeeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045745696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating expense - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories', window );">Gain from reversal of inventory impairment charges</a></td>
<td class="nump">$ 7,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (7,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment loss recognised in profit or loss, property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,617<span></span>
</td>
<td class="nump">$ 16,587<span></span>
</td>
<td class="nump">56,868<span></span>
</td>
<td class="nump">$ 53,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ExpensesByNatureAxis=adc_ExecutiveCompensationMember', window );">Executive Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InventoryAxis=adc_ManufacturingOfAntibodiesMember', window );">Manufacturing Of Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories', window );">Gain from reversal of inventory impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Expenses By Nature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ExpensesByNatureAxis=adc_ExecutiveCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ExpensesByNatureAxis=adc_ExecutiveCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InventoryAxis=adc_ManufacturingOfAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InventoryAxis=adc_ManufacturingOfAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614044918832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and cash equivalents (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents', window );">Cash and cash equivalents, minimum quarterly balance</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614049167520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InventoryAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Current work in progress</a></td>
<td class="nump">$ 15,407<span></span>
</td>
<td class="nump">$ 10,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Current finished goods</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Inventories</a></td>
<td class="nump">15,745<span></span>
</td>
<td class="nump">$ 11,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_CurrentFinishedGoodsHeldOnConsignment', window );">Current Finished Goods Held On Consignment</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_CurrentFinishedGoodsHeldOnConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current Finished Goods Held On Consignment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_CurrentFinishedGoodsHeldOnConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024027904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories', window );">Gain from reversal of inventory impairment charges</a></td>
<td class="nump">$ 7,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (7,049)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InventoryAxis=adc_ZYNLONTAForRDMember', window );">ZYNLONTA For R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems', window );"><strong>Disclosure Of Detailed Information About Expenses By Nature [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories', window );">Gain from reversal of inventory impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Expenses By Nature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InventoryAxis=adc_ZYNLONTAForRDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InventoryAxis=adc_ZYNLONTAForRDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614025056032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Rollforward of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 13,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">14,598<span></span>
</td>
<td class="nump">$ 13,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">14,844<span></span>
</td>
<td class="nump">11,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">3,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">15,942<span></span>
</td>
<td class="nump">14,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(1,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="num">(1,344)<span></span>
</td>
<td class="num">(1,230)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesIndefiniteLivedMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">12,611<span></span>
</td>
<td class="nump">11,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesIndefiniteLivedMember', window );">Licenses | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">12,985<span></span>
</td>
<td class="nump">11,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">13,680<span></span>
</td>
<td class="nump">12,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesIndefiniteLivedMember', window );">Licenses | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(1,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(1,069)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_InternalDevelopmentCostsMember', window );">Internal development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_InternalDevelopmentCostsMember', window );">Internal development costs | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_InternalDevelopmentCostsMember', window );">Internal development costs | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesDefiniteLivedMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesDefiniteLivedMember', window );">Licenses | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesDefiniteLivedMember', window );">Licenses | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TransfersIntangibleAssetsOtherThanGoodwill', window );">Transfers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Beginning balance</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Increase (decrease) through net exchange differences, intangible assets other than goodwill</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortisation, intangible assets other than goodwill</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Ending balance</a></td>
<td class="num">$ (169)<span></span>
</td>
<td class="num">$ (130)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_TransfersIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfers, Intangible Assets Other Than Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_TransfersIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesIndefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesIndefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_InternalDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_InternalDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesDefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicensesDefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045801152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_DosingOfSpecificNumberOfPatientsMember', window );">Dosing Of Specific Number Of Patients | Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember', window );">Successful Completion Of In-Vivo Efficacy Studies | Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToAcquireAnAntibodyZYNLONTAMember', window );">License To Acquire An Antibody, ZYNLONTA | Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_ZYNLONTAMember', window );">ZYNLONTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life measured as period of time, intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember', window );">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA | Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member', window );">License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2) | License Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Disclosure of detailed information about intangible assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_DosingOfSpecificNumberOfPatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_DosingOfSpecificNumberOfPatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PaymentTypeAxis=adc_MilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PaymentTypeAxis=adc_MilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToAcquireAnAntibodyZYNLONTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToAcquireAnAntibodyZYNLONTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_ZYNLONTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_ZYNLONTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PaymentTypeAxis=adc_LicensePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PaymentTypeAxis=adc_LicensePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024583312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-operating income - Schedule of Other Income (Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="num">$ (4,660)<span></span>
</td>
<td class="num">$ (6,943)<span></span>
</td>
<td class="nump">$ 25,650<span></span>
</td>
<td class="nump">$ 16,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsDeferredFinancingCosts', window );">Convertible loans, derivatives, transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnExtinguishmentOfBorrowings', window );">Loss on extinguishment</a></td>
<td class="num">(42,114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42,114)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantObligationsTransactionCosts', window );">Warrant Obligations, Transaction Costs</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod', window );">Share of results with joint venture</a></td>
<td class="num">(2,130)<span></span>
</td>
<td class="num">(2,210)<span></span>
</td>
<td class="num">(6,549)<span></span>
</td>
<td class="num">(3,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain (loss)</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_TaxEffectOfResearchAndDevelopmentTaxCredits', window );">Tax Effect Of Research And Development Tax Credits</a></td>
<td class="nump">122<span></span>
</td>
<td class="num">(203)<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NonOperatingIncomeExpense', window );">Non-operating income (expense)</a></td>
<td class="num">(37,122)<span></span>
</td>
<td class="num">(9,363)<span></span>
</td>
<td class="num">(10,805)<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember', window );">Facility Agreement with Deerfield Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnExtinguishmentOfBorrowings', window );">Loss on extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnChangeInFairValueWarrants', window );">Deerfield warrant obligation, change in fair value income</a></td>
<td class="nump">9,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,418<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityMember', window );">Senior Secured Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Disclosure of attribution of expenses by nature to their function [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnChangeInFairValueWarrants', window );">Deerfield warrant obligation, change in fair value income</a></td>
<td class="nump">$ 2,543<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,543<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Deferred Financing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GainsLossOnChangeInFairValueWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Loss) On Change In Fair Value, Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GainsLossOnChangeInFairValueWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GainsLossOnExtinguishmentOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Loss) On Extinguishment Of Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GainsLossOnExtinguishmentOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NonOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Operating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NonOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_TaxEffectOfResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Research And Development Tax Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_TaxEffectOfResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantObligationsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Obligations, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantObligationsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024067344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-operating income - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 19, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember', window );">Warrants, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">4,412,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember', window );">Facility Agreement with Deerfield Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Facilities, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingFacilitiesMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045105008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest in joint venture - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2020 </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DeferredGainOnInvestmentInJointVenture', window );">Deferred Gain On Investment In Joint Venture | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember', window );">Overland ADCT BioPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture', window );">Number of product candidates developed and commercialized in joint venture</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture', window );">Number of products developed and commercialized in joint venture</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DeferredGainOnInvestmentInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Gain On Investment In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DeferredGainOnInvestmentInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates Developed And Commercialized In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NumberOfProductsDevelopedAndCommercializedInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Products Developed And Commercialized In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NumberOfProductsDevelopedAndCommercializedInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045759728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest in joint venture - Schedule of movement in interest in joint venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Beginning balance</a></td>
<td class="nump">$ 41,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Ending balance</a></td>
<td class="nump">34,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember', window );">Overland ADCT BioPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Beginning balance</a></td>
<td class="nump">41,236<span></span>
</td>
<td class="nump">$ 47,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults', window );">Share of results in joint venture</a></td>
<td class="num">(6,549)<span></span>
</td>
<td class="num">(3,906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod', window );">Ending balance</a></td>
<td class="nump">$ 34,687<span></span>
</td>
<td class="nump">$ 44,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024997104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest in joint venture - Summary of financial information in joint venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 380,860<span></span>
</td>
<td class="nump">$ 530,194<span></span>
</td>
<td class="nump">$ 380,860<span></span>
</td>
<td class="nump">$ 530,194<span></span>
</td>
<td class="nump">$ 466,544<span></span>
</td>
<td class="nump">$ 439,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,598<span></span>
</td>
<td class="nump">13,316<span></span>
</td>
<td class="nump">14,598<span></span>
</td>
<td class="nump">13,316<span></span>
</td>
<td class="nump">13,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">426,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expense</a></td>
<td class="nump">79,435<span></span>
</td>
<td class="nump">70,939<span></span>
</td>
<td class="nump">252,999<span></span>
</td>
<td class="nump">215,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(50,608)<span></span>
</td>
<td class="num">(71,549)<span></span>
</td>
<td class="num">(131,643)<span></span>
</td>
<td class="num">(195,645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember', window );">Overland ADCT BioPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfJointVenturesLineItems', window );"><strong>Disclosure of joint ventures [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">24,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">48,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net assets</a></td>
<td class="nump">69,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expense</a></td>
<td class="nump">4,950<span></span>
</td>
<td class="nump">4,465<span></span>
</td>
<td class="nump">14,317<span></span>
</td>
<td class="nump">8,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 4,346<span></span>
</td>
<td class="nump">$ 4,511<span></span>
</td>
<td class="nump">$ 13,009<span></span>
</td>
<td class="nump">$ 7,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfJointVenturesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfJointVenturesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_JointVenturesAxis=adc_OverlandADCTBioPharmaCYLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614048435920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LeaseArea', window );">Lease area (in square meters)</a></td>
<td class="nump">1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024147616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-Use Assets and Accumulated Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="num">$ (290)<span></span>
</td>
<td class="num">$ (395)<span></span>
</td>
<td class="num">(896)<span></span>
</td>
<td class="num">$ (1,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="nump">6,708<span></span>
</td>
<td class="nump">7,540<span></span>
</td>
<td class="nump">6,708<span></span>
</td>
<td class="nump">7,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,139<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">5,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets', window );">Lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="nump">9,462<span></span>
</td>
<td class="nump">10,124<span></span>
</td>
<td class="nump">9,462<span></span>
</td>
<td class="nump">10,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(2,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(896)<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets', window );">Lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="num">(2,754)<span></span>
</td>
<td class="num">(2,584)<span></span>
</td>
<td class="num">(2,754)<span></span>
</td>
<td class="num">(2,584)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Properties (Offices)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="nump">6,649<span></span>
</td>
<td class="nump">7,448<span></span>
</td>
<td class="nump">6,649<span></span>
</td>
<td class="nump">7,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Properties (Offices) | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,005<span></span>
</td>
<td class="nump">5,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">5,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(911)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets', window );">Lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="nump">9,328<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
<td class="nump">9,328<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Properties (Offices) | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,925)<span></span>
</td>
<td class="num">(2,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(871)<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets', window );">Lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="num">(2,679)<span></span>
</td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">(2,679)<span></span>
</td>
<td class="num">(2,542)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets', window );">Lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Vehicles | Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets', window );">Lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset, ending balance</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045743808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-Use Asset Depreciation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 896<span></span>
</td>
<td class="nump">$ 1,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncomeStatementLocationAxis=adc_ResearchAndDevelopmentExpenseMember', window );">R&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncomeStatementLocationAxis=adc_GeneralAndAdministrativeExpenseMember', window );">G&amp;A expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncomeStatementLocationAxis=adc_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncomeStatementLocationAxis=adc_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncomeStatementLocationAxis=adc_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncomeStatementLocationAxis=adc_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614023325680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Beginning balance</a></td>
<td class="nump">$ 8,023<span></span>
</td>
<td class="nump">$ 8,023<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdditionsToLeaseLiabilities', window );">Additions</a></td>
<td class="nump">5,718<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow (including interest)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901)<span></span>
</td>
<td class="num">(916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,043)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,457<span></span>
</td>
<td class="nump">8,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,622<span></span>
</td>
<td class="nump">7,183<span></span>
</td>
<td class="nump">$ 6,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_BuildingsMember', window );">Properties (Offices)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Beginning balance</a></td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdditionsToLeaseLiabilities', window );">Additions</a></td>
<td class="nump">5,662<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow (including interest)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(901)<span></span>
</td>
<td class="num">(892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(978)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,397<span></span>
</td>
<td class="nump">8,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="nump">981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
<td class="nump">7,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems', window );"><strong>Disclosure Of Quantitative Information About Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Beginning balance</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AdditionsToLeaseLiabilities', window );">Additions</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow (including interest)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities', window );">Exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AdditionsToLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions To Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AdditionsToLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Net Exchange Differences, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614023058224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Senior secured term loan facility and warrants - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 19, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents', window );">Cash and cash equivalents, minimum quarterly balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,660<span></span>
</td>
<td class="nump">$ 6,943<span></span>
</td>
<td class="num">(25,650)<span></span>
</td>
<td class="num">$ (16,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Convertible loans, derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Convertible loans, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceeds from senior secured term loans, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantObligationFairValue', window );">Warrant Obligation, Fair Value</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsFairValue', window );">Borrowings, Fair Value</a></td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember', window );">Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
<td class="nump">2,961<span></span>
</td>
<td class="nump">$ 7,684<span></span>
</td>
<td class="nump">7,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsFacilitiesExitFeePercentage', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember', window );">Facility Agreement with Deerfield Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantObligationFairValue', window );">Warrant Obligation, Fair Value</a></td>
<td class="nump">12,297<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,913<span></span>
</td>
<td class="num">(15,556)<span></span>
</td>
<td class="num">(16,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">2,142<span></span>
</td>
<td class="nump">5,664<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="nump">$ 2,020<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">527,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsSharesConvertedExercisePrice', window );">Warrants, Shares Converted, Exercise Price</a></td>
<td class="nump">$ 8.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsFacilitiesExitFeePercentage', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_OakTreeAndOwlRockWarrantObligationsMember', window );">Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantObligationFairValue', window );">Warrant Obligation, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Facilities, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingFacilitiesMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsFacilitiesExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Facilities, Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsFacilitiesExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantObligationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Obligation, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantObligationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsSharesConvertedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Shares Converted, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsSharesConvertedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_OakTreeAndOwlRockWarrantObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_OakTreeAndOwlRockWarrantObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024776352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Senior secured term loan facility and warrants - Valuation of Derivative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember', window );">Written put options (in USD per share) | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">8.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember', window );">Written put options (in USD per share) | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">8.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember', window );">Share Price (in USD per share) | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">4.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember', window );">Share Price (in USD per share) | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">10.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember', window );">Risk Free, Interest Rate | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0.042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember', window );">Risk Free, Interest Rate | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0.029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember', window );">Expected Volatility | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember', window );">Expected Volatility | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember', window );">Expected Term | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">58.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember', window );">Expected Term | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember', window );">Dividend Yield [Member] | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember', window );">Dividend Yield [Member] | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_BlackScholesValueMember', window );">Black-Scholes Value | Oak Tree And Owl Rock Warrant Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">2.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_BlackScholesValueMember', window );">Black-Scholes Value | Derivatives | Senior Secured Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">7.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_OakTreeAndOwlRockWarrantObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_OakTreeAndOwlRockWarrantObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_SharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_BlackScholesValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_BlackScholesValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024905856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details) - Senior Secured Term Loan Facility, Tranche One - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Cost | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">3,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Cost | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">116,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">7,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Transaction costs | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Transaction costs | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">7,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Net Carrying Amount | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 108,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=adc_DeferredFinancingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=adc_DeferredFinancingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=adc_NetCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=adc_NetCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614021776896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible loans - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 19, 2020</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents', window );">Cash and cash equivalents, minimum quarterly balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,660,000<span></span>
</td>
<td class="nump">$ 6,943,000<span></span>
</td>
<td class="num">(25,650,000)<span></span>
</td>
<td class="num">$ (16,279,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Convertible loans, derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,947,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Convertible loans, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceeds from senior secured term loans, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,490,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ExchangeOfConvertibleNotesForWarrants', window );">Exchange Of Convertible Notes For Warrants</a></td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesValueConverted', window );">Convertible Notes, Value Converted</a></td>
<td class="nump">$ 117,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember', window );">Warrants, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">4,412,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember', window );">Warrants, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">2,390,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsFacilitiesExitFeePercentage', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember', window );">Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536,000<span></span>
</td>
<td class="nump">2,961,000<span></span>
</td>
<td class="nump">$ 7,684,000<span></span>
</td>
<td class="nump">7,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember', window );">Facility Agreement with Deerfield Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,822,000<span></span>
</td>
<td class="nump">3,913,000<span></span>
</td>
<td class="num">(15,556,000)<span></span>
</td>
<td class="num">(16,867,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditDerivativeFairValue', window );">Credit derivative, fair value</a></td>
<td class="nump">$ 7,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,132,000<span></span>
</td>
<td class="nump">2,142,000<span></span>
</td>
<td class="nump">5,664,000<span></span>
</td>
<td class="nump">6,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CreditDerivativeFairValue', window );">Credit derivative, fair value</a></td>
<td class="nump">4,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two | Residual Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,000<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="nump">$ 2,020,000<span></span>
</td>
<td class="nump">1,209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives', window );">Gains on change in fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,816,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity', window );">Borrowings, maximum borrowing capacity</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">527,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingsFacilitiesExitFeePercentage', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Secured Overnight Financing Rate (SOFR) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Secured Overnight Financing Rate (SOFR) | First Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Secured Overnight Financing Rate (SOFR) | After First Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Base Rate | First Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember', window );">Loan Agreement | Base Rate | After First Five Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember', window );">Senior Secured Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember', window );">Senior Secured Term Loans | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">14.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingFacilitiesMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Facilities, Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingFacilitiesMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingsFacilitiesExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Facilities, Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingsFacilitiesExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesValueConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Value Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesValueConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ExchangeOfConvertibleNotesForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange Of Convertible Notes For Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ExchangeOfConvertibleNotesForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CreditDerivativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of a credit derivative. [Refer: At fair value [member]; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 24G<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24G_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CreditDerivativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=adc_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=adc_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingPeriodAxis=adc_FirstFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingPeriodAxis=adc_FirstFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingPeriodAxis=adc_AfterFirstFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingPeriodAxis=adc_AfterFirstFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=adc_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=adc_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_SeniorSecuredTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614025130368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible loans - Valuation of Derivative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 19, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>period </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>period</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockAxis=adc_InitialPublicOfferingMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_OfferingPricePerShare', window );">Offering price per share (in USD per share)</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember', window );">Written put options (in USD per share) | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.70<span></span>
</td>
<td class="nump">24.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember', window );">Written put options (in USD per share) | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.07<span></span>
</td>
<td class="nump">28.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ForcedConversionPriceMember', window );">Forced Conversion Price (in USD per share) | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.93<span></span>
</td>
<td class="nump">67.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ForcedConversionPriceMember', window );">Forced Conversion Price (in USD per share) | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.19<span></span>
</td>
<td class="nump">77.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember', window );">Share Price (in USD per share) | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.33<span></span>
</td>
<td class="nump">20.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember', window );">Share Price (in USD per share) | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.33<span></span>
</td>
<td class="nump">20.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember', window );">Risk Free, Interest Rate | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.032<span></span>
</td>
<td class="nump">0.010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember', window );">Risk Free, Interest Rate | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.032<span></span>
</td>
<td class="nump">0.010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember', window );">Expected Volatility | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
<td class="nump">0.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember', window );">Expected Volatility | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
<td class="nump">0.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember', window );">Expected Term | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember', window );">Expected Term | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.5<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember', window );">Dividend Yield [Member] | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember', window );">Dividend Yield [Member] | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_RecoveryRateMember', window );">Recovery Rate [Member] | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_RecoveryRateMember', window );">Recovery Rate [Member] | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ImpliedBondYieldMember', window );">Implied Bond Yield [Member] | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.120<span></span>
</td>
<td class="nump">0.088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=adc_ImpliedBondYieldMember', window );">Implied Bond Yield [Member] | Derivatives | Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.120<span></span>
</td>
<td class="nump">0.088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_OfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_OfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockAxis=adc_InitialPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockAxis=adc_InitialPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_WrittenPutOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ForcedConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ForcedConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_SharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_DividendYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_RecoveryRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_RecoveryRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ImpliedBondYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ImpliedBondYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024577360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible loans - Interest Expense (Details) - Residual Loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="nump">$ 1,536<span></span>
</td>
<td class="nump">$ 2,961<span></span>
</td>
<td class="nump">$ 7,684<span></span>
</td>
<td class="nump">$ 7,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">2,142<span></span>
</td>
<td class="nump">5,664<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense on borrowings</a></td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">$ 2,020<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=adc_ResidualLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614049272432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible loans - Change in Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="num">$ (4,660)<span></span>
</td>
<td class="num">$ (6,943)<span></span>
</td>
<td class="nump">$ 25,650<span></span>
</td>
<td class="nump">$ 16,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="num">(2,822)<span></span>
</td>
<td class="num">(3,913)<span></span>
</td>
<td class="nump">15,556<span></span>
</td>
<td class="nump">16,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember', window );">Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Gains (losses) on change in fair value of derivatives</a></td>
<td class="num">$ (1,838)<span></span>
</td>
<td class="num">$ (3,030)<span></span>
</td>
<td class="nump">$ 10,094<span></span>
</td>
<td class="num">$ (4,042)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614022922704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deerfield Warrants - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantObligationFairValue', window );">Warrant Obligation, Fair Value</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember', window );">Facility Agreement with Deerfield Partners, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnChangeInFairValueWarrants', window );">Deerfield warrant obligation, change in fair value income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,418<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,418<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantObligationFairValue', window );">Warrant Obligation, Fair Value</a></td>
<td class="nump">$ 12,297<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember', window );">Warrants, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">4,412,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember', window );">Warrants, Tranche One, Price One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">2,631,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsSharesConvertedExercisePrice', window );">Warrants, Shares Converted, Exercise Price</a></td>
<td class="nump">$ 24.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember', window );">Warrants, Tranche One, Price Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">1,781,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsSharesConvertedExercisePrice', window );">Warrants, Shares Converted, Exercise Price</a></td>
<td class="nump">$ 28.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GainsLossOnChangeInFairValueWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Loss) On Change In Fair Value, Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GainsLossOnChangeInFairValueWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantObligationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Obligation, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantObligationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsSharesConvertedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Shares Converted, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsSharesConvertedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_FacilityAgreementWithDeerfieldPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheOnePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614023246976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deerfield Warrants - Schedule of Valuation Inputs (Details) - Deerfield Warrants<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>period </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Exercise Price | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">24.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Exercise Price | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">28.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Black-Scholes Value | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations | shares</a></td>
<td class="nump">0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Black-Scholes Value | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations | shares</a></td>
<td class="nump">0.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Derivatives | Forced Conversion Price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">4.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Derivatives | Share Price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0.042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Derivatives | Risk Free, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Derivatives | Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations</a></td>
<td class="nump">31.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember', window );">Derivatives | Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Key inputs for valuations | period</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=adc_DeerfieldWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_BlackScholesValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_BlackScholesValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ForcedConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ForcedConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_SharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_SharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_RiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExpectedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=adc_ExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614021525872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 11, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,565<span></span>
</td>
<td class="nump">$ 14,798<span></span>
</td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">$ 47,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Number of shares reserved for issue under options and contracts for sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,565<span></span>
</td>
<td class="nump">14,798<span></span>
</td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">47,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,757,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,757,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,640,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_AccruedShareBasedCompensation', window );">Accrued Share Based Compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember', window );">Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,193<span></span>
</td>
<td class="nump">$ 12,105<span></span>
</td>
<td class="nump">$ 27,158<span></span>
</td>
<td class="nump">$ 40,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted in share-based payment arrangement</a></td>
<td class="nump">1,298,700<span></span>
</td>
<td class="nump">1,867,076<span></span>
</td>
<td class="nump">14,565,000<span></span>
</td>
<td class="nump">14,798,000<span></span>
</td>
<td class="nump">42,293,000<span></span>
</td>
<td class="nump">47,016,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted', window );">Weighted-average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement', window );">Awards vested and exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,457,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,457,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement', window );">Weighted average strike price, vested and exercisable (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining life, vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember', window );">Share Options | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember', window );">Share Options | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember', window );">Share Options | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember', window );">Share Options | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedShareUnitsRSUMember', window );">Restricted Share Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570,340<span></span>
</td>
<td class="nump">6,372,000<span></span>
</td>
<td class="nump">2,693,000<span></span>
</td>
<td class="nump">15,135,000<span></span>
</td>
<td class="nump">6,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted', window );">Weighted average grant date fair value, granted (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Number of shares reserved for issue under options and contracts for sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,349,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,349,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,820,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_AnnualEquityAwardMember', window );">Annual Equity Award | Restricted Share Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted', window );">Weighted average grant date fair value, granted (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_SpecialRetentionAwardMember', window );">Special Retention Award | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_SpecialRetentionAwardMember', window );">Special Retention Award | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_SpecialRetentionAwardMember', window );">Special Retention Award | Restricted Share Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted', window );">Weighted average grant date fair value, granted (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_AccruedShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_AccruedShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life Of Outstanding Share Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_VestingPeriodAxis=adc_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_VestingPeriodAxis=adc_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_VestingPeriodAxis=adc_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_VestingPeriodAxis=adc_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_VestingPeriodAxis=adc_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_VestingPeriodAxis=adc_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_VestingPeriodAxis=adc_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_VestingPeriodAxis=adc_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedShareUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedShareUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PlanNameAxis=adc_AnnualEquityAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PlanNameAxis=adc_AnnualEquityAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PlanNameAxis=adc_SpecialRetentionAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PlanNameAxis=adc_SpecialRetentionAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614021485744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ShareBasedPaymentArrangementsAbstract', window );"><strong>Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Average strike price in USD per share, At beginning of the year (in USD per share) | $ / shares</a></td>
<td class="nump">$ 27.23<span></span>
</td>
<td class="nump">$ 27.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Fair value grant date (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Average strike price in USD per share, Forfeited (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Average strike price in USD per share, At end of the year (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of awards, At beginning of the year (in shares) | shares</a></td>
<td class="nump">6,640,200<span></span>
</td>
<td class="nump">6,640,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of awards, Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,937,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of awards, Forfeited (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(820,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of awards, At end of the year (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,757,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life of outstanding share options</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions', window );">Weighted average remaining contractual life of granted share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 20 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life Of Granted Share Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024947232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Expected dividends | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in USD per share)</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike price (in USD per share)</a></td>
<td class="nump">$ 4.83<span></span>
</td>
<td class="nump">$ 4.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Award life | shares</a></td>
<td class="nump">6.08<span></span>
</td>
<td class="nump">6.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">261.00%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price (in USD per share)</a></td>
<td class="nump">$ 8.54<span></span>
</td>
<td class="nump">$ 19.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Strike price (in USD per share)</a></td>
<td class="nump">$ 8.54<span></span>
</td>
<td class="nump">$ 19.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">3.77%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045490944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details) - Restricted Share Units (RSU)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards, beginning of period (in shares) | shares</a></td>
<td class="nump">663,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of awards, granted (in shares) | shares</a></td>
<td class="nump">2,129,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of awards, vested (in shares) | shares</a></td>
<td class="num">(344,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of awards, forfeited (in shares) | shares</a></td>
<td class="num">(135,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of awards, end of period (in shares) | shares</a></td>
<td class="nump">2,313,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding', window );">Weighted average grant date fair value, beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 30.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted', window );">Weighted average grant date fair value, granted (in USD per share) | $ / shares</a></td>
<td class="nump">9.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested', window );">Weighted average grant date fair value, vested (in dollars per share) | $ / shares</a></td>
<td class="nump">30.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited', window );">Weighted average grant date fair value, forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">21.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding', window );">Weighted average grant date fair value, ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 11.71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedShareUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedShareUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614025326640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based compensation - Schedule of Share-based Compensation Reserve (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense recognized</a></td>
<td class="nump">$ 14,565<span></span>
</td>
<td class="nump">$ 14,798<span></span>
</td>
<td class="nump">$ 41,781<span></span>
</td>
<td class="nump">$ 47,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_IncentivePlan2014Member', window );">Incentive Plan 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions', window );">Tax expense from share-based payment transactions with employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions', window );">Tax expense from share-based payment transactions with employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseInReserveOfShareBasedPayments', window );">Increase in reserve of share-based payments</a></td>
<td class="nump">8,193<span></span>
</td>
<td class="nump">12,105<span></span>
</td>
<td class="nump">27,158<span></span>
</td>
<td class="nump">40,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IncreaseDecreaseInReserveOfShareBasedPayments', window );">Increase in reserve of share-based payments</a></td>
<td class="nump">$ 6,372<span></span>
</td>
<td class="nump">$ 2,693<span></span>
</td>
<td class="nump">$ 15,135<span></span>
</td>
<td class="nump">$ 6,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncreaseDecreaseInReserveOfShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Reserve Of Share-Based Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncreaseDecreaseInReserveOfShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PlanNameAxis=adc_IncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PlanNameAxis=adc_IncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_PlanNameAxis=adc_A2019EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=adc_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045747360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=adc_AuvenTherapeuticsHoldingsLPMember', window );">Auven Therapeutics Holdings, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_NumberOfSubsidiariesProvideServicesTo', window );">Number of subsidiaries provide services to | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ServicesProvidedRelatedPartyTransactions', window );">Services provided to, related party transactions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=adc_OverlandADCTBioPharmaCYLimitedMember', window );">Overland ADCT BioPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ServicesProvidedRelatedPartyTransactions', window );">Services provided to, related party transactions</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">2,014<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SuppliesProvidedRelatedPartyTransactions', window );">Supplies Provided, Related Party Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsReceivableRelatedPartyTransactions', window );">Amounts receivable, related party transactions</a></td>
<td class="nump">$ 1,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_NumberOfSubsidiariesProvideServicesTo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Subsidiaries Provide Services To</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_NumberOfSubsidiariesProvideServicesTo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ServicesProvidedRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Services Provided, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ServicesProvidedRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SuppliesProvidedRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplies Provided, Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SuppliesProvidedRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsReceivableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsReceivableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=adc_AuvenTherapeuticsHoldingsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=adc_AuvenTherapeuticsHoldingsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=adc_OverlandADCTBioPharmaCYLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=adc_OverlandADCTBioPharmaCYLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614045977424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related parties - Schedule of Key Management Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Salaries and other short-term employee costs</a></td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">$ 2,279<span></span>
</td>
<td class="nump">$ 6,383<span></span>
</td>
<td class="nump">$ 6,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits', window );">Pension costs</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation expense</a></td>
<td class="nump">8,011<span></span>
</td>
<td class="nump">6,448<span></span>
</td>
<td class="nump">20,460<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits', window );">Other compensation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management compensation</a></td>
<td class="nump">$ 10,242<span></span>
</td>
<td class="nump">$ 8,837<span></span>
</td>
<td class="nump">$ 27,119<span></span>
</td>
<td class="nump">$ 26,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614046008480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (50,608)<span></span>
</td>
<td class="num">$ (71,549)<span></span>
</td>
<td class="num">$ (131,643)<span></span>
</td>
<td class="num">$ (195,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares outstanding</a></td>
<td class="nump">78,372,680<span></span>
</td>
<td class="nump">76,739,770<span></span>
</td>
<td class="nump">77,374,388<span></span>
</td>
<td class="nump">76,730,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
<td class="num">$ (2.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.70)<span></span>
</td>
<td class="num">$ (2.55)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614023308544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per share -Schedule of Potentially Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare', window );">Potentially dilutive securities</a></td>
<td class="nump">14,668,591<span></span>
</td>
<td class="nump">11,334,313<span></span>
</td>
<td class="nump">11,189,349<span></span>
</td>
<td class="nump">9,893,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_A2019EquityIncentivePlanShareOptionsMember', window );">Equity Incentive Plan 2019 - Share Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare', window );">Potentially dilutive securities</a></td>
<td class="nump">9,725,094<span></span>
</td>
<td class="nump">6,326,518<span></span>
</td>
<td class="nump">8,625,415<span></span>
</td>
<td class="nump">5,759,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_A2019EquityIncentivePlanRSUsMember', window );">Equity Incentive Plan 2019 - RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare', window );">Potentially dilutive securities</a></td>
<td class="nump">2,473,429<span></span>
</td>
<td class="nump">594,955<span></span>
</td>
<td class="nump">1,731,530<span></span>
</td>
<td class="nump">451,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_ConvertibleLoansContingentlyIssuableSharesMember', window );">Conversion of the principal amount of convertible loans into the Company&#8217;s common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare', window );">Potentially dilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,412,840<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,682,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_OutstandingWarrantsMember', window );">Outstanding Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareLineItems', window );"><strong>Earnings per share [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare', window );">Potentially dilutive securities</a></td>
<td class="nump">2,470,068<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">832,404<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_A2019EquityIncentivePlanShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_A2019EquityIncentivePlanShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_A2019EquityIncentivePlanRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_A2019EquityIncentivePlanRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_ConvertibleLoansContingentlyIssuableSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_ConvertibleLoansContingentlyIssuableSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_OutstandingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis=adc_OutstandingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024768128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Events after the reporting date (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ProceedsFromLicenseAgreement', window );">Proceeds From License Agreement</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementMilestonePayments', window );">License Agreement, Milestone Payments</a></td>
<td class="nump">$ 205.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ProceedsFromLicenseAgreement', window );">Proceeds From License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementMilestonePayments', window );">License Agreement, Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid', window );">License Agreement, Percent Of Clinical Trial Costs Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementCappedContribution', window );">License Agreement, Capped Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_ApplicationApprovalMember', window );">Application Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_LicenseAgreementMilestonePayments', window );">License Agreement, Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LicenseAgreementCappedContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Capped Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LicenseAgreementCappedContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_LicenseAgreementPercentOfClinicalTrialCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percent Of Clinical Trial Costs Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_LicenseAgreementPercentOfClinicalTrialCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ProceedsFromLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ProceedsFromLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_ApplicationApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=adc_ApplicationApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024985328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred royalty obligation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyPurchaseAgreement', window );">Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ProceedsFromRoyaltyPurchaseAgreementGross', window );">Proceeds From Royalty Purchase Agreement, Gross</a></td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyObligationTransactionCosts', window );">Royalty Obligation, Transaction Costs</a></td>
<td class="nump">6,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyObligationInterest', window );">Royalty Obligation, Interest</a></td>
<td class="nump">6,752,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyPurchaseAdditionalProceedsEligibility', window );">Royalty Purchase Additional Proceeds Eligibility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_DeferredRoyaltyObligation', window );">Deferred Royalty Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,144,000<span></span>
</td>
<td class="nump">$ 225,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyPurchaseAgreementEffectiveInterestRate', window );">Royalty Purchase Agreement, Effective Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyObligationPayments', window );">Royalty Obligation, Payments</a></td>
<td class="nump">213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment', window );">Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment</a></td>
<td class="nump">$ 936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,033,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_DeferredRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_DeferredRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ProceedsFromRoyaltyPurchaseAgreementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Royalty Purchase Agreement, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ProceedsFromRoyaltyPurchaseAgreementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyObligationInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyObligationInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyObligationPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyObligationPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyObligationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyObligationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyPurchaseAdditionalProceedsEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Additional Proceeds Eligibility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyPurchaseAdditionalProceedsEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_RoyaltyPurchaseAgreementEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement, Effective Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_RoyaltyPurchaseAgreementEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140614024975008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssueOfEquityThroughExchangeAgreement', window );">Issuance of shares, Deerfield exchange agreement, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_GainsLossOnExtinguishmentOfBorrowings', window );">Loss on extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,114)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(42,114)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from equity issuance, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,192<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember', window );">Warrants, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_ConvertibleNotesSharesConverted', window );">Convertible Notes, Shares Converted</a></td>
<td class="nump">2,390,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockAxis=adc_PurchasersMember', window );">Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">733,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_SaleOfStockPricePerShare', window );">Sale Of Stock, Price Per Share</a></td>
<td class="nump">$ 8.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from equity issuance, net of transaction costs</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems', window );"><strong>Disclosure of reserves within equity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adc_IssueOfEquityThroughExchangeAgreement', window );">Issuance of shares, Deerfield exchange agreement, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_ConvertibleNotesSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Notes, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_ConvertibleNotesSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_GainsLossOnExtinguishmentOfBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Loss) On Extinguishment Of Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_GainsLossOnExtinguishmentOfBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_IssueOfEquityThroughExchangeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity Through Exchange Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_IssueOfEquityThroughExchangeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesWithinEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesWithinEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_WarrantsTrancheAxis=adc_WarrantsTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adc_SaleOfStockAxis=adc_PurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adc_SaleOfStockAxis=adc_PurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>adc-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adc="http://adctherapeutics.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adc-20220930.xsd" xlink:type="simple"/>
    <context id="i7aa73f459e1249118a657516d64db79a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf907986f9804ac79096e6421bac5248_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia10551f99c2f4f2cba09a2c4825b83fb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c7edac15bd64992b9404d86947ee31e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0adb4408d5b64d2eb32d81b113d64564_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:ProductRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i938ba22ab3bc44038aab586a16722948_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia884bbbb5b2d4ef6bea649be380f3574_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b077300e1064ae1bddacda3d1e0be4a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28b78358bf294bc5b11aea256ecda3f4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adc:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id894c180529648fe9b583c546c2b3660_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i002154ec55ee4138b998ace2483bb162_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i59c7697f17a94ce9a360033092cabb0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd2e5e5704574aebbaa2380a7fde3845_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i93f34ddf4b844d758babc0b90fe80e66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d737f742272444ea08949e847328dde_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:ConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6cf4592fe28044fabfe4047cabbd76e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:ConvertibleLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b4ab23200b64567b35b0dc47c38e42b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0b5bb52172f94f6abd0bb6713cb6131b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i35596c2c71984cccaef883c93b78c04e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i246b440f84cd4fefaca5cc8ab1014c64_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife3e54de10ce40b29aa3c37bcd67ea64_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i027b22679fb54ad388c26ce8c669aac5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic28832b49da3403a8b557a594e965059_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ea2e58acd5f40adb6d20b24a516fd32_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i01a70943059b47938af04f86d913bf7f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i421702717ad84eeaa1925dceb63c2981_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7fa267740ce54fae899738589cb13c74_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a3d958595654cd685c236012143b763_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie97eb94da1244cedb49b709a60205ff8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic96fd76ea6094201873babaf44147e90_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4a369d72d0de4d07b601c6485cd111ac_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3f2800d230b840698a1df635aef0fb1e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1275b5a441e64681a4536db9f8517583_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i678984f32c6242569e8813e4669c4d66_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0cf2a41c1b0f412dbadb0ec7cc9807ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3987240b95a941f3a745b6bce9358ab2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d159e8735254990a623ac7081d8a5e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i223e1c18b9e048b4a57a8347875e6217_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e72f4f26f6741079eb2df83e9327373_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie48cd9a814c44291b865fd727b17518f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31afbe725ae54907a860c98c67e10f1a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if71b176729574174b972671a573dc05e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2e733662e17549aebf656747ad4422c8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2584a401285d424c9fba045da1553201_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6fe83d69badf4b52947c1251a39d7037_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic7ca719fc24c4758a77b58d789173cfc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia3cdb002a7f247dba0b4723c76def055_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7aadc701136f486fb9d540ba984fa396_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6300840ba2e145df92c265753e78fc30_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3732a765dbee4267b31e29ecc8de0b94_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8a916c5c42b145e7ab29ea4d88cb1cff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i402dfab004dd492aae570021cbed2be1_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb2644136b7844bd8f3ed9546fa55a15_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i99128419613143609193e10731703076_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic08137b9d07d47458bd80e38918070fb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia00516d757c74b41ab5ec5b14024dbfd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie6e3d0984c7640a6812965fc4399b0ab_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i09effb3b4b9b463691f066e4f85ccde9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i819688b0196b4f8180d3a454630743bf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie65cd89c7bf24557946ea885c4873749_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i62705c1b99444245ac17369673cc7dcf_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i04c2941ce0a845c4ad2292d13e712648_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8a9da342b454067adcd289ef23fbf0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9e12d33e41234842815adf403479484b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea3ac90d7b74494ab57a78dc23262650_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4e071b05a6648619ca531f90eac8afe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8a1526b17d348e3a7c97fc3293c2a37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a3acb2e8256494bb21952f83d8f6892_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if85b8fd87bd6425ebe37b622aaa8b6fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9070db993da44bb4b9180949625e0bfe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifba43579460b45abb618bce784d2265a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ab68b9957bd493da33d7c58f46e02a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i57f104a5fe60467090a2d49a6f15319b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i313fda5b91c745ca8a9287f47d161560_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ie29ccfe5e9104ba781990be9d5a74c93_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i417e476b63a34ff7a49e6530cd7b944c_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementFutureTranchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i9e5a1305a7604d6e87bd11283adef044_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="i2b93ddb8d53d4ec2872793932c99d612_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="i474416e45737460d849fb01685ad11e6_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="i7754055a3c2b48f1973108a8654c2f44_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:WarrantsTrancheAxis">adc:WarrantsTrancheOnePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e1a14874532471a96f7d73129d6c1ca_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:PurchasersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ia6c9b855c1f247cdae6ad0bac21a2df8_D20220815-20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:PurchasersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-15</startDate>
            <endDate>2022-08-15</endDate>
        </period>
    </context>
    <context id="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i77985cac7eeb4add951edd6bccf0d37e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:ShareSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i196dad762149431fa1779f78c8388406_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:ShareSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i914b59538ffb4aff97128d35a7aec14f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iac01c43c0d9347968cf7c0f6d6589b05_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib75271c7003f455ea3762473084eeb29_D20220118-20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">adc:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i49f1b9c6855e4deba1fc15d4e267a2c3_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">adc:ApplicationApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExternalCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0531f2c694374cb1b481540b22706efe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:EmployeeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie05957f8cf6440c0b15060319d7b1f2a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ManufacturingOfAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c36d77e8cc54708a0792a5def59ba80_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ManufacturingOfAntibodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i589e24d9d8e0409fb5e40f80435eaa18_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:ExpensesByNatureAxis">adc:ExecutiveCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1269616118a045b48128c0d3db3063c8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2f5e11a889cb4519ad08ba38236480fd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i158d2be3e937431ea999c2367040412b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia84b491c52c74ac69be308c96ea954a1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife2c56e209614e089bacd12b15145e97_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibcfcf3a44f2c4765be8da06698d39b1c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifa06a2e32fd743d8a7b60007f9ae048d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5e033a22ecb478bb31362e9dd46dcbe_I20200519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-19</instant>
        </period>
    </context>
    <context id="idd6e0c7ae1fc42dabeef85f1e367666d_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="i6f345e8135d943ddb82dfb8c7d312b08_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ZYNLONTAForRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i52142027ddf44c8eab013214816b70f1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InventoryAxis">adc:ZYNLONTAForRDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6898024e6a424206b1716d13c24b930b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:DosingOfSpecificNumberOfPatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6510f05326e840eb9346f0cb3062ac1e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:SuccessfulCompletionOfInVivoEfficacyStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieea878441dfa4efc8a9b70801ddadd56_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicenseToAcquireAnAntibodyZYNLONTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i74f1e1d5ebdb414f9b5247864591ca9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:MilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i766d2e3cc1bf4d91a572ee7391121b0e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:ZYNLONTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9cd70bd278774a99b8e19ac8da87c400_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PaymentTypeAxis">adc:LicensePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3831a84c41e469fa75f28c8e4d66842_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0af6d42a54a4ea29ac6d823b1489254_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9911d0f78184a2082a9741569f80af9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f8c5ec28bf64c13b28d322cc15764ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf2aa78bd37e48d8afb1437f35585633_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i090393068e7e4ce2a9bf4269cb47d7aa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5fe126a6d63476e9d69e3a8dd0f33b0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie56be2cd7a6c41c7bcd4c44c05784db9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i576b3e5ad10f4c98a00d3c16839a707c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i06c1a842a7a74eb19e9e9fb576dfa486_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0735d735202d4e8fa9fe0243e3d57875_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03ecc9946c714265bbb8a89418c63c01_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6bd5f9550f6048c28bee5f1bfdd5d74d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i15b225beffa44b3d87f67b9e69f699fa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8151bd1bc2a04b71adee09c08447999a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b0a40aaa46242f9b8c656439b48a32c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6029eb697ae4501b1bce9cb044843bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide8f1760047640c38a5d3005f9bc6157_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id32707d201834dc793295ca00533da1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c4fdcd15f36441b91d6a6497571a82b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i69b42fc0ddec473598e886ec0f5e3c9b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0bd15bcdf0a64b5898e159fda31b9d99_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85b68b5b42e242f1985aa0054fda3aaa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if3ffc2c26d6241199c0010549c56f460_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5cb5c39e47594c269f24f5e7a5544869_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i83b175bbb0a9439e8c3c4647daa448dc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1870dc5d8b164d9ebd63b4021e920cd6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9da30f3755c743e08b48e072dc09209d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i06eae1c2401f49908e95968065439f57_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i23ac58a635804353bcd123924428ff13_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2f3dddcfe8e2427c8d4ff2eee0c6350f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i668c47e9660643d9a0bc7afaf9b7bc1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2e692aa8462f4f09aaf7e7b3b896724f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2450f8f780347a6b493d4432cbc51da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e3cf7b0b5824c3fbf851545e1194289_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bc4fa9f79eb4710ae4034d037363f25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i35cab614c8934a419edc6f7cccb644a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i335db87da9ad4f00b7b7b94870fddfb6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe0468c473d542f88ffed8e8f6fa3499_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1fae3e626a164280b7a488b6bde2fb6b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i50390a1027184daa809325bb39041f9e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7bfcb651885a4be4a64db35b2e3b0dfe_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i334c4a99388b47a7ab36175bbe1622f3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifde88f7e0bcd430389cd38d465e25601_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i18ce56a8c03a4b7889fd8e92506bdba4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i244793ab5a7249738bab95a309aaad60_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8d06ca9dbb9943bf87caccfc0bdd279c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0dfcc8b323e454089332943aea91f52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0721e1ef08f74225930b348ccc978392_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3456ecf300704b57b6adcd05b7963d67_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i792cccf378ee4050923e53f4a38c7136_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68593cdfc71c4bbd922f69c3283cf601_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31cbfc1404b44ac995974a2da34c1713_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia197fa03b4e0485c894377210f9a37ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7a6a0f0a03341b7a23b2a47027ce477_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia441c664cd094fa08cfec8c6325f59c0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3f566215e8c446edbf6ba6023c4a6697_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1fe02702964a4fedba3bbd1c9e2ed7a0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i93a88ce2c37e481c91710d8d7e711e27_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6a7ddc9b4e1e4c0f82705cfe7c527db7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i328297d89f3241aa834368d0776dfb39_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesIndefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i37ad95fb7fdc49e69f2db1a90d8872e9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:InternalDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib728077ca1d24854ad85579c7c79d6de_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">adc:LicensesDefiniteLivedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i72ecf67eda5b4214b2a1b3dec7c45988_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i228965fb30b84e8ebf7eb20761e08272_D20201214-20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf7428455ece4b7882dc15984214fcea_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8a6d95c9c71c445896f3f224ee1f25ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic66b9b3ea6b24e6596d461fd96900933_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i42d1c8d670234c8ea810b1ad8b5d520f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id388d0fa6213478cba6b2c29801561e0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b56cf9b484847d5ab3c287aa7060a0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b4ebc1ad16249d59d9a2b9574c68a62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0cfdd333541408ba83d32b7e1c51e80_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a4d6ad6c402432badd52332e50082ba_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifc44f11da71445b9bd1dd055c47f9f73_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3ef43b851dc04cf9825b1deb88d8f139_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i161a5506dfed4a31a2fb1ac7f5c47782_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaada04dc38054738b85ebb285ca09c21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5477a4b1928548ebbe20d629b66b14ce_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d3ba12574b44bb38c8be7706e8aac18_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8b0b55146cdb49e48b45bad254647bc6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9e763260b1f442488b72bf74a7c49c11_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i834b4d3caeae4e77b67d0f0dc2d552e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i638129f1bcc5425ba52dd51ffd7e9490_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i401425c5856840c4a0bb4fd8fb8835ae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2efd49a30baa4077ae95107fcc999447_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5abfbc2b76094ac5a51ad5a1de5beced_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i135ebd8bed6a4537b47040a2f4e822d3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie2ff798d025b459fa18da647bcec866b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15cd499c06e344418b49e009c7d8d193_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80cd1d5cda1f4e74862567135c82703e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id5a94dcf4e4844cf92a3de1535f49f1e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i81b5c8e6664d477fa65cefde7362ee81_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibce8feac9624457fae2210499d43d84a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie83b9d46aa9540e49e84d64af9846e39_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i66e6d9b588aa47d19ad6aad08a538bf5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia8b0181426584e10a750977ea6280fb4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a67346f88234740b156f2c58bfbebe1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1961636ee14e4def8d8cc7b2018774e3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5672677502cf4414a866c09aa425cb21_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06457785463e407c8483fbe337aa3902_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if3c884b0bc284c6388a42f8607e2d444_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:IncomeStatementLocationAxis">adc:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28da2485dc9a4fa783f820e72033822c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic61fb64598ff4cd0ad1e2271aed1a821_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie22662b5873248c984d6c1930b5c5647_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i614c4a744d9442189dae06d6e76db4c9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6b3f2601891941a49171d77873081724_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fee265512e746a9a555451fac8020e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied99ac8b277c4b408fb02863f8dffb5e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b95a2cc92564802b7a6cf3d8824d376_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icada6f229ced49ecacd2e102988715eb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i80fc52680e63461a82201650861575d2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib0f3a3c6371f4c089828c4cce5d73dd3_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:FirstFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ie6f2ae527c2944308bb08da4da7ab273_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:FirstFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ie4435c71c4fa4639bb03f664766ee514_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:AfterFirstFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i35e15f9b287246acba0bdc6c93bd00b7_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:BorrowingPeriodAxis">adc:AfterFirstFiveYearsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="iaf3da50e0c50456c822d82239d1251be_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="if31c404deeed4a629f5368280fa99dd7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i98de5d1ddb2243a1b01f6acc1c57c72e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i77b99ef7cc0b4e7ab11c5073c019b286_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i31f57aba65894b669b8fadd39cc8a133_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i89faf473a32b42bd935a511f8ee7a191_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff9bc94da04d47ae9a9b849234ad3c6e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icb8358f51a2445159e899b48be721e8d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9091a412696c4780b52173364c99f1bd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0d4e15e2a100434397a55b4e43e929c3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iea17a01e38b140129bf22b46808b9404_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="id0d75589019241a5b049c49c03ebd9c4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieed9dd529b364aa5a0dfd1de03035963_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idda45a536b784d9a83b51c5690223542_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9df49cf53777407aaff962bcab6cbb00_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:DeferredFinancingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ida5b2446ccaa4c5c85766d73baef671b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:DeferredFinancingCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id9114014f71e4e669763623118aa0ba8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:DeferredFinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0581d534bc684ee0bee89a6945a375ad_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">adc:NetCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i328f49717bbc4a43869005d9a11ccde6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i552db3596e754dcaac31cd578b8a44be_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4d4202329f3c4f6f8e9950a5e0783159_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i63733b9453004d72806e33eea5e62eb1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia734cd26f3504a1883266d439ca95b0d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic29dc84c1b3c4a498fd95b9388f8e481_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i07af9d83010848bb8b52ef3ad5f34f34_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03d2b5b155c54c47aefdb36bca46343a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:OakTreeAndOwlRockWarrantObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if1d37dac85a149669ce03adcbf4ccc8e_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">adc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="icf3fa17cff6e42feb53051b533840f31_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i13ee928b02464d82ab56ff3cd45a2c59_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:SeniorSecuredTermLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0957db7bd16a421a88aa3e02e84a59f4_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="i1dba557902d64fd2b341f02674834b60_I20200424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="i4282540cb4d245d89cd058fd40102cd0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4c1c3f7a35f3450ca62c6907d078e8e2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if1a8de23046f4460ad2c010b046624fc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i424298b8a03c4c6291deae71a0a00390_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8541b30e628240598a82d1a6e8ece81c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i510177f707e04303ad7498a272eb89fe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5bfbbc2c610147c3a34fba908fd852ec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47d31600d9f0428d8b62b78002cda536_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78bbf9c8e62844d986598b81c243a4e8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30f2235b8f984b71a72137b6c9c711ed_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff0912cb42094f0b8c2cf9d89bea012a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i52bdc445f4e04e91a6b705a99bc90fa5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i025881af419e4a3192fb9cf499462a5f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff062fd0475a492786d931f7f5c45f6e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i82d563da995d45569288f830e5149dfb_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i2b7c1b8716664d0c8a84d93d75702409_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a3bdac45860479dabcb75dfdd6867f4_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="i97aa7f5a5df243008d7ef0e4a3eb306e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3d81122c2c840e4b693968f8c508748_D20200519-20200519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:SaleOfStockAxis">adc:InitialPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-19</startDate>
            <endDate>2020-05-19</endDate>
        </period>
    </context>
    <context id="i710642318daa4f7daf7095ef7f4be22a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id466e5c2487a4ac1b5b6504272a8f609_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac273354477741cf86e47def8ffcd7a1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i99f4af969dd2458582b9d874b88cbbf4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8931b5a8351240ac87b0246c2abe8dd9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9d8669ba09764fbb9a618a4a6edae470_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9928a9264d740c89377de3cdebcd1e5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7c66eb70f2894de98ed215565f60df64_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9de9014907024e3189eac77111a06a63_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i45da12590d9f4047b6bd3403ac33f3c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ef057b084c9401b842b0fe5bdd4e853_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3f8646e19d5e4d45b7ef56c2360fcbc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86670cf410ee493e8877ad4c966d0671_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2b3ec2e705764730bd7acdc7796976e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib148dbac37274e269a90f2f14e60f877_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i090c3d455bb74e6281428f2f07643108_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f702cd53b354e9881252bcbf57c2f1c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic8afbb48cf2d48cfbd405ff609f28cc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56eace5f28ad4674b7f788baea9f47e8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i63e9f713f46b436eb737b72a7e01713b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:WrittenPutOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibffd8b0c78d841a5a370b35fad8ace99_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i03318851c1c0465f8efb9f6dbe913d26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ef20d84bc4a4f9589901030b1ae9dde_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i20780f1e715242878284103f33e5a95b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d107c4c0c244c4986cf5e94e684cfa3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1b8a345318c14c5cb9e3dd2c0e1b53e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cc325fcfe32426097e9538a2b3302b5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7b376657412246a595f43060ab7c5581_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i379eff6d11204554bf233766e8da501f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia13a616afebd445f954de55db94ff515_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c15e42527ff44a3a5c93c9c96208bcf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i19368979b8a145d5a6a63e3b0d6e8636_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:DividendYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic268075c47794e01a968504730a874e2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i35e5cd27137b4e10b214c3577489cc0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RecoveryRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5c4b1a0cc67448cbc5473e914944c11_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic4621be8061f40f29a22f85bd1a3ce97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ImpliedBondYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bb83ca124504d81bae6bd67b59bdcad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8696a50af25a4d5698814222277a2b26_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71dfb6d248ff4198a8951d34e0f3e61b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f2027858cad46a39efcfcb65c359818_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0eb58365b3f6457d8705fd6e8d0e13d4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie7aa01b4ce9b4ddf9ea12f4230135446_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica385bd851294fa8a39c826b2ecb7376_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad41e5db92cf4b05819e5ee0b2c622f0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i785f01a211a243bda6e912eb3ec1e0a2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib977e7d27b6240c08c35a9a983b92e2b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22eebd39c0444c7a8b3ec579b6376df0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id5dfc30cca8047389598bb92059469df_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">adc:ResidualLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ecc2b598dba46c28662f729e6defde9_I20220815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:FacilityAgreementWithDeerfieldPartnersLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <context id="ia26abd4a41954e9e9346a99a9f049985_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieca945cdabd9410cbc9c13e7257adfb4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i596a372cc69b47f19dc090d174f662f3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ForcedConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5b3bb514320f434fb2c8f0bbf4378a14_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:SharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i164cd50484d545a2af9114f0c1debbd9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:RiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f02e5be548f4f8dbc48b21e80389512_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7a71734534bd4767beb6925c131abf14_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:ExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5908e3933d294f34ad3a587158cb41e9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i079987d8ff4843f5aa3402f23485ad3e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">adc:DeerfieldWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">adc:BlackScholesValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i676dd5e5964f478cb2a4ee69ccbedc9c_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i2afee1f6b2004f1493e2dcbd25a219d0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2d4b84bf34674d74a74743921df55fbc_D20210322-20210322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="i554dfdb979b34373ae4b5733abf1276e_D20210322-20210322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="i99eeeb04107b4ce58f0f4c3600598f48_D20220511-20220511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-11</startDate>
            <endDate>2022-05-11</endDate>
        </period>
    </context>
    <context id="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i42b2f8cecf45438c8f21adf9eec38ecf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i03009233bf004bb08cea9b8dc88563c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idfe39b129e824b348d51d6de645307b0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a10848ed433473dacbefea93eb427b0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2713424043c64085a64de9bf55b5640e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i52a52dd4005c426b875e0cc78e2afab5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9d76a10a56a3493d8f750d9aff98a946_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i45a1053498d5476e8f8d62e1e4575acb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:SpecialRetentionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie78f96aef8b8454a82071adaaa117569_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:SpecialRetentionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib9d5fe10351e4449b949a8a8feb2c71d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:SpecialRetentionAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adc:VestingPeriodAxis">adc:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a0283334e204aed9dac9cea1dfc698a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib1e58e63d94a49548e999adc4a660174_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8b357e6573a4bd4b45f578e3c65b1e4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1eb06d614e3447ffb6c90235d957a286_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05e1cf39bbc742f2bcd482dcd9e52fff_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6744fd46428b46519b3f53dabe6cec74_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:AnnualEquityAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedShareUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4af9ebeb2297423eb394125254b4a972_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id3811cf7e2644eda9263cf885c93077f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i98d5c21d03c745b5a671f6735837b959_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i23f74715d84641a0818c9605970c3d58_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cefde464eaa45adbdc8ce7283826a3b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3425d423d7cb4ed7841d8808eb8b91ee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if85a6bc595a6484baa94ff58c1ba727d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7bcf43c8d3a64ab28d95b0e02490e5a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">adc:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6b8e02492be4003ab27ad39ebc0924a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:IncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3528d529fe714216bcf41e3b8f352130_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:IncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idab02ef85658428ead895ef5a19a0884_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:PlanNameAxis">adc:IncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie7216894bf0e483e85c7a8417528b234_I20210825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if51de663eeeb43a9905288c2f5ec4bed_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i08246b7245ce401f95f5c264b9f4aa66_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icf7164681d554945ae3e0bb0a2aba4a1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:AuvenTherapeuticsHoldingsLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i12b130040d7a4b73bd260af53f216810_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i519cc478c39244318ef4ce155c0494b8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16371fe343804f21aa8c01b295fcfe36_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i048e0b2056c24818a8680d84acca00a4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icaa43634d02840d5a9bcbd7fa627fe61_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i65354fc22fe5421c886bb333bb47840b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">adc:OverlandADCTBioPharmaCYLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic02e5a8396a24328a44c3c3ca993fbf8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae551281e83e4030b20c9779e840a6db_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if17b1e60018b4848b0cc478a5439fcbe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icef2d3daf96e4c52ba4ccd1c33c624a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanShareOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i42e1e606ace84d21a6ec9a6aee9fd665_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb44ceb2a6a84f44b55476a168ce4fa4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5eb0fcfe2e954886a15fb411a8e3ec9a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iff327b0f65fe4fce9a6d78995be93ca9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:A2019EquityIncentivePlanRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ccd7f1b706c4d9f8b0853b7bb915ab8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9715b3a7f0dc46af8427382e8c4b913b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ccb7c3256654c6bab2e6cdeb30d200f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia12624d220a540beba94b39cc8891315_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:ConvertibleLoansContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i367482dece7c4a8a868d61236759bb2a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i68337702bbe542648d3b07bc46ecffc9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ed07caeea2c4158a84e9c7fe843387a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2c3724a1c9b64111a1170ea671562e28_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001771910</identifier>
            <segment>
                <xbrldi:explicitMember dimension="adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis">adc:OutstandingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>adc:subsidiary</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerGBP">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>iso4217:GBP</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>adc:segment</measure>
    </unit>
    <unit id="product">
        <measure>adc:product</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="period">
        <measure>adc:period</measure>
    </unit>
    <dei:DocumentPeriodEndDate
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV8xLTEtMS0xLTg2NzA3_223f03d3-ae4f-437d-9c07-f55abd614966">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV8yLTEtMS0xLTg2NzA3_c8fd79cc-8705-4ea4-b081-f7362806b49d">0001771910</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV8zLTEtMS0xLTg2NzA3_611eb58d-9eca-4176-a8b6-f55d60ab69b1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV80LTEtMS0xLTg2NzA3_bf46951d-2d49-4248-9a89-41766f596e01">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV81LTEtMS0xLTg2NzA3_dea7c57d-601f-43d0-b26b-77763d0b01a9">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV80L2ZyYWc6YjAwNzIyNTkxMjkzNDBhOWIzYWQxNTNkMTI0NmVlZmMvdGFibGU6YTM2Nzk5MDA4MTY2NDNkNmI4ZWIxZTU1NjBmZTg2ZTEvdGFibGVyYW5nZTphMzY3OTkwMDgxNjY0M2Q2YjhlYjFlNTU2MGZlODZlMV82LTEtMS0xLTg2NzA3_cdeb853e-637a-4080-ade6-a94b301327b2">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTg_3b631a8b-f11c-49cc-9550-22caf5b73c16">6-K</dei:DocumentType>
    <dei:EntityFileNumber
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV84MDU_aa8cd83b-b308-4e7e-8564-ef825bfe47f8">001-39071</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTk_4554f807-96cc-4266-8f0b-ddee7781666a">ADC Therapeutics SA</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTY_3a0411de-a2d1-40d7-842c-63000648597d">Biop&#xf4;le</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV83OTc_07e70199-a014-4060-a20c-564a605ebb91">Route de la Corniche 3B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressPostalZipCode
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV8zNTg_4562b74e-7ba9-4fee-90c0-54d1cba846ac">1066</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV84MDI_c4cda4df-2ff8-4ceb-a997-dc2d3a5f4772">Epalinges</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMzUzNTNlODI3MTQxZmViNmE3NGNiYTNlNjUyNTA5L3NlYzozYTM1MzUzZTgyNzE0MWZlYjZhNzRjYmEzZTY1MjUwOV8xL2ZyYWc6ZjQ0NGZlMjk3NTU4NDQ2OWE2NmY4ZWJlMjM3NDRiNTEvdGV4dHJlZ2lvbjpmNDQ0ZmUyOTc1NTg0NDY5YTY2ZjhlYmUyMzc0NGI1MV84MDQ_7b319215-f6f9-40c9-9196-faaa6afee7dd">CH</dei:EntityAddressCountry>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ibf907986f9804ac79096e6421bac5248_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTQtMS0xLTg2NzA5_b789e6c1-b047-48c8-8996-a32b5f5e2158"
      unitRef="usd">21321000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ia10551f99c2f4f2cba09a2c4825b83fb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTYtMS0xLTg2NzA5_83c7c907-f77c-4e52-bf7b-715dfedc34e8"
      unitRef="usd">13147000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i3c7edac15bd64992b9404d86947ee31e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTgtMS0xLTg2NzA5_00f42a76-6801-4bb5-9c40-353dbe0724c8"
      unitRef="usd">55110000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i0adb4408d5b64d2eb32d81b113d64564_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yLTEwLTEtMS04NjcwOQ_3e6591cb-beb5-4459-8caa-eabb1a167ef9"
      unitRef="usd">16907000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i938ba22ab3bc44038aab586a16722948_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTQtMS0xLTg2NzA5_1b9563d4-e26b-4174-97cb-93f363efceda"
      unitRef="usd">55000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ia884bbbb5b2d4ef6bea649be380f3574_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTYtMS0xLTg2NzA5_26991492-b907-4fa0-a195-a6aaf1d42f6b"
      unitRef="usd">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i6b077300e1064ae1bddacda3d1e0be4a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTgtMS0xLTg2NzA5_45c35fe7-1e67-4326-9e0c-765ed01af4cd"
      unitRef="usd">85000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i28b78358bf294bc5b11aea256ecda3f4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8zLTEwLTEtMS04NjcwOQ_e80ff51f-d061-40d7-8b28-0f1c6db4f629"
      unitRef="usd">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTQtMS0xLTg2NzA5_9c83e195-ab8d-4f10-ba64-d322b1d08bce"
      unitRef="usd">76321000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTYtMS0xLTg2NzA5_b7b11c62-2f89-4d37-b41f-67f3d23f1942"
      unitRef="usd">13147000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTgtMS0xLTg2NzA5_c251c425-ed03-4171-abf5-f9c66b8f5d6e"
      unitRef="usd">140110000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl80LTEwLTEtMS04NjcwOQ_9a51ca66-7e3e-4aeb-85a4-65eb47651413"
      unitRef="usd">16907000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTQtMS0xLTg2NzA5_b7c985a3-9da0-4413-ad75-575f382dd358"
      unitRef="usd">1295000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTYtMS0xLTg2NzA5_25eda286-3cf2-4d70-889c-3cc03a86fc09"
      unitRef="usd">502000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTgtMS0xLTg2NzA5_f89e8383-418b-4999-86cb-4e5114e19f54"
      unitRef="usd">4090000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl83LTEwLTEtMS04NjcwOQ_8ddcf3ad-fa37-4827-98cc-aadf1f422e86"
      unitRef="usd">623000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTQtMS0xLTg2NzA5_966511e1-7dd9-448c-ae63-3aeb44316ffe"
      unitRef="usd">41676000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTYtMS0xLTg2NzA5_3366d125-1a72-423d-b5b8-40987c667dfa"
      unitRef="usd">36805000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTgtMS0xLTg2NzA5_d4d56b85-76e5-4a76-8c5d-4a8e65d0a5c5"
      unitRef="usd">139165000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl84LTEwLTEtMS04NjcwOQ_6e1dcb40-384a-42f8-8774-e5955a205aed"
      unitRef="usd">115510000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTQtMS0xLTg2NzA5_f20d9ac5-5251-4902-9fac-6603ae32d50a"
      unitRef="usd">16847000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTYtMS0xLTg2NzA5_67718635-f824-49d2-922b-f84be7ce8282"
      unitRef="usd">17045000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTgtMS0xLTg2NzA5_e842c6b3-6fa0-422c-bcf6-49c392f9fc04"
      unitRef="usd">52876000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl85LTEwLTEtMS04NjcwOQ_28ba9e9f-0a36-4533-a285-82fe5aa72bc8"
      unitRef="usd">46177000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC00LTEtMS04NjcwOQ_972a965c-a5c8-49f2-9778-f00e6f435455"
      unitRef="usd">19617000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC02LTEtMS04NjcwOQ_11f87d67-adfe-4eca-be90-32b7c1c234cc"
      unitRef="usd">16587000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC04LTEtMS04NjcwOQ_b1cbe8a5-90c6-46e3-aade-134c1d53a4e3"
      unitRef="usd">56868000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMC0xMC0xLTEtODY3MDk_db3594f6-37ff-464c-a643-d646527a73e6"
      unitRef="usd">53536000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS00LTEtMS04NjcwOQ_a1072a7f-70f3-4207-a5c2-534695ff8462"
      unitRef="usd">79435000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS02LTEtMS04NjcwOQ_b5ced65d-bc7c-4aca-8a2d-03116be39a69"
      unitRef="usd">70939000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS04LTEtMS04NjcwOQ_8944ede4-a832-4430-b766-212e71ce9381"
      unitRef="usd">252999000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMS0xMC0xLTEtODY3MDk_4523f15f-4b53-4a80-a73b-bc9bd0431765"
      unitRef="usd">215846000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi00LTEtMS04NjcwOQ_2b85b49d-8047-42db-8acc-418058ffcec4"
      unitRef="usd">-3114000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi02LTEtMS04NjcwOQ_0e1d3872-ca48-4b82-974f-90a788dae843"
      unitRef="usd">-57792000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi04LTEtMS04NjcwOQ_17eb2222-450e-4f99-aaf4-335668054342"
      unitRef="usd">-112889000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xMi0xMC0xLTEtODY3MDk_0f74c9b4-58a6-4531-b0b3-16fe2512b7b6"
      unitRef="usd">-198939000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi00LTEtMS04NjcwOQ_eee4a2b4-6b26-4f84-a235-e85bc1f6ba11"
      unitRef="usd">273000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi02LTEtMS04NjcwOQ_831f642e-dd11-42ed-939c-da35b71ada50"
      unitRef="usd">16000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi04LTEtMS04NjcwOQ_b29a2382-669b-4b99-8c4a-1c07440b72f0"
      unitRef="usd">18597000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNi0xMC0xLTEtODY3MDk_1b49b30d-0450-4b2a-aeb9-eaca70a02f0a"
      unitRef="usd">46000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy00LTEtMS04NjcwOQ_21d9fb54-4d25-426c-acb0-6036946be2e2"
      unitRef="usd">11356000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy02LTEtMS04NjcwOQ_5028f264-071b-4e8e-bbf4-ea1a18438e6c"
      unitRef="usd">4265000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy04LTEtMS04NjcwOQ_5eb267c8-46a5-4f20-9ef7-25b8019e7abd"
      unitRef="usd">29374000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xNy0xMC0xLTEtODY3MDk_35189d22-7fbd-41d9-a2c4-3d6488f7af60"
      unitRef="usd">8820000</ifrs-full:FinanceCosts>
    <adc:OtherNonOperatingIncome
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC00LTEtMS04NjcwOQ_41629eb1-510c-49b6-8eb1-86cfc35c9259"
      unitRef="usd">-37122000</adc:OtherNonOperatingIncome>
    <adc:OtherNonOperatingIncome
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC02LTEtMS04NjcwOQ_beb8ea85-7593-4f6f-b3c8-cb26ee9b592d"
      unitRef="usd">-9363000</adc:OtherNonOperatingIncome>
    <adc:OtherNonOperatingIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC04LTEtMS04NjcwOQ_036469f5-5ea0-4827-a1d5-09bbbe2d75ab"
      unitRef="usd">-10805000</adc:OtherNonOperatingIncome>
    <adc:OtherNonOperatingIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOC0xMC0xLTEtODY3MDk_aeba0ac7-1653-4b30-8266-1996c6a0fe6d"
      unitRef="usd">12560000</adc:OtherNonOperatingIncome>
    <adc:OtherNonOperatingIncomeExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS00LTEtMS04NjcwOQ_8baa9012-3388-4dbd-883e-a7e54f9b662a"
      unitRef="usd">-48205000</adc:OtherNonOperatingIncomeExpense>
    <adc:OtherNonOperatingIncomeExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS02LTEtMS04NjcwOQ_5df17494-5660-4f07-91af-0c5feafdfd56"
      unitRef="usd">-13612000</adc:OtherNonOperatingIncomeExpense>
    <adc:OtherNonOperatingIncomeExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS04LTEtMS04NjcwOQ_9e23b9ec-b547-495d-9159-abf3707ed673"
      unitRef="usd">-21582000</adc:OtherNonOperatingIncomeExpense>
    <adc:OtherNonOperatingIncomeExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8xOS0xMC0xLTEtODY3MDk_1a1c617c-29b5-4f55-aab7-b251bcee614f"
      unitRef="usd">3786000</adc:OtherNonOperatingIncomeExpense>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC00LTEtMS04NjcwOQ_5119f777-80e5-4de5-9aee-0045d66696a3"
      unitRef="usd">-51319000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC02LTEtMS04NjcwOQ_054c0c8e-c2bf-466c-8ee0-6120373e2880"
      unitRef="usd">-71404000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC04LTEtMS04NjcwOQ_7067f296-49a2-4d1a-a8e3-9f227094221e"
      unitRef="usd">-134471000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMC0xMC0xLTEtODY3MDk_148e025e-193d-4db7-9dd5-5c24772cd9fa"
      unitRef="usd">-195153000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS00LTEtMS04NjcwOQ_29bb728a-0f73-49b6-b46e-16d321261c6b"
      unitRef="usd">-711000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS02LTEtMS04NjcwOQ_c0c9eae2-ae92-42da-acd8-7ded76312db3"
      unitRef="usd">145000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS04LTEtMS04NjcwOQ_58391a12-debc-4041-8be4-21f6e67c024d"
      unitRef="usd">-2828000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMS0xMC0xLTEtODY3MDk_b4719e1b-f865-450f-ae6b-54de4fdd02ec"
      unitRef="usd">492000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi00LTEtMS04NjcwOQ_0fd6e1e4-5ee9-46a0-9a02-64e39ed52014"
      unitRef="usd">-50608000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi02LTEtMS04NjcwOQ_de972a89-2494-4006-b18c-678c773c40a5"
      unitRef="usd">-71549000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi04LTEtMS04NjcwOQ_d386fa8a-5876-4351-9aa9-4c74af34722e"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi04LTEtMS04NjcwOQ_ee5cd402-d090-4597-9a44-59d05b277822"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yMi0xMC0xLTEtODY3MDk_fa92adfe-ee70-481d-8111-1eb8e6f2d85e"
      unitRef="usd">-195645000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS00LTEtMS04NjcwOQ_04011699-53fc-4a4a-abfe-d6d9c5eb8588"
      unitRef="usd">-50608000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS02LTEtMS04NjcwOQ_385f9d88-3d3a-4148-a8e8-5071b2e18505"
      unitRef="usd">-71549000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS04LTEtMS04NjcwOQ_f97e98a0-bf8e-49a6-80eb-f1bd5939242c"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNS0xMC0xLTEtODY3MDk_76cc14fe-ade4-42c8-b3c2-da75d4ec31bf"
      unitRef="usd">-195645000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy00LTEtMS04NjcwOQ_0fcc2a70-3201-41dc-a472-5e7425ed45a8"
      unitRef="usdPerShare">-0.65</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy00LTEtMS04NjcwOQ_fb9dc6a4-a2e7-4ae0-a3bb-0e5905e6be29"
      unitRef="usdPerShare">-0.65</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy02LTEtMS04NjcwOQ_65b5ab39-da29-4a13-b38e-3af098bb6aee"
      unitRef="usdPerShare">-0.93</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy02LTEtMS04NjcwOQ_d44b7b1e-0f90-41e8-9b1e-4944c82fd0c3"
      unitRef="usdPerShare">-0.93</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy04LTEtMS04NjcwOQ_12b11a32-c463-49d9-9ae0-1e7e39a6e632"
      unitRef="usdPerShare">-1.70</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy04LTEtMS04NjcwOQ_60ff3eb9-5872-471b-9371-859f1cd3c0dc"
      unitRef="usdPerShare">-1.70</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy0xMC0xLTEtODY3MDk_8a32af70-df56-495a-bdc4-d5fda9af7f90"
      unitRef="usdPerShare">-2.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80L2ZyYWc6MGIyYzkyMTQxMzk5NGE4Mzk3YzI0ODc1ZDFmNzdhMDAvdGFibGU6NWRlYWQ0MjJkOWZjNGQ2NjhlMmZkZDY2Mzk3ZDI3MzIvdGFibGVyYW5nZTo1ZGVhZDQyMmQ5ZmM0ZDY2OGUyZmRkNjYzOTdkMjczMl8yNy0xMC0xLTEtODY3MDk_f905c0c8-6cba-4236-bd15-065233a1fa62"
      unitRef="usdPerShare">-2.55</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTQtMS0xLTg2NzA5_04011699-53fc-4a4a-abfe-d6d9c5eb8588"
      unitRef="usd">-50608000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTYtMS0xLTg2NzA5_8062bb1d-d50c-452f-bb68-61e8c67cf3b0"
      unitRef="usd">-71549000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTgtMS0xLTg2NzA5_f97e98a0-bf8e-49a6-80eb-f1bd5939242c"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18yLTEwLTEtMS04NjcwOQ_59a86ad9-be93-43f3-a7dc-212356955527"
      unitRef="usd">-195645000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTQtMS0xLTg2NzA5_80f4de30-2b3d-4f37-b04d-4327619e68fc"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTYtMS0xLTg2NzA5_4b08fe15-f4ad-42ec-b965-96bcdd83012b"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTgtMS0xLTg2NzA5_bb9e759b-2115-4fff-8047-8d124f988bdb"
      unitRef="usd">3618000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM182LTEwLTEtMS04NjcwOQ_66ed7f3e-bed8-4d20-9a28-091f76bb4699"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTQtMS0xLTg2NzA5_ff9d273e-a43a-4a78-887d-ab5dff395bdf"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTYtMS0xLTg2NzA5_d4f8a779-f473-4a4c-8855-4fc6fc7a486a"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTgtMS0xLTg2NzA5_bca0ad94-42ea-4bfc-aca5-e8bcb8511982"
      unitRef="usd">3618000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM183LTEwLTEtMS04NjcwOQ_67eb7ccb-8524-496b-ad51-c7cbf42824f4"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC00LTEtMS04NjcwOQ_4284edb9-438c-4ff1-90c3-79f73db91d2a"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC02LTEtMS04NjcwOQ_d9ea5b6e-720c-4630-be27-874dff021d2f"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC04LTEtMS04NjcwOQ_8363d33f-1f25-40c0-bedd-fb8f3a66f305"
      unitRef="usd">-1025000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMC0xMC0xLTEtODY3MDk_9f54ea06-3391-4df2-bab8-2a6cd4202bcf"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS00LTEtMS04NjcwOQ_858cb7df-1e63-44dd-b6f0-05382c7aac50"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS02LTEtMS04NjcwOQ_acf19a50-73b4-413d-aa44-e81a72a4a346"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS04LTEtMS04NjcwOQ_403e0436-5056-4591-81eb-860c3862d953"
      unitRef="usd">-1025000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMS0xMC0xLTEtODY3MDk_96c55d8f-38e6-4648-a09a-7311ec335d50"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi00LTEtMS04NjcwOQ_7cc781f5-097c-47b2-96da-5af485c16e0a"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi02LTEtMS04NjcwOQ_82c65339-76ff-4934-af77-8364e0a679b5"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi04LTEtMS04NjcwOQ_dafefe4c-0167-44c0-892a-d6794eb858b3"
      unitRef="usd">2593000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMi0xMC0xLTEtODY3MDk_1e45378d-dea4-41fc-bf89-83f0ab6e056f"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy00LTEtMS04NjcwOQ_07d715a6-71a8-4c5e-a8a6-dc48d1d9b943"
      unitRef="usd">-51092000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy02LTEtMS04NjcwOQ_f333eeef-3267-43dc-bc1b-e57487437d73"
      unitRef="usd">-71689000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy04LTEtMS04NjcwOQ_98a946c6-693a-4b9f-b529-a6b4361a2f52"
      unitRef="usd">-129050000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xMy0xMC0xLTEtODY3MDk_262c5187-9c86-4620-927e-1551386a930d"
      unitRef="usd">-195729000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi00LTEtMS04NjcwOQ_e5573be5-597a-4855-83f1-3da67468e57e"
      unitRef="usd">-51092000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi02LTEtMS04NjcwOQ_53e3dd4d-c538-4d93-8ba1-4cbed955da04"
      unitRef="usd">-71689000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi04LTEtMS04NjcwOQ_52ded227-e334-4f24-b30a-f18cf6335579"
      unitRef="usd">-129050000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83L2ZyYWc6MTU3NjM5ZTlkNjdiNGNlNzhlMWI4MmY1MDQxZmZkMTcvdGFibGU6YTAwMjI1NGE2ZmY5NDE1YjkxZjVhZTEyYjllMzI2MzMvdGFibGVyYW5nZTphMDAyMjU0YTZmZjk0MTViOTFmNWFlMTJiOWUzMjYzM18xNi0xMC0xLTEtODY3MDk_fdd542b4-e234-4237-83e3-86e8c7bdd466"
      unitRef="usd">-195729000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMy0zLTEtMS04NjcwOQ_d215f9cd-944d-4457-9305-c41d2304e124"
      unitRef="usd">380860000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMy01LTEtMS04NjcwOQ_d5e493e5-532a-45ea-8d30-72afaafe29c0"
      unitRef="usd">466544000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNC0zLTEtMS04NjcwOQ_2686f8ec-21ae-453e-85c5-883d5e8870fd"
      unitRef="usd">23251000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNC01LTEtMS04NjcwOQ_665abd19-bbde-4a43-a8bf-8d535bef5fef"
      unitRef="usd">30218000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:Inventories
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNS0zLTEtMS04NjcwOQ_36d3ca28-3660-445d-8de2-18082153455a"
      unitRef="usd">15745000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNS01LTEtMS04NjcwOQ_0da3ce43-8c57-4d32-903a-4d7544f3ccca"
      unitRef="usd">11122000</ifrs-full:Inventories>
    <ifrs-full:OtherCurrentAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNi0zLTEtMS04NjcwOQ_b057d93d-7c74-40c9-b6cc-05524dd8ca4b"
      unitRef="usd">18243000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNi01LTEtMS04NjcwOQ_bce7b4c5-0292-4f8d-b03e-6a6208b89ed1"
      unitRef="usd">17298000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNy0zLTEtMS04NjcwOQ_548b6ee7-0c7f-4e5f-b9a6-cc510e25062e"
      unitRef="usd">438099000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNy01LTEtMS04NjcwOQ_339f2643-0b42-4790-b9b9-5401789d10fc"
      unitRef="usd">525182000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfOS0zLTEtMS04NjcwOQ_5c9b0850-1c5b-43c3-8436-6ba8b280c0d4"
      unitRef="usd">3169000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfOS01LTEtMS04NjcwOQ_e4a744a6-85f2-4a3b-849e-788b2ac54b76"
      unitRef="usd">4066000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTAtMy0xLTEtODY3MDk_a0e2395e-9b11-463b-84dd-ccb6e674e622"
      unitRef="usd">6708000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTAtNS0xLTEtODY3MDk_6ec88291-3573-4b1f-9401-076893c8084d"
      unitRef="usd">7164000</ifrs-full:RightofuseAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTEtMy0xLTEtODY3MDk_8b91d21c-92e3-4d37-9286-22a193950808"
      unitRef="usd">14598000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTEtNS0xLTEtODY3MDk_471a1db5-7f38-4a67-b751-b1b3a867c093"
      unitRef="usd">13582000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTItMy0xLTEtODY3MDk_a49afe57-0964-468d-8f16-ca6cc2299da6"
      unitRef="usd">34687000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTItNS0xLTEtODY3MDk_9d4ab6a3-610a-46b5-ae99-752d2194a2b2"
      unitRef="usd">41236000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTMtMy0xLTEtODY3MDk_024f6da3-e4aa-4535-a222-7beef78a5e09"
      unitRef="usd">33599000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTMtNS0xLTEtODY3MDk_e987ed5e-3608-4343-b529-eac5d104c18c"
      unitRef="usd">26049000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTQtMy0xLTEtODY3MDk_4217b55e-bf83-4bd7-9984-d45ddf78f7ee"
      unitRef="usd">899000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTQtNS0xLTEtODY3MDk_4935c74c-d1d3-4146-a3cb-8b09438fbfdf"
      unitRef="usd">693000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTUtMy0xLTEtODY3MDk_b0d84c04-e3db-41f5-be50-9c07a1648080"
      unitRef="usd">93660000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTUtNS0xLTEtODY3MDk_37f99765-d06b-4861-b722-278c3b13af47"
      unitRef="usd">92790000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTctMy0xLTEtODY3MDk_bbc77fca-b417-460a-acc4-33d8761d128f"
      unitRef="usd">531759000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMTctNS0xLTEtODY3MDk_c7eeb559-f24f-44f1-a3b7-7e37f436bbc4"
      unitRef="usd">617972000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjEtMy0xLTEtODY3MDk_ddd66e73-5959-4234-a329-527b6361e0f5"
      unitRef="usd">11611000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjEtNS0xLTEtODY3MDk_14b5ca80-a031-422f-b453-16ac77c11bae"
      unitRef="usd">12080000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjItMy0xLTEtODY3MDk_2e079f1e-6077-4e18-90e6-1e345b3fa602"
      unitRef="usd">62658000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjItNS0xLTEtODY3MDk_5a197220-bb93-45b9-bca6-d0812137bc05"
      unitRef="usd">50497000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjMtMy0xLTEtODY3MDk_d6214f6c-e142-4b78-acdf-2b6a92a6bc64"
      unitRef="usd">835000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjMtNS0xLTEtODY3MDk_62778250-e9ce-436c-a7b9-cec3e744b104"
      unitRef="usd">1029000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjQtMy0xLTEtODY3MDk_f4db14de-98b6-4352-9eb2-a0dda5a5cc2c"
      unitRef="usd">0</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjQtNS0xLTEtODY3MDk_617c0ef7-6f09-428e-b4b8-8b0b5b0a0471"
      unitRef="usd">3754000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <adc:ShortTermBorrowings
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtMy0xLTEtOTc2Njg_7804eba0-d656-4336-b9d5-9cd07626db44"
      unitRef="usd">12469000</adc:ShortTermBorrowings>
    <adc:ShortTermBorrowings
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtNS0xLTEtOTc2Njg_6ee76c72-bbb4-44c5-ace6-2148105c7145"
      unitRef="usd">0</adc:ShortTermBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtMy0xLTEtODY3MDk_a45c5fd1-6651-41f9-9d48-7ebd1612780c"
      unitRef="usd">0</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjUtNS0xLTEtODY3MDk_9136b62c-17ec-4c49-b51c-459b47d0f463"
      unitRef="usd">6575000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
    <ifrs-full:CurrentLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjYtMy0xLTEtODY3MDk_aad4c431-58c1-4a40-845a-55173704f7e1"
      unitRef="usd">87573000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjYtNS0xLTEtODY3MDk_f75bdf83-23bb-4779-8773-6e5570f455d0"
      unitRef="usd">73935000</ifrs-full:CurrentLiabilities>
    <ifrs-full:LongtermBorrowings
      contextRef="ibd2e5e5704574aebbaa2380a7fde3845_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktMy0xLTEtOTA3NTg_1abfb0cd-1124-42b9-a8a4-7c81b7d7b4ab"
      unitRef="usd">96731000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="i93f34ddf4b844d758babc0b90fe80e66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktNS0xLTEtOTA3NTg_5e572ea5-37c4-40cb-96d8-ecb04610ecc0"
      unitRef="usd">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="i4d737f742272444ea08949e847328dde_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjgtMy0xLTEtODY3MDk_f165c078-31d3-4db4-9ca6-151ca495a494"
      unitRef="usd">0</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="i6cf4592fe28044fabfe4047cabbd76e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjgtNS0xLTEtODY3MDk_a9efc0d6-7355-4dd5-884a-17b51654ba52"
      unitRef="usd">87153000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktMy0xLTEtODY3MDk_8e1f267a-9351-4ded-8772-9743c67f295d"
      unitRef="usd">0</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMjktNS0xLTEtODY3MDk_17fcb4fe-6078-42f4-bda2-df8750dae56e"
      unitRef="usd">37947000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentWarrantLiability
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItMy0xLTEtOTA3NzY_0f14169d-b1a0-415c-a568-a19b7e04a0aa"
      unitRef="usd">4293000</ifrs-full:NoncurrentWarrantLiability>
    <ifrs-full:NoncurrentWarrantLiability
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItNS0xLTEtOTA3NzY_11923e8d-0c37-4fdc-a88c-71fca0eeea25"
      unitRef="usd">0</ifrs-full:NoncurrentWarrantLiability>
    <adc:DeferredRoyaltyObligationNoncurrent
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzAtMy0xLTEtODY3MDk_23299660-18f7-4ecb-b695-daa9b5454f87"
      unitRef="usd">208218000</adc:DeferredRoyaltyObligationNoncurrent>
    <adc:DeferredRoyaltyObligationNoncurrent
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzAtNS0xLTEtODY3MDk_f72f9ec7-fbda-4c65-95d4-aaeeea20948b"
      unitRef="usd">218664000</adc:DeferredRoyaltyObligationNoncurrent>
    <ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzEtMy0xLTEtODY3MDk_4cb2aa5d-6b76-4edf-aaf9-7f3aceda4a14"
      unitRef="usd">23539000</ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures>
    <ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzEtNS0xLTEtODY3MDk_cd3dc221-11e9-4af8-a3a1-3b494f232546"
      unitRef="usd">23539000</ifrs-full:ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItMy0xLTEtODY3MDk_0be6fe50-f6ae-4f5d-9fd8-5586f28c5e00"
      unitRef="usd">6622000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzItNS0xLTEtODY3MDk_b409bc47-f356-409a-9090-d15517e9e39f"
      unitRef="usd">6994000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzMtMy0xLTEtODY3MDk_1424f97b-6b82-41e2-b5d8-6d35cde7643f"
      unitRef="usd">0</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzMtNS0xLTEtODY3MDk_a0f7892f-6baf-411e-a2ba-35c6933ec732"
      unitRef="usd">3652000</ifrs-full:NoncurrentRecognisedLiabilitiesDefinedBenefitPlan>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzUtMy0xLTEtODY3MDk_2c3d4687-96bb-4b8c-89ad-8c4c3a70f14e"
      unitRef="usd">339403000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzUtNS0xLTEtODY3MDk_9d6d4d5c-a640-4078-bc41-a88f45f80dc2"
      unitRef="usd">377949000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzctMy0xLTEtODY3MDk_ce5a9220-ae49-485d-a811-d87ebf1ca666"
      unitRef="usd">426976000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfMzctNS0xLTEtODY3MDk_abd6739c-140e-43a7-ae63-c0d832593723"
      unitRef="usd">451884000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDAtMy0xLTEtODY3MDk_5be5934e-54b8-416e-943c-2901a5da24a6"
      unitRef="usd">6699000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDAtNS0xLTEtODY3MDk_7cc2f68a-3621-449a-a00c-02825a089bbd"
      unitRef="usd">6445000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDEtMy0xLTEtODY3MDk_959aae01-b85c-478f-b785-f9ad62afcd30"
      unitRef="usd">1007510000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDEtNS0xLTEtODY3MDk_06da9752-d02b-4bcc-9ed2-b4137f49e9c0"
      unitRef="usd">981827000</ifrs-full:SharePremium>
    <ifrs-full:TreasuryShares
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDItMy0xLTEtODY3MDk_b1185b5c-d5ec-4841-9b8e-c8d28ffb419a"
      unitRef="usd">101000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDItNS0xLTEtODY3MDk_d4d0d0df-2207-4f3a-bdb7-94cd41949f51"
      unitRef="usd">128000</ifrs-full:TreasuryShares>
    <ifrs-full:OtherReserves
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDMtMy0xLTEtODY3MDk_73d54d02-a1a4-4bf7-8e6d-d147c7931092"
      unitRef="usd">148045000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDMtNS0xLTEtODY3MDk_fe137a18-ed68-46c2-bac0-19c19d096ed4"
      unitRef="usd">102646000</ifrs-full:OtherReserves>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDQtMy0xLTEtODY3MDk_8f22132e-54b8-4f12-8592-4e7af61d64c7"
      unitRef="usd">-842000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDQtNS0xLTEtODY3MDk_0bd54f00-e12c-48de-9d92-9639979614c5"
      unitRef="usd">183000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:RetainedEarnings
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDUtMy0xLTEtODY3MDk_9316f0f6-60cb-45ce-a0d6-7577a5085458"
      unitRef="usd">-1056528000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDUtNS0xLTEtODY3MDk_ac4c9526-c9fb-4b13-a121-d1b289b40b6f"
      unitRef="usd">-924885000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDYtMy0xLTEtODY3MDk_094240e7-5f04-4563-a599-a91b8de62700"
      unitRef="usd">104783000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDYtNS0xLTEtODY3MDk_4af7dd10-0419-4845-9bce-2e98794841be"
      unitRef="usd">166088000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDgtMy0xLTEtODY3MDk_61f28293-47fa-4e35-8bff-5e6963e336a7"
      unitRef="usd">531759000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMC9mcmFnOmQwMDg2M2Y3YzBmNDRmZjZiZTMzNjc3Yzg3ODcwZWFhL3RhYmxlOjQ0MzE5ZDcxNDhkYTQyZDA4OGVkMWYxNmRkMTg3NjExL3RhYmxlcmFuZ2U6NDQzMTlkNzE0OGRhNDJkMDg4ZWQxZjE2ZGQxODc2MTFfNDgtNS0xLTEtODY3MDk_3527c816-7b73-4761-9c89-925f45c4c664"
      unitRef="usd">617972000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="i3b4ab23200b64567b35b0dc47c38e42b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0zLTEtMS04NjcwOQ_88ce685e-f592-454e-9edf-b0e441bfcd56"
      unitRef="usd">6445000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i0b5bb52172f94f6abd0bb6713cb6131b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS01LTEtMS04NjcwOQ_75dc3205-8612-4255-94d1-e6659b43c51b"
      unitRef="usd">981818000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i35596c2c71984cccaef883c93b78c04e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS03LTEtMS04NjcwOQ_2e287208-f3ee-48fe-a0da-dc0fa8057170"
      unitRef="usd">133480000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i246b440f84cd4fefaca5cc8ab1014c64_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS05LTEtMS04NjcwOQ_1ea0ca21-4216-481f-8220-b74d67fd2ea2"
      unitRef="usd">-119000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ife3e54de10ce40b29aa3c37bcd67ea64_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0xMS0xLTEtODY3MDk_c6e8fbc3-01dc-4d50-80c6-c5b74a5a0ba0"
      unitRef="usd">-358000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i027b22679fb54ad388c26ce8c669aac5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0xMy0xLTEtODY3MDk_92fdea9e-b310-480d-8b5e-4d0b525e5d2a"
      unitRef="usd">-1005920000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ic28832b49da3403a8b557a594e965059_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMS0xNS0xLTEtODY3MDk_d639d7a7-32de-4e42-9e80-e4ffc7744af2"
      unitRef="usd">115346000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i2ea2e58acd5f40adb6d20b24a516fd32_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMy0xMy0xLTEtODY3MDk_a2e60c43-7543-4a27-be2f-53d8cf34faa0"
      unitRef="usd">-50608000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMy0xNS0xLTEtODY3MDk_2aa7614e-ff76-4843-b02e-5a0735ef6416"
      unitRef="usd">-50608000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfNi0xMS0xLTEtODY3MDk_a808aa9e-61fb-4d42-8e29-cc8f5795b89a"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfNi0xNS0xLTEtODY3MDk_49224ce3-44df-4de7-97d8-7f2866435de0"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfOC03LTEtMS04NjcwOQ_be512fcd-4243-4b18-b785-de1197965204"
      unitRef="usd">0</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfOC0xMS0xLTEtODY3MDk_2460dbad-0a54-40a9-88ed-48878ed7e4ff"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfOC0xNS0xLTEtODY3MDk_d43b3fbc-9f2e-481b-b7b6-46eed9cc84c8"
      unitRef="usd">-484000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtNy0xLTEtODY3MDk_1de6f727-654e-40f2-9be9-3bdd5521f079"
      unitRef="usd">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i5d071ce8105a498eaa50d4f8ec06322d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTEtMS0xLTg2NzA5_f4944ac4-6914-43e8-9449-5ecdc579f3e8"
      unitRef="usd">-484000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i2ea2e58acd5f40adb6d20b24a516fd32_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTMtMS0xLTg2NzA5_9d50bb6c-4fbc-466c-a428-c63b7cbac73e"
      unitRef="usd">-50608000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTUtMS0xLTg2NzA5_aa2682a3-c8a3-41e2-a417-8b40d7566e9b"
      unitRef="usd">-51092000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i421702717ad84eeaa1925dceb63c2981_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMy0xLTEtOTk2Njk_862217eb-34a1-4946-88e2-26a5a9615612"
      unitRef="usd">254000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtOTk2Njk_679e45d2-5354-4dad-8fe1-a7fb88a3d02e"
      unitRef="usd">-254000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTAtMTUtMS0xLTEwMTQ0MA_3b8a7618-a016-4394-9111-d1fedd191d95"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtNS0xLTEtOTI0NTM_3342519c-5e8d-4dab-8c52-8fab5db5f991"
      unitRef="usd">19640000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtOTI0NTM_0e4cfe6b-123d-4ec1-9955-cd5156e3b187"
      unitRef="usd">194000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMTUtMS0xLTkyNDUz_e4c1e93e-4987-4a29-975e-2c0aec11dd53"
      unitRef="usd">19834000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:IssueOfEquityThroughPurchaseAgreement
      contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtNS0xLTEtOTI1MDg_9ebb2027-1631-4897-86b6-f3e649805fb4"
      unitRef="usd">6070000</adc:IssueOfEquityThroughPurchaseAgreement>
    <adc:IssueOfEquityThroughPurchaseAgreement
      contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtOTI1MDg_6e10e51b-f61b-41e1-8fe2-a59d8fdd1e33"
      unitRef="usd">60000</adc:IssueOfEquityThroughPurchaseAgreement>
    <adc:IssueOfEquityThroughPurchaseAgreement
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMTUtMS0xLTkyNTA4_a442028d-86da-4ec4-a997-d4851bc4717b"
      unitRef="usd">6130000</adc:IssueOfEquityThroughPurchaseAgreement>
    <adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption
      contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtNS0xLTEtODY3MDk_56cbf051-b136-415f-b4e2-587b58019b8c"
      unitRef="usd">-18000</adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption>
    <adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption
      contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtOS0xLTEtODY3MDk_2f5a7fe3-2a8e-4211-99cb-9642a8068268"
      unitRef="usd">18000</adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption>
    <adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTMtMTUtMS0xLTg2NzA5_bd14feb8-3d78-4329-9faf-38ad9acbdcba"
      unitRef="usd">0</adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTQtNy0xLTEtODY3MDk_34d66dd2-cf33-4941-b562-2411d0203284"
      unitRef="usd">14565000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTQtMTUtMS0xLTg2NzA5_7ca39be3-ecf6-4144-9508-460e5450f0ae"
      unitRef="usd">14565000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i421702717ad84eeaa1925dceb63c2981_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtMy0xLTEtODY3MDk_6bba75ed-d395-4479-873f-827bfe47b519"
      unitRef="usd">254000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i6a3d958595654cd685c236012143b763_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtNS0xLTEtODY3MDk_b07bfab2-a569-4d60-a89c-64c046f1a253"
      unitRef="usd">25692000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i01a70943059b47938af04f86d913bf7f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtNy0xLTEtODY3MDk_4271990c-c879-4478-b4b0-a8759e8d441d"
      unitRef="usd">14565000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i7fa267740ce54fae899738589cb13c74_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtOS0xLTEtODY3MDk_8d2dbd0b-44a9-45ce-8e1c-45a4151e5075"
      unitRef="usd">18000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTUtMTUtMS0xLTg2NzA5_b5ed0611-eadb-40f5-84a2-0d9beed8f071"
      unitRef="usd">40529000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="ie97eb94da1244cedb49b709a60205ff8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMy0xLTEtODY3MDk_bc96034f-1421-44c3-a79a-caa61cda731f"
      unitRef="usd">6699000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ic96fd76ea6094201873babaf44147e90_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctNS0xLTEtODY3MDk_f800dba6-abdf-4f8a-bf58-6927b067dca8"
      unitRef="usd">1007510000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i4a369d72d0de4d07b601c6485cd111ac_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctNy0xLTEtODY3MDk_d28d13b2-e402-4482-8568-13538829f1fc"
      unitRef="usd">148045000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i3f2800d230b840698a1df635aef0fb1e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctOS0xLTEtODY3MDk_68244e97-dbd1-4636-9be6-3b5dcd955289"
      unitRef="usd">-101000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1275b5a441e64681a4536db9f8517583_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMTEtMS0xLTg2NzA5_48a377f8-49f0-4ae0-ba07-ba99937f01c6"
      unitRef="usd">-842000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i678984f32c6242569e8813e4669c4d66_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMTMtMS0xLTg2NzA5_9c778851-c296-4217-a138-25a197f2b4ac"
      unitRef="usd">-1056528000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjQ1NzIyYjJmM2YyNDRiMzg5ZTc5OTU0NjE0YWViMWQ3L3RhYmxlcmFuZ2U6NDU3MjJiMmYzZjI0NGIzODllNzk5NTQ2MTRhZWIxZDdfMTctMTUtMS0xLTg2NzA5_ceca22af-25d3-49ab-9d42-67b68ac1a9b0"
      unitRef="usd">104783000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i0cf2a41c1b0f412dbadb0ec7cc9807ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0zLTEtMS04NjcwOQ_414d7896-3d76-4967-8ba0-92b68049a666"
      unitRef="usd">6445000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i3987240b95a941f3a745b6bce9358ab2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi01LTEtMS04NjcwOQ_42ea63c6-d6f8-4104-822f-6c760f0cf299"
      unitRef="usd">981827000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6d159e8735254990a623ac7081d8a5e2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi03LTEtMS04NjcwOQ_db19d541-042a-4c1a-b962-68bd94476dbd"
      unitRef="usd">102646000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i223e1c18b9e048b4a57a8347875e6217_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi05LTEtMS04NjcwOQ_b1ad5e26-ba5e-446e-bd04-eae3da46757e"
      unitRef="usd">-128000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i3e72f4f26f6741079eb2df83e9327373_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0xMS0xLTEtODY3MDk_77b2fd5e-e21e-4e97-985e-3d16362d79e6"
      unitRef="usd">183000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie48cd9a814c44291b865fd727b17518f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0xMy0xLTEtODY3MDk_500d6466-b0f5-4f80-91bd-555db8301481"
      unitRef="usd">-924885000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMi0xNS0xLTEtODY3MDk_4de505a1-9ee5-49e8-85a0-1fcc50ac588e"
      unitRef="usd">166088000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i31afbe725ae54907a860c98c67e10f1a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNC0xMy0xLTEtODY3MDk_db44bb11-ec8f-41d5-bec2-d7b742e45778"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNC0xNS0xLTEtODY3MDk_4f0af197-8d42-4e12-9183-f8bb9ed6ea3b"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNi03LTEtMS04NjcwOQ_a1da04f7-a7d4-44a8-b9e3-571e6c168817"
      unitRef="usd">-3618000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNi0xNS0xLTEtODY3MDk_6d3a76d9-8b98-4e9e-98b6-746b6d977b0a"
      unitRef="usd">-3618000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNy0xMS0xLTEtODY3MDk_e3f2dcab-fe0b-4b68-9775-92ad7b33916c"
      unitRef="usd">-1025000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfNy0xNS0xLTEtODY3MDk_93878ad7-3c44-4aca-ba89-29c9f298c960"
      unitRef="usd">-1025000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfOS03LTEtMS04NjcwOQ_3f38b2a3-b067-4a01-9464-b8244bc01811"
      unitRef="usd">3618000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfOS0xMS0xLTEtODY3MDk_06e4146c-b85b-4988-8718-c44c9bf1f914"
      unitRef="usd">-1025000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfOS0xNS0xLTEtODY3MDk_be2c056b-846d-4d94-87ed-b8d02aaa6162"
      unitRef="usd">2593000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtNy0xLTEtODY3MDk_68587201-0f0b-43be-ba4f-e682b4651ab7"
      unitRef="usd">3618000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i0b068b29ee904c3bad9d03778f3e53b7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtMTEtMS0xLTg2NzA5_6ba4fe04-8cbc-4ce0-97d0-3ef07b443eda"
      unitRef="usd">-1025000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i31afbe725ae54907a860c98c67e10f1a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtMTMtMS0xLTg2NzA5_d3ca2daf-dc90-422f-bd33-7a1a4b1374c5"
      unitRef="usd">-131643000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTEtMTUtMS0xLTg2NzA5_19d961b9-4e86-4482-9d18-c0bd8e7c0041"
      unitRef="usd">-129050000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="if71b176729574174b972671a573dc05e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTUtMy0xLTEtODY3MDk_537d6192-0303-402f-885d-195f8b76f8cb"
      unitRef="usd">254000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTUtOS0xLTEtODY3MDk_fe9d4f41-79b8-4b48-be6d-440bba806862"
      unitRef="usd">-254000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTUtMTUtMS0xLTg2NzA5_4a3a790c-4a1e-4015-bcf9-9803ff92f7b5"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTYtNS0xLTEtODY3MDk_fb5e5bf5-54de-4500-9504-c2e81d81f9b9"
      unitRef="usd">19640000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTYtOS0xLTEtODY3MDk_db18ccd0-0e29-4a61-9cb6-8765fcf12ed5"
      unitRef="usd">194000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTYtMTUtMS0xLTg2NzA5_661d3851-e5a2-4f07-bd67-e0fe3d3221e9"
      unitRef="usd">19834000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:IssueOfEquityThroughPurchaseAgreement
      contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTctNS0xLTEtODY3MDk_331fb640-f4f4-4c75-b43b-24db4cbbdc4b"
      unitRef="usd">6070000</adc:IssueOfEquityThroughPurchaseAgreement>
    <adc:IssueOfEquityThroughPurchaseAgreement
      contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTctOS0xLTEtODY3MDk_ea4294a1-486b-45a1-958d-81371ddc0a57"
      unitRef="usd">60000</adc:IssueOfEquityThroughPurchaseAgreement>
    <adc:IssueOfEquityThroughPurchaseAgreement
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTctMTUtMS0xLTg2NzA5_880b2c91-2508-4a6c-888f-c2bd379b7fd4"
      unitRef="usd">6130000</adc:IssueOfEquityThroughPurchaseAgreement>
    <adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption
      contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTktNS0xLTEtODY3MDk_2ed055e8-c18d-44f4-bc81-5c24d8ef7ae7"
      unitRef="usd">27000</adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption>
    <adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption
      contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTktOS0xLTEtODY3MDk_a1fcc979-0a29-4380-b24a-834552e98f7d"
      unitRef="usd">-27000</adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption>
    <adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMTktMTUtMS0xLTg2NzA5_01978bc1-b23d-4578-a075-aa61ed776e24"
      unitRef="usd">0</adc:ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjAtNy0xLTEtODY3MDk_13510e00-db09-4b87-bbf2-944fb93559dd"
      unitRef="usd">41781000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjAtMTUtMS0xLTg2NzA5_57192abb-1fb0-4fbc-b45f-dfa5b2d7e63c"
      unitRef="usd">41781000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="if71b176729574174b972671a573dc05e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtMy0xLTEtODY3MDk_e27e9fbd-6ce8-4d03-8881-68444ab8b1fc"
      unitRef="usd">254000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtNS0xLTEtODY3MDk_25faf00e-d4fd-45d2-9220-64f4b04bedb0"
      unitRef="usd">25683000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i255c4136af1449c1b362c3e30c0684f8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtNy0xLTEtODY3MDk_dc6d73fd-af4c-44e0-9df0-397af473f31e"
      unitRef="usd">41781000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i2e733662e17549aebf656747ad4422c8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtOS0xLTEtODY3MDk_870e9b1b-a045-4beb-aa5e-1a125d7686b1"
      unitRef="usd">27000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjEtMTUtMS0xLTg2NzA5_1ec5c368-2e40-4bc4-b091-c4ae1588e693"
      unitRef="usd">67745000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="ie97eb94da1244cedb49b709a60205ff8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMy0xLTEtODY3MDk_573ca0a9-a3af-4283-ae2c-46c9f0873076"
      unitRef="usd">6699000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ic96fd76ea6094201873babaf44147e90_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtNS0xLTEtODY3MDk_3b89dfe7-1218-4601-b3e8-861417bc8b0d"
      unitRef="usd">1007510000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i4a369d72d0de4d07b601c6485cd111ac_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtNy0xLTEtODY3MDk_b6e866e4-e258-4701-9c77-6eb38e9aba20"
      unitRef="usd">148045000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i3f2800d230b840698a1df635aef0fb1e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtOS0xLTEtODY3MDk_df4ecb43-ac11-47bf-9a43-0a814adc0cc2"
      unitRef="usd">-101000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1275b5a441e64681a4536db9f8517583_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMTEtMS0xLTg2NzA5_52b0eebf-0da2-4cbf-b0a1-8cfe81e2fca3"
      unitRef="usd">-842000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i678984f32c6242569e8813e4669c4d66_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMTMtMS0xLTg2NzA5_8279bac4-ce42-4890-980f-52c7a509a813"
      unitRef="usd">-1056528000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjdlMWJhMDNlN2NiNzQwMjBiNzQwOTUwMmJlOTQwZDUwL3RhYmxlcmFuZ2U6N2UxYmEwM2U3Y2I3NDAyMGI3NDA5NTAyYmU5NDBkNTBfMjMtMTUtMS0xLTg2NzA5_7bf3eda6-b7ac-4fde-890f-8486a3e5b13c"
      unitRef="usd">104783000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6fe83d69badf4b52947c1251a39d7037_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0zLTEtMS04NjcwOQ_4784237b-16b8-4700-baf3-b17acc1cb838"
      unitRef="usd">6445000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ic7ca719fc24c4758a77b58d789173cfc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS01LTEtMS04NjcwOQ_f8708617-af3d-45f3-ac33-1413c590e27f"
      unitRef="usd">981290000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ia3cdb002a7f247dba0b4723c76def055_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS03LTEtMS04NjcwOQ_f35c6973-8cea-4438-843a-da85c0aae8e2"
      unitRef="usd">74971000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i7aadc701136f486fb9d540ba984fa396_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS05LTEtMS04NjcwOQ_8df2c351-9c84-4bdc-9e64-40ee01138c32"
      unitRef="usd">-134000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i6300840ba2e145df92c265753e78fc30_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0xMS0xLTEtODY3MDk_513f0ec0-c2ad-45e7-94db-0ac4fb579fd3"
      unitRef="usd">301000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i3732a765dbee4267b31e29ecc8de0b94_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0xMy0xLTEtODY3MDk_94729cf5-307d-4506-b31e-bdc6b949a383"
      unitRef="usd">-818955000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i8a916c5c42b145e7ab29ea4d88cb1cff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMS0xNS0xLTEtODY3MDk_b22b7f90-4bc9-4080-a9c9-bb4eebd73e37"
      unitRef="usd">243918000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMy0xMy0xLTEtODY3MDk_de972a89-2494-4006-b18c-678c773c40a5"
      unitRef="usd">-71549000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMy0xNS0xLTEtODY3MDk_9ccea513-f150-4944-8881-6c3c9cdb2f93"
      unitRef="usd">-71549000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNS0xMS0xLTEtODY3MDk_9495d142-f8cc-43a9-b928-a9b6d0a205ce"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNS0xNS0xLTEtODY3MDk_b1281a1e-dab6-4eb3-a304-f631f11bc05a"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNi0xMS0xLTEtODY3MDk_7b40c28a-3477-4258-8fd6-88fc7c48e42e"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfNi0xNS0xLTEtODY3MDk_51f04e17-8468-443c-a7f9-f635f87a85c4"
      unitRef="usd">-140000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i4adf6f7e8e87499caa5b8f16fed0a4fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfOC0xMS0xLTEtODY3MDk_38c83dbe-97f3-438e-bfea-4b56d8b0c888"
      unitRef="usd">-140000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i0736e5e2125d4cad852cb1e1f974e35c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfOC0xMy0xLTEtODY3MDk_db441d6f-bf0c-40a6-82f4-fade01fdd6dd"
      unitRef="usd">-71549000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfOC0xNS0xLTEtODY3MDk_508483eb-ea18-42d0-a949-24566fbb7d63"
      unitRef="usd">-71689000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i402dfab004dd492aae570021cbed2be1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTEtNS0xLTEtODY3MDk_003587e2-7bb2-4650-8d33-0774a1907400"
      unitRef="usd">280000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ifb2644136b7844bd8f3ed9546fa55a15_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTEtOS0xLTEtODY3MDk_e70e9c23-b72e-4dda-affe-33c38c952c0e"
      unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTEtMTUtMS0xLTg2NzA5_f2c384cf-b444-4671-b786-c5699b4b20a5"
      unitRef="usd">281000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i99128419613143609193e10731703076_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTItNy0xLTEtODY3MDk_1193a9cd-0296-483d-b465-89d8071b705f"
      unitRef="usd">14798000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTItMTUtMS0xLTg2NzA5_c5a281c5-519e-49a7-ac7a-ecc502cc17be"
      unitRef="usd">14798000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i402dfab004dd492aae570021cbed2be1_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtNS0xLTEtODY3MDk_b31a909f-167a-4201-8a2c-d453c919f06a"
      unitRef="usd">280000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i99128419613143609193e10731703076_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtNy0xLTEtODY3MDk_ad6e24e3-0ba0-4031-b4a0-d7d48d076177"
      unitRef="usd">14798000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="ifb2644136b7844bd8f3ed9546fa55a15_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtOS0xLTEtODY3MDk_2332fbe7-2108-4d16-a1b7-3678e395557a"
      unitRef="usd">1000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTMtMTUtMS0xLTg2NzA5_24239315-8e37-4cf1-a559-50136fe97030"
      unitRef="usd">15079000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="ic08137b9d07d47458bd80e38918070fb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMy0xLTEtODY3MDk_deac4048-5da5-4558-baf1-f5b5b0cb29af"
      unitRef="usd">6445000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ia00516d757c74b41ab5ec5b14024dbfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtNS0xLTEtODY3MDk_f02c17a1-d176-4c28-a03c-23ca4dbd5cb7"
      unitRef="usd">981570000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie6e3d0984c7640a6812965fc4399b0ab_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtNy0xLTEtODY3MDk_d61fb487-4aa8-40df-8a8b-998e22c9ca27"
      unitRef="usd">89769000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i09effb3b4b9b463691f066e4f85ccde9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtOS0xLTEtODY3MDk_1304a3b9-f08f-4ddb-9b55-eba2ade6db89"
      unitRef="usd">-133000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i819688b0196b4f8180d3a454630743bf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMTEtMS0xLTg2NzA5_23bb69bb-2b20-4caa-ac05-47a495a770b9"
      unitRef="usd">161000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie65cd89c7bf24557946ea885c4873749_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMTMtMS0xLTg2NzA5_b005160f-5e0c-4ac5-a45a-a54f3559064d"
      unitRef="usd">-890504000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjkyNmJhN2JlYjcyNzQyZDlhODE3OWIwODIyNDczMzFmL3RhYmxlcmFuZ2U6OTI2YmE3YmViNzI3NDJkOWE4MTc5YjA4MjI0NzMzMWZfMTUtMTUtMS0xLTg2NzA5_a33d6f84-83e4-4372-9692-e694da2ab541"
      unitRef="usd">187308000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i04c2941ce0a845c4ad2292d13e712648_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0zLTEtMS04NjcwOQ_205f22f6-259b-4f42-8c9e-676d1fc12a00"
      unitRef="usd">6314000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="id8a9da342b454067adcd289ef23fbf0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS01LTEtMS04NjcwOQ_0dbdb292-e94d-47f0-9f83-e033a7ad6828"
      unitRef="usd">981056000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i9e12d33e41234842815adf403479484b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS03LTEtMS04NjcwOQ_b55f18ac-389c-4236-b33a-e629a4fb8c9c"
      unitRef="usd">42753000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="iea3ac90d7b74494ab57a78dc23262650_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS05LTEtMS04NjcwOQ_e3574b88-46b3-4299-b23d-49964d42e090"
      unitRef="usd">-4000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ic4e071b05a6648619ca531f90eac8afe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0xMS0xLTEtODY3MDk_01fda5ad-a769-465f-ad0c-802a0613586b"
      unitRef="usd">245000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="if8a1526b17d348e3a7c97fc3293c2a37_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0xMy0xLTEtODY3MDk_7e6b5dcb-74f0-495f-ab02-9106d2276224"
      unitRef="usd">-694859000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMS0xNS0xLTEtODY3MDk_cf83ad46-ed2c-4867-9151-2c36412ae594"
      unitRef="usd">335505000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="if85b8fd87bd6425ebe37b622aaa8b6fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMy0xMy0xLTEtODY3MDk_f0d8e307-fb88-4b74-a8bd-ac3ff58b650f"
      unitRef="usd">-195645000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMy0xNS0xLTEtODY3MDk_66ae14d3-bf61-409a-bc07-1adce5ea1812"
      unitRef="usd">-195645000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNS0xMS0xLTEtODY3MDk_3f94cad2-760a-4998-9764-a2c59bbc84bf"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNS0xNS0xLTEtODY3MDk_9e37109e-6b7f-4315-a3e6-8779de4d3a98"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNy0xMS0xLTEtODY3MDk_fe2cd005-a0fd-478f-80e1-0bc32d0961b4"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfNy0xNS0xLTEtODY3MDk_b700dbfd-773c-4e2b-aff1-70b061a8351d"
      unitRef="usd">-84000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="i77cc1012cf7b4d518bed518d0dab9951_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfOS0xMS0xLTEtODY3MDk_2c575cc2-e061-4b94-ab57-332a49209332"
      unitRef="usd">-84000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="if85b8fd87bd6425ebe37b622aaa8b6fd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfOS0xMy0xLTEtODY3MDk_e63ba5f7-c88a-4510-8871-82b1379eb51b"
      unitRef="usd">-195645000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfOS0xNS0xLTEtODY3MDk_56cf5722-659d-42fb-9297-23ab95a6fb1e"
      unitRef="usd">-195729000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="i9070db993da44bb4b9180949625e0bfe_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTMtMy0xLTEtODY3MDk_e648b81a-98ec-4ac4-a52b-fefc5778734b"
      unitRef="usd">131000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="ifba43579460b45abb618bce784d2265a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTMtOS0xLTEtODY3MDk_855a6333-04a9-41ec-898e-547a4e835504"
      unitRef="usd">-131000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTMtMTUtMS0xLTg2NzA5_b1226f6b-92af-4a60-a022-4e1ac30772be"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="i8ab68b9957bd493da33d7c58f46e02a6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTQtNS0xLTEtODY3MDk_1750c0c3-7e47-44ad-90fe-b66a7df35d17"
      unitRef="usd">514000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="ifba43579460b45abb618bce784d2265a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTQtOS0xLTEtODY3MDk_7c94695f-3f85-449e-a919-55838f56dd38"
      unitRef="usd">2000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMTQtMTUtMS0xLTg2NzA5_b2fd2678-79f3-49d8-9f8a-7084bac3654a"
      unitRef="usd">516000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i57f104a5fe60467090a2d49a6f15319b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjAtNy0xLTEtODY3MDk_8613c943-d36b-4fa0-b5d7-da1db20b9800"
      unitRef="usd">47016000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjAtMTUtMS0xLTg2NzA5_7bb74688-efcc-466d-9338-afef5e103eb3"
      unitRef="usd">47016000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i9070db993da44bb4b9180949625e0bfe_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtMy0xLTEtODY3MDk_043a47e0-f6d7-42ab-9044-0f786a6ee83b"
      unitRef="usd">131000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i8ab68b9957bd493da33d7c58f46e02a6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtNS0xLTEtODY3MDk_74149101-fc3c-4a91-b559-e34f6bceb6fd"
      unitRef="usd">514000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="i57f104a5fe60467090a2d49a6f15319b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtNy0xLTEtODY3MDk_c186c2a8-3af1-4221-9d2e-13a2af31e127"
      unitRef="usd">47016000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="ifba43579460b45abb618bce784d2265a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtOS0xLTEtODY3MDk_58fa49a9-0e52-484d-89f5-37391f028532"
      unitRef="usd">-129000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjEtMTUtMS0xLTg2NzA5_3ff8b927-e6af-41f6-87d1-1a5de2b9b0f0"
      unitRef="usd">47532000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="ic08137b9d07d47458bd80e38918070fb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMy0xLTEtODY3MDk_1fd4a14b-6bd3-451f-b319-de0d12f3d336"
      unitRef="usd">6445000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ia00516d757c74b41ab5ec5b14024dbfd_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtNS0xLTEtODY3MDk_7f96b8e7-89cc-47e2-850c-09641f407d44"
      unitRef="usd">981570000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie6e3d0984c7640a6812965fc4399b0ab_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtNy0xLTEtODY3MDk_7eddb428-48fb-4890-9b7c-ce0682888c1a"
      unitRef="usd">89769000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i09effb3b4b9b463691f066e4f85ccde9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtOS0xLTEtODY3MDk_28db4813-c86a-407d-8c92-fe00f64fa595"
      unitRef="usd">-133000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i819688b0196b4f8180d3a454630743bf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMTEtMS0xLTg2NzA5_eb9ea806-71b0-45c6-bb83-e9564dccb52b"
      unitRef="usd">161000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="ie65cd89c7bf24557946ea885c4873749_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMTMtMS0xLTg2NzA5_97f8b33c-5043-4a61-8492-ff7ed0b9c7da"
      unitRef="usd">-890504000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMy9mcmFnOjlkOTIyZTVhZDJjNDRlMmY4YTg1NTVkYzBkNmYyOTgzL3RhYmxlOjA4Y2Q0NmQwZjU3MjQ1NmFiYzk0Zjc4NDk4MzU3ODJlL3RhYmxlcmFuZ2U6MDhjZDQ2ZDBmNTcyNDU2YWJjOTRmNzg0OTgzNTc4MmVfMjMtMTUtMS0xLTg2NzA5_577c71fe-8cbb-4823-9d4e-f491e0e52c00"
      unitRef="usd">187308000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMy0zLTEtMS04NjcwOQ_6c883aa2-fbce-493a-a0b3-1341fbaa5ea1"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMy01LTEtMS04NjcwOQ_dc5a8265-ba85-4fde-8c13-4576c78a77c0"
      unitRef="usd">-195645000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNS0zLTEtMS04NjcwOQ_7c19057c-2afb-4589-9c22-8f6a2f9e5035"
      unitRef="usd">41781000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNS01LTEtMS04NjcwOQ_1ba05789-2c19-4441-9b31-9757069ea229"
      unitRef="usd">47016000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNi0zLTEtMS04NjcwOQ_f0a133ae-4e62-484b-bb7c-6bfb26171842"
      unitRef="usd">2704000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNi01LTEtMS04NjcwOQ_f7d5d528-053d-47ee-ada6-6d7a44e8b070"
      unitRef="usd">0</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <adc:AdjustmentsForDepreciationExpensePropertyPlantAndEquipment
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNy0zLTEtMS04NjcwOQ_d2291f97-bc51-4ea7-a0cb-ef998c1b5e06"
      unitRef="usd">768000</adc:AdjustmentsForDepreciationExpensePropertyPlantAndEquipment>
    <adc:AdjustmentsForDepreciationExpensePropertyPlantAndEquipment
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNy01LTEtMS04NjcwOQ_7ecbfea3-cb0b-4203-a534-6e1007e54b94"
      unitRef="usd">581000</adc:AdjustmentsForDepreciationExpensePropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOC0zLTEtMS04NjcwOQ_9c7e7875-cbb0-4d21-ba7a-abe72fc03e5d"
      unitRef="usd">88000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOC01LTEtMS04NjcwOQ_248a1b19-7e89-4f41-9677-9027af747dd7"
      unitRef="usd">96000</ifrs-full:AdjustmentsForAmortisationExpense>
    <adc:AdjustmentsForDepreciationExpenseOfRightOfUseAssets
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOS0zLTEtMS04NjcwOQ_0c7073f9-22cb-486b-a582-f1cad4695d37"
      unitRef="usd">896000</adc:AdjustmentsForDepreciationExpenseOfRightOfUseAssets>
    <adc:AdjustmentsForDepreciationExpenseOfRightOfUseAssets
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfOS01LTEtMS04NjcwOQ_4f9cf747-6da1-4291-8d14-0526c44af7c4"
      unitRef="usd">1194000</adc:AdjustmentsForDepreciationExpenseOfRightOfUseAssets>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTAtMy0xLTEtODY3MDk_81c4781d-46d9-4117-afd3-955587e43b4c"
      unitRef="usd">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTAtNS0xLTEtODY3MDk_78f9c1f0-e473-409e-a08f-ac2f8eb23ddb"
      unitRef="usd">-7049000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTEtMy0xLTEtODY3MDk_c1bfe38b-70b0-45cf-bc90-220a5b28848c"
      unitRef="usd">-6549000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTEtNS0xLTEtODY3MDk_64dd917c-a7be-464f-99a6-f9db31279de0"
      unitRef="usd">-3906000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTItMy0xLTEtODY3MDk_ffa3dbf0-34e9-40c5-ab85-2c57a6cccd68"
      unitRef="usd">7550000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTItNS0xLTEtODY3MDk_59725019-145f-480b-9f0e-3dc568ad5c6f"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <adc:AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTMtMy0xLTEtODY3MDk_72ad332c-42b4-4166-a647-6e590aa614da"
      unitRef="usd">132000</adc:AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability>
    <adc:AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTMtNS0xLTEtODY3MDk_91a38704-f605-4152-a194-f1e6bec0edd4"
      unitRef="usd">235000</adc:AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTQtMy0xLTEtODY3MDk_1d00510a-0e3e-4d53-a557-0d8f306e613f"
      unitRef="usd">25650000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTQtNS0xLTEtODY3MDk_020afed9-da1a-4ef5-9b28-23991a6ae678"
      unitRef="usd">16279000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <adc:AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtMy0xLTEtOTA4ODA_14dbc923-8a85-45c4-8dc3-5b379e59a35b"
      unitRef="usd">11961000</adc:AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants>
    <adc:AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtNS0xLTEtOTA4ODA_6c183b91-c339-4174-b009-73fe2bcd0569"
      unitRef="usd">0</adc:AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtMy0xLTEtODY3MDk_53bfd35c-14b0-4afb-b6b1-e390817434a3"
      unitRef="usd">18597000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTUtNS0xLTEtODY3MDk_c4ae3f14-e1ae-41ed-b48c-5f50321fa3b1"
      unitRef="usd">46000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTYtMy0xLTEtODY3MDk_e6895bc0-f4a7-495d-80f6-2ee636069577"
      unitRef="usd">29230000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTYtNS0xLTEtODY3MDk_5e8fad53-af7a-418f-add9-1f6e945e8453"
      unitRef="usd">8650000</ifrs-full:AdjustmentsForFinanceCosts>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtMy0xLTEtOTkxMjU_6919b394-dc3c-48a8-ac4d-e03a231e1120"
      unitRef="usd">-42114000</adc:GainsLossOnExtinguishmentOfBorrowings>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtNS0xLTEtOTkxMjU_5e05f4a8-586b-4b67-a4e0-a10fd5edc212"
      unitRef="usd">0</adc:GainsLossOnExtinguishmentOfBorrowings>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTctMy0xLTEtODY3MDk_8ac5f676-91e4-4684-acd5-1ae60d69e458"
      unitRef="usd">-322000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTctNS0xLTEtODY3MDk_f399ddbf-3221-405c-946b-0f9d08a11da3"
      unitRef="usd">-311000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtMy0xLTEtODY3MDk_a6f5bcc9-3382-476a-a02a-7ded69990909"
      unitRef="usd">-71461000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMTgtNS0xLTEtODY3MDk_c26d10f5-ae1d-4e37-9023-c17e3b8c449f"
      unitRef="usd">-157652000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjAtMy0xLTEtODY3MDk_6e5c85de-2823-4945-a75e-18e74073108d"
      unitRef="usd">6936000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjAtNS0xLTEtODY3MDk_897d84b8-74e8-4c41-9743-e66b2bbeb6c4"
      unitRef="usd">-15896000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjEtMy0xLTEtODY3MDk_70f09bfc-ec8f-49b6-8bd0-4b528b92ec73"
      unitRef="usd">-6145000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjEtNS0xLTEtODY3MDk_69d54af1-ebfc-4eb9-aead-22be61ce5e83"
      unitRef="usd">-959000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjItMy0xLTEtODY3MDk_395fc023-ef1e-407a-a809-3dc81e05dede"
      unitRef="usd">489000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjItNS0xLTEtODY3MDk_01b935f4-02c4-44f0-8fd9-677c786db009"
      unitRef="usd">-3395000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjQtMy0xLTEtODY3MDk_efbb0491-47b7-4183-b588-f28d0fc0cb52"
      unitRef="usd">-411000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjQtNS0xLTEtODY3MDk_0b2f24c2-16e5-4048-b5a3-5449ea1a23cc"
      unitRef="usd">5055000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjUtMy0xLTEtODY3MDk_2d5d7b8f-9d4f-4399-bd46-ae35188b38d7"
      unitRef="usd">4722000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjUtNS0xLTEtODY3MDk_d2fb1d60-768f-43b4-bcce-c4996af43a2d"
      unitRef="usd">492000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjYtMy0xLTEtODY3MDk_63cc0423-a7a5-4dba-b7eb-b004eea16108"
      unitRef="usd">4681000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjYtNS0xLTEtODY3MDk_b5c0c74b-ef65-48e9-b45f-2f9765490311"
      unitRef="usd">4495000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjctMy0xLTEtODY3MDk_2653f84c-3830-4208-9056-8b31977f45e5"
      unitRef="usd">-61189000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjctNS0xLTEtODY3MDk_8e80b368-0115-427d-bac5-dfc4b1c56038"
      unitRef="usd">-167860000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjktMy0xLTEtODY3MDk_a1aadfcc-06f2-4244-9836-2b9dbb5ffca6"
      unitRef="usd">6924000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMjktNS0xLTEtODY3MDk_e00450b4-f259-40cc-8c37-0321134acdaf"
      unitRef="usd">3475000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzAtMy0xLTEtODY3MDk_ab6b2d7c-3d3d-487d-bfde-9562fd5be7f1"
      unitRef="usd">309000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzAtNS0xLTEtODY3MDk_62e98837-931d-46d0-8917-415a65eec08b"
      unitRef="usd">36000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzEtMy0xLTEtODY3MDk_92c26aa8-4fc8-4f28-bdd2-b486f6194309"
      unitRef="usd">144000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzEtNS0xLTEtODY3MDk_63c3442c-7ec2-457f-a9e8-c7693891dca4"
      unitRef="usd">170000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <adc:PaymentsMadeUnderRoyaltyFinancingTransactions
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzItMy0xLTEtODY3MDk_21e3b45c-1be2-4be8-a80e-a402ded16729"
      unitRef="usd">5656000</adc:PaymentsMadeUnderRoyaltyFinancingTransactions>
    <adc:PaymentsMadeUnderRoyaltyFinancingTransactions
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzItNS0xLTEtODY3MDk_09981e98-dc43-491d-be5d-72e1368891ea"
      unitRef="usd">0</adc:PaymentsMadeUnderRoyaltyFinancingTransactions>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzMtMy0xLTEtODY3MDk_4c8d396e-d7e8-442b-82b9-088dc0306a70"
      unitRef="usd">11381000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzMtNS0xLTEtODY3MDk_b28471c7-6aad-4f5e-b558-2f0c0e6fea1f"
      unitRef="usd">618000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzQtMy0xLTEtODY3MDk_40a9ed1d-635e-4b7b-b7d5-9f24d22f9765"
      unitRef="usd">-84697000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzQtNS0xLTEtODY3MDk_ded6a062-8f0b-4c39-ae2c-3f97aba8225d"
      unitRef="usd">-171747000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzctMy0xLTEtODY3MDk_cf856931-aaca-4cb4-88b9-346e0b250741"
      unitRef="usd">473000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzctNS0xLTEtODY3MDk_8475b6b5-c902-456f-89d8-c5abc3ba0485"
      unitRef="usd">3010000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzgtMy0xLTEtODY3MDk_eaf415c9-ffcb-4eb6-a439-8593e5ad0914"
      unitRef="usd">1708000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzgtNS0xLTEtODY3MDk_c285ac6f-d34e-4663-bf24-388c6421b0c1"
      unitRef="usd">2833000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <adc:PaymentForRentDeposits
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzktMy0xLTEtODY3MDk_56bfa934-f361-40ac-be93-218d4c65ffb4"
      unitRef="usd">210000</adc:PaymentForRentDeposits>
    <adc:PaymentForRentDeposits
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfMzktNS0xLTEtODY3MDk_3c12123b-7905-4c74-a812-6f5890619f1d"
      unitRef="usd">0</adc:PaymentForRentDeposits>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDAtMy0xLTEtODY3MDk_9238c757-e0b6-4fc4-82a6-7e214fe84aad"
      unitRef="usd">-2391000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDAtNS0xLTEtODY3MDk_06140de3-6a44-42b4-9fc7-f7cfa4319dba"
      unitRef="usd">-5843000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDQtMy0xLTEtODY3MDk_28af995a-b650-4456-b9dd-e022e2995a4b"
      unitRef="usd">114490000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDQtNS0xLTEtODY3MDk_1f98be85-bd4d-45c7-976c-9e5f262895c2"
      unitRef="usd">0</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtMy0xLTEtOTUwMTY_6c79c61f-1752-4af1-8e57-0846a46b6931"
      unitRef="usd">6192000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtNS0xLTEtOTUwMTY_780b0776-7e46-4ad6-aa7f-bce6305109b2"
      unitRef="usd">0</ifrs-full:ProceedsFromIssuingShares>
    <adc:ConvertibleLoansExchange
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtMy0xLTEtOTUwMTY_b8654fd1-039a-40de-9fae-e70fd4748113"
      unitRef="usd">118070000</adc:ConvertibleLoansExchange>
    <adc:ConvertibleLoansExchange
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtNS0xLTEtOTUwMTY_48983b34-c268-46b1-be2d-38d6935212b3"
      unitRef="usd">0</adc:ConvertibleLoansExchange>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDUtMy0xLTEtODY3MDk_66541b53-5211-4988-ba6b-7c2a42d30987"
      unitRef="usd">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDUtNS0xLTEtODY3MDk_cb6a6a99-db05-4a7b-b4d5-277d60805e55"
      unitRef="usd">49591000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <adc:ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtMy0xLTEtODY3MDk_2d515161-a866-4dd2-8f8c-e38eb265ca86"
      unitRef="usd">0</adc:ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts>
    <adc:ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDYtNS0xLTEtODY3MDk_5a061de7-d87f-431e-acaf-03c8eeb2f16e"
      unitRef="usd">219251000</adc:ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDctMy0xLTEtODY3MDk_235ca409-5723-482b-bd84-3a9303e86dbb"
      unitRef="usd">0</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDctNS0xLTEtODY3MDk_b240dec6-ad50-4b88-a3f6-1af8bcc83c35"
      unitRef="usd">516000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtMy0xLTEtODY3MDk_8e60178d-1500-4426-b4b7-777c81bdf37c"
      unitRef="usd">757000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDgtNS0xLTEtODY3MDk_e899ea0d-f6a1-4c7a-abfa-50e2fbb328c2"
      unitRef="usd">746000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDktMy0xLTEtODY3MDk_41b0a5b4-1cf6-40b2-ba92-468acd1bf4c4"
      unitRef="usd">1855000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNDktNS0xLTEtODY3MDk_735b89e7-e7ee-4c74-b19d-65db143d07e3"
      unitRef="usd">268612000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTEtMy0xLTEtODY3MDk_7d70e77b-97b4-4401-828f-7ab4fca57a3f"
      unitRef="usd">-85233000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTEtNS0xLTEtODY3MDk_765deed9-a3bf-473c-947c-1b37dde9a0b2"
      unitRef="usd">91022000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTItMy0xLTEtODY3MDk_9245548f-b33b-4dc3-968c-04e89dc96b3b"
      unitRef="usd">-451000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTItNS0xLTEtODY3MDk_d726abc7-deca-494b-92f1-05affd42aa60"
      unitRef="usd">-23000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTMtMy0xLTEtODY3MDk_158501b0-3c56-48a8-8a7b-feeb8d5a8120"
      unitRef="usd">466544000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTMtNS0xLTEtODY3MDk_3cefa338-3a15-42e4-8cc0-7249949a6cc4"
      unitRef="usd">439195000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTQtMy0xLTEtODY3MDk_8fbe6101-e87d-4d78-972a-40d2b9c50afd"
      unitRef="usd">380860000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTQtNS0xLTEtODY3MDk_01912548-ff79-47c7-94a3-4dd33b0d89a3"
      unitRef="usd">530194000</ifrs-full:CashAndCashEquivalents>
    <adc:IssuanceOfShares
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNjEtMy0xLTEtOTcwNjc_769bac1c-9a48-4aec-a493-df0381dd270e"
      unitRef="usd">19834000</adc:IssuanceOfShares>
    <adc:IssuanceOfShares
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNjEtNS0xLTEtOTcwNjc_7c4c2c17-dd55-4d30-a15e-710a91478a88"
      unitRef="usd">0</adc:IssuanceOfShares>
    <adc:FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtMy0xLTEtOTQ5NDY_0ec772bd-40ca-45bf-85fc-67fe4ae44cdc"
      unitRef="usd">2171000</adc:FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities>
    <adc:FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtNS0xLTEtOTQ5NDY_da015c09-17a8-4088-9fe6-41b55742c8c9"
      unitRef="usd">0</adc:FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities>
    <adc:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTctMy0xLTEtODY3MDk_2d678b78-9fdf-4926-be6b-6f27ce0ded4b"
      unitRef="usd">0</adc:CapitalExpendituresIncurredButNotYetPaid>
    <adc:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTctNS0xLTEtODY3MDk_fa1cd089-bb1c-4344-a43b-86e28c509439"
      unitRef="usd">455000</adc:CapitalExpendituresIncurredButNotYetPaid>
    <adc:AccountsPayableDeferredRoyaltyObligationTransactionCosts
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtMy0xLTEtODczMDQ_889d9e5f-3a7f-4f94-a585-60f820f11bd2"
      unitRef="usd">0</adc:AccountsPayableDeferredRoyaltyObligationTransactionCosts>
    <adc:AccountsPayableDeferredRoyaltyObligationTransactionCosts
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xOS9mcmFnOjA0NDRkNzAzM2VmZTRjOGU5YWEzN2UwZGExYjUxN2MyL3RhYmxlOjIzYzhmNzRhN2Y0YTQzMDRiMDVkNDYxNTFkZGMzYWM5L3RhYmxlcmFuZ2U6MjNjOGY3NGE3ZjRhNDMwNGIwNWQ0NjE1MWRkYzNhYzlfNTgtNS0xLTEtODcyOTY_a9505dc0-c029-47d4-a091-4c96ebb0ffe9"
      unitRef="usd">1248000</adc:AccountsPayableDeferredRoyaltyObligationTransactionCosts>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8yNS9mcmFnOjg3Y2Q2ZGNiMGI3MzRmNTNhZGYxMDkyY2Q4ZjI2NzUwL3RleHRyZWdpb246ODdjZDZkY2IwYjczNGY1M2FkZjEwOTJjZDhmMjY3NTBfMjY_1f17b1bb-676f-40c5-bb98-f9e7a58dc705">Corporate information&lt;div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ADC Therapeutics SA (the &#x201c;Company&#x201d; or &#x201c;ADCT&#x201d;) was incorporated on June 6, 2011 under the laws of Switzerland. The registered office of the Company is located at Route de la Corniche 3B, 1066 Epalinges, Switzerland. The Company controls three wholly-owned subsidiaries: ADC Therapeutics America, Inc. (&#x201c;ADCT America&#x201d;), which was incorporated in Delaware, USA on December 10, 2014, ADC Therapeutics (UK) Ltd (&#x201c;ADCT UK&#x201d;), which was incorporated in England on December 12, 2014 and ADC Therapeutics (NL) B.V. which was incorporated in the Netherlands on February 25, 2022. The Company and its three subsidiaries form the ADCT Group (the &#x201c;Group&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group is focused on the development and commercialization of antibody drug conjugates (&#x201c;ADCs&#x201d;), including research, development, human clinical trials, regulatory approval and commercialization. On April 23, 2021, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approved ZYNLONTA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (&#x201c;DLBCL&#x201d;) and the Company commenced recognizing revenue upon the sale of ZYNLONTA during the second quarter of 2021. ADCs are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill any cancer cell to which the ADC attaches. ADCs have extensive potential therapeutic applications in cancer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated interim financial statements were authorized for issue by the Board of Directors on November&#160;8, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Going concern basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ADCT is a commercial-stage company developing innovative therapeutics. The Group is exposed to all risks inherent in establishing and developing its business, including the substantial uncertainty that current projects will succeed. The Group&#x2019;s success may also depend on its ability to:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;establish and maintain a strong patent position and protection;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;develop, gain regulatory approval and commercialize drug products;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;enter into collaborations with partners in the pharmaceutical industry;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;acquire and retain key personnel; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;acquire additional funding to support its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its incorporation, the Group has primarily funded its growth through capital increases and additional funds provided by research collaborations, license agreements, the issuance of the Company&#x2019;s common shares, the issuance of convertible loans, the issuance of term loans and proceeds from a royalty purchase agreement. During the first quarter of 2022 and third quarter of 2022, the Company entered into exclusive license agreements with Mitsubishi Tanabe Pharma Corporation ("MTPC") and Swedish Orphan Biovitrum AB ("Sobi"), respectively, for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan and all territories outside the U.S., greater China, Singapore and Japan, respectively. During the third quarter of 2022, the Company drew down USD 120.0&#160;million principal amount of senior secured term loans, entered into an exchange agreement with Deerfield Partners, L.P., and Deerfield Private Design Fund IV, L.P. (collectively, &#x201c;Deerfield&#x201d;) and sold shares to Owl Rock Opportunistic Master Fund II, L.P. and OR Opportunistic DL (C), L.P. (the "Purchasers") under a share purchase agreement. See note 14, "Senior secured term loan facility and warrants", note 15, "Convertible loans" and note 17, "Equity" for further information. The Group does not have recourse to bank loans. As a result, the Group is not exposed to liquidity risk through requests for early repayment of loans, other than, pursuant to the senior secured term loan facility, it must maintain a balance of at least USD 60 million in cash and cash equivalents plus any accounts payable that are greater than ninety days old at the end of each quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Group&#x2019;s cash and cash equivalents amounted to USD 380.9 million (December&#160;31, 2021: USD 466.5 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the Group has sufficient resources to meet its financial obligations for at least the next 12 months from the date of issuance of these unaudited condensed consolidated interim financial statements and, as a result, is presenting these unaudited condensed consolidated interim financial statements of the Group on a going concern basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;COVID &#x2013; 19&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Group continues to monitor the COVID-19 pandemic and its impact to operations. The Group is commercializing ZYNLONTA using hybrid launch plans. The Company continued to see an increase in face-to-face interactions with physicians in the third quarter, which it believes is a key pillar of its continued success in driving the adoption of ZYNLONTA through ongoing dialogs with the healthcare provider community on ZYNLONTA's differentiated product profile. The Group is in close contact with its principal investigators and clinical sites, which are located in jurisdictions affected by the COVID-19 pandemic and is assessing the impact of the COVID-19 pandemic on its clinical trials, expected timelines and costs on an ongoing basis. In response to the spread of COVID-19, the Group has also modified its business practices based on local guidelines. At this time, Group employees are meeting with investigators and site staff in person as allowed by institutions. The Group continues to closely monitor the potential effects of the COVID-19 pandemic on its clinical trials, commercialization efforts and supply chain, and will work closely with its clinical trial sites and principal investigators, contract research organizations, customers and distributors and contract manufacturing partners to mitigate such impact. As the COVID-19 pandemic continues to evolve, the Group believes the impact to its operations, operating results, cash flows, liquidity and financial condition will be primarily driven by the severity and duration, the impact on the U.S. and global economies, the timing, the availability, and acceptance and effectiveness of vaccines and treatments, particularly against emerging variants of the novel coronavirus, and the scope and effectiveness of national and local governmental responses to the pandemic. Those primary drivers are beyond the Group&#x2019;s knowledge and control, and as a result, the ultimate impact of the COVID-19 pandemic on the Group's results of operations, cash flows and financial position for the remainder of 2022 and thereafter cannot be reasonably predicted. However, on the basis of the risk mitigation measures undertaken, the Group has concluded that there is no material uncertainty that may cast a significant doubt upon the Group&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior secured term loan facility and warrants, convertible loan exchange and share purchase&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, the Company, ADCT UK and ADCT America entered into a loan agreement and guaranty (the &#x201c;Loan Agreement&#x201d;) with certain affiliates and/or funds managed by each of Oaktree Capital Management, L.P. and Owl Rock Capital Advisors LLC, as lenders, and Owl Rock Opportunistic Master Fund I, L.P., as administrative agent and collateral agent, pursuant to which the Company may borrow up to USD 175.0&#160;million principal amount of secured term loans, including (i) an initial tranche of USD 120.0&#160;million principal amount of term loans (the &#x201c;First Tranche&#x201d;) and (ii) up to two additional tranches (&#x201c;Future Tranches&#x201d;), each up to USD 27.5&#160;million principal amount of term loans that the Company may draw upon before February 15, 2024, subject to satisfaction of certain customary conditions including compliance with the Company&#x2019;s other material agreements for the incurrence of such debt. On August 15, 2022, the Company drew down USD 120.0&#160;million principal amount of term loans under the Loan Agreement and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. See note 14, &#x201c;Senior secured term loan facility and warrants&#x201d; for further information on this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD 115.0&#160;million aggregate principal amount of the Company&#x2019;s senior secured convertible notes for warrants to purchase an aggregate of 4,412,840 common shares, an aggregate of 2,390,297 common shares and cash equal to USD 117.3&#160;million. The warrants consist of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share. As a result of the exchange agreement, the Company recognized a loss on extinguishment of USD 42.1 million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#x201c;Convertible loans,&#x201d; note 16, &#x201c;Deerfield warrants&#x201d; and note 17 &#x201c;Equity&#x201d; for further information on this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, the Company entered into a share purchase agreement with the Purchasers, pursuant to which, on September 6, 2022, the Company issued and sold to the Purchasers an aggregate of 733,568 common shares at USD 8.52 per share for USD 6.1&#160;million in net cash proceeds. See note 17, &#x201c;Equity&#x201d; for further information on this transaction.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <adc:NumberOfSubsidiaries
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8yOC9mcmFnOmRlYmE4ZmY1OTA3ZTQ0Mzg5OGM4MmZiZTA0Yjc3MDRkL3RleHRyZWdpb246ZGViYThmZjU5MDdlNDQzODk4YzgyZmJlMDRiNzcwNGRfMjQx_3d1089a8-3750-466c-bac3-317f1eb6ddb6"
      unitRef="subsidiary">3</adc:NumberOfSubsidiaries>
    <adc:NumberOfSubsidiaries
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8yOC9mcmFnOmRlYmE4ZmY1OTA3ZTQ0Mzg5OGM4MmZiZTA0Yjc3MDRkL3RleHRyZWdpb246ZGViYThmZjU5MDdlNDQzODk4YzgyZmJlMDRiNzcwNGRfNTkx_d9f4d1b5-bded-4c16-baf4-cad4f476ded8"
      unitRef="subsidiary">3</adc:NumberOfSubsidiaries>
    <ifrs-full:Borrowings
      contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMzg0ODI5MDcwMjEzMA_d5020953-a9e4-4ccc-9386-a5e4e974b235"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMTY0Mg_335b1877-ae32-43c5-86bf-da3af7f772c8"
      unitRef="usd">60000000</adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMTc2Ng_e135e8ef-a8b5-4406-a058-1b554d5786bc"
      unitRef="usd">380900000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNy9mcmFnOjk0MjU5N2U3NTc4MjRmZThiYjYzMWVhZmQzOTFlY2E2L3RleHRyZWdpb246OTQyNTk3ZTc1NzgyNGZlOGJiNjMxZWFmZDM5MWVjYTZfMTc4Ng_3c8d0f85-2b95-4bd1-b852-750fef462365"
      unitRef="usd">466500000</ifrs-full:CashAndCashEquivalents>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzEzMg_d9cc1dce-4106-45a7-98d5-e5a1e4ff82c5"
      unitRef="usd">175000000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="ie29ccfe5e9104ba781990be9d5a74c93_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE0Nw_ad3dfa24-850c-460c-8958-e60acb3ec8ca"
      unitRef="usd">120000000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="i417e476b63a34ff7a49e6530cd7b944c_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE3Nw_bf96bbea-3717-4997-8c06-62f1f3792864"
      unitRef="usd">27500000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <ifrs-full:Borrowings
      contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE2Mg_523691ac-1024-48b6-a95b-33802838b945"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <adc:ConvertibleNotesSharesConverted
      contextRef="i9e5a1305a7604d6e87bd11283adef044_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE5Nw_c356b854-8784-4249-a5c9-632f82023928"
      unitRef="shares">527295</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzE5MQ_b28f689c-9bd6-44a5-829c-ed123fccf09f"
      unitRef="usdPerShare">8.30</adc:WarrantsSharesConvertedExercisePrice>
    <adc:ExchangeOfConvertibleNotesForWarrants
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA5NQ_386d6bbb-52b2-46a7-84c2-cd127401e915"
      unitRef="usd">115000000</adc:ExchangeOfConvertibleNotesForWarrants>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA2Mg_04bcbe7b-5f27-4660-936e-13e79f4d10f7"
      unitRef="shares">4412840</adc:ConvertibleNotesSharesConverted>
    <adc:ConvertibleNotesSharesConverted
      contextRef="i474416e45737460d849fb01685ad11e6_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA3Mw_f300271e-3792-45ae-9d0e-5c80810c57ae"
      unitRef="shares">2390297</adc:ConvertibleNotesSharesConverted>
    <adc:ConvertibleNotesValueConverted
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzExMA_ec59f2b5-be86-4934-be54-7d7d5be1aee4"
      unitRef="usd">117300000</adc:ConvertibleNotesValueConverted>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzA4NA_a384a831-e090-49dd-b90a-3a6a5433cdbc"
      unitRef="shares">2631578</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="i7754055a3c2b48f1973108a8654c2f44_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzEyNQ_b2361d0a-c1b7-450b-9529-6aff4adf2df3"
      unitRef="usdPerShare">24.70</adc:WarrantsSharesConvertedExercisePrice>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIwNg_0a829778-ba3c-4543-a0ca-6a554d1bc8af"
      unitRef="shares">1781262</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIxNw_ccdaac7f-6ee3-419b-81ae-d443116a086a"
      unitRef="usdPerShare">28.07</adc:WarrantsSharesConvertedExercisePrice>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMTA5OTUxMTYzMzg3Ng_3d0c17a1-e3a2-4118-8dee-e500459b2618"
      unitRef="usd">-42100000</adc:GainsLossOnExtinguishmentOfBorrowings>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIyNA_2465515d-0a6a-4398-a2c3-c325dc9c2707"
      unitRef="shares">733568</ifrs-full:NumberOfSharesIssued>
    <adc:SaleOfStockPricePerShare
      contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIzMw_f2d80cc7-6796-49dc-bec7-4add247f70ef"
      unitRef="usdPerShare">8.52</adc:SaleOfStockPricePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ia6c9b855c1f247cdae6ad0bac21a2df8_D20220815-20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80MC9mcmFnOjI0MjNjY2I3NjVkZDRlOTRhNzE5MjhlOTdjYzY4YTcwL3RleHRyZWdpb246MjQyM2NjYjc2NWRkNGU5NGE3MTkyOGU5N2NjNjhhNzBfMzg0ODI5MDcwMzIzOQ_4bd758a3-117c-4312-bd0e-cc1c9dcdd4a3"
      unitRef="usd">6100000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMw_001548a4-dd13-4c74-b28e-0088604495a4">Basis of preparation&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statement of Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated interim financial statements as of and for the three and nine months ended September&#160;30, 2022 have been prepared in accordance with International Accounting Standard 34&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;IAS 34&#x201d;) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Functional and reporting currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated interim financial statements are presented in United States Dollars (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), which is the Company&#x2019;s functional currency and the Group&#x2019;s reporting currency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A subsidiary of the Company, ADCT UK, has a functional currency of the British Pound (&#x201c;GBP&#x201d;). The following exchange rates have been used for the translation of the financial statements of ADCT UK:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.805%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;USD / GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Closing rate, GBP 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.11348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.34593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Weighted average exchange rate, GBP 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.18746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.39209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated interim financial statements incorporate the financial statements of the Company and entities controlled by the Company which are the same as those contained in the audited consolidated financial statements as of and for the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;Use of estimates and judgements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are based on management&#x2019;s knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;As a result of increases in interest rates, the Company assessed the impact of utilizing a higher discount rate, 2.0%, in its most recent pension obligation actuarial valuation performed as of December 31, 2021. The use of a higher discount rate resulted in a decrease of KUSD 3.6&#160;million to its Defined benefit pension liabilities with a corresponding offset to Other comprehensive loss which was recorded during the second quarter of 2022. The reduction in its Defined benefit pension liability was capped at the fair value of the Company&#x2019;s pension plan assets. The Company expects to perform its annual actuarial valuation in conjunction with its fiscal year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#x2019;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December 31, 2021. There have been no material changes to the significant accounting policies other than those described in note 3, "Significant accounting policies". In addition, significant judgements were required in determining the fair value of the Company&#x2019;s warrant obligations as set out in note 14 &#x201c;Senior secured term loan facility and warrants&#x201d; and note 16 &#x201d;Deerfield warrants,&#x201d; including the selection of the valuation methodology to use, as well as determining the underlying valuation assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods prior to December 31, 2021, individual components of Non-operating (expense) income were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#x201c;Non-operating (expense) income&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share Subscription Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three-months ended September 30, 2022, the Company issued 3,123,865 common shares to ADCT America pursuant to a share subscription agreement and immediately repurchased these shares as treasury shares at par value. As described above, the Company subsequently issued 733,568 treasury shares to the Purchasers, in accordance with the share purchase agreement and 2,390,297 treasury shares to Deerfield in accordance with the exchange agreement entered into on August 15, 2022. See note 17, &#x201c;Equity&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxNA_34d991b4-1001-4c0a-94a3-cfd58de96926">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statement of Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated interim financial statements as of and for the three and nine months ended September&#160;30, 2022 have been prepared in accordance with International Accounting Standard 34&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;IAS 34&#x201d;) and should be read in conjunction with the audited consolidated financial statements as of and for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxNQ_a6b7684a-6e47-4321-98e3-d4b8c8a5c065">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Functional and reporting currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated interim financial statements are presented in United States Dollars (&#x201c;USD&#x201d; or &#x201c;$&#x201d;), which is the Company&#x2019;s functional currency and the Group&#x2019;s reporting currency.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMA_b71d0939-b914-4773-b8c2-510053d3ff68">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A subsidiary of the Company, ADCT UK, has a functional currency of the British Pound (&#x201c;GBP&#x201d;). The following exchange rates have been used for the translation of the financial statements of ADCT UK:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.805%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;USD / GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Closing rate, GBP 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.11348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.34593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Weighted average exchange rate, GBP 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.18746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.39209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfMy0xLTEtMS04NjcwOQ_09d529e8-0c02-47ab-87be-03e5cbc3e1d8"
      unitRef="usdPerGBP">1.11348</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfMy0zLTEtMS04NjcwOQ_ca5fe848-5f82-4c1a-a325-c606509c20da"
      unitRef="usdPerGBP">1.34593</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfNC0xLTEtMS04NjcwOQ_ac2b901e-5395-4fa8-894b-4747c87c7f0f"
      unitRef="usdPerGBP">1.18746</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RhYmxlOjBiNGJkMTA1ODBmYjQyNmM5NDNkNTI2MmU3YjRkY2U5L3RhYmxlcmFuZ2U6MGI0YmQxMDU4MGZiNDI2Yzk0M2Q1MjYyZTdiNGRjZTlfNC0zLTEtMS04NjcwOQ_9cba1711-9cfd-41d8-a673-bbe853b5bee1"
      unitRef="usdPerGBP">1.39209</ifrs-full:AverageForeignExchangeRate>
    <adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMQ_569b03e5-95cd-4796-a29c-0eb41268a53f">&lt;div style="margin-bottom:0.1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;Use of estimates and judgements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the unaudited condensed consolidated interim financial statements in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates are based on management&#x2019;s knowledge of current events and actions that the Company may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;As a result of increases in interest rates, the Company assessed the impact of utilizing a higher discount rate, 2.0%, in its most recent pension obligation actuarial valuation performed as of December 31, 2021. The use of a higher discount rate resulted in a decrease of KUSD 3.6&#160;million to its Defined benefit pension liabilities with a corresponding offset to Other comprehensive loss which was recorded during the second quarter of 2022. The reduction in its Defined benefit pension liability was capped at the fair value of the Company&#x2019;s pension plan assets. The Company expects to perform its annual actuarial valuation in conjunction with its fiscal year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;In preparing these unaudited condensed consolidated interim financial statements, the significant judgements made by management in applying the Group&#x2019;s accounting policies and the key sources of estimation uncertainty included those that applied to the consolidated financial statements for the year ended December 31, 2021. There have been no material changes to the significant accounting policies other than those described in note 3, "Significant accounting policies". In addition, significant judgements were required in determining the fair value of the Company&#x2019;s warrant obligations as set out in note 14 &#x201c;Senior secured term loan facility and warrants&#x201d; and note 16 &#x201d;Deerfield warrants,&#x201d; including the selection of the valuation methodology to use, as well as determining the underlying valuation assumptions.</adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock>
    <adc:PensionObligationDiscountRate
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMjA2MQ_3feedbdb-017d-4560-84fb-e5519024b199"
      unitRef="number">0.020</adc:PensionObligationDiscountRate>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMjIyMw_d12cc556-5277-43d9-9d5d-249cae7edc29"
      unitRef="usd">-3600000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <adc:DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzIxMg_2bc5371b-efb9-4554-9e32-3ba0bf086855">&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;Other income (expense)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods prior to December 31, 2021, individual components of Non-operating (expense) income were reported separately within the statement of operations. Prior periods have been recast to conform to the current period presentation. See Note 8, &#x201c;Non-operating (expense) income&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;</adc:DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i77985cac7eeb4add951edd6bccf0d37e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzg0ODI5MDcwMzMwMg_be9d11de-c33c-437d-ae04-a8c04a88fbc2"
      unitRef="shares">3123865</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="i196dad762149431fa1779f78c8388406_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzg0ODI5MDcwMzMxMw_c4302352-0457-4ca3-8087-0991a4b48431"
      unitRef="usd">733568</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="i914b59538ffb4aff97128d35a7aec14f_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80My9mcmFnOjI1Yjg2ZWQzMTNmZTRiN2Y4NTQ2ZjQxZmFlY2Y5YTJiL3RleHRyZWdpb246MjViODZlZDMxM2ZlNGI3Zjg1NDZmNDFmYWVjZjlhMmJfMzg0ODI5MDcwMzMyMg_2fffbe29-1b88-44d9-863b-70192eca4636"
      unitRef="usd">2390297</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfNDE3Mw_f4698a45-214a-4437-86b7-6091eecb64a8">Significant accounting policies&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies applied by the Company in these unaudited condensed consolidated interim financial statements are the same as those applied by the Company in its audited consolidated financial statements as of and for the year ended December&#160;31, 2021 and have been applied consistently to all periods presented in these unaudited condensed consolidated interim financial statements, except for the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Furthermore, on July 8, 2022, the Company entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. In previous years, the Company had generated revenue from the sale of its product candidates and service revenues from a license and collaboration arrangement. See note 5 &#x201c;License Revenue&#x201d; for further information on the MTPC and Sobi arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenues from license fees for intellectual property (IP) either at a point in time or over time. The Company must make an assessment as to whether such a license represents a right-to-use the IP (at a point in time) or a right to access the IP (over time). The Company recognizes revenue for a right-to-use license immediately if the licensee can begin to use and benefit from the IP upon commencement of the license term and the Company has no further obligations in the context of the IP. A license is considered a right to access the IP when the Company undertakes activities during the license term that may significantly affect the IP, which directly exposes the customer to any positive or negative effects arising from such activities. These activities do not result in the immediate transfer of a good or service to the customer. As such, revenues from the right to access the IP are recognized over time. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may enter into agreements with multiple performance obligations. Performance obligations are identified and separated when the other party can benefit from the license on its own or together with other resources that are readily available, and the license is separately identifiable from other goods or services in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction prices for out-license arrangements may include fixed up-front amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development and regulatory milestones because the ultimate outcomes are binary in nature. Variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price when sold separately or estimated stand-alone selling price on the basis of comparable transactions with other customers when such goods or services are not sold separately. The residual approach is the method used to estimate a stand-alone selling price when the selling price for a good or service is highly variable or uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction prices, sales milestones and royalties attributable to licenses are excluded from the variable consideration guidance and recognized at the later of when the subsequent sales transaction occurs, or the satisfaction or partial satisfaction of the performance obligation to which some or all of the royalty has been allocated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior secured term loan facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, ADCT UK and ADCT America entered into a USD 175.0&#160;million Loan Agreement on August 15, 2022, pursuant to which the counterparty agreed to extend secured term loans to the Company in disbursements as follows: (i) a First Tranche and (ii) Future Tranches. See note 14, &#x201c;Senior secured term loan facility and warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for the First Tranche &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, the Company drew down the First Tranche of the senior secured term loans in the amount of USD 120.0 million and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. These senior secured term loans have been &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized as a hybrid financial instrument and accounted for as two separate components: (i) a warrant obligation and (ii) a loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i)  The warrant obligation is presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value using a Black-Scholes pricing model and is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii) The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;senior secured term loan&#x2019;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the warrant obligation. The loan is subsequently measured at its amortized cost using an effective interest rate ("EIR") in accordance with IFRS 9. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. The revised EIR will be used prospectively with no income or expense recorded in the period of interest rate change. The loan is presented as a financial liability in the unaudited condensed consolidated interim balance sheet.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses and fees payable upon the issuance of the First Tranche of senior secured term loans were allocated pro rata to the above two components. The share of expenses allocated to the warrant obligation were charged directly to the unaudited condensed consolidated interim statement of operations, while the share of expenses allocated to the residual senior secured term loans was deducted from the loan and included in the calculation of the EIR.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for the Future Tranches &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no obligation to draw down the Future Tranches of the senior secured term loans. Therefore, the Company will account for the Future Tranches when drawn upon as a liability and subsequently measure the liability at amortized cost in accordance with IFRS 9. Transaction costs associated with the Future Tranches will be deducted from the loan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Deerfield Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The agreement consists of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These warrants have been recognized as a warrant obligation and presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value and was determined to approximate the fair value of the existing embedded conversion option features immediately prior to the consummation of the Exchange Agreement. The liability is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. See note 16, &#x201c;Deerfield Warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Employee Benefits - 2022 Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company adopted the 2022 Employee Stock Purchase Plan (&#x201c;2022 ESPP&#x201d;), which was approved by shareholders at the Company&#x2019;s 2022 Annual General Meeting. The Company will account for the 2022 ESPP similar to the Company&#x2019;s other share plans. The 2022 ESPP allows eligible employees to purchase designated shares of the Company's common shares at a discount, over a series of offering periods through accumulated payroll deductions. The Company will offer the ESPP to employees twice a year with each having a six-month offering period. The first offering period will generally be from January 1st through June 30th and the second offering period will be from July 1st through December 31st. The grant date is the first day of each offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of purchase rights granted under the 2022 ESPP is recognized as an employee share-based compensation expense with a corresponding increase in other reserves. The total amount to be expensed is determined by reference to the fair value of the purchase rights granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total expense is recognized over the offering period, which is the period over which all of the specified vesting conditions are to be satisfied. Participants that voluntarily withdrawal from the plan are accounted for as a cancellation and total share-based compensation recorded in the period in which the participant withdrawals. Terminations are accounted for as forfeitures and any share-based compensation expense reversed in the period the participant terminates. Accumulated payroll deductions are recorded within Accrued expenses in other current liabilities in the unaudited condensed consolidated interim balance sheet until shares are purchased by the participant at the end of the offering period. See note 18, &#x201c;Share-based compensation&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;New and amended IFRS standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2022, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, are not listed here.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg2MQ_b0572e10-6f1a-4af0-aa5e-138abcbc0195">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Furthermore, on July 8, 2022, the Company entered into an exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. In previous years, the Company had generated revenue from the sale of its product candidates and service revenues from a license and collaboration arrangement. See note 5 &#x201c;License Revenue&#x201d; for further information on the MTPC and Sobi arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenues from license fees for intellectual property (IP) either at a point in time or over time. The Company must make an assessment as to whether such a license represents a right-to-use the IP (at a point in time) or a right to access the IP (over time). The Company recognizes revenue for a right-to-use license immediately if the licensee can begin to use and benefit from the IP upon commencement of the license term and the Company has no further obligations in the context of the IP. A license is considered a right to access the IP when the Company undertakes activities during the license term that may significantly affect the IP, which directly exposes the customer to any positive or negative effects arising from such activities. These activities do not result in the immediate transfer of a good or service to the customer. As such, revenues from the right to access the IP are recognized over time. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may enter into agreements with multiple performance obligations. Performance obligations are identified and separated when the other party can benefit from the license on its own or together with other resources that are readily available, and the license is separately identifiable from other goods or services in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction prices for out-license arrangements may include fixed up-front amounts as well as variable consideration such as contingent development and regulatory milestones, sales-based milestones and royalties. The most likely amount method is used to estimate contingent development and regulatory milestones because the ultimate outcomes are binary in nature. Variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved. To the extent arrangements include multiple performance obligations that are separable, the transaction price assigned to each distinct performance obligation is reflective of the relative stand-alone selling price when sold separately or estimated stand-alone selling price on the basis of comparable transactions with other customers when such goods or services are not sold separately. The residual approach is the method used to estimate a stand-alone selling price when the selling price for a good or service is highly variable or uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction prices, sales milestones and royalties attributable to licenses are excluded from the variable consideration guidance and recognized at the later of when the subsequent sales transaction occurs, or the satisfaction or partial satisfaction of the performance obligation to which some or all of the royalty has been allocated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior secured term loan facility&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, ADCT UK and ADCT America entered into a USD 175.0&#160;million Loan Agreement on August 15, 2022, pursuant to which the counterparty agreed to extend secured term loans to the Company in disbursements as follows: (i) a First Tranche and (ii) Future Tranches. See note 14, &#x201c;Senior secured term loan facility and warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for the First Tranche &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, the Company drew down the First Tranche of the senior secured term loans in the amount of USD 120.0 million and issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. These senior secured term loans have been &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized as a hybrid financial instrument and accounted for as two separate components: (i) a warrant obligation and (ii) a loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i)  The warrant obligation is presented in the unaudited condensed consolidated interim balance sheet as a liability given the warrants may be settled through a cash or cashless exercise by the warrant holder. The liability was initially measured at fair value using a Black-Scholes pricing model and is subsequently remeasured to fair value at each reporting date. Changes in the fair value (gains or losses) of the warrant obligation at the end of each period are recorded in the unaudited condensed consolidated interim statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii) The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;senior secured term loan&#x2019;s initial fair value is the residual amount of the consideration received, net of attributable costs, after separating out the fair value of the warrant obligation. The loan is subsequently measured at its amortized cost using an effective interest rate ("EIR") in accordance with IFRS 9. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. The revised EIR will be used prospectively with no income or expense recorded in the period of interest rate change. The loan is presented as a financial liability in the unaudited condensed consolidated interim balance sheet.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses and fees payable upon the issuance of the First Tranche of senior secured term loans were allocated pro rata to the above two components. The share of expenses allocated to the warrant obligation were charged directly to the unaudited condensed consolidated interim statement of operations, while the share of expenses allocated to the residual senior secured term loans was deducted from the loan and included in the calculation of the EIR.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for the Future Tranches &lt;/span&gt;&lt;/div&gt;The Company has no obligation to draw down the Future Tranches of the senior secured term loans. Therefore, the Company will account for the Future Tranches when drawn upon as a liability and subsequently measure the liability at amortized cost in accordance with IFRS 9. Transaction costs associated with the Future Tranches will be deducted from the loan.</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMzg0ODI5MDcyMjYwNg_3bbb3c15-effe-4b56-98d3-815dbcd218e6"
      unitRef="usd">175000000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg2NA_2874c5cb-15b1-42b1-b514-28af6c58fe44"
      unitRef="shares">4412840</adc:ConvertibleNotesSharesConverted>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg4Ng_4b775825-7f70-4cfc-8b87-010512707a55"
      unitRef="shares">2631578</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="i7754055a3c2b48f1973108a8654c2f44_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1MjkwNA_bd6dd00d-37d4-422d-b468-0cc924f6110e"
      unitRef="usdPerShare">24.70</adc:WarrantsSharesConvertedExercisePrice>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg3NQ_0b90fc6d-964e-4b08-a6a3-aff005250305"
      unitRef="shares">1781262</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg5Nw_a7d1021c-4b1b-45a9-9b1b-79cca5072dad"
      unitRef="usdPerShare">28.07</adc:WarrantsSharesConvertedExercisePrice>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV80OS9mcmFnOjYyNjU0ZjBlMWM1MjQwYzY4NTU2N2UyMjA0NmY1OTM4L3RleHRyZWdpb246NjI2NTRmMGUxYzUyNDBjNjg1NTY3ZTIyMDQ2ZjU5MzhfMTA5OTUxMTY1Mjg2Mg_8dbde3b9-219a-4ef6-8125-d6b93e1c8da7">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;New and amended IFRS standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on January 1, 2022, that are relevant to the Group and that have had any impact in the interim period. New standards, amendments to standards and interpretations that are not yet effective, which have been deemed by the Group as currently not relevant, are not listed here.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81Mi9mcmFnOjg1ZTI1NTg2NmI3OTQxMzI5M2EyZDg1ZGMzMjQ1Yjk1L3RleHRyZWdpb246ODVlMjU1ODY2Yjc5NDEzMjkzYTJkODVkYzMyNDViOTVfNDUzOA_f8237557-fae0-4e45-84aa-90d89d5be3d9">Financial risk management&#160;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Financial risk factors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Group&#x2019;s activities are exposed to a variety of financial risks: market risk (including changes in the Company&#x2019;s share price, exposure to fluctuation in currency exchange rates and exposure to interest rate movements), credit risk and liquidity risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated interim financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group&#x2019;s consolidated financial statements as of December&#160;31, 2021. In relation to the royalty purchase agreement with entities managed by Healthcare Royalty Management, LLC ("HCR"), the Company is obligated to pay interest in the form of royalties in connection with certain net sales and licensing revenue. As the EIR on the deferred royalty obligation does not depend on market performance, the exposure to interest rate and market risk is deemed low. See note 19, &#x201c;Deferred royalty obligation&#x201d; for further information. In regards to the senior secured term loans, the interest rate is variable and dependent upon market factors. The Company will update the EIR at the end of each reporting period for changes in the rate. See note 14, "Senior secured term loan facility and warrants" for further information. A hypothetical 100 basis point increase (decrease) in the interest rate as of September 30, 2022 would have increased (decreased) the effective interest expense associated with the Company's senior secured term loan facility by KUSD 272 and (KUSD 273), respectively. There have been no other material changes in financial risk management since year-end.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Fair value estimation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the carrying amount is a reasonable approximation of fair value for the following financial assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12.53pt"&gt;Trade accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:12.53pt"&gt;Trade accounts payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the nine months ended September&#160;30, 2022, there were no significant changes in the business or economic circumstances that affected the fair value of the Group&#x2019;s financial assets and financial liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair values must be estimated at the end of each quarter with regard to the senior secured term loan warrant obligation and the Deerfield warrants. The approach to valuation follows the grant date fair value principle, and the key input factors are described for the senior secured term loan facility warrant obligation in note 14, "Senior secured term loan facility and warrants" and for the Deerfield warrants in note 16, "Deerfield warrants". Commonly accepted pricing models (Black-Scholes) have been used to calculate the fair values. The valuation of the senior secured term loan facility warrant obligation and Deerfield warrants are classified as pertaining to Level 2 of the valuation hierarchy. The convertible loan derivatives previously were classified as pertaining to Level 3 of the valuation hierarchy and were extinguished on August 15, 2022. See note 15, "Convertible loans" for further information. The Company no longer has any inputs pertaining to level 3 of the valuation hierarchy set out below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The different levels of the valuation hierarchy have been defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Level 2: inputs other than quoted prices that are observable for the asset or liability, either directly (for example, as prices) or indirectly (for example, derived from prices);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Level 3: inputs for the asset or liability that are not based on observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between the respective levels during the period.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues
      contextRef="iac01c43c0d9347968cf7c0f6d6589b05_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81Mi9mcmFnOjg1ZTI1NTg2NmI3OTQxMzI5M2EyZDg1ZGMzMjQ1Yjk1L3RleHRyZWdpb246ODVlMjU1ODY2Yjc5NDEzMjkzYTJkODVkYzMyNDViOTVfMTA5OTUxMTYzNzkwMQ_a1e1eac4-2978-439f-beb7-a34d261ec449"
      unitRef="usd">272000</adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues>
    <adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues
      contextRef="iac01c43c0d9347968cf7c0f6d6589b05_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81Mi9mcmFnOjg1ZTI1NTg2NmI3OTQxMzI5M2EyZDg1ZGMzMjQ1Yjk1L3RleHRyZWdpb246ODVlMjU1ODY2Yjc5NDEzMjkzYTJkODVkYzMyNDViOTVfMTA5OTUxMTYzNzkwNg_a8260d27-c22e-47a4-898e-2e243843fe62"
      unitRef="usd">273000</adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzgzOA_803e3922-7b5c-46b0-918d-84233e4ebaea">Revenue recognition&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 23, 2021, the Company received FDA accelerated regulatory and marketing approval for ZYNLONTA and launched in the U.S. shortly thereafter. To date, the Company&#x2019;s only source of product revenue, which commenced during May 2021, has been sales of ZYNLONTA in the U.S. Product revenues, net were KUSD 21,321 and KUSD 55,110 for the three and nine months ended September&#160;30, 2022, respectively. Product revenues, net were KUSD 13,147 and KUSD 16,907 for the three and nine months ended September&#160;30, 2021, respectively. The Company records its best estimate of gross-to-net ("GTN") sales adjustments to which customers are likely to be entitled. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a rollforward of the Company&#x2019;s accruals related to the GTN sales adjustments for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;GTN sales adjustments for current year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;GTN sales adjustments for prior year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Credits, payments and reclassifications to Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(9,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Ending balance as of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company&#x2019;s unaudited condensed consolidated interim balance sheet as of September&#160;30, 2022 and December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s inventory is no longer held on consignment by the Company&#x2019;s third-party logistics and distribution provider and as a result of receiving a permanent J-code for ZYNLONTA, the Company&#x2019;s payment terms currently range from 30 days to 90 days. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;License revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company entered into an exclusive license agreement with MTPC for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications in Japan. Under the terms of the agreement, the Company received an upfront payment of USD 30&#160;million and may receive up to an additional USD 205&#160;million in milestones if certain development and commercial events are achieved. The Company will also be entitled to receive royalties ranging in percentage from the high teens to the low twenties based on net sales of ZYNLONTA in Japan. MTPC will conduct clinical studies of ZYNLONTA in Japan and will have the right to participate in any global clinical studies by bearing a portion of the study costs. In addition, the Company will supply ZYNLONTA to MTPC for its drug development and commercialization under a supply agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 8, 2022, the Company entered into exclusive license agreement with Sobi for the development and commercialization of ZYNLONTA for all hematologic and solid tumor indications outside of the U.S., greater China, Singapore and Japan. Under the terms of the agreement, the Company received an upfront payment of USD 55&#160;million and is eligible to receive up to USD 382.5&#160;million in regulatory and net sales-based milestones, including USD 50&#160;million upon approval of a Marketing Authorisation Application by the European Commission for ZYNLONTA in third-line DLBCL. The Company will also receive royalties ranging in percentage from the mid-teens to the mid-twenties based on net sales of &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the product in Sobi&#x2019;s licensed territories, subject to certain adjustments. Sobi will also contribute 25 percent of clinical trial costs for select global ZYNLONTA trials, up to a cap of USD 10&#160;million per year. In addition, the Company has agreed to supply product to Sobi for its drug development and commercialization under a supply agreement which will be entered into.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MTPC and Sobi license arrangements are accounted for separately. Each agreement includes a license and a performance obligation to supply product. The license and supply obligations are accounted for as separate performance obligations as they are considered distinct because MTPC and Sobi can benefit from the licenses on their own or together with other resources that are readily available, and the licenses are separately identifiable from other goods or services in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company completed significant development work which resulted in FDA approval of ZYNLONTA in the U.S. for the treatment of relapsed or refractory DLBCL. As a result, the up-front license fees for both MTPC and Sobi are recognized immediately at the time of license execution, as MTPC and Sobi can use and benefit from the IP and the Company has no further performance obligation with respect to the IP upon commencement of the license terms. &lt;/span&gt;&lt;/div&gt;Although contingent development milestone amounts are assessed each period for the likelihood of achievement, they are typically constrained and recognized when the uncertainty is subsequently resolved for the full amount of the milestone and will be classified as license revenue. Sales milestones and royalties are recognized when the subsequent sales occur and classified as license revenue.</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ibf907986f9804ac79096e6421bac5248_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzUz_b789e6c1-b047-48c8-8996-a32b5f5e2158"
      unitRef="usd">21321000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i3c7edac15bd64992b9404d86947ee31e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzY1_00f42a76-6801-4bb5-9c40-353dbe0724c8"
      unitRef="usd">55110000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="ia10551f99c2f4f2cba09a2c4825b83fb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfNDQy_83c7c907-f77c-4e52-bf7b-715dfedc34e8"
      unitRef="usd">13147000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="i0adb4408d5b64d2eb32d81b113d64564_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfNTQ5NzU1ODE3NzY2_3e6591cb-beb5-4459-8caa-eabb1a167ef9"
      unitRef="usd">16907000</ifrs-full:RevenueFromContractsWithCustomers>
    <adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzgzOQ_a8d39557-539e-4c6d-9fc1-5eddf4c89a01">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a rollforward of the Company&#x2019;s accruals related to the GTN sales adjustments for the three and nine months ended September&#160;30, 2022 and September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;GTN sales adjustments for current year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;GTN sales adjustments for prior year sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Credits, payments and reclassifications to Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(9,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Ending balance as of September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,727&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock>
    <adc:GTNSalesAdjustment
      contextRef="ic28832b49da3403a8b557a594e965059_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy0yLTEtMS04NjcwOQ_f520c0d1-54d2-4966-8e83-7e256b4c8e24"
      unitRef="usd">3464000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i8a916c5c42b145e7ab29ea4d88cb1cff_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy00LTEtMS04NjcwOQ_099c85c2-da96-4a52-af4a-5d251be20ca0"
      unitRef="usd">730000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy02LTEtMS04NjcwOQ_31787f1a-d344-4cae-acb7-869005dd7d6a"
      unitRef="usd">2590000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfMy04LTEtMS04NjcwOQ_48af29de-3194-4b01-883c-ac6c40dd3133"
      unitRef="usd">0</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustmentProvision
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC0yLTEtMS04NjcwOQ_c93ccfe9-628e-4a8c-88cf-21a2e43d6da3"
      unitRef="usd">3706000</adc:GTNSalesAdjustmentProvision>
    <adc:GTNSalesAdjustmentProvision
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC00LTEtMS04NjcwOQ_e33178ff-02c9-4193-9d23-9109ec6eb4e7"
      unitRef="usd">2081000</adc:GTNSalesAdjustmentProvision>
    <adc:GTNSalesAdjustmentProvision
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC02LTEtMS04NjcwOQ_d30ffee4-4463-4ab1-8a0d-f294a301b582"
      unitRef="usd">10403000</adc:GTNSalesAdjustmentProvision>
    <adc:GTNSalesAdjustmentProvision
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNC04LTEtMS04NjcwOQ_8ad095a4-4f4d-441d-9420-6c4186d2c289"
      unitRef="usd">2833000</adc:GTNSalesAdjustmentProvision>
    <adc:GTNSalesAdjustmentProvisionPriorPeriodSales
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS0yLTEtMS04NjcwOQ_282c3772-7c7b-4204-b601-0d0104bcbcc7"
      unitRef="usd">-253000</adc:GTNSalesAdjustmentProvisionPriorPeriodSales>
    <adc:GTNSalesAdjustmentProvisionPriorPeriodSales
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS00LTEtMS04NjcwOQ_f30a8752-84d8-4b2a-a502-e2b18cc972dd"
      unitRef="usd">0</adc:GTNSalesAdjustmentProvisionPriorPeriodSales>
    <adc:GTNSalesAdjustmentProvisionPriorPeriodSales
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS02LTEtMS04NjcwOQ_c8c8b012-203d-465d-86e4-8a3ed9ec0f43"
      unitRef="usd">-358000</adc:GTNSalesAdjustmentProvisionPriorPeriodSales>
    <adc:GTNSalesAdjustmentProvisionPriorPeriodSales
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNS04LTEtMS04NjcwOQ_e6d48ea6-b096-427a-89c4-93bd536ec683"
      unitRef="usd">0</adc:GTNSalesAdjustmentProvisionPriorPeriodSales>
    <adc:GTNSalesAdjustmentCreditsAndPayments
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi0yLTEtMS04NjcwOQ_50547dac-dc7d-4458-9fab-a9086a3dd1df"
      unitRef="usd">-3624000</adc:GTNSalesAdjustmentCreditsAndPayments>
    <adc:GTNSalesAdjustmentCreditsAndPayments
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi00LTEtMS04NjcwOQ_20c17a3d-d29c-464c-b467-42c357ea7940"
      unitRef="usd">-84000</adc:GTNSalesAdjustmentCreditsAndPayments>
    <adc:GTNSalesAdjustmentCreditsAndPayments
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi02LTEtMS04NjcwOQ_2766fd0c-5a9a-4d0f-b897-fcff359e108b"
      unitRef="usd">-9342000</adc:GTNSalesAdjustmentCreditsAndPayments>
    <adc:GTNSalesAdjustmentCreditsAndPayments
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNi04LTEtMS04NjcwOQ_ea8665bf-323a-43d4-82b8-ea43da895fe8"
      unitRef="usd">-106000</adc:GTNSalesAdjustmentCreditsAndPayments>
    <adc:GTNSalesAdjustment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy0yLTEtMS04NjcwOQ_d4f65220-c5dd-41fc-a970-87b7261caa9d"
      unitRef="usd">3293000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy00LTEtMS04NjcwOQ_099655e7-3faf-46a3-8832-9dc4b5bba739"
      unitRef="usd">2727000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy02LTEtMS04NjcwOQ_91da36ad-f434-4188-8fe7-e5f87bd37430"
      unitRef="usd">3293000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOmRmNDAwYzY0YjBjZTRiMTU5OTE1NWVkNDEzM2ZiZmZmL3RhYmxlcmFuZ2U6ZGY0MDBjNjRiMGNlNGIxNTk5MTU1ZWQ0MTMzZmJmZmZfNy04LTEtMS04NjcwOQ_23009dfb-d2bc-4d33-8bb3-e1a06b88c676"
      unitRef="usd">2727000</adc:GTNSalesAdjustment>
    <adc:DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzg0MA_b71c32ac-d3ce-49d5-a0d9-c3f17e6da590">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides the classification of the accruals related to the GTN sales adjustment included in the Company&#x2019;s unaudited condensed consolidated interim balance sheet as of September&#160;30, 2022 and December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.138%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.644%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</adc:DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock>
    <adc:TradeAndOtherCurrentReceivablesSalesAdjustment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMS0yLTEtMS04NjcwOQ_cf619242-3195-476e-9b23-4526b050cbaa"
      unitRef="usd">1414000</adc:TradeAndOtherCurrentReceivablesSalesAdjustment>
    <adc:TradeAndOtherCurrentReceivablesSalesAdjustment
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMS00LTEtMS04NjcwOQ_b864a75c-5578-4b5d-9c29-2d0cfe741c67"
      unitRef="usd">1204000</adc:TradeAndOtherCurrentReceivablesSalesAdjustment>
    <adc:CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMi0yLTEtMS04NjcwOQ_4d0ad6da-18ef-43d5-9bf8-6eabd10a695b"
      unitRef="usd">1879000</adc:CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment>
    <adc:CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMi00LTEtMS04NjcwOQ_4c73fc6f-8e30-434b-b09b-b7a7f59f6025"
      unitRef="usd">1386000</adc:CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMy0yLTEtMS04NjcwOQ_637b8b8b-369c-453c-a541-559796f638bf"
      unitRef="usd">3293000</adc:GTNSalesAdjustment>
    <adc:GTNSalesAdjustment
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RhYmxlOjQ2Y2RkZjVmMDkzYTQzNTA4ZDQ3YmM3ODQzM2ZmODc4L3RhYmxlcmFuZ2U6NDZjZGRmNWYwOTNhNDM1MDhkNDdiYzc4NDMzZmY4NzhfMy00LTEtMS04NjcwOQ_f9c7af5b-0b25-4d27-bc1d-3f94c10857eb"
      unitRef="usd">2590000</adc:GTNSalesAdjustment>
    <adc:ProceedsFromLicenseAgreement
      contextRef="ib75271c7003f455ea3762473084eeb29_D20220118-20220118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTUxMQ_b896d4a0-3d94-4119-8315-1fc7557973e9"
      unitRef="usd">30000000</adc:ProceedsFromLicenseAgreement>
    <adc:LicenseAgreementMilestonePayments
      contextRef="ib75271c7003f455ea3762473084eeb29_D20220118-20220118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTU1NA_c869a3f9-949e-4239-8f56-1f8171e0e02a"
      unitRef="usd">205000000</adc:LicenseAgreementMilestonePayments>
    <adc:ProceedsFromLicenseAgreement
      contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTAyNg_56da93b3-3367-417c-b8b0-a0ed95c5fcff"
      unitRef="usd">55000000</adc:ProceedsFromLicenseAgreement>
    <adc:LicenseAgreementMilestonePayments
      contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTA1MA_0b37a5ef-a19c-4e54-98a8-38c48f6f263b"
      unitRef="usd">382500000</adc:LicenseAgreementMilestonePayments>
    <adc:LicenseAgreementMilestonePayments
      contextRef="i49f1b9c6855e4deba1fc15d4e267a2c3_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTAzOA_cd8ee883-768b-41ae-a506-f2f021c9afe9"
      unitRef="usd">50000000</adc:LicenseAgreementMilestonePayments>
    <adc:LicenseAgreementPercentOfClinicalTrialCostsPaid
      contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMzg0ODI5MDcxNDUxNw_0e63d672-b21e-4b73-8e7b-69e4ab2dd17c"
      unitRef="number">0.25</adc:LicenseAgreementPercentOfClinicalTrialCostsPaid>
    <adc:LicenseAgreementCappedContribution
      contextRef="i824c0207495f47f7832597cb71e67ea7_D20220701-20220731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV81OC9mcmFnOjJhM2MyNDQ0NmE2NzRhYzE5ZDgyNTQ1ODgxMjBiMzVmL3RleHRyZWdpb246MmEzYzI0NDQ2YTY3NGFjMTlkODI1NDU4ODEyMGIzNWZfMTA5OTUxMTY0NTA2NQ_324452d1-e679-4f30-8706-ef3c7bcbfc4f"
      unitRef="usd">10000000</adc:LicenseAgreementCappedContribution>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82MS9mcmFnOjVlNTI3OGMyODA5YzQ5OGI5OTdiZTEzMGIyN2UyNmRmL3RleHRyZWdpb246NWU1Mjc4YzI4MDljNDk4Yjk5N2JlMTMwYjI3ZTI2ZGZfMjg1_bda31e76-05f3-45c6-be0b-41d7f05681b8">Segment informationThe Company is managed and operated as one business. A single management team that reports to the chief executive officer comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one operating segment.</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <adc:NumberOfBusinessSegments
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82MS9mcmFnOjVlNTI3OGMyODA5YzQ5OGI5OTdiZTEzMGIyN2UyNmRmL3RleHRyZWdpb246NWU1Mjc4YzI4MDljNDk4Yjk5N2JlMTMwYjI3ZTI2ZGZfNjQ_ec91275d-002d-49a0-b1a6-c94b8b35f81b"
      unitRef="segment">1</adc:NumberOfBusinessSegments>
    <adc:NumberOfBusinessSegments
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82MS9mcmFnOjVlNTI3OGMyODA5YzQ5OGI5OTdiZTEzMGIyN2UyNmRmL3RleHRyZWdpb246NWU1Mjc4YzI4MDljNDk4Yjk5N2JlMTMwYjI3ZTI2ZGZfMjY1_ec91275d-002d-49a0-b1a6-c94b8b35f81b"
      unitRef="segment">1</adc:NumberOfBusinessSegments>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMjI5NA_f3575309-8ffa-4a93-9844-d1d8f1d23c08">Operating expense&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the unaudited condensed consolidated interim statement of operations classification of the Company's total operating expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;4,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;External costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;83,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;66,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Employee expense&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;17,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;55,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;49,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;41,676&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;36,805&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;139,165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;115,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;S&amp;amp;M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;18,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee expense&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;27,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;S&amp;amp;M expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;16,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;17,045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;52,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;46,177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External costs&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;18,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;11,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;38,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;38,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;G&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;19,617&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;16,587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;56,868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;53,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;79,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;70,939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;252,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;215,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes depreciation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes depreciation expense for Property, plant and equipment for the three and nine months ended September&#160;30, 2022. All other depreciation expense was not material for the three and nine months ended September&#160;30, 2022. All depreciation expense was not material for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The increase in Cost of product sales in the three and nine months ended September&#160;30, 2022, was primarily associated with USD 0.8&#160;million and USD 2.5&#160;million of impairment charges, respectively. The USD 0.8&#160;million of impairment charges was recorded during both the three months and nine months ended September 30, 2022 and was associated with inventory manufactured using the Company's existing process at a new facility that did not meet the Company's specifications. Additionally, impairment charges of USD 1.7&#160;million was recorded during the nine months ended September 30, 2022 and related to the manufacturing of antibodies that did not meet the Company's specifications. In addition, Cost of product sales during the nine months ended September&#160;30, 2022 increased due to a full nine months of sales activity in 2022 as compared to the same period in 2021 due to the commencement of ZYNLONTA sales in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;As a result of FDA approval of ZYNLONTA in April 2021, the Company reversed KUSD 7,049 of previously recorded impairment charges during the nine months ended September 30, 2021, relating to inventory costs incurred for the manufacture of product prior to FDA approval. R&amp;amp;D external costs increased primarily as a result of higher chemistry, manufacturing and controls ("CMC") expense due to manufacturing activities to support the ADCT-212 program during the three and nine months ended September 30, 2022 as well as our continued clinical trials to expand the potential market opportunities for ZYNLONTA in earlier lines of therapy, advance Cami to support a BLA submission and build our pipeline. Employee expense increased for the nine months ended September 30, 2022 primarily due to higher contract labor expenses, wages and benefits and share-based compensation expense.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in S&amp;amp;M expenses in the three months ended September&#160;30, 2022 was primarily due to lower employee expense due to lower share-based compensation expense. External costs increased for the three months ended September 30, 2022 primarily as a result of higher expenses relating to the commercial launch of ZYNLONTA. The increase in S&amp;amp;M expenses in the nine months ended September&#160;30, 2022 was primarily due to increased professional expenses relating to the commercial launch of ZYNLONTA. This increase during the nine months ended September 30, 2022 was partially offset by lower employee expenses primarily due to lower share-based compensation expense. &lt;/span&gt;&lt;/div&gt;The increase in G&amp;amp;A expenses in the three months ended September&#160;30, 2022 was primarily due to higher employee expenses primarily related to USD 1.3&#160;million of executive compensation associated with the CEO transition and higher share-based compensation expense. External costs for the three months ended September 30, 2022 was primarily due to higher professional expenses. The increase in G&amp;amp;A expenses in the nine months ended September 30, 2022 was primarily due to higher professional fees, including the fees associated with the license agreement entered into with MTPC. Employee expense for the nine months ended September&#160;30, 2022 remained virtually flat at USD 38.3&#160;million primarily as a result of lower share-based compensation expense offset by higher wages and benefits including USD 1.3&#160;million of executive compensation associated with the CEO transition.</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMjI5Mw_5930ef88-eb22-477a-889a-7a82bd8cb7c2">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the unaudited condensed consolidated interim statement of operations classification of the Company's total operating expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;Cost of product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;502&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;4,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;External costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;83,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;66,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Employee expense&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;17,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;55,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;49,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;41,676&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;36,805&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;139,165&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;115,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;S&amp;amp;M&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;18,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee expense&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;27,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;S&amp;amp;M expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;16,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;17,045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;52,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;46,177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%;text-decoration:underline"&gt;G&amp;amp;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;External costs&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;18,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;11,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;38,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;38,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;G&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;19,617&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;16,587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;56,868&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;53,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;79,435&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;70,939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;252,999&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;215,846&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes depreciation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes depreciation expense for Property, plant and equipment for the three and nine months ended September&#160;30, 2022. All other depreciation expense was not material for the three and nine months ended September&#160;30, 2022. All depreciation expense was not material for the three and nine months ended September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock>
    <ifrs-full:CostOfSales
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi0xLTEtMS04NjcwOQ_f01f878b-ffd7-437c-8196-4b0e0c37c69e"
      unitRef="usd">1295000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi0zLTEtMS04NjcwOQ_1c3ca29f-af4c-456d-a574-4345f127d0ed"
      unitRef="usd">502000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi01LTEtMS04NjcwOQ_648d9d3f-0ca4-4f37-8df5-30472cb83342"
      unitRef="usd">4090000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMi03LTEtMS04NjcwOQ_7b913f92-48fe-41e8-bc67-d1f80582bb2e"
      unitRef="usd">623000</ifrs-full:CostOfSales>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS0xLTEtMS04NjcwOQ_39253689-8b65-4e92-b772-0c333bb5b9b6"
      unitRef="usd">24363000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS0zLTEtMS04NjcwOQ_20a191ab-22ad-4443-a438-45437f9110e9"
      unitRef="usd">20041000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS01LTEtMS04NjcwOQ_64fef6d2-6151-4fbb-b196-d145365b6d7b"
      unitRef="usd">83706000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNS03LTEtMS04NjcwOQ_14ff698d-f25e-4523-9500-9ccd0a9b7bc0"
      unitRef="usd">66330000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi0xLTEtMS04NjcwOQ_96a68d28-ff1c-45f2-bf1f-5e14607885e0"
      unitRef="usd">17313000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i0531f2c694374cb1b481540b22706efe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi0zLTEtMS04NjcwOQ_44e53623-7882-4ef8-951c-ce6d4d8c197c"
      unitRef="usd">16764000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi01LTEtMS04NjcwOQ_e12f09a5-fb5b-4479-a100-ee4f68e23369"
      unitRef="usd">55459000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNi03LTEtMS04NjcwOQ_154d17c6-7dda-4a81-a881-0d12be56e73e"
      unitRef="usd">49180000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy0xLTEtMS04NjcwOQ_6495bd24-6fb7-43aa-a88e-9ab16765cefe"
      unitRef="usd">41676000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy0zLTEtMS04NjcwOQ_126746a4-e700-4bdd-beab-4d946b77963c"
      unitRef="usd">36805000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy01LTEtMS04NjcwOQ_2aab5ad7-3129-497a-8084-390b1240c58d"
      unitRef="usd">139165000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfNy03LTEtMS04NjcwOQ_be67834f-f78c-43e5-a905-773f5450a991"
      unitRef="usd">115510000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtMS0xLTEtODY3MDk_1499598f-4cf5-4f28-ab12-ec147a37fc27"
      unitRef="usd">8236000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtMy0xLTEtODY3MDk_129ba382-b0f2-4c8a-8b60-f228ad2b5c1a"
      unitRef="usd">7973000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtNS0xLTEtODY3MDk_3237c410-2eae-4893-af62-65ce79249148"
      unitRef="usd">26406000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTAtNy0xLTEtODY3MDk_595bd49d-6bf4-4135-8b9f-714470e88f71"
      unitRef="usd">18989000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtMS0xLTEtODY3MDk_7c4f3db2-dff3-4752-9028-09a190f7ebcd"
      unitRef="usd">8611000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i0531f2c694374cb1b481540b22706efe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtMy0xLTEtODY3MDk_62ca871a-dfaf-448b-ae10-cf4ee2fc0934"
      unitRef="usd">9072000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtNS0xLTEtODY3MDk_dea1fe0e-e903-42e5-9297-f4db4e5d84e1"
      unitRef="usd">26470000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTEtNy0xLTEtODY3MDk_f6ba2d47-9fb9-47be-a9cb-ebafc7584e7f"
      unitRef="usd">27188000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItMS0xLTEtODY3MDk_f4cc78a9-ebda-4210-b81d-7c19307592ad"
      unitRef="usd">16847000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItMy0xLTEtODY3MDk_7268cdf5-e40d-4e95-a239-c38626e635d1"
      unitRef="usd">17045000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItNS0xLTEtODY3MDk_f8a03e45-c40e-450b-b88b-4dbd92abc6ec"
      unitRef="usd">52876000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTItNy0xLTEtODY3MDk_090215b0-f782-4ae7-adc9-8eb32e0feb85"
      unitRef="usd">46177000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtMS0xLTEtODY3MDk_70258d49-8476-4080-bd47-5503805fe230"
      unitRef="usd">5020000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i40d7809f090647fcab8ce6268c36f734_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtMy0xLTEtODY3MDk_21783956-d439-4539-8baa-a3e3377f0920"
      unitRef="usd">4599000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i17ae2766be904dcd94c036a75e8a8522_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtNS0xLTEtODY3MDk_26e82753-0cde-446b-b34b-149b28ef0d08"
      unitRef="usd">18539000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ib47efea9779d4af78654a05b3e1f0e4e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTUtNy0xLTEtODY3MDk_51226808-bec0-4aa6-b859-f52577b17876"
      unitRef="usd">15204000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ie89f060cf9ad4796b9ae3d037c2b8f75_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtMS0xLTEtODY3MDk_f702d16f-0aa3-4f59-81f6-c281e8016f2e"
      unitRef="usd">14597000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i0531f2c694374cb1b481540b22706efe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtMy0xLTEtODY3MDk_12866360-abff-4313-bcac-7d37bb10970b"
      unitRef="usd">11988000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtNS0xLTEtODY3MDk_eeaca74f-4775-47c9-b5e1-69067c295b55"
      unitRef="usd">38329000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ib4101b8197aa46a4bde0efdf469880f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTYtNy0xLTEtODY3MDk_2b45d480-0ae5-4c14-bb7a-7fd9ddc49ea7"
      unitRef="usd">38332000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctMS0xLTEtODY3MDk_cfc3e9bb-9164-482b-9d4b-7d7464f196ac"
      unitRef="usd">19617000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctMy0xLTEtODY3MDk_02fec8fa-dfe7-4a22-94d7-db3b59644915"
      unitRef="usd">16587000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctNS0xLTEtODY3MDk_07a19b6a-1175-4a69-b87a-bdb0f2f647c4"
      unitRef="usd">56868000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTctNy0xLTEtODY3MDk_c033e798-9c46-4a3f-a918-b4ac09af6a7f"
      unitRef="usd">53536000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtMS0xLTEtODY3MDk_149250d1-749d-404b-b08a-7c7a3548a5ba"
      unitRef="usd">79435000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtMy0xLTEtODY3MDk_e5146acd-5333-4327-b455-643a3b2f882e"
      unitRef="usd">70939000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtNS0xLTEtODY3MDk_0db4136d-3384-4f4e-8573-8082b3ef42d0"
      unitRef="usd">252999000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RhYmxlOjIzZDZjOWMzOWVhZTRlNjhiYjBmOTI2ODBhZjQ1MTk4L3RhYmxlcmFuZ2U6MjNkNmM5YzM5ZWFlNGU2OGJiMGY5MjY4MGFmNDUxOThfMTgtNy0xLTEtODY3MDk_6040df27-f296-4771-afa4-46fd9df73cad"
      unitRef="usd">215846000</ifrs-full:OperatingExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="ie05957f8cf6440c0b15060319d7b1f2a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjc3OA_1ee076e9-6614-4fcc-8b13-e1a32869a714"
      unitRef="usd">800000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="i9c36d77e8cc54708a0792a5def59ba80_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjc5MQ_c5d41fd2-80e4-4e6a-a39a-6947aa2df4d5"
      unitRef="usd">2500000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="ie05957f8cf6440c0b15060319d7b1f2a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgwNA_3bf131e0-54ad-4838-9d7b-fbf12ded15fa"
      unitRef="usd">800000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgxNw_d1a7ae88-9b08-45f0-89a2-6b7d59e2e36b"
      unitRef="usd">1700000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgzMA_747ead8c-2a90-49cd-ba8f-08c23ce2a479"
      unitRef="usd">7049000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i589e24d9d8e0409fb5e40f80435eaa18_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjgzNw_da6f52e3-f79b-4c69-a595-7b2dec922dba"
      unitRef="usd">1300000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="ia26a24dc521c449eaa978b0303ff7ef7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjkyNw_d2dd54f1-1909-40d0-992a-490f746e4c83"
      unitRef="usd">38300000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="i589e24d9d8e0409fb5e40f80435eaa18_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV82Ny9mcmFnOjgzNTYwNzQ1ODViOTQxMGZiMDk1OTFhOTE1MjkyZWNmL3RleHRyZWdpb246ODM1NjA3NDU4NWI5NDEwZmIwOTU5MWE5MTUyOTJlY2ZfMTA5OTUxMTYzNjg1MA_eb749dae-033f-4c8d-921e-5979fbf3dee5"
      unitRef="usd">1300000</ifrs-full:GeneralAndAdministrativeExpense>
    <adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMjMxNA_0cc86bb1-24bf-448f-ac2b-31ff55acd24c">Non-operating (expense) income&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible loans, derivatives, change in fair value (expense) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(4,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;25,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible loans, derivatives, transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(42,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(42,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deerfield warrant obligation, change in fair value income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured term loan facility, warrants, transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured term loan facility, warrants, change in fair value income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share of results with joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(2,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(2,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange differences (loss) gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-operating income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(37,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(9,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(10,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;12,560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Convertible loans, derivatives, change in fair value (expense) income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in derivative fair values are explained in note 15, &#x201c;Convertible loans&#x201d;. Pursuant to the Facility Agreement with Deerfield, the Company drew down the Deerfield First Tranche of the convertible loans amounting to USD 65&#160;million on May 19, 2020. Additionally, in connection with the FDA approval of ZYNLONTA, the Company drew down the Deerfield Second Tranche of convertible loans amounting to USD 50&#160;million on May 17, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Convertible loans, derivatives, transaction costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The transaction costs associated with the embedded derivatives associated with the draw-down of the second tranche of the convertible loans on April 23, 2021 were charged directly to the unaudited condensed consolidated interim statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Loss on debt extinguishment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the exchange agreement, the Company recognized a loss on extinguishment, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date. See note 15, &#x201c;Convertible loans.&#x201d; for further information on this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deerfield warrant obligation, change in fair value income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to an exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The Deerfield warrant obligation has been recorded at its initial fair value and is remeasured to fair value on a quarterly basis. Changes in fair value of the Deerfield warrant obligation are explained in note 16, "Deerfield warrants".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Senior secured term loan facility, warrants, transaction costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The transaction costs associated with the warrants in connection with the August 15, 2022 Loan Agreement were charged directly to the unaudited condensed consolidated interim statement of operations. See note 14, "Senior secured term loan facility and warrants", for further information on this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior secured term loan facility, warrants, change in fair value income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for the First Tranche of the senior secured term loan and warrants as one hybrid financial instrument, with the USD 120&#160;million proceeds separated into two components: a warrant obligation and a loan. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrant obligation has been recorded at its initial fair value and is remeasured to fair value on a quarterly basis. Changes in fair value of the warrant obligation are explained in note 14, "Senior secured term loan facility and warrants".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:4.5pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Share of results with joint venture&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the formation of Overland ADCT BioPharma in December 2020, the Company recorded its proportionate share of Overland ADCT BioPharma&#x2019;s net loss. See note 12, &#x201c;Interest in joint venture&#x201d;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Exchange differences (loss) gain&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Also included in non-operating (expense) income are favorable or unfavorable Exchange differences. The Company is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to British pounds, Euros and Swiss francs. Exchange differences represent gain or (loss) based on favorable or unfavorable changes in foreign currencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;R&amp;amp;D tax credit (expense)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes as income (expense) amounts received and receivable by its subsidiary, ADCT UK, under the United Kingdom&#x2019;s R&amp;amp;D Expenditure Credit scheme (&#x201c;UK R&amp;amp;D Credit Scheme&#x201d;). The grants represent 12% of eligible expenditure. The claims are payable through the tax system, as a refund of corporation tax or of other taxes, including income tax and social security payments deducted at source from qualifying (research) employees&#x2019; payroll and VAT. The relevant amounts have been therefore presented net in the balance sheet. As the credit is independent of ADCT UK&#x2019;s taxable profit, is clearly designed to incentivize companies to invest in R&amp;amp;D activities and is itself taxable income, the Group has recognized the income as government grants within non-operating (expense) income and not as a credit to income tax expense.&lt;/span&gt;&lt;/div&gt;</adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock>
    <adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMjMxNQ_d0f04dfb-3e29-4146-a241-2e267f69ae86">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible loans, derivatives, change in fair value (expense) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(4,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;25,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible loans, derivatives, transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(42,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(42,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deerfield warrant obligation, change in fair value income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured term loan facility, warrants, transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured term loan facility, warrants, change in fair value income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share of results with joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(2,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(2,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange differences (loss) gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-operating income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(37,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(9,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(10,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;12,560&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi00LTEtMS04NjcwOQ_b9c17c8d-09ff-4190-b666-2eecbc651430"
      unitRef="usd">-4660000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi02LTEtMS04NjcwOQ_4f49ec46-2645-4196-a9b4-9eccbed455fa"
      unitRef="usd">-6943000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi04LTEtMS04NjcwOQ_3caddf01-9198-4c30-bbd8-ba313406a347"
      unitRef="usd">25650000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMi0xMC0xLTEtODY3MDk_494a5496-1151-47eb-8c82-16f36acce80b"
      unitRef="usd">16279000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <adc:BorrowingsDeferredFinancingCosts
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy00LTEtMS0xMDI3MzE_4472dec2-bde9-4324-b3b8-741f14980810"
      unitRef="usd">0</adc:BorrowingsDeferredFinancingCosts>
    <adc:BorrowingsDeferredFinancingCosts
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy02LTEtMS0xMDI3MzE_c6d81548-67ed-4fe1-85d0-f58ecf475603"
      unitRef="usd">0</adc:BorrowingsDeferredFinancingCosts>
    <adc:BorrowingsDeferredFinancingCosts
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy04LTEtMS0xMDI3MzE_1ee343a8-0b4e-450e-bf94-4f13de00f1f6"
      unitRef="usd">0</adc:BorrowingsDeferredFinancingCosts>
    <adc:BorrowingsDeferredFinancingCosts
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfMy0xMC0xLTEtMTAyNzI5_df781226-d842-4307-af77-42861bc04e13"
      unitRef="usd">-148000</adc:BorrowingsDeferredFinancingCosts>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC00LTEtMS05MzE0OQ_7b535a31-a86c-4822-a8de-43032d3c8a92"
      unitRef="usd">-42114000</adc:GainsLossOnExtinguishmentOfBorrowings>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC02LTEtMS0xMDI3MzE_b1507ba5-c726-499d-81d9-f62beeca16b0"
      unitRef="usd">0</adc:GainsLossOnExtinguishmentOfBorrowings>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC04LTEtMS05MzE2OA_e096f12b-b6dd-40bb-90d7-225087bbaaba"
      unitRef="usd">-42114000</adc:GainsLossOnExtinguishmentOfBorrowings>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC0xMC0xLTEtMTAyNzMx_948ee2b1-82f8-46af-aeb4-8d39b0479906"
      unitRef="usd">0</adc:GainsLossOnExtinguishmentOfBorrowings>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="i1269616118a045b48128c0d3db3063c8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS00LTEtMS05NjcwNw_1726621d-f265-49ca-bfa6-1d91d90a24b3"
      unitRef="usd">9418000</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="i2f5e11a889cb4519ad08ba38236480fd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS02LTEtMS05NjcwNw_30edaf2f-65a7-42af-80dd-8be95d003e90"
      unitRef="usd">0</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS04LTEtMS05NjcwNw_e7a9b90a-5833-4039-bfef-d24bbe40a786"
      unitRef="usd">9418000</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="i158d2be3e937431ea999c2367040412b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS0xMC0xLTEtOTY3MDc_2f2ab8d6-d8bd-4843-8f8f-2d6501141701"
      unitRef="usd">0</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:WarrantObligationsTransactionCosts
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi00LTEtMS0xMDI3MTk_6de486e3-9fe1-44c3-b9a9-95aa49cd60e2"
      unitRef="usd">-245000</adc:WarrantObligationsTransactionCosts>
    <adc:WarrantObligationsTransactionCosts
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi02LTEtMS0xMDI3MzE_c8bb43f3-67f8-4edf-b6c5-87f271ee37cd"
      unitRef="usd">0</adc:WarrantObligationsTransactionCosts>
    <adc:WarrantObligationsTransactionCosts
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi04LTEtMS0xMDI3Mjc_519e6fa6-6caf-406e-80a2-a7cae15389fa"
      unitRef="usd">-245000</adc:WarrantObligationsTransactionCosts>
    <adc:WarrantObligationsTransactionCosts
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi0xMC0xLTEtMTAyNzMx_7478efad-5091-4557-866e-f1cf34ab570d"
      unitRef="usd">0</adc:WarrantObligationsTransactionCosts>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="ia84b491c52c74ac69be308c96ea954a1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS00LTEtMS05MzIwNg_9827825a-5531-4596-8596-5f045ae10557"
      unitRef="usd">2543000</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="ife2c56e209614e089bacd12b15145e97_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi02LTEtMS05NjY2MA_26539283-66ac-444d-8708-8aea8070d2cd"
      unitRef="usd">0</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="ibcfcf3a44f2c4765be8da06698d39b1c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS04LTEtMS05MzI1MQ_90baa370-d401-48a5-994b-f68f16fea3e2"
      unitRef="usd">2543000</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="ifa06a2e32fd743d8a7b60007f9ae048d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi0xMC0xLTEtOTY2NjA_5a991655-b746-41a8-a477-cf3748d68d65"
      unitRef="usd">0</adc:GainsLossOnChangeInFairValueWarrants>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC00LTEtMS04NjcwOQ_43a332d5-8552-4923-a669-6e0725fa7ab1"
      unitRef="usd">-2130000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC02LTEtMS04NjcwOQ_bba98efe-a301-4bc0-a29a-880874de8400"
      unitRef="usd">-2210000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC04LTEtMS04NjcwOQ_808f1e75-ba00-4c2b-b6a6-842d6e230d31"
      unitRef="usd">-6549000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNC0xMC0xLTEtODY3MDk_0ff9a205-1967-4903-98e3-849100d1a9e3"
      unitRef="usd">-3906000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS00LTEtMS04NjcwOQ_d29daedd-6ee9-464f-bf09-525733a09440"
      unitRef="usd">-56000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS02LTEtMS04NjcwOQ_de66d476-73ce-494a-9a61-c4ef81815975"
      unitRef="usd">-7000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS04LTEtMS04NjcwOQ_87eab164-0070-4556-ba84-550d23db41d1"
      unitRef="usd">248000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNS0xMC0xLTEtODY3MDk_3d52065e-2b7a-46d5-841d-2d57034e99d7"
      unitRef="usd">145000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <adc:TaxEffectOfResearchAndDevelopmentTaxCredits
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi00LTEtMS04NjcwOQ_02616aee-c99b-458b-8382-fc779f99dae6"
      unitRef="usd">122000</adc:TaxEffectOfResearchAndDevelopmentTaxCredits>
    <adc:TaxEffectOfResearchAndDevelopmentTaxCredits
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi02LTEtMS04NjcwOQ_49de9302-ff4f-4e1d-a56c-02c2911c1128"
      unitRef="usd">-203000</adc:TaxEffectOfResearchAndDevelopmentTaxCredits>
    <adc:TaxEffectOfResearchAndDevelopmentTaxCredits
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi04LTEtMS04NjcwOQ_cec83d15-d1c3-414c-a282-154f0395a57a"
      unitRef="usd">244000</adc:TaxEffectOfResearchAndDevelopmentTaxCredits>
    <adc:TaxEffectOfResearchAndDevelopmentTaxCredits
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNi0xMC0xLTEtODY3MDk_b2e9c16d-81f4-4d35-ba3c-8d72c687f84e"
      unitRef="usd">190000</adc:TaxEffectOfResearchAndDevelopmentTaxCredits>
    <adc:NonOperatingIncomeExpense
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy00LTEtMS04NjcwOQ_707b6ac0-e1d5-4237-8966-b5ce469ef86f"
      unitRef="usd">-37122000</adc:NonOperatingIncomeExpense>
    <adc:NonOperatingIncomeExpense
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy02LTEtMS04NjcwOQ_15d9d7e2-a9c6-448f-8574-4d777017ef58"
      unitRef="usd">-9363000</adc:NonOperatingIncomeExpense>
    <adc:NonOperatingIncomeExpense
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy04LTEtMS04NjcwOQ_0516b2e7-a8b6-4fdb-a75f-85de04ba828a"
      unitRef="usd">-10805000</adc:NonOperatingIncomeExpense>
    <adc:NonOperatingIncomeExpense
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RhYmxlOjhiNTQ3MzVmZTE3NTQ4NWZiOTBhYTdlMTg1YzhkOTVkL3RhYmxlcmFuZ2U6OGI1NDczNWZlMTc1NDg1ZmI5MGFhN2UxODVjOGQ5NWRfNy0xMC0xLTEtODY3MDk_f80eb88d-3b49-449d-a9c5-6ebaee4ba311"
      unitRef="usd">12560000</adc:NonOperatingIncomeExpense>
    <ifrs-full:Borrowings
      contextRef="id5e033a22ecb478bb31362e9dd46dcbe_I20200519"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMzIz_af0ad6cc-179d-4032-a7fd-824b5e42096d"
      unitRef="usd">65000000</ifrs-full:Borrowings>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="idd6e0c7ae1fc42dabeef85f1e367666d_I20200424"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfNDg1_a1cc33e6-955f-45df-9e07-5f52df04e4b8"
      unitRef="usd">50000000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMTA5OTUxMTYzNTczNA_44bba8ab-b627-45ed-b1be-f777bd24dec9"
      unitRef="shares">4412840</adc:ConvertibleNotesSharesConverted>
    <ifrs-full:Borrowings
      contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV83MC9mcmFnOjM5MjM3OTRlZmQ5OTQxNDFiYjZiNGI5MWQyOGYxYmExL3RleHRyZWdpb246MzkyMzc5NGVmZDk5NDE0MWJiNmI0YjkxZDI4ZjFiYTFfMzg0ODI5MDcwNTMwOA_9bd22298-4c04-4c16-a3b6-e4dbc319e13f"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84Mi9mcmFnOjA1YTU0OWU1MmU3MTQ2NGE4MTlhZTI1YmU5OWI4YzA4L3RleHRyZWdpb246MDVhNTQ5ZTUyZTcxNDY0YTgxOWFlMjViZTk5YjhjMDhfNDA1_b543601d-63cf-4ce8-975a-31a981a04b45">Cash and cash equivalentsPursuant to the Loan Agreement entered into on August 15, 2022 (see note 14, &#x201c;Senior secured term loan facility and warrants&#x201d;), the Company is subject to a covenant that requires it to maintain a balance at the end of each quarter of at least USD 60&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the date of the original invoice.</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84Mi9mcmFnOjA1YTU0OWU1MmU3MTQ2NGE4MTlhZTI1YmU5OWI4YzA4L3RleHRyZWdpb246MDVhNTQ5ZTUyZTcxNDY0YTgxOWFlMjViZTk5YjhjMDhfNDA2_c307e039-29d4-48af-9820-86eef06e51e8"
      unitRef="usd">60000000</adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTE3NQ_13167e76-5032-4c65-90d6-3582ae922f4c">Inventory&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Finished goods &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;15,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Subsequent to December&#160;31, 2021, the Company's inventory is no longer held on consignment by the third-party logistics and distribution provider. Finished goods includes KUSD 3 relating to ZYNLONTA held on consignment by the Company&#x2019;s third-party logistics and distribution provider as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;For the nine months ended September 30, 2021, the Company recognized a gain from reversal of previously recorded impairment charges of KUSD 7,049 as a result of receiving FDA approval of ZYNLONTA in April 2021. The reversal of previously recorded impairment charges is based on the existence of inventory on hand and estimated demand, as well as expiration dating. For the nine months ended September&#160;30, 2022, the Company designated certain capitalized pre-approval ZYNLONTA inventory for R&amp;amp;D use and recorded a charge to R&amp;amp;D expenses, which was partially offset by a reversal of previously recorded impairment charges. The Company recorded an expense to R&amp;amp;D in the Company&#x2019;s unaudited condensed consolidated interim statement of operations for the three and nine months ended September&#160;30, 2022, of nil and KUSD 75 respectively.</ifrs-full:DisclosureOfInventoriesExplanatory>
    <adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTE3NA_3dfa1f86-6a70-49a5-a447-842d63502dae">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory as of September&#160;30, 2022 and December&#160;31, 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Finished goods &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;15,745&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,122&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Subsequent to December&#160;31, 2021, the Company's inventory is no longer held on consignment by the third-party logistics and distribution provider. Finished goods includes KUSD 3 relating to ZYNLONTA held on consignment by the Company&#x2019;s third-party logistics and distribution provider as of December&#160;31, 2021.</adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock>
    <ifrs-full:WorkInProgress
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMi0yLTEtMS04NjcwOQ_aa575a82-8a88-480b-a507-ab1ffd92f252"
      unitRef="usd">15407000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMi00LTEtMS04NjcwOQ_94d31c2c-18d6-4f0e-b5f2-e57e3cf58ada"
      unitRef="usd">10562000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMy0yLTEtMS04NjcwOQ_53b5d812-e64e-4129-aa60-6544b0d0a592"
      unitRef="usd">338000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfMy00LTEtMS04NjcwOQ_fc5a55af-6565-4538-952a-be5c7081868d"
      unitRef="usd">560000</ifrs-full:FinishedGoods>
    <ifrs-full:InventoriesTotal
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfNC0yLTEtMS04NjcwOQ_d9f50485-4f00-4cbb-b29e-90ccbc8555dc"
      unitRef="usd">15745000</ifrs-full:InventoriesTotal>
    <ifrs-full:InventoriesTotal
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RhYmxlOjgwZWRlMzIyMzFjNDQ5YjU5NzYxNWVhN2M3ZjlhNjExL3RhYmxlcmFuZ2U6ODBlZGUzMjIzMWM0NDliNTk3NjE1ZWE3YzdmOWE2MTFfNC00LTEtMS04NjcwOQ_1e621d19-90b9-4296-9caf-eb0ef95e58ce"
      unitRef="usd">11122000</ifrs-full:InventoriesTotal>
    <adc:CurrentFinishedGoodsHeldOnConsignment
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMjM3_05de1bc9-b236-49bf-8339-522b8588f533"
      unitRef="usd">3000</adc:CurrentFinishedGoodsHeldOnConsignment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfNDc2_978ccd51-705a-4ef2-90df-1400db539819"
      unitRef="usd">7049000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="i6f345e8135d943ddb82dfb8c7d312b08_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTA5OTUxMTYyOTUzMA_6d1d0e55-6056-432a-ae16-31ca9b5ff9eb"
      unitRef="usd">75000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories
      contextRef="i52142027ddf44c8eab013214816b70f1_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84NS9mcmFnOjkyNzc5ZGVjMzg4NTQzNTY5MjFhNWZmYmVhMDMxYzhmL3RleHRyZWdpb246OTI3NzlkZWMzODg1NDM1NjkyMWE1ZmZiZWEwMzFjOGZfMTA5OTUxMTYyOTUzMA_a49df772-3003-4b0c-bfaa-7635afe4ed7b"
      unitRef="usd">75000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMzM3NA_bfd9af89-552d-4e8b-9611-4bb2165036d5">Intangible assets&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Licenses classified as definite-lived intangible assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. The Company classifies its licenses relating to product candidates for which regulatory approval has not been received as indefinite-lived intangible assets and did not recognize amortization expense relating to these licenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internal development costs are classified as indefinite-lived intangible assets and are expected to be capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. The Company began to capitalize internal development costs for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYNLONTA as an internally generated intangible asset upon the FDA approval in the U.S. and if certain recognition criteria were met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022, the Company capitalized the following license fees paid or accrued to third parties as intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;An amount of KUSD 500 paid upon the dosing of a specific number of patients in the first in-human clinical study related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%;padding-left:14.5pt"&gt;An amount of KUSD 195 paid upon the successful completion of in-vivo efficacy studies related to a license with a third party to use their specific binding proteins in the development, manufacturing and commercialization of products. The amount was capitalized as an indefinite-lived intangible asset.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2021, the Company capitalized the following as intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%;text-decoration:underline"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2022;&#160;&#160;&#160;&#160;An amount of KUSD 1,050 paid upon the successful completion of a pre-clinical toxicology study and IND submission related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&#160;&#160;&#160;&#160;An amount of KUSD 600 paid upon final regulatory approval of ZYNLONTA related to a license agreement with a third party to use their technology to research, develop, manufacture and commercialize products. The amount was capitalized as a definite-lived intangible asset and will be amortized over its estimated useful life of 14 years based on the expected patent life, which includes an extension period that the Company believes is highly probable of being granted. This estimated useful life does not include additional patent protection that may be granted under applications filed but not yet approved other than the extension period discussed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;License Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&#160;&#160;&#160;&#160;An amount of KUSD 400 relating to a license agreement with a third party to use their proprietary conjugation technology to research, develop, manufacture and commercialize products. The amount was capitalized as an indefinite-lived intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&#160;&#160;&#160;&#160;An amount of KUSD 250 paid relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The table below provides a rollforward of the Company&#x2019;s intangible assets as of September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Definite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Internal development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;13,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Net book amount as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;12,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;954&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;946&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,598&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;11,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;11,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Net book amount as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;926&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;13,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i6898024e6a424206b1716d13c24b930b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMTMxMQ_e3c26561-9735-436d-8457-36d60b128be4"
      unitRef="usd">500000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i6510f05326e840eb9346f0cb3062ac1e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMTYzNA_e91032e9-0c48-4e60-866a-7ce121d80054"
      unitRef="usd">195000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ieea878441dfa4efc8a9b70801ddadd56_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMjA2Mw_b738d9c5-6450-4b9e-a18a-06fcd198aedd"
      unitRef="usd">1050000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i74f1e1d5ebdb414f9b5247864591ca9c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMjM4NQ_897bf47d-a410-43b2-b268-4b2ab8c7da7e"
      unitRef="usd">600000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill
      contextRef="i766d2e3cc1bf4d91a572ee7391121b0e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMjY5Mg_6f5df45e-6b79-4ff0-839c-115052720aee">P14Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i9cd70bd278774a99b8e19ac8da87c400_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMzA1Mw_801aa461-bf34-4be6-8b32-66c079399de6"
      unitRef="usd">250000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RleHRyZWdpb246MzM0NzUwMDExODhkNGU3YzliOGE2ZTYyNWY3ZDFmYmFfMzM3NQ_d02ef384-b0a9-4099-b245-48ff3b0f8ba3">below provides a rollforward of the Company&#x2019;s intangible assets as of September&#160;30, 2022 and 2021. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.172%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Indefinite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Definite lived&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Internal development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;13,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exchange differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Net book amount as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;12,611&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;954&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;946&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,598&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;11,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;11,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Net book amount as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;926&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;13,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ie3831a84c41e469fa75f28c8e4d66842_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi0xLTEtMS04NjcwOQ_6df7a681-49c2-4b30-8273-3b1dd6ff4458"
      unitRef="usd">12985000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ib0af6d42a54a4ea29ac6d823b1489254_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi0zLTEtMS04NjcwOQ_fa177e9b-785c-419b-a1bc-ec68e2658532"
      unitRef="usd">631000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id9911d0f78184a2082a9741569f80af9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi01LTEtMS04NjcwOQ_c1bd2559-206d-40a6-ad18-e7cc94152df9"
      unitRef="usd">1052000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i2f8c5ec28bf64c13b28d322cc15764ef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi03LTEtMS04NjcwOQ_9463c10a-eb4f-43d4-bf13-924db48be861"
      unitRef="usd">176000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="icf2aa78bd37e48d8afb1437f35585633_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMi05LTEtMS04NjcwOQ_c3b35428-a958-4a07-ac44-b660137343a1"
      unitRef="usd">14844000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i090393068e7e4ce2a9bf4269cb47d7aa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy0xLTEtMS04NjcwOQ_018e2b1a-7cb6-4fc8-a486-ab9b7fd29f26"
      unitRef="usd">695000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="id5fe126a6d63476e9d69e3a8dd0f33b0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy0zLTEtMS04NjcwOQ_2229ffee-07f0-42ba-853a-7cf00b86e484"
      unitRef="usd">323000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ie56be2cd7a6c41c7bcd4c44c05784db9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy01LTEtMS04NjcwOQ_a5d3901b-6e07-4e7c-9f2b-b0cecb5a4542"
      unitRef="usd">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i576b3e5ad10f4c98a00d3c16839a707c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy03LTEtMS04NjcwOQ_59abae2d-bbce-4213-a712-c399662d7634"
      unitRef="usd">97000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMy05LTEtMS04NjcwOQ_ca4a9065-2ae8-4c18-b707-ffabb4fe3848"
      unitRef="usd">1115000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i090393068e7e4ce2a9bf4269cb47d7aa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS0xLTEtMS04NjcwOQ_136dfc83-96e5-4ff5-82d5-2d94a39dc949"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="id5fe126a6d63476e9d69e3a8dd0f33b0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS0zLTEtMS04NjcwOQ_6b2c67df-3214-4efc-b444-597c30a15a0b"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="ie56be2cd7a6c41c7bcd4c44c05784db9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS01LTEtMS04NjcwOQ_cb2ed10f-228a-4ce3-8431-74406ccb1879"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i576b3e5ad10f4c98a00d3c16839a707c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS03LTEtMS04NjcwOQ_1825f932-ffdb-4dbe-aa46-66b6c8807ca8"
      unitRef="usd">-17000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNS05LTEtMS04NjcwOQ_e81e8a95-c1b2-4ceb-b49a-7f0b1bf18c66"
      unitRef="usd">-17000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i06c1a842a7a74eb19e9e9fb576dfa486_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi0xLTEtMS04NjcwOQ_072b7165-9514-4358-b7cd-beeb13a9182d"
      unitRef="usd">13680000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i0735d735202d4e8fa9fe0243e3d57875_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi0zLTEtMS04NjcwOQ_5f934586-ee42-4bec-bbd0-9a4bd5ed6ebf"
      unitRef="usd">954000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i03ecc9946c714265bbb8a89418c63c01_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi01LTEtMS04NjcwOQ_cc6a8b1a-e1fe-458a-af87-e023bfcbee9e"
      unitRef="usd">1052000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i6bd5f9550f6048c28bee5f1bfdd5d74d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi03LTEtMS04NjcwOQ_092171a8-3752-4f2d-88e9-40a209ca8d28"
      unitRef="usd">256000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i15b225beffa44b3d87f67b9e69f699fa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfNi05LTEtMS04NjcwOQ_f66b0d6c-0ecc-4f7b-9c82-886b9ae2fad9"
      unitRef="usd">15942000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i8151bd1bc2a04b71adee09c08447999a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS0xLTEtMS04NjcwOQ_b4017615-0688-47d5-9854-aafc50e0a5f3"
      unitRef="usd">-1069000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i1b0a40aaa46242f9b8c656439b48a32c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS0zLTEtMS04NjcwOQ_2475ec33-6a94-4cc1-80c3-09f24bf5b47e"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id6029eb697ae4501b1bce9cb044843bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS01LTEtMS04NjcwOQ_e94199d6-343e-4b61-b5be-f37bacd06896"
      unitRef="usd">-50000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ide8f1760047640c38a5d3005f9bc6157_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS03LTEtMS04NjcwOQ_11040e23-c05c-4b16-accf-befef1ba271a"
      unitRef="usd">-143000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id32707d201834dc793295ca00533da1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfOS05LTEtMS04NjcwOQ_4a8a6647-329b-4550-a4e3-1712ada49b99"
      unitRef="usd">-1262000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i5c4fdcd15f36441b91d6a6497571a82b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtMS0xLTEtODY3MDk_236abee1-538a-459d-bdf4-45ed72554956"
      unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i69b42fc0ddec473598e886ec0f5e3c9b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtMy0xLTEtODY3MDk_6d27c612-36e4-4f2a-a405-e3b30b761e77"
      unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i0bd15bcdf0a64b5898e159fda31b9d99_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtNS0xLTEtODY3MDk_fa75c7bd-fee8-4e53-b104-14067ed7d259"
      unitRef="usd">56000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i85b68b5b42e242f1985aa0054fda3aaa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtNy0xLTEtODY3MDk_ac46f4ee-dcf4-44b5-98c9-f82c642dfd6a"
      unitRef="usd">32000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTAtOS0xLTEtODY3MDk_fb0e4d1e-88a5-430a-8cc4-8b703fde8397"
      unitRef="usd">88000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i5c4fdcd15f36441b91d6a6497571a82b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtMS0xLTEtODY3MDk_ad03b7df-82b8-493b-b76e-18ed10e14ca9"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i0bd15bcdf0a64b5898e159fda31b9d99_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtNS0xLTEtODY3MDk_6c9a3d9a-2238-47a1-9d8f-bdeae923d9bb"
      unitRef="usd">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="i85b68b5b42e242f1985aa0054fda3aaa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtNy0xLTEtODY3MDk_479b8352-8002-4f09-855d-7f40d0ab4adf"
      unitRef="usd">-6000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTEtOS0xLTEtODY3MDk_772b43d1-4b24-4fef-ba91-1eec72b2691f"
      unitRef="usd">-6000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="if3ffc2c26d6241199c0010549c56f460_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItMS0xLTEtODY3MDk_b5c28669-cf80-4700-b57f-eb739de11671"
      unitRef="usd">-1069000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i5cb5c39e47594c269f24f5e7a5544869_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItMy0xLTEtODY3MDk_d3fea46b-1cc2-4eb1-8161-2cafcf566ccf"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i83b175bbb0a9439e8c3c4647daa448dc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItNS0xLTEtODY3MDk_2cab843b-4bf5-4b8c-bb4d-6a8f34544409"
      unitRef="usd">-106000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i1870dc5d8b164d9ebd63b4021e920cd6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItNy0xLTEtODY3MDk_49d0c68b-b8bb-4947-8964-c6ba840c6c63"
      unitRef="usd">-169000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i9da30f3755c743e08b48e072dc09209d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTItOS0xLTEtODY3MDk_1c86f9ec-911a-4873-a3c6-ab0f5c28f77e"
      unitRef="usd">-1344000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i06eae1c2401f49908e95968065439f57_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtMS0xLTEtODY3MDk_57919932-2acc-4afd-8abf-fbe4f86b841f"
      unitRef="usd">12611000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i23ac58a635804353bcd123924428ff13_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtMy0xLTEtODY3MDk_6e880307-7bde-4198-b118-9caa05dee46b"
      unitRef="usd">954000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i2f3dddcfe8e2427c8d4ff2eee0c6350f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtNS0xLTEtODY3MDk_85e7a4b1-88ca-47a5-b47a-a1446ff6051c"
      unitRef="usd">946000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i668c47e9660643d9a0bc7afaf9b7bc1a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtNy0xLTEtODY3MDk_13c5fbc8-1027-4464-8911-5a3b62ab3656"
      unitRef="usd">87000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTQtOS0xLTEtODY3MDk_5f5b4974-b432-429f-b329-4de8cd975ce9"
      unitRef="usd">14598000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i2e692aa8462f4f09aaf7e7b3b896724f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctMS0xLTEtODY3MDk_1eb0576d-9914-4284-b8ed-6a15d9696515"
      unitRef="usd">11144000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="id2450f8f780347a6b493d4432cbc51da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctMy0xLTEtODY3MDk_e3b607e9-bf1d-44d8-ad49-b2628d31353e"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i7e3cf7b0b5824c3fbf851545e1194289_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctNS0xLTEtODY3MDk_52a116c0-2e9d-49fd-ad32-c94efd0eb16d"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i8bc4fa9f79eb4710ae4034d037363f25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctNy0xLTEtODY3MDk_4dd0827a-e9f4-4372-b890-96f86dd8d10b"
      unitRef="usd">168000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i35cab614c8934a419edc6f7cccb644a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTctOS0xLTEtODY3MDk_77ff1318-a02b-41e2-a422-be4260f25081"
      unitRef="usd">11312000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i335db87da9ad4f00b7b7b94870fddfb6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtMS0xLTEtODY3MDk_1036fdb8-9609-4e73-8ad2-663443f84d8f"
      unitRef="usd">1700000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ibe0468c473d542f88ffed8e8f6fa3499_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtMy0xLTEtODY3MDk_1b98e491-b4fa-43fc-9f79-e8259cbfa922"
      unitRef="usd">926000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i1fae3e626a164280b7a488b6bde2fb6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtNS0xLTEtODY3MDk_5d7c16c4-f0a2-4449-adb9-60de91a38f10"
      unitRef="usd">600000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="i50390a1027184daa809325bb39041f9e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtNy0xLTEtODY3MDk_543cfcdc-5e23-47ce-bd98-a17cc2a7030e"
      unitRef="usd">14000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTgtOS0xLTEtODY3MDk_ebfb9a51-97a0-4798-8a24-69a181d69255"
      unitRef="usd">3240000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <adc:TransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i335db87da9ad4f00b7b7b94870fddfb6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktMS0xLTEtODY3MDk_fea3a548-7420-4792-98ec-1fde105d274f"
      unitRef="usd">-452000</adc:TransfersIntangibleAssetsOtherThanGoodwill>
    <adc:TransfersIntangibleAssetsOtherThanGoodwill
      contextRef="ibe0468c473d542f88ffed8e8f6fa3499_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktMy0xLTEtODY3MDk_3b6b454e-91ad-4ae7-ad88-8a47d780320b"
      unitRef="usd">0</adc:TransfersIntangibleAssetsOtherThanGoodwill>
    <adc:TransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i1fae3e626a164280b7a488b6bde2fb6b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktNS0xLTEtODY3MDk_03bb2c07-1dac-49e1-90a8-79558648b01c"
      unitRef="usd">452000</adc:TransfersIntangibleAssetsOtherThanGoodwill>
    <adc:TransfersIntangibleAssetsOtherThanGoodwill
      contextRef="i50390a1027184daa809325bb39041f9e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktNy0xLTEtODY3MDk_786108c0-0326-4122-9db3-7a093f59fef0"
      unitRef="usd">-6000</adc:TransfersIntangibleAssetsOtherThanGoodwill>
    <adc:TransfersIntangibleAssetsOtherThanGoodwill
      contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMTktOS0xLTEtODY3MDk_0e7e2b68-c0b8-4717-a768-9f9ee0e86884"
      unitRef="usd">-6000</adc:TransfersIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i7bfcb651885a4be4a64db35b2e3b0dfe_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtMS0xLTEtODY3MDk_8167d9ed-16aa-4b7f-94c6-fe38a8e4d1da"
      unitRef="usd">12392000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i334c4a99388b47a7ab36175bbe1622f3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtMy0xLTEtODY3MDk_997cf641-7522-43d3-a85b-6898f60cac5b"
      unitRef="usd">926000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ifde88f7e0bcd430389cd38d465e25601_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtNS0xLTEtODY3MDk_65b10a0b-2db5-46a3-a844-f3c658d8b028"
      unitRef="usd">1052000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i18ce56a8c03a4b7889fd8e92506bdba4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtNy0xLTEtODY3MDk_21ae7837-ddec-45de-ab69-b8042a9b06af"
      unitRef="usd">176000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i244793ab5a7249738bab95a309aaad60_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjEtOS0xLTEtODY3MDk_d97b8eb3-0413-44ee-994e-b1ea259835b6"
      unitRef="usd">14546000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i8d06ca9dbb9943bf87caccfc0bdd279c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtMS0xLTEtODY3MDk_5d74f029-4332-428c-ad5d-a95a7ccb5248"
      unitRef="usd">-1069000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="if0dfcc8b323e454089332943aea91f52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtMy0xLTEtODY3MDk_c1e6e2b7-2514-4998-887c-687d87d3c2ab"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i0721e1ef08f74225930b348ccc978392_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtNS0xLTEtODY3MDk_96cdb53d-15b3-4b4c-a472-a23091b61911"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i3456ecf300704b57b6adcd05b7963d67_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtNy0xLTEtODY3MDk_c19efa4f-b639-479f-b0df-65bc39046911"
      unitRef="usd">-64000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i792cccf378ee4050923e53f4a38c7136_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjQtOS0xLTEtODY3MDk_044bb523-a502-48a3-8e4c-5fc1e14dacd9"
      unitRef="usd">-1133000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i68593cdfc71c4bbd922f69c3283cf601_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtMS0xLTEtODY3MDk_f5425c50-246f-41f8-808e-968034b5e162"
      unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i31cbfc1404b44ac995974a2da34c1713_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtMy0xLTEtODY3MDk_4c4de9cc-47a7-4371-a543-0b6e591d3aad"
      unitRef="usd">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="ia197fa03b4e0485c894377210f9a37ae_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtNS0xLTEtODY3MDk_275bd3dc-5c5d-4cac-9def-1db31590194e"
      unitRef="usd">31000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="if7a6a0f0a03341b7a23b2a47027ce477_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtNy0xLTEtODY3MDk_d90921b2-f977-4e71-9a41-69d904af8da8"
      unitRef="usd">65000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjUtOS0xLTEtODY3MDk_d4677b7b-708d-45de-8f15-28a87be3d58b"
      unitRef="usd">96000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ia441c664cd094fa08cfec8c6325f59c0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtMS0xLTEtODY3MDk_dbad6b77-e845-4aa2-ba96-87146cf14151"
      unitRef="usd">-1069000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i3f566215e8c446edbf6ba6023c4a6697_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtMy0xLTEtODY3MDk_5915a1f7-c552-4a6a-a0d6-0974aa6e822a"
      unitRef="usd">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i1fe02702964a4fedba3bbd1c9e2ed7a0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtNS0xLTEtODY3MDk_ee05c889-a53a-4ab1-9dc6-3cf2112fd13f"
      unitRef="usd">-31000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i93a88ce2c37e481c91710d8d7e711e27_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtNy0xLTEtODY3MDk_32b4070c-3066-4761-8ecc-475a54d3f636"
      unitRef="usd">-130000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i6a7ddc9b4e1e4c0f82705cfe7c527db7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMjgtOS0xLTEtODY3MDk_fd47c10d-4480-49e5-91bc-163fa08a2dc1"
      unitRef="usd">-1230000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i328297d89f3241aa834368d0776dfb39_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtMS0xLTEtODY3MDk_1cab2364-5ec1-47ad-ad99-8a9246c0fbc2"
      unitRef="usd">11323000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i37ad95fb7fdc49e69f2db1a90d8872e9_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtMy0xLTEtODY3MDk_94e70ad2-e00e-44d1-8ead-4168b5bb9776"
      unitRef="usd">926000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="ib728077ca1d24854ad85579c7c79d6de_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtNS0xLTEtODY3MDk_83c7b094-bda9-4678-b590-91e0a5359c3e"
      unitRef="usd">1021000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i72ecf67eda5b4214b2a1b3dec7c45988_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtNy0xLTEtODY3MDk_db1402a9-3ff2-41d9-8af2-3c8a97f4be3a"
      unitRef="usd">46000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV84OC9mcmFnOjMzNDc1MDAxMTg4ZDRlN2M5YjhhNmU2MjVmN2QxZmJhL3RhYmxlOjUzODUxNTU4MDJlMjQ4NzBiZGM2YTM1YTQ4NjFiZGVkL3RhYmxlcmFuZ2U6NTM4NTE1NTgwMmUyNDg3MGJkYzZhMzVhNDg2MWJkZWRfMzAtOS0xLTEtODY3MDk_9e54d551-9ebe-4ab1-940d-b89568f6ccd7"
      unitRef="usd">13316000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfJointVenturesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMjU4OQ_401b8b2c-0c97-4d57-866c-640f0bfce456">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2020, the Company announced the formation of a new joint venture company, Overland ADCT BioPharma, with Overland Pharmaceuticals (&#x201c;Overland&#x201d;), a fully integrated biopharmaceutical company backed by Hillhouse Capital. Overland ADCT BioPharma will develop and commercialize one of the Company&#x2019;s ADC products, ZYNLONTA, and three of the Company&#x2019;s ADC product candidates, ADCT-601, ADCT-602 and ADCT-901, in greater China and Singapore. The table below provides a rollforward of the Company&#x2019;s interest in Overland ADCT BioPharma as of September&#160;30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Interest in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;41,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share of results in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;34,687&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;47,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share of results in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;44,002&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the deferred gain of USD 23.5&#160;million arising from the Company&#x2019;s contribution for its equity investment in the joint venture remained unchanged from December&#160;31, 2021. The Company&#x2019;s carrying value of its investment in a joint venture increases or decreases in relation to the Company&#x2019;s proportionate share of comprehensive income or loss of the joint venture. When the Company&#x2019;s share of losses of a joint venture exceeds the Company&#x2019;s interest in that joint venture less the carrying value of the deferred gain described above, the Company ceases to recognize its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company&#x2019;s share of those amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Summarized Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;39,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;48,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;48,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;69,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Summarized Statement of Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;13,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfJointVenturesExplanatory>
    <adc:NumberOfProductsDevelopedAndCommercializedInJointVenture
      contextRef="i228965fb30b84e8ebf7eb20761e08272_D20201214-20201214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMTI4Nw_d4c472be-7c42-40e7-ad38-754187b0edf5"
      unitRef="product">1</adc:NumberOfProductsDevelopedAndCommercializedInJointVenture>
    <adc:NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture
      contextRef="i228965fb30b84e8ebf7eb20761e08272_D20201214-20201214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMTMzNQ_8aefb112-7219-4573-8e38-0a1e320b6580"
      unitRef="product">3</adc:NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture>
    <ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMjU5MA_566c155c-deeb-4c54-aa8b-914348afcbd1">The table below provides a rollforward of the Company&#x2019;s interest in Overland ADCT BioPharma as of September&#160;30, 2022 and 2021, respectively. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Interest in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;41,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share of results in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(6,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;34,687&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;47,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share of results in joint venture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;44,002&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod
      contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfMi0yLTEtMS04NjcwOQ_8f06f9b9-4151-41d5-9efc-33f440e754fc"
      unitRef="usd">41236000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <adc:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults
      contextRef="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfNC0yLTEtMS04NjcwOQ_d4807d5e-d866-4eec-80e9-552a1649e737"
      unitRef="usd">-6549000</adc:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod
      contextRef="icf7428455ece4b7882dc15984214fcea_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfNS0yLTEtMS04NjcwOQ_7cafaee5-4604-4969-aa44-af8784c67af5"
      unitRef="usd">34687000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod
      contextRef="i8a6d95c9c71c445896f3f224ee1f25ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfNy0yLTEtMS04NjcwOQ_3e2180d4-86e5-46bd-84e2-3ac9fb0b7725"
      unitRef="usd">47908000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <adc:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults
      contextRef="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfOC0yLTEtMS04NjcwOQ_0b6d6851-d481-4754-b018-17f057b4d247"
      unitRef="usd">-3906000</adc:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults>
    <ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod
      contextRef="ic66b9b3ea6b24e6596d461fd96900933_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjBjYjM3ZjllNjlkYTQ3M2ZiYmEwYTc1ODVkNWQzYTkzL3RhYmxlcmFuZ2U6MGNiMzdmOWU2OWRhNDczZmJiYTBhNzU4NWQ1ZDNhOTNfOS0yLTEtMS04NjcwOQ_9be44222-de83-4709-a167-bb9abef7a561"
      unitRef="usd">44002000</ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod>
    <adc:DeferredGainOnInvestmentInJointVenture
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMTYwNQ_c864cab4-f6ff-42ff-9290-fd8072b61a8f"
      unitRef="usd">23500000</adc:DeferredGainOnInvestmentInJointVenture>
    <ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RleHRyZWdpb246MGExOTQ2NTlmZGRhNDg1ZDk1NWI2OTA4NmQ5OTM4YjFfMjU5MQ_89a37c26-0426-406b-977f-92cae85deee1">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below provide summarized financial information for Overland ADCT BioPharma that is material to the Company. The following information reflects the amounts presented in the financial statements of Overland ADCT BioPharma and not the Company&#x2019;s share of those amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Summarized Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;39,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;48,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;48,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;69,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;84,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Summarized Statement of Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;14,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;13,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="icf7428455ece4b7882dc15984214fcea_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMi0yLTEtMS04NjcwOQ_ccea867f-216a-4e02-b8ee-dd2fe4de9ce1"
      unitRef="usd">24445000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMi00LTEtMS04NjcwOQ_f8a5bdf6-1e61-4957-9883-990326850eb4"
      unitRef="usd">39318000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="icf7428455ece4b7882dc15984214fcea_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMy0yLTEtMS04NjcwOQ_32ba743e-d2b9-4afa-86e7-978ab351b4ff"
      unitRef="usd">516000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMy00LTEtMS04NjcwOQ_5c5a5ba1-8797-4ab1-a843-5da80544b258"
      unitRef="usd">15000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="icf7428455ece4b7882dc15984214fcea_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNC0yLTEtMS04NjcwOQ_54d05d6c-733c-441f-a510-408573de3a89"
      unitRef="usd">48040000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNC00LTEtMS04NjcwOQ_c7ee41a2-e294-42da-be0e-20eb1a56ebb1"
      unitRef="usd">48040000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:Liabilities
      contextRef="icf7428455ece4b7882dc15984214fcea_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNS0yLTEtMS04NjcwOQ_03a8af56-1cb2-4cfb-9dbc-1d44178f65ad"
      unitRef="usd">3711000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNS00LTEtMS04NjcwOQ_4d536e70-77c5-4e77-b5ed-3cc0afc28470"
      unitRef="usd">2828000</ifrs-full:Liabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="icf7428455ece4b7882dc15984214fcea_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNi0yLTEtMS04NjcwOQ_e29f933f-bfb1-4313-a260-9aeb2e07ec52"
      unitRef="usd">69290000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:NetAssetsLiabilities
      contextRef="i0eb53627542b4cdba6ba59b049a5b8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfNi00LTEtMS04NjcwOQ_1c53fad6-8a13-4135-9bcb-3c76cd07874d"
      unitRef="usd">84545000</ifrs-full:NetAssetsLiabilities>
    <ifrs-full:OperatingExpense
      contextRef="i42d1c8d670234c8ea810b1ad8b5d520f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtMi0xLTEtODY3MDk_f5f20928-66e5-46b5-8e3d-b90277c38b0f"
      unitRef="usd">4950000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="id388d0fa6213478cba6b2c29801561e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtNC0xLTEtODY3MDk_29a7f2d2-8377-453e-9647-6b950cf77b82"
      unitRef="usd">4465000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtNi0xLTEtODY3MDk_65001abb-027f-4ef5-9c6b-f909e842f454"
      unitRef="usd">14317000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTAtOC0xLTEtODY3MDk_aace4afe-af2b-4402-867b-4d9bffca4d72"
      unitRef="usd">8120000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLoss
      contextRef="i42d1c8d670234c8ea810b1ad8b5d520f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItMi0xLTEtODY3MDk_d4684778-52e6-4cbb-966b-d0a1a4f136d6"
      unitRef="usd">4346000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="id388d0fa6213478cba6b2c29801561e0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItNC0xLTEtODY3MDk_b0f4235b-aaf4-4b2a-8720-14fbfb1f281d"
      unitRef="usd">4511000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i0314f485f0134dc68de6c2f8e39a147c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItNi0xLTEtODY3MDk_714575d9-b24b-4265-83cf-9e77e91f27e2"
      unitRef="usd">13009000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="ia32b7019c3e84db88e8e0c9094fadff2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85MS9mcmFnOjBhMTk0NjU5ZmRkYTQ4NWQ5NTViNjkwODZkOTkzOGIxL3RhYmxlOjU2NDk0NjY4YTExYzQwMDRhNGI0OWRiMDI0M2E0OTYwL3RhYmxlcmFuZ2U6NTY0OTQ2NjhhMTFjNDAwNGE0YjQ5ZGIwMjQzYTQ5NjBfMTItOC0xLTEtODY3MDk_45db5859-9339-4311-8511-4a0c8fe15ef2"
      unitRef="usd">7972000</ifrs-full:ProfitLoss>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfODA2_adf72658-96ae-4672-95de-b8bcd78c36ae">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a rollforward of the Company's right-of-use assets as of September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Properties (Offices)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(1,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(1,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;6,649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;6,708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;5,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;5,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;10,124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the third quarter of 2022, the Company extended the term of its existing lease related to its U.S. corporate offices in New Jersey for an additional two years commencing on December 1, 2022, including an extension option for three additional years. The Company is reasonably certain it will exercise the extension option and therefore has accounted for the lease using a five-year lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;During the first quarter of 2021, the Company entered into a new lease agreement with a ten-year term commencing in January 2021 for space in the iHub building on the Imperial University college campus in White City, West London. The primary function of the new facility, which consists of approximately 1,100 square meters, is R&amp;amp;D. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of right-of-use assets have been charged to the following categories in the unaudited condensed consolidated interim statement of operations. Depreciation expense for S&amp;amp;M expenses was not material for any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;G&amp;amp;A expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;395&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;896&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a rollforward of the Company's lease liabilities as of September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Properties (Offices)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash outflow (including interest)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,467&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash outflow (including interest)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfODA3_ae9df0f4-fddc-44f2-8203-2de94abd8e31">&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Properties (Offices)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,328&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,462&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(1,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(1,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(896)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;6,649&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;6,708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;5,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;5,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(864)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,990&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;10,124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net book amount as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,448&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the third quarter of 2022, the Company extended the term of its existing lease related to its U.S. corporate offices in New Jersey for an additional two years commencing on December 1, 2022, including an extension option for three additional years. The Company is reasonably certain it will exercise the extension option and therefore has accounted for the lease using a five-year lease term.&lt;/span&gt;&lt;/div&gt;During the first quarter of 2021, the Company entered into a new lease agreement with a ten-year term commencing in January 2021 for space in the iHub building on the Imperial University college campus in White City, West London. The primary function of the new facility, which consists of approximately 1,100 square meters, is R&amp;amp;D.</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets
      contextRef="i2b56cf9b484847d5ab3c287aa7060a0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMy0yLTEtMS04NjcwOQ_b9ef76e4-3e0f-4b82-befd-0d667ee00931"
      unitRef="usd">9005000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i9b4ebc1ad16249d59d9a2b9574c68a62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMy00LTEtMS04NjcwOQ_363079fc-6562-41ca-87ad-2ecb0bfea79d"
      unitRef="usd">134000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="icf2aa78bd37e48d8afb1437f35585633_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMy02LTEtMS04NjcwOQ_c03ae7d7-2df2-40fd-9587-1f1f5af52449"
      unitRef="usd">9139000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="ib0cfdd333541408ba83d32b7e1c51e80_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNC0yLTEtMS04NjcwOQ_f4db451d-f2d6-48ed-910a-945980404ced"
      unitRef="usd">1234000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i6a4d6ad6c402432badd52332e50082ba_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNC00LTEtMS04NjcwOQ_a68118b2-11c4-4b15-ade9-ad2b3583cbce"
      unitRef="usd">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNC02LTEtMS04NjcwOQ_8969a864-19ee-4d9f-aaf7-1ddc331dad0a"
      unitRef="usd">1234000</ifrs-full:AdditionsToRightofuseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="ib0cfdd333541408ba83d32b7e1c51e80_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNi0yLTEtMS04NjcwOQ_e4a8c681-7715-4a21-b1ca-22185b501134"
      unitRef="usd">-911000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i6a4d6ad6c402432badd52332e50082ba_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNi00LTEtMS04NjcwOQ_b9fd30af-34fe-40ef-a8b5-5cd8d78722ae"
      unitRef="usd">0</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i0fc86fd6a18d498595a9dee95d40b65d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNi02LTEtMS04NjcwOQ_f10aec1e-80f2-4397-8de6-a226ac269eed"
      unitRef="usd">-911000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="ifc44f11da71445b9bd1dd055c47f9f73_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNy0yLTEtMS04NjcwOQ_baaf2d2b-6a4f-4a3f-ae69-3636e05b8150"
      unitRef="usd">9328000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i3ef43b851dc04cf9825b1deb88d8f139_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNy00LTEtMS04NjcwOQ_0c6b3dc5-4112-48b0-ae42-6dd8bcd8f334"
      unitRef="usd">134000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i15b225beffa44b3d87f67b9e69f699fa_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfNy02LTEtMS04NjcwOQ_2a50f0e4-d5b2-47a2-8983-7e72c43a7c13"
      unitRef="usd">9462000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i161a5506dfed4a31a2fb1ac7f5c47782_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTAtMi0xLTEtODY3MDk_befeec10-985a-4416-9092-c7c26a2749e9"
      unitRef="usd">-1925000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="iaada04dc38054738b85ebb285ca09c21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTAtNC0xLTEtODY3MDk_38e6ec5b-902d-440d-ade2-8f6fa2df7c8e"
      unitRef="usd">-50000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="id32707d201834dc793295ca00533da1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTAtNi0xLTEtODY3MDk_f8719053-f4c9-4fd8-a88b-20331b3d696f"
      unitRef="usd">-1975000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i5477a4b1928548ebbe20d629b66b14ce_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTEtMi0xLTEtODY3MDk_4bb9a029-2f97-47c3-b4ea-72aabb1f6da2"
      unitRef="usd">871000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i2d3ba12574b44bb38c8be7706e8aac18_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTEtNC0xLTEtODY3MDk_5c7421a2-fd16-4e6b-a364-b75a1acf7345"
      unitRef="usd">25000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTEtNi0xLTEtODY3MDk_54bde6d3-e108-4365-b068-0cfc23bf8a40"
      unitRef="usd">896000</ifrs-full:DepreciationRightofuseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i5477a4b1928548ebbe20d629b66b14ce_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTMtMi0xLTEtODY3MDk_6c41b383-94b0-4a02-a91d-e69a1acf9935"
      unitRef="usd">117000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i2d3ba12574b44bb38c8be7706e8aac18_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTMtNC0xLTEtODY3MDk_efa95572-7ef3-4bc3-9a04-fc68648ade5f"
      unitRef="usd">0</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="icf3db513ed254ec8b9d7be67fa51795d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTMtNi0xLTEtODY3MDk_3361ff7d-d6d1-47dd-8b80-2f4a45c5828e"
      unitRef="usd">117000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i8b0b55146cdb49e48b45bad254647bc6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTQtMi0xLTEtODY3MDk_067cda98-20b7-485f-9edb-94420fdf651d"
      unitRef="usd">-2679000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i9e763260b1f442488b72bf74a7c49c11_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTQtNC0xLTEtODY3MDk_d1b2f34e-6723-47d4-8fc1-95c5f9038fcf"
      unitRef="usd">-75000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i9da30f3755c743e08b48e072dc09209d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTQtNi0xLTEtODY3MDk_ea2c9855-79fd-4ccd-b5e4-524d3930912d"
      unitRef="usd">-2754000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i834b4d3caeae4e77b67d0f0dc2d552e9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTYtMi0xLTEtODY3MDk_c3bd9f35-7cd6-4294-936e-5d483ab015f1"
      unitRef="usd">6649000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i638129f1bcc5425ba52dd51ffd7e9490_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTYtNC0xLTEtODY3MDk_1625f35a-afdb-4a5f-9d10-64413cc019b2"
      unitRef="usd">59000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTYtNi0xLTEtODY3MDk_c4e52e3c-54a0-4d64-82a7-1cba9d4c77c8"
      unitRef="usd">6708000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i401425c5856840c4a0bb4fd8fb8835ae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTktMi0xLTEtODY3MDk_6755eb13-3b81-4174-b2ea-08eb8e22089c"
      unitRef="usd">5324000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i2efd49a30baa4077ae95107fcc999447_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTktNC0xLTEtODY3MDk_c898901b-1c16-4ec5-957c-4da6a5711477"
      unitRef="usd">78000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i35cab614c8934a419edc6f7cccb644a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMTktNi0xLTEtODY3MDk_571d4e4d-6259-4a4c-8a29-5f8b65c200e4"
      unitRef="usd">5402000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjAtMi0xLTEtODY3MDk_2f9c67de-3eec-4b97-975c-05d606285b63"
      unitRef="usd">5662000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjAtNC0xLTEtODY3MDk_ffc4c2da-f4d3-41cb-afc6-d3c00e9c5af3"
      unitRef="usd">56000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjAtNi0xLTEtODY3MDk_13541016-3895-47a6-9902-c0222cf1274e"
      unitRef="usd">5718000</ifrs-full:AdditionsToRightofuseAssets>
    <adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets
      contextRef="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjEtMi0xLTEtODY3MDk_3d4c34aa-a798-4b64-baaa-bde602b5f858"
      unitRef="usd">-864000</adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets>
    <adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets
      contextRef="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjEtNC0xLTEtODY3MDk_24984894-dd08-4a3b-a453-86d99b28eb8d"
      unitRef="usd">0</adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets>
    <adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets
      contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjEtNi0xLTEtODY3MDk_9108807c-c74f-441e-92f5-38aa61f494dd"
      unitRef="usd">-864000</adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="ie65c5dfa475e4d1f8cef8bf017e0613c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjItMi0xLTEtODY3MDk_eb730c46-75d9-4ca7-a4f4-8e924a44a823"
      unitRef="usd">-132000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i8ae5c9fc58154cdcae46a930340b9a80_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjItNC0xLTEtODY3MDk_02e28b5d-529e-4c61-8419-b8b89299c1ad"
      unitRef="usd">0</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="ie9e31cf23e2348929bee5159945984bf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjItNi0xLTEtODY3MDk_b0b66b74-d43a-4aa4-aca4-5b5f9969907a"
      unitRef="usd">-132000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i5abfbc2b76094ac5a51ad5a1de5beced_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjMtMi0xLTEtODY3MDk_36a19f92-2cbe-46f6-962c-162c945a25c4"
      unitRef="usd">9990000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i135ebd8bed6a4537b47040a2f4e822d3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjMtNC0xLTEtODY3MDk_77dcedef-9316-4adf-863d-4db810a46fac"
      unitRef="usd">134000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i244793ab5a7249738bab95a309aaad60_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjMtNi0xLTEtODY3MDk_29fb9e47-ae46-4170-a609-01dae409b268"
      unitRef="usd">10124000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="ie2ff798d025b459fa18da647bcec866b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjYtMi0xLTEtODY3MDk_83d22c77-6ecd-40fd-ab4f-87b716beda0b"
      unitRef="usd">-2253000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i15cd499c06e344418b49e009c7d8d193_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjYtNC0xLTEtODY3MDk_980a855c-355a-4271-944f-27a7d6be14b1"
      unitRef="usd">-20000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i792cccf378ee4050923e53f4a38c7136_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjYtNi0xLTEtODY3MDk_4927eaf6-551a-41c4-a2df-75f635dbb13e"
      unitRef="usd">-2273000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjctMi0xLTEtODY3MDk_aff88388-cf9c-4a9c-89a2-5932ad9d3c6b"
      unitRef="usd">1172000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjctNC0xLTEtODY3MDk_785f0def-80ce-43cf-9617-c1cef3657282"
      unitRef="usd">22000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjctNi0xLTEtODY3MDk_498ba012-74e9-4724-a447-de7891bbbb9c"
      unitRef="usd">1194000</ifrs-full:DepreciationRightofuseAssets>
    <adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets
      contextRef="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjgtMi0xLTEtODY3MDk_ae97f8b0-546d-412f-a382-15ca994859a0"
      unitRef="usd">-864000</adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets>
    <adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets
      contextRef="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjgtNC0xLTEtODY3MDk_86e89964-7703-44b5-a70f-807ce9e83cf4"
      unitRef="usd">0</adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets>
    <adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets
      contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjgtNi0xLTEtODY3MDk_ea180631-b773-4b13-b453-12c32b597f9c"
      unitRef="usd">-864000</adc:IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i3dc74adfa1cd4bb39fb202708962b37c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjktMi0xLTEtODY3MDk_822434cb-00d3-4178-9385-d46d2dac3206"
      unitRef="usd">19000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="ic4b67687c92444b0b99e3d3e03882e73_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjktNC0xLTEtODY3MDk_a5a29130-41b2-46bf-acaa-ad70e4fc23df"
      unitRef="usd">0</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets
      contextRef="i3613503d8df34be6b9d532951ea5ad24_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMjktNi0xLTEtODY3MDk_024f47b1-a94e-48be-9448-c107119aad79"
      unitRef="usd">19000</adc:IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i80cd1d5cda1f4e74862567135c82703e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzAtMi0xLTEtODY3MDk_24a32a7e-c6f8-4ce0-9814-42094c638c0d"
      unitRef="usd">-2542000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="id5a94dcf4e4844cf92a3de1535f49f1e_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzAtNC0xLTEtODY3MDk_be6b6243-31c9-42bd-bcd2-67a8e09d2f6e"
      unitRef="usd">-42000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i6a7ddc9b4e1e4c0f82705cfe7c527db7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzAtNi0xLTEtODY3MDk_a5270402-fabb-4727-b683-1a7bf167d13a"
      unitRef="usd">-2584000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i81b5c8e6664d477fa65cefde7362ee81_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzItMi0xLTEtODY3MDk_444398ac-246d-4711-8f7c-34c66301e20b"
      unitRef="usd">7448000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="ibce8feac9624457fae2210499d43d84a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzItNC0xLTEtODY3MDk_10269c85-4ae8-4b88-a0b5-a7ca8036b7e4"
      unitRef="usd">92000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjUzN2Y4MjBlYmQ1MTQwZmZiMjk1YWM3ODk5M2NhYmMyL3RhYmxlcmFuZ2U6NTM3ZjgyMGViZDUxNDBmZmIyOTVhYzc4OTkzY2FiYzJfMzItNi0xLTEtODY3MDk_456299af-5ef8-4184-8b8b-a81f7ca959d6"
      unitRef="usd">7540000</ifrs-full:RightofuseAssets>
    <adc:LeaseArea
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfNDI1_2cf3b579-8532-48d2-a1f7-f3a21dc56492"
      unitRef="sqm">1100</adc:LeaseArea>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ie83b9d46aa9540e49e84d64af9846e39_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi0yLTEtMS04NjcwOQ_d1cb8ced-e5df-4b1e-b57c-8f62a3499acf"
      unitRef="usd">228000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i66e6d9b588aa47d19ad6aad08a538bf5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi00LTEtMS04NjcwOQ_12874089-216e-45dc-abcd-e5d3023d20a9"
      unitRef="usd">334000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="ia8b0181426584e10a750977ea6280fb4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi02LTEtMS04NjcwOQ_0fca1bfc-edbb-4694-9513-9be40c25f6d5"
      unitRef="usd">711000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i5a67346f88234740b156f2c58bfbebe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfMi04LTEtMS04NjcwOQ_dbe9b895-e416-42af-857a-1e23f9a87455"
      unitRef="usd">1016000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i1961636ee14e4def8d8cc7b2018774e3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC0yLTEtMS04NjcwOQ_b1231824-9dc7-4203-98c3-d01a90f2e79c"
      unitRef="usd">62000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i5672677502cf4414a866c09aa425cb21_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC00LTEtMS04NjcwOQ_3a758f04-7147-4dcc-a206-430058a4218e"
      unitRef="usd">61000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i06457785463e407c8483fbe337aa3902_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC02LTEtMS04NjcwOQ_cccab1b9-d78e-45b0-88e0-f6ab0781d7bf"
      unitRef="usd">185000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="if3c884b0bc284c6388a42f8607e2d444_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNC04LTEtMS04NjcwOQ_b7f5c64f-19f4-440e-a138-661b5dfb149e"
      unitRef="usd">178000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS0yLTEtMS04NjcwOQ_34339a17-b984-43b5-b587-5fc8f2c64ead"
      unitRef="usd">290000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS00LTEtMS04NjcwOQ_3018eac9-4bd4-45f7-9d00-97c17210f97f"
      unitRef="usd">395000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS02LTEtMS04NjcwOQ_adb8b910-7ff6-4762-9a01-7d73a09cedab"
      unitRef="usd">896000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOmE4NjhmZTY3NjlmMjQzMjJhMWI1ZTNiYTA2Y2JlM2I2L3RhYmxlcmFuZ2U6YTg2OGZlNjc2OWYyNDMyMmExYjVlM2JhMDZjYmUzYjZfNS04LTEtMS04NjcwOQ_639686b3-471b-44b3-b823-557501741156"
      unitRef="usd">1194000</ifrs-full:DepreciationRightofuseAssets>
    <adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RleHRyZWdpb246Zjc5MTg0NmNmODZjNDA3M2JjMzNmM2M0ZDQxYWU1NmNfODEw_152fb02b-5964-4a17-80b0-a37b0a13d483">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.006%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Properties (Offices)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash outflow (including interest)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,402&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;3,467&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash outflow (including interest)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange difference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.65pt;text-align:left;text-indent:-8.65pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock>
    <ifrs-full:LeaseLiabilities
      contextRef="i28da2485dc9a4fa783f820e72033822c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMi0yLTEtMS04NjcwOQ_91e6ec73-eae8-4bd9-bc44-1bc8d4918b7f"
      unitRef="usd">7898000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="ic61fb64598ff4cd0ad1e2271aed1a821_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMi00LTEtMS04NjcwOQ_737d209e-ed3d-4ec2-a99f-cc9efa8bf298"
      unitRef="usd">125000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMi02LTEtMS04NjcwOQ_2d19b0f9-c76f-4787-9cb8-4fb3b213932d"
      unitRef="usd">8023000</ifrs-full:LeaseLiabilities>
    <adc:AdditionsToLeaseLiabilities
      contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMy0yLTEtMS04NjcwOQ_6c0473fe-2e38-4fca-9e4d-f631c6e8e1ae"
      unitRef="usd">1234000</adc:AdditionsToLeaseLiabilities>
    <adc:AdditionsToLeaseLiabilities
      contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMy00LTEtMS04NjcwOQ_b598c9c2-39e7-4262-9c00-c08c5ccb8093"
      unitRef="usd">0</adc:AdditionsToLeaseLiabilities>
    <adc:AdditionsToLeaseLiabilities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMy02LTEtMS04NjcwOQ_df587481-f516-455f-acca-b7fb480f6b52"
      unitRef="usd">1234000</adc:AdditionsToLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNS0yLTEtMS04NjcwOQ_a0a2b4ee-054d-4008-810d-b49977ee16c4"
      unitRef="usd">901000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNS00LTEtMS04NjcwOQ_eca4b5c3-9d83-4ab8-a4a9-028db62f8e3f"
      unitRef="usd">0</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNS02LTEtMS04NjcwOQ_54d8e271-36ef-4884-95c8-4322182b3f44"
      unitRef="usd">901000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNi0yLTEtMS04NjcwOQ_11e5e838-f342-405b-b958-41029daecbe8"
      unitRef="usd">144000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNi00LTEtMS04NjcwOQ_85b06ce8-282e-4aab-9dd6-44a03fb519a1"
      unitRef="usd">0</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNi02LTEtMS04NjcwOQ_c6c39554-6bc5-4d84-8791-e8d96d71d3be"
      unitRef="usd">144000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities
      contextRef="i3a0458ee4b8449d7b8512476e90c38fe_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNy0yLTEtMS04NjcwOQ_55a7725a-a00d-4bf7-86a7-00a6b8a84eca"
      unitRef="usd">-978000</adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities
      contextRef="ia30d0c408d0d473c8e258de7af8b1db8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNy00LTEtMS04NjcwOQ_1beead2d-d9a7-49b8-8fc2-4f14488dc054"
      unitRef="usd">-65000</adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfNy02LTEtMS04NjcwOQ_ee8cbb4a-01ca-493c-a638-fff440358f5c"
      unitRef="usd">-1043000</adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfOC0yLTEtMS04NjcwOQ_c4130d8f-3be1-4391-9c45-b631bb9be97c"
      unitRef="usd">7397000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfOC00LTEtMS04NjcwOQ_ff385293-3197-4278-babf-53e5e570798e"
      unitRef="usd">60000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfOC02LTEtMS04NjcwOQ_8a672d9c-a1d5-4e93-836e-1ab1e1680738"
      unitRef="usd">7457000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i6b3f2601891941a49171d77873081724_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTAtMi0xLTEtODY3MDk_1c669556-d5f6-4d9e-811e-a51fff83b3f6"
      unitRef="usd">3402000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i1fee265512e746a9a555451fac8020e8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTAtNC0xLTEtODY3MDk_ceae1942-70b3-4d21-91b4-0eee23b94149"
      unitRef="usd">65000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTAtNi0xLTEtODY3MDk_6384b7ee-93c7-407f-a5d6-64607d4b4717"
      unitRef="usd">3467000</ifrs-full:LeaseLiabilities>
    <adc:AdditionsToLeaseLiabilities
      contextRef="ied99ac8b277c4b408fb02863f8dffb5e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTEtMi0xLTEtODY3MDk_cb02cd46-ceda-4578-a2f2-34c1e61009ac"
      unitRef="usd">5662000</adc:AdditionsToLeaseLiabilities>
    <adc:AdditionsToLeaseLiabilities
      contextRef="i5b95a2cc92564802b7a6cf3d8824d376_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTEtNC0xLTEtODY3MDk_3b3a8225-c7f2-4340-96ad-4e0951fd425c"
      unitRef="usd">56000</adc:AdditionsToLeaseLiabilities>
    <adc:AdditionsToLeaseLiabilities
      contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTEtNi0xLTEtODY3MDk_ad89a19d-58b1-4d21-b584-e8ed5803a224"
      unitRef="usd">5718000</adc:AdditionsToLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="icada6f229ced49ecacd2e102988715eb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTMtMi0xLTEtODY3MDk_fb664841-8a72-485f-b9c7-eca04191e381"
      unitRef="usd">892000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTMtNC0xLTEtODY3MDk_816fb1a5-087f-41e7-a309-49763fafb846"
      unitRef="usd">24000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTMtNi0xLTEtODY3MDk_0c9bbf09-41a9-4bd9-b907-ee5fe85783d2"
      unitRef="usd">916000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="icada6f229ced49ecacd2e102988715eb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTQtMi0xLTEtODY3MDk_9d97f3c2-9964-4bc6-b3b0-576d9e5d33d1"
      unitRef="usd">168000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTQtNC0xLTEtODY3MDk_96779f06-dd31-4311-8580-5edf148eff7a"
      unitRef="usd">2000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTQtNi0xLTEtODY3MDk_59fa691b-b3f2-4854-b26e-880e5b547e2d"
      unitRef="usd">170000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities
      contextRef="icada6f229ced49ecacd2e102988715eb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTUtMi0xLTEtODY3MDk_2c1c59dd-7dcf-4a70-ad6e-f03738e8fbb6"
      unitRef="usd">-234000</adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities
      contextRef="i16a3373e39844aefbc9b6eb28250aabf_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTUtNC0xLTEtODY3MDk_82dea3e3-e8de-4475-9bbb-3398a50e8ab3"
      unitRef="usd">-10000</adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities>
    <adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTUtNi0xLTEtODY3MDk_8c4bf92c-533a-43b8-bdf4-d2f4387e2410"
      unitRef="usd">-244000</adc:IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTYtMi0xLTEtODY3MDk_e2acf936-d41e-4008-a561-a813c9ae942c"
      unitRef="usd">8106000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i80fc52680e63461a82201650861575d2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTYtNC0xLTEtODY3MDk_f94ddd94-a976-44b6-a916-2511a87b2b06"
      unitRef="usd">89000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTYtNi0xLTEtODY3MDk_8b8201bc-293a-4393-9534-1e6a19c5b336"
      unitRef="usd">8195000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTktMi0xLTEtODY3MDk_3ed53a03-ab25-4460-9161-a74d97425419"
      unitRef="usd">801000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTktNC0xLTEtODY3MDk_56ae546b-8f42-4b9c-80ae-3bdbc78bfda7"
      unitRef="usd">34000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMTktNi0xLTEtODY3MDk_a5a185b9-fa4a-4e88-9f6c-df5f5a851a36"
      unitRef="usd">835000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjAtMi0xLTEtODY3MDk_9a96da47-4033-49e8-afbc-952c7399195d"
      unitRef="usd">6596000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjAtNC0xLTEtODY3MDk_48ae2708-bf0b-4105-9c4d-4b748b895b7f"
      unitRef="usd">26000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjAtNi0xLTEtODY3MDk_09687efc-bc29-4ac8-82e7-23e40138e621"
      unitRef="usd">6622000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="ie22662b5873248c984d6c1930b5c5647_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjEtMi0xLTEtODY3MDk_25de58ea-b021-4656-ad39-ede999b72f87"
      unitRef="usd">7397000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i614c4a744d9442189dae06d6e76db4c9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjEtNC0xLTEtODY3MDk_336fba6e-a0ab-4ef2-b610-707911812b98"
      unitRef="usd">60000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjEtNi0xLTEtODY3MDk_9b105154-76ce-4eb3-afbf-73214ce35777"
      unitRef="usd">7457000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjQtMi0xLTEtODY3MDk_1301f873-1b21-45aa-9232-03c42af3fabd"
      unitRef="usd">981000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i80fc52680e63461a82201650861575d2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjQtNC0xLTEtODY3MDk_ec372ac0-4512-41f2-9a58-0f44b62d2cce"
      unitRef="usd">31000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjQtNi0xLTEtODY3MDk_5abd3b05-91e5-41b3-9df4-72b66c0dd99b"
      unitRef="usd">1012000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjUtMi0xLTEtODY3MDk_c4e1cb1c-c81f-4317-9584-00c555a9b454"
      unitRef="usd">7125000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i80fc52680e63461a82201650861575d2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjUtNC0xLTEtODY3MDk_fcf2c61f-9df4-470f-a0ce-943e1ba5275e"
      unitRef="usd">58000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjUtNi0xLTEtODY3MDk_e90693bd-593e-4023-9392-f20e35388d6e"
      unitRef="usd">7183000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i8e9ecb9661d64ff0ad6c386e6d797b28_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjYtMi0xLTEtODY3MDk_5f779ffb-1dbc-4748-85b9-3433e7b94098"
      unitRef="usd">8106000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i80fc52680e63461a82201650861575d2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjYtNC0xLTEtODY3MDk_dbee3d5c-39ea-4f60-b24c-e991419da1d1"
      unitRef="usd">89000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="i62705c1b99444245ac17369673cc7dcf_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85NC9mcmFnOmY3OTE4NDZjZjg2YzQwNzNiYzMzZjNjNGQ0MWFlNTZjL3RhYmxlOjExZmYyM2I2ZjI4ODQwZDA5ZWZlYmM4ODg2OGZlNDY2L3RhYmxlcmFuZ2U6MTFmZjIzYjZmMjg4NDBkMDllZmViYzg4ODY4ZmU0NjZfMjYtNi0xLTEtODY3MDk_4278df63-30b5-456a-9f0e-04635e371dd6"
      unitRef="usd">8195000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfDebtSecuritiesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTUwMzk_ae9f0242-1f66-4d8d-b4e3-6bb11c9da6c4">Senior secured term loan facility and warrants&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, the Company, ADCT UK and ADCT America entered into the Loan Agreement, pursuant to which the Company may borrow up to USD 175.0&#160;million principal amount of secured term loans, including (i) a First Tranche and (ii) Future Tranches. On August 15, 2022, the Company drew down USD 120.0&#160;million principal amount of term loans under the Loan Agreement. The secured term loans are scheduled to mature on August 15, 2029 and accrue interest at an annual rate of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;secured overnight financing rate (SOFR) plus 7.50% per annum (with respect to SOFR loans) or a base rate plus 6.50% per annum (with respect to alternative base rate ("ABR") loans) for the first five years of the term loans, and thereafter, at an annual rate of SOFR plus 9.25% (with respect to SOFR loans) or a base rate plus 8.25% (with respect to ABR loans), in each case subject to a 1.00% per annum SOFR floor. The Company has the option to elect for the loans to be either a SOFR loan or ABR loan. The Company has elected the First Tranche of the secured term loan to be a SOFR loan. Interest is paid on the last business day of each quarter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is obligated to pay certain exit fees upon certain prepayments and repayments of the principal amount of the term loans in an amount ranging from zero to 4.0% of the amount of the loan so paid. In addition, The Company has the right to prepay the term loans at any time subject to certain prepayment premiums applicable until the August 15, 2026. The Loan Agreement also contains certain prepayment provisions, including mandatory prepayments from the proceeds from certain asset sales, casualty events and from issuances or incurrences of debt, which may also be subject to prepayment premiums if made on or prior to August 15, 2026. The obligations under the Loan Agreement are secured by substantially all of the Company's assets and those of certain of the Company's subsidiaries and are guaranteed initially by the Company's subsidiaries in the US and the UK. The Loan Agreement contains customary covenants, including a covenant to maintain a balance at the end of each quarter of at least USD 60.0&#160;million in cash and cash equivalents that are included on the unaudited condensed consolidated interim balance sheet plus an amount equal to any accounts payable that remain unpaid more than ninety days after the original invoice therefore, and negative covenants including limitations on indebtedness, liens, fundamental changes, asset sales, investments, dividends and other restricted payments and other matters customarily restricted in such agreements. The Loan Agreement also contains customary events of default, after which the term loan may become due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults (including creation of any liens other than those that are expressly permitted), bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the Company and its subsidiaries and change in control.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, the Company also issued to the lenders under the Loan Agreement warrants to purchase an aggregate of 527,295 common shares, which warrants have an exercise price of USD 8.30 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder at any time on or prior to August 15, 2032. The warrants contain customary anti-dilution adjustments and will entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for First Tranche of senior secured term loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for the First Tranche of the senior secured term loans and the warrants described above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hybrid financial instrument, with the USD 120.0&#160;million draw down separated into two components&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a warrant obligation and a loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligation, using the Black-Scholes option-pricing model. The warrant obligation has been recorded at an initial fair value of USD 4.0&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;August 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;60 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Black-Scholes value in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan&#x2019;s initial fair value was recorded at USD 116.0&#160;million on August 15, 2022, representing the residual amount of the USD 120.0&#160;million draw down, after separating out the initial fair value of USD 4.0&#160;million of the warrant obligation. The loan is subsequently measured at its amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;in KUSD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;Warrant obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Loan Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;116,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Transaction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;(7,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;(7,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Carrying value of loan at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;108,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Oak Tree and Owl Rock Warrant Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2022, the Company recognized income of KUSD 2,543 as a result of changes in the fair value of the warrant obligations from the issuance date of August 15, 2022. The fair value of the warrant obligations as of September 30, 2022 was KUSD 1,414. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period, which was recorded directly to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;58.5 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Black-Scholes value in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As illustrated in the table above, the transaction costs of the residual loan (net of the fair value of warrant obligations) were deducted from the loan to determine the deemed net present value as of August 15, 2022 of all future cash outflows associated with the loan. The implied EIR that would be needed to increase the book value of the loan to cover all future expected outflows, taking into account the deduction of transaction costs from the initial loan balance, and based on a 360-&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;day year for a SOFR loan, was computed at inception at 14.99%. Given the interest rate in the senior secured term loans is variable and dependent upon market factors, the Company will update the EIR at the end of each reporting period for changes in the rate. For the three and nine months ended September 30, 2022, the Company recorded interest expense on the senior secured term loan in the amount of KUSD 1,933 which was recorded in Financial expense in the unaudited condensed consolidated interim statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount at which the senior secured term loan is presented as a liability in the unaudited condensed consolidated interim balance sheet represents the net present value of all future cash outflows associated with the loan discounted at the EIR. The net present value of those cash outflows occurring within 12 months of the balance sheet date discounted at the same rate is presented as a short-term liability in the unaudited condensed consolidated interim balance sheet. The remainder of the amount is presented as a long-term liability in the unaudited condensed consolidated interim balance sheet. The carrying value of the senior secured term loan was USD 109.2 million as of September 30, 2022, of which USD 12.5 million and USD 96.7 million represented the short-term and long-term portion of the liability, respectively. &lt;/span&gt;&lt;/div&gt;Convertible loans&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 24, 2020, the Company entered into a USD 115&#160;million Facility Agreement with Deerfield, pursuant to which Deerfield extended a tranche of USD 65&#160;million of convertible loans on May 19, 2020 upon completion of the Company&#x2019;s initial public offering (the &#x201c;Deerfield First Tranche&#x201d;) and a tranche of USD 50&#160;million of convertible loans on May 17, 2021 after the receipt of regulatory approval for ZYNLONTA (the &#x201c;Deerfield Second Tranche&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2022, pursuant to an exchange agreement with Deerfield, Deerfield exchanged USD 115.0&#160;million aggregate principal amount of the Company's senior secured convertible notes for warrants to purchase an aggregate of 4,412,840 common shares, an aggregate of 2,390,297 common shares and cash equal to USD 117.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the exchange agreement on August 15, 2022, the Company recognized a loss on extinguishment of USD 42.1 million, which primarily consists of the difference between the aggregate principal amount and carrying value of the convertible loans, exit fee, as well as the unpaid interest payments through the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Embedded conversion option derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the exchange, the Company accounted for the Facility agreement as a loan and embedded conversion option features. The embedded conversion option derivative was marked-to-market while the loan was measured at its amortized cost on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in fair value income (expense) and profit or loss activity of the embedded conversion option derivatives during the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield First Tranche &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield Second Tranche - prior to FDA approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield Second Tranche - after FDA approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(4,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(4,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;25,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;16,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value expense recognized during the three and nine months ended September 30, 2022 represents the change in fair value up until the point of exchange on August 15, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition to the changes in fair value, the Company recorded a gain of KUSD 1,816 during the nine months ended September 30, 2021 with the receipt of the USD 50&#160;million subsequent disbursement, the establishment of the embedded derivative and residual loan associated with the subsequent disbursement and elimination of the derivative immediately prior to FDA approval of ZYNLONTA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The increases (decreases) in fair values of the embedded derivatives are primarily due to increases (decreases) in the fair value of the underlying shares during the respective periods. These amounts were charged directly to the unaudited &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;condensed consolidated interim statements of operations. See note 8, &#x201c;Non-operating (expense) income&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the embedded derivative associated with the Deerfield First Tranche was KUSD 7,670 at the time of exchange on August 15, 2022 and KUSD 23,226 on December 31, 2021. The fair value of the embedded derivative associated with the Deerfield Second Tranche was KUSD 4,627 at the time of exchange on August 15, 2022 and KUSD 14,721 as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield First Tranche and Deerfield Second Tranche of the embedded conversion option derivatives, which is based on the mean of values derived from application of the Hull and Goldman Sachs convertible bond pricing models. Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deerfield First Tranche&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;August 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price at 130% of the IPO price of 19.00, in USD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forced conversion price, in USD &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;67.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;67.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;32.5 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;40 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Recovery rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Implied bond yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deerfield Second Tranche&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;August 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;28.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;28.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forced conversion price, in USD &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;32.5 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;40 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Recovery rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Implied bond yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Residual convertible loan&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield First Tranche &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield Second Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,961&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDebtSecuritiesExplanatory>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQwMA_ae50cacc-2020-40b4-99fe-151d696359ea"
      unitRef="usd">175000000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <ifrs-full:Borrowings
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQxNQ_f6c81123-7838-42b0-9620-575c90900a63"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRate
      contextRef="ib0f3a3c6371f4c089828c4cce5d73dd3_I20220815"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMwMg_1f3e9233-bd4c-41dc-8f9d-14f4960839f6"
      unitRef="number">0.0750</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="ie6f2ae527c2944308bb08da4da7ab273_I20220815"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMwOQ_b96b797b-c402-475a-ba7d-427d7b1c46bc"
      unitRef="number">0.0650</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="ie4435c71c4fa4639bb03f664766ee514_I20220815"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMxNg_a5ab7a61-4251-4bb7-83ef-b3ee47c5b650"
      unitRef="number">0.0925</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="i35e15f9b287246acba0bdc6c93bd00b7_I20220815"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMyMw_06c5cd4c-1092-495b-8a07-012fe5c3fd45"
      unitRef="number">0.0825</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="iaf3da50e0c50456c822d82239d1251be_I20220815"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMzMA_19f68fc6-3974-4ccd-9ab0-09317046b815"
      unitRef="number">0.0100</ifrs-full:BorrowingsInterestRate>
    <adc:BorrowingsFacilitiesExitFeePercentage
      contextRef="if31c404deeed4a629f5368280fa99dd7_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDk0Ng_8f85ae70-958b-4834-9878-de84aa1cf56e"
      unitRef="number">0</adc:BorrowingsFacilitiesExitFeePercentage>
    <adc:BorrowingsFacilitiesExitFeePercentage
      contextRef="i98de5d1ddb2243a1b01f6acc1c57c72e_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM1MQ_0e15c1f0-a21e-484f-a45f-7ea3637820b9"
      unitRef="number">0.040</adc:BorrowingsFacilitiesExitFeePercentage>
    <adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDMzNw_179e730a-434b-4f27-aec9-06135fbb8b5e"
      unitRef="usd">60000000</adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents>
    <adc:ConvertibleNotesSharesConverted
      contextRef="i9e5a1305a7604d6e87bd11283adef044_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM1Nw_214d94f2-a83e-4a1b-a3a1-54069456c106"
      unitRef="shares">527295</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM2Ng_517fe607-a614-427b-b714-43cbd045a9d5"
      unitRef="usdPerShare">8.30</adc:WarrantsSharesConvertedExercisePrice>
    <ifrs-full:Borrowings
      contextRef="i313fda5b91c745ca8a9287f47d161560_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM3Mg_11c23fe1-9b0d-4119-a31d-9c0dae7a3459"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQyOQ_2b39a4e4-a359-44c4-bbb9-ba087de56fbe">The warrant obligation has been recorded at an initial fair value of USD 4.0&#160;million on August 15, 2022 and is remeasured to fair value on a quarterly basis. Key inputs for the valuation of the warrant obligation as of August 15, 2022 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;August 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;60 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Black-Scholes value in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an independent valuation firm to assist in calculating the fair value of the warrant obligations, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligations as of September 30, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;58.5 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Black-Scholes value in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Key inputs for the valuations as of August 15, 2022 and December 31, 2021 were as follows:&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deerfield First Tranche&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;August 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price at 130% of the IPO price of 19.00, in USD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forced conversion price, in USD &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;67.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;67.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;32.5 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;40 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Recovery rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Implied bond yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deerfield Second Tranche&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;August 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;28.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;28.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forced conversion price, in USD &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;32.5 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;40 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Recovery rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Implied bond yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <adc:WarrantObligationFairValue
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDM4Nw_2bb64b84-8b3d-45b2-af6e-db7d96499b1c"
      unitRef="usd">4000000</adc:WarrantObligationFairValue>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i77b99ef7cc0b4e7ab11c5073c019b286_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfMi0xLTEtMS0xMDMwMjQ_74a52c6f-11be-4155-b14e-a514ea1c5fc0"
      unitRef="shares">8.30</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i31f57aba65894b669b8fadd39cc8a133_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfMy0xLTEtMS0xMDMwMjQ_23249f69-9661-4d04-856a-30733b8973b9"
      unitRef="shares">10.33</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i89faf473a32b42bd935a511f8ee7a191_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNC0xLTEtMS0xMDMwMjQ_00d94064-3f3b-41c8-9236-c082015154d1"
      unitRef="shares">0.029</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="iff9bc94da04d47ae9a9b849234ad3c6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNS0xLTEtMS0xMDMwMjQ_61eda9ef-1d1f-4db6-b1da-e6e0a0095c27"
      unitRef="shares">0.87</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="icb8358f51a2445159e899b48be721e8d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNi0xLTEtMS0xMDMwMjQ_b847ed58-da70-4100-a984-6af565e2c5ae"
      unitRef="shares">60</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i9091a412696c4780b52173364c99f1bd_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfNy0xLTEtMS0xMDMwMjQ_9ba0674a-ef2e-4942-8a59-5b74981a38ea"
      unitRef="shares">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i0d4e15e2a100434397a55b4e43e929c3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjQyMTdhYjhhMzg4NzRiMDI5NTcxNWI4MDc3Y2M2MDFhL3RhYmxlcmFuZ2U6NDIxN2FiOGEzODg3NGIwMjk1NzE1YjgwNzdjYzYwMWFfOC0xLTEtMS0xMDMwMjQ_91cd84d7-c655-4cab-9011-b64b23ec2b51"
      unitRef="shares">7.51</ifrs-full:SignificantUnobservableInputLiabilities>
    <adc:BorrowingsFairValue
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQzMQ_7615f518-b2c4-4f74-b99c-300eda53f675"
      unitRef="usd">116000000</adc:BorrowingsFairValue>
    <ifrs-full:Borrowings
      contextRef="iea17a01e38b140129bf22b46808b9404_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ1OQ_6dd9ffb5-9a90-467c-92ad-b962b0caa0d9"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <adc:WarrantObligationFairValue
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ0Ng_f06831c5-b9da-4a8d-a889-f17ee573ca8d"
      unitRef="usd">4000000</adc:WarrantObligationFairValue>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ3Mw_c98ca6c4-9cff-42c6-81b2-99a50569d7f4">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs have been allocated to the above two components. Transaction costs associated to the warrant obligation have been charged directly to the unaudited condensed consolidated interim statement of operations, while transaction costs associated to the residual loan have been deducted from the loan. See further illustration in table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;in KUSD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;Warrant obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Residual loan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:132%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Loan Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;3,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;116,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Transaction costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;(7,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;(7,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;Carrying value of loan at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:132%"&gt;108,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the interest expense recorded on the convertible loan for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield First Tranche &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield Second Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;1,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,961&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;7,393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a rollforward of the Company&#x2019;s debt obligation relating to the royalty purchase agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;225,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Plus: interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;17,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: cumulative catch-up adjustment, Financial income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;221,144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Proceeds from the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Plus: interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Plus: cumulative catch-up adjustment, Financial expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;225,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:Borrowings
      contextRef="id0d75589019241a5b049c49c03ebd9c4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMS0yLTEtMS0xMDMwMTQ_08405a7d-3462-416b-b957-224a1fbc3b09"
      unitRef="usd">3957000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="ieed9dd529b364aa5a0dfd1de03035963_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMS00LTEtMS0xMDMwMTY_cca17efb-ee03-4ee9-b81d-0b3238665c3c"
      unitRef="usd">116043000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="idda45a536b784d9a83b51c5690223542_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMS02LTEtMS0xMDMwMTg_260a6d15-a7f7-4203-a70c-a64db269114b"
      unitRef="usd">120000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="i9df49cf53777407aaff962bcab6cbb00_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMi0yLTEtMS0xMDMwMTQ_57722ae6-841d-4bff-991e-0f316a2e1240"
      unitRef="usd">245000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="ida5b2446ccaa4c5c85766d73baef671b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMi00LTEtMS0xMDMwMTY_59314fb8-e547-4b70-9cbe-4bd0d95b6b19"
      unitRef="usd">7187000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="id9114014f71e4e669763623118aa0ba8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMi02LTEtMS0xMDMwMTg_eb05e36a-1ec7-4f29-b307-ccae33e33fae"
      unitRef="usd">7432000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="i0581d534bc684ee0bee89a6945a375ad_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOjdlYzdhYjRlMWIwNTRiY2I5MmZlZTRlMTM1NzI5NzNlL3RhYmxlcmFuZ2U6N2VjN2FiNGUxYjA1NGJjYjkyZmVlNGUxMzU3Mjk3M2VfMy00LTEtMS0xMDMwMTY_f9325eaa-edac-4644-bbd4-cc6c065adee8"
      unitRef="usd">108856000</ifrs-full:Borrowings>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="ibcfcf3a44f2c4765be8da06698d39b1c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfNTQ5NzU1ODY3NzIy_90baa370-d401-48a5-994b-f68f16fea3e2"
      unitRef="usd">2543000</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:WarrantObligationFairValue
      contextRef="i328f49717bbc4a43869005d9a11ccde6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfNTQ5NzU1ODY3NzMy_921da4cf-38ed-4a34-b775-7bff8bf72b58"
      unitRef="usd">1414000</adc:WarrantObligationFairValue>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i552db3596e754dcaac31cd578b8a44be_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfMi0xLTEtMS0xMDMwMjE_7a51bcf8-0545-400a-95bf-4168e4a0c7d4"
      unitRef="shares">8.30</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i4d4202329f3c4f6f8e9950a5e0783159_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfMy0xLTEtMS0xMDMwMjE_f2be3425-7e46-410f-b084-62b9f1cdc3ec"
      unitRef="shares">4.82</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i63733b9453004d72806e33eea5e62eb1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNC0xLTEtMS0xMDMwMjE_2c086aff-2f3c-4e26-856d-d15f4545643d"
      unitRef="shares">0.042</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ia734cd26f3504a1883266d439ca95b0d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNS0xLTEtMS0xMDMwMjE_d0e7aa91-fe0f-4a40-bfdc-109a936dd9bb"
      unitRef="shares">0.80</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ic29dc84c1b3c4a498fd95b9388f8e481_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNi0xLTEtMS0xMDMwMjE_e27135ad-ed09-4454-9ebb-3e805070880b"
      unitRef="shares">58.5</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i07af9d83010848bb8b52ef3ad5f34f34_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfNy0xLTEtMS0xMDMwMjE_d15f2fa6-2ce3-495f-b8f8-923f87d7e0c7"
      unitRef="shares">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i03d2b5b155c54c47aefdb36bca46343a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RhYmxlOmE1M2U5NzY0ZTIwMDQ4ZWZiYWU2NThmYTNkYmEwZmJmL3RhYmxlcmFuZ2U6YTUzZTk3NjRlMjAwNDhlZmJhZTY1OGZhM2RiYTBmYmZfOC0xLTEtMS0xMDMwMjE_9e2e3c8c-a8c1-4c99-bd0a-14cf266e6e1e"
      unitRef="shares">2.68</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="if1d37dac85a149669ce03adcbf4ccc8e_I20220815"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDQ3Ng_cb860f0f-fe5a-4987-88d8-a46b4231b085"
      unitRef="number">0.1499</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="icf3fa17cff6e42feb53051b533840f31_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTY0OTI2NzQ5NTU2OQ_3e9b10d5-8fce-4b36-8bad-5806cfe2f55b"
      unitRef="usd">1933000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i13ee928b02464d82ab56ff3cd45a2c59_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTY0OTI2NzQ5NTU2OQ_e12003c9-9009-4125-b2db-01863aef8b36"
      unitRef="usd">1933000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:Borrowings
      contextRef="ibd2e5e5704574aebbaa2380a7fde3845_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfNTQ5NzU1ODY3NzUx_4dcf7a87-bf6e-4a5a-8ade-72f4b7c35efc"
      unitRef="usd">109200000</ifrs-full:Borrowings>
    <adc:ShortTermBorrowings
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDkyNg_3ac63800-0e77-413b-9126-2ac5be13f0c2"
      unitRef="usd">12500000</adc:ShortTermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="ibd2e5e5704574aebbaa2380a7fde3845_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV85Ny9mcmFnOmM2MzU4MTkwOWY3ZDRhYWZhZDY3OGU4ZTIwNGRiODQzL3RleHRyZWdpb246YzYzNTgxOTA5ZjdkNGFhZmFkNjc4ZThlMjA0ZGI4NDNfMTA5OTUxMTY5NDkzNA_b742eae0-138c-41dc-a033-4e73f6a933df"
      unitRef="usd">96700000</ifrs-full:LongtermBorrowings>
    <adc:BorrowingFacilitiesMaximumBorrowingCapacity
      contextRef="i0957db7bd16a421a88aa3e02e84a59f4_I20200424"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY3OTY_6c976752-5871-4137-b0be-68a9810b6609"
      unitRef="usd">115000000</adc:BorrowingFacilitiesMaximumBorrowingCapacity>
    <ifrs-full:Borrowings
      contextRef="i1dba557902d64fd2b341f02674834b60_I20200424"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4MDk_f6d9f261-a1e6-4ba9-9072-5dea30843112"
      unitRef="usd">65000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="idd6e0c7ae1fc42dabeef85f1e367666d_I20200424"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4MjE_1fc2e4fc-a3eb-4121-ae7b-854884ed36ac"
      unitRef="usd">50000000</ifrs-full:Borrowings>
    <adc:ExchangeOfConvertibleNotesForWarrants
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4NzA_ca6f3733-7206-4dc1-b2bd-8f220533a15f"
      unitRef="usd">115000000</adc:ExchangeOfConvertibleNotesForWarrants>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4MzM_60e3a638-6976-45f8-8ce9-f019ce523ec3"
      unitRef="shares">4412840</adc:ConvertibleNotesSharesConverted>
    <adc:ConvertibleNotesSharesConverted
      contextRef="i474416e45737460d849fb01685ad11e6_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4NTk_8be2e7ca-9519-4b84-9f1c-e6a3cdd54224"
      unitRef="shares">2390297</adc:ConvertibleNotesSharesConverted>
    <adc:ConvertibleNotesValueConverted
      contextRef="i2b93ddb8d53d4ec2872793932c99d612_I20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4NDQ_ff28ac57-a4d9-43e7-bdcb-45743ee767bc"
      unitRef="usd">117300000</adc:ConvertibleNotesValueConverted>
    <adc:GainsLossOnExtinguishmentOfBorrowings
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzcxMzY_fbcf9fa8-6b8c-4524-b575-f21401792c7c"
      unitRef="usd">-42100000</adc:GainsLossOnExtinguishmentOfBorrowings>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4ODQ_259ad9ee-3228-44a8-9a51-b5684c31153d">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in fair value income (expense) and profit or loss activity of the embedded conversion option derivatives during the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield First Tranche &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(2,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield Second Tranche - prior to FDA approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Deerfield Second Tranche - after FDA approval&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(1,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(3,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;10,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(4,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(4,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;25,650&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;16,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The fair value expense recognized during the three and nine months ended September 30, 2022 represents the change in fair value up until the point of exchange on August 15, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition to the changes in fair value, the Company recorded a gain of KUSD 1,816 during the nine months ended September 30, 2021 with the receipt of the USD 50&#160;million subsequent disbursement, the establishment of the embedded derivative and residual loan associated with the subsequent disbursement and elimination of the derivative immediately prior to FDA approval of ZYNLONTA.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i4282540cb4d245d89cd058fd40102cd0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtMi0xLTEtMTAyOTk0_f604b7c8-aadd-4a22-a1a1-fae4ad7d231e"
      unitRef="usd">-2822000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i4c1c3f7a35f3450ca62c6907d078e8e2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtNC0xLTEtMTAzMDAw_101e2217-9fa3-4f87-a29c-d38584270305"
      unitRef="usd">-3913000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="if1a8de23046f4460ad2c010b046624fc_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtNi0xLTEtMTAzMDAy_33a3cf71-bc2f-413d-8647-538aa10d82b1"
      unitRef="usd">15556000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i424298b8a03c4c6291deae71a0a00390_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzMtOC0xLTEtMTAzMDA0_7d803a0e-847c-4106-b21f-52b43b1aa050"
      unitRef="usd">16867000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i8541b30e628240598a82d1a6e8ece81c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtMi0xLTEtMTAyOTk0_f9010412-b3cd-4537-9808-4cf601992aea"
      unitRef="usd">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i510177f707e04303ad7498a272eb89fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtNC0xLTEtMTAzMDAw_ebf395f8-6c78-42b9-b4eb-4026f66b6a97"
      unitRef="usd">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i5bfbbc2c610147c3a34fba908fd852ec_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtNi0xLTEtMTAzMDAy_0da66489-830e-4a5b-96c9-a4d33d859730"
      unitRef="usd">0</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i47d31600d9f0428d8b62b78002cda536_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzQtOC0xLTEtMTAzMDA0_012ec193-2074-4a9a-9286-6adf0adfd09f"
      unitRef="usd">3454000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i78bbf9c8e62844d986598b81c243a4e8_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtMi0xLTEtMTAyOTk0_e6bb35f5-8146-4124-a8a9-b73eacca89b7"
      unitRef="usd">-1838000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i30f2235b8f984b71a72137b6c9c711ed_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtNC0xLTEtMTAzMDAw_2700c87a-0648-485a-96a0-827a3abf3ecf"
      unitRef="usd">-3030000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="iff0912cb42094f0b8c2cf9d89bea012a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtNi0xLTEtMTAzMDAy_8ec4eaea-712a-49ce-bc56-7b7d7843c948"
      unitRef="usd">10094000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i52bdc445f4e04e91a6b705a99bc90fa5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzUtOC0xLTEtMTAzMDA0_2e70afa2-d24b-42b7-9044-d12471302435"
      unitRef="usd">-4042000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctMi0xLTEtMTAyOTk0_33781565-64a9-447c-af9b-dd6c5a7b401d"
      unitRef="usd">-4660000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctNC0xLTEtMTAzMDAw_030ccde9-c3f5-4cd1-acf5-0c2cb98ba3cc"
      unitRef="usd">-6943000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctNi0xLTEtMTAzMDAy_4e78083b-cb02-44f0-ac98-b7edba819deb"
      unitRef="usd">25650000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTo5MjA0OWQwYTczOTI0MzE3YmQ0YTc0ZmI2OTZiZGU5Ni90YWJsZXJhbmdlOjkyMDQ5ZDBhNzM5MjQzMTdiZDRhNzRmYjY5NmJkZTk2XzctOC0xLTEtMTAzMDA0_725779d7-677f-4122-946c-e96d5fc94b74"
      unitRef="usd">16279000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsOnChangeInFairValueOfDerivatives
      contextRef="i025881af419e4a3192fb9cf499462a5f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzcxMTk_aa6e8652-b08b-4e7a-84d0-26980741ce9e"
      unitRef="usd">1816000</ifrs-full:GainsOnChangeInFairValueOfDerivatives>
    <ifrs-full:Borrowings
      contextRef="iff062fd0475a492786d931f7f5c45f6e_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzcxMDc_9cd18f0c-a6df-4def-bcc1-91fdf6fb5bd2"
      unitRef="usd">50000000</ifrs-full:Borrowings>
    <ifrs-full:CreditDerivativeFairValue
      contextRef="i82d563da995d45569288f830e5149dfb_I20220815"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4OTU_ab7049bd-b360-48dd-b90c-e34f33df5003"
      unitRef="usd">7670000</ifrs-full:CreditDerivativeFairValue>
    <ifrs-full:CreditDerivativeFairValue
      contextRef="i2b7c1b8716664d0c8a84d93d75702409_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY4ODc_3b182a37-0523-42f4-9c27-5aa1a7d4fab2"
      unitRef="usd">23226</ifrs-full:CreditDerivativeFairValue>
    <ifrs-full:CreditDerivativeFairValue
      contextRef="i0a3bdac45860479dabcb75dfdd6867f4_I20220815"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY5MDI_7e4630c3-d719-472a-8e57-1c8fe364342b"
      unitRef="usd">4627000</ifrs-full:CreditDerivativeFairValue>
    <ifrs-full:CreditDerivativeFairValue
      contextRef="i97aa7f5a5df243008d7ef0e4a3eb306e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90ZXh0cmVnaW9uOmRiNWQyZjZjNDAzNDQ5OGI4MmE4Y2Y5MDNlMTkzN2QyXzEwOTk1MTE2MzY5MDk_da53f6b1-49e3-48d0-a22e-5c066d01edd0"
      unitRef="usd">14721</ifrs-full:CreditDerivativeFairValue>
    <adc:BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice
      contextRef="if1a8de23046f4460ad2c010b046624fc_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMC0xLTEtOTM3MjMvdGV4dHJlZ2lvbjplOWMxNjNiMzM5ZTU0OTM0YTE1MTU4NzY2M2ZhNDI5Y18yMg_07bcc5d6-2985-4d8f-af9c-29e880c9238d"
      unitRef="number">1.30</adc:BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice>
    <adc:OfferingPricePerShare
      contextRef="ic3d81122c2c840e4b693968f8c508748_D20200519-20200519"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMC0xLTEtOTM3MjMvdGV4dHJlZ2lvbjplOWMxNjNiMzM5ZTU0OTM0YTE1MTU4NzY2M2ZhNDI5Y180NQ_71e7d73d-b0f3-4860-a38c-7efb66422384"
      unitRef="usdPerShare">19.00</adc:OfferingPricePerShare>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i710642318daa4f7daf7095ef7f4be22a_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMS0xLTEtMTAyODU3_36d5541d-a10b-40bc-b020-5948bce548b8"
      unitRef="usdPerShare">24.70</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="id466e5c2487a4ac1b5b6504272a8f609_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzItMy0xLTEtMTAyODU3_55708dec-2cf5-4597-ac96-197ed18716c0"
      unitRef="usdPerShare">24.70</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="iac273354477741cf86e47def8ffcd7a1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzMtMS0xLTEtMTAyODU3_be87a916-ba5a-4f2f-a555-071d19dffae6"
      unitRef="usdPerShare">67.93</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i99f4af969dd2458582b9d874b88cbbf4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzMtMy0xLTEtMTAyODU3_9912e479-dd34-40c1-9b13-72f4d636147d"
      unitRef="usdPerShare">67.93</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i8931b5a8351240ac87b0246c2abe8dd9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzQtMS0xLTEtMTAyODU3_f4c93a22-7769-413b-90a3-df30af8d6fa9"
      unitRef="usdPerShare">10.33</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i9d8669ba09764fbb9a618a4a6edae470_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzQtMy0xLTEtMTAyODU3_1cdd4fb3-2d23-4169-8edb-65f7af1a87a7"
      unitRef="usdPerShare">20.20</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ic9928a9264d740c89377de3cdebcd1e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzUtMS0xLTEtMTAyODU3_040cf785-0dfa-4136-aea1-a1664b32cd16"
      unitRef="number">0.032</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i7c66eb70f2894de98ed215565f60df64_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzUtMy0xLTEtMTAyODU3_00d763d3-1c6c-42e4-8e68-8070f9c88006"
      unitRef="number">0.010</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i9de9014907024e3189eac77111a06a63_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzYtMS0xLTEtMTAyODU3_5686cadd-625e-4ea4-a604-89ae941cc0a9"
      unitRef="number">0.85</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i45da12590d9f4047b6bd3403ac33f3c7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzYtMy0xLTEtMTAyODU3_5419cd98-83aa-4a69-b604-bce4142a56f6"
      unitRef="number">0.77</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i3ef057b084c9401b842b0fe5bdd4e853_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzctMS0xLTEtMTAyODU3_00217663-ec2c-447d-8ee3-3ffb144a696f"
      unitRef="period">32.5</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i3f8646e19d5e4d45b7ef56c2360fcbc8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzctMy0xLTEtMTAyODU3_b2aa0f4b-67af-4cba-8940-02773c989f70"
      unitRef="period">40</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i86670cf410ee493e8877ad4c966d0671_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzgtMS0xLTEtMTAyODU3_8ebef965-002b-4e98-96a4-98fda59f33f0"
      unitRef="number">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i2b3ec2e705764730bd7acdc7796976e0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzgtMy0xLTEtMTAyODU3_8319557e-df8c-4dd5-ac5a-8185592f99b3"
      unitRef="number">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ib148dbac37274e269a90f2f14e60f877_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzktMS0xLTEtMTAyODU3_7eb16de3-d751-4980-b612-2745100f724f"
      unitRef="number">0.05</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i090c3d455bb74e6281428f2f07643108_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzktMy0xLTEtMTAyODU3_027446b4-6786-4b7b-86fb-4eb61899659c"
      unitRef="number">0.05</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i4f702cd53b354e9881252bcbf57c2f1c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzEwLTEtMS0xLTEwMjg1Nw_2e342264-08f7-457e-a5b3-e5cda609ab27"
      unitRef="number">0.120</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ic8afbb48cf2d48cfbd405ff609f28cc4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTplOWExOTBmMTlkNDM0YzNhYWRlNWY3NGFiY2VhOWM3MC90YWJsZXJhbmdlOmU5YTE5MGYxOWQ0MzRjM2FhZGU1Zjc0YWJjZWE5YzcwXzEwLTMtMS0xLTEwMjg1Nw_1bc947dc-762c-4fe2-aeb9-b320f9088fe1"
      unitRef="number">0.088</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i56eace5f28ad4674b7f788baea9f47e8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzItMi0xLTEtMTAyODU5_cf9d877f-f879-4b74-8392-99a21546ceb8"
      unitRef="usdPerShare">28.07</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i63e9f713f46b436eb737b72a7e01713b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzItNC0xLTEtMTAyODU5_69db7540-eeef-4693-a91b-90e45a8fab45"
      unitRef="usdPerShare">28.07</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ibffd8b0c78d841a5a370b35fad8ace99_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzMtMi0xLTEtMTAyODU5_601df330-3f1d-486c-827d-73a35d3deb59"
      unitRef="usdPerShare">77.19</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i03318851c1c0465f8efb9f6dbe913d26_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzMtNC0xLTEtMTAyODU5_f8ca0186-b8d6-48b2-8865-a9b47332732a"
      unitRef="usdPerShare">77.19</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i0ef20d84bc4a4f9589901030b1ae9dde_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzQtMi0xLTEtMTAyODU5_054c54e6-43a9-4910-9ed9-6348fd69da2e"
      unitRef="usdPerShare">10.33</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i20780f1e715242878284103f33e5a95b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzQtNC0xLTEtMTAyODU5_cc9df8e3-af72-42eb-95d4-d5a09a9eab2b"
      unitRef="usdPerShare">20.20</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i0d107c4c0c244c4986cf5e94e684cfa3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzUtMi0xLTEtMTAyODU5_d7a0cb58-c7cc-41a6-b30b-b1fee732f2df"
      unitRef="number">0.032</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i1b8a345318c14c5cb9e3dd2c0e1b53e6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzUtNC0xLTEtMTAyODU5_195fa227-c2df-4276-b083-4c73d3ff24de"
      unitRef="number">0.010</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i7cc325fcfe32426097e9538a2b3302b5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzYtMi0xLTEtMTAyODU5_4cf2da01-d72e-401f-b5e5-a091d2620841"
      unitRef="number">0.85</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i7b376657412246a595f43060ab7c5581_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzYtNC0xLTEtMTAyODU5_2dbc372d-68d5-4c49-8f48-a8285a51ffda"
      unitRef="number">0.77</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i379eff6d11204554bf233766e8da501f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzctMi0xLTEtMTAyODU5_3119714d-5f57-435b-a35d-5441a6378c1d"
      unitRef="period">32.5</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ia13a616afebd445f954de55db94ff515_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzctNC0xLTEtMTAyODU5_cfc6dda5-6465-40d1-8554-ba2a0a06dc8b"
      unitRef="period">40</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i7c15e42527ff44a3a5c93c9c96208bcf_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzgtMi0xLTEtMTAyODU5_c81614b5-1afa-40cf-9c54-5272cdc054a6"
      unitRef="number">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i19368979b8a145d5a6a63e3b0d6e8636_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzgtNC0xLTEtMTAyODU5_da8a18a2-affa-4c32-95d7-ac84c5a80ee8"
      unitRef="number">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ic268075c47794e01a968504730a874e2_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzktMi0xLTEtMTAyODU5_64e89cd6-63b0-4d99-856a-1f340bf2743d"
      unitRef="number">0.05</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i35e5cd27137b4e10b214c3577489cc0c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzktNC0xLTEtMTAyODU5_31d0117c-7125-4c92-ad58-7d970ee843bb"
      unitRef="number">0.05</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ia5c4b1a0cc67448cbc5473e914944c11_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzEwLTItMS0xLTEwMjg1OQ_303ca624-0944-4620-82a5-cf9ea8ae8631"
      unitRef="number">0.120</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ic4621be8061f40f29a22f85bd1a3ce97_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZTpjZWIwM2YwNzhiOWI0NGU5YTg0YTM4ZWYwZGRhNmI0ZS90YWJsZXJhbmdlOmNlYjAzZjA3OGI5YjQ0ZTlhODRhMzhlZjBkZGE2YjRlXzEwLTQtMS0xLTEwMjg1OQ_a45104a7-ea70-431b-898d-d206457cfa7d"
      unitRef="number">0.088</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i3bb83ca124504d81bae6bd67b59bdcad_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtMi0xLTEtMTAzMDA2_08b6bfd8-a741-447a-b9c8-8980a2e8e3ab"
      unitRef="usd">1132000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i8696a50af25a4d5698814222277a2b26_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtNC0xLTEtMTAzMDA4_36bd452a-d4a7-44f2-8f83-c9f3e96ddecb"
      unitRef="usd">2142000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i71dfb6d248ff4198a8951d34e0f3e61b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtNi0xLTEtMTAzMDEw_b858f470-7e31-4c6f-9557-6894f690af31"
      unitRef="usd">5664000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i9f2027858cad46a39efcfcb65c359818_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzMtOC0xLTEtMTAzMDEy_d9f33fc6-6609-44e6-924a-e31e42f4ba40"
      unitRef="usd">6184000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i0eb58365b3f6457d8705fd6e8d0e13d4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtMi0xLTEtMTAzMDA2_15d8e4b1-a316-4f88-91ae-73ce40938c46"
      unitRef="usd">404000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="ie7aa01b4ce9b4ddf9ea12f4230135446_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtNC0xLTEtMTAzMDA4_dd6b77a7-81a0-4b69-b6e2-7370c4e548a0"
      unitRef="usd">819000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="ica385bd851294fa8a39c826b2ecb7376_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtNi0xLTEtMTAzMDEw_88d8688a-5e16-4ba2-a21b-d523815c5f81"
      unitRef="usd">2020000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="iad41e5db92cf4b05819e5ee0b2c622f0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzQtOC0xLTEtMTAzMDEy_8b0e6a85-d527-42a7-a304-c2e3bcfd35a7"
      unitRef="usd">1209000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i785f01a211a243bda6e912eb3ec1e0a2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtMi0xLTEtMTAzMDA2_5db50011-e17d-4373-9e9d-ee95862e2072"
      unitRef="usd">1536000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="ib977e7d27b6240c08c35a9a983b92e2b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtNC0xLTEtMTAzMDA4_10fbf0c8-6e6b-4b8a-ab2d-068fdf0caef7"
      unitRef="usd">2961000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="i22eebd39c0444c7a8b3ec579b6376df0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtNi0xLTEtMTAzMDEw_0c8ce6af-8cf4-44a2-a796-fe698fd7a466"
      unitRef="usd">7684000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="id5dfc30cca8047389598bb92059469df_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjIvZnJhZzpkYjVkMmY2YzQwMzQ0OThiODJhOGNmOTAzZTE5MzdkMi90YWJsZToxZDRjYWQ2Y2Y4ZjQ0MmMyYTBiNmU2MzMwYTcxNTY0Mi90YWJsZXJhbmdlOjFkNGNhZDZjZjhmNDQyYzJhMGI2ZTYzMzBhNzE1NjQyXzUtOC0xLTEtMTAzMDEy_e5f4153c-1b89-4805-b61e-bf7b02d785e6"
      unitRef="usd">7393000</ifrs-full:InterestExpenseOnBorrowings>
    <adc:DisclosureOfWarrantsTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNjU_b03925a8-8aa2-4563-8622-6f07028f9ea1">Deerfield warrants&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the exchange agreement with Deerfield entered into on August 15, 2022, the Company issued warrants to purchase an aggregate of 4,412,840 common shares. The warrants consist of warrants to purchase an aggregate of 2,631,578 common shares at an exercise price of USD 24.70 per share and warrants to purchase an aggregate of 1,781,262 common shares at an exercise price of USD 28.07 per share. Each warrant is exercisable, on a cash or a cashless basis, at the option of the holder, at any time on or prior to May 19, 2025. The warrants contain customary anti-dilution adjustments and entitle holders to receive any dividends or other distributions paid on the underlying common shares prior to their expiration on an as-exercised basis. Each holder also may require the Company to repurchase the warrants for their Black Scholes-based fair value in connection with certain transformative transactions or change of control of the Company that occur prior to their expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the warrants are reflective of the terms of the embedded conversion option features of the Deerfield Facility Agreement prior to the Exchange Agreement. As a result, the fair value of the warrants was determined to approximate the fair value of the existing embedded conversion option features immediately prior to the consummation of the Exchange Agreement. As such, the warrant obligation was recorded at an initial fair value of KUSD 12,297 on August 15, 2022. Subsequent to issuance, the warrant obligation will be remeasured to fair value on a quarterly basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2022, the Company recognized income of KUSD 9,418 as a result of changes in the fair value of the warrant obligation. The fair value of the warrant obligation as of September 30, 2022 was KUSD 2,879. The decrease in fair value of the warrant obligation from August 15, 2022 to September 30, 2022 was primarily due to the decrease in the fair value of the underlying shares during that period. These amounts were recorded to Non-operating (expense) income in the unaudited condensed consolidated interim statement of operations. See note 8, "Non-operating (expense) income" for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an independent valuation firm to assist in calculating the fair value of the Deerfield warrant obligation, using the Black-Scholes option-pricing model. Key inputs for the valuation of the warrant obligation as of September 30, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24.70 and 28.07&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;31.7 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Black-Scholes value in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;0.69 and 0.60&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</adc:DisclosureOfWarrantsTextBlock>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMjI_d685211e-59bd-4bc6-90b5-9af4ac6bc440"
      unitRef="shares">4412840</adc:ConvertibleNotesSharesConverted>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ic61b06ba04bb455c96af4c895e3fbab5_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMzM_00c58b73-adeb-476c-b40a-ec09badc62ae"
      unitRef="shares">2631578</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="i7754055a3c2b48f1973108a8654c2f44_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMDQ_d5673c0c-dbd7-46b3-a3d8-1c4c169fe209"
      unitRef="usdPerShare">24.70</adc:WarrantsSharesConvertedExercisePrice>
    <adc:ConvertibleNotesSharesConverted
      contextRef="ic773f1ac351d475884fb8d697e7ba151_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyMTE_2c65e2bd-d4ea-44b5-a3bb-bca05e453b56"
      unitRef="shares">1781262</adc:ConvertibleNotesSharesConverted>
    <adc:WarrantsSharesConvertedExercisePrice
      contextRef="ida52356d4ff3403a8d3af122a8d3ebe5_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNDQ_20464735-f538-451e-8169-ae993135e7e1"
      unitRef="usdPerShare">28.07</adc:WarrantsSharesConvertedExercisePrice>
    <adc:WarrantObligationFairValue
      contextRef="i6ecc2b598dba46c28662f729e6defde9_I20220815"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNTE_5d12856d-cccd-4b5b-96ba-55de46a90f84"
      unitRef="usd">12297000</adc:WarrantObligationFairValue>
    <adc:GainsLossOnChangeInFairValueWarrants
      contextRef="if5b8cb0e3d9b4f7eb2ed274185dc0e11_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzU0OTc1NTgxOTMwOA_e7a9b90a-5833-4039-bfef-d24bbe40a786"
      unitRef="usd">9418000</adc:GainsLossOnChangeInFairValueWarrants>
    <adc:WarrantObligationFairValue
      contextRef="i9d5e9a2305fb4a7085bc82c1eb6cfd25_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzU0OTc1NTgxOTEzMQ_a2a605bc-1259-4443-a090-9ab5a7af5015"
      unitRef="usd">2879000</adc:WarrantObligationFairValue>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90ZXh0cmVnaW9uOjQzZDYwZjk2ODYwYTQwNDg5Y2ZkMGE3MzllZTUxNWM2XzEwOTk1MTE2MzMyNjQ_119280b9-f124-47ae-aeb5-5eb86b4f680a">Key inputs for the valuation of the warrant obligation as of September 30, 2022 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Exercise price in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;24.70 and 28.07&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price in USD&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:133%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected term (months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;31.7 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Black-Scholes value in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;0.69 and 0.60&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ia26abd4a41954e9e9346a99a9f049985_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzItMS0xLTEtMTAzNDczL3RleHRyZWdpb246N2UyY2MwN2YzMGI5NDRkMWFlNjU5ODU2ZDQxOWQ3Y2ZfMTA5OTUxMTYyNzgwMA_587da360-bb8b-4b21-9c97-ce62e5c7d13e"
      unitRef="usdPerShare">24.70</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="ieca945cdabd9410cbc9c13e7257adfb4_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzItMS0xLTEtMTAzNDczL3RleHRyZWdpb246N2UyY2MwN2YzMGI5NDRkMWFlNjU5ODU2ZDQxOWQ3Y2ZfMTA5OTUxMTYyNzgxMA_b91a893b-d674-4a1c-8a56-ede81288b23d"
      unitRef="usdPerShare">28.07</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i596a372cc69b47f19dc090d174f662f3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzMtMS0xLTEtMTAzNDcz_c3ac645c-1ff8-4a0e-a9e2-96211938f1c7"
      unitRef="usdPerShare">4.82</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i5b3bb514320f434fb2c8f0bbf4378a14_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzQtMS0xLTEtMTAzNDcz_9cd3e0a8-0467-4d7f-b7a3-7f5917e0d78c"
      unitRef="usdPerShare">0.042</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i164cd50484d545a2af9114f0c1debbd9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzUtMS0xLTEtMTAzNDcz_9c2a5a19-c699-4933-99ac-4cea8841dbc9"
      unitRef="number">0.80</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i8f02e5be548f4f8dbc48b21e80389512_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzYtMS0xLTEtMTAzNDcz_bd738c74-5754-46d5-a14c-88ada9d242f8"
      unitRef="number">31.7</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i7a71734534bd4767beb6925c131abf14_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzctMS0xLTEtMTAzNDcz_45bd2e6b-1ddf-49e0-8c5a-31b601c06156"
      unitRef="period">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i5908e3933d294f34ad3a587158cb41e9_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzgtMS0xLTEtMTAzNjE1L3RleHRyZWdpb246MDViMDZiNzgzZWM0NDVlNWE0MGFmODcyY2Y5YzExYTNfMTA5OTUxMTYyNzc5Nw_63ffcea2-02e8-411b-86bd-9b772c1b2f14"
      unitRef="shares">0.69</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="i079987d8ff4843f5aa3402f23485ad3e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNjgvZnJhZzo0M2Q2MGY5Njg2MGE0MDQ4OWNmZDBhNzM5ZWU1MTVjNi90YWJsZTpjMGJmMmY3ZDRlZGE0Yzc1ODg5YTc1ZDg0MDllMmQyNC90YWJsZXJhbmdlOmMwYmYyZjdkNGVkYTRjNzU4ODlhNzVkODQwOWUyZDI0XzgtMS0xLTEtMTAzNjE1L3RleHRyZWdpb246MDViMDZiNzgzZWM0NDVlNWE0MGFmODcyY2Y5YzExYTNfMTA5OTUxMTYyNzgwNA_a77af946-2272-4c85-9931-d1d4e8e14540"
      unitRef="shares">0.60</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzM4NDgyOTA2OTkwMDM_428ea27c-7fab-458b-adf0-a3d837f046db">EquityOn August 15, 2022, the Company entered into a share purchase agreement with the Purchasers, pursuant to which, on September 6, 2022, the Company issued and sold to the purchasers an aggregate of 733,568 common shares at USD 8.52 per share. The shares were issued from the Company&#x2019;s treasury shares at par value, which arose from the Share Subscription Agreement. See note 2, &#x201c;Basis of Preparation." The transaction was recorded as a USD 6.1&#160;million net increase to share premium for the issuance of the common shares, net of transaction costs accrued and paid, and an increase in cash and cash equivalents.The Company also recorded a USD 19.6&#160;million non-cash net increase to share premium for the issuance of the 2,390,297 common shares to Deerfield in connection with the exchange of the senior secured convertible notes. The shares were issued from the Company&#x2019;s treasury shares at par value, which arose from the Share Subscription Agreement. See note 15, &#x201c;Convertible loans&#x201d; and note 2, &#x201c;Basis of Preparation&#x201d; for further information on this transaction and Share Subscription Agreement, respectively.</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1MTE_632e2bba-0d97-47f6-9a3c-7c136fd390dd"
      unitRef="shares">733568</ifrs-full:NumberOfSharesIssued>
    <adc:SaleOfStockPricePerShare
      contextRef="i8e1a14874532471a96f7d73129d6c1ca_I20220815"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1MjA_946ddf21-fcea-4ef6-b525-d95f47abe1f0"
      unitRef="usdPerShare">8.52</adc:SaleOfStockPricePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="ia6c9b855c1f247cdae6ad0bac21a2df8_D20220815-20220815"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzM4NDgyOTA2OTg5OTE_15fc2076-35ee-4f93-a707-797fde694107"
      unitRef="usd">6100000</ifrs-full:ProceedsFromIssuingShares>
    <adc:IssueOfEquityThroughExchangeAgreement
      contextRef="i2584a401285d424c9fba045da1553201_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1MjY_73fdc0f3-c463-4c6a-9a1f-67b417d4f02d"
      unitRef="usd">19600000</adc:IssueOfEquityThroughExchangeAgreement>
    <adc:ConvertibleNotesSharesConverted
      contextRef="i474416e45737460d849fb01685ad11e6_D20220815-20220815"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8zNzQvZnJhZzo4MzAxZjg1MjMxZmU0M2ZkYTdjZWFmZGY2OWU0MGNkNS90ZXh0cmVnaW9uOjgzMDFmODUyMzFmZTQzZmRhN2NlYWZkZjY5ZTQwY2Q1XzEwOTk1MTE2Mjk1NDA_6457350e-e5ef-4c2d-85ce-fc669099ddc6"
      unitRef="shares">2390297</adc:ConvertibleNotesSharesConverted>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzM_f43fc059-a316-4257-b1bb-59b2165b529e">Share-based compensation&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Incentive Plan 2019&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company adopted the Equity Incentive Plan 2019. Under the Equity Incentive Plan 2019, the Company may at its discretion grant to plan participants, such as directors, certain employees and service providers, awards in the form of restricted shares and restricted share units (&#x201c;RSUs&#x201d;), share options, share appreciation rights, performance awards and other share-based awards. The Company has reserved 13,820,000 common shares for future issuance under the Equity Incentive Plan 2019 (including share-based equity awards granted to date less awards forfeited). As of September&#160;30, 2022, the Company has 1,349,944 common shares available for the future issuance of share-based equity awards. On March 7, 2022, the Company issued its annual equity award, which was approved by the Compensation Committee of the Board of Directors and consisted of 1,867,076 share options and 570,340 RSUs. On May 11, 2022, the Company issued a special retention award to select employees, which was approved by the Compensation Committee of the Board of Directors and consisted of 1,298,700 RSU's. As of September&#160;30, 2022, the Company has only granted share options, RSUs and performance awards under the Equity Incentive Plan 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the cumulative amount recorded as an increase to Other Reserves within equity in the unaudited condensed consolidated interim balance sheet of the Equity Incentive Plan 2019 was KUSD 137,759. An amount of KUSD 512 was withheld for tax charges during the three months ended March 31, 2022. There were no amounts withheld for tax charges during both the three months ended September 30, 2022 and June 30, 2022. The amount of expense for all awards recognized for services received during the three and nine months ended September&#160;30, 2022 were KUSD 14,565 and KUSD 42,293, respectively, and for the three and nine months ended September&#160;30, 2021 were KUSD 14,798 and KUSD 47,016, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Equity Incentive Plan 2019, the Company may grant share options to its directors, certain employees and service providers working for the benefit of the Company at the time. The exercise price per share option is set by the Company at the fair market value of the underlying common shares on the date of grant, as determined by the Company, which is generally the closing share price of the Company&#x2019;s common shares traded on the NYSE. The awards generally vest 25% on the first anniversary of the date of grant, and thereafter evenly on a monthly basis over the subsequent three years. The contractual term of each share option award granted is ten years. Under the grant, the options may be settled only in common shares of the Company. Therefore, the grants of share options under the Equity Incentive Plan 2019 have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company&#x2019;s unaudited condensed consolidated interim statement of operations and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expense recognized for services received during the three and nine months ended September&#160;30, 2022 was KUSD 8,193 and KUSD 27,158, respectively. The expense recognized for services received during the three and nine months ended September&#160;30, 2021 was KUSD 12,105 and KUSD 40,112, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the share option awards outstanding as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Average strike price per share in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Number of awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Weighted average remaining life&lt;br/&gt;in years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;27.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,640,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,937,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(820,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;21.23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,757,225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards outstanding as of September&#160;30, 2022 and December&#160;31, 2021, expire through 2032 and 2031, respectively. The options granted during 2022 include the Company&#x2019;s annual equity award discussed above. The grant-date fair value of the options relating to the annual equity awards was USD 8.85 per share. As of September&#160;30, 2022, 3,457,420 awards are vested and exercisable out of the total outstanding awards of 9,757,225 common shares. The weighted average strike price and weighted average remaining life for vested and exercisable awards is USD 25.67 and 7.44 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the options granted were determined on the date of the grant using the Black-Scholes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;option-pricing&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; model. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Company used an independent valuation firm to assist in calculating the fair value of the award grants per participant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;values&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the options granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the three and nine months ended September&#160;30, 2022 were determined on the date of the grant using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price, in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 8.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 19.69&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Strike price, in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 8.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 19.69&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;70% to 80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;70% to 80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Award life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6.08 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2.61% - 3.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.46% - 3.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility was based on the Company&#x2019;s historical volatility and selected volatility determined by median values observed among other comparable public companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The award life is based on the time interval between the date of grant and the date during the ten-year life after which, when making the grant, the Company expected on average that participants would exercise their options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Equity Incentive Plan 2019, the Company may grant RSUs to its directors, certain employees and service providers working for the benefit of the Company at the time. The awards generally vest annually over a period of three years commencing on the first anniversary of the date of grant. The special retention awards discussed above vest 50% and the remainder at the six-month and one year anniversaries, respectively, of the grant date. The RSUs may be settled only in common shares of the Company. Therefore, the grants of RSUs under the Equity Incentive Plan 2019 have been accounted for as equity-settled under IFRS 2. As such, the Company records a charge for the vested portion of award grants and for partially earned but non-vested portions of award grants. This results in a front-loaded charge to the Company&#x2019;s unaudited condensed consolidated interim statement of operations and a corresponding increase to Other Reserves within equity on the unaudited condensed consolidated interim balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expense recognized for services received during the three and nine months ended September&#160;30, 2022 was KUSD 6,372 and KUSD 15,135, respectively. The expense recognized for services received during the three and nine months ended September&#160;30, 2021 was KUSD 2,693 and KUSD 6,904, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Number of awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;663,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;30.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,129,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(344,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;30.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(135,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,313,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RSUs granted during 2022 include the annual equity award and special retention award discussed above, which had grant date fair values of USD 14.00 and USD 6.93, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share-based Compensation Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movement in the Share-based Compensation Reserves (included in Other reserves within equity) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - Share Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;40,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Tax and social charge deductions - Incentive Plan 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;41,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;47,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2022 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company adopted the 2022 ESPP, which was approved by shareholders at the Company's 2022 Annual General Meeting. The Company has 782,700 common shares reserved and available for the future issuance. The number of shares available for grant and issuance under the 2022 ESPP will increase on January 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of each of the first ten calendar years during the term of the 2022 ESPP by the number of shares equal to 1% of the shares outstanding as of the immediately preceding December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or lesser number as may be determined by the Board. The aggregate number of shares that may be issued under the 2022 ESPP Plan is equal to 1% of the ordinary share capital of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 ESPP allows eligible employees to purchase designated shares of the Company's common shares at a discount, over a series of offering periods through accumulated payroll deductions. No offering period may be longer than 27 months. The purchase price for shares purchased under the 2022 ESPP during any given purchase period will be 85% of the lesser of the market price of the Company&#x2019;s common shares on (i) the offering date or (ii) the purchase date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant date of the initial offering period was July 18, 2022, and that offering period will end on December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes share-based compensation expense related to purchase rights granted pursuant to its 2022 ESPP on a straight-line basis over the requisite service period, which is generally a six-month period. The fair value of the purchase rights granted were determined on the date of the grant using the Black-Scholes option-pricing model. The Company used an independent valuation firm to assist in calculating the fair value of the purchase rights. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expense for services received during the three and nine months ended September 30, 2022 was not material to the overall financial statements. As of September 30, 2022, the Company recorded a liability of KUSD 220 related to the accumulated payroll deductions, which are refundable to employees who withdraw from the ESPP. This amount is included within Accrued expenses in other current liabilities in the unaudited condensed consolidated interim balance sheet.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="i676dd5e5964f478cb2a4ee69ccbedc9c_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzQ4MA_516f6046-3a28-4556-99c4-332f65107711"
      unitRef="shares">13820000</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="i2afee1f6b2004f1493e2dcbd25a219d0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzY1Nw_af4d2898-713e-464a-97b1-03779d4a02bc"
      unitRef="shares">1349944</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i2d4b84bf34674d74a74743921df55fbc_D20210322-20210322"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4Xzg5Mg_6ed5de76-df6b-44c9-847a-c3d05e80a016"
      unitRef="shares">1867076</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i554dfdb979b34373ae4b5733abf1276e_D20210322-20210322"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzkxMw_53abf8fa-e067-4b1a-86f3-c8274321fcfb"
      unitRef="shares">570340</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i99eeeb04107b4ce58f0f4c3600598f48_D20220511-20220511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzEwOTc_076a5591-512d-47e3-9aaa-ba3e4f54ed52"
      unitRef="shares">1298700</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE0MjA_0b05eb0a-0aa2-40cb-b935-d077a3bc9481"
      unitRef="usd">137759000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions
      contextRef="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE0NDI_4f385df0-b8b2-4e0a-9a90-f2806c084fab"
      unitRef="usd">-512000</adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE2OTI_2fb6ab2a-ab15-42d3-a6c9-68a92c56eafc"
      unitRef="shares">14565000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE3MDQ_7288592d-c396-4687-92b7-655b5acd88d3"
      unitRef="shares">42293000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i42b2f8cecf45438c8f21adf9eec38ecf_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE3NjM_2584bfac-9379-4ff5-8944-2da7a18f28bd"
      unitRef="shares">14798000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i03009233bf004bb08cea9b8dc88563c8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzE3NzU_4691d6b7-96e1-4161-a04f-3dce06696a8e"
      unitRef="shares">47016000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="idfe39b129e824b348d51d6de645307b0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_4535d92c-cafc-4cdf-bee7-0ebc2717c5d5"
      unitRef="number">0.25</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i6a10848ed433473dacbefea93eb427b0_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_884233ce-5627-4454-b9ca-29470ea7e27d"
      unitRef="number">0.25</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i2713424043c64085a64de9bf55b5640e_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_fc085a33-79d3-438c-83f8-1838a624ee54"
      unitRef="number">0.25</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i52a52dd4005c426b875e0cc78e2afab5_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIyODU_fe9b7f10-24c1-4586-9ddf-6e9e2743b781"
      unitRef="number">0.25</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzIzOTY_ff418baf-4d49-4b87-b662-c4c91a6da840">P3Y</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <adc:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
      contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzI0NTk_a20cccf6-fa0e-4316-8c57-a265fdc28b8c">P10Y</adc:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMxNDg_ca5b84ed-f294-486a-b54b-a340757660a3"
      unitRef="usd">8193000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMxNjA_d8125196-6ba7-4e53-bd3e-fd0f8c3da484"
      unitRef="usd">27158000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i42b2f8cecf45438c8f21adf9eec38ecf_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMyNjI_ae6cbec9-a394-4dcb-b646-6547f4fe9f4f"
      unitRef="usd">12105000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="i03009233bf004bb08cea9b8dc88563c8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzMyNzQ_bb5a33f7-d1fb-431e-bbc1-c19b8e3b9012"
      unitRef="usd">40112000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzQ_4b405c5b-e1f9-461a-8d40-6e6027435371">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the share option awards outstanding as of September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Average strike price per share in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Number of awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Weighted average remaining life&lt;br/&gt;in years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;27.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,640,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,937,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;26.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(820,031)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;21.23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,757,225&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzEtMS0xLTEtODY3MDk_c4bdcd2f-c704-4c95-9e4d-cf83106d1dbc"
      unitRef="usdPerShare">27.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzEtMy0xLTEtODY3MDk_ec713a04-285d-4175-a851-18151d364793"
      unitRef="shares">6640200</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzEtNS0xLTEtODY3MDk_5759370c-8f5a-4040-a416-e18844eb9a09">P8Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzItMS0xLTEtODY3MDk_24d8805e-0f8c-46f0-9b7c-ec61898214f4"
      unitRef="usdPerShare">12.26</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzItMy0xLTEtODY3MDk_aa98b97d-56a9-4917-af4a-e12ca344bd56"
      unitRef="shares">3937056</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <adc:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzItNS0xLTEtODY3MDk_6f1eef89-5014-4261-ba7d-4d5296de16c8">P9Y4M20D</adc:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzMtMS0xLTEtODY3MDk_5c6c93bf-fc7b-4710-acde-b6924e861119"
      unitRef="usdPerShare">26.71</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzMtMy0xLTEtODY3MDk_86c45467-ca14-49a7-ab4b-2d39cdfbb7ee"
      unitRef="shares">820031</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzYtMS0xLTEtODY3MDk_f577c67b-d0a5-45d6-a2c4-ab5e84caea02"
      unitRef="usdPerShare">21.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzYtMy0xLTEtODY3MDk_5ee6ba91-0cb9-4852-91ca-19775d64a9ab"
      unitRef="shares">9757225</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTo0YjY1MWJkNmNmZTM0ODU2YjU5MWU3MzE0YzIxNzNhOC90YWJsZXJhbmdlOjRiNjUxYmQ2Y2ZlMzQ4NTZiNTkxZTczMTRjMjE3M2E4XzYtNS0xLTEtODY3MDk_8698aa6c-2d7e-45d4-b42f-bc3f61870e1f">P8Y4M20D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <adc:WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted
      contextRef="if98a725792564f8fb8fd4a6250ee5a60_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM2MDM_d6a201c3-9cf7-4fd0-ac03-6359973aec3e"
      unitRef="usdPerShare">8.85</adc:WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted>
    <adc:NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement
      contextRef="i9d76a10a56a3493d8f750d9aff98a946_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM2Mjc_9312f0c6-04da-4e16-ba4a-d99a9c99756e"
      unitRef="shares">3457420</adc:NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM3MDM_5ee6ba91-0cb9-4852-91ca-19775d64a9ab"
      unitRef="shares">9757225</ifrs-full:NumberOfOutstandingShareOptions>
    <adc:WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement
      contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM4MzI_c738929d-a821-45d2-9cf6-65b4f392f79b"
      unitRef="usdPerShare">25.67</adc:WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement>
    <adc:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions
      contextRef="id6e0316681674d2296c8b2b713a8201a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzM4Mzk_b3f58118-d73c-46d8-b40a-65cf47e69f10">P7Y5M8D</adc:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzU_fb3ed550-3e22-4479-bc40-9db3ca8d1440">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;values&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the options granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the three and nine months ended September&#160;30, 2022 were determined on the date of the grant using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share price, in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 8.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 19.69&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Strike price, in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 8.54&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4.83 - 19.69&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;70% to 80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;70% to 80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Award life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6.08 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2.61% - 3.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:0.1pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1.46% - 3.77%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxMGIzYzhiMWRhOWI0MDZlYjU5MzA0MjQ5ZTAzZDBiMV80_f71f1dae-113a-4365-8510-14e1946286f8"
      unitRef="usdPerShare">4.83</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxMGIzYzhiMWRhOWI0MDZlYjU5MzA0MjQ5ZTAzZDBiMV85_609eaf8f-744c-4bde-97e9-024af5e65ba4"
      unitRef="usdPerShare">8.54</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNDVkYmRiOTU1NTY0YzgyOTc3NDU4NWY0MjhkZDViNF80_b05725cb-c291-4404-893e-711522bd38eb"
      unitRef="usdPerShare">4.83</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzItMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNDVkYmRiOTU1NTY0YzgyOTc3NDU4NWY0MjhkZDViNF85_8f054c58-6e99-4e34-90dd-7a954a74da04"
      unitRef="usdPerShare">19.69</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5ZmQ5OTM3ZjJjYmY0ZmJkYTk3NDI2NTE2M2NjOGExN180_8731e318-a80f-45f2-bfcd-a3351647fef0"
      unitRef="usdPerShare">4.83</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5ZmQ5OTM3ZjJjYmY0ZmJkYTk3NDI2NTE2M2NjOGExN185_bc8a8ee4-e600-4a5b-9602-f2a14ac8b572"
      unitRef="usdPerShare">8.54</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNGVlM2E4YzVhYWM0MzYwOGRkMzFlNTAwZGEyMmE3MV80_e10a611a-ecee-45d5-a6ab-f8e764f44428"
      unitRef="usdPerShare">4.83</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzMtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxNGVlM2E4YzVhYWM0MzYwOGRkMzFlNTAwZGEyMmE3MV85_9da53f11-5a6c-4b8c-a605-be4f825b31ef"
      unitRef="usdPerShare">19.69</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxZmI3Zjk2NTNhYzg0MzFiOGY4OTJiMDU0ZjVmODU5OF81_c147cc4b-26e4-433b-bc11-088a8b97b90d"
      unitRef="number">0.70</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoxZmI3Zjk2NTNhYzg0MzFiOGY4OTJiMDU0ZjVmODU5OF8xMQ_f66b7e27-1741-43fa-ac62-6faeedf09971"
      unitRef="number">0.80</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo4Njg2NmZkOTEzMTA0OTc1YTM2NTM3YzQ5ZDgzODA5M180_35a0cd50-e5a6-4c23-b4f0-bdaf872ee751"
      unitRef="number">0.70</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzQtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo4Njg2NmZkOTEzMTA0OTc1YTM2NTM3YzQ5ZDgzODA5M18xMA_99cdd41e-d2c1-4e70-95ee-356bbca82c8b"
      unitRef="number">0.80</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzUtMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjo3ZjM0OTYwMWQ4OTc0MWM3YTlkN2ZhNjRmMDgzZGJjY180_bc440aa4-cfe3-47e7-8ac7-50c3f4d6ef1b"
      unitRef="shares">6.08</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
      contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzUtMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo0ZWMyNWEzY2VjMGI0ZmQ2YTEyYjEzMTBjY2NiMDBkY180_3a08cbd2-d492-47a0-9a0b-dfb43f7df410"
      unitRef="shares">6.08</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendShareOptionsGranted
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzYtMS0xLTEtODY3MDk_a3438c21-ae0b-47ff-b54c-8821629e1923"
      unitRef="usd">0</ifrs-full:ExpectedDividendShareOptionsGranted>
    <ifrs-full:ExpectedDividendShareOptionsGranted
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzYtMy0xLTEtODY3MDk_493ebf11-56a3-445a-a8ea-e7346e6ffd27"
      unitRef="usd">0</ifrs-full:ExpectedDividendShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i97719552e7124715a29a90b8e72ff4c3_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoyMjUzM2IyODVkMDE0NDI2ODc3MDg3MTBiYmRhNDNmZl80_bb31a8bb-d1d6-4092-9893-a55c3cbd05a0"
      unitRef="number">2.61</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i754b45fd7b484d78a137b358dfa93899_D20220701-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMS0xLTEtODY3MDkvdGV4dHJlZ2lvbjoyMjUzM2IyODVkMDE0NDI2ODc3MDg3MTBiYmRhNDNmZl85_2ff4b5be-8d2c-4aa2-b923-2c06307a73e6"
      unitRef="number">0.0377</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="i2982031b7cc14d83b72afe32f3c6f4ee_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5NGY4Nzc4YmM0YTI0ZjNiYWMxYzI4MTljYjg1NTc1MV80_ccf86189-b783-42a9-93bd-451c319fae63"
      unitRef="number">0.0146</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="ia2be07cf7d8345f2b11c6de511b04dfa_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZToyNzUwNGY1OTQ3Mzg0MTdhYThlMjViZmI0YzAwMWFhMS90YWJsZXJhbmdlOjI3NTA0ZjU5NDczODQxN2FhOGUyNWJmYjRjMDAxYWExXzctMy0xLTEtODY3MDkvdGV4dHJlZ2lvbjo5NGY4Nzc4YmM0YTI0ZjNiYWMxYzI4MTljYjg1NTc1MV85_70c767b3-b6c6-4cee-849b-6ddd7b993cde"
      unitRef="number">0.0377</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <adc:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMjg_e044905d-b08a-4b0d-8a77-30d11d46ddc2">P10Y</adc:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzQ4OTE_1e627cfe-7da1-446f-8ffa-82e86f494d4a">P3Y</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage
      contextRef="i45a1053498d5476e8f8d62e1e4575acb_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzUwMDI_1fc229c5-9885-4c8f-8be2-be1545c41f28"
      unitRef="number">0.50</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPercentage>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="ie78f96aef8b8454a82071adaaa117569_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMjk_f7a2156b-08cf-4425-8ea8-2c65b235e972">P6M</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod
      contextRef="ib9d5fe10351e4449b949a8a8feb2c71d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzUwNDM_01bb6ce8-1deb-4f08-a7ca-cd121bcaf2e0">P1Y</adc:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="i3a0283334e204aed9dac9cea1dfc698a_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU3Njc_13e0ba7d-83a9-4c83-95f8-6d38ae2bf88c"
      unitRef="shares">6372000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU3Nzk_7402fcad-fb88-4672-9fb7-e4be6e7f9bc4"
      unitRef="shares">15135000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="ib1e58e63d94a49548e999adc4a660174_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU4ODE_e28d4222-493c-4c78-8128-daf464f161c9"
      unitRef="shares">2693000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="ic8b357e6573a4bd4b45f578e3c65b1e4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU4OTM_a16b7678-8900-4f86-b08c-b9c742966746"
      unitRef="shares">6904000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzE_ccf25ea9-3af5-45a4-90f2-db1288df7323">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Number of awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;663,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;30.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,129,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(344,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;30.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(135,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2,313,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i1eb06d614e3447ffb6c90235d957a286_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzEtMS0xLTEtODY3MDk_6948de5b-f4e0-4202-9286-20cf59d734e7"
      unitRef="shares">663055</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding
      contextRef="i1eb06d614e3447ffb6c90235d957a286_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzEtMy0xLTEtODY3MDk_c98c99f0-bcef-4951-acf7-80bf0b9c7c39"
      unitRef="usdPerShare">30.95</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzItMS0xLTEtODY3MDk_89efa2e7-4d75-4ca2-8331-b5e902e78b81"
      unitRef="shares">2129991</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzItMy0xLTEtODY3MDk_1057e6b2-4d0a-4844-8fd8-617169c9dd63"
      unitRef="usdPerShare">9.36</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzMtMS0xLTEtODY3MDk_53de8327-de09-488e-b13f-6715188b2980"
      unitRef="shares">344446</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzMtMy0xLTEtODY3MDk_8df990bd-e826-4a5b-b9fd-7ab3b92121f1"
      unitRef="usdPerShare">30.54</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzQtMS0xLTEtODY3MDk_0eab69c9-bf89-4382-bec2-04b5b64eeca4"
      unitRef="shares">135416</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited
      contextRef="ia93aa87bd88d40f1a17fa4e47e765518_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzQtMy0xLTEtODY3MDk_0d328e83-0f80-40d6-b7c3-2101a4ce66d0"
      unitRef="usdPerShare">21.10</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="i05e1cf39bbc742f2bcd482dcd9e52fff_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzUtMS0xLTEtODY3MDk_15d9a726-a15d-4864-88c0-4197dfd3396f"
      unitRef="shares">2313184</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding
      contextRef="i05e1cf39bbc742f2bcd482dcd9e52fff_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphMjIyOWE2NDJiYTA0NTFhOWEwMjU1NjZhMjg0ZWM2MC90YWJsZXJhbmdlOmEyMjI5YTY0MmJhMDQ1MWE5YTAyNTU2NmEyODRlYzYwXzUtMy0xLTEtODY3MDk_8e3e5289-0e27-4f94-804d-cf354b4be946"
      unitRef="usdPerShare">11.71</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted
      contextRef="i6744fd46428b46519b3f53dabe6cec74_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYwNTc_04576190-9583-4004-b3b4-c5132a574474"
      unitRef="usdPerShare">14.00</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted>
    <adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted
      contextRef="i45a1053498d5476e8f8d62e1e4575acb_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYwNjQ_52828aff-99b3-4f66-affc-5cae7afbd904"
      unitRef="usdPerShare">6.93</adc:WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted>
    <adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzYyMzI_920556d3-685b-40b1-ba78-efa968dc8884">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movement in the Share-based Compensation Reserves (included in Other reserves within equity) is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - Share Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;27,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;40,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;15,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Tax and social charge deductions - Incentive Plan 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;41,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;47,016&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="i4af9ebeb2297423eb394125254b4a972_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtMS0xLTEtODY3MDk_a0a2c19e-b015-4e6b-b503-6b81dab24bc4"
      unitRef="usd">8193000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="id3811cf7e2644eda9263cf885c93077f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtMy0xLTEtODY3MDk_69155556-c2c9-4229-9396-24596595f41c"
      unitRef="usd">12105000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="i98d5c21d03c745b5a671f6735837b959_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtNS0xLTEtODY3MDk_d5fb3f16-68cd-4629-a304-2b1b0d29f9d4"
      unitRef="usd">27158000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="i23f74715d84641a0818c9605970c3d58_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzQtNy0xLTEtODY3MDk_0c72a740-cc11-46cf-82fb-5c23cb22a73b"
      unitRef="usd">40112000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="i6cefde464eaa45adbdc8ce7283826a3b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtMS0xLTEtODY3MDk_bdf31e77-5644-4493-b3ae-16f6de893b48"
      unitRef="usd">6372000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="i3425d423d7cb4ed7841d8808eb8b91ee_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtMy0xLTEtODY3MDk_94b4c444-d8dc-487d-89a0-8b9de054ab2d"
      unitRef="usd">2693000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="if85a6bc595a6484baa94ff58c1ba727d_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtNS0xLTEtODY3MDk_64749b91-45f2-4341-8498-bf43283a6933"
      unitRef="usd">15135000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPayments
      contextRef="i7bcf43c8d3a64ab28d95b0e02490e5a6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzUtNy0xLTEtODY3MDk_4b0c2fb9-d5b9-474e-ae4c-878928e59d91"
      unitRef="usd">6904000</adc:IncreaseDecreaseInReserveOfShareBasedPayments>
    <adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions
      contextRef="if6b8e02492be4003ab27ad39ebc0924a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtMS0xLTEtODY3MDk_874a5b2a-e519-4632-97e5-4d34b7719c71"
      unitRef="usd">0</adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions>
    <adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions
      contextRef="i3528d529fe714216bcf41e3b8f352130_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtMy0xLTEtODY3MDk_c8ed9486-460b-4ca0-95ee-bbdefd2797b2"
      unitRef="usd">0</adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions>
    <adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions
      contextRef="i3d4dfb8b4ea142f78d5e31fa1de04f8c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtNS0xLTEtODY3MDk_4f385df0-b8b2-4e0a-9a90-f2806c084fab"
      unitRef="usd">-512000</adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions>
    <adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions
      contextRef="idab02ef85658428ead895ef5a19a0884_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzYtNy0xLTEtODY3MDk_97178e96-17f5-4821-b0dc-b51bf410b6dd"
      unitRef="usd">0</adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctMS0xLTEtODY3MDk_2c4710b6-a7bb-4e7c-a567-b205cebe13e3"
      unitRef="usd">14565000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctMy0xLTEtODY3MDk_58fb4cff-fbeb-438a-b89a-04a9f003d8d0"
      unitRef="usd">14798000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctNS0xLTEtODY3MDk_28b4aa33-83f7-410a-90d3-8651144a6869"
      unitRef="usd">41781000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90YWJsZTphOGE4MWU0ZmI3YWQ0Y2Y1ODc3MDViYmE1OGU2YTZhMy90YWJsZXJhbmdlOmE4YTgxZTRmYjdhZDRjZjU4NzcwNWJiYTU4ZTZhNmEzXzctNy0xLTEtODY3MDk_32624cd9-ba68-4dd3-8cee-fd87202c0a2c"
      unitRef="usd">47016000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="ic28832b49da3403a8b557a594e965059_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzEwOTk1MTE2NDgyMTU_69e88421-e21a-4502-bca5-3892530cc0a3"
      unitRef="shares">782700</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <adc:AccruedShareBasedCompensation
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDAvZnJhZzozYTA4MWFlYmYyYjI0NWU2ODhhNGUxNGM2YWRkZjE1OC90ZXh0cmVnaW9uOjNhMDgxYWViZjJiMjQ1ZTY4OGE0ZTE0YzZhZGRmMTU4XzU0OTc1NTgzMTQ0Nw_7c7a17e6-5149-4f89-bf74-9a0fcf0ca9d5"
      unitRef="usd">220000</adc:AccruedShareBasedCompensation>
    <adc:DeferredRoyaltyObligationTextBlock
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzQyMzM_e30dc284-55c9-43e9-9089-2909cb6909c7">Deferred royalty obligation&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2021, the Company entered into a royalty purchase agreement with HCR for up to USD 325.0&#160;million of which the Company received gross proceeds of USD 225.0&#160;million during 2021 and is eligible to receive an additional USD 100.0&#160;million upon the occurrence of certain commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below provides a rollforward of the Company&#x2019;s debt obligation relating to the royalty purchase agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;225,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Plus: interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;17,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: cumulative catch-up adjustment, Financial income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;16,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;221,144&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Proceeds from the sale of future royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Less: royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Plus: interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Plus: cumulative catch-up adjustment, Financial expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;225,477&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a liability relating to the initial gross proceeds received less transaction costs. The Company will record additional liabilities upon the receipt of eligible amounts when such contingent events occur. To determine the accretion of the liability related to the deferred royalty obligation, the Company is required to estimate the total amount of future royalty payments and estimated timing of such payment to HCR based on the Company's revenue projections. Based on the Company's initial revenue projections, the Company used an independent valuation firm to assist in determining the total amount of future royalty payments and estimated timing of such payment to HCR using an option pricing Monte Carlo simulation model. The amount ultimately received by the Company will be accreted to the total amount of the royalty payments necessary to extinguish the Company&#x2019;s obligation under the agreement, which will be recorded as interest expense over the life of the royalty purchase agreement. The estimate of this total interest expense resulted in an EIR of 10%. As royalty payments are made to HCR, the balance of the debt obligation will be effectively repaid over the life of the royalty purchase agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's periodic review, the exact amount and timing of repayment is likely to be different each reporting period as compared to those estimated based on the Company's initial revenue projections. A significant increase or decrease in actual net sales of ZYNLONTA compared to the Company&#x2019;s revenue projections, and regulatory approval and commercialization of Cami, as well as ZYNLONTA in other indications as well as licensing revenue could change the royalty rate and royalty cap due to HCR, which could materially impact the debt obligation as well as interest expense associated with the royalty purchase agreement. Also, the Company&#x2019;s total obligation to HCR can vary depending on the achievement of the sales milestones as well as the timing of a change in control event. The Company will periodically assess the expected payments to HCR based on its underlying revenue projections and to the extent the amount or timing of such payments is materially different than its initial estimates it will record a cumulative catch-up adjustment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's 2022 strategic planning decisions including updated development plans, the Company updated the valuation model during the first quarter of 2022, which resulted in a cumulative catch-up adjustment of KUSD 18,288 recorded as Financial income within the unaudited condensed consolidated interim statement of operations for the three months ended March 31, 2022. The Company updated the valuation model in the second quarter of 2022 for revised revenue forecasts, which had the effect of reducing the Company&#x2019;s deferred royalty obligation, as well as including upfront and downstream milestone payments related to the Sobi exclusive license agreement, which had the effect of increasing the Company&#x2019;s deferred royalty obligation. As a result of the updated valuation model in the second quarter of 2022, the Company recorded a non-material cumulative catch-up adjustment recorded as Financial expense within the unaudited condensed consolidated interim statement of operations for the three months ended June 30, 2022. In the third quarter of &lt;/span&gt;&lt;/div&gt;2022, the Company updated the valuation model for actual net sales reported in the third quarter 2022, as well as refined the estimated timing of receipt for the downstream milestone payments related to the Sobi exclusive license agreement, which had the effect of increasing the Company&#x2019;s deferred royalty obligation. As a result of the updated valuation model used in the third quarter of 2022, the Company recorded a KUSD 2,175 cumulative catch-up adjustment as Financial expense within the unaudited condensed consolidated interim statement of operations for the three months ended September 30, 2022. Under the cumulative catch-up method, the EIR is not revised when actual or estimated net sales differ from those estimated as of the inception of the debt obligation. Instead, the carrying amount of the debt obligation is adjusted to an amount equal to the present value of the estimated remaining future payments, discounted by using the original EIR, 10%, as of the date on which the estimate changes.</adc:DeferredRoyaltyObligationTextBlock>
    <adc:RoyaltyPurchaseAgreement
      contextRef="ie7216894bf0e483e85c7a8417528b234_I20210825"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzEzMA_63a9a39f-cb81-4305-8eb0-027214a796a4"
      unitRef="usd">325000000</adc:RoyaltyPurchaseAgreement>
    <adc:ProceedsFromRoyaltyPurchaseAgreementGross
      contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzE4NQ_43509ef7-e43e-40b3-ae32-b76f478b091a"
      unitRef="usd">225000000</adc:ProceedsFromRoyaltyPurchaseAgreementGross>
    <adc:RoyaltyPurchaseAdditionalProceedsEligibility
      contextRef="i2b323768a0a7410a9f148da7b1aa077e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzI0NQ_441bf515-6170-4b07-ac1a-568c254c85b2"
      unitRef="usd">100000000</adc:RoyaltyPurchaseAdditionalProceedsEligibility>
    <adc:DeferredRoyaltyObligation
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEtMi0xLTEtODY3MDk_7db9e915-49f9-4582-a2b3-0ea27b5e8a87"
      unitRef="usd">225477000</adc:DeferredRoyaltyObligation>
    <adc:RoyaltyObligationPayments
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzItMi0xLTEtODY3MDk_617d0e77-ff78-4971-ba4f-361a2fa0234c"
      unitRef="usd">5656000</adc:RoyaltyObligationPayments>
    <adc:RoyaltyObligationInterest
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzMtMi0xLTEtODY3MDk_b550023d-c962-4f6a-8a2b-a4773e594029"
      unitRef="usd">17356000</adc:RoyaltyObligationInterest>
    <adc:RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzQtMi0xLTEtODY3MDk_1e33e419-23c6-4610-9e68-ae752d85ee65"
      unitRef="usd">16033000</adc:RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment>
    <adc:DeferredRoyaltyObligation
      contextRef="i002154ec55ee4138b998ace2483bb162_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzUtMi0xLTEtODY3MDk_f62ca834-f229-42ef-b403-65d4f18ea4b3"
      unitRef="usd">221144000</adc:DeferredRoyaltyObligation>
    <adc:DeferredRoyaltyObligation
      contextRef="i1a3acb2e8256494bb21952f83d8f6892_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzctMi0xLTEtODY3MDk_815449ff-4ba4-4a09-8991-dd92dcdf7b59"
      unitRef="usd">0</adc:DeferredRoyaltyObligation>
    <adc:ProceedsFromRoyaltyPurchaseAgreementGross
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzgtMi0xLTEtODY3MDk_a655c510-d65a-4b3d-97d9-3a8523a664c1"
      unitRef="usd">225000000</adc:ProceedsFromRoyaltyPurchaseAgreementGross>
    <adc:RoyaltyObligationTransactionCosts
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzktMi0xLTEtODY3MDk_1200662c-2228-4024-aeb2-fe2e338bbbeb"
      unitRef="usd">6998000</adc:RoyaltyObligationTransactionCosts>
    <adc:RoyaltyObligationPayments
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEwLTItMS0xLTg2NzA5_15b74da6-1959-4f66-b1fb-e978c6d43e05"
      unitRef="usd">213000</adc:RoyaltyObligationPayments>
    <adc:RoyaltyObligationInterest
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzExLTItMS0xLTg2NzA5_9036c0f4-9377-4e0b-89fd-0e82d66e5a06"
      unitRef="usd">6752000</adc:RoyaltyObligationInterest>
    <adc:RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment
      contextRef="i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEyLTItMS0xLTg2NzA5_6fe2c3eb-a4ce-401c-acd7-bf354d924ac6"
      unitRef="usd">936000</adc:RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment>
    <adc:DeferredRoyaltyObligation
      contextRef="i59c7697f17a94ce9a360033092cabb0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90YWJsZTo3YTk1ZjcxZmE0ZDE0YjEyYjljYWMxZDQ3NzU5YWYyYy90YWJsZXJhbmdlOjdhOTVmNzFmYTRkMTRiMTJiOWNhYzFkNDc3NTlhZjJjXzEzLTItMS0xLTg2NzA5_3570b782-43b3-4193-bc23-8ebac5235816"
      unitRef="usd">225477000</adc:DeferredRoyaltyObligation>
    <adc:RoyaltyPurchaseAgreementEffectiveInterestRate
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMDkvZnJhZzpiNDI3MjA2ODBiYmU0NTc3OTA4OGMzMTZjNDUzM2MwZi90ZXh0cmVnaW9uOmI0MjcyMDY4MGJiZTQ1Nzc5MDg4YzMxNmM0NTMzYzBmXzE1MjI_b2cf8ec7-e5b3-47a5-90f4-67684e3e6ae3"
      unitRef="number">0.10</adc:RoyaltyPurchaseAgreementEffectiveInterestRate>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzMwOTk_6d466294-6f45-4959-907c-7b4e1ea30ff3">Related parties&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A.T. Holdings II S&#xe0;rl (&#x201c;AT Holdings II&#x201d;) is a shareholder in the Company. AT Holdings II is in turn ultimately wholly owned by Auven Therapeutics Holdings, L.P. (&#x201c;ATH&#x201d;), a limited partnership registered in the British Virgin Islands. ATH&#x2019;s General Partner is Auven Therapeutics General L.P., which itself is a limited partnership whose General Partner is Auven Therapeutics GP Ltd. The manager of ATH is Auven Therapeutics Management L.L.L.P. (&#x201c;ATM&#x201d;). As a result, ATH is considered a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s contribution and equity interest in Overland ADCT BioPharma, certain of the Company&#x2019;s employees serve on its board of directors. As a result, Overland ADCT BioPharma is considered a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Services provided by the Company to related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides registered office and other simple administrative services to three subsidiaries of ATH. The amounts invoiced for the three and nine months ended September&#160;30, 2022 and recovered through G&amp;amp;A expenses, amounted to nil and KUSD 1, respectively (three and nine months ended September&#160;30, 2021: KUSD 1 and KUSD 3, respectively).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As contemplated by the license agreement with Overland ADCT BioPharma, Overland ADCT BioPharma has elected to participate in certain of the Company&#x2019;s global clinical trials, in exchange for which it reimburses the Company for a portion of the cost of those trials. Overland ADCT BioPharma also reimburses the Company for certain expenses in connection with technology transfer and assistance of clinical personnel. During the three and nine months ended September&#160;30, 2022, the Company incurred KUSD 818 and KUSD 2,014, respectively, of clinical trial and service costs to be reimbursed by Overland ADCT BioPharma, which is recorded as a reduction of R&amp;amp;D expenses in the Company&#x2019;s unaudited condensed consolidated interim statement of operations (three and nine months ended September&#160;30, 2021: KUSD 812 and KUSD 1,602, respectively).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;In addition, the Company entered into a supply agreement with Overland ADCT BioPharma whereby the Company provides Overland ADCT BioPharma clinical supply for use in trials and supply for early access programs. For the three and nine months ended September&#160;30, 2022, KUSD 5 and KUSD 45, respectively, of supply was provided to Overland ADCT BioPharma which is recorded as a reduction of R&amp;amp;D expenses in the Company&#x2019;s unaudited condensed consolidated interim statement of operations. There were no such sales to Overland ADCT BioPharma during the three and nine months ended September&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Related party balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a related party receivable balance with Overland ADCT BioPharma of KUSD 1,695 and KUSD 789 as of September&#160;30, 2022 and December&#160;31, 2021, respectively. There were no trade accounts payable with related parties as of September&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Key management compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation of key management is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Salaries and other short-term employee costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Pension costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Other compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;10,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;27,119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;26,921&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;During the second quarter of 2022, there was an organizational realignment of certain key management as a result of the appointment of the Company's new CEO. The key management compensation for the three and nine months ended September&#160;30, 2022 reflects the new management structure, while the comparable prior periods have not been recast to conform to the current structure.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <adc:NumberOfSubsidiariesProvideServicesTo
      contextRef="i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzk3OQ_3d1e29c2-2ac4-48d5-8dcc-d5c6ebe422d5"
      unitRef="subsidiary">3</adc:NumberOfSubsidiariesProvideServicesTo>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="if51de663eeeb43a9905288c2f5ec4bed_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzEwOTk_734ccb14-5829-48be-bee8-de15f1535b9d"
      unitRef="usd">0</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzExMTE_985c2276-3a48-4121-9752-b73686730cad"
      unitRef="usd">1000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="i08246b7245ce401f95f5c264b9f4aa66_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzExNTQ_1430311c-d040-489b-b392-ace7019a3b62"
      unitRef="usd">1000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="icf7164681d554945ae3e0bb0a2aba4a1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzExNjY_a786339d-da5d-4b5b-b1c4-afb9a4563450"
      unitRef="usd">3000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="i12b130040d7a4b73bd260af53f216810_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE2NTc_d0f9959a-04cf-4092-9dda-d6837af822cf"
      unitRef="usd">818000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="i519cc478c39244318ef4ce155c0494b8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE2Njk_e2ffd5ca-a218-4d25-a015-23b296aa4ce6"
      unitRef="usd">2014000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="i16371fe343804f21aa8c01b295fcfe36_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE5MjU_5dd47327-6d12-47e2-9e38-f80b906b2467"
      unitRef="usd">812000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:ServicesProvidedRelatedPartyTransactions
      contextRef="i048e0b2056c24818a8680d84acca00a4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzE5MjU_e62bffe9-ce2d-4a20-b4cf-d5f4e23f12a9"
      unitRef="usd">812000</adc:ServicesProvidedRelatedPartyTransactions>
    <adc:SuppliesProvidedRelatedPartyTransactions
      contextRef="i519cc478c39244318ef4ce155c0494b8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzIxNDQ_6739a502-2c44-4f84-abd6-ff8020a56eab"
      unitRef="usd">45000</adc:SuppliesProvidedRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="icaa43634d02840d5a9bcbd7fa627fe61_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzI1NDc_009dcc85-4281-4131-8ee6-2e86de54ac2a"
      unitRef="usd">1695000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="i65354fc22fe5421c886bb333bb47840b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzI1NTk_9dd5fe9d-0968-4850-afa1-6543b4d54abd"
      unitRef="usd">789000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90ZXh0cmVnaW9uOmEyYTJhNjQyODdlMzQ2ZWRiZWFlYmM3M2FmOWQxZjhmXzMxMDA_13cf3f95-21ba-4463-bf80-fffdcf63602c">&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation of key management is shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine months ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Salaries and other short-term employee costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Pension costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;20,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Other compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;10,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;8,837&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;27,119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;26,921&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItMS0xLTEtODY3MDk_4f25b41b-a20e-41f9-bbc9-e163145374f3"
      unitRef="usd">2177000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItMy0xLTEtODY3MDk_52110144-cfde-4442-92d6-77a4f31677b7"
      unitRef="usd">2279000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItNS0xLTEtODY3MDk_204ceb5b-6f4a-4070-9cd1-6b8fad61b616"
      unitRef="usd">6383000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzItNy0xLTEtODY3MDk_70e41af9-b8ba-405e-a087-a0dfdab91ec2"
      unitRef="usd">6280000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtMS0xLTEtODY3MDk_a432c1de-d62a-406c-9762-f1aa090d943f"
      unitRef="usd">47000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtMy0xLTEtODY3MDk_d2486791-59b8-4871-be74-6fdb27356f39"
      unitRef="usd">98000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtNS0xLTEtODY3MDk_56b552da-110c-46e5-9f29-4e80e0ca2340"
      unitRef="usd">251000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzMtNy0xLTEtODY3MDk_41777c39-65f8-434d-8410-e7479a4a0c30"
      unitRef="usd">338000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtMS0xLTEtODY3MDk_ce8f1be8-9db5-44b6-af00-fb5fff2946b3"
      unitRef="usd">8011000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtMy0xLTEtODY3MDk_6c7f3af5-5580-4be8-8a9e-9a7f21aa47c6"
      unitRef="usd">6448000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtNS0xLTEtODY3MDk_14855c52-4568-4344-9bf0-811a3c88047d"
      unitRef="usd">20460000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzQtNy0xLTEtODY3MDk_1c924639-44e0-428c-abf9-2dbaab8d0ef0"
      unitRef="usd">20269000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtMS0xLTEtODY3MDk_434c1262-619f-407c-9c65-1a2b9dd10357"
      unitRef="usd">7000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtMy0xLTEtODY3MDk_7a4f4890-dbdd-41a3-ae75-0c2a0956c1e1"
      unitRef="usd">12000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtNS0xLTEtODY3MDk_5abe314a-f53a-4c16-b27d-a72d825e8bf0"
      unitRef="usd">25000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzUtNy0xLTEtODY3MDk_02766f06-6cb8-4b42-99e5-0688b731d985"
      unitRef="usd">34000</ifrs-full:KeyManagementPersonnelCompensationOtherLongtermBenefits>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtMS0xLTEtODY3MDk_b5165a83-ebcf-4d9a-a776-ecd1fb9b25e8"
      unitRef="usd">10242000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtMy0xLTEtODY3MDk_01ed1b26-b04c-4f5a-af56-2c92855a06c5"
      unitRef="usd">8837000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtNS0xLTEtODY3MDk_ea366019-3ea3-44fe-87f9-711ebdc1fd4c"
      unitRef="usd">27119000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTIvZnJhZzphMmEyYTY0Mjg3ZTM0NmVkYmVhZWJjNzNhZjlkMWY4Zi90YWJsZTo4MzMxNTZkMzhjOGE0NDdlYTVkMTgwM2FmODgyYjY1MS90YWJsZXJhbmdlOjgzMzE1NmQzOGM4YTQ0N2VhNWQxODAzYWY4ODJiNjUxXzYtNy0xLTEtODY3MDk_299aa75f-3268-4ebf-ac43-01ed1972f42f"
      unitRef="usd">26921000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90ZXh0cmVnaW9uOjhmZWU3YmViZTllZDRkNmRiOTNiYzhkYWVmNjI2ZDc3XzQ3NA_a372bca9-9c0d-435a-9419-c95d68c21a31">Loss per share&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Loss attributable to owners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(50,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(71,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(131,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(195,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;78,372,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;76,739,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77,374,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;76,730,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(0.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(1.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2022 and 2021, basic and diluted loss per share are calculated on the weighted average number of shares issued and outstanding and exclude shares to be issued under the Equity Incentive Plan 2019, as the effect of including those shares would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because the effect of including them would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - Share Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,725,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,326,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,625,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,759,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,473,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;594,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,731,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;451,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Conversion of the principal amount of convertible loans into the Company&#x2019;s common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,412,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,682,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Outstanding warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,470,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;832,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,668,591&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,334,313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,189,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,893,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 ESPP share activity was not presented as the effects were not material.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90ZXh0cmVnaW9uOjhmZWU3YmViZTllZDRkNmRiOTNiYzhkYWVmNjI2ZDc3XzQ3NQ_6cc524ea-b65f-44f4-8196-f7efa51abcb7">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(in KUSD, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Loss attributable to owners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(50,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(71,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(131,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;(195,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;78,372,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;76,739,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;77,374,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;76,730,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(0.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(1.70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;(2.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because the effect of including them would be anti-dilutive were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - Share Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;9,725,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;6,326,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;8,625,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;5,759,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Equity Incentive Plan 2019 - RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,473,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;594,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;1,731,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;451,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Conversion of the principal amount of convertible loans into the Company&#x2019;s common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;4,412,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;3,682,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;Outstanding warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;2,470,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;832,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;14,668,591&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,334,313&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;11,189,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%"&gt;9,893,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItMS0xLTEtODY3MDk_aceabf18-25f6-4d7a-8321-068a1b0c4253"
      unitRef="usd">-50608000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItMy0xLTEtODY3MDk_719480c4-06e0-4109-8368-3cfa4c23ab26"
      unitRef="usd">-71549000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItNS0xLTEtODY3MDk_d386fa8a-5876-4351-9aa9-4c74af34722e"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItNS0xLTEtODY3MDk_ee5cd402-d090-4597-9a44-59d05b277822"
      unitRef="usd">-131643000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzItNy0xLTEtODY3MDk_b0efb59d-1cda-42b6-9592-fdee8833b040"
      unitRef="usd">-195645000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtMS0xLTEtODY3MDk_51e977ff-887b-4e19-ab74-077923343a82"
      unitRef="shares">78372680</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtMy0xLTEtODY3MDk_218fa4ec-78b1-46c8-9064-92704087d2d7"
      unitRef="shares">76739770</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtNS0xLTEtODY3MDk_ebaf38f4-3fc8-48c4-9c53-9dcb07ae5232"
      unitRef="shares">77374388</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzMtNy0xLTEtODY3MDk_6c574fe2-017a-4085-b572-1a93997718a4"
      unitRef="shares">76730117</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMS0xLTEtODY3MDk_0fcc2a70-3201-41dc-a472-5e7425ed45a8"
      unitRef="usdPerShare">-0.65</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMS0xLTEtODY3MDk_fb9dc6a4-a2e7-4ae0-a3bb-0e5905e6be29"
      unitRef="usdPerShare">-0.65</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMy0xLTEtODY3MDk_d4d4db6e-0493-4116-a086-fe0c6e95a6c1"
      unitRef="usdPerShare">-0.93</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtMy0xLTEtODY3MDk_f45b51ae-799c-49ad-bb16-a7e107c90f5d"
      unitRef="usdPerShare">-0.93</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNS0xLTEtODY3MDk_12b11a32-c463-49d9-9ae0-1e7e39a6e632"
      unitRef="usdPerShare">-1.70</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNS0xLTEtODY3MDk_60ff3eb9-5872-471b-9371-859f1cd3c0dc"
      unitRef="usdPerShare">-1.70</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNy0xLTEtODY3MDk_6ceca30d-b33b-4252-80ca-f7aec43bd2c3"
      unitRef="usdPerShare">-2.55</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTo3NGZjZDRhMTI1NDI0ZjAzOGJiYmY1NTUzNjU0OGIxMy90YWJsZXJhbmdlOjc0ZmNkNGExMjU0MjRmMDM4YmJiZjU1NTM2NTQ4YjEzXzQtNy0xLTEtODY3MDk_ddc6fbdc-eba1-474f-8493-cad0a4ef682e"
      unitRef="usdPerShare">-2.55</ifrs-full:DilutedEarningsLossPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="ic02e5a8396a24328a44c3c3ca993fbf8_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtMS0xLTEtODY3MDk_3baf50d6-2010-4516-9706-4723e24899ef"
      unitRef="shares">9725094</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="iae551281e83e4030b20c9779e840a6db_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtMy0xLTEtODY3MDk_d55dd54f-3b2f-401e-93d7-0c6707ebf550"
      unitRef="shares">6326518</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="if17b1e60018b4848b0cc478a5439fcbe_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtNS0xLTEtODY3MDk_7f6ae5ec-e3c7-478f-8c1c-451175df55dc"
      unitRef="shares">8625415</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="icef2d3daf96e4c52ba4ccd1c33c624a6_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzQtNy0xLTEtODY3MDk_ca2f7676-50af-4c06-916c-2de54daf5415"
      unitRef="shares">5759262</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i42e1e606ace84d21a6ec9a6aee9fd665_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtMS0xLTEtODY3MDk_aed51bfb-80fe-4c31-b8da-93b23eeded5a"
      unitRef="shares">2473429</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="idb44ceb2a6a84f44b55476a168ce4fa4_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtMy0xLTEtODY3MDk_e3f2bc1f-9bde-4dd0-9490-08b70b129bd4"
      unitRef="shares">594955</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i5eb0fcfe2e954886a15fb411a8e3ec9a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtNS0xLTEtODY3MDk_426ef5a4-c2b1-425c-a8f1-02d7f65397fd"
      unitRef="shares">1731530</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="iff327b0f65fe4fce9a6d78995be93ca9_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzUtNy0xLTEtODY3MDk_466cb110-3f23-49b2-9959-82b760bb557b"
      unitRef="shares">451761</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i5ccd7f1b706c4d9f8b0853b7bb915ab8_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtMS0xLTEtODY3MDk_3ffb8b82-43a2-4e8a-acbf-ecef0157464a"
      unitRef="shares">0</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i9715b3a7f0dc46af8427382e8c4b913b_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtMy0xLTEtODY3MDk_ac47867e-5273-4762-af45-42faef34daaa"
      unitRef="shares">4412840</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i9ccb7c3256654c6bab2e6cdeb30d200f_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtNS0xLTEtODY3MDk_0f3d8d4a-cea1-4cbf-8b45-22c482a805ec"
      unitRef="shares">0</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="ia12624d220a540beba94b39cc8891315_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzYtNy0xLTEtODY3MDk_6e6d9884-ea53-4656-b0f5-0426c0727067"
      unitRef="shares">3682066</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i367482dece7c4a8a868d61236759bb2a_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMS0xLTEtOTQ0OTU_6520c3f5-f8fb-494d-9fe4-656ffbf56332"
      unitRef="shares">2470068</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i68337702bbe542648d3b07bc46ecffc9_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMy0xLTEtOTQ0OTU_7188fb2f-f2e1-4823-9487-a34c39f05b14"
      unitRef="shares">0</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i6ed07caeea2c4158a84e9c7fe843387a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNS0xLTEtOTQ0OTU_6fe5f04b-2c88-4624-97ee-f25d78d8ba5b"
      unitRef="shares">832404</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i2c3724a1c9b64111a1170ea671562e28_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNy0xLTEtOTQ0OTU_5de643f5-670d-40cc-b46d-21cfb979f5a1"
      unitRef="shares">0</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMS0xLTEtODY3MDk_b481df0f-ca6b-4f96-88fa-9cdbb6bc88b7"
      unitRef="shares">14668591</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i3a785d10bc57445fa3630cba6d9965b5_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctMy0xLTEtODY3MDk_3c879f12-ceef-413b-9d10-bfea31fe06ad"
      unitRef="shares">11334313</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNS0xLTEtODY3MDk_fee522e6-c35c-4f89-9010-a5c30ce45327"
      unitRef="shares">11189349</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare
      contextRef="id894c180529648fe9b583c546c2b3660_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMTUvZnJhZzo4ZmVlN2JlYmU5ZWQ0ZDZkYjkzYmM4ZGFlZjYyNmQ3Ny90YWJsZTphYjI4YjExM2QwOTA0OWQ2OGZlODhmMDZkMjFjYWJkMy90YWJsZXJhbmdlOmFiMjhiMTEzZDA5MDQ5ZDY4ZmU4OGYwNmQyMWNhYmQzXzctNy0xLTEtODY3MDk_a93e6e7e-db61-4592-881c-807d95a115a2"
      unitRef="shares">9893089</adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="i7aa73f459e1249118a657516d64db79a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjY0OGM4ZTFhYzkxYjQ4M2ViNTJlYjUwNjFmODQ3NWVlL3NlYzo2NDhjOGUxYWM5MWI0ODNlYjUyZWI1MDYxZjg0NzVlZV8xMjEvZnJhZzpjMDg5NDk1ZDMyMDc0NzE5YTlkOWE2YzEwMTcxNGQ5Mi90ZXh0cmVnaW9uOmMwODk0OTVkMzIwNzQ3MTlhOWQ5YTZjMTAxNzE0ZDkyXzEzMzE_bf3546c6-a762-4d1d-a8d7-b8bda350f6c2">Events after the reporting date&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company has evaluated its subsequent events through November&#160;8, 2022, the date the financial statements were available to be issued, and has concluded that there are no subsequent events requiring disclosure in these unaudited condensed consolidated interim financial statements, other than those described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company held a pre-BLA meeting in September 2022 and a Type C meeting with the FDA in late October. During the Type C meeting, the FDA provided strong guidance that, for it to consider an accelerated approval path, a randomized confirmatory Phase 3 study must be well underway and ideally fully enrolled at the time of any BLA filing for Cami.  As a result, the Company will not file the BLA for Cami next year, as it estimates that it would take at least two years to fully enroll a randomized confirmatory Phase 3 study. The Company is engaged with the FDA in an ongoing and constructive dialogue regarding their guidance and the potential regulatory path forward, including the design and timing of the required confirmatory Phase 3 study. At this time, the Company is pausing any material investments in the Hodgkin lymphoma program.  The Company will evaluate its options for Cami with a disciplined and strategic approach to resource allocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%"&gt;The Company discontinued enrollment in the Phase 1b clinical trial of Cami in combination with pembrolizumab for the treatment of solid tumors. The combination was an immune-based approach and intended to enhance the benefit of PD1. While the Company observed signals of immunomodulatory activity, the clinical data were not compelling enough to move forward. The Company recognizes the considerable effort required to fully pursue the opportunity and intend to consider strategic alternatives including a partner for the future development of the program. As this combination was an immunotherapy approach and different from the Company's other solid tumor programs, the Company does not see any read through to its other programs, which it continues to advance.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MTHJWF&( XR_+!(N5+B3F*Q;-"58>'&-B\"K:I3)69.Q/6>)2:>=NGE'DP6!
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M;K'"!^TFX/NU4O;0<0NT_QFF_P!02P,$%     @ PSAH5:6W=Q?/!@  ]"0
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M@PAX700\8P1NE(=(B[LZ ,K*?&>RNC+)]X"!N+Y>Q$L(YEF.+A^ 4>+KP8P
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M*RN ^G[-N7RZJ#KH7G1:_ M02P,$%     @ PSAH5;0XCJ)N!   ZA,  !@
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MBN)BJ6@HOLUO3I9<*9[FCPG!,1$: ._7G*O7AAZ@NMZ;_@M02P,$%     @
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M!OKO=T*HYS?F9S7;GU'-_@-02P,$%     @ PSAH5;J())W&"@  7ET  !@
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MTW$SIQOZK#X E1S+U>Z<FK.-GNU081RJ6H2J%J.J)9=[J^^6CMKQ"]1N\$T
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M\]Y_J8MM^VKH;T5=%YOVXTJD2U$V ?+_[XNB_OFE>=OT\97J-W\#4$L#!!0
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M?RR,OY^'K4]I)O5&0J$MVSV^^6Z=[8L&(J%S!%>/88UR9YUA=E0DL6 >%RP
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M2*J[([[=AT;MVU.R-ZIIU*Z]W,HLE[4Q@+]OE&J>/I@?& Y:G_T/4$L#!!0
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M+S)Q,_R,RS*CZ;ZU>DEMRK5R>@8NB=@2'WX-:\4SBJ?.=XF"I,T;- 2N*&+
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M"XAHJ"_BGL7+>[4S&"'24C8TSD@LT*I ]P49R.Z=C]&8*R>*ARX(S1L-6(G
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ML;?'F:'/;Q-);_*7$B+D\; ]M(#,  HU\<,?A>I/C[9Z1NL>4V^&9V3/+K9
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MJ2T%+S&6U6$>BH"^9>;6JTE03@C D&49E\8#+)XT@39Q&RE5@;P)M23H;]A
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M.EWZG[E -S2T >\S#;?B REH/W%?_!=02P,$%     @ PSAH531,%=>&#P
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M.7+].G)(@; -=W@\K["30D%7'"M_W.]?VKXM'9RT(%J1OK8A3\2!/&S9FYY
M(VQ7BTC  0[QQ=_@AB>FZKX)M"<0'UE0?#")0[Q5+#P;R-2I.%ATYF<G'0%I
MP$$>S3.'23&1(KO@7X=1OKLVB_:'YC?XE:.BI0(G_#R@3 YX,3W**LF(;^T>
M\C9E]BR+)<=JXFS5;0#NO,,][W'OA[)%SF?513QN<.=MPVB/;5 ]V0W];LK@
MY[3QR*9'DL*:\Q0/8/TQH4MQT;A8,WB9SFVC7;^:QX.O&Q6Y5?R&PS]1,!33
MAX[^:?^9Z#)]'=DN3]^8ODBW4L;#_Q);)Z-W;S(</.)WFW03;!V_E2QL"+:*
MER5^-9'C!6^X3Y#=]H8=]!_/+OX/4$L#!!0    ( ,,X:%6%_#=/\@@  +X7
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;+U8;7/;N!'^*QC=S(TS
M(^N%DFPYL3TC.[DVU[QXXJ0W;:<?(!*2< $)%@"MZ'Y]GUV0E&3+2N^F[0?+
M! GL+IY]]@6X7%OWU:^4"N);;@I_U5F%4+[L]WVZ4KGT/5NJ E\6UN4R8.B6
M?5\Z)3->E)M^,AB<]7.IB\[U);^[<]>7M@I&%^K."5_EN72;&V7L^JHS[#0O
M/NGE*M"+_O5E*9?J7H4OY9W#J-]*R72N"J]M(9Q:7'5FPY<W8YK/$_ZJU=KO
M/ O:R=S:KS1XFUUU!F20,BH-)$'BWX.Z5<:0()CQKUIFIU5)"W>?&^D_\=ZQ
ME[GTZM::7W065E>=:4=D:B$K$S[9]9]5O9\)R4NM\?PKUG'N^*(CTLH'F]>+
M84&NB_A??JMQV%DP'3RS(*D7)&QW5,16OI9!7E\ZNQ:.9D,:/?!6>36,TP4Y
MY3XX?-58%Z[OG,VJ- #?!U54RG=%H<)E/T T3>BGM9B;*"9Y1LR%>&^+L/+B
M39&I;']]'R:U=B6-73?)48'WJNR)T: KDD&2')$W:O<Y8GFC9^1]BOL3/SF;
MBUO8ZL '+W[1825N&6;EO/C';.[YRS\/01 UC ]KH.AYZ4N9JJL.PL,K]Z Z
MUS_^,#P;O#IB_[BU?WQ,^F,_/>NFHU(.V]A XU1JEX7F8'FD3GPLQ*QTVHAD
MQ"X9=D58*0"9E[+8T%*%X,K$3Z]G"+040>=DP-BI965DL&XC9)&!N.ZK"KI8
M"EF6SCY((Y!7Q-__]N'=QP^?9SS'R*I ZLF$+EC'E]Y]3_B5=<%LZ 52SR(H
MUQ.?K<B@9,^2'W^8)L/S5U[8 K.]K5RJA%V(\C%\ZY5.5R*U.1),"F59Y<BL
M]W)3;V\EO9@K50@OC?(DH[5RU["#\2/6L%+\Y<O]:P%1HV3(&^/Q9-(=#@>\
M:Y(15DXI_EK 52*/0:0HB 1"(*A\KEP;!UVH\:7B1&8VWU<^''6'X_.M\N%9
M]V)P_L>4#Q\K_[SO?^LR+W0@T'P0^--(F8S]TEGO3X,])>-..G_Z_*'SHD95
M9K\B]N "K NV<4H;CA(;,?JK(L=;"(9M00>CLJ@]R+E1>(W"0@Y^T!F)%,X:
MJE9KZ3)2?X@=H*BKI/$PW#!/(9[FP;8#EOTQ9_'$IS"2Z23FR.H/WY%^ @*2
M/U]$/21UY^E&+751$)GGTDB06XRZX[.Q.!\-1-*=7 P$PY"\.K+;M'(. [%1
MTM531MWSP1D$#*9#,1QTQX,1!M/1Z(@4) S\[L@X22:C%ZWZD]%DNAW=.I6!
M/EU1RDT40?B!6$9ZKQ<ZE928F":S-+45S<!4IL#)J'N6C%^(DRG]7'1'XP3_
MAX.S%U2/=J&0',G[<(ZZR05MYCPYWWM^EF+$A7VS&I[]'EXAC:2FRK:)[C%)
MJT)6@ 034@L6%#X^>6MTQL)U@3RH\W9SL8L[M,66CZ^1J./;84/'+9MFSZV,
M'YZLW3HBYG_"*J:@87<\'.,W&8S%1\K9+:.,EG-M4&2 Q; [/;_ [VAZU@)/
M_#P@EDPXA)$ND/FXO&@O"BN,+9;0ME(&L5\P7'I9,-SSS4$)8:5==EI*%S98
MO=1(7&GD7H9GI^<5.[AVON,ODM.,\NC\")AH)E<U42JTB@7I^_DTM9G:JV^'
M2U5-> %GYKX!"BG/2>Q%+*AA0>AF<L/DOXB//?%.I\2)W1+]LRPJ=-9B.&WJ
MQ6Z15D272!N+;0CU#?SSR.9P2A0EE\A,;,N:^J+WG^]NV^2708VQ)7\E#+AT
MNE1+HW]K8Z MD;1*&B/H"!$LX9KR*B:O"%6.[QJAV42U)N-A94]\*0AE3K>,
M1Q-9C6G/-![83U4"*UC7X(F55/2 7:Z-X2, MR#M*JP0$0J99=SWH!_AHCV8
MM&M@&1Y1SVP!RNJ%2)4+..P< 4201T(L7S)=:0RS_7JYAG#@X_>*&MG26.;L
M1AH.$F(!40L:P2WX*<B&%03$"J<.(*5B9J0WE*K"FH1B-1U8.!(H*@]V,C7L
M[&LVBY(--14IFD?XQP@?D(:>6<@[YV4K^:!8OZ-S$!E#,:5375(;H&GF1BR-
M1;)Z*AJQ.4>9J$,(K=Y.3J4Y&UCE<?@4;[>^VB<"V^"KLD3@M%;"B);#U)ID
MKEK^!T2NF(*R$==2K\<Q5N'5]^/KN\%U;^?Z_Q1<.(M[Y*X&4.I;N^C*%!SC
MQ.U*%[(K[H&]!/*QO_E?Q>)DLA>+R-G*Z*6F!+]#_AB6'+O3I+<7BH_.$RVK
M3R/1MY':K<LK48HU;[- 59+ZYOP!RR3:_N9<,JL"CAK:1]1G($!3XNOZ\:9R
MME38(K:=:\^7$WMG&*[F5%/H\"5>O[NY??=<\/_N:,]U=KH7[/SB>+#3M.;X
M ['$N[;TU-S,R+]. U9-R/EJ_BOZ?-+1)+N=UJX7J;O=14JG::J32B23QFS2
MW(8Y/E/44P@S5O%2ILD&VW"E:=!?IV61RK(ASG#K/BC@GO)(,J"S&Y.4<VH=
MQ@T&>-/&WG\A*=2'%H8C)O,V"42W<P;BLP!I;;.!X_*>[Q0*;GJP-"*$[(GX
MI(/6&]20'7UUVT@M2"N,>A("AB_IJ!6T<\15-/P) M&LW;7U]^VB0R8!T\:J
M9U1YF@,_;'@U]UX9@T&=%,Q&#Z926?G'F*2(IKDJU$*'+=5K^^@D3V/MA%TC
M#2(=V:7BEI+3J.5']&)\U"?U,K!ZNJ'4Y*@'J4WL3$GAGFB:MT5:P%H$TD)S
MP\F&1.E+:W&V9:^X!TU:ZHX]K>^1]N,;W"F-(MBH]^0S MRVRS"ZJ*QY$[O(
M> C@RY.=O'3PPJ$]C%+^;G(K'3=*#G["8D$V48JLD\]LVZ[&.*G*TYB>&Q(L
ME(J1.;=-W]=Z)X+)5T._D9T(C$Q'P  UFZ)S+BZ--/5-I56,2A#BJ:^KFG9/
M?/[VKO71;BBCKU]4CEWQ#,>9"O7U1),:(8PS?7/'TV"UPX!8UGKBT/U<?^=.
M%:E@R3?':,\I(N+U:ONVO9R>Q3O9[?1XLXWJ@J2.;*L66#KHG4\ZL4MJ!L&6
M?$,+](/-^7$%^BI'$_!]86UH!J2@O;*__C=02P,$%     @ PSAH5;B*P#Q[
M @  JP4  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULE53+;MLP$/R5
M!0OT%%B*[*1I:@NPW1;M(6@0]W$H>J"EE41$)%62LN._[Y)ZU $<H[U87')W
M=H;T['ROS:.M$!T\R5K9!:N<:VZCR&852FXGND%%)X4VDCL*31G9QB#/0Y&L
MHR2.KR/)A6+I/.S=FW2N6U<+A?<&;"LE-X<5UGJ_8)=LV'@09>7\1I3.&U[B
M!MVWYMY0%(THN9"HK- *#!8+MKR\7<U\?DCX+G!OC];@E6RU?O3!YWS!8D\(
M:\R<1^#TV>$:Z]H#$8W?/28;6_K"X_6 _C%H)RU;;G&MZQ\B=]6"W3#(L>!M
M[1[T_A/V>JX\7J9K&WYAW^5.8P99:YV6?3$QD$)U7_[4W\-1P<U+!4E?D 3>
M7:/ \CUW/)T;O0?CLPG-+X+44$WDA/*/LG&&3@75N72#)5VQ Z&Z!Z:;FD>.
M@/UQE/4@JPXD>0'D+=QIY2H+'U2.^?/ZB B-K)*!U2HY"[C!9@+3^ *2.$G.
MX$U'E=. -WT![TN#AK2I$GJ]%GXNM]89^E/\.J6W@YN=AO-&N;4-SW#!R D6
MS0Y9^OK5Y77\[@S9V4AV=@[]7Y_DOT&^5@AK+1NN#B L_8D4N2X'KG+0X7Y\
M8$$KA&UK"<_:"2R!5F6-?7K =,@EN(H[<F6C#5VFTQ0C9)7  O )L]9[#711
MB P-9-358.6MO,/ZT&/94$. PCSKF&7:Y+[IX2)D#)QWWI$@J-V0'+@/8/Z@
MTT%:[:!$CR]ONQN9G'JAZ,A $DT9QH0EWJURG9?&W7$2+3L#_DWOQM@=-Z6@
M_C465!I/WEPQ,-UHZ *GFV#'K79D[K"L:)JB\0ET7FCMAL W&.=S^@=02P,$
M%     @ PSAH51"#Z<K7!@  $A,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&ULM5A;;]O&$OXK Q5H8X"5>">5V@9D.VF#UFD0I^>@+?JP(E?6(DLN
MN[NTK']_9I821=F2+Z?HBT1RY_+-?<C3E=)?S9)S"_>5K,W9:&EM\W8R,<62
M5\R,5<-K/%DH73&+M_IV8AK-6>F8*CD)?3^=5$S4H_-3]^R3/C]5K96BYI\T
MF+:JF%Y?<*E69Z-@M'WP6=PN+3V8G)\V[);?</M;\TGCW:274HJ*UT:H&C1?
MG(UFP=N+F.@=P7\$7YG!-9 E<Z6^TLV'\FSD$R N>6%) L._.W[)I21!"./O
MC<Q1KY(8A]=;Z>^=[6C+G!E^J>1_16F79Z-\!"5?L%;:SVKU$]_8DY"\0DGC
M?F'5T<;A"(K66%5MF!%!)>KNG]UO_#!@R/TC#.&&(72X.T4.Y16S[/Q4JQ5H
MHD9I=.%,==P(3M04E!NK\50@GSW_M>&:65'? K_'0!M^.K$HE@XGQ4;$12<B
M/")B"M>JMDL#[^J2E_O\$X338PJWF"[")P7>\&8,D>]!Z(?A$_*BWL;(R8N.
MR)O53*Z-,* 6(.I"51Q876X-AC_9W%B-Z?'7(=L[T?%AT50R;TW#"GXVPIHP
M7-_QT?FWWP2I_\,3P.,>>/R4])<%YTD1AP$^D@M?EAP62F*)TE/+YI)#H]6=
M*+D!BX=MS=I26%Y"H3#,R..NC)*B9/18U)9K48&Q>(M5:\G;JE.$=%!(9HQ8
MB,+=TR&)O515P^KU=ZA$62:W##MD;^&-J.'GWVZN3A"DYARJ+MDX)1M@JJ"V
M.=<N7SZB\4^=4S[13S"XNE3&045KR[:P8)A$DP,OG":0^"'$GC_U(0TC^/PM
MJYH?KN#=/5J**87V&VO@37 "8>Q%:80"/3\.((^\S$\A3;TH\N%=U4BU1N!;
M7[\)3R#(O"B(($B]+(TA2;PXF4(\]8+<[_5LZ W$@9=F*42IE_L)!!&2I?@?
M)%X2^'#CR*\?P8I.(/?"*(7,FV:(+?5B!!7DWC2?'@:5>VD0P-3SL]"19SZ$
M&4+*>QT]) 2>QQF9X<?HI]#+$6"<>D&6P8^.>';(3XGGASZZ-)E."4D2X5_B
MA7Y\Q$M$B5H"Q)Q#E'M1.'5_4=AKV4&:(OR,D"5Y!@D"3'-((E22PI?#R079
MU(NC!#+?FR*4$.V8(K(0,>5QZA!_J O94A&4'.NG$%WV#D'V%&;)-/^>1@25
M1D44#ZBCY^3AD(5/FG#:M0>-9%A&KE7]W8K&%1514.%85PMT5K\@Z<<PDV@_
M,NK#BE?,0*TL3A:J8O35/]'S+VH(QJY581?'#<30Q9$"QH/7P_<<R@;;&--"
MK@$[EB([D'@E[!*P"X$_SG$.2^E6"I1+S\)QTC^C&8,]36@7K@)SXI8;#_<7
MTW"W@<AU9\-#80<9'2!TIM*$N&PU9>\< SFP;F/42XUTA"3VH76BOD/-2J\Q
M1G6[P('8:CQKC1L)>\V:WPOC"@F=7G"#LC!/H<8=#-F$%':-#/BL%&47=%HO
M]T60._IQ8#!Q2APO>,FDQ-0_X GT#[DL&&>]RPXYA[2\V V:2V>_58YO9S=)
M0H58?V*N2N&&X.OL^8#IL3').Y*CKT6\S7JRE1-F!HL6ZVW(C$HZX6[=I4!@
M)73V&M>5F-[9:QBN0MALA"HW9,%6-!TC.4:@Z*?Y'[]__.77CU]FNQ*[9NM-
M5<Y0(R4Y+L-$^OYJ!JRA#8+Z[H 5F6988-*Q>4,?(O<=UV0=37N@R3+M?,;O
MA&J-7.]B?2 ]7N?,P.MB[UC4(/6[686>;C4Y:MND!A4QC"-:0@1JS][Q8(+O
M3<!=_(8M9L]O2WR)0)3TZH45IK$2]G.2DA;7+JMQ[8<WH\OKR]%)WV(WH7O
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M!3I\K,%WNW_[%F?9[8OI,V\.O<V=2NV:7@<^*5#!O@>-I#RO!>'YP\5\QL+
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M$E@R0?&L>W.=]R:[\-8'%'PTE^@\V)'F,!U%E D+P(;*1&P@0*X 0=]GN *
MPXM533C;U/O#8)2;L-L. >R)?-ZH"G$.W/@3TECZKM/ZBJ 76WJQ;*'!B<K/
M%C5TJ+I?P$Q0#H(,D*CC$3S99KG>T=MWEMAOG?L6 L,1G6XC-I2=< 3</&T.
MT*?AW'BW/)R^?\!LA>;.<C''UD'O>-P!L?D3[7#C=.E/D6?:.5WXRZ7@*$M:
M@/=S#9ZO;TA!\]\*E_\%4$L#!!0    ( ,,X:%4D%RV3U 4   H.   9
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)57;6_;-A#^*P<7*%I M259=NSF
M!<C+AK9KDZ!)5VS#/M#2V>)*D2I)V<E^_>XHV[$3.^V^V!3%>^ZY=^IH8>PW
M5R)ZN*N4=L>=TOOZ;:_G\A(KX;JF1DUOIL96PM.CG?5<;5$40:A2O32.A[U*
M2-TY.0I[U_;DR#1>28W7%EQ35<+>GZ$RB^-.TEEM?):STO-&[^2H%C.\0?^E
MOK;TU%NC%+)"[:318'%ZW#E-WIYE?#X<^%WBPFVL@2V9&/.-']X7QYV8":'"
MW#."H+\YGJ-2#$0TOB\Q.VN5++BY7J'_&FPG6R;"X;E17V7AR^/.J ,%3D6C
M_&>S>(=+>P:,EQOEPB\LVK/]<0?RQGE3+86)025U^R_NEG[8$!C%>P32I4 :
M>+>* LL+X<7)D34+L'R:T'@13 W21$YJ#LJ-M_16DIP_>:\]6G0>I(9_C-0>
MYJA]8_&HYPF>#_7R)=19"Y7N@1K#)Z-]Z> 776"Q+=\C6FMNZ8K;6?HLX W6
M7>C'$:1QFCZ#UU_;V@]X_1_8ZN"]ABM?HB6J7GJ)#OXZG3AO*4?^WF5XBYOM
MQN6Z>>MJD>-QAPK#H9UCY^3EBV08'S[#.ENSSIY#_W\1>A9J-]$K#1>88S4A
M=R19<#:YG+P#YZ:JA;X'H;5I=(Y%V&T; 5>4F8( 386W10OR5BR"JSE:)70!
MIQ?GMW FS74I2#:B%/?EP]MV-\?&RUPH!Z]>OABE:7RX.A >D\/7$6F;-DK=
MDR<\SJSPQ&@B3;TEOU)/M9I_XP/W\$XJ59K&D46BEEZH[CYJQ$PI*NHY-:L:
M^#VA56AS*93\%\%H9*LWG,/DDH-#QT!06U,TN7<1_/G'Y<>KR]O3*(#XTN+/
M"$).IV5!AA$$,WLSC)/U*H45X3=CWJ9\F%$?INR \U)J$5[?2#T3M;'8A5M2
MYL5$(4RX][*2N2PHUP58H[BA+X0M]M&2&VFWSUO"L325J6_39U6K@0DMB"1!
MU!@ZK[KOPBL"^^W+S<5KV)O5\$'HAL8#)$NL+(G2_A!N2&7P(4E1QW5/!5\-
MHT$V?KV+3S^+AJ.#1] )9 ?1.![]#'2?#@YW0!-&%L44FM,]KF@KB<8$6DO9
M.*,QR0?)!Y#VNP-JZ4J%Z62EH]#!U)IJ9SQRZJU63II0>10[D$04OS?2<SW,
MR94T*H,[67J;OD4>SZ2>JK@4>D:KH&==]_VE1]JD>:):6'O/Y.9"-<%1,CAI
M4ZEXI%+JG'+34;81U0)7#Y(GN6K;AS<[#:4TI?SE$Y3:X%:QX;*V6/)U8![@
M386,K8QSJQS>HM"%KW1ZIXHU* NC:QO9-G^\RQ$+]\/2\*7PCT05NE;NJ=^>
MY@+58TYAI4<Q,7/<;KQYZS1RE,7<S#2W(';]FO^TL6&,M79TX;0H9/"<6IDF
M0OB7PE3LFMKGTO%XYSEXP8)-K:5@$_,FD%0X(S#R,^4?#<@FE#*8B9*S$,40
MWTH4"+6XYV2@#4T-IQ1JNB<LZ[[DMAO3\F(8>$ZIGVGNNL3D8>!PVN_K1<$,
MZ8@+!8<%M].K53NEOF<6'))-6+H'\B6Q#9JH:-9Y3D,:D)I'S+*D'B@Y3SJ6
MMD[W-T?:TL8_GX"^-&ZM<[,_+OO)@T?.!"G)D9H57]5W]+@GQ4S3SI7M$.,%
M]PI*Q$ [S:(L&T!_'/63$5Q;K(4LPE$3\BD$GV(F*(?H^" 90C+@GDW-0_)$
M6;[(1E&<Q:N_6^,Y\:282-7>JOK109) &HW2$5SB&F\XCM)Q#*.,&O9@T\B;
ME6?9^/.MBO_(=7X;!FG57C.1KYF//'%);>ZY]\%3P3D/JZL:Z2[!28%W]*W#
M59-%XP&9%67# =^)^LD!C*(DC8,1H>/09C:DWP'9E_1I!(R!ALE!"KMN?+V-
M^SG=)F;A*X1;.D6]O:JO=]<?.J?M_?[A>/N5]$G8F:2J4S@ET;A[,.B ;;\\
MV@=OZG#;GQA/WPYA6=+'&EH^0.^GQOC5 RM8?_Z=_ =02P,$%     @ PSAH
M55:HCE2?!@  >Q   !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULI5AK
M;]PV%OTKQ!1(QX RH_<CL0TX=KM--\D&\;KY4/0#1^)81"51)3D9^]_ON93F
M85MV@^T7#RGR7IYSGZ1/MTK_:6HA++MKF\Z<S6IK^S?+I2EKT7*S4+WHL+)6
MNN464WV[-+T6O')";;,,?3]=MEQVL_-3]^VS/C]5&]O(3GS6S&S:ENO[=Z)1
MV[-9,-M]^")O:TL?EN>G/;\5U\+>])\U9LN]EDJVHC-2=4R+]=GL(GCS+J;]
M;L-O4FS-T9@1DY52?]+D?74V\PF0:$1I20/'SS=Q*9J&% '&7Z/.V?Y($CP>
M[[3_[+B#RXH;<:F:K[*R]=DLG[%*K/FFL5_4]A<Q\DE(7ZD:X_ZR[; WP.9R
M8ZQJ1V$@:&4W_/*[T0Y' KG_C$ X"H0.]W"00WG%+3\_U6K+-.V&-AHXJDX:
MX&1'3KFV&JL2<O;\@P E<[JTT$5?EN4H]VZ0"Y^1*]A'U=G:L)^Z2E0/Y9?
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MQU^W,@*PTX IG84B$7$7M$#]&\E7_P!02P,$%     @ PSAH5:)7S6N"$0
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M"2:69"(IES:,4D\A;UD^1&;JT_6O!TAV)0P5$,Z6VXOV"ZN5'KF\**FT"N.
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M2F>A2$3<!2U0_PSRU3\ 4$L#!!0    ( ,,X:%7F(),(,@8  &@/   9
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M"U:U5&Q3'VZH-"?ET2.7,3(OV0-GD<IOE#^G/WPVX$.D4Z.K6S)+-G0/PX=
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M/(-;X_A1#<.2OV+0>@/>WQE.4S?Q#OKOHOD/4$L#!!0    ( ,,X:%409=C
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MF^_8Z#ES>*D2QC]A4]OV^P&D:V-5V3@3@Y++^LU>FSSL. RB3QR2QB'QO.M
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MELK2\/'+@J8]:F= WW.E[';C K3_C_%_4$L#!!0    ( ,,X:%6)<<">XP,
M +4)   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+56VVX;-Q#]E<$&
M"&1@X;WJ8D<2(,E)&Q1)#,MI'HH^4+LCB0V7W))<R_[[#KG26D9DM7GH"Z\S
M9RZ<0W*\4_J[V2):>*R$-)-@:VU]'46FV&+%S*6J4=+.6NF*69KJ361JC:ST
M2I6(TC@>1!7C,IB._=JMGHY58P67>*O!-%7%]-,<A=I-@B0X+-SQS=:ZA6@Z
MKMD&EVB_UK>:9E&'4O(*I>%*@L;U))@EU_.^D_<"OW/<F:,QN$A62GUWDX_E
M)(B=0RBPL Z!4?> "Q3" 9$;?^\Q@\ZD4SP>'] _^-@IEA4SN%#B&R_M=A*,
M BAQS1IA[]3N5]S'XQTLE#"^A=U>-@Z@:(Q5U5Z9/*BX;'OVN,_#?U%(]PJI
M][LUY+V\899-QUKM0#MI0G,#'ZK7)N>X=(>RM)IV.>G9Z:U695-8RN\#R@9-
M")(JH7?/5@+-Q3BR9,-)1L4>;][BI:_@7<$G)>W6P'M98OE2/R+?.@?3@X/S
M]"S@$NM+R.(0TCA-S^!E7<"9Q\M>P;MK X4/6E6P(%\U%8:!;]QN8>'SC=K
M'[.5\3M_GDI!:R$_;<'1Z-K4K,!)0#PQJ!\PF+Y]DPSB=V?\SSO_\W/HTQMN
M"J%,HQ&^K.$&+>,"2_@H6X*Z2I^MB'VP9'2","O_HJ"(113C^\=:,,FLTD^G
MHCIK]W14]UL$ZTH%5H[>4&OUP$LRRT KX>Z,'=,EJ#58DERHJF;RZ>V;49H,
MWY%04>B&"4/%)YBE(*SR<K_<?P;CO6='WA.8W[5;C0A,EB#)1:C:<D-7;D#%
M8K%:H>XJQ@O^L)Q<PKV'.:/]^5_0>US";U^7-Q>M'8=Z-)KCADMR<$-W!B6]
M0,C"?)##,(LA#?M7,?@TI._.1%LT6M,$GI#IO4@6#N,! <2C!)(XS..,)J,L
M.X-2:T[M$48O[6<7G?E>UA\]SQ8:2V[I%JC94POA\J>Q$,P8ON:%KS#C3FI6
M%*IQ$B3J2Z"7A8,TOX#>R#5789:GU"?QX,)=!L>I8,:5Q,MT9F%ZY8(9IL,7
MXS.4Z7>4Z?\_E"&10C2EE_6U-]\'L'3WK3E%HK.>_"2)G,67B3\PZ6>8 _P0
M!)<G:=A(UM"ADT"AJ,ZE:4=&"5YZ<"XM:EYUQ]?^%DX=8L>X&RSVJ\F!<,]\
MF;VFV6[\H/M<:E2(R!]<KMIW*@GS)*<VC7/X0K$]<T9PMN*"6TZY2,+1\(K:
M;#3H2LLQ\%1I14=/*;T$&_]A,.#MMZ]JM]K]26;M4_PLWGYH/C%-=X !@6M2
MC2^'5!NZ_22T$ZMJ_S"OE*5GQP^W]*]"[01H?ZV4/4R<@>ZG-OT'4$L#!!0
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M<+Y'_]AI1RUS;L6UKG^5E5M-@CR 2BSXNG8/>O.3V.E)/%ZI:]L]8=/;9BR
M<FV=;G;.R*"1JA_YR^X>#AQR^H8#VSFPCG<?J&-YPQV?CHW>@/'6B.8GG=3.
M&\E)Y5_*HS-X*M'/33^WPG GU1+$"[YH*^#LB<]K8<_'(X?XWFI4[K"N>BSV
M!E8!=UJYE84/JA+5G_U'R&L@Q_;DKMA)P$?17D!$"3#*V F\:! ;=7C1&W@S
MQ>NME1;T J0J=2. JVI0_AN?6V<P3WX_IKV'CH]#^]JYM"TOQ23 XK#"/(M@
M^NZ[,*7O3Q"/!^+Q*?3IC;1EK>W:"/B\@!OAN*Q%!;>JKTJ?WK,YEAQ\Z*58
MN-K")^Z\ V[57'&GS?:8K-.!GU8"%KK&TO4IXGQF0&OTLZPPAL/#M>+K2CHD
M4VI\ZQB[FUE=RXK[;:F<,+(!ZW")U>S\Y>L^Z] .RII;*Q>R[&7@H8>]UDW+
MU?9[#*(=K_<.KVEZ"6=2P<]?'F_.X6EEA("FSSWA<P\P<S#:7)@N?3ZAJE/G
M/KW\(SR876O;446UU;IT8#D6!82$%0DDE$%,:$$A91$\O.--^_X&+QJ58H:A
M?NLLG(7GP&(2I1$"$AJ'D$<DHRFD*8DB"A^:MM9;)#X4'CN',"-1&$&8DBR-
M(4E(G!00%R3,Z1!'[-]Q')(T2R%*24X3"",T2W$,$Y*$%!X[\[N_T8K.(2<L
M2B$C18;<4A(CJ3 G15X<)Y63- RA(#1CG7E&@65(*1]B#)20>!YG7@:-\9X8
MR9%@G)(PR^#'SGAV[)X20AG%*TV*PC-)(AP2PFC\QBUY2XP2(N<<HIQ$K.B&
MB U17BD52#_SS)(\@P0)ICDD$09)X>EX<D%6D#A*(*.D0"H,=13(C"&G/$X[
MQK>JK->^""J!]5[*/GL/20X6=L6-^,&W#E\:C;?XBW7T3WA8YG!O/$^W)>#K
MV?5?KF]KV79%Y2U\X;BN%OR9^A=)?P&S&O6CHSD>>,,M*.VPX_@JQKOZ+W'^
MQPCAQ;&O[.B@+S;"++ONCY\<O5:N;Y'#[O"#,>O[ZJMY_W=RQ\U2XN>J%@MT
MI1=9$H#I.WZ_<+KMNNQ<.^S9W72%/TG"> ,\7VCM]@L?8/CMFOX!4$L#!!0
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M5I8LW2Q+FJ&H70*=YTK9W<85Z*=R\@=02P,$%     @ PSAH56!TMOCC P
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M#-, 3'M=MQVGZ^:*7&B'%V[SNL8O'&Z\ <XOM7;[CE_@\,TT_0]02P,$%
M  @ PSAH55 K;].; P  +@@  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&ULE5;;;N,V$/V5@18(9$"-).H2.[$-Y+)%BW;3(-YM'XH^T-+(8E<B79*V
MD[_O4+*U3NNXZ(O%H3AGSM$,9SS=*?W5U(@67MI&FIE76[N^#D-3U-AR<ZG6
M*.E-I73++9EZ%9JU1EYV3FT3LBC*PY8+Z<VGW=Z3GD_5QC9"XI,&LVE;KE_O
ML%&[F1=[AXUGL:JMVPCGTS5?X0+ME_63)BL<4$K1HC1"2=!8S;S;^/HN=>>[
M [\*W)FC-3@E2Z6^.N/'<N9%CA V6%B'P.FQQ7ML&@=$-/[:8WI#2.=XO#Z@
M?]]I)RU+;O!>-;^)TM8S;^Q!B17?-/99[7[ O9[,X16J,=TO[/JS*?.@V!BK
MVKTS,6B%[)_\9?\=CAS&T3L.;._ .MY]H([E [=\/M5J!]J=)C2WZ*1VWD1.
M2)>4A=7T5I"?G3\J^1UE6',KY J$+%2+X'_FRP;-:!I:"N$.AL4>[JZ'8^_
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MY;&26U!6FM#LP)GJM(F<:&U0KHRB74%Z9OD1R20-TR]\5:.>'2\,@=JM13$
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M\,#ZS]_@-X2ZO_QV?WW4<#9<M^ZN&9-SSO*,?.12:?(@X5F0=^@?D6'@)$&
M_]"9^N$1\<?.>!P3/W:2>+)%><\ 0]:3'@,]#N2T(!^O+PBM ":@!KLC\M,/
M2> ''][\ATXTC@ZQI',-?5[R,R+Z3A(F5D0O]""BYWC3B PCQXNPW8/09F'D
MQ#$^#F-G&D&/8.S$8\_H$4RFEHUUGHU+M*Z 9)V*10G_R?X+4TIF(\I$Z,8)
M7_E@79&ZU#RW*RK!2VT\C3VWB^%6%_4"2=28P')U+9HW")XLX];O@/9>'W?L
MIRM15+1<6ZVD$9:2!:J=V<GX!P&4?KRMZ#O4\Y'F]=*N!EO&*]V%B.$(D N>
MYT8\5<\4^UH#!I)Q-:NE8B9K-9(Q9>*5JZ5Y]2;&-A%E00>8/*MA5I/F"55*
M(!-JK.LEV;.7I68Y1_6A%K)VHRW^O"A89KCEZSU.#)J__^WSIR^?'R[< YEQ
MW&?&\;LSXR-;PVQ5#4>I%?1!IV+-9X7=E1 /LS8^O:(2$01(@>ZB47I)%9DQ
M5FZY@4$&.\./H."65T(F8\7(W9CQK2=:5+D"NX)154LP!&;;7& D\K6F$@$,
M6-%Z<.627S;*&CV-'7I=.\/LD!["X^-K$59,,O.IR?_JA%SL7/;S,Y,I1US#
MM*D-0:->XH8>N5]2^>J][[EA2.ZX>CR>FX!'4&(;\)/P#Q*X4_(C.%;HRJ#R
MD\@A8&Y*1#+9_@":@@R;(#HBL=?%TS7J28:@(FN;[[H\>)G3]/$87B'0NO0%
MRLHS<<>^351='%LGL9;+6&7B$U!M,)QS; Q+($ XA :3E.9I;<1LP_NEI7<#
MKAQLTQ&\%*ZI=\<&,[.@$!G+O]>NJC7LCO2YQ[8[5OXY\T9N$NRU;N0&^ZSK
M[;?N.'''WV_?P(V3O>5XMT-?(^4V&/AM-GZ% 4+;#[T?.^!O;K^T'_#"G[H>
MH.MVC]R)UUXQ)J0O>QM+U*^-)^XT;*][ R?PW,#;"W!H ?9=;Q_,8WR8'(BD
M,-A@'7TKJKK_.Z0\J+1N9#!;F-]-4>4<&\Q$3^@'5K+$37#=VY5\IU$ZQ!/7
MF[37;R$^F;C^M+W^_R-^H*[&?5V-WUU79T)*.Q6H747T()_=<Y&QOZ+--)X*
MA52WI&@>;%6ER%*I;4?:AHS.  #1*X&E125*TPBZY"V+K4:FI=Q9O+M]T.?)
MA6F...JX1EUMB>J2UN@(&V?*3!=K[Y3(>6:96Z_@!4'+I5G7;XF*R2[?KY8<
MN.EW"/BR$]O(AJ:BM@XTEZ*P*\T"%^&#HE-+O) $_41MIE6[ =RX&=AFYG#E
MA+03"_GC+0)W+_9L^GLS,));M*TIK_"(:64\(3[:>R\*X5@8"3QO!^+#(!IC
M*)@X?C*Q_U&(GOH*>ZY-0>LK8]-GHH0J52/P&<(M<1(,0N\8.?L8W!XI;-=E
M6G;3K[\ZM^BKYO_:P.@[?H@ECA\%!/-5')$8P!Z8Z2(O(@GR6>!X2%N^$WC3
MUIZ^,PYCO)_&/IDX,9A,G!"UQN"]Y2=F2#?)!ZY)),P Y! R65?LVC;)9J+)
M!PSC;/;"DR3K>J'6F\6:YDB$52T17# 570!($R'N%B1_I25:V37Q6]P##),1
MTN8GIM";]#SHNCF3,9-F3&[AZR=O?<&'6OC:D*9U89LS!!'R1[H\QDQ(LW\A
M2)HY:7/F\_K PB$ETV::]5 $=KA&$, V4?1*=+_/T;=2I(QE:A.NBC:9<UYK
M-/2M5AQ &VU-,#4BO\T1&+"GR3XL C_<AT3L3,9!^_']0'344WC+VZK;6697
M-1EM'306#(G4'*<J*($IO#ES[-_V)[87S4'E9GESW/LK\C!' YNS.4@]=X*I
M3#9'J,V#%I4]MIP)K45A;Y>,8N@T"_!]+H3N'LP&_3GV^7\ 4$L#!!0    (
M ,,X:%6\X"8,V (  !<&   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM
M;'U5;6_:,!#^*Z=,JUJI)2%0H!202MMITU2I*NOZ8=H')[D0"R=.;8>4?[^S
M QF;@"_$]_;<<S[?,:FE6ND,T<!'+@H]]3)CRK'OZSC#G.F.++$@2RI5S@R)
M:NGK4B%+7% N_# (!G[.>.'-)D[WK&8361G!"WQ6H*L\9VHS1R'KJ=?U=HH7
MOLR,5?BS2<F6N$#S6CXKDOP6)>$Y%IK+ A2F4^^N.Y[WK;]S^,FQUGMGL)5$
M4JZL\"V9>H$EA )C8Q$8?=9XCT)8(*+QOL7TVI0V</^\0__B:J=:(J;Q7HHW
MGIALZHT\2#!EE3 OLOZ*VWJN+5XLA7:_4#>^@X$'<:6-S+?!Q"#G1?-E']M[
MV L8!4<"PFU Z'@WB1S+!V;8;*)D#<IZ$YH]N%)=-)'CA6W*PBBR<HHSLP=$
ME7(4";PQI5AA-)S_8)% ?3'Q#26P;GZ\!9LW8.$1L!MXDH7)-#P6"2;_QOM$
MK&47[MC-PY. "RP[T LN(0S"\ 1>KZVVY_!ZQ_"J*!9,:Y[RF-E7H4&F0 HT
M^A($9Q$7W'#4P(H$\+UJA%\LTD;1 _I]Z$Z:E/W#*>U0C77)8IQZ-#4:U1J]
MV=FG[B"X/5%0ORVH?PI]MJ A32J!MHPU$Y4K"GA15D8?XGH:[3MNMK% XPXF
MPSU0RF 5=?-,0$:"+QL+<[=(O3*81ZC:AD&-"JTUE8*&7X_A[ICGXP>JF&N$
M4O$8B02\+AX@['>&@6M%..H$0UAD3/WGTN^,0GCA>G65*K1:0SFU <4,DC&$
MSX1=T@K !-92$&%J\ 9&P;Z!8G(XS]W;O8!>MS.$1H 'ON8)$H&-FY&S3Z.P
M&]["7+!X=467+VE0W!VUA(+.X,91ID-PJ,/^WK#FJ)9N)6F(95689FY;;;OU
M[IIA_^O>K,PGII:<WK# E$*#SO#: ]6LH48PLG2C'TE#B\0=,]K<J*P#V5,I
MS4ZP"=K_@MD?4$L#!!0    ( ,,X:%5\@S3E^00  )L,   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;)57VV[;.!#]E8&+% F@R")UL]+$@-/+;K%H
M$L1I^[#8!T:B;2*2Z)*4G>S7[Y"2%7=7=;(O%F]SYG9F2)]OI7K0*\X-/%9E
MK2]&*V/69^.QSE>\8MJ7:U[CSD*JBAF<JN58KQ5GA1.JRC$-@F1<,5&/IN=N
M[49-SV5C2E'S&P6ZJ2JFGBYY*;<7(S+:+=R*Y<K8A?'T?,V6?,[-U_6-PMFX
M1RE$Q6LM9 V*+RY&,W)VF=KS[L WP;=Z;PS6DWLI'^SD<W$Q"JQ!O.2YL0@,
M/QO^GI>E!4(S?G28HUZE%=P?[] _.=_1EWNF^7M9?A>%65V,)B,H^((UI;F5
MV]]YYT]L\7)9:O<+V_9L'(T@;[2152>,%E2B;K_LL8O#GL D^(4 [02HL[M5
MY*S\P R;GBNY!65/(YH=.%>=-!HG:IN4N5&X*U#.3.<KIOBI]:N 7%:8:\U<
MN([OV'W)]<GYV* :>WB<=Y"7+23]!60&7V1M5AH^U@4O?I8?HWF]C71GXR4]
M"#CG:Q_"P ,:4'H +^Q]#AU>^ J?;]@34LS 3"E6+[D=:_AS=J^-0L+\->1]
M"QX-@]LB.M-KEO.+$5:)YFK#1].W;T@2O#M@>M2;'AU"G\ZQ*(NFY" 7X-S0
M<-T8;5A=B'HY9.UAO+L5AX4LL311'(Q->5>?XF_$-KBMK1J0Z[:(MDP5&N2S
M3F#:&</7AE?W7/6).H/9ABLL;,!8B@<.:R5R_,4C+:2HX>O\ UPU3@PQ.O#O
MKI(P-ZR35]QV%ZNK% L.'WC>:2).$P&:^C2$Q$NBP,-N!!,_#> W3*A%(=2G
M"81>%J9>$">0^6$&6-$++NPV3?R4P/&$!EX0DA.X&L\&G %*K(K,2^/4HS1&
M%6%V()]QG\_XU?G\Q(2";ZQL.,PT)J&-.%H*UVZH=RX-I?FP&I=F"[^Q\"YA
M-K6RPUUVH2H:Y6B 6V:E. =,,6#@.51M17-;T4/AV7),:,$-5]BC\ @:;E$*
M9OA.F5,"C=YI>*8=Z[W59W#G%.]W$+BR%ORT,F#!T)*CF:.=MV-;Y$]".,7T
MQ=%N3#(_R6"^1]*73W]\7..U@I9L9(G]LA3F"=+@"(R$"7[VAC-+ZI:XB1],
MVI]>O! ;46!4-;Q],Z&$ONN_MT(_G"YL+ 3F!@O=@++1I'Y"CM".T$_3(R!^
ME/2S WQ,>CXFK^;C-69)P<<?C77N<XU5W+3M\86.<U##<']\N0>T['%\>B;R
M0"M(DA"K/$82^%G<]P#J$9IY649L]2?P#:.)J\=A%'E1E)S8TYCAYZ9P3,+8
MBPCN8-V38+ A>"$)/3*)@!#;00X$/^V#G_Z_YM[=4>_W[^7;-F9#@3^(/AQX
MVQ@JN7'WGB6]+<R75&LX%G5>-K804:2EB=KM;859X2IWM#D!H>T%T=9Z7]T_
M=9.K__07A(<_L/Q.7E7GY)6G>B+GZ"N^!.&F9#5ND0SKIVT5NSX[\4@6XL7A
MD2#&R\4C\03P:B&$'D:YG7_5> V%J:5'8B%B#YF$2UD0P1U[= U5RURP$G)4
MN;1-LVCR5NWI(.R_&\-Q3.A)/[N3!K%(Y,5);#]IAJ82+YT0B/"^(\D@,<=[
M#\:*HQGV6:SQ =C4IGT[]JO]RWO6/CB?C[?/]B_HA4#C2[Y T<!/\292[5.X
MG1BY=L_/>VGP,>N&*_SWP)4]@/L+*<UN8A7T_T>F_P!02P,$%     @ PSAH
M55HI1"3/ @  &P8  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULA55M
M;]HP$/XKITR:6HDVB1,@,(C4ETV;JFZHT.W#M ^&'"1J'&>V*>7?[^Q 2B7*
MOCAG^Y[GGN-\QV@CU9/.$0V\B++28R\WIA[ZOE[D*+B^E#56=+.42G!#6[7R
M=:V09PXD2I\%0<\7O*B\=.3.)BH=R;4IBPHG"O1:"*ZVUUC*S=@+O?W!0['*
MC3WPTU'-5SA%\UA/%.W\EB4K!%:ZD!4H7(Z]JW!X'5M_Y_"SP(T^L,%F,I?R
MR6Z^96,OL(*PQ(6Q#)P^SWB#96F)2,;?':?7AK3 0WO/_L7E3KG,N<8;6?XJ
M,I./O<2##)=\79H'N?F*NWRZEF\A2^U6V#2^C)P7:VVDV(%)@2BJYLM?=K_#
M 2 )W@&P'8 YW4T@I_*6&YZ.E-R LM[$9@V7JD.3N**R19D:1;<%X4SZ@"4W
MF$'-E2E0P]F,STO4YR/?$+OU\1<[INN&B;W#-(![69E<P^<JP^PMWB=5K32V
MEW;-3A).L;Z$*.@ "Q@[P1>UJ4:.+_I/JA-*=0N_K^;:*'H4?XZEVC#%QYEL
MHPQUS1<X]J@3-*IG]-*/'\)>\.F$SKC5&9]B3^]P"_>\HI:@QV_@1@KJ0,WM
M(SXF]239<:FS'&%Q0 MR"4\45;Q&+33H7&XJF-N^'<(L5X@@F@JCK3!0?0R*
M.2I7I.\4^-3]65'!W>/T]MR5TR[A@37E)5?V_?$J VER E%X92X,*@$HZE)N
MT8K61@/KA/T^K:P_@%XG2B):61+ 9#<K&J^X#X,$6#>$*$I@FG.%%[9_L[>I
MXXNU$9).$(9$%,<$"CIQ+[ ?UAO #R?G#:@/(0GO0A3#3!I>0DBN,2.2)")E
M_4X8#H#U.@-*[=B+\ \:5J!:N;&D*<:Z,DWOMJ?MY+MJ&O[5O1F;]URMBDI#
MB4N"!I?]K@>J&47-QLC:M?]<&AHFSLQI>J.R#G2_E-+L-S9 ^W^0_@-02P,$
M%     @ PSAH54^!B9?\ P  I0@  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&ULI5;;;MLX$/V5@0H4"<!:]UMB&VC2+%KL=AO$S?9AL0^T3-M$*5(E
MJ3CY^QU2CNH4CE_Z8@V',X=G+N1XNE/ZN]DR9N&Q%=+,@JVUW448FF;+6FHF
MJF,2=]9*M]3B4F]"TVE&5]ZI%6$214784BZ#^=3K;O5\JGHKN&2W&DS?ME0_
M73&A=K,@#IX5=WRSM4X1SJ<=W; %L_?=K<95.**L>,NDX4J"9NM9\#Z^N,J<
MO3?XA[.=.9#!1;)4ZKM;?%K-@L@18H(UUB%0_#RP:R:$ T(:/_:8P7BD<SR4
MG]'_\+%C+$MJV+42W_C*;F=!%<"*K6DO[)W:?63[>'*'URAA_"_L!MLB#:#I
MC57MWAD9M%P.7_JXS\.!0Q6]XI#L'1+/>SC(L_Q +9U/M=J!=M:(Y@0?JO=&
M<ERZHBRLQEV.?G;^ES(&.H9EVE+-X.PK70IFSJ>A17!G$C9[H*L!*'D%J(;/
M2MJM@1NY8JN7_B&2&IDES\RNDI. "]9-((T()%&2G,!+QTA3CY>^@G=#M>1R
M<QCMOW1IK,;&^.]8O -<=AS.798+T]&&S0*\#8;I!Q;,W[Z)B^CR!-EL))N=
M0I\O\/*M>L% K4&\+!&5*^B49=)R*L03K+CH76>#84VON>7,'(OFY'G'HX&O
M6\W8B[H"5L6R=HEL7&G^1IA3^V=<PI_WBP\$V&.#.X=AM*J7UIS[\KJ?^$#R
M74FMU7S96]>18!6HG63:P%D>D2*JSN&LC$F>U2C$:4R*+'52G:.4G\,W?QV1
M$'U@&E\7D+UGA?GTYQO %\I83";V!)052<N$%%4$94'*M"9EB6*)VHRD535H
M(Q+')5Q1PQM?!9]Y/.*7 IU%DP(9X*?VE"9EA)]DDJ/R]G3AP&ZIA1U#%*DL
M<-F(WF45TVBW;#SPYUD-%4TOJ'O@#"Q90WO#O"E;K_'=<^$.("Y*U+?X2/9B
MA:88@>7O1@[^3&I@K02^T^;B]VM_K*XW/WING^"3;%P6\-A;025NQ36\@X6/
MZ$LW!(,E2'(2U1D4)$T*DL<55*1 71;GD),RKTE2)*<A[Q;W!A*2E2G)DAKR
M.B-UGD.,Q<3>22/(<I2+&*Z5Q#[QDP93YA+8:4P<[ZC8=ZK3-][*<M>00E%D
MR24VIC._5FU'Y=/;-U42EY<&3=L6P?:]YM7))61(/B%5%HV:%)LN(5%1P)>#
M?MQ1K;$^ _<(MZO1H4I1%V7C.LY(450DKV.(8Y*FV*]QZL2XJDF:U9C(JDY)
M5-5P[%T*#T9'R_3&#TA''T,>ILBH'6?P^V'T_#0?!OAGJC<<<R+8&EVC29D'
MH(>A."RLZOP@6BJ+8\V+6_P?P;0SP/VUPMNQ7[@#QG\F\_\!4$L#!!0    (
M ,,X:%4V^@W.! D   QA   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;+V=;V_B. *'OXK%K4Y[$@+BA "S+=*4Q+Z3=O>J[<SNB]6]2(-;H@D)XX1V
M1MH/?PX)!">II]G^AKX8_C1^[-0_;.<!/%?/J?R4;83(R9=MG&37@TV>[]Z-
MQUFX$=L@&Z4[D:C?/*1R&^3JH7P<9SLI@O6AT#8>T\G$'6^#*!DLKP[/W<KE
M5;K/XR@1MY)D^^TVD%]O1)P^7P^LP?&)WZ+'35X\,5Y>[8)'<2?RC[M;J1Z-
M3Y1UM!5)%J4)D>+A>O#>>L<=IRAP..+W2#QG9_=)<2KW:?JI>/"?]?5@4K1(
MQ"+,"T2@;I[$2L1Q05+M^%Q!!Z<ZBX+G]X]T=CAY=3+W0296:?Q'M,XWUX/Y
M@*S%0["/\]_2YW^+ZH2F!2],X^SP+WDNCW75P>$^R]-M55BU8!LEY6WPI?I#
MG!5P)B\4H%4!VBA@VR\4L*L"=J, I2\4<*H"SFL+3*L"T]<6<*L"[FL+S*H"
MLT-GE7_=0]=X01XLKV3Z3&1QM*(5=P[]>RBM>B1*BBC>Y5+]-E+E\N4JE;M4
M!KD@45(&NPC(CY[(@RC._D5^(&.2;0(I,G4 ^9A$>3943ZK['S;I/@N2=78U
MSE5#"MPXK"I=E972%RI=D%_2)-]DQ$_68JV7'ZL3.)T%/9[%#34"W^\?1\2:
M#@F=4$H^WGGDQQ^TMI<W72TU@^_$;D3L20.<[>^S:!VIEVX'T7L]T3H2.S"^
M&>.)4&&L;V+8ZS$3 X9_X^^_DR-"'1-&ZU?[E$[[P+5?:EZ4A7&:[:4@Z8,:
M88I0BK46U>!>#;#D/I4*'26/&?FS@) H%]OL?QUG<E/6Z'376(S\[[)=$(KK
M@1K:,R&?Q&#YSW]8[N2GKO0@81X2YB-A# GC()@6*.<4*,=$7_ZZW]X+683I
M]!J.U/#PE_DE?6.$]LU,"7,/L&*E\+2TK\9/YT% 5N<C80P)XR"8%H3I*0A3
M8Q!60;8A:O8B87%'?-Y'3T$LDF)V4[-LM-UOR>=](',AXZ]JK1,'22BZDF&L
MI6\R2MCT+!GN1/TTTH&LTD?"&!+&03 M'>XI'>[?2T=7!(RHOA%PVX/#?#)W
MFQEP6TF9VA-KX>B'^>W#'->=.HW#6,=A]L):3/7#..A$M1Z9G7ID9NP1_TNX
M"9)'0?[[0%9I\B1D'MW'@OR:YFK\5E<EY(] RN"%+IJU3M"RIJU7ULK8A+ZS
M.1+F(V$,">,@F!:*^2D4<_/+M!F$(?D]B/?BF)#FM449AGE'&&9V*PS&JON&
M 0GSD3"&A'$03 O#XA2&A3$,MS(-A5AGY$&FV\.8G7\E49;MBZE[2!*1%\N^
M7(T165!JD##-NH<+8T5]1_1%:T1WK05MC.>+5B8;<?21;6)(& ?!M$ZW)K6_
MF)B[?2_5S*"XG3UI+MRW*Z$T#TKSH30&I7$438_(F>*R+FX1JBI1P4+2/"C-
MA](8E,91-#U8M X6?:U-J!2IFFY4LOYZV3?>5,CS^6!FVU-WWEA^F*ON'0DD
MS8?2&)3&430]$K6PM(SZ:GFGKA.+:Y2[/ T_#<FMC$)!;E5([HI$J&344KHS
M'25]=I:.^6A*F]F :D<HS8?2&)3&430]&[5[M,SR$;A"K6K25)'5NH0QMZ=W
M3J!:$DIC4!I'T?2<U&K2,KO)H\D8D@_J-MRH 27IE(]F3N]%")+F06D^E,:@
M-(ZBZ6FI5:7E7GYU"W6:4)H'I?E0&H/2.(JF!ZLVKI99N7;8M;MRF7O2:^:5
M[JRUTG4<B\Z=UC0%]:Y0F@^E,2B-HVAZ/FKY:IGM:WN:^O"<=@8!Z1A74)H'
MI?E0&H/2.(JFIZ6VL];B\M,45-1":1Z4YD-I#$KC*)K^R:]: %.S '[K-%7A
MSZ<I:B\F=#%K3%/F=O3-!Y3F0VD,2N,HFIZ/VOY2HP3LOIHZFID7+JS,R+X#
M"Y3F06D^E,:@-(ZBZ<&I[2ZE%Y^Q*-)UKJ T#TKSH30&I7$430]6[8BIV1&_
M><:RVS.6:UO36?,]!',[>N<#ZHFA- :E<11-ST?MB:G9$]<S5C,60^)_$3*,
M,E'-7]]Z/Z&JZ?S]!.J,6BL;J">&TGPHC4%I'$73<U)[8OHW//%Q9?/"M;@9
MV7L"@BIC*,V'TAB4QE$T/3BU,J:75\84JHRA- ]*\Z$T!J5Q%$T/5JV,Z?=5
MQK2MC*W9W*)N\QUP<SMZYP.JC*$T!J5Q%$W/1ZV,Z6N5\=M7-O/VRF8^FK26
M-E!;#*7Y4!J#TCB*I@>EML74_&%>%H117'P\XOVC%&(KDIP\1_F&>$+(ATC$
M:W(;R#P14D7IY]'MJ#,A4#L,I7E0F@^E,2B-HVCZ]T=K.VQ/+K[4L:$?*H;2
M/"C-A](8E,91-#U8M5:VS5KYYI278?%]_,,W!D\9(F&@JE;C5V=\H'(92O.@
M-!]*8U :KVB&[X3IP:BUL6W^4' =C,[.APK@BJ:=!.WXRBBT5A]*8U :1]'T
MSC_;K\"L=G].@Z1>LW0& +O_ '8# NP.!-@M"+![$'P/PVO7AM=V+K\J0:K-
M%93F06D^E,:@-(ZBZ<&JE;!M5L)O6)6T-Q^P9AW?D38WH'<PH,H72F-0&D?1
M]&#4RM<V[VCPC55)>P> KG7$REQ)[\Z':EDHC4%I'$73.[_6LO;WU;)V6\M.
MZ8PV-XA8F9O1.QY0*PNE,2B-HVAZ/&HK:U_,RMIM*SL?V9/S'ZL9&JBAA=)\
M*(U!:1Q%TT-3&UK;;&CU*YTA89',\N,;T9W1@.I8*,V#TGPHC4%I'$73=U^K
M=:QS>1WK0'4LE.9!:3Z4QJ TCJ+IP:IUK/.]=*S3(0*[UK[F!O0.!E2T0FD,
M2N,HFAZ,6L<Z9AW;FJ?V>3'Z5!-5YR+&3.P]H$ _I NE^5 :@](XBJ;GIC:Y
MSN6WGG6@[A=*\Z T'TIC4!I'T?1@G>U :U2 ;YFIG-9,10M%UYRHH.H62O.A
M- :E<12MS,7X;$_VK9"/A^WV,Q*F^R0O-S8_/7O:TO_]82/[QO,KZYU7;LQ?
M8\K_)^"70#Y&249B\:"0D]%,)4.66^^7#_)T=]CY_3[-\W1[N+L1P5K(X@#U
M^X<TS8\/B@I._P'"\O]02P,$%     @ PSAH567IJ&NG @  IP8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&ULK571;MHP%/T5*YNF3=I(2$(+'42"
M=-7Z4*TJVO8P[<$D-\2J8V>V@?;O=^V$#%"*^K 7L*_O.3[WVCZ9[J1ZU"6
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M9.V<924-^I0;EO@E 643<+V0TNPG=H/NVY3\!5!+ P04    " ##.&A53X<
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M*>?!+$!KR$G#S:UL/T ?T,3Q4<FU_T5MMW>" T0;;635@ZV"BHFN)8]](K8
M.-X#P#T >]W=05[E-3$D2Y5LD7*[+9OK^% ]VHICPMW*TBB[RBS.9$M6")8S
M2H2Q&:*R$8:) M62,\I HS?78 CC^FT:&GN< X6TI[[LJ/$>ZHNF.$7QY 3A
M"&.D2Z) _\D26K&#8CPHQIYVO(?VGBAEU>H3=&=;ZU+T6< N=0=IG-O/=4TH
MS -K9PUJ T'V^E6<1.\.B!P-(D>>?;1'Y#73E$O=*$ R1Y03K6TR;=>G 5%2
M,T,X^N9PB!FH]/==(8R.$,)X"&%\,,]74FQ &;;B@#Y) S;A2W^'J%^!]2[)
M'6GB2=U?PB8;CV,\&T=IN-FA9C*HF?S_K9^@A6)TKP$.,CXS>\F@-WD) R1'
M"&$ZA# ]A@&F_Q@ )Z-X,IWM-L!L4#-[O@'N6KE+RD'&9V;O;-![]A(&.#M"
M"''TNSA$Q[! S[KM@7@ZBW&"__) N%6XW"/@AJB""8TXY!89G4[M)ZRZNMH-
MC*Q]+5M)8RNC[Y;V+0+*;;#KN;0J^X$KC\/K)OL%4$L#!!0    ( ,,X:%7F
MIB3PD@(  -D%   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;,5444_;
M,!#^*Z<,32 !"6F!B:61!A4:$I,0A>UAVH.;7!L+Q\Y\3DO__<Y.B+JM(.UI
M+['/N?O\?7>^R];&/E&%Z."Y5IHF4>5<<Q''5%18"SHV#6K^LS"V%HY-NXRI
ML2C*$%2K.$V2L[@64D=Y%L[N;)Z9UBFI\<X"M74M[.82E5E/HI/HY>!>+BOG
M#^(\:\029^@>FSO+5CR@E+)&3=)HL+B81)].+B['WC\X?)6XIJT]>"5S8YZ\
M<5-.HL030H6%\PB"EQ5>H5(>B&G\[#&CX4H?N+U_0;\.VEG+7!!>&?5-EJZ:
M1!\B*'$A6N7NS?HS]GI./5YA%(4OK'O?)(*B)6?J/I@9U%)WJWCN\[ 5D*:O
M!*1]0!IX=Q<%EE/A1)Y9LP;KO1G-;X+4$,WDI/9%F3G+?R7'N?Q::J$+*118
M24^,K+D4G'0'^U-T0BHZ@".XT0XMD@,K'':>1S!#+8WEI6@MEO" MH9;(S1<
MBT(JZ3:P!U+#0V5:$KJD+'9,V%\;%SVYRXY<^@JY&3;',$H.(4W2%!YG4]C?
M._@=)F:]@^AT$)T&W-$KN%-)A3+$M,$LN(9>)RN0NGODX;7,^07#8LB.U.1L
MZQ-#\-WC@718TX]=HKK+Q[LO]UUV08TH<!)Q&Q':%4;Y^W<G9\G'-Z2-!FFC
MM] Y9=PO_-!]^KF6:D.2@&6!VS1(7J[\JY:'W%V"C!9SM8'&$,FY0B@JH9?H
M*QCJO1)6L@,>\DGA_3EWFG-GY4KXQF('U>+.(G>,3P-C/R16>7J>9O%JA\SQ
M('/\OV66^(\RQSMDCOZ0&6]UJA]Z7X1=\M,"A0N.2H[/.=QV@Z0SG&E"\\Z-
MXU$0MA7/7K3>@?\OC'$OAI\'PS3/?P%02P,$%     @ PSAH58;1K(1]!
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M2#, [V^%T(\7QD%](+?Z#U!+ P04    " ##.&A5[?&(FQX"  ";!   &0
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M>2\\[^("[]<.E,U6-&BL@$8_-X4VRK;)KW-Y![KE>3HW.FO=D1(R;&=#@SH
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M32XBH_C!T%&R<LES43),G4661=LX28PU@G0?D-]I*=CD%W8$A&65X!.3=:-
M"3@Z\;HCCDG,HUY?FTEN0."0.[V=S3:K31*6(HF%JRPOX[_J+&8TU2H*V-*F
M.BYA 'F72N3($AXT]70.V$"2-A",&T<E<Z0CQQ7"3 MBDYB@CIX@EM"!8.IX
M[<3#H.39N'H.2$&24A XP$]OZZY<U'%\BJ>^[FG0!4F3T*0O,4F&0#!$')$Y
M=3BX0D1#"*,8)GVCM80(!%/$S_&,IP4W#]9@T<$9P)(V=:(KL02[E\J4V"K4
MV-*FUI/$'PSCS^&(Q3JQB"R)4"=B36*(X)XTB26,8!A&GB/6^=OIFZ?!&@8W
MB"5MJK^2;?#%%D6P512RI4VM)XE"V,+"2*-#C=U)T)T9F<00:B5EU4:)(1C&
M$'#.AG6N8!/-,L.RB._V# -8L@>&V0.<M,%E!X>)@3L\VC,9QI(5,,P*KTQ/
M6,<%M]M4YUB]P!(]\*GH@0WK$H0%FA\&,4PF?2TFT0,?AQXBD0^9O\%:!T?C
M.:B$2"HA%Z,28I5*;&E3ZTE2"8&IY*CD3DQ+*2Z;=.+YH)AJHP03 H/)*V<@
MHJ^E='LN;/!+&ZVUFW-@5<;.]*UY"N@H)*):+WF"P#QQ.'\2G1*,\79(3#50
MP@2!8>)C6O(\#1.1-IYXDJU7/"V=F4!BXR .*QN<#BQI4UV7N$+8Q=*F5=BQ
MI4VM)PE%!(:B(V)8YY@)[2X^F(1PS]H(D8!"8$#ICU]@:@?K'-P\EK2I-2 )
MB$PN%L96*<F6-G7'6U*2!V\I';?GK6\&,=)=E# (]0P4GF03#V83<%+GZ;#1
M7@-IK-*%>ON7)WG$@WD$G-/!98?&AP>QB&J^I </IH=7QBGO,&7 !K^T%[0.
M?IP*))Y.&GHR-PGU!IN$$>^E,#)P>@<_9W!@GH-3/,DIWL4XQ;/**;:TJ?4D
M.<6#.>6X!']XR04446V3F.+!F&)I%N/IJRB:]9"(:KU$# ]>9#DB:>C'0#3#
M(!'U^)<<TRD\ID,;3W#1H;%M2YOJJ,0#BBZ5 ZBE8R%-/9WCD F5N$)//61"
M=<J8>-TM:X,0JD^G&L-5T@B%:>2(72=8P^#6. =L4 D;]&('2ZC5@R6VM*GU
MU#K&:N%@"35LVKBT>Z[$(-67926 4'A?!YR;4'TGIIOY#2*L;[>)RN&>PL,]
M.#.!RPX.#YT(>C>;J&0">FCIXE7G)O0P.\ &O[0;2,R@IV(&-1Q)-?2! U+J
M<6X)&^PXV!@X%X&U#C[P?0X.89)#V,4XA%GE$%O:U'J2',)@#CDJHS.=,JYH
MMT\:A'I2)Y,<POZO5D78X541V."7-I<$%0:OBEB:GC'#)@WMLJ5)B/2@)9,(
MP4Z]"L-,)TY=S3J#5*]UK:LP,$$\9/-R&^9FN^Q>B#G'&@234,(N=B>&644:
M6]K4>I+LPTX]5\)T7 FZ-QH,,GW7 )BD$ 93R'.L I,T6,/@ICC'OH@OL<:_
MV.D1WRKZV-*FUI-$']_"Z1'?<%[5[^98DQ +S''K2^3P8>0 9VF^8=6CVYL,
M,JCGL*(O4<.'40.<I<%E!\>'CAE]%[E\208^3 :OC$J^Z9B'UE#G6*WP)6KX
MIZ*&KT,$UCC((-3N*JIQDC3\XTACX"0-UCHX$L]R+;=U+_=R%W/MWLP]!X3X
M$D)\"Y=S?=.=&:^[^6Z28GW)4Z*(#Z/(:R<??=U$N\P%6_S2V]025@)X#<;2
M1"TPW/DEW64DDQ"CYC8-)$8$IUZ-:110)>*T X%&*>TJU[CUPI(5SQ?U>UP*
M9Y9MTG+WAH_]K_MWQ=S6;TCI_'Z'WM_OWO@BU>Q>0/-+F(MN5#@)GPN5[KLJ
MK^>[=[KLOI39NGXMRF-6EMFJ_KCD8<3S2D#\?9YEY?.7Z@'[-^M,_P%02P,$
M%     @ Q#AH5<R<+M96!   B18  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3@N>&ULQ5AM;]LV$/XKA%8,*9!&+W[)RVP#CM-M 9HTJ),.V[ /M'22N%*D
M2E)Q#>S'CY1ER4H<-@Y4! @B\:1[>/>0)SZ^T9*++S(%4.A;1ID<.ZE2^9GK
MRC"%#,LCG@/33V(N,JST4"2NS 7@J'3*J!MXWM#-,&'.9%3:;L1DQ M%"8,;
M@62195BLSH'RY=CQG8WA$TE290SN9)3C!.:@[O(;H4=NC1*1#)@DG"$!\=B9
M^F>SP#,.Y1N?"2SEUCTRJ2PX_V(&E]'8\4Q$0"%4!@+KRSW,@%*#I./X6H$Z
M]9S&<?M^@_YKF;Q.9H$ES#C]@T0J'3LG#HH@Q@55G_CR=Z@2&AB\D%-9_D?+
MZEW/06$A%<\J9QU!1MCZBK]51&PY:)S=#D'E$#QTZ#_AT*L<>F6BZ\C*M"ZP
MPI.1X$LDS-L:S=R4W)3>.AO"S#+.E=!/B?93DTNF,$O(@@+"4H*2Z!VZQD)@
MPRXZN "%"95OM?5N?H$.WKQ%;Q!AZ#;EA<0LDB-7Z2@,EAM6,YZO9PR>F/$4
M77&F4HG>LPBBMK^KHZ]3"#8IG =6P#GD1ZCG':+ "X(=\<R>[^Y;PNG5C/9*
MO/X3>!=<$I:@CS&:YQ"2F(3HNL@6((SI1O,*3+/\'[HB%/3R,M#&E2X,M8M*
MZU2FQ,]DCD,8.[J&)8A[<"8__^0/O5]V\= 16(N5?LU*OT3O/<4*D2'ELA"
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M&\CW:TK%TTU-T!_WS_X#4$L#!!0    ( ,0X:%5'VY2?\@$   <$   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;'V3;6O;,!#'OXK08'2P1GY8DY+9
MAJ9E;+"5T+#MQ=@+Q3G'HI+E27+<??N=9,=DD.:-?2?=_?0_Z2[KM7FV-8 C
M+THV-J>U<^V2,5O6H+B=Z18:W*FT4=RA:_;,M@;X+B0IR9(HFC/%14.++*RM
M39'ISDG1P-H0VRG%S=\52-WG-*;'A2>QKYU?8$76\CULP'UOUP8]-E%V0D%C
MA6Z(@2JG=_%RE?KX$/!#0&]/;.(KV6K][)TONYQ&7A!(*)TG</P=X!ZD]""4
M\6=DTNE(GWAJ'^F?0NU8RY9;N-?RI]BY.J>WE.R@XIUT3[K_#&,]-YY7:FG#
ME_1#;!I14G;6:34FHP(EFN'/7\9[.$F(%Z\D)&-"$G0/!P65#]SQ(C.Z)\9'
M(\T;H=20C>)$XQ]EXPSN"LQSQ5? DBRY)H_<&.YOB%P]@.-"VG<9<WB"CV/E
M2%L-M.05V@;:&4FC]R2)DH2HMV_BQ>W'_S$,!4XJDTEE$KCI996_[K;6&7S(
MW^>D#8@/YQ&^N9>VY27D%+O7@CD +5#@/+HD,)T$II?H@T#"<2S(E6BPMSJT
MB0('YOP]#KAYP/G!.11Q'$49.YR*8"?OZD?D&S=[T5@BH<*T:+:XH<0,;3<X
M3K?AJ;?:8>,$L\9)!>,#<+_2VAT=WSW3[!?_ %!+ P04    " #$.&A5IP F
ME$4(  !>3   &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6S%G%UOVS84
M0/\*X15#"]2U2'W8RA(#B<EA U8L:-;N8=B#8M.Q4%OR)#GIAOWX4;)BFA)%
MB]D-_-+&SN61>"]-\S"2+I_2[&N^XKQ WS;K)+\:K(IB>S$:Y?,5WT3YAW3+
M$_&;99IMHD*\S!Y&^3;CT:)JM%F/B.,$HTT4)X/I9?7>;3:]3'?%.D[X;8;R
MW68397_?\'7Z=#7 @^<W/L4/JZ)\8S2]W$8/_(X7G[>WF7@U.E 6\88G>9PF
M*./+J\$UOF"^5S:H(K[$_"D_^AF57;E/TZ_EBY\75P.G/".^YO.B1$3BOT<^
MX^MU21+G\5<-'1R.638\_OF9_F/5>=&9^RCGLW3]>[PH5E>#R0 M^#+:K8M/
MZ=-/O.Z07_+FZ3JO_D5/=:PS0/-=7J2;NK$X@TV<[/^/OM6).&H@./H&I&Y
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MRNKIMUX(6NKQ[IX*.2SJRRW@%)@"R/MK2L5^H0RT_T&$_P)02P,$%     @
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MJ*@!K'D':ZZ%%3[&FRA?8Y"0U8IC>Z9M:47&<IO+(PC:KMC?%%%(Q!L:JFN
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M/DV+UQ=E@N<T^[;>G<O_ U!+ P04    " #$.&A5<"UII0@%   C(@  &0
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M)MF*@W\4"" "I_S?+@'*CGYW1_46N.(;%.&))1]SCMD66^'//\&!\VN7'(;
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MPSW/T(3N-..L[-3W^^M?RP.#F6>Y]8;E@:^]*(KZIX29]:'Q-.[?X(!#G[6
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M37G3AGS4'N>;IEQO/ERJ;*&J[@'MWU^59?/P23?!?5G]L7DZY_\%4$L#!!0
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M9[)$1.K/AK_F25*25#O^J:&#W3G+BLW7C_2+JO.J,].HX*_SY&,\E\O3P?&
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MLID4BTV*)8;$.F5SG:?QQ#'<81K!XV^*P.GUA<4 :.).>QUF *0^IYU>BQE
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M!/+/]:ZYK62UJW<M623F(3$?B5$D%B"Q$(DQ),9!F-($QJ YMS]X ><"ZXT
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MJ+:#%Q-=L9$L,T/1DDDU8IGE5DW!R/4!]?^:,7G8: /57#W]#U!+ P04
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M^%4R^/E*_IZ5[I@,(BXSD>^U A%+@KN#B9&$K-A=G)>UE$GI&[[3BE"!N[Z
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MC083O"%T4_LU':LJ7V^ME,7JS3<+K)=!NPGX?JV4?>JX!;H*?/$O4$L#!!0
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M#$Y4J6,4T4SV'R<E@R=H)9LRWJ6 Z!JUS2[:9M? @=T#>A^ ($G*/TC'FU6
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MLNJ(I+H1M"C/ &ZI$#0K+[= 8F#*0'Z^IE0\W:@ S4'5\E]02P,$%     @
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M->B7!OT\]D6P\DA[6.#IF-$#8JJWI*F+7*[<6@:8)"JS5H+)IT3:B>DS1%A
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MG: CE!;H>T+7G!0Q']I"9JCBV(LZF\LJ&_Q,-AZZHH5(.)H6,<0&_N0P?W"
M;\O*-.7!C^6YQ <%YU">(<_Y@+"#L2&?\>OIKLG._T6?_G/TO6)XS5[QM)[W
MPEZ9R;WR@'Y=W'+!Y$'_;5KG2LDW*ZF/WSDOR0)&EORZ<6 ;L*+W[]S ^6@J
M\EN*3=Y2;/I&8GO+X3?+X1]2C^8D(TR=67G6$!4)R,]_0IDX%<!R!'F9T0<
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MLZT=L\L'>(9"+PD&TG%I%_DH"F$\4(Y+NSA"80##@7!<VH6S,$$1&A>.N(M
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M,(DHK+6D-YKJ#8FRR5,.%,^+ML<]5XIGQ>46< K"+-#WUYRKAX%Q4+?:HO\
M4$L#!!0    ( ,0X:%4"8_+3@@0  &H:   9    >&PO=V]R:W-H965T<R]S
M:&5E=#@W+GAM;*U96W.C-AC]*QK:Z>S.9,/-0)S:GLF:2[<SF7J2IGWH]$$&
MV587D%<2<?+O*P$A]H)5TU$>$L ZYT@ZQY\4,3L0^I7M$.+@I<A+-C=VG.]O
M39.E.U1 =DWVJ!2?; @M(!>W=&NR/44PJT%%;CJ6Y9L%Q*6QF-7/5G0Q(Q7/
M<8E6%+"J*"!]_8QR<I@;MO'VX %O=UP^,!>S/=RB1\2?]BLJ[LR.)<,%*ADF
M):!H,S?N[-O$=B2@;O$'1@=V= WD4-:$?)4W7[*Y8<D>H1RE7%) \><9+5&>
M2R;1CV\MJ=%I2N#Q]1M[7 ]>#&8-&5J2_$^<\=W<N#% AC:PROD#.?R"V@%Y
MDB\E.:M_@T/3UI\:(*T8)T4+%CTH<-G\A2_M1!P!!,\PP&D!SJ4 MP6XEP(F
M+6#R/6!R!N"U .]2@-\"_$L!00L(:K.:V:VM"2&'BQDE!T!E:\$F+VI_:[1P
M!)<RBH^<BD^QP/%%B#:(4I0!2EYASE\!6>=X"^N8? @1ASAG'\$G\/08@@\_
M?IR97(A*J)FV I\; >>,@ ON2<EW#$1EAK(!_%*-]_\+'ZKQ4P7>%)/5S9CS
M-F.?'27A/:37P+6O@&,YSM!XU/!?JU+ K;/P4 U_1'LE/%+#0Y1VG;<'X+$:
M?E=MKX'CG84GEZM;"BO<+KQNS>>>X\,LS0FK* )D(PJ03*N(,BZ;$EV7NK6H
MOV!-J*#&Y9:!OR0)P!P5[.^A-#>*DV%%N3#<LCU,T=P0E9\A^HR,Q4\_V+[U
M\U 4=)*%.LDBG62Q3K)$$]E)H"9=H"8J]L5#6P17%4UW8H$#=UN*D%AY^5!4
ME%QCHZ*3+-1)%NDDBQLRKR:3VZ3GA>MX5OTS,Y^/<Z!)]B0'7I<#3YF#%24I
M0AD#,24%.)^**Y!0PMA0.+S>0)WA@2XO;ADJ.SW65IUDL4ZR1!/9B?-^Y[Q_
M407XK=L&78'?*2P9;+;.2\+XH-\-K7_DHC^=WO3=5LJ/_9[K)(MTDL4ZR1)-
M9">!"+I !*,#\:7D2"@-+@I!/P>!Y_1SH%0=FX.@5T+LP/7\GFJD4S76299H
M(COQ^*;S^&;DLI]E6%H-<] M!9'P'Z]QCOGKD.]*A;&;@9N^GY8UN"3HE(UT
MDL4ZR1)-9"?IF';IF"K3T?V+W"\%0T%0DHT-@DZR<#JPT;#MR:1?)H9:>I,@
MZ+6,=78PZ<N^RYU89UOOQQO6_]S17X%HLT'U25A7T,$#Y&CPC$.I,M95K6QA
MRS8]GK9K^SM'M4K&6MD276RG$3DZ ;-'K_ K^"HS,KC3:^F.EWC'=OLKO%IV
MM,MV[\OA^4-+O%;96"M;HHOMU&GGW6EGM-,Q+F&98K'21R][5(H*L:R**H=U
M75A"GNX^/>W%AN"?BO%S!P&M[+$W4[=OS5+=O=&)Z*N*IFX_B9%6W5@K6Z*+
MK8F$>7027B"ZK5]R,)"2JN3-H7CWM'N1<E>_/C#?FS=O8>XAW>*2@1QM!-2Z
M#L1$T^;%1G/#R;X^5U\3SDE17^X0S!"5#<3G&T+XVXT4Z%XO+?X%4$L#!!0
M   ( ,0X:%7O["5UVP0  * @   9    >&PO=V]R:W-H965T<R]S:&5E=#@X
M+GAM;+V:76_;-A2&_PJA%4,+I-&';=G.; .)):$%ULZHD_5BV 4CTQ81271)
M*D[__4A)D2U'(>SM9#>QOL[S2N>E2.HPDQWC#R(A1**G+,W%U$JDW%[9MH@3
MDF%QR;8D5V?6C&=8JEV^L<66$[PJ@[+4]AS'MS-,<VLV*8\M^&S""IG2G"PX
M$D668?[SAJ1L-[5<Z_G -[I)I#Y@SR9;O"%+(N^V"Z[V[(:RHAG)!64YXF0]
MM:[=J\@=ZH#RBC\IV8F#;:0?Y9ZQ![WS>36U''U')"6QU BL?A[)G*2I)JG[
M^%%#K493!QYN/].C\N'5P]QC0>8L_4Y7,IE:(PNMR!H7J?S&=I](_4 #S8M9
M*LJ_:%==.QQ8*"Z$9%D=K.X@HWGUBY_J1!P$N/U7 KPZP#L.>$VA5P?T3E7H
MUP']4Q4&=<#@5 6_#O#+W%?)*C,=8(EG$\YVB.NK%4UOE':5T2K!--<M:RFY
M.DM5G)R%/PHJ?Z+W 9&8IN(#^HCNE@%Z_^X#>H=L)!+,B4 T1W<YE>)"'53;
MMPDK!,Y78F)+=0^:9,>UWKS2\U[1ZZ$O+)>)0&&^(JN.^- </S;$V^K9FP1X
MSPFX\8S ZV)SB=S!!?(<S^MZ'G/XDFPO4<]Y-3PX/=SMRL9_4X_^M7HKE[VF
M,?5*7N\57D!%G#)1<(+86O4[@O!'U7IV5":JU9"JJ?VEHQ"5)!-_=]SR3271
M[Y;0'>V5V.*83*UM+6#-?OW%]9W?NLR#A 60L! 2%@'!6J;W&]/[)OKLLQ %
MSN/2\JJ[N$ !(7Q-2;I"Y"E.<+XA"&\X(6I(DA<H5P.FNEARG M<#3 Q$[*K
M-[DQ:I_;&BK8H(3I(?=QYHY'O?[$?CRT&5(R/$DR I)L^3=H_!L8_?N="8&4
M!>1)TGQ34)%HE[J\,'+.]:*"^0>)^=CW7/?8C,&+_#GM*\+30)$)U,J;W^3-
M-^9MP5E,R$J@-6?9<^=&ZY?AO$9N%#HWL9"P !(6^B^<\MVQ=^23?ZI/P\:G
MH=&G[Y@K#_3<Y5;]JIDYNMVQ+A>,F'-=@(0%D+ 0$A8!P5K&CAIC1V\_VQA!
MF@X)"R!A(20L H*U3!\WIH^-;_.<Y8^$2WJ?$O2523W96%;?*/69SH^*F_&+
MKL?KC1UO/&SW/G.C^+D.0L)"2%@$!&LYZ#K[3T['/'(67$T*%;=S,#0'G_M*
M@M("4%H(2HN@:&U3#^H([MOWQK4&E/>0M "4%H+2(BA:VWMO[[UG?*&_%MD]
MX?L/P'(:W-T1UZ3#GGC8ZPW\T5%';%8\VSM(6@A*BZ!H;>_V)1O76!R8+;$:
M2?]8HZ5D\<,%6G"J/N47RLUR6.VTL (.#RP<70Z\8P-!2R^@M!"4%D'1V@;N
MRR^NN?X"^!WJOJQ6^*[C'#L+62 )0&DA*"V"HK6=W1=F7'-EIGP#U1M),EID
MG7Z!5F1 :0$H+02E15"TMJ_[PI'K_P]3)="B$2@M *6%H+0(BM;V?E^,<LW5
MJ+>MEIO%SVX4PX[BM=\_&@\"4-'P--$(2K2RT3Y80,T(WY1+W4+EN<AEM?S5
M'&V6TZ_+1>2CXW/W*G [CH=Z^;U<L-WCJ[7[+YAO:"Y02M9*RKG4B]V\6@ZO
M=B3;ELNW]TQ*EI6;"<$KPO4%ZOR:,?F\HP6:?TJ8_0-02P,$%     @ Q#AH
M52]9FUQ4 P  D!4   T   !X;"]S='EL97,N>&ULW5C13MLP%/V5*(P)I(DT
MS0C-:"MME9 F;1,2/.P-N8W36G+LS'%9NZ^?KYVF:?%%P,,H2P6Q[_$Y]]B^
M:0S#6J\YO5E0JH-5R44]"A=:5Y^BJ)XM:$GJ,UE189!"JI)HTU7SJ*X4)7D-
MI))'_5XOC4K"1#@>BF5Y5>HZF,FET*-PT(8"=_N:C\(X_1@&3FXB<SH*[T[>
M_UI*??DN</>C#T='O;O3R_WXB05.P\@K>OX$T;,>KFLP3#K=E=X,[UFUDTX7
M$[CP"!RWW&.,-GC2E!Z9$2:<(1/:F0Y"ONAYR1TJ1HS]68^[6=U:1$T=C8>%
M%-MR2D(7,.JDI,$]X:-P0CB;*@:L@I2,KUVX#X&9Y%(%VM2Q21=#I/[CX-CU
MH,0;G9()J6QNE\']GC;#]X!-#PPRSEN#_= %QL.*:$V5N#(=.]@&'T!!T[Y=
M5\;A7)%UW#\/MP1[,TFF4N54M6GB<!,:#SDMP(YB\P7<M:PB +66I6GDC,RE
M(-;#AM$TC.R,<GX#S__/8D=[573VS6ZW:)O&4--T,JX#^ETUI]V5/7^1;E"Q
M>ZF_+,UTA.U#>=-K10NVLOU5T1K U&-<G5057W_F;"Y*ZB;_Y(3C(=GP@H54
M[(_)!J4R,P&JPN">*LUFW<AO1:I;NM*;<EH5N.?^&_3\;]=Y3@55A'=-F]H_
MY%5^L>/FA?D:GNW7RKYCK\GDXO ]-H>$0S>9O@63;V*[!X=O,LD.WV-S8#QP
MDQ>O]LW^')/Q09J,FN-:YTRX<R)LHP&<O$?A#SC'\VW28+ID7#/1]!8LSZEX
M<# T\II,S9^;._IF?$X+LN3ZM@5'X;;]G>9L66;MJ&M8B&;4MOT-IA>G[;'?
MY&(BIRN:3YJNFD]M,S -D[6Y@+"/7-G+CV <A_D1P+ \F .,XUA8GO]I/@-T
M/@[#O V\R #E#%".8_F0B?U@>?R<S%S^F699DJ0IMJ*3B=?!!%NW-(4?OQKF
M#1A8'LCTO+7&=QNOD,?K -O3QRH$FRE>B=A,\;4&Q+]NP,@R_VYC>8"![0)6
M.Y#?GP=JRL])$MA5S!OV!.-(EF$(U**_1M,469T4/O[]P9Z2),DR/P*8WT&2
M8 @\C3B".0 /&)(D]CVX]SZ*-N^I:/L_V/%?4$L#!!0    ( ,0X:%67BKL<
MP    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$
M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E
MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
MQ#AH5<>M$!<U!@  >SD   \   !X;"]W;W)K8F]O:RYX;6S%F]^3VC80@/\5
M#4_I3"EGXU_)W&4FS27M36^2S)%>'SO"%J#&EJ@DN%S^^DIV+K?&9J<O"T^
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M4$L! A0#%     @ PSAH58#F1)'O    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ PSAH59E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " ##.&A5+M!SC6H#   _#   &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ PSAH5:6W=Q?/!@  ]"0
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M965T-BYX;6Q02P$"% ,4    " ##.&A5I1O4Y@,0  "<*@  &
M    @($"-   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
MPSAH58-/=1ZD"   [A8  !@              ("!.T0  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,,X:%4T3!77A@\  %HO   8
M          " @15-  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " ##.&A5_,0D/9D'  !($P  &0              @('17   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,,X:%6%_#=/\@@  +X7
M   9              " @:%D  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ PSAH5;B*P#Q[ @  JP4  !D              ("!RFT
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " ##.&A5$(/I
MRM<&   2$P  &0              @(%\<   >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( ,,X:%5A#0/7$P,  +H&   9
M  " @8IW  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
MPSAH5?G<1KL  P  UP8  !D              ("!U'H  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " ##.&A5Y.T3Q[T'   $%P  &0
M            @($+?@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( ,,X:%5X/6].P@@  &(8   9              " @?^%  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ PSAH5207+9/4!0
M"@X  !D              ("!^(X  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " ##.&A55JB.5)\&  ![$   &0              @($#
ME0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,,X:%7W
M\+;.AA$  "\Y   9              " @=F;  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ PSAH5:)7S6N"$0  $CD  !D
M     ("!EJT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,,X:%5"#! (E@4  ,<,   9              "
M@6S?  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ PSAH
M551>Z60Z"0  QAL  !D              ("!.>4  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " ##.&A5_.SEY<X#   C"0  &0
M        @(&J[@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( ,,X:%409=C :0\  !HM   9              " @:_R  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ PSAH5;2]KX+U @  2P8
M !D              ("!3P(! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " ##.&A5B7' GN,#  "U"0  &0              @(%[!0$
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,,X:%6PRP(X
M+@0  (()   9              " @94) 0!X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ PSAH5;I?!96) @  H04  !D
M ("!^@T! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " ##
M.&A58'2V^.,#   _"0  &0              @(&Z$ $ >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,,X:%50*V_3FP,  "X(   9
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M970S.2YX;6Q02P$"% ,4    " ##.&A5O. F#-@"   7!@  &0
M    @(%Y,0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M ,,X:%5\@S3E^00  )L,   9              " @8@T 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ PSAH55HI1"3/ @  &P8  !D
M             ("!N#D! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " ##.&A53X&)E_P#  "E"   &0              @(&^/ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,,X:%4V^@W.! D
M  QA   9              " @?%  0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ PSAH567IJ&NG @  IP8  !D              ("!
M+$H! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " ##.&A5
M3X< 7ZD#  "\$   &0              @($*30$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,,X:%72:8)OF0(  .D(   9
M      " @>I0 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ PSAH5>:F)/"2 @  V04  !D              ("!NE,! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " ##.&A5AM&LA'T$  #,&
M&0              @(&#5@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( ,,X:%6^P:02V ,  )P3   9              " @3=; 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ PSAH5>WQB)L>
M @  FP0  !D              ("!1E\! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " #$.&A5X-SCL? $  !\&   &0
M@(&;80$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,0X
M:%7$G4P"2@0  /P7   9              " @<)F 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ Q#AH5='?Z$H% @  1 0  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( ,0X:%6KX?I.7@4  (,9   9
M  " @1J! 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
MQ#AH5=,"[H@#!   (AH  !D              ("!KX8! 'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    " #$.&A5K]R)(@(#  #:"0  &0
M            @('IB@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( ,0X:%4+BSZX%@,  +X*   9              " @2*. 0!X;"]W
M;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ Q#AH56[7'KY8!0
M^A\  !D              ("!;Y$! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6Q02P$"% ,4    " #$.&A51]N4G_(!   '!   &0              @('^
ME@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ,0X:%6G
M ":410@  %Y,   9              " @2>9 0!X;"]W;W)K<VAE971S+W-H
M965T-C4N>&UL4$L! A0#%     @ Q#AH5:T$F!5U P  CQ   !D
M     ("!HZ$! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,0X:%6,1$<<WPX  &O2   9              "
M@2'! 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ Q#AH
M50-QOHI)"   B50  !D              ("!-] ! 'AL+W=O<FMS:&5E=',O
M<VAE970W,BYX;6Q02P$"% ,4    " #$.&A5MAV+Q*0#  #1$   &0
M        @(&WV $ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0
M   ( ,0X:%6(R(S;&00  ,$5   9              " @9+< 0!X;"]W;W)K
M<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ Q#AH50^"VX@.!0  #B4
M !D              ("!XN ! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q0
M2P$"% ,4    " #$.&A50A'EM1 $  "G%0  &0              @($GY@$
M>&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( ,0X:%7VMIR
MV0P  !*G   9              " @6[J 0!X;"]W;W)K<VAE971S+W-H965T
M-S<N>&UL4$L! A0#%     @ Q#AH54Y$+W/K P  8P\  !D
M ("!?O<! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " #$
M.&A5(1'DS!$$  #B$   &0              @(&@^P$ >&PO=V]R:W-H965T
M<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ,0X:%79V .CF0,  (T+   9
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M970X-"YX;6Q02P$"% ,4    " #$.&A5T$,5"W4$  #[&   &0
M    @(':$P( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    (
M ,0X:%6U>URKR@,  '83   9              " @888 @!X;"]W;W)K<VAE
M971S+W-H965T.#8N>&UL4$L! A0#%     @ Q#AH50)C\M."!   :AH  !D
M             ("!AQP" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"
M% ,4    " #$.&A5[^PE==L$  "@(   &0              @(% (0( >&PO
M=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( ,0X:%4O69M<5 ,
M ) 5   -              "  5(F @!X;"]S='EL97,N>&UL4$L! A0#%
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K @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !@ &  5QH  $TV @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>440</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Interim Statement of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations</Role>
      <ShortName>Condensed Consolidated Interim Statement of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Interim Statement of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Interim Statement of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Interim Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet</Role>
      <ShortName>Condensed Consolidated Interim Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Interim Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity</Role>
      <ShortName>Condensed Consolidated Interim Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Interim Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Corporate information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Corporateinformation</Role>
      <ShortName>Corporate information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Basisofpreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Significantaccountingpolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Financial risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Financialriskmanagement</Role>
      <ShortName>Financial risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Product revenues, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Productrevenuesnet</Role>
      <ShortName>Product revenues, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Segment information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Segmentinformation</Role>
      <ShortName>Segment information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Operating expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Operatingexpense</Role>
      <ShortName>Operating expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Cashandcashequivalents</Role>
      <ShortName>Cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Non-operating income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Nonoperatingincome</Role>
      <ShortName>Non-operating income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Interest in joint venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Interestinjointventure</Role>
      <ShortName>Interest in joint venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Senior secured term loan facility and warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants</Role>
      <ShortName>Senior secured term loan facility and warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Convertible loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Convertibleloans</Role>
      <ShortName>Convertible loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Deerfield Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/DeerfieldWarrants</Role>
      <ShortName>Deerfield Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Share-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Sharebasedcompensation</Role>
      <ShortName>Share-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Relatedparties</Role>
      <ShortName>Related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Losspershare</Role>
      <ShortName>Loss per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Events after the reporting date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Eventsafterthereportingdate</Role>
      <ShortName>Events after the reporting date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Deferred royalty obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Deferredroyaltyobligation</Role>
      <ShortName>Deferred royalty obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Basis of preparation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/BasisofpreparationTables</Role>
      <ShortName>Basis of preparation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Basisofpreparation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Product revenues, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ProductrevenuesnetTables</Role>
      <ShortName>Product revenues, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Productrevenuesnet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Operating expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/OperatingexpenseTables</Role>
      <ShortName>Operating expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Operatingexpense</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Inventories</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Intangibleassets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Non-operating income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/NonoperatingincomeTables</Role>
      <ShortName>Non-operating income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Nonoperatingincome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Interest in joint venture (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InterestinjointventureTables</Role>
      <ShortName>Interest in joint venture (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Interestinjointventure</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Senior secured term loan facility and warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables</Role>
      <ShortName>Senior secured term loan facility and warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Convertible loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ConvertibleloansTables</Role>
      <ShortName>Convertible loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Convertibleloans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Deerfield Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/DeerfieldWarrantsTables</Role>
      <ShortName>Deerfield Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/DeerfieldWarrants</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Share-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SharebasedcompensationTables</Role>
      <ShortName>Share-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Sharebasedcompensation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/RelatedpartiesTables</Role>
      <ShortName>Related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Relatedparties</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Loss per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LosspershareTables</Role>
      <ShortName>Loss per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Losspershare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Corporate information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CorporateinformationDetails</Role>
      <ShortName>Corporate information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Corporateinformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Basis of preparation - Schedule of Foreign currency exchange rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails</Role>
      <ShortName>Basis of preparation - Schedule of Foreign currency exchange rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Basis of preparation - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails</Role>
      <ShortName>Basis of preparation - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails</Role>
      <ShortName>Significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Financial risk management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/FinancialriskmanagementDetails</Role>
      <ShortName>Financial risk management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Financialriskmanagement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Product revenues, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ProductrevenuesnetDetails</Role>
      <ShortName>Product revenues, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/ProductrevenuesnetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Product revenues, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails</Role>
      <ShortName>Product revenues, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segment information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SegmentinformationDetails</Role>
      <ShortName>Segment information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Segmentinformation</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Operating expense - Schedule of Expenses by Nature (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails</Role>
      <ShortName>Operating expense - Schedule of Expenses by Nature (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Operating expense - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails</Role>
      <ShortName>Operating expense - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/CashandcashequivalentsDetails</Role>
      <ShortName>Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Cashandcashequivalents</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Intangible assets - Rollforward of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Rollforward of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails</Role>
      <ShortName>Intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Non-operating income - Schedule of Other Income (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails</Role>
      <ShortName>Non-operating income - Schedule of Other Income (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Non-operating income - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails</Role>
      <ShortName>Non-operating income - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Interest in joint venture - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails</Role>
      <ShortName>Interest in joint venture - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Interest in joint venture - Schedule of movement in interest in joint venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails</Role>
      <ShortName>Interest in joint venture - Schedule of movement in interest in joint venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Interest in joint venture - Summary of financial information in joint venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails</Role>
      <ShortName>Interest in joint venture - Summary of financial information in joint venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Leases - Right-of-Use Assets and Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails</Role>
      <ShortName>Leases - Right-of-Use Assets and Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Leases - Right-of-Use Asset Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails</Role>
      <ShortName>Leases - Right-of-Use Asset Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Leases - Schedule of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Senior secured term loan facility and warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails</Role>
      <ShortName>Senior secured term loan facility and warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Senior secured term loan facility and warrants - Valuation of Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails</Role>
      <ShortName>Senior secured term loan facility and warrants - Valuation of Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails</Role>
      <ShortName>Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Convertible loans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails</Role>
      <ShortName>Convertible loans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Convertible loans - Valuation of Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails</Role>
      <ShortName>Convertible loans - Valuation of Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Convertible loans - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails</Role>
      <ShortName>Convertible loans - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Convertible loans - Change in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails</Role>
      <ShortName>Convertible loans - Change in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Deerfield Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails</Role>
      <ShortName>Deerfield Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Deerfield Warrants - Schedule of Valuation Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails</Role>
      <ShortName>Deerfield Warrants - Schedule of Valuation Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Share-based compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails</Role>
      <ShortName>Share-based compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails</Role>
      <ShortName>Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails</Role>
      <ShortName>Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails</Role>
      <ShortName>Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Share-based compensation - Schedule of Share-based Compensation Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails</Role>
      <ShortName>Share-based compensation - Schedule of Share-based Compensation Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Related parties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails</Role>
      <ShortName>Related parties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Related parties - Schedule of Key Management Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails</Role>
      <ShortName>Related parties - Schedule of Key Management Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LosspershareDetails</Role>
      <ShortName>Loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/LosspershareTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Loss per share -Schedule of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Loss per share -Schedule of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Events after the reporting date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/EventsafterthereportingdateDetails</Role>
      <ShortName>Events after the reporting date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Eventsafterthereportingdate</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Deferred royalty obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/DeferredroyaltyobligationDetails</Role>
      <ShortName>Deferred royalty obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Deferredroyaltyobligation</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="adc-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://adctherapeutics.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://adctherapeutics.com/role/Equity</ParentRole>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="adc-20220930.htm">adc-20220930.htm</File>
    <File doctype="6-K" original="adc-20220930_d2.htm">adc-20220930_d2.htm</File>
    <File>adc-20220930.xsd</File>
    <File>adc-20220930_cal.xml</File>
    <File>adc-20220930_def.xml</File>
    <File>adc-20220930_lab.xml</File>
    <File>adc-20220930_pre.xml</File>
    <File>adct-20220930ex993.htm</File>
    <File>adct-20220930x6kex992.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="933">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adc-20220930.htm adc-20220930_d2.htm": {
   "axisCustom": 10,
   "axisStandard": 16,
   "contextCount": 440,
   "dts": {
    "calculationLink": {
     "local": [
      "adc-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adc-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "adc-20220930.htm",
      "adc-20220930_d2.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adc-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adc-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adc-20220930.xsd",
      "reference-2009-12-16.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 596,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 6
   },
   "keyCustom": 104,
   "keyStandard": 198,
   "memberCustom": 78,
   "memberStandard": 16,
   "nsprefix": "adc",
   "nsuri": "http://adctherapeutics.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://adctherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Financial risk management",
     "role": "http://adctherapeutics.com/role/Financialriskmanagement",
     "shortName": "Financial risk management",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Product revenues, net",
     "role": "http://adctherapeutics.com/role/Productrevenuesnet",
     "shortName": "Product revenues, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Segment information",
     "role": "http://adctherapeutics.com/role/Segmentinformation",
     "shortName": "Segment information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Operating expense",
     "role": "http://adctherapeutics.com/role/Operatingexpense",
     "shortName": "Operating expense",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Cash and cash equivalents",
     "role": "http://adctherapeutics.com/role/Cashandcashequivalents",
     "shortName": "Cash and cash equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Inventories",
     "role": "http://adctherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Intangible assets",
     "role": "http://adctherapeutics.com/role/Intangibleassets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Non-operating income",
     "role": "http://adctherapeutics.com/role/Nonoperatingincome",
     "shortName": "Non-operating income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Interest in joint venture",
     "role": "http://adctherapeutics.com/role/Interestinjointventure",
     "shortName": "Interest in joint venture",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfJointVenturesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Leases",
     "role": "http://adctherapeutics.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Interim Statement of Operations",
     "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
     "shortName": "Condensed Consolidated Interim Statement of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Senior secured term loan facility and warrants",
     "role": "http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants",
     "shortName": "Senior secured term loan facility and warrants",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Convertible loans",
     "role": "http://adctherapeutics.com/role/Convertibleloans",
     "shortName": "Convertible loans",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Deerfield Warrants",
     "role": "http://adctherapeutics.com/role/DeerfieldWarrants",
     "shortName": "Deerfield Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Share-based compensation",
     "role": "http://adctherapeutics.com/role/Sharebasedcompensation",
     "shortName": "Share-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Related parties",
     "role": "http://adctherapeutics.com/role/Relatedparties",
     "shortName": "Related parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Loss per share",
     "role": "http://adctherapeutics.com/role/Losspershare",
     "shortName": "Loss per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Events after the reporting date",
     "role": "http://adctherapeutics.com/role/Eventsafterthereportingdate",
     "shortName": "Events after the reporting date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DeferredRoyaltyObligationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Deferred royalty obligation",
     "role": "http://adctherapeutics.com/role/Deferredroyaltyobligation",
     "shortName": "Deferred royalty obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DeferredRoyaltyObligationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Equity",
     "role": "http://adctherapeutics.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Significant accounting policies (Policies)",
     "role": "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies",
     "shortName": "Significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Interim Statement of Comprehensive Loss",
     "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss",
     "shortName": "Condensed Consolidated Interim Statement of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Basis of preparation (Tables)",
     "role": "http://adctherapeutics.com/role/BasisofpreparationTables",
     "shortName": "Basis of preparation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Product revenues, net (Tables)",
     "role": "http://adctherapeutics.com/role/ProductrevenuesnetTables",
     "shortName": "Product revenues, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Operating expense (Tables)",
     "role": "http://adctherapeutics.com/role/OperatingexpenseTables",
     "shortName": "Operating expense (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Inventories (Tables)",
     "role": "http://adctherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Intangible assets (Tables)",
     "role": "http://adctherapeutics.com/role/IntangibleassetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Non-operating income (Tables)",
     "role": "http://adctherapeutics.com/role/NonoperatingincomeTables",
     "shortName": "Non-operating income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfJointVenturesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Interest in joint venture (Tables)",
     "role": "http://adctherapeutics.com/role/InterestinjointventureTables",
     "shortName": "Interest in joint venture (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfJointVenturesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInterestsInJointArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Leases (Tables)",
     "role": "http://adctherapeutics.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Senior secured term loan facility and warrants (Tables)",
     "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables",
     "shortName": "Senior secured term loan facility and warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Convertible loans (Tables)",
     "role": "http://adctherapeutics.com/role/ConvertibleloansTables",
     "shortName": "Convertible loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Interim Balance Sheet",
     "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
     "shortName": "Condensed Consolidated Interim Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Deerfield Warrants (Tables)",
     "role": "http://adctherapeutics.com/role/DeerfieldWarrantsTables",
     "shortName": "Deerfield Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Share-based compensation (Tables)",
     "role": "http://adctherapeutics.com/role/SharebasedcompensationTables",
     "shortName": "Share-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Related parties (Tables)",
     "role": "http://adctherapeutics.com/role/RelatedpartiesTables",
     "shortName": "Related parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Loss per share (Tables)",
     "role": "http://adctherapeutics.com/role/LosspershareTables",
     "shortName": "Loss per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Corporate information (Details)",
     "role": "http://adctherapeutics.com/role/CorporateinformationDetails",
     "shortName": "Corporate information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerGBP",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Basis of preparation - Schedule of Foreign currency exchange rate (Details)",
     "role": "http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails",
     "shortName": "Basis of preparation - Schedule of Foreign currency exchange rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerGBP",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "adc:PensionObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Basis of preparation - Additional information (Details)",
     "role": "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails",
     "shortName": "Basis of preparation - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "adc:DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i2d4b3b75218f411da612447c22d31b3d_D20220101-20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "adc:PensionObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:ConvertibleNotesSharesConverted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Significant accounting policies (Details)",
     "role": "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails",
     "shortName": "Significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "iac01c43c0d9347968cf7c0f6d6589b05_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Financial risk management (Details)",
     "role": "http://adctherapeutics.com/role/FinancialriskmanagementDetails",
     "shortName": "Financial risk management (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "iac01c43c0d9347968cf7c0f6d6589b05_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "adc:SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "adc:GTNSalesAdjustment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Product revenues, net (Details)",
     "role": "http://adctherapeutics.com/role/ProductrevenuesnetDetails",
     "shortName": "Product revenues, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ic28832b49da3403a8b557a594e965059_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "adc:GTNSalesAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i1a3acb2e8256494bb21952f83d8f6892_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Interim Statement of Changes in Equity",
     "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
     "shortName": "Condensed Consolidated Interim Statement of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i1a3acb2e8256494bb21952f83d8f6892_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ib75271c7003f455ea3762473084eeb29_D20220118-20220118",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "adc:LicenseAgreementMilestonePayments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Product revenues, net - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails",
     "shortName": "Product revenues, net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:NumberOfBusinessSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segment information (Details)",
     "role": "http://adctherapeutics.com/role/SegmentinformationDetails",
     "shortName": "Segment information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:NumberOfBusinessSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Operating expense - Schedule of Expenses by Nature (Details)",
     "role": "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails",
     "shortName": "Operating expense - Schedule of Expenses by Nature (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ic1c935c9ab6d481e9bca06fcabb63e20_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Operating expense - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails",
     "shortName": "Operating expense - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Cash and cash equivalents (Details)",
     "role": "http://adctherapeutics.com/role/CashandcashequivalentsDetails",
     "shortName": "Cash and cash equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WorkInProgress",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Inventories (Details)",
     "role": "http://adctherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfInventoryInformationExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WorkInProgress",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i08d8e433a2ba4906a5fa1cd18d822aba_D20210401-20210430",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Inventories - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i6f345e8135d943ddb82dfb8c7d312b08_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Intangible assets - Rollforward of Intangible Assets (Details)",
     "role": "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails",
     "shortName": "Intangible assets - Rollforward of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "icf2aa78bd37e48d8afb1437f35585633_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i6898024e6a424206b1716d13c24b930b_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Intangible assets - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails",
     "shortName": "Intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i6898024e6a424206b1716d13c24b930b_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Non-operating income - Schedule of Other Income (Expense) (Details)",
     "role": "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails",
     "shortName": "Non-operating income - Schedule of Other Income (Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "adc:BorrowingsDeferredFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Interim Statement of Cash Flows",
     "role": "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
     "shortName": "Condensed Consolidated Interim Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ia03dc1593e1c40fcab567ebcfef1680b_D20220815-20220815",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:ConvertibleNotesSharesConverted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Non-operating income - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
     "shortName": "Non-operating income - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfJointVenturesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adc:DeferredGainOnInvestmentInJointVenture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Interest in joint venture - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails",
     "shortName": "Interest in joint venture - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DisclosureOfJointVenturesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adc:DeferredGainOnInvestmentInJointVenture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Interest in joint venture - Schedule of movement in interest in joint venture (Details)",
     "role": "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails",
     "shortName": "Interest in joint venture - Schedule of movement in interest in joint venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DisclosureOfJointVenturesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i0eb53627542b4cdba6ba59b049a5b8cc_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:InvestmentsInJointVenturesAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Interest in joint venture - Summary of financial information in joint venture (Details)",
     "role": "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails",
     "shortName": "Interest in joint venture - Summary of financial information in joint venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory",
       "ifrs-full:DisclosureOfJointVenturesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i0eb53627542b4cdba6ba59b049a5b8cc_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "adc:LeaseArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqm",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Leases - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "adc:LeaseArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqm",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Leases - Right-of-Use Assets and Accumulated Depreciation (Details)",
     "role": "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails",
     "shortName": "Leases - Right-of-Use Assets and Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "icf2aa78bd37e48d8afb1437f35585633_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Leases - Right-of-Use Asset Depreciation (Details)",
     "role": "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails",
     "shortName": "Leases - Right-of-Use Asset Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ie83b9d46aa9540e49e84d64af9846e39_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:DepreciationRightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Leases - Schedule of Lease Liabilities (Details)",
     "role": "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "adc:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i1a3acb2e8256494bb21952f83d8f6892_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:LeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Senior secured term loan facility and warrants - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
     "shortName": "Senior secured term loan facility and warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i2b93ddb8d53d4ec2872793932c99d612_I20220815",
      "decimals": "-5",
      "lang": "en-US",
      "name": "adc:BorrowingsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i552db3596e754dcaac31cd578b8a44be_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Senior secured term loan facility and warrants - Valuation of Derivative (Details)",
     "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails",
     "shortName": "Senior secured term loan facility and warrants - Valuation of Derivative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i552db3596e754dcaac31cd578b8a44be_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Corporate information",
     "role": "http://adctherapeutics.com/role/Corporateinformation",
     "shortName": "Corporate information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "iea17a01e38b140129bf22b46808b9404_I20220815",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)",
     "role": "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
     "shortName": "Senior secured term loan facility and warrants - Schedule of the First and Second Tranche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "idda45a536b784d9a83b51c5690223542_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:Borrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i002154ec55ee4138b998ace2483bb162_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adc:BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Convertible loans - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
     "shortName": "Convertible loans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i82d563da995d45569288f830e5149dfb_I20220815",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:CreditDerivativeFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ic3d81122c2c840e4b693968f8c508748_D20200519-20200519",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:OfferingPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Convertible loans - Valuation of Derivative (Details)",
     "role": "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
     "shortName": "Convertible loans - Valuation of Derivative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ic3d81122c2c840e4b693968f8c508748_D20200519-20200519",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:OfferingPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i785f01a211a243bda6e912eb3ec1e0a2_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:InterestExpenseOnBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Convertible loans - Interest Expense (Details)",
     "role": "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
     "shortName": "Convertible loans - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "adc:DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Convertible loans - Change in Fair Value (Details)",
     "role": "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
     "shortName": "Convertible loans - Change in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i8541b30e628240598a82d1a6e8ece81c_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i2b93ddb8d53d4ec2872793932c99d612_I20220815",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "adc:WarrantObligationFairValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Deerfield Warrants - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
     "shortName": "Deerfield Warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ia26abd4a41954e9e9346a99a9f049985_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Deerfield Warrants - Schedule of Valuation Inputs (Details)",
     "role": "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
     "shortName": "Deerfield Warrants - Schedule of Valuation Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ia26abd4a41954e9e9346a99a9f049985_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Share-based compensation - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
     "shortName": "Share-based compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ic28832b49da3403a8b557a594e965059_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i59c7697f17a94ce9a360033092cabb0d_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)",
     "role": "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails",
     "shortName": "Share-based compensation - Schedule of Number of Awards Outstanding and Weighted Average Strike Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": "2",
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpectedDividendShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)",
     "role": "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails",
     "shortName": "Share-based compensation expense - Schedule of Fair Value Assumptions For Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpectedDividendShareOptionsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of preparation",
     "role": "http://adctherapeutics.com/role/Basisofpreparation",
     "shortName": "Basis of preparation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i1eb06d614e3447ffb6c90235d957a286_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)",
     "role": "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails",
     "shortName": "Share-based compensation - Schedule of Other Equity Instruments Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i1eb06d614e3447ffb6c90235d957a286_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Share-based compensation - Schedule of Share-based Compensation Reserve (Details)",
     "role": "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails",
     "shortName": "Share-based compensation - Schedule of Share-based Compensation Reserve (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "adc:DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if6b8e02492be4003ab27ad39ebc0924a_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "adc:IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:NumberOfSubsidiariesProvideServicesTo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Related parties - Narrative (Details)",
     "role": "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails",
     "shortName": "Related parties - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i98a2f8fc7cd9404b87f21bd1a00d4fef_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:NumberOfSubsidiariesProvideServicesTo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Related parties - Schedule of Key Management Compensation (Details)",
     "role": "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails",
     "shortName": "Related parties - Schedule of Key Management Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Loss per share (Details)",
     "role": "http://adctherapeutics.com/role/LosspershareDetails",
     "shortName": "Loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "0",
      "lang": "en-US",
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Loss per share -Schedule of Potentially Dilutive Securities (Details)",
     "role": "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails",
     "shortName": "Loss per share -Schedule of Potentially Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "adc:InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ib75271c7003f455ea3762473084eeb29_D20220118-20220118",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "adc:ProceedsFromLicenseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Events after the reporting date (Details)",
     "role": "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
     "shortName": "Events after the reporting date (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ie7216894bf0e483e85c7a8417528b234_I20210825",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:RoyaltyPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Deferred royalty obligation (Details)",
     "role": "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails",
     "shortName": "Deferred royalty obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "ie7216894bf0e483e85c7a8417528b234_I20210825",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "adc:RoyaltyPurchaseAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "if3fb552bfcfb4e1698fcae791865a60c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "adc:IssueOfEquityThroughExchangeAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Equity (Details)",
     "role": "http://adctherapeutics.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Significant accounting policies",
     "role": "http://adctherapeutics.com/role/Significantaccountingpolicies",
     "shortName": "Significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adc-20220930_d2.htm",
      "contextRef": "i7aa73f459e1249118a657516d64db79a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 99,
   "tag": {
    "adc_A2019EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Equity Incentive Plan",
        "label": "2019 Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019EquityIncentivePlanMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_A2019EquityIncentivePlanRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Equity Incentive Plan - RSUs",
        "label": "2019 Equity Incentive Plan - RSUs [Member]",
        "terseLabel": "Equity Incentive Plan 2019 - RSUs"
       }
      }
     },
     "localname": "A2019EquityIncentivePlanRSUsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_A2019EquityIncentivePlanShareOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Equity Incentive Plan - Share Options",
        "label": "2019 Equity Incentive Plan - Share Options [Member]",
        "terseLabel": "Equity Incentive Plan 2019 - Share Options"
       }
      }
     },
     "localname": "A2019EquityIncentivePlanShareOptionsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_A2022ESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 ESPP",
        "label": "2022 ESPP [Member]",
        "terseLabel": "2022 ESPP"
       }
      }
     },
     "localname": "A2022ESPPMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]",
        "label": "Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]",
        "terseLabel": "Accounting Policies, Changes in Accounting Estimates And Errors [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesChangesInAccountingEstimatesAndErrorsAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_AccountsPayableDeferredRoyaltyObligationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Deferred Royalty Obligation Transaction Costs",
        "label": "Accounts Payable, Deferred Royalty Obligation Transaction Costs",
        "terseLabel": "Deferred royalty obligation transaction costs recorded in Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableDeferredRoyaltyObligationTransactionCosts",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AccruedShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Share Based Compensation",
        "label": "Accrued Share Based Compensation",
        "terseLabel": "Accrued Share Based Compensation"
       }
      }
     },
     "localname": "AccruedShareBasedCompensation",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AdditionsToLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions To Lease Liabilities",
        "label": "Additions To Lease Liabilities",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToLeaseLiabilities",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AdjustmentsForDepreciationExpenseOfRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Depreciation Expense Of Right-Of-Use Assets",
        "label": "Adjustments For Depreciation Expense Of Right-Of-Use Assets",
        "terseLabel": "Depreciation of right-of-use assets"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationExpenseOfRightOfUseAssets",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AdjustmentsForDepreciationExpensePropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Depreciation Expense, Property, Plant And Equipment",
        "label": "Adjustments For Depreciation Expense, Property, Plant And Equipment",
        "terseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationExpensePropertyPlantAndEquipment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Gains (Losses) On change In Fair Value Of Warrants",
        "label": "Adjustments For Gains (Losses) On change In Fair Value Of Warrants",
        "negatedTerseLabel": "Warrant obligations, decrease in fair value"
       }
      }
     },
     "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfWarrants",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability",
        "label": "Adjustments For Increase (Decrease) In Non-Current Net Defined Benefit Liability",
        "terseLabel": "Change in defined benefit pension liability"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInNonCurrentNetDefinedBenefitLiability",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AfterFirstFiveYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After First Five Years",
        "label": "After First Five Years [Member]",
        "terseLabel": "After First Five Years"
       }
      }
     },
     "localname": "AfterFirstFiveYearsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_AmountsDueFromRelatedParties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due From Related Parties",
        "label": "Amounts Due From Related Parties",
        "terseLabel": "Amounts due from related parties"
       }
      }
     },
     "localname": "AmountsDueFromRelatedParties",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_AnnualEquityAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Equity Award",
        "label": "Annual Equity Award [Member]",
        "terseLabel": "Annual Equity Award"
       }
      }
     },
     "localname": "AnnualEquityAwardMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ApplicationApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Application Approval",
        "label": "Application Approval [Member]",
        "terseLabel": "Application Approval"
       }
      }
     },
     "localname": "ApplicationApprovalMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_AuvenTherapeuticsHoldingsLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auven Therapeutics Holdings, L.P.",
        "label": "Auven Therapeutics Holdings, L.P. [Member]",
        "terseLabel": "Auven Therapeutics Holdings, L.P."
       }
      }
     },
     "localname": "AuvenTherapeuticsHoldingsLPMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_BlackScholesValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Value",
        "label": "Black-Scholes Value [Member]",
        "terseLabel": "Black-Scholes Value"
       }
      }
     },
     "localname": "BlackScholesValueMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_BorrowingConversionPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing Conversion Period",
        "label": "Borrowing Conversion Period [Domain]",
        "terseLabel": "Borrowing Conversion Period [Domain]"
       }
      }
     },
     "localname": "BorrowingConversionPeriodDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price",
        "label": "Borrowing Facilities, Conversion Price Per Share, Percentage Of IPO Share Price",
        "terseLabel": "Conversion percentage"
       }
      }
     },
     "localname": "BorrowingFacilitiesConversionPricePerSharePercentageOfIPOSharePrice",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_BorrowingFacilitiesMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing Facilities, Maximum Borrowing Capacity",
        "label": "Borrowing Facilities, Maximum Borrowing Capacity",
        "terseLabel": "Borrowings, maximum borrowing capacity"
       }
      }
     },
     "localname": "BorrowingFacilitiesMaximumBorrowingCapacity",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_BorrowingNumberOfComponents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing, Number Of Components",
        "label": "Borrowing, Number Of Components",
        "terseLabel": "Number of borrowing components"
       }
      }
     },
     "localname": "BorrowingNumberOfComponents",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adc_BorrowingPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing Period",
        "label": "Borrowing Period [Axis]",
        "terseLabel": "Borrowing Period [Axis]"
       }
      }
     },
     "localname": "BorrowingPeriodAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_BorrowingPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing Period [Domain]",
        "label": "Borrowing Period [Domain]",
        "terseLabel": "Borrowing Period [Domain]"
       }
      }
     },
     "localname": "BorrowingPeriodDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_BorrowingsConversionPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings Conversion Period",
        "label": "Borrowings Conversion Period [Axis]",
        "terseLabel": "Borrowings Conversion Period [Axis]"
       }
      }
     },
     "localname": "BorrowingsConversionPeriodAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_BorrowingsConversionPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings Conversion Period One",
        "label": "Borrowings Conversion Period One [Member]",
        "terseLabel": "Conversion period one"
       }
      }
     },
     "localname": "BorrowingsConversionPeriodOneMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents",
        "label": "Borrowings, Covenant, Minimum Required Quarter End Cash And Cash Equivalents",
        "terseLabel": "Cash and cash equivalents, minimum quarterly balance"
       }
      }
     },
     "localname": "BorrowingsCovenantMinimumRequiredQuarterEndCashAndCashEquivalents",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CashandcashequivalentsDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_BorrowingsDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings, Deferred Financing Costs",
        "label": "Borrowings, Deferred Financing Costs",
        "terseLabel": "Convertible loans, derivatives, transaction costs"
       }
      }
     },
     "localname": "BorrowingsDeferredFinancingCosts",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_BorrowingsFacilitiesExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings Facilities, Exit Fee, Percentage",
        "label": "Borrowings Facilities, Exit Fee, Percentage",
        "terseLabel": "Exit fee"
       }
      }
     },
     "localname": "BorrowingsFacilitiesExitFeePercentage",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_BorrowingsFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings, Fair Value",
        "label": "Borrowings, Fair Value",
        "terseLabel": "Borrowings, Fair Value"
       }
      }
     },
     "localname": "BorrowingsFairValue",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_BorrowingsImpliedEffectiveInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings, Implied Effective Interest Rate",
        "label": "Borrowings, Implied Effective Interest Rate",
        "terseLabel": "Implied effective interest rate"
       }
      }
     },
     "localname": "BorrowingsImpliedEffectiveInterestRate",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_CamiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cami",
        "label": "Cami [Member]",
        "terseLabel": "Cami"
       }
      }
     },
     "localname": "CamiMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Expenditures, Incurred But Not Yet Paid",
        "label": "Capital Expenditures, Incurred But Not Yet Paid",
        "terseLabel": "Capital expenditures and intangible asset acquisitions recorded in Accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ConsolidatedStatementOfFinancialPositionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statement of Financial Position [Line Items]",
        "label": "Consolidated Statement of Financial Position [Line Items]",
        "terseLabel": "Consolidated Statement of Financial Position [Line Items]"
       }
      }
     },
     "localname": "ConsolidatedStatementOfFinancialPositionLineItems",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_ConsolidatedStatementOfFinancialPositionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statement of Financial Position [Table]",
        "label": "Consolidated Statement of Financial Position [Table]",
        "terseLabel": "Consolidated Statement of Financial Position [Table]"
       }
      }
     },
     "localname": "ConsolidatedStatementOfFinancialPositionTable",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_ConversionPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Period Two",
        "label": "Conversion Period Two [Member]",
        "terseLabel": "Conversion period two"
       }
      }
     },
     "localname": "ConversionPeriodTwoMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ConvertibleLoansContingentlyIssuableSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Loans, Contingently Issuable Shares",
        "label": "Convertible Loans, Contingently Issuable Shares [Member]",
        "terseLabel": "Conversion of the principal amount of convertible loans into the Company\u2019s common shares"
       }
      }
     },
     "localname": "ConvertibleLoansContingentlyIssuableSharesMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ConvertibleLoansExchange": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Loans Exchange",
        "label": "Convertible Loans Exchange",
        "negatedTerseLabel": "Convertible loans exchange"
       }
      }
     },
     "localname": "ConvertibleLoansExchange",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ConvertibleLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Loans",
        "label": "Convertible Loans [Member]",
        "terseLabel": "Convertible Loans"
       }
      }
     },
     "localname": "ConvertibleLoansMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ConvertibleNotesSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes, Shares Converted",
        "label": "Convertible Notes, Shares Converted",
        "terseLabel": "Convertible Notes, Shares Converted"
       }
      }
     },
     "localname": "ConvertibleNotesSharesConverted",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/EquityDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adc_ConvertibleNotesValueConverted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Notes, Value Converted",
        "label": "Convertible Notes, Value Converted",
        "terseLabel": "Convertible Notes, Value Converted"
       }
      }
     },
     "localname": "ConvertibleNotesValueConverted",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]"
       }
      }
     },
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Accrued Expenses And Other Current Liabilities, Sales Adjustment",
        "label": "Current Accrued Expenses And Other Current Liabilities, Sales Adjustment",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_CurrentFinishedGoodsHeldOnConsignment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Finished Goods Held On Consignment",
        "label": "Current Finished Goods Held On Consignment",
        "terseLabel": "Current Finished Goods Held On Consignment"
       }
      }
     },
     "localname": "CurrentFinishedGoodsHeldOnConsignment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_DeerfieldWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deerfield Warrants",
        "label": "Deerfield Warrants [Member]",
        "terseLabel": "Deerfield Warrants"
       }
      }
     },
     "localname": "DeerfieldWarrantsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_DeferredFinancingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Costs",
        "label": "Deferred Financing Costs [Member]",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "DeferredFinancingCostsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_DeferredGainOnInvestmentInJointVenture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Gain On Investment In Joint Venture",
        "label": "Deferred Gain On Investment In Joint Venture",
        "terseLabel": "Deferred Gain On Investment In Joint Venture"
       }
      }
     },
     "localname": "DeferredGainOnInvestmentInJointVenture",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_DeferredRoyaltyObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation",
        "label": "Deferred Royalty Obligation",
        "terseLabel": "Deferred Royalty Obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligation",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_DeferredRoyaltyObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation [Abstract]",
        "label": "Deferred Royalty Obligation [Abstract]"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_DeferredRoyaltyObligationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 7.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation, Noncurrent",
        "label": "Deferred Royalty Obligation, Noncurrent",
        "terseLabel": "Deferred royalty obligation, long-term"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationNoncurrent",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_DeferredRoyaltyObligationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation",
        "label": "Deferred Royalty Obligation [Text Block]",
        "terseLabel": "Deferred royalty obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/Deferredroyaltyobligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Other Income (Expense) Explanatory",
        "label": "Description Of Accounting Policy For Other Income (Expense) Explanatory [Policy Text Block]",
        "terseLabel": "Description Of Accounting Policy For Other Income (Expense) Explanatory"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForOtherIncomeExpenseExplanatoryPolicyTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Selling And Marketing Expenses Explanatory",
        "label": "Description Of Accounting Policy For Selling And Marketing Expenses Explanatory [Policy Text Block]",
        "terseLabel": "Selling and marketing (\"S&amp;M\") expenses"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSellingAndMarketingExpensesExplanatoryPolicyTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory",
        "label": "Description Of Accounting Policy For Use Of Estimates And Judgements Explanatory [Policy Text Block]",
        "terseLabel": "Use of estimates and judgements"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForUseOfEstimatesAndJudgementsExplanatoryPolicyTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed Information About Foreign Currency Exchange Rate Explanatory",
        "label": "Detailed Information About Foreign Currency Exchange Rate Explanatory [Table Text Block]",
        "terseLabel": "Schedule of Foreign currency exchange rate"
       }
      }
     },
     "localname": "DetailedInformationAboutForeignCurrencyExchangeRateExplanatoryTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Expenses By Nature Explanatory",
        "label": "Disclosure Of Detailed Information About Expenses By Nature Explanatory [Table Text Block]",
        "terseLabel": "Disclosure Of Detailed Information About Expenses By Nature Explanatory"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutExpensesByNatureExplanatoryTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutExpensesByNatureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Expenses By Nature",
        "label": "Disclosure Of Detailed Information About Expenses By Nature [Line Items]",
        "terseLabel": "Disclosure Of Detailed Information About Expenses By Nature [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutExpensesByNatureLineItems",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutExpensesByNatureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Expenses By Nature [Table]",
        "label": "Disclosure Of Detailed Information About Expenses By Nature [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Expenses By Nature [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutExpensesByNatureTable",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Lease Liabilities [Table]",
        "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]",
        "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Other Income (Expense) Explanatory",
        "label": "Disclosure Of Detailed Information About Other Income (Expense) Explanatory [Table Text Block]",
        "terseLabel": "Schedule of Other income (expense)"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExpenseExplanatoryTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets",
        "label": "Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets [Table Text Block]",
        "terseLabel": "Disclosure Of Detailed Information About Sales Adjustment Included In the Balance Sheets"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutSalesAdjustmentIncludedInTheBalanceSheetsTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Sales Adjustments Explanatory",
        "label": "Disclosure Of Detailed Information About Sales Adjustments Explanatory [Table Text Block]",
        "terseLabel": "Disclosure Of Detailed Information About Sales Adjustments Explanatory"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutSalesAdjustmentsExplanatoryTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory",
        "label": "Disclosure Of Detailed Information About Share-based Compensation Reserve Explanatory [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Reserve"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedCompensationReserveExplanatoryTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfInventoryInformationExplanatoryTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Inventory Information Explanatory",
        "label": "Disclosure Of Inventory Information Explanatory [Table Text Block]",
        "terseLabel": "Disclosure Of Inventory Information Explanatory"
       }
      }
     },
     "localname": "DisclosureOfInventoryInformationExplanatoryTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Other Non-Operating Income, Explanatory",
        "label": "Disclosure Of Other Non-Operating Income, Explanatory [Text Block]",
        "terseLabel": "Non-operating income"
       }
      }
     },
     "localname": "DisclosureOfOtherNonOperatingIncomeExplanatoryTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/Nonoperatingincome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Line Items]",
        "terseLabel": "Disclosure Of Quantitative Information About Lease Liabilities [Line Items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesLineItems",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Table Text Block]",
        "terseLabel": "Schedule of quantitative information about lease liabilities"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DisclosureOfWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Warrants",
        "label": "Disclosure Of Warrants [Text Block]",
        "terseLabel": "Deerfield Warrants"
       }
      }
     },
     "localname": "DisclosureOfWarrantsTextBlock",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adc_DividendYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Yield",
        "label": "Dividend Yield [Member]",
        "terseLabel": "Dividend Yield [Member]"
       }
      }
     },
     "localname": "DividendYieldMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_DosingOfSpecificNumberOfPatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dosing Of Specific Number Of Patients",
        "label": "Dosing Of Specific Number Of Patients [Member]",
        "terseLabel": "Dosing Of Specific Number Of Patients"
       }
      }
     },
     "localname": "DosingOfSpecificNumberOfPatientsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_EmployeeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Expenses",
        "label": "Employee Expenses [Member]",
        "terseLabel": "Employee expense"
       }
      }
     },
     "localname": "EmployeeExpensesMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Share Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_EventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Events After Reporting Period [Abstract]",
        "label": "Events After Reporting Period [Abstract]"
       }
      }
     },
     "localname": "EventsAfterReportingPeriodAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement",
        "label": "Exchange Agreement [Member]",
        "terseLabel": "Exchange Agreement"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExchangeOfConvertibleNotesForWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Of Convertible Notes For Warrants",
        "label": "Exchange Of Convertible Notes For Warrants",
        "terseLabel": "Exchange Of Convertible Notes For Warrants"
       }
      }
     },
     "localname": "ExchangeOfConvertibleNotesForWarrants",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ExecutiveCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Compensation",
        "label": "Executive Compensation [Member]",
        "terseLabel": "Executive Compensation"
       }
      }
     },
     "localname": "ExecutiveCompensationMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExercisePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price",
        "label": "Exercise Price [Member]",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ExercisePriceMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExpectedTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Term",
        "label": "Expected Term [Member]",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "ExpectedTermMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExpectedVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected Volatility",
        "label": "Expected Volatility [Member]",
        "terseLabel": "Expected Volatility"
       }
      }
     },
     "localname": "ExpectedVolatilityMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExpensesByNatureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses By Nature",
        "label": "Expenses By Nature [Axis]",
        "terseLabel": "Expenses By Nature [Axis]"
       }
      }
     },
     "localname": "ExpensesByNatureAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_ExpensesByNatureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses By Nature [Domain]",
        "label": "Expenses By Nature [Domain]",
        "terseLabel": "Expenses By Nature [Domain]"
       }
      }
     },
     "localname": "ExpensesByNatureDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExpensesByNatureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses By Nature",
        "label": "Expenses By Nature [Member]",
        "terseLabel": "Expenses By Nature"
       }
      }
     },
     "localname": "ExpensesByNatureMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ExternalCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "External Costs",
        "label": "External Costs [Member]",
        "terseLabel": "External costs"
       }
      }
     },
     "localname": "ExternalCostsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FacilityAgreementWithDeerfieldPartnersLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Agreement with Deerfield Partners, L.P.",
        "label": "Facility Agreement with Deerfield Partners, L.P. [Member]",
        "terseLabel": "Facility Agreement with Deerfield Partners, L.P."
       }
      }
     },
     "localname": "FacilityAgreementWithDeerfieldPartnersLPMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche One",
        "label": "Facility Agreement With Deerfield Partners, L.P., Tranche One [Member]",
        "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche One"
       }
      }
     },
     "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheOneMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval",
        "label": "Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval [Member]",
        "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche Two After FDA Approval"
       }
      }
     },
     "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheTwoAfterFDAApprovalMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche Two",
        "label": "Facility Agreement With Deerfield Partners, L.P., Tranche Two [Member]",
        "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche Two"
       }
      }
     },
     "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheTwoMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval",
        "label": "Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval [Member]",
        "terseLabel": "Facility Agreement With Deerfield Partners, L.P., Tranche Two Prior to FDA Approval"
       }
      }
     },
     "localname": "FacilityAgreementWithDeerfieldPartnersLPTrancheTwoPriorToFDAApprovalMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "terseLabel": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_FirstFiveYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Five Years",
        "label": "First Five Years [Member]",
        "terseLabel": "First Five Years"
       }
      }
     },
     "localname": "FirstFiveYearsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FirstInvestmentAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Investment Amount",
        "label": "First Investment Amount [Member]",
        "terseLabel": "First Investment Amount"
       }
      }
     },
     "localname": "FirstInvestmentAmountMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities",
        "label": "Follow-On Transaction Costs, Accounts Payable And Other Current Liabilities",
        "terseLabel": "Follow-on transaction costs recorded in Accounts payable and Other current liabilities"
       }
      }
     },
     "localname": "FollowOnTransactionCostsAccountsPayableAndOtherCurrentLiabilities",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ForcedConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forced Conversion Price",
        "label": "Forced Conversion Price [Member]",
        "terseLabel": "Forced Conversion Price (in USD per share)"
       }
      }
     },
     "localname": "ForcedConversionPriceMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_GTNSalesAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GTN Sales Adjustment",
        "label": "GTN Sales Adjustment",
        "periodEndLabel": "Sales adjustment, ending balance",
        "terseLabel": "Sales adjustment, beginning balance"
       }
      }
     },
     "localname": "GTNSalesAdjustment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_GTNSalesAdjustmentCreditsAndPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GTN Sales Adjustment, Credits And Payments",
        "label": "GTN Sales Adjustment, Credits And Payments",
        "terseLabel": "GTN Sales Adjustment, Credits And Payments"
       }
      }
     },
     "localname": "GTNSalesAdjustmentCreditsAndPayments",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_GTNSalesAdjustmentProvision": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GTN Sales Adjustment, Provision",
        "label": "GTN Sales Adjustment, Provision",
        "terseLabel": "GTN Sales Adjustment, Provision"
       }
      }
     },
     "localname": "GTNSalesAdjustmentProvision",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_GTNSalesAdjustmentProvisionPriorPeriodSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GTN Sales Adjustment, Provision, Prior Period Sales",
        "label": "GTN Sales Adjustment, Provision, Prior Period Sales",
        "terseLabel": "GTN Sales Adjustment, Provision, Prior Period Sales"
       }
      }
     },
     "localname": "GTNSalesAdjustmentProvisionPriorPeriodSales",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_GainsLossOnChangeInFairValueWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (Loss) On Change In Fair Value, Warrants",
        "label": "Gains (Loss) On Change In Fair Value, Warrants",
        "terseLabel": "Deerfield warrant obligation, change in fair value income"
       }
      }
     },
     "localname": "GainsLossOnChangeInFairValueWarrants",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_GainsLossOnExtinguishmentOfBorrowings": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains (Loss) On Extinguishment Of Borrowings",
        "label": "Gains (Loss) On Extinguishment Of Borrowings",
        "terseLabel": "Loss on extinguishment"
       }
      }
     },
     "localname": "GainsLossOnExtinguishmentOfBorrowings",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/EquityDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General And Administrative Expense",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "G&amp;A expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ImpliedBondYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implied Bond Yield",
        "label": "Implied Bond Yield [Member]",
        "terseLabel": "Implied Bond Yield [Member]"
       }
      }
     },
     "localname": "ImpliedBondYieldMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_IncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Plan 2014",
        "label": "Incentive Plan 2014 [Member]",
        "terseLabel": "Incentive Plan 2014 [Member]"
       }
      }
     },
     "localname": "IncentivePlan2014Member",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_IncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Member]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_IncreaseDecreaseInReserveOfShareBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Reserve Of Share-Based Payments",
        "label": "Increase (Decrease) In Reserve Of Share-Based Payments",
        "terseLabel": "Increase in reserve of share-based payments"
       }
      }
     },
     "localname": "IncreaseDecreaseInReserveOfShareBasedPayments",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions",
        "label": "Increase (Decrease) In Reserve Of Share-Based Payments, Tax And Social Charge Deductions",
        "terseLabel": "Tax expense from share-based payment transactions with employees"
       }
      }
     },
     "localname": "IncreaseDecreaseInReserveOfShareBasedPaymentsTaxAndSocialChargeDeductions",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 5.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IncreaseDecreaseThroughIssuanceToSettleIncentivePlanAwards",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Modification Of Lease Terms, Lease Liabilities",
        "label": "Increase (Decrease) Through Modification Of Lease Terms, Lease Liabilities",
        "terseLabel": "Modification of lease terms"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughModificationOfLeaseTermsLeaseLiabilities",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets",
        "label": "Increase (Decrease) Through Modification Of Lease Terms, Right-Of-Use Assets",
        "negatedTerseLabel": "Lease termination"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughModificationOfLeaseTermsRightOfUseAssets",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Net Exchange Differences, Lease Liabilities",
        "label": "Increase (Decrease) Through Net Exchange Differences, Lease Liabilities",
        "terseLabel": "Exchange difference"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesLeaseLiabilities",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets",
        "label": "Increase (Decrease) Through Net Exchange Differences, Right-Of-Use Assets",
        "terseLabel": "Exchange difference"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesRightOfUseAssets",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IncreaseDecreaseThroughSharesSurrenderedToRedeemSharePurchasePlanPromissoryNotes",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_InitialPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering",
        "label": "Initial Public Offering [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share",
        "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShare",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share",
        "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]",
        "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]",
        "terseLabel": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Domain]"
       }
      }
     },
     "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share",
        "label": "Instruments With Potential Future Dilutive Effect Not Included In Calculation Of Diluted Earnings Per Share [Member]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "InstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_IntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets [Abstract]",
        "label": "Intangible Assets [Abstract]",
        "terseLabel": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_InterestsInOtherEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interests In Other Entities [Abstract]",
        "label": "Interests In Other Entities [Abstract]"
       }
      }
     },
     "localname": "InterestsInOtherEntitiesAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_InternalDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Development Costs",
        "label": "Internal Development Costs [Member]",
        "terseLabel": "Internal development costs"
       }
      }
     },
     "localname": "InternalDevelopmentCostsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_InventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Abstract]",
        "label": "Inventory [Abstract]",
        "terseLabel": "Inventory [Abstract]"
       }
      }
     },
     "localname": "InventoryAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_InventoryAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "InventoryAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_InventoryDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Domain]",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "InventoryDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_IssuanceOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Of Shares",
        "label": "Issuance Of Shares",
        "terseLabel": "Issuance of shares, Deerfield exchange agreement"
       }
      }
     },
     "localname": "IssuanceOfShares",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IssueOfEquityThroughCapitalizationOfReserves": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 4.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IssueOfEquityThroughCapitalizationOfReserves",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_IssueOfEquityThroughExchangeAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Of Equity Through Exchange Agreement",
        "label": "Issue Of Equity Through Exchange Agreement",
        "terseLabel": "Issuance of shares, Deerfield exchange agreement, net of transaction costs"
       }
      }
     },
     "localname": "IssueOfEquityThroughExchangeAgreement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_IssueOfEquityThroughFollowOnOffering": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 6.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IssueOfEquityThroughFollowOnOffering",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_IssueOfEquityThroughInitialPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IssueOfEquityThroughInitialPublicOffering",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_IssueOfEquityThroughOverAllotmentOption": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 8.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IssueOfEquityThroughOverAllotmentOption",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_IssueOfEquityThroughPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue Of Equity Through Purchase Agreement",
        "label": "Issue Of Equity Through Purchase Agreement",
        "terseLabel": "Issuance of shares, share purchase agreement, net of transaction costs"
       }
      }
     },
     "localname": "IssueOfEquityThroughPurchaseAgreement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_LeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Area",
        "label": "Lease Area",
        "terseLabel": "Lease area (in square meters)"
       }
      }
     },
     "localname": "LeaseArea",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "adc_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_LicenseAgreementCappedContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Capped Contribution",
        "label": "License Agreement, Capped Contribution",
        "terseLabel": "License Agreement, Capped Contribution"
       }
      }
     },
     "localname": "LicenseAgreementCappedContribution",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicenseAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payments",
        "label": "License Agreement, Milestone Payments",
        "terseLabel": "License Agreement, Milestone Payments"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePayments",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_LicenseAgreementPercentOfClinicalTrialCostsPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percent Of Clinical Trial Costs Paid",
        "label": "License Agreement, Percent Of Clinical Trial Costs Paid",
        "terseLabel": "License Agreement, Percent Of Clinical Trial Costs Paid"
       }
      }
     },
     "localname": "LicenseAgreementPercentOfClinicalTrialCostsPaid",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_LicensePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Payment",
        "label": "License Payment [Member]",
        "terseLabel": "License Payment"
       }
      }
     },
     "localname": "LicensePaymentMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Revenue",
        "label": "License Revenue [Member]",
        "terseLabel": "License revenue"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicenseToAcquireAnAntibodyZYNLONTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License To Acquire An Antibody, ZYNLONTA",
        "label": "License To Acquire An Antibody, ZYNLONTA [Member]",
        "terseLabel": "License To Acquire An Antibody, ZYNLONTA"
       }
      }
     },
     "localname": "LicenseToAcquireAnAntibodyZYNLONTAMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2)",
        "label": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2) [Member]",
        "terseLabel": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA (2)"
       }
      }
     },
     "localname": "LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTA2Member",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA",
        "label": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA [Member]",
        "terseLabel": "License To Use Technology To Generate Antibody Drug Conjugates, ZYNLONTA"
       }
      }
     },
     "localname": "LicenseToUseTechnologyToGenerateAntibodyDrugConjugatesZYNLONTAMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicensesDefiniteLivedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses, Definite-Lived",
        "label": "Licenses, Definite-Lived [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensesDefiniteLivedMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LicensesIndefiniteLivedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses, Indefinite-Lived",
        "label": "Licenses, Indefinite-Lived [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensesIndefiniteLivedMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LoanAgreementFirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, First Tranche",
        "label": "Loan Agreement, First Tranche [Member]",
        "terseLabel": "Loan Agreement, First Tranche"
       }
      }
     },
     "localname": "LoanAgreementFirstTrancheMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LoanAgreementFutureTranchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Future Tranches",
        "label": "Loan Agreement, Future Tranches [Member]",
        "terseLabel": "Loan Agreement, Future Tranches"
       }
      }
     },
     "localname": "LoanAgreementFutureTranchesMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement",
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ManufacturingOfAntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Of Antibodies",
        "label": "Manufacturing Of Antibodies [Member]",
        "terseLabel": "Manufacturing Of Antibodies"
       }
      }
     },
     "localname": "ManufacturingOfAntibodiesMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Term Of Options Granted For Share-Based Payment Arrangement",
        "label": "Maximum Term Of Options Granted For Share-Based Payment Arrangement",
        "terseLabel": "Contractual term"
       }
      }
     },
     "localname": "MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adc_MilestonePaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment [Member]",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePaymentMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_NetCarryingAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Carrying Amount",
        "label": "Net Carrying Amount [Member]",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "NetCarryingAmountMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_NonOperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Operating Income (Expense)",
        "label": "Non-Operating Income (Expense)",
        "terseLabel": "Non-operating income (expense)"
       }
      }
     },
     "localname": "NonOperatingIncomeExpense",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_NumberOfBusinessSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Segments",
        "label": "Number Of Business Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfBusinessSegments",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SegmentinformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adc_NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates Developed And Commercialized In Joint Venture",
        "label": "Number Of Product Candidates Developed And Commercialized In Joint Venture",
        "terseLabel": "Number of product candidates developed and commercialized in joint venture"
       }
      }
     },
     "localname": "NumberOfProductCandidatesDevelopedAndCommercializedInJointVenture",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adc_NumberOfProductsDevelopedAndCommercializedInJointVenture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Products Developed And Commercialized In Joint Venture",
        "label": "Number Of Products Developed And Commercialized In Joint Venture",
        "terseLabel": "Number of products developed and commercialized in joint venture"
       }
      }
     },
     "localname": "NumberOfProductsDevelopedAndCommercializedInJointVenture",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adc_NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement",
        "label": "Number Of Share Options Vested And Exercisable In Share-Based Payment Arrangement",
        "terseLabel": "Awards vested and exercisable (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adc_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Subsidiaries",
        "label": "Number Of Subsidiaries",
        "terseLabel": "Number of subsidiaries"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adc_NumberOfSubsidiariesProvideServicesTo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Subsidiaries Provide Services To",
        "label": "Number Of Subsidiaries Provide Services To",
        "terseLabel": "Number of subsidiaries provide services to"
       }
      }
     },
     "localname": "NumberOfSubsidiariesProvideServicesTo",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adc_OakTreeAndOwlRockWarrantObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oak Tree And Owl Rock Warrant Obligations",
        "label": "Oak Tree And Owl Rock Warrant Obligations [Member]",
        "terseLabel": "Oak Tree And Owl Rock Warrant Obligations"
       }
      }
     },
     "localname": "OakTreeAndOwlRockWarrantObligationsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_OfferingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Price Per Share",
        "label": "Offering Price Per Share",
        "terseLabel": "Offering price per share (in USD per share)"
       }
      }
     },
     "localname": "OfferingPricePerShare",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_OperatingSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Segments [Abstract]",
        "label": "Operating Segments [Abstract]",
        "terseLabel": "Operating Segments [Abstract]"
       }
      }
     },
     "localname": "OperatingSegmentsAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_OtherIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense)",
        "label": "Other Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherIncomeExpenseAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_OtherNonOperatingIncome": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 1.0,
       "parentTag": "adc_OtherNonOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non-Operating Income",
        "label": "Other Non-Operating Income",
        "terseLabel": "Non-operating (expense) income"
       }
      }
     },
     "localname": "OtherNonOperatingIncome",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_OtherNonOperatingIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non-Operating Income (Expense)",
        "label": "Other Non-Operating Income (Expense)",
        "totalLabel": "Total other (expense) income"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpense",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_OutsideOfTheUnitedStatesAndEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside Of The United States And Europe",
        "label": "Outside Of The United States And Europe [Member]",
        "terseLabel": "Outside Of The United States And Europe"
       }
      }
     },
     "localname": "OutsideOfTheUnitedStatesAndEuropeMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_OutstandingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding Warrants",
        "label": "Outstanding Warrants [Member]",
        "terseLabel": "Outstanding Warrants"
       }
      }
     },
     "localname": "OutstandingWarrantsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_OverlandADCTBioPharmaCYLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overland ADCT BioPharma (CY) Limited",
        "label": "Overland ADCT BioPharma (CY) Limited [Member]",
        "terseLabel": "Overland ADCT BioPharma"
       }
      }
     },
     "localname": "OverlandADCTBioPharmaCYLimitedMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails",
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails",
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_PaymentForRentDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Rent Deposits",
        "label": "Payment For Rent Deposits",
        "negatedTerseLabel": "Payment for deposits"
       }
      }
     },
     "localname": "PaymentForRentDeposits",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_PaymentTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Type",
        "label": "Payment Type [Axis]",
        "terseLabel": "Payment Type [Axis]"
       }
      }
     },
     "localname": "PaymentTypeAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_PaymentTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Type [Domain]",
        "label": "Payment Type [Domain]",
        "terseLabel": "Payment Type [Domain]"
       }
      }
     },
     "localname": "PaymentTypeDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_PaymentsMadeUnderRoyaltyFinancingTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Made Under Royalty Financing Transactions",
        "label": "Payments Made Under Royalty Financing Transactions",
        "negatedTerseLabel": "Interest paid under royalty financing transaction"
       }
      }
     },
     "localname": "PaymentsMadeUnderRoyaltyFinancingTransactions",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_PensionObligationDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension Obligation, Discount Rate",
        "label": "Pension Obligation, Discount Rate",
        "terseLabel": "Pension Obligation, Discount Rate"
       }
      }
     },
     "localname": "PensionObligationDiscountRate",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_PlanNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan Name",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_PlanNameMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan Name",
        "label": "Plan Name [Member]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs",
        "label": "Proceeds From Deferred Royalty Transaction, Net Of Transaction Costs",
        "terseLabel": "Proceeds from deferred royalty transaction, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromDeferredRoyaltyTransactionNetOfTransactionCosts",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ProceedsFromLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From License Agreement",
        "label": "Proceeds From License Agreement",
        "terseLabel": "Proceeds From License Agreement"
       }
      }
     },
     "localname": "ProceedsFromLicenseAgreement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ProceedsFromRoyaltyPurchaseAgreementGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Royalty Purchase Agreement, Gross",
        "label": "Proceeds From Royalty Purchase Agreement, Gross",
        "terseLabel": "Proceeds From Royalty Purchase Agreement, Gross"
       }
      }
     },
     "localname": "ProceedsFromRoyaltyPurchaseAgreementGross",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ProceedsFromRoyaltyPurchaseAgreementNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Royalty Purchase Agreement, Net",
        "label": "Proceeds From Royalty Purchase Agreement, Net",
        "terseLabel": "Proceeds From Royalty Purchase Agreement, Net"
       }
      }
     },
     "localname": "ProceedsFromRoyaltyPurchaseAgreementNet",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ProductRevenueNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Revenue, Net",
        "label": "Product Revenue, Net [Member]",
        "terseLabel": "Product revenues, net"
       }
      }
     },
     "localname": "ProductRevenueNetMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_PurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchasers",
        "label": "Purchasers [Member]",
        "terseLabel": "Purchasers"
       }
      }
     },
     "localname": "PurchasersMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RecoveryRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery Rate",
        "label": "Recovery Rate [Member]",
        "terseLabel": "Recovery Rate [Member]"
       }
      }
     },
     "localname": "RecoveryRateMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party [Abstract]",
        "label": "Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "R&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ResidualLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Residual Loan",
        "label": "Residual Loan [Member]",
        "terseLabel": "Residual Loan"
       }
      }
     },
     "localname": "ResidualLoanMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RestrictedShareUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Share Units (RSU)",
        "label": "Restricted Share Units (RSU) [Member]",
        "terseLabel": "Restricted Share Units (RSU)"
       }
      }
     },
     "localname": "RestrictedShareUnitsRSUMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units",
        "label": "Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RevenueFromContractsWithCustomersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contracts With Customers [Abstract]",
        "label": "Revenue From Contracts With Customers [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomersAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_RiskFreeInterestRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Free, Interest Rate",
        "label": "Risk Free, Interest Rate [Member]",
        "terseLabel": "Risk Free, Interest Rate"
       }
      }
     },
     "localname": "RiskFreeInterestRateMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RoyaltyObligationExpectedFutureTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Expected Future Transaction Costs",
        "label": "Royalty Obligation, Expected Future Transaction Costs",
        "terseLabel": "Royalty Obligation, Expected Future Transaction Costs"
       }
      }
     },
     "localname": "RoyaltyObligationExpectedFutureTransactionCosts",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment",
        "label": "Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment",
        "terseLabel": "Royalty Obligation, Financial Expense Cumulative Catch-Up Adjustment"
       }
      }
     },
     "localname": "RoyaltyObligationFinancialExpenseCumulativeCatchUpAdjustment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyObligationInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Interest",
        "label": "Royalty Obligation, Interest",
        "terseLabel": "Royalty Obligation, Interest"
       }
      }
     },
     "localname": "RoyaltyObligationInterest",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyObligationPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Payments",
        "label": "Royalty Obligation, Payments",
        "terseLabel": "Royalty Obligation, Payments"
       }
      }
     },
     "localname": "RoyaltyObligationPayments",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyObligationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Transaction Costs",
        "label": "Royalty Obligation, Transaction Costs",
        "terseLabel": "Royalty Obligation, Transaction Costs"
       }
      }
     },
     "localname": "RoyaltyObligationTransactionCosts",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyPurchaseAdditionalProceedsEligibility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Additional Proceeds Eligibility",
        "label": "Royalty Purchase Additional Proceeds Eligibility",
        "terseLabel": "Royalty Purchase Additional Proceeds Eligibility"
       }
      }
     },
     "localname": "RoyaltyPurchaseAdditionalProceedsEligibility",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement",
        "label": "Royalty Purchase Agreement",
        "terseLabel": "Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_RoyaltyPurchaseAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement",
        "label": "Royalty Purchase Agreement [Axis]",
        "terseLabel": "Royalty Purchase Agreement [Axis]"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_RoyaltyPurchaseAgreementBuyoutAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Buyout Amount",
        "label": "Royalty Purchase Agreement, Buyout Amount",
        "terseLabel": "Royalty Purchase Agreement, Buyout Amount"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementBuyoutAmount",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Buyout Percent, Continued Payment",
        "label": "Royalty Purchase Agreement, Buyout Percent, Continued Payment",
        "terseLabel": "Royalty Purchase Agreement, Buyout Percent, Continued Payment"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementBuyoutPercentContinuedPayment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementBuyoutPercentPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Buyout Percent, Payment",
        "label": "Royalty Purchase Agreement, Buyout Percent, Payment",
        "terseLabel": "Royalty Purchase Agreement, Buyout Percent, Payment"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementBuyoutPercentPayment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement [Domain]",
        "label": "Royalty Purchase Agreement [Domain]",
        "terseLabel": "Royalty Purchase Agreement [Domain]"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RoyaltyPurchaseAgreementEffectiveInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Effective Interest Rate",
        "label": "Royalty Purchase Agreement, Effective Interest Rate",
        "terseLabel": "Royalty Purchase Agreement, Effective Interest Rate"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementEffectiveInterestRate",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementHighSingleDigitPercentageRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, High-Single-Digit Percentage Rate",
        "label": "Royalty Purchase Agreement, High-Single-Digit Percentage Rate",
        "terseLabel": "Royalty Purchase Agreement, High-Single-Digit Percentage Rate"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementHighSingleDigitPercentageRate",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses",
        "label": "Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses",
        "terseLabel": "Royalty Purchase Agreement, Payment Percent Of Upfront Or Miestone Payments From Licenses"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementPaymentPercentOfUpfrontOrMiestonePaymentsFromLicenses",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementPaymentPercentOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Payment Percent On Net Sales",
        "label": "Royalty Purchase Agreement, Payment Percent On Net Sales",
        "terseLabel": "Royalty Purchase Agreement, Payment Percent On Net Sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementPaymentPercentOnNetSales",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit",
        "label": "Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit [Member]",
        "terseLabel": "Royalty Purchase Agreement, Royalties Paid Exceeding Mid-Nine Digit"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPaidExceedingMidNineDigitMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Royalties Paid Under Agreement",
        "label": "Royalty Purchase Agreement, Royalties Paid Under Agreement [Member]",
        "terseLabel": "Royalty Purchase Agreement, Royalties Paid Under Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPaidUnderAgreementMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RoyaltyPurchaseAgreementRoyaltyCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Royalty Cap",
        "label": "Royalty Purchase Agreement, Royalty Cap",
        "terseLabel": "Royalty Purchase Agreement, Royalty Cap"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltyCap",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Royalty Cap, Payment Maximum",
        "label": "Royalty Purchase Agreement, Royalty Cap, Payment Maximum",
        "terseLabel": "Royalty Purchase Agreement, Royalty Cap, Payment Maximum"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltyCapPaymentMaximum",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Royalty Cap, Period Of Payment",
        "label": "Royalty Purchase Agreement, Royalty Cap, Period Of Payment",
        "terseLabel": "Royalty Purchase Agreement, Royalty Cap, Period Of Payment"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adc_RoyaltyPurchaseAgreementRoyaltyRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Royalty Rate Percent",
        "label": "Royalty Purchase Agreement, Royalty Rate Percent",
        "terseLabel": "Royalty Purchase Agreement, Royalty Rate Percent"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltyRatePercent",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_RoyaltyPurchaseAgreementTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Termination Period",
        "label": "Royalty Purchase Agreement, Termination Period",
        "terseLabel": "Royalty Purchase Agreement, Termination Period"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTerminationPeriod",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adc_RoyaltyPurchaseAgreementTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement Terms",
        "label": "Royalty Purchase Agreement Terms [Axis]",
        "terseLabel": "Royalty Purchase Agreement Terms [Axis]"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTermsAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_RoyaltyPurchaseAgreementTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement Terms [Domain]",
        "label": "Royalty Purchase Agreement Terms [Domain]",
        "terseLabel": "Royalty Purchase Agreement Terms [Domain]"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTermsDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests",
        "label": "Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests",
        "negatedTerseLabel": "Royalty Purchase Agreement, Upward Adjustment Percent, Based On Performance Tests"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementUpwardAdjustmentPercentBasedOnPerformanceTests",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_SaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock",
        "label": "Sale Of Stock [Axis]",
        "terseLabel": "Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SaleOfStockAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_SaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock",
        "label": "Sale Of Stock [Domain]",
        "terseLabel": "Sale Of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Price Per Share",
        "label": "Sale Of Stock, Price Per Share",
        "terseLabel": "Sale Of Stock, Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_SecondInvestmentAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Investment Amount",
        "label": "Second Investment Amount [Member]",
        "terseLabel": "Second Investment Amount"
       }
      }
     },
     "localname": "SecondInvestmentAmountMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SeniorSecuredTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loan Facility",
        "label": "Senior Secured Term Loan Facility [Member]",
        "terseLabel": "Senior Secured Term Loan Facility"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanFacilityMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SeniorSecuredTermLoanFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loan Facility, Tranche One",
        "label": "Senior Secured Term Loan Facility, Tranche One [Member]",
        "terseLabel": "Senior Secured Term Loan Facility, Tranche One"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanFacilityTrancheOneMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SeniorSecuredTermLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loans",
        "label": "Senior Secured Term Loans [Member]",
        "terseLabel": "Senior Secured Term Loans"
       }
      }
     },
     "localname": "SeniorSecuredTermLoansMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Increase (Decrease) In Derivative",
        "label": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Increase (Decrease) In Derivative",
        "terseLabel": "Value of change in derivative"
       }
      }
     },
     "localname": "SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariableIncreaseDecreaseInDerivative",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Percent",
        "label": "Sensitivity Analysis For Probability Estimate Of Obtaining Regulatory Approval For Lonca, Reasonably Possible Change In Risk Variable, Percent",
        "terseLabel": "Increase (decrease) in estimated probability of derivative"
       }
      }
     },
     "localname": "SensitivityAnalysisForProbabilityEstimateOfObtainingRegulatoryApprovalForLoncaReasonablyPossibleChangeInRiskVariablePercent",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values",
        "label": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Decrease On Derivative Values",
        "terseLabel": "Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, decrease on derivative values"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableDecreaseOnDerivativeValues",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values",
        "label": "Sensitivity Analysis For Types Of Interest Rate Risk, Reasonably Possible Change In Risk Variable, Increase On Derivative Values",
        "terseLabel": "Sensitivity analysis for types of interest rate risk, reasonably possible change in risk variable, increase on derivative values"
       }
      }
     },
     "localname": "SensitivityAnalysisForTypesOfInterestRateRiskReasonablyPossibleChangeInRiskVariableIncreaseOnDerivativeValues",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ServicesProvidedRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Provided, Related Party Transactions",
        "label": "Services Provided, Related Party Transactions",
        "terseLabel": "Services provided to, related party transactions"
       }
      }
     },
     "localname": "ServicesProvidedRelatedPartyTransactions",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ShareBasedPaymentArrangementSharesIssuedTaxWithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Shares Issued, Tax Withheld",
        "label": "Share-Based Payment Arrangement, Shares Issued, Tax Withheld",
        "terseLabel": "Share-Based Payment Arrangement, Shares Issued, Tax Withheld"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementSharesIssuedTaxWithheld",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ShareBasedPaymentArrangementSharesTransferredToParticipants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Shares Transferred To Participants",
        "label": "Share-Based Payment Arrangement, Shares Transferred To Participants",
        "terseLabel": "Share-Based Payment Arrangement, Shares Transferred To Participants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementSharesTransferredToParticipants",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adc_ShareBasedPaymentArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangements [Abstract]",
        "label": "Share-based Payment Arrangements [Abstract]",
        "terseLabel": "Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementsAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "stringItemType"
    },
    "adc_ShareIssueRelatedCostThroughFollowOnOffering": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 7.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "localname": "ShareIssueRelatedCostThroughFollowOnOffering",
     "nsuri": "http://adctherapeutics.com/20220930",
     "xbrltype": "monetaryItemType"
    },
    "adc_ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option",
        "label": "Share Issue Related Cost Through Initial Public Offering And Over-Allotment Option",
        "terseLabel": "Exercise of options and vestings of RSUs"
       }
      }
     },
     "localname": "ShareIssueRelatedCostThroughInitialPublicOfferingAndOverAllotmentOption",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results",
        "label": "Share Of Profit (Loss) Of Joint Ventures Accounted For Using Equity Method, Proportionate Share Of Results",
        "terseLabel": "Share of results in joint venture"
       }
      }
     },
     "localname": "ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethodProportionateShareOfResults",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_SharePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price",
        "label": "Share Price [Member]",
        "terseLabel": "Share Price (in USD per share)"
       }
      }
     },
     "localname": "SharePriceMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SharePurchasePlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Plan 2016",
        "label": "Share Purchase Plan 2016 [Member]",
        "terseLabel": "Share Purchase Plan 2016 [Member]"
       }
      }
     },
     "localname": "SharePurchasePlan2016Member",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ShareSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Subscription Agreement",
        "label": "Share Subscription Agreement [Member]",
        "terseLabel": "Share Subscription Agreement"
       }
      }
     },
     "localname": "ShareSubscriptionAgreementMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ShortTermBorrowings": {
     "auth_ref": [],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Borrowings",
        "label": "Short-Term Borrowings",
        "terseLabel": "Senior secured term loans, short-term"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_SpecialRetentionAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Retention Award",
        "label": "Special Retention Award [Member]",
        "terseLabel": "Special Retention Award"
       }
      }
     },
     "localname": "SpecialRetentionAwardMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SuccessfulCompletionOfInVivoEfficacyStudiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Successful Completion Of In-Vivo Efficacy Studies",
        "label": "Successful Completion Of In-Vivo Efficacy Studies [Member]",
        "terseLabel": "Successful Completion Of In-Vivo Efficacy Studies"
       }
      }
     },
     "localname": "SuccessfulCompletionOfInVivoEfficacyStudiesMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Cash Flow Information",
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Non-Cash Investing Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_SuppliesProvidedRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplies Provided, Related Party Transactions",
        "label": "Supplies Provided, Related Party Transactions",
        "terseLabel": "Supplies Provided, Related Party Transactions"
       }
      }
     },
     "localname": "SuppliesProvidedRelatedPartyTransactions",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_TaxEffectOfResearchAndDevelopmentTaxCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Effect Of Research And Development Tax Credits",
        "label": "Tax Effect Of Research And Development Tax Credits",
        "terseLabel": "Tax Effect Of Research And Development Tax Credits"
       }
      }
     },
     "localname": "TaxEffectOfResearchAndDevelopmentTaxCredits",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_ThirdInvestmentAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Investment Amount",
        "label": "Third Investment Amount [Member]",
        "terseLabel": "Third Investment Amount"
       }
      }
     },
     "localname": "ThirdInvestmentAmountMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_TradeAndOtherCurrentReceivablesSalesAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and other current receivables, Sales Adjustment",
        "label": "Trade and other current receivables, Sales Adjustment",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivablesSalesAdjustment",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_TrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Four",
        "label": "Tranche Four [Member]",
        "terseLabel": "Tranche Four"
       }
      }
     },
     "localname": "TrancheFourMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche One",
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Three",
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche Two",
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_TransfersIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfers, Intangible Assets Other Than Goodwill",
        "label": "Transfers, Intangible Assets Other Than Goodwill",
        "terseLabel": "Transfers"
       }
      }
     },
     "localname": "TransfersIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_VestingPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period",
        "label": "Vesting Period [Axis]",
        "terseLabel": "Vesting Period [Axis]"
       }
      }
     },
     "localname": "VestingPeriodAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_VestingPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period",
        "label": "Vesting Period [Member]",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "VestingPeriodMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_VestingRequirementsForShareBasedPaymentArrangementVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPercentage",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adc_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adc_WarrantObligationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Obligation, Fair Value",
        "label": "Warrant Obligation, Fair Value",
        "terseLabel": "Warrant Obligation, Fair Value"
       }
      }
     },
     "localname": "WarrantObligationFairValue",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_WarrantObligationsTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Obligations, Transaction Costs",
        "label": "Warrant Obligations, Transaction Costs",
        "terseLabel": "Warrant Obligations, Transaction Costs"
       }
      }
     },
     "localname": "WarrantObligationsTransactionCosts",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adc_WarrantsSharesConvertedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Shares Converted, Exercise Price",
        "label": "Warrants, Shares Converted, Exercise Price",
        "terseLabel": "Warrants, Shares Converted, Exercise Price"
       }
      }
     },
     "localname": "WarrantsSharesConvertedExercisePrice",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WarrantsTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Tranche",
        "label": "Warrants, Tranche [Axis]",
        "terseLabel": "Warrants, Tranche [Axis]"
       }
      }
     },
     "localname": "WarrantsTrancheAxis",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/EquityDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adc_WarrantsTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Tranche [Domain]",
        "label": "Warrants, Tranche [Domain]",
        "terseLabel": "Warrants, Tranche [Domain]"
       }
      }
     },
     "localname": "WarrantsTrancheDomain",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/EquityDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_WarrantsTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Tranche One",
        "label": "Warrants, Tranche One [Member]",
        "terseLabel": "Warrants, Tranche One"
       }
      }
     },
     "localname": "WarrantsTrancheOneMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_WarrantsTrancheOnePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Tranche One, Price One",
        "label": "Warrants, Tranche One, Price One [Member]",
        "terseLabel": "Warrants, Tranche One, Price One"
       }
      }
     },
     "localname": "WarrantsTrancheOnePriceOneMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_WarrantsTrancheOnePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Tranche One, Price Two",
        "label": "Warrants, Tranche One, Price Two [Member]",
        "terseLabel": "Warrants, Tranche One, Price Two"
       }
      }
     },
     "localname": "WarrantsTrancheOnePriceTwoMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_WarrantsTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Tranche Two",
        "label": "Warrants, Tranche Two [Member]",
        "terseLabel": "Warrants, Tranche Two"
       }
      }
     },
     "localname": "WarrantsTrancheTwoMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement",
        "label": "Weighted Average Exercise Price Of Share Options Vested And Exercisable In Share-Based Payment Arrangement",
        "terseLabel": "Weighted average strike price, vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsVestedAndExercisableInShareBasedPaymentArrangement",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted",
        "label": "Weighted Average Fair Value At Measurement Date Per Share, Share Options Granted",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageFairValueAtMeasurementDatePerShareShareOptionsGranted",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited",
        "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Forfeited",
        "terseLabel": "Weighted average grant date fair value, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementForfeited",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted",
        "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Granted",
        "terseLabel": "Weighted average grant date fair value, granted (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementGranted",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding",
        "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Outstanding",
        "periodEndLabel": "Weighted average grant date fair value, ending balance (in USD per share)",
        "periodStartLabel": "Weighted average grant date fair value, beginning balance (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementOutstanding",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested",
        "label": "Weighted Average Grant Date Fair Value Of Other Equity Instruments In Share-based Payment Arrangement, Vested",
        "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueOfOtherEquityInstrumentsInShareBasedPaymentArrangementVested",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adc_WeightedAverageRemainingContractualLifeOfGrantedShareOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Life Of Granted Share Options",
        "label": "Weighted Average Remaining Contractual Life Of Granted Share Options",
        "terseLabel": "Weighted average remaining contractual life of granted share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfGrantedShareOptions",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adc_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Life Of Outstanding Share Options",
        "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options",
        "terseLabel": "Weighted average remaining life, vested and exercisable"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adc_WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea)",
        "label": "Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea) [Member]",
        "terseLabel": "Worldwide (Excluding, China, Hong Kong, Macau, Taiwan, Singapore And South Korea)"
       }
      }
     },
     "localname": "WorldwideExcludingChinaHongKongMacauTaiwanSingaporeAndSouthKoreaMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_WorldwideMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide",
        "label": "Worldwide [Member]",
        "terseLabel": "Worldwide"
       }
      }
     },
     "localname": "WorldwideMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ZYNLONTAForRDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYNLONTA For R&amp;D",
        "label": "ZYNLONTA For R&amp;D [Member]",
        "terseLabel": "ZYNLONTA For R&amp;D"
       }
      }
     },
     "localname": "ZYNLONTAForRDMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adc_ZYNLONTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYNLONTA",
        "label": "ZYNLONTA [Member]",
        "terseLabel": "ZYNLONTA"
       }
      }
     },
     "localname": "ZYNLONTAMember",
     "nsuri": "http://adctherapeutics.com/20220930",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails",
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://adctherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "auth_ref": [
      "r56",
      "r59",
      "r92",
      "r103",
      "r106"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated depreciation and amortisation [member]",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails",
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for amortisation expense",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AdjustmentsForAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Decrease (increase) in other current assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other current assets",
        "terseLabel": "Decrease (increase) in other current assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "terseLabel": "Decrease (increase) in accounts receivable, net"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Financial expense"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedTerseLabel": "Financial income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for gains (losses) on change in fair value of derivatives",
        "negatedTerseLabel": "Convertible loans, derivatives, decrease in fair value"
       }
      }
     },
     "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories",
        "terseLabel": "Gain from reversal of inventory impairment charges"
       }
      }
     },
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/InventoriesNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Increase in income taxes"
       }
      }
     },
     "localname": "AdjustmentsForIncomeTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other liabilities",
        "terseLabel": "Increase in other liabilities and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "(Decrease) increase in accounts payable"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments for non-monetary items:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r116",
      "r125"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Exchange differences"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "negatedTerseLabel": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortisation, intangible assets other than goodwill"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails",
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AmountsReceivableRelatedPartyTransactions": {
     "auth_ref": [
      "r72",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts receivable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amounts receivable, related party transactions",
        "terseLabel": "Amounts receivable, related party transactions"
       }
      }
     },
     "localname": "AmountsReceivableRelatedPartyTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r22",
      "r147",
      "r148",
      "r150",
      "r203",
      "r205"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      },
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Average foreign exchange rate"
       }
      }
     },
     "localname": "AverageForeignExchangeRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Net loss per share, basic (in USD per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/LosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_Borrowings": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "Borrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]",
        "terseLabel": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]",
        "terseLabel": "Borrowings by name"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Borrowings, interest rate"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings [member]",
        "terseLabel": "Properties (Offices)"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r92",
      "r96",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r184",
      "r191",
      "r192",
      "r220",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CarryingAmountMember": {
     "auth_ref": [
      "r58",
      "r96",
      "r102",
      "r104",
      "r105",
      "r184",
      "r191",
      "r192",
      "r220",
      "r221"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "CarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r19",
      "r123",
      "r142"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      },
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r107",
      "r124"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r107",
      "r124"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r124"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "auth_ref": [
      "r118",
      "r125"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "auth_ref": [
      "r118",
      "r125"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operations before changes in working capital",
        "totalLabel": "Operating loss before working capital changes"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashOutflowForLeases": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash outflow for leases",
        "negatedTerseLabel": "Cash outflow (including interest)"
       }
      }
     },
     "localname": "CashOutflowForLeases",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]",
        "terseLabel": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r87",
      "r90",
      "r152",
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]",
        "terseLabel": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r87",
      "r152",
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]",
        "terseLabel": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]",
        "terseLabel": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails",
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]",
        "terseLabel": "Classes of liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      },
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Closing foreign exchange rate"
       }
      }
     },
     "localname": "ClosingForeignExchangeRate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationScheduleofForeigncurrencyexchangerateDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, before tax [abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "terseLabel": "Items that may be reclassified to profit and loss"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r37",
      "r128",
      "r130",
      "r135",
      "r140"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive loss for the period",
        "totalLabel": "Total comprehensive loss for the period"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income attributable to [abstract]",
        "terseLabel": "Total comprehensive loss attributable to:"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "auth_ref": [
      "r4",
      "r39"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income, attributable to owners of parent",
        "totalLabel": "Owners of the parent"
       }
      }
     },
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerSoftwareMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer software [member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contingent liabilities incurred in relation to interests in joint ventures. [Refer: Contingent liabilities [member]; Joint ventures [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities incurred in relation to interests in joint ventures",
        "terseLabel": "Deferred gain of joint venture"
       }
      }
     },
     "localname": "ContingentLiabilitiesIncurredByVenturerInRelationToInterestsInJointVentures",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r2",
      "r46"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 4.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "negatedTerseLabel": "Cost of product sales",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CreditDerivativeFairValue": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The fair value of a credit derivative. [Refer: At fair value [member]; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit derivative, fair value",
        "terseLabel": "Credit derivative, fair value"
       }
      }
     },
     "localname": "CreditDerivativeFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current accrued expenses and other current liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r23",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current borrowings and current portion of non-current borrowings",
        "terseLabel": "Convertible loans, short-term"
       }
      }
     },
     "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities, short-term"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r25",
      "r135",
      "r138"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepayments and other current assets",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Current income tax payable"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "negatedLabel": "Depreciation charge",
        "terseLabel": "Depreciation, right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DerivativesMember": {
     "auth_ref": [
      "r153",
      "r155",
      "r197",
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Derivatives [member]",
        "terseLabel": "Derivatives",
        "verboseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r207",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Functional and reporting currency"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r207",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "auth_ref": [
      "r207",
      "r217"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for recognition of revenue [text block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of initial application of standards or interpretations [text block]",
        "terseLabel": "New and amended IFRS standards"
       }
      }
     },
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Option life, share options granted",
        "terseLabel": "Award life"
       }
      }
     },
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/LosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [line items]",
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]"
       }
      }
     },
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": {
     "auth_ref": [
      "r3",
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [table]",
        "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]"
       }
      }
     },
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Basisofpreparation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Cashandcashequivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Disclosure of classes of share capital [line items]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]",
        "terseLabel": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDebtSecuritiesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of debt instruments [text block]",
        "terseLabel": "Convertible loans"
       }
      }
     },
     "localname": "DisclosureOfDebtSecuritiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Convertibleloans",
      "http://adctherapeutics.com/role/Seniorsecuredtermloanfacilityandwarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Schedule of borrowings"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansTables",
      "http://adctherapeutics.com/role/Deferredroyaltyobligation",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]",
        "terseLabel": "Disclosure of detailed information about borrowings [line items]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]",
        "terseLabel": "Disclosure of detailed information about borrowings [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r188",
      "r193",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "terseLabel": "Schedule of Derivative Option and Convertible Loan"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]",
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Losspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Events after the reporting date"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Eventsafterthereportingdate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Operatingexpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "auth_ref": [
      "r188",
      "r193",
      "r198"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Financial risk management"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Financialriskmanagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "Corporate information"
       }
      }
     },
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Corporateinformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Schedule of Fair Value Assumption For Options Granted"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of intangible assets [text block]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Intangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails",
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]",
        "terseLabel": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInterestsInJointArrangementsExplanatory": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of interests in joint arrangements. A joint arrangement is an arrangement of which two or more parties have joint control."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interests in joint arrangements [text block]",
        "terseLabel": "Schedule of movement in interest in joint venture"
       }
      }
     },
     "localname": "DisclosureOfInterestsInJointArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of interests in subsidiaries [text block]",
        "terseLabel": "Schedule of consolidated entities"
       }
      }
     },
     "localname": "DisclosureOfInterestsInSubsidiariesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Disclosure of inventories [text block]"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfJointVenturesExplanatory": {
     "auth_ref": [
      "r78",
      "r79",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of joint ventures. [Refer: Joint ventures [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of joint ventures [text block]",
        "terseLabel": "Interest in joint venture"
       }
      }
     },
     "localname": "DisclosureOfJointVenturesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Interestinjointventure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfJointVenturesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of joint ventures [line items]",
        "terseLabel": "Disclosure of joint ventures [line items]"
       }
      }
     },
     "localname": "DisclosureOfJointVenturesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails",
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfJointVenturesTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to joint ventures."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of joint ventures [table]",
        "terseLabel": "Disclosure of joint ventures [table]"
       }
      }
     },
     "localname": "DisclosureOfJointVenturesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails",
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r167",
      "r168"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Schedule of Other Equity Instruments Outstanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of Shares Outstanding"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Segment information"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Segmentinformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [text block]",
        "terseLabel": "Schedule of quantitative information about right-of-use assets"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]",
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetDepreciationDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]",
        "terseLabel": "Disclosure of reconciliation of changes in intangible assets and goodwill [text block]"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of the summarised financial information of a joint venture accounted for using the equity method to the carrying amount of the reporting entity's interest in the joint venture. [Refer: Carrying amount [member]; Joint ventures [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of summarised financial information of joint venture accounted for using equity method to carrying amount of interest in joint venture [text block]",
        "terseLabel": "Summary of financial information in join venture"
       }
      }
     },
     "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfJointVentureAccountedForUsingEquityMethodToCarryingAmountOfInterestInJointVentureExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Relatedparties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReservesWithinEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [line items]",
        "terseLabel": "Disclosure of reserves within equity [line items]"
       }
      }
     },
     "localname": "DisclosureOfReservesWithinEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfReservesWithinEquityTable": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to reserves within equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [table]",
        "terseLabel": "Disclosure of reserves within equity [table]"
       }
      }
     },
     "localname": "DisclosureOfReservesWithinEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue [text block]",
        "verboseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "DisclosureOfRevenueExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Productrevenuesnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Sharebasedcompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]",
        "terseLabel": "Disclosure of subsidiaries [line items]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r145"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]",
        "terseLabel": "Disclosure of subsidiaries [table]"
       }
      }
     },
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Entity's own equity instruments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]",
        "terseLabel": "Schedule of valuation inputs"
       }
      }
     },
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/DeerfieldWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]",
        "terseLabel": "Schedule of key inputs used for valuation"
       }
      }
     },
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansTables",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Significant accounting policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/Significantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [text block]",
        "terseLabel": "Key Management Compensation"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]",
        "terseLabel": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Schedule of loss per share and potentially dilutive securities"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [line items]",
        "terseLabel": "Earnings per share [line items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [table]",
        "terseLabel": "Earnings per share [table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareScheduleofPotentiallyDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Exchange losses on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForJointVenturesMember": {
     "auth_ref": [
      "r78",
      "r79",
      "r146",
      "r216",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Joint ventures' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for joint ventures [member]",
        "terseLabel": "Entity's total for joint ventures [member]"
       }
      }
     },
     "localname": "EntitysTotalForJointVenturesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails",
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]",
        "terseLabel": "Entity's total for related parties"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r22",
      "r29",
      "r127",
      "r129",
      "r147",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total equity attributable to owners of the parent"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity attributable to owners of the parent"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise price, share options granted",
        "terseLabel": "Strike price (in USD per share)"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendShareOptionsGranted": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected dividend, share options granted",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ExpectedDividendShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Expense recognized"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 3.0,
       "parentTag": "adc_OtherNonOperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedTerseLabel": "Financial expense"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 2.0,
       "parentTag": "adc_OtherNonOperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Financial income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinishedGoods": {
     "auth_ref": [
      "r28",
      "r63"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Current finished goods"
       }
      }
     },
     "localname": "FinishedGoods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income",
        "negatedTerseLabel": "Remeasurement of defined benefit pension liability"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in fair value of derivatives",
        "negatedTerseLabel": "Gains (losses) on change in fair value of derivatives",
        "terseLabel": "Gains (losses) on change in fair value of derivatives"
       }
      }
     },
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansChangeinFairValueDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r13",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "terseLabel": "Foreign exchange gain (loss)"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsOnChangeInFairValueOfDerivatives": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains on change in fair value of derivatives",
        "terseLabel": "Gains on change in fair value of derivatives"
       }
      }
     },
     "localname": "GainsOnChangeInFairValueOfDerivatives",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 1.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedTerseLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r56",
      "r92",
      "r103",
      "r106",
      "r184",
      "r192",
      "r194",
      "r195",
      "r220",
      "r222"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "terseLabel": "Impairment loss recognised in profit or loss, property, plant and equipment"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/OperatingexpenseNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss",
        "terseLabel": "Impairments of Assets"
       }
      }
     },
     "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r41",
      "r50",
      "r51",
      "r52",
      "r77",
      "r143",
      "r202"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedTerseLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r108",
      "r122"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedTerseLabel": "Taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCreditDerivativeFairValue": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value of a credit derivative. [Refer: Credit derivative, fair value]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in credit derivative, fair value",
        "terseLabel": "Increase (decrease) in credit derivative, fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInCreditDerivativeFairValue",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in deferred tax liability (asset)",
        "negatedTerseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 10.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 9.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transactions with owners, equity",
        "totalLabel": "Total transactions with owners"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 11.0,
       "parentTag": "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Issuance of shares to be held as treasury shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r16",
      "r96"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      },
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r88",
      "r97",
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill [member]",
        "terseLabel": "Intangible assets other than goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails",
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on borrowings",
        "terseLabel": "Interest expense on borrowings"
       }
      }
     },
     "localname": "InterestExpenseOnBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense on lease obligations",
        "verboseLabel": "Interest"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestRateRiskMember": {
     "auth_ref": [
      "r201",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate risk [member]",
        "terseLabel": "Interest rate risk"
       }
      }
     },
     "localname": "InterestRateRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestRateTypesMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate types [member]",
        "terseLabel": "Interest rate types [member]"
       }
      }
     },
     "localname": "InterestRateTypesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r17",
      "r24",
      "r62"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoriesTotal": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoriesTotal",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentsInJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments in joint ventures accounted for using the equity method. [Refer: Joint ventures [member]; Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments in joint ventures accounted for using equity method",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Interest in joint venture"
       }
      }
     },
     "localname": "InvestmentsInJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_JointVenturesAxis": {
     "auth_ref": [
      "r78",
      "r79",
      "r146",
      "r216",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Joint ventures [axis]",
        "terseLabel": "Joint ventures [axis]"
       }
      }
     },
     "localname": "JointVenturesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureNarrativeDetails",
      "http://adctherapeutics.com/role/InterestinjointventureScheduleofmovementininterestinjointventureDetails",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Key management compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationOtherLongtermBenefits": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of other long-term employee benefits. [Refer: Other long-term employee benefits; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, other long-term employee benefits",
        "terseLabel": "Other compensation"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationOtherLongtermBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, post-employment benefits",
        "terseLabel": "Pension costs"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Salaries and other short-term employee costs"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesScheduleofKeyManagementCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r22",
      "r147",
      "r148",
      "r150",
      "r203",
      "r206"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      },
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_NetAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities [member]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansInterestExpenseDetails",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsScheduleoftheFirstandSecondTrancheDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LicencesMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Licences [member]",
        "terseLabel": "Licences [member]"
       }
      }
     },
     "localname": "LicencesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsRollforwardofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LoansReceived": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      },
      "en-us": {
       "role": {
        "label": "Loans received",
        "terseLabel": "Loans received"
       }
      }
     },
     "localname": "LoansReceived",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LongtermBorrowings": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current portion of non-current borrowings",
        "terseLabel": "Convertible loans, long-term"
       }
      }
     },
     "localname": "LongtermBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetAssetsLiabilities": {
     "auth_ref": [
      "r11",
      "r131"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets (liabilities)",
        "totalLabel": "Net assets"
       }
      }
     },
     "localname": "NetAssetsLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]",
        "terseLabel": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/EventsafterthereportingdateDetails",
      "http://adctherapeutics.com/role/ProductrevenuesnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r23",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current derivative financial liabilities",
        "terseLabel": "Convertible loans, derivatives"
       }
      }
     },
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities, long-term"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r25",
      "r135",
      "r139"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentRecognisedLiabilitiesDefinedBenefitPlan": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current net defined benefit liability. [Refer: Net defined benefit liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current net defined benefit liability",
        "terseLabel": "Defined benefit pension liabilities"
       }
      }
     },
     "localname": "NoncurrentRecognisedLiabilitiesDefinedBenefitPlan",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentWarrantLiability": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current warrant liabilities. [Refer: Warrant liability]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current warrant liability",
        "terseLabel": "Warrant obligations"
       }
      }
     },
     "localname": "NoncurrentWarrantLiability",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r170",
      "r183"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "terseLabel": "Number of instruments granted in share-based payment arrangement"
       }
      }
     },
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r179",
      "r182"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of awards, granted (in shares)"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedLabel": "Number of awards, vested (in shares)",
        "terseLabel": "Shares vested (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Number of awards, forfeited (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of awards, end of period (in shares)",
        "periodStartLabel": "Number of awards, beginning of period (in shares)"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r171",
      "r176",
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Number of awards, At end of the year (in shares)",
        "periodStartLabel": "Number of awards, At beginning of the year (in shares)",
        "terseLabel": "Number of share options outstanding in share-based payment arrangement (in shares)"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedTerseLabel": "Number of awards, Exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "negatedTerseLabel": "Number of awards, Expired (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedTerseLabel": "Number of awards, Forfeited (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of awards, Granted (in shares)"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number of shares authorised (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesAuthorised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedTotalLabel": "Total operating expense",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r6",
      "r36",
      "r44",
      "r141"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "totalLabel": "Other comprehensive (loss) income for the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r26",
      "r44"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      },
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Currency translation differences",
        "verboseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "auth_ref": [
      "r26",
      "r44",
      "r60"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Remeasurement of defined benefit pension liability"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r47"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Total items that may be reclassified to profit and loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r47"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax",
        "terseLabel": "Total items that will not be reclassified to profit and loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Other reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r9",
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "terseLabel": "Other Reserves"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Principal portion of lease obligation payments"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Proceeds from convertible loans, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromCurrentBorrowings": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from current borrowings",
        "terseLabel": "Proceeds from senior secured term loans, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromCurrentBorrowings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from equity issuance, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/CorporateinformationDetails",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r35",
      "r114",
      "r128",
      "r130",
      "r135",
      "r203",
      "r204",
      "r208",
      "r215"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0
      },
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      },
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Loss for the period"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofComprehensiveLoss",
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/InterestinjointventureSummaryoffinancialinformationinjointventureDetails",
      "http://adctherapeutics.com/role/LosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to [abstract]",
        "terseLabel": "Net loss attributable to:"
       }
      }
     },
     "localname": "ProfitLossAttributableToAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss), attributable to owners of parent",
        "terseLabel": "Owners of the parent"
       }
      }
     },
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r185",
      "r203",
      "r204"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r43",
      "r81"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r58"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Payment for purchase of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Payment for purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r178",
      "r198",
      "r209"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]",
        "terseLabel": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r178",
      "r198",
      "r209"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RawMaterials": {
     "auth_ref": [
      "r28",
      "r63"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current raw materials",
        "terseLabel": "Current raw materials"
       }
      }
     },
     "localname": "RawMaterials",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RelatedPartiesMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Related parties [member]",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "RelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/RelatedpartiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 2.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedTerseLabel": "Research and development expenses",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation",
        "terseLabel": "Cumulative translation adjustments"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "auth_ref": [
      "r10",
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Cumulative Translation Adjustments"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r29",
      "r47"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated losses"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r9",
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Losses"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r86",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of impairment loss recognised in profit or loss",
        "terseLabel": "Reversal of impairment loss recognised in profit or loss"
       }
      }
     },
     "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "periodEndLabel": "Right-of-use asset, ending balance",
        "periodStartLabel": "Right-of-use asset, beginning balance",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet",
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Sale or issue of treasury shares"
       }
      }
     },
     "localname": "SaleOrIssueOfTreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/BasisofpreparationAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations": {
       "order": 3.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedTerseLabel": "Selling and marketing expenses",
        "terseLabel": "Sales and marketing expense"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/OperatingexpenseScheduleofExpensesbyNatureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of joint ventures accounted for using the equity method. [Refer: Investments accounted for using equity method; Joint ventures [member]; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of joint ventures accounted for using equity method",
        "negatedTerseLabel": "Share of results in joint venture",
        "terseLabel": "Share of results with joint venture"
       }
      }
     },
     "localname": "ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofCashFlows",
      "http://adctherapeutics.com/role/NonoperatingincomeScheduleofOtherIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share premium"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Share Premium"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity",
      "http://adctherapeutics.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]",
        "terseLabel": "Share-based payment arrangements"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares reserved for issue under options and contracts for sale of shares",
        "terseLabel": "Number of shares reserved for issue under options and contracts for sale of shares"
       }
      }
     },
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Significant unobservable input, liabilities",
        "terseLabel": "Key inputs for valuations"
       }
      }
     },
     "localname": "SignificantUnobservableInputLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of IFRS compliance [text block]",
        "terseLabel": "Statement of Compliance"
       }
      }
     },
     "localname": "StatementOfIFRSCompliance",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r178",
      "r198",
      "r209"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r18",
      "r27"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r29",
      "r80"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedTerseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares [member]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofChangesinEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of interest rates [axis]",
        "terseLabel": "Types of interest rates [axis]"
       }
      }
     },
     "localname": "TypesOfInterestRatesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r186",
      "r189",
      "r190",
      "r210",
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]",
        "terseLabel": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r186",
      "r189",
      "r190",
      "r210",
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]",
        "terseLabel": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/FinancialriskmanagementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]",
        "terseLabel": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofOtherEquityInstrumentsOutstandingDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofSharebasedCompensationReserveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnobservableInputsAxis": {
     "auth_ref": [
      "r149",
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]",
        "terseLabel": "Unobservable inputs [axis]"
       }
      }
     },
     "localname": "UnobservableInputsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_UnobservableInputsMember": {
     "auth_ref": [
      "r149",
      "r151"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]",
        "terseLabel": "Unobservable inputs"
       }
      }
     },
     "localname": "UnobservableInputsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Useful life measured as period of time, intangible assets other than goodwill",
        "terseLabel": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_VehiclesMember": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Vehicles [member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LeasesRightofUseAssetsandAccumulatedDepreciationDetails",
      "http://adctherapeutics.com/role/LeasesScheduleofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Average strike price in USD per share, Exercised (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement",
        "terseLabel": "Average strike price in USD per share, Expired (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement",
        "terseLabel": "Average strike price in USD per share, Forfeited (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "terseLabel": "Fair value grant date (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r171",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Average strike price in USD per share, At end of the year (in USD per share)",
        "periodStartLabel": "Average strike price in USD per share, At beginning of the year (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of outstanding share options",
        "terseLabel": "Weighted average remaining contractual life of outstanding share options"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationScheduleofNumberofAwardsOutstandingandWeightedAverageStrikePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "terseLabel": "Weighted average share price (in USD per share)"
       }
      }
     },
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of ordinary shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/LosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_WorkInProgress": {
     "auth_ref": [
      "r28",
      "r63"
     ],
     "calculation": {
      "http://adctherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current work in progress",
        "terseLabel": "Current work in progress"
       }
      }
     },
     "localname": "WorkInProgress",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WrittenPutOptionsMember": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for derivative financial contracts sold that oblige the entity to purchase an underlying asset at a specified strike price if the other party exercises the option. [Refer: Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Written put options [member]",
        "terseLabel": "Written put options (in USD per share)"
       }
      }
     },
     "localname": "WrittenPutOptionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansValuationofDerivativeDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsValuationofDerivativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedIncomeStatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]",
        "terseLabel": "Condensed Income Statement [Table]"
       }
      }
     },
     "localname": "CondensedIncomeStatementTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statements, Captions [Line Items]",
        "terseLabel": "Condensed Income Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails",
      "http://adctherapeutics.com/role/SharebasedcompensationexpenseScheduleofFairValueAssumptionsForOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/CondensedConsolidatedInterimStatementofOperations",
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/ConvertibleloansNarrativeDetails",
      "http://adctherapeutics.com/role/DeerfieldWarrantsScheduleofValuationInputsDetails",
      "http://adctherapeutics.com/role/SeniorsecuredtermloanfacilityandwarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://adctherapeutics.com/role/DeferredroyaltyobligationDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI",
   "URIDate": "2022-03-24"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r111": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r112": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r113": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r114": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r115": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r116": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r117": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r118": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r120": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r121": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r122": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2022-03-24"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r129": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r130": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r131": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24"
  },
  "r132": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "2",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r133": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "2",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "23",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_23_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r136": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r137": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r138": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r139": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r140": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r141": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B14",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r145": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B4",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r150": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r151": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r152": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r158": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r159": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r160": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r163": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r166": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r167": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g51-60__IFRS16_g51-60_TI",
   "URIDate": "2022-03-24"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS16_g47-50__IFRS16_g47-50_TI",
   "URIDate": "2022-03-24"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r170": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r171": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r172": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r173": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r174": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r175": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r176": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r178": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r180": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r185": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r186": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r187": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24G",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_24G_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r188": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r189": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r190": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r191": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r196": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r197": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B33&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI",
   "URIDate": "2022-03-24"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r206": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r208": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r209": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r210": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r211": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r212": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r213": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r214": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r215": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39J",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b",
   "URIDate": "2022-03-24"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24"
  },
  "r222": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24"
  },
  "r223": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r3": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r30": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r31": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r35": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r36": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r37": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r38": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r39": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r4": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r41": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r42": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r43": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r44": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r49": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r51": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r52": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r53": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r57": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r59": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r6": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r60": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r61": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r62": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2022-03-24"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r67": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r69": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r7": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r70": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r71": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r74": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r75": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r76": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24"
  },
  "r77": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r78": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r80": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r84": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r85": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI",
   "URIDate": "2022-03-24"
  },
  "r86": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r87": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "129",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_129_b&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r90": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r93": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r94": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r95": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2022-03-24"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2022-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001628280-22-028752-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-028752-xbrl.zip
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MP&;C72[4I 4T]QQBY^[Z/)#9F7C='C"C766+4<'N/2 $]&FD!+@(9MP1>![
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MQ<<_KN:(HF3/+H]J#LR0DM1,'01KTMC9!N;,4+2Q^'"]D+F.R5(2N)0H2F#
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M:PU.VBR3DX_1QP$2L5K8ZWHL*4F!J X94%T)39PQL4XC@^\(^I^<PLM*ZB6
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MZ#+2? Y06ZJM4N":"EA<:O9C$IPZ2(2W-RB^UJ<+.=7;7@W8%J7826\MQIC
M@T,FC&UH>_62O**;U/3&T5Y->$HF$[1,+0NX $9!:J9I8PR:G$-[.BTF'B0O
MIF#E]D_$+@#=^T;% R0+B)MOS:4D4'KM95KM](Z6\&^XV>W-9T;M$!F3;^+
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MM_J A\:AF-+@"KKNM?@4(&#!8,[?Q1ZCIM'&<PJF],C/0^/G%NUG\ZX(B),
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M$91W'S9Z99=;]J 1H/3.6:H+,;6:"@6<1-/$ P7W5CJVN*1>>JS,4B#TP-(
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M+]P \9ZNRA)H<T?@USE6"EQI]]+N);CW*(&_A-0,F_Z.=)F_=X7>!:M:*?T
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MV;$=%D4[+*[2OU9B0"NHJ]L[P.-J@^O6VA6-'9A&Q9X@+L(R*D8MGRD!]F<
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M<#F]^'U%/U0$+,K96_K'E8F..%L_:?7Q+7[WM)M>O)WAU7OG2RS?/:5GL8H
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M\HFN/GG\'LMBB:_APZ0X59Q)@H4 P'04@5YYPZ073@MN<X[^!,Q>$S@NI^M
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M2*\NI*7#2C&,@6#)+1 7@O7!LD  .^"V1'::C>N)R X7GHD("A&0"=>,2F0
M>Z2D@(")C=R'M0U=-/6*PYIJIS03VL5D;CLO'"$6+!42,KCC'*(T15/?$]%3
M 1I(UE44)** )4$<!X6THQKA2+P,CD=)31-U]6I5 EU?_K37']GN@Z(P-58
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MR>&2'EGO,)*82<.E PI5 4F;B8;T5BCX;6#!:,'OG/ [&3 1F.I()4=8D7R
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MH2A1S1+5S.2R"1$&N?ART#^UW='I)0OSH>GRI8QNFA+=;+"=F3LCG4OLV['
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M@UZ:N.*.U\CRTTT7#2,RXBB1Q-XA+CP@BX-$2BAE!=:""UW5WPG9%@]*Y)1
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M^L+)_-)<);OY(V%KYQ<=7 0WCNP^(#< ^QG9F![PJ>U^M:?#M2=7YR5-ROF
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M.#<Z4X9I&W%R^V4PA+FHXBTLO]L:?%>K/F+G! +Z!H-^,?#N8.#MO)CJ+.5
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M>K0Q5FU!IOL'%IHI-+.8RDW+I F*!AR !ZR<Q,1+KH4/A!#K"\TLE&8F+)E
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M%"IZFXUD6AJ!2'!OGIV" M]F!')/4RH 0&-M^QC*=YXZ1DS(R;#$<W!B8\L
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M"GNQ5D$$GJ@M5M$BP7*HRNU7Y7GJ,$"J3:ZH=$J!4<P&)P7+EB87C,MI?K:
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M[A@59I*"%0,:DR#* 1#@'HC-09.L0W8@F(W>U41_ TMP$6&D9OOC(-L_PT=
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M'"3L*TBOT?GZQ![NQ%QG59DT&UDG!$_L.>;/BN%@8'O_Q4_6Y_'PYP&?(><
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M9@1<9H9G@Q;60-R@&#DUPJ:2LE!DBLLX3(32"=68,]&9H6(%IK!83+6_'8Z
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M44[;G"5"-(6 !&4<A=Q$-HF5(01V0!J;A9R7"!0@MX-E GP.@:)1#NCPT/R
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M4=XLU,D'Q7@TJ2-"9?%1.8L,LS-GP]JA;G2C5=IYL9=WJJ*EX_,;!2&?O'Z
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MK='Y$$N0[6\:1'VB69$GR,&/,(*PR+?K[,A]\/-\,"%CH4QB08.$FR3@BLI
MBI &EBJ2:)W&U)C[SHZL&?LQJN9[B">L5?-#LO)\+$$G.E$AH7 \#-R/2)@@
MB2P/$LFL2:T.,XXQ?I&L5?/3X>!'&$-8J^;?P\_SX00;&9Y8&04JQ&I$&LL@
M234/4J:,8)'547+OA0OK\H3KL>4[-^>U:./DCW(&Z  AU2JP>NV *AR^QM:J
M(2'K0.I3CC"4%+ U,)]+$EC'5N]-&.8+<0<1"AX;J0.C8XRMBB1(,ZD"F89)
M))DQQ&18P!#1Q5Z+ZYLWZQ3)(^;L>P@]W)JSU\Q[$^:=#S+04),8F#0P-$50
M7:X#Q:,8;!K-1&QEG/)PXTVRYMQGRKD/%5I8Z^3?RM;S 0<:1U%F0AT(F<J
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MM0EX/U&HLU0:'J>12J5E)F2QIBK)8K$.:SQ:N;I8LYA&,DH,38(L(UA>E-%
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M*2'."$/.6X]48,HY6#^%72X(O6D>GF12<+VZN'Z$--""ZR?$];2+(T;KK>(
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M:9"1,AP8R;W;!)_MR%* _R* O_S:P@7XJP?\F69,."5C*1:(&*E U\<,@0K
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M^-S6*][_.6LCSW>(;@!*5A81PU;_)$_2;;.RXKNZ.BC?@9TYJG@YWFYQ7-_
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MK$"6<U7W-V4"4UCHZ?6-5&EK%)7*$:ZPL[!]/0W"A.2-\6IZ[ZVIWGNY>ZI
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M\2JPF-OG2TTZU3]).EV'!%/RRA-,![93%57:Z8.(7:$LTX.K K\7H.G!^SL
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M!^=K%(R_,(RSZ+TQ7.;*L%0*YYRVVO"LN#*/29'SJTD ,UY&+ZW.J0^1I(B
M"BRR22L$A,U<\B#N<QW<I:1F%PIX610@04(D(P1.$G.=4[1C% F,UQ! _/-0
MQ/RSH7S:KX@-)0KL,L24 #&?:$!:QUQ$W<(">:L#U;E=S(-3LPO&7Q;&B7"4
M"A<3&._<L:!5DLJ9*$V2QB1;Q/QJ$L"TNS%)Z7"0'F%0VX  E$/&:PHL()VQ
MD28;<@46L6GX>LCYD4=R/(KQ_N85PI=],%&N4:[Q&-=X66[U^45>=[P?G@[K
MYL8[=4/@*D3^+@6#[RW1RS7*-1X,MC4,KU]B;>$UU&L7.6G71! 7B//48N[
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M]<B$F! )CA%A,#$\;FPS\@ CH@!XA0&<E)46)PP89IPX92ESU'*%J?*1*U4
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M<TWI<\/YWAO8.?D4(8#FZ%3J )P 39JX* S1$IC1GJ:8Y=IFKYOFW,HB_>=
MTB0RZ5\'1:!:$VD8K+<^?MCYY^[.WLOU1IA627Q>X8#:$3%4Y>AV<K3];>?M
M)^-2]HQQHCFS!*0NE5!1CJAC27#JE31T;7-XT$\WDJ16.%NM]8:RB*+L[#?>
MFC(9L>5E= [VT;%$5Z'UZJ#==<W;[U#]N.->/VVT[M6NF+HL@XDPO>SW77<_
M':%,/6\S0VZ__"31IF!2!A)3\@2"!.*<\<0R$&!<#CZR,2FTNR,$:,%>3AX]
M;.^44!J2\S[X%!4U@8)./,R9)7LH6DT\I^41YB=%I+ZT(]H/KM7O=3J(Z1/7
MCY<)8?N<QWF9TIPY@SD.>DT.8HYEL\19UUMXG>,42ABH<XI2^/<+8K@@RG!Y
M;./7G]I7XT#Q^2#56,!^.GN;_S.>K+.X5!-M0V.LXXX'Z<7TEU^GI2[:W<:D
M:K[TZ\6AEH#-3+"ML?K&;T]B.59M") EG#,YN3NY\232L]%$>F8BA^/WM-PP
M BY]&R?JAN\!53?ZYH\&R]F&4)>_??ZR/SG&_)A.*_^"J/F_]^^VYK(=?O!<
M5S@6_FQ/?U\:_[I1^\?:C_/V*W*Q12"_TS:<3[/.VG6:&"4OA>+HG' /(:(6
M\TY:3\$ZZ4T8=QED5VMB] 5AU!AA%XW\P<L02F)%BK_W^N\'.)>O_S-J#T^W
MT_"@%Q_%-N=-C;G)-N=OAQ\.M\7'PTYGY[!3OB.V^<?VAZ/7)Q_V MO=^O=G
MO,:W#_B]V6W.[3]VVMO?XM'N7^_Y[E_%  S?/A[]H_UA[[>#G6_OR[W1(-PY
MV-W;R=MM>EJV.+??4=@Y#">[Z$-DJK+UZ#XPR<KQ#$ELRH$(M,>+9RHAA[5-
M*/ETRVJJ_2 ]%59:[UQ2WPL-W52,7 3(J#,<W*_^J:UCJ&"0P<A,F8 8E(E)
M!9[1Q;:.@0X+O=(?)A&7B$BSJDU )+>'_^P-!C-1\!]2(7[KN%2H[*'_FB97
M^G,L'94EE\62.Z_F6#*"H3K*1*(IM0=2"L309(F4W#$%-FFAUS;5NH05Z<OZ
M'*S N?S+!S<$G^N9MU#:6QJ0,H4$7AM3DO"E->5L;@[)-2;B0H*L)N*JD=^[
M.?+3P667DB2@:&EGJRQQ#H"X;+2!H+0KVQ4"UI71C_D@W+5 O.2:#_):-1_N
M.H9PS6N<F['9<X,U1/&3R@ U1+&$$(5Q*EH9;--0#:2Q*HO,.=II+'.9\G7Z
M+%?]\[#ZYW1._XC$F:$1B%&-$O*1&$B<"!=L]M1KS5'_@%ZWU-0010U1/*,0
MA1/<:\I*BJ>!Z(U))M%@FT+F,6=^A188-43Q"%ER=SY$0;V*RDA&(IA28$4"
M\909PG2F4GN('#1:Z4B2M^FG44,4MPM1/+@A6)/V%@8PE/+6B^241ZM12:LB
M*)8C^KH425-<)VFO&I /2XWS 0SK$P#G'.?3"*1&:HEC2A/OK?,I:R<50P,2
MUBGE3R> L;J9?(N/K,O5/K'^\D?GS<9'UV/*J=]/L;7OVLU!]??OMBX_?KN@
MK,%-CD&>HR-YWHC;F@SF#QS+;O<[+?W@>.VEO*,>)^_<XGSMAY.=MY^"41"<
M!Y)5S@0X_K#<4I*CH9I[Q9S):YM<;,RW&!R+!XIAIZRYZ[<+X;=ROW>T\,!C
M$8-^VX\:"<$5:;71ETJ-?D"7:KITQ;LJW[Z8^=!/1[C$*'6C;C@HIUSC^#[3
M_(J)I$X"41NMO47W=_W^:1GA%]<9-0Y=NW'FSM_9S=RWW0W]Y :(,!PO2LSD
M#_SD..\6GV386_BTQ^==A-9@ZD.6'(I^.DC=0?M+<_G>42K7[J ',CTI>F$(
M&ZV_\-,+;W%VT?+E-!AGC5P<?_J*MFP<_/0 ZO# #6>^VDF#\??FYVV>!V(:
M!%Q;_-/YWI=T,<LEC"<-)ZJ?0F^_6_(]RM2?C3^/^B7M?_(<&ZV72)#-S'6F
MC^8:&9A\.;9ZW<[I=.*16<KB-4]P_JX'KCQB&#6#[*1]O!C.,PKA8-@?-6=E
M6SV/G-NL8K.^1RZFUK$[;0P;O$?+IP/7R9<LR\,EE/V)$]$-[4Z[&?IN?C<Z
M.BKH0ZNKW77=DF/PIGN63'31K_VA@;;7>S59ZY=-#=CO9\PO$NHS/UW^]I,I
M[:\#5X0"_@"J/+%:%^8,+AD94TKLB22QG1UR'UP\Y=X:C*6NP#%/Q0X!]SV)
MK5#\90?;&[2V!P@YE*_RQ8LL.B;PW.O@#0OSG+]L/^5."L,Q-XUK%1>V38-2
MF2!.U<?W(0V&>(\)I//E)^WQI6YO^&.>18P,SNXYRP!+.%=_[^?CF34W.1_/
M]8;E^D[.Q]_LJC\:+-,;THK',UAN[&,9+&QH*A_/8*4T-4WB%FD2]BI3,"X0
MLU*3,/9J[R%1Y$'23QZ3.+[[;C/\YE -A]1Z=Y#2<+EK<^7HSXK+[<W._OWT
MX9_1#)Z57Q!7/Z+R*$G@26RTOW*#@W%IB/)+B0Q]<9UBN#_T!OLCW3&Z]9&C
MY1UY+4M;BB#@/Z^_K^MSV!!ZC_<JW_D '_9>?_WP[>W)]M:?!SM_X#W_^K.]
MO?6&;O/7='?OP\E\;4=\KA*7.#S ^_Y^N+/U\F3GC]<4GT]^_./-R?9AV4C"
M^Q_^MBCI"677&:4SX4PY HERXDU*)$:>$\1D0V*EI-XZP&6AW=7J)%:!_PC3
M(2OP[QSX= ;XV> BQ:P(2XH1L%(3:XP@UE+!E9&XN+"V*>RZ8+<^2KA2P'\,
MG>0>I!O=2A\J6DQ6_^JG8X="5,S!7K,YU.SD-'WI2IWHASYB]+3Y?XF&WWC5
MFN4<;ZRA-FB*?$_>&9?]KIQ_'<Y?<'R<>Z=!H'7'2YJ[RZX<)$?BU\9Y(9F'
MG-<VY8(BW@]W=KRB=G6MMHK:NT#MK*4F@\25<8P876JAENK[SH @,CI#)8#G
MTJQMLEN[9RL,VL=^C><0E_O>H^,VQM?S3GAYH$3SI]!<Y5&P^X)Z&A(BE5$%
MHH4(!(!EXB2C!*B16L0DG+%KFV#6*= E^>&/-,SVM/&\S-IB%<_WA^=9:RWH
ME( Y3A*W0(!'1WRBB7!<8.:D2MZS1XSGQV!MU>C9U=AIKS<L9Z?;SK<[[6$[
MU7#9(['8_OE]R2J7+XW+Y[/E*!I?+DM%6/"<0,B>V.@#81'M-&VRDBZ61&+-
MYOL)/QWG^]D#=WFF607NW0!WU@B#B N6-"5:!TD@:4V\3)&($*C+ 5E8T[5-
MOF[X*I5)617;9U6N\1RB9COI5GN5U;V^=^,+5VSL5U<ROPLRGS^BAHYTMD)D
MXK-G! 03Q'%%B77)\T1U"I*O;2J[SNUC]*@KA._=#*L0OF,(S]IC+$B1753$
M.$0O,"&)]<&C/:95B%0;#>A(&5B72SME6@VR.S/(IE^^6<76Q_"@]1JK>8VG
MF>3V;II[7A(07UTH_5%*#BXW*?,FD>L5S-G:*ZT<6T?XN8-!*W5CF<;SB7!U
MTA8YF_C*5>?LMAL@#\T?3R4Y\;;-'):3Z?D,9OENZU$^K[FL$GO_$OL<HJ6[
MQZGOAJ763_IZC";2#;>L:^[?K8,QP",+)BI-N8!@DC.,>N:B\3)*3O.D7)G^
M04>PV:C,V>*^'J]MC<@L[5#YWLOA=IM^+5&9W2V<G:W/G[+,N"K<$#5I)2!+
MQ_1(O*5<ZR",IWEM$]:M7%90=372_RKV;XW]*(R)-#O%F0!M0HG$\L"MH4PJ
MENBDU+[^0:G]BOW[Q/[.JXO8Y];IS",G1FA-0(I$K )-E$>TAZRU-[Q@'U3-
M^:_87W8GT(K]>\7^C-Y7DE+FO">HYC.!E"6Q07F2+;7) ,\@86V3P;I@\RWL
M*OB?-?B7T&.G@O\^P;\[H_B="PE<3L1E[@D 11- :?PM6I]S<! U*GZSSOCC
M,/I_$O.8UL#%QT@_IHOZR9M^\CDD2I1#>IVK[<358]:K%%+ZWK>MZI7EZ94W
M<\&D",J UH9(GA2!@.:E56A41NJ8@\R$BJHXE )J:9$GC. [" Q5!-\-@F=#
M0IYFX$)ZXEP& IX[8C2G!+W]<NPV<\-B0;"LJ4Y/&<%W$-ZI"+XC!,_H8,U
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MLY-,VQNE!U:\+A.O,PI6@H])14$2HX: 4))XJ@RA(0<N?#8.*"I8.]]U\D$
M^ZSV'Q8[#34W\)[SB);F,]24@OMEN^TY=T(%8&A#"F+!T](4C!-G621)V<8Z
ML5:@=<*8KLE"3Q?/2W,I:E[@JN!\U@M)V5DI-2<Z94' !T2\HT!R4$:!<3')
M7!,#GP'6E^:.5-U][YB>T=U"*):SCB2JR CH&(GQAA*>P8$,TO"R0[E:NOM9
M[7'4I, 5W^,UGGHI&:@0/=@$QH/TKC"C NV#NOQ@?=WC?0 *?#OGOE"E0W36
MH*[RFI0F\\2FZ-&; 4YSS$JRN+;)UY6>KTQ[[7!-S:=Y*KBW22O!%?4LHZ"
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MD+T69.>VI(W,M&Q)&QH2 1$RL8II$EA(62BIN>%HI52\/E&\"L6$I +]_BS
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M'Y5.'CN=2!NTLCHS[2R$9)U0%.T6:GDI.$]C-5Y6@FMF#V_PR*RGV1)<O4Q
M&TUL\&C&9"\\9\(*'M<VS3KEHK)-S=W_V4[8RTD/D9JT?Z>I2<)1D"8E\ ;
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MI+T%6@[S/;$"P+?"[B.*_U:JJL6#5YJ-9CVNZ%,2408B;'($LJ+$<P@D6<N
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M<8;JLEH^P_K1!VG[?H!FP?-LKM'6Q89H;6[1]8U=%HTC. BDD\],-TPB[6Q
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MH(YQDC"5"JP!=Q+?)&3W)Y_\X)+$FRN'NTD&DZ@DR)(H$7<V)ZH4"%:(EF'
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M4^Z7%82;D-R<0:DSG/0_^F U3ZX<\DLOO7;,;S4;:W-KUSJ%N7$! =Q@Q'6
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MWDK*$89M0EQ2C#2U OED(H23.0= :O;?&CR>.%X#P2,N:BQ)XCA18RE-6KA
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MN%;K2Y-N?_\*)FF5K/\Q:<9:^\V5/?B^O]L[!W^VFP<;9&=SFZ]_6<4[F_E
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M<*/D7'K_2UJZ+I>9Q4&]>G=9O:&_U["59/9CU[:/LKWNM%,LS&G[,D7^;J=
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M)X5X"KG>C1F23!B3)?@\RW6O53V'1>#RI-B=ZE</%$\+*I.G6B$MXX8%G93
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M!BWZPX)]]\YKY%G"CUP5]_#G.4SR&:D16YU#[YO3G!+]^H-7"ID%!.61B!9
M!?XN!JW9ZP."Q$XM.TTGV%[M/%K E9%22/[.(/;:X^]?C0D T6#> ,?_S<@S
MZ-;(W\87C3[I7FG\9);FT8?-=CN&IAW$UGGMM!=]+#[?@!]*]K5JB!\XQ/4:
M.%8K]N'R\>A ;[?M><WES<1Y-.&:,![ 7[NV%TIGM8>'O7B8E5MF1G5P!(%F
M=(_LJG#]/$<M-B4WYQH!Y%7-3O;9XHY@;J<YE1A_.@I*J[7W&OMWK_63+0C*
M:V OA\V,A7$\T\E]=CK.A4+,NY%L3@S&+I2FHOUUA(8QLH4V#Z2] ["#'WGL
M:[G%Y;7=E&+AUJ?P5S?D884,^?"H9KT?MH>MXE&G]KS7!;R]VG>^6MON3E\[
M-H96MW-8F$'>C:Y&%+RE.5V^QRDDMB7>C]HY_F2^$8V@)^<HA^!RG8D;E8\N
MP@$\6XM+ZQK9^^A?D#B?Q,'HN=?[K-@MH/XUW7/PT]^;_R@-=?RBA881-/KO
MS=$G5P,#GZPNA<E-J#&-\192O&;A>-?',V>9?PP!A(FNCS+4')<+QY_Y;AX
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MTX@+_IJ)NK&Y7!G%]/M<XPD9OTP';MKOYQUAV1Q^9LL<-OM'<TE()OA'KIC
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MTFRV[EFA6(5B2XABKU(4JE!LD2@V71R*-D__B4$,?D*<IXBT2@8I0J(+GJ3
M_<H:575"9M>2*QBK8&P)8>Q5BF$5C"T4QJ:2,6H,Q":1$*-Y^UMT"5G/&2J2
M-*-HXC0!C,FZH;.[VBL8>W Q[Y^%XL%8>>&?UT1#%J7$4';)TX45WX3"13'8
M$P+=_9AEWFK_.[2]0>QEJ8M+#>XLA9-UY#JU;N_0=IH7!7[85JT7BY<8:[^-
MQ<2G-#)&$G3]86LP%C&WIZ?=9F<POG!"?N[_]FL=>+??-G<*%9[I>UT[/94>
M+ZL([4E9WKU41,]/G'A(?] ;^L&P%PN=X%8<Z:Y#^WJ%%L=IKPE//H4N[X9^
M[<C^R"I!@YJ+L9-5R6Q_D!7NH#LSP.8?B^NS>OGDS:<4?[+)YJ#0[ QM"0(3
M9C4:-":S.77[A3CF+X7T4/-'O%+N^-MUJ96Q%5Y=8AWXWG!P\R73ZBPS[,VO
M),62CRQ>ZZV)/W/SBQ@%L=/K2*PWQ''-HA,4_L.2),V5B/& $+$RONJH=T5J
M?AB1 UL^@?DRO.(OMG5FS_LK_[S>,] MHR;QK*1R1P].(L MT/%8M:=F5F0<
M_()>1*=U)K\IAF1"L^KE'W^]7\2J*+KA):6B-FT/T.:P#[E5L=OX+2E#?1NE
M3%V^W_ZKM4WAONUO8O_[%[R_L7^R=WQRL=>&YW_ZO;5_O'<.*0[;/I]2ACH^
M:N]__\8@O6KN[[9:^QM?3[;;7YL[N]O-O8NCD[WO?[6WC[?H_H9G_[F Z]</
M+%/4>6N0\3@@SH1%AL,\SAL1I/:4V"R2-X*X&-9SXND)$]%+KZDD7!*GO3)*
M<,8I8=JQ."TD]>]NUM4M^,JARV?"_+1NV"2>EF-RYP,7(;WVW&98F=XUT_MR
M(+T7E$>+G(2,F_/$D29&HJ1BLH)8YYV:,3W!.:',$I8\M]@Z:W$@/G#J&98B
MS&B8+8\.%U\5BCZ' !,XRO*H156-?;[&JD7H<+V+\Q5W**:8)[WM&Q1,*37&
M&N44:_-1&F/5N"_AN!?Z:?<<]O?E][<+J]5K\:>'GKC*2FNV5'J^E^3:35WQ
MCO25[J6>M=!^6#:P^%CV<!^=N26#B&K4*Q2H[*%2W;MU^(O:E1T,>DTW+&L)
M@VZM>]:)O4ID[S*K>MF-V'UX8?AIML+VN==-S4$>L659)7]<W6VT2LZV/^T?
M[V]\/6KL;I'MC2V\?[Q^L?/IC^9>>X]L[WZ[V#[^!NW?^MDXGUXE]WB_O7VR
M_6GS9P.^TSC^VFYL-/A>^X_F_O$WN+9!MW>_\+WCS8MYZGG61^L2T8B*)!$/
MRB+-*,E'1RQQV',JV,J:P'6)9PFA9A+LQ;C*\NVF^7B^OX#=RY7OO[3O3Q_J
M)H9K<'%P]DP: X,$OB\U8CY9[BFSCLJ5-47J@L]N]*M\_\/Z_@+V_%:^_\*^
M/[W)-S MD]46":UD7BLFR%AK$/>*V\2XHC2^]$;PRBA>V2AB%#YP3%' !@*"
M, J,@G,D3,#"4:4TI2MKA)&ZY+/RAU6(J$+$ O=35VCPTF@PE1XZ'&%^;P(B
M/EC$J9/("$-1"C%JS9C#69R$& %H,,L4\L:<_Z57Q(H-4*^Q3_-[\8\8:A::
M9@]C#=S"E=N)B\6Q?JT['/0'MI-?:VHKY ?G2"G[9[%%KCF;Q\8CM%X.T)^C
MI]X'RG %9?> LED=1$&B42HEI+5R"(;1(.L43'R5,I0QSJR&Q$;I.E.T+I^N
MV5KQ'KUIGWYB\:KRZ5?QZ>GS740GRZ-'2CN"(+/4R&#)D:$*$A.M @V98%36
M%3-UI2J??M\^_<3Z0^73K^'3,P4(9Q/3B2.6?-8W]>#.7C!D@G=8V2@HRW%:
M09SF=:;?DHI:Y=.+]^DG5A$JGWX5GYY1'((D*T6*,%%9@UP+Y(2BB%C##&3E
M@-1\%*=QG9"WQ C^OC;%S-\)]*OM-WUQ=#<T\\'44&M-'?&J^ OOLQOYMN+H
M^)C88DL+])8:Z48YEN-S:KE8>M6("M > &BS:HDX>4^MPHA!.HDX"1Y9#H F
MHN)4Q,"%U;<OG;V\/11>7EG#,UA#<I"<2LN1I5$A;B-&ECF'<!0&BRA=I&9E
M#:_*V1+YPFKF%7=1%4^>7M:JXLD+(<A4@APX_-_)B# W#.()D<AB+5&*V,MH
M /H]>50\>49[J.+)<UE#XC RQ$:DC/&(&QN0<]DD5(2A\@8G$7(\,<^X :.*
M)U4\>7I)M<*/E\"/&=57ZK*^*T6>2X@F)AAD<E)*HHK,6!EE+J&^+6NHLHOG
MLP>)4V+1F;S1DR*NB$.&*8*T,(GXP#P.?F6-K,Y9(*OB215/%AE/GEC.K^+)
MB^#'3/D^>LLP9*&,.<2IH$AC;U%2-GK.7*">/2J>/*,U5/'D^>PA!"^3"QY%
M9PG$$YZ0SO-6;P.V/":I\\$!NBK>6[WK.LGM-._=;2R2^,U2T!8[1G]_ HEK
M_G;VSGK-W;&.5,O_0=_Z8<OF3P$D\D//[MRNVNSWA_ESN//$SM7BW_&G;PU#
M'']ST*VY./X^&$\LWVOS?X?-P7EMJY//X3=_Q-KG%G0R9*JFGIEQ\U? MJ(O
MB'";G7S+DI*WV[^\]5EWV KY[A9N@8HWA#NMWH?O\"Z6NV4UF\_=0>Y/VVJ=
MU\8=DCF,A[WFH)E'X\@.8'A[)35OV:\P+LURW,=&<F4?8]N GNM#3WL[[,=;
M!B>V;QB4\IDPL*G;:G7/^K_<117]4'+)Y:$A9*M&WX\H[H'\<U*;Y2'+JQK[
M;(TU][[MG*G8V$,@CL9%'=.X<?;V[NC@7H(&\./TYD/(]=Z -7\LIJ)G9JZJ
M>GEQK'!57U9<:Q77VJ-\:R$!Y$UO0)UO*#=/SVNH5M3L:CNGQ:RP(FE[U"YZ
MCVG,XLI&6LH9U99SS^#_UAB67-+W/<%J@_]EJY/5<[)&3_][<W!T60/X?9@%
M=39&4_#-8L:^W1ULC6;]6YW?KF;W.VFJ/GM5FWW_^_!/C_:.MW)Q]6>#?CG;
MV5W'.]^_T)U/^ZV=C:-V ZYO'/]^#-\]F2G<MG]O-HZ/FHW=S8O]C771V/@B
M]C?VH W?^,ZGO3-XSGGC^_;17OO+W(V*S-DD<) HK]$B+HA$1F&)N*(L4JZ-
MB6EES=05%75L^%.WX5>4'N\.2&P4@E!-HF:18X8=Q=XH9:+FV,K@[GMLM@*2
MY0*2Z14@(4(0/"'F:$(<DX@,"PIA+Q56T24A\,J:K#,JZX(\^8Q>!23O#D@2
M48Y$B3'1CFNN'?:>*VT%9R9Y%^][5K<"DJ4"DNFM22I)""G1H\B\@CQ$)Z0]
M\3DW(4H$P)&\-4G7)60DG,RN)U= \M&!Q,=$ PLV&1FY%]19[GT@GC$O*;?R
MO@>$*R!9+B"9RDB\I4E))9' %C(2#[,:0Z1'-$3!P3H$S[*CHJZ$J5-)EQA(
MGF.58>F+1%___/:XVM!'X5'@-.9T2UH/4[5 B971&PO!-YH4I!15!>@=PN2W
M6:[_& 1QR2&-4P289 0Y'2S,WAQE,<(H";NR1NM<L3JGLY3?%;G*>P*%X#CW
MT5'  <T3YTX(KJ0E4OO(D^55->=]@L)4[A19HLZ3A(P+  HA8&2XP0AKI[ C
M%'[-(7<RO&[F;.FM(.$]08*(#B>?(HU&<*T!#$1RG!"K(\L90U67>9>0,%V7
MX53&)"Q'GF9F12H\LCH1A&E020IF5 HK:Z2N&*D+5A$KOF]02(E1!;@@18*\
MP$>8. 2EC1$NFKR(7-58WB<H3.4)7$KO",$(\H5\KMA1!#9@D*9.2>P@>U1N
M98T+@ 5)WCPD?-3--K]U.]"<?O;Z;BI.5YSVFAW?/+6MD6IR_KTOOC5HYG,.
MK2X\KM;L#+K%UW_KMJ'9Y__U?S0EZE]]^&J[#3<KD>,I&W3>/8X*[R%\$LBJ
MI>?!).VP%LPIYPP1UKW5;3BI^3,&=!%[W0I"'P2A>[,[<%)RVFF*.+/P1]06
M6>\2BCXF3(3BDMN\<1)<B_YK047J)5W3>O=H8!01CEF5</!<VJ0Y54S3J#T'
M/&#57IIW"@GGT_*K7&FI(A(P_(@K29%-7,"D*]F8& _6 B3P.B>TKOF3IUH5
M*+QM4/#>*<^HD%)P+YUU-$H?HF,X4(S3&ZV_5"G"H_%@NO2"$PLZ<(M\S.P*
M.3O0#O" 4L\UM1J+Z*L4X6.@@2544A[ SZW@V$5G#7<,,$)KR!"(J HO[Q,2
MI@EXH@Q&:XZB%9 B2"&1PTD@S*GT6%&83ZJ5-5:7FM:QE&\>%#[J%I:="?*2
M,]OK6?#%:M?*;2I=4D', QB)RG.KK98Z2$+AU\(X1^T;+9A4^/<4_/-759/=
M+WAG]]N!%!1[!H"7='*(&QZ029$C ,*47!*294++O&L% _Y5DD#O&Q2D9DPI
M3)V+ @(@UX$YK)SG,OJ4O'FC=9-JBO1X/#B_C@>*:  "FE"B$:9(FC)DN%;(
M,NZ925@XPA<V1:K0X&VC00Q8>1NCA?DQ$9 C\&B\2E%SQK2J-JR\3TC8GDX1
M4A0)<X<HS(UABD0Y,BI&0 @1E [:6>%6UC2#) $_^6!S!0EO&A*H9XIR2[QQ
MDA-"+"$*1RL5$9)&JM]HU:1*$!Z/!E,)@@A1\CQAD H'Q+'WR'$9$"4^.:-,
M$I8L3X+PHKQB]P"0#\1Q_L!]<D]3;ZMRD>5$G^E-'HYK$A).R%OI$$]&(IBO
M6&1\<$XZ2%"<6EDCO"ZEK@LSNU5N##UOA[3K)2#AA5*H)[ !5MCXA%+NTY3(
M*FQ<4FR<6LIB7D/Z12C*:TR($^:0 :M +D7+2(I8VGRP@-09XW5&YBF<5=A8
M8>/[PL8GZFI5V+B<V#B]\R?%*"B-$GDF/.2-VB"3B?JL\! J(Q>,J@(;B39U
MQF=/9U?86&'C>\/&)VI$5=BXI-@XO4O:L"BCBB@X21"$2@IS:N*1QBH880D1
MEF;J4FU8'>L*&E^T#GDIB57(Z_QS2@1I$8([+SQLA;K1[E$L%:XV__S\>:Q@
M!=;T(],0G=E^(6IT"HB5^<;#=1VI_I7L$4 "/-^VII2BYO=2@0V <UY'8KTA
MCFL6G:#P'Y8D::Y$C >$9C7PQXH9-3L!6OP+RK]Y^1!0="VEJR_CD/,>?[U?
MQ*HHNN&:FML"TO-90<*^;W7[$&=VTN:/'(+6$QC&UWC:!4?L'$(8:7;#YD_P
ML(X=='OGKQTH\G.*0'%ZW-@X%-L;)V1_HW'>V/#PG4VQM]LZV?F^2?<N-L\:
MN_[G]J<OHM$T>/\_1]BW_^K8[V:XTVZ<[6R<X)W=OTX:%UMGVQ=?6&.W=01!
M Z[?/V[LKO^$>T'@.3G_S\7F1>-B\\ EEH-[5CN7%/%  K(Z*.2T"Y8)G"#P
MERD">$X,ZSG>:LH9IL9K&0P7(9^J$LDG8["(/$2]4HL0?D]A/"#\ W25_5^S
M>0 *I^V-1Z$6P%MGI?TF'7?6X480C5?)I4.M_3_7^^?4A7.UX>YL^ET/?*,(
M.A(HNCPM7#L"?(P_;&M82/\UH?O[0]>/_SN$H8 /B@$9'$$@/#RJ;7=_3"@-
MZE)HL%Z*QL'EQ0^IV;$=#[@*+P6_*Y*ZD>[;#]ML%0)MDVJ ]4(N,+<"!F$D
M1%?HT\'-1M*$G>Z<-O7@G\U>81J7'CQ2L.M'R%WM,#3S&\%= 5;[Y4]%."Y?
M-&M1--MSFUNO=?/#<S,Z(ZW! (;::[J8->U:W;/5AYC>S>,^SQK?B57%%D3>
M'(71K_]>K[5C++P8QN=*O.E2I=+6=L]/X=K+KYW!)* PIM\WUO,U69:RMN,'
M7;ALM;8Q[(UT!J>NJU]><]KK_FAF2X)Y11>^>SB$8>_X6%A6/4\(P-*S&6:;
M:&8U2N@NZWULQ5YA'O8TWP*LXM0.CL!$:SUH:+<-O5'846KF&04$@]IGL-Q8
M8_"@83BOM6$ LFF?Q5:KE+D\L^?%.\)#"CG&''/.:['3Z[9:^3F#4M\3QB&?
M[L]=E_LK-5OY%7,[?X.A6JW5UONY$;$_; WJDZ?]H:_@43F?@6M*#RQN,+JR
MU@'KJ)U'VRL$->&E(YA(3GU&*I#PFU*K<6!/8FY.*UIXA\%9M[BJ4.Z<;/-]
MNV*U-FD.S2Q6>F@/X9+IL86.AQ'JCG5#\X! ,/ %DV0 O^P>#G,<.+2]L;ID
MLW<UGOF2@BIA/&7,7\TSPMR@/':Y)\[@VOIUA<KLT. QY?7-=O[MB'2AQ)4[
MWFT]#QN\5!ZWZ\,!OSRUPW[Y.N>7228\_0?T?(F&(YW-_^Z&PY-LW>?MTR-P
MOVRUASW;AM'>G1[@,4(7 -TM-5>N!KGH4UL 8?,T.V:IR0H="9<<9NW7;,[6
M'^71!"/J#GNY[UJMKB]"7@5G=\!9[MEQ9C-RA#R4XY$LK8.XFH?;Y,E;;5 ,
M.IA4,3[P-=]M.P@U18)1#-<I@"#<IWDQ;%M7#&4!!+UH"RLI5':+R>-@V.[V
M^J4_7;L+^#/T2K/='D+3G>V/82N/<P$Y$.(*O3P8]-@Y&N%?!'SJQ-0LGO!Y
M@ZS6OA^-D6/\NET(MKT?&3YA&&RK7PB\YN=TV]TP]J[QE*NT_\LWA_!JKR99
MT.!3P,+L#K%3Y!#0F#:D$6._O(X3O>B[AQT8I'+.-D;G(FF "1SD@E?^>0E,
MI\,>)!+%!=W3G"_FPM7Y1!=< _H)IVB!;^;._)&EC"_1 ?S0]@8=^.IX4%)1
MA@+(^ &Q_W0\.B5#R\ACU_LE(-PT0$5"84_/KX]0:,*DM)?OEWK=]N00_-_^
M* >9L('QT_K7$2=T8SGE[1<2T;D3;;A,V>#5"\@H;G9U@[.C)K2A.;A,V N@
MM^%'MI)[S8@?E6HOXL*1D_(LT7O:[3=SDW[IQ58QD%?*O'^[GJ&/GW-UB770
MM\/!S9=,"S[/2)F]4OV#F:GQF?S3=<,Y_'4T:+?6_C]02P,$%     @ Q#AH
M5;6$019SG   WLX& !0   !A9&,M,C R,C Y,S!?9&5F+GAM;.R]6W,;.;(N
M^KY^19\^KP>K<;],K%D[W+Y,>$>WY65[9O8^+XP$D+"X1R*]BI3;/K_^)"CJ
M1E)2D:PJRE3']-@2)1<^9'X%9"82F?_Q/[Z=G_WT%9O9>#KYZ\_BW_G//^$D
M3?-X\OFO/__]TQOF?_X?__EO__8?_Q=C_^O7#[_]]&J:+LYQ,O_I98,PQ_S3
M'^/YZ4__S#C[UT^EF9[_],]I\Z_Q5V#L/Q?_Z.7TR_=F_/ET_I/D4J[^M/F+
MC4&'9 VS@D>F@\\L&"E9*#H8Y84*D?\_G_\2I>4>E6=%&<TTIZ^\E8+11\X;
M6;Q!LWCHV7CRK[_4/R+,\">:W&2V^/:O/Y_.YU_^\LLO?_SQQ[]_B\W9OT^;
MS[](SM4O5[_]\_+7OZW]_A]J\=LBA/#+XJ?7OSH;;_I%>JSXY7_]_MO'=(KG
MP,:3V1PFZ68 &C[/K__A;33FE\L?TJ_.QG^9+?[];],$\X5Z'IW"3_?^1OV.
M7?T:JQ\Q(9D2__YMEG_^SW_[Z:=+R4&3FND9?L#RT_++OW]XNXYT/)G_DL?G
MORQ_YQ<X.R/$BR?,OW_!O_X\&Y]_.<.KSTX;+/>BOYIR!64JG/^[/NV7O3&=
M$I F741D]"E.*L$[Q+CIZ?MCOGX6RUC@XFS>(>+U9W>*=WH.XRX%O/;H#M N
M'L3.\3QBTR74.\^]A?,*Y"I"R&E^B@U\P8OY.,W^/4W/?UD@?#F=9)HU9OIB
M-CT;Y[K$OIW,L1F??YS3-W7IG983XMYB29@]/@L:B]6EEP?%%VBW'^/6C(@Z
MX\FX?OP;?;L<J$+O?6[X;8[T@/SS3^/\UY_'%IQQ*5@I:0/1*H4"(EFN/4^:
M-HHXVGZX.LNK>9Y-TYW1S^H:/+TFS1E$/%M\.IHU\YNQWM+6>8[7CY^]A"^+
M9Y.P\"U]-AOES',I1C!%HF3:(F=!N\B\0"X@9VNU7:?A[(K6!69Q040:]I>J
MUE_P;#ZKWRV4O%#P=H@NM;O]O,>EF;%R<78V^H!?<7*!;VCWIV'G#:3Y[)]D
M%;R\F,UI[&8V*N!UL;3?2!,-T]X&%B$C*S9I(8K27HL')EV'6DQZ#M^FD^GY
M]\7,&6UA4O^R@%!_X^8KEJ;-Z.97%D+9 NY=B=PP_D5S)9OE@K+CBE/-I-ZY
M,Y_VJZ9+>M \?_YIVF1L_OHSWY])+Z>S^4GY"&<X&_G R;(3B?&<D.E,.,C(
M \9Y4JC!TCL>!N/,+6!'RHY=1;_. ]'%BC)#>N3IBTE^1:P]FWZI<W[][4L5
MQ4BBB,49Q;),DFG-'?/% DV9W ?,"K2. ZXF#T ]4JYTIYYU]LC]V;,@,6'[
M'9I_X9P<V2MD4<84DHHLUZEKC8)%4QW.(K@,WG@+9C#BW(?R2#G3B5+6Z:+V
MI\O?<$(FX!EA>Y'/2=BS>34(O^(50!=]2K)$)F),3$LO6>0:6$P(.;CHE):#
ML>81L$=*GBY5M,XAO3^'EE[$+58+&9POA1DC.--8- N&)NU-XD4YD[0<;H]:
M17>D+-E+">NT,/O3XGTS+>/Y;]/9K%K=U_A>)"(O2;R:6E*9(J-ER4ABKK/(
M@#C+G/*V!.D]EN&LW$?A'BEQNE73.I/LKDR"G$8G-9IR*8$EKU_$V<)[&Y4D
M4Y#@F"Z>4"5: $.)@F4 &;*I/ML*>=:"00^/<%3Z[E"8ZRIV^R\6;\:3>DAP
MB6X$&J5+@;8T2($P%4=;FD(68N F*AVS]X,M#'>@#4>*+C6V]M+O+NY>7-XE
MG.J&TW(#0IM,!HPMO-HSJK @R16'(JP746>'PYF<MY$=E^ZW%W:'_NKU!-]-
M)]=;SI*-PEH()F0&/A,;?2 TP1AFL@2=<N*)Q[8+^_KC?V@E=B6V#EW)!R!=
M6Z)%*95DW:!\75Z<8\#),!4@@A0I@"EI=X4.;M8/J]==A-B+EW=C)_Z*9=K@
M)_@V4M(:X$"@HM5D&4K/8E22>9ET2"K%8-,!#/AK@$=EPG6GBG5^^/WY<3EI
M@K)D;#UF&4\NB,@WIXRCD!WYGC8PD3+-6Q9!+/;TABA%IH<(VIHR&&':(#Y2
M!G6NK'5*A2Z7G)'S"2!ZPU!DS[0NF7E0B>:<DQ0Y:LT/$2HX4GKL*/@-OD$'
MYZ(W8%[,Y\TX7LPAGN&GZ?6.JQ!**<(P!=HP'9QFT012G2O2211D#QV"&YO1
M'CUC.E#2!AYUX&3>!_'DCPDVLY/R'AJ2S"BH+(TWGMGD)"//N# ?!&>0/;T!
M2DJ,PP6OVV$>CE-]*;PUG_905B^1B]?03&C7G+W'YN,I8;J>O@O*%(.>&8>6
M[+'DR!13D3FC>9(NJN0W9-SU1*/[4![I8M2)4C;0I8/C^5]A-DY7^"J]KS".
MR*6S9,0+,J\X85,66$#Z5GA;A$VAI#3<+G8OS$,L-=VH<XTEW:BBEU7EU?CL
M8HYY,S@TD8,&)B("TU$!\P5HA8523_RRTU(/QI,'@!X14[I21X<!U(?6TT]U
MJQPEJ0"X,\QGQ<EPS\A"UH%)YPN&(@&]ZS'7=@&B0P[<NF0QZ*[2K: WK18_
M76;4_R6=36F(O_X\;R[PYD-RS/';_/798L"__CS#S^=K%M]VM"'3*E^D^4GS
M$9NOXX0OOHUG(XE2"N\Y,RK0)(0N#"!IYJ1)*B09N'G(7&G+EDUC=TB2!VZ]
MM"/-#AJ==BC9#C>36WAJYMD2T>S58BEM!6JT<@MG?[6O ^ERD[CO]M!=S>^O
MHW6%=R3@P;0O:%?* )YALHII\L=8Y#*PQ+EW](?D^B$3XHEJ_<X=K(,H?1NY
M=JCL>GJT!+6\YO .Y[\OC*41^=X"@D6F9,YDRI()%*6)#(.*GNP@#?*Q*U,/
M/'Y8_[$CP4^[E5J'=T$JI-]H6K0Q+2$M\?@D(Q?DBU@C:7Y&&195D<1<IS2/
M(87D6FAQT[-_=!7N+:][7\3_^&5%)&1(_JNGZXV_PEG-R?AXBMCBUNM6MQKO
M/+K_RXSWSV3E#J,(6'3UG IZ+7SQ*HL2@N:V*"MB>O .XYU1=G_9;C_YV@8\
M*9<9,F,X>S^=74GHRH6HAZF<"Y:LUTQ[XECPD5?3T&G-<TRYS9NX]<#[QQ1>
MS&9(+]Z51QQ*3F"T9#0C)+^57K40,3,$':1*KE@YW$GL76S#IG+TRX'U8,(>
M>NCGVN%%4T/I*["$CSG[6FA"6$]SC))64"48.&-24<4%>.BF;L<7$#=!/$1\
M:1_=K5\ZW%OPO<0>7\*LWFVK?[W^[XOQ5SBKP901E!03.$TV<LTO2<(RKX)@
MMEZ;53F*! />2-V(\1",Z$")Z\387P.],.-3 QD)V")3;3GQ#YB0$,9Z<U:2
MB:R4"8R,9WH=#  !=-6(]D(I&6((>3"*/ +V6+C2I4YZN8_Z=O*UEIIHZD62
ME$"JD"W+7!2F.0+-DCSNHLCHS[J(Q(<[$[T%[%C(L*NL>[E9>IN1E[,<61ME
M1"E8 !6)C*@8&%K+9 G.*"&\%<-=05['=RPTV%/RO60/K\ QC@=)CE'(SC"M
MR'J*/M73.5J0B)N6K*K#6)?'PH'=Y=W+7=!WTTG:.$N+)CGC"N.8].4L Y>.
M(6J4Z%,4?KCB./>A_.%=C4[$WXMY\+Z9?L%F_OW]&1"X2:X&[Z*@QBB!-ZZB
M*DYG5LLDLDBD90DL9JV]3($/F8>W&>8AJ-&--C>EW'6@BGY*XM0:FM-R,</E
M@@99E>SJ,B:]HYG2IN8-2MK4I 59P/L![PBNHCLB3NPE^)[\B3E,/H_)N;E$
MM#!V/IW"Y&_3:?YC3+\1),B,RK)0SVVTLYD%'3DSL6+G) &K!O0R'H%[1&3I
M5C6]."750YK-%^E!;R?_<TH2_ =]?='@[$5*TXO)'/.;:?/W6:VC0<O?_/OO
M.#^=YI&*QCL+NB8-$7 AR90JP%DD>SJ(X(.*PX4V=IS$43&M?S7VX@:]P_DK
M+$@2R9_@VW)-C9A,%"72]@JY5IQ;5!XTS"5/;TO.18GACF(V(3PBYNRM@%[<
MHZN[OW=F/'(VVI ,,A_KW7P3R.PBQX\E)Y/Q&J2*PWG)&R$>$3'V5T&'I6_N
MG^T(D7/R_X$))8"V4!%J)G-@(B?.46"283A2'#$?]A)\+R5RKF,YJ)/TEID4
M%=/)U=M.VK!@HK7>Z!S<<'[QX=3>:7QD!]'V8IY>&BOD>_\VAC@^6Y3?NBDL
MD15X6R^DQ,29YM8RGS.1.I5HC#0^J8<2^KM5_$-(CSM_HS,=]7-Z?[EF;<(F
M,DHGG6,EU1.A5 SSJ%PM/:HYK92@TN!!]X.RIP^=WA>(WU<A@QWHOX?OER?'
MP"V -I$E*6G:QDGFN0^,D$G/$T**P]5V>0CI 8]L]M9JJ_/\G532Y^I"3G9S
M@7E9.V2V O>64$8<,OE.$)GC2I+11#MJH%V67B5.1I.B73L,Y]INB_ZHB-6K
MZGJ)]%YA0ICA;6#>D"$NE69<%-J^0R@L!L[KJR MF>1DJ0UG -\#\ABILY<B
M>C&7E\ ^P;=;L)8?CE0R'-!'YBTZ8BTY@L$458M0<$^&H[$#%A=^".DQ<F5_
ME708?JU>PL?3:3/_A,WYK].FF?Y1KW&/$**%8&EJ.D4R[()@P1G+T&&B?182
MKG8CVIC+O^'11Z#2+H362ZQT.<\;2#55=FDH$5R2\DFY"=[<0FYK;RS:N9CQ
M (0\TTJ%WC%4-'UC7+)F./]YUUD< ;,&5F4O8=D-]I(U*>3(@47A:#=$%UF4
MB802M"H@,D@<+I/I>1BSNXJ_E_#L#5$WS1>\#[;Z:A&1EDT/M/7%6J<WA2!"
M;=N7AJLJ]B#4(XN_=*>67IR<WZ:3S_.[.VSR7&)0EHGH%=,VUR0)\*R0AU\-
M[BSB<%GRZ_@.>\:SMQ+7"+*G!GJ)L]S,]Q4VXZ^+=C_7 >W;JYXPO- D/:UZ
MM((N+CK[+$D(6I@2P5CRU0^PK#R,^M@8U(NV>EEM;I#^$YH&;H3Q?622M19E
M9C+GV@A &@9\4>=5VR12,EX-F(1R+\[CY<Y>&NFXH/]5BLR'Z7<XFW\_B6?C
MSXNBT#=P1XE;)Y)+#+6NLQ69>0&6@4%E=?3"\94>+1N]YQ9#'8?.^Y!K/U=U
M%K7 /]^=^MM+?/G7[\M,N^;MY .>+<!_FBZJ,N!L+1MO%,CNSGH1(JPGZD$F
MYBT9_(GV4*5URCX/=XC4X<2.@Y*'UWG/EXW60M:R5A_F0;/H.4DI.V2!(V>V
MD(@\+]$.>*GD?IS'1J^.--)SAMT'3-//D_$,;[NAKZKPZ1W "7TQKW=C2!99
M6^TM"TXZ,N-JNR2'B3EK7? A>+=:4VL0$K6$?[S<ZD-_PX6*1D6 ,<*1UZG)
M]=3"%@;%(BOD(KC,(>& %7DV0CQ>ZNRJAUXZZ=Q9'H5'CZ2D;,D3T%@GZ$.B
MO35$XJS*F(:[Z'9@*O08)=Q5Y'UF@5[G,<NL?"8#RFGA:;FJV>B%U,.#R"4X
M(;D=;EVXB^W(6+"'X'OQQ-[.9A>87\*7\1S.1BGPX))7S/#:4"-;LJN+SBR
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MCG+OQ6WY&PFE(CF9?*!)U[/CY=POR\G>2C"]OKZS*"DXDDZ$(HID5M<@DQ3
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MBRB#ENW:#//8Z=.UIOJYH;2=1"XSN3E/(@8%3+K:A!1K=8S"D7RII#%H87#
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MM0E*\)+M<-VZ'X5[F/X:?;U>W6KGT*<ZM^J"GM4 S&Q]4FL,7_8@51$DV>$
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M-N\+C)].8?*WZ33_,:;?R$[%C*$PT#8RC61N1./(IN7@=/)&\]43YU[C?H_
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M8^D3G$S6R,V3U<$6Q8HCG+I4B%+5#I, BJO()0Z7D/DHW.?%J6ZU=\@[N&O
MC8DT]44H*[H*/# ?=6 J<2]X@)1BF]:T>X%X#F0:5E.]U'I>0Z2,2HL$>^XY
M,*V=K$<;B5G#2X+@':3ASBT?)M5.N_UENX_U=UVC42@B<Z%VTPW@F8>H64'A
M7<E>13U@%NAFD,_AE>I64^NOC.N@J<)TDN[!9IW*Q2O!G#&Y6K21 ??(@HQH
M$VJ=!MSO[\?YO(C4D;[6N>3WV>%O2^4RR(CY,8DL+Y)@<4X:Q9RN_0$$J1\2
MSRRIG'5(%IW;-ARX%8"^\T$.NY\/HY=#YW]LN'!W:SZ+D]$B()?D#,,2$AD"
MMEZ4=)IEY$ZG9,D]'ZZHQWTHA\XB&9 A]U]JWD=3O=Q^N 5H>3#6!M+@][?6
M8!Z\(,)>FGRH]=0>:AB((2@QB)PEDS7*3- T S".66NERB%Y/J2?,0PSVE="
MZ)L8VTA_D%((&027Q1J64HA,>U$KA7):BXT/KJ@8C1\NX/H$2B'LJ;)'RR!L
M(^\ARB#PFJ;K%; 2R/[6GF;G02JFN,\JE 3*RL'T?_@R"%VK?P]I#Y:W\A$G
MXVDS0W+6,,^Q.3^;PJ1 JG+X#I/\!S0->0*S=_7OZ@SLGLBR\U#=9+9T,].5
M5!>('+T&CSR@QBPB"&<]8A2>8RYQM/.H75ZDN,]@_G7:--,_Z@)UX\+QC%YD
M8COP>E$XI<3 U LA]!DJZPO&PW09VV(2^X0(KA_WYE))=3& ;^/SB_/KG[R$
M+_2S^?=1S<P0&3PM#_6L H5CWOC$C!5:!E!.B?S(2['ED(>^L-07DVX' _K2
M0"\[ZLW$1UHDJ'-F661U&=>*J4A6"MGZ3OIBY'#52F]P'3ME]M9%/Z;V-9:K
M(\\/,,>13E[HX@V+)7JFG8NUPVB=+T_HHRI<#%=X:C/&Y\B7G77487+,G:5O
M=K/VO?XVGK]!?(]-PLD</M>B1E*'FD\MC.#5C9#DEP*Y$=I 09O!EK+-MO/0
M8,?.AGZDWG$M^AN +Z=?<4+VXN^D!MH0/^!_7XS)L/RO"VB(P:\GN2;MO+C\
MZS7]["N<$?QZY$W/J1T9BHB6:<D-\RD!TU 2=QF#2]M19D<@SXM.0VBKEP[E
M?R/)SFI39)R=3%XN$BK>3M[ N/D'G%TLQ-@0V.JNS$:6 WIN:E$_$YC.JK H
MB#P*A"Q>(C=IN".++8 ?.Q7[UV8ON3$W!\<WL-Z,Z2U*8SB[?8SL3%16\LRX
MK3UGB@L,O*9%V2BMN4L*Q7#!J[:HGP_I>M%C+VW7UW(2;_D11AI/V"SQ'PJ]
M#K;>.<=ZL4U[<-R*D(:[*O, T.?#JZZTU6&6TMU-_^WYE[,QYM?D:J;+[(E;
MOH5!ZR#'3,J-=>X@&&!Q3'IC(Z"I"3!;V6$/C7;LI.A)[AWF'-TZ6YC"9/8!
M$Q*R/!+1B2@L,IIV)**66F:'[#V?H[6I6(T8ACN'O0WMV#G3A4;6"1(ZRY&]
MF6?U"RX_>U^KW]4;/3=[ZNU%3Z>@>>(,<ZGA"I]8, H8R00LK7S6Q\&3:+>>
MQ?.AW2!ZWA#2W.MJZ,>:3$&+ZGC^_<4$SK[/QK,WT^9],XV7=MSWU[/YF,1&
MDCR)),D)(?Z GVLQQVGS_<67+\WTZZ*-^6\T,_B ,)M.()Y]?T].R3B>X953
M\F$\^]<_H!G7Q*UEZ&6$OH VL3 .]%)J+3T+UKIJ'P:E@W5208LM\X!3.'9R
M_T@,V?!F['5O]A#S7KW]\G9RXV*-"G<!='*T0JAZ@1P4"QX]B\GQ* JO-TJ>
MZ.ORT+S^?(>>.)<VO%@=W!.FR2?$/'M#ZEG;.4?%:\L]6F8YKPEZ&5@H*9*T
MDW#.URZ1P^4J/ CUV.G;A\8V,*J#^\/O+JK<3LK'4R#O\,7%_'3:C&?5 \A%
M%$>3-8N2"T60\6^380BIT [CLW'#]86Z#^7SX5$G>MI H0Y.1];7S)<-YO'M
M0.=5<'V4#%>YH*FA=,VTBLB\XI'EI**N=<IS$(.Q:@O@SX=H?6ES _=V/AZI
MUL'+Z>0KDH-(F_:[Z1QGER_&\E-Z+VIRJ8W1,55*8+6(!XM8:\F8XH,M(JH8
M6AA^CPQS[+SH6M(;6+#SD47%]L]EON@*IM??R!>BY?%],TXX"@9,M"&R4AM>
MZ?^_O3=K<NM(T@7?YU=<N^\^%?MB-C-F+$JJEEV5R"&I+NMY2?/82$PE$VP
M28G__GH B5RP9!X <0Z0R&SKHLBD=,+#/X\(WSUY 5XE!=JI:)AT/J<NT?XN
M:[T$>6C.\PU"<5#PX8; =^%R]'G.@KL;"YWPD8<(AI.8JEK-XJPD*IU!BXQN
MKTY=1[>O\(($X%#^;H#]H&KF^WE+2WJ$RMP)$T!'00JV<[63!)&7C9(IQ1 T
MZ^(MV_#IEP#TH1S=@'"#T,!N7+CIF$[_)R2WD(O.=!V1C>6#C,!3<"R%Z/2
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M-?LGP4":T(?\W]>C24[_[S5.2()_ODIO<?KES>(?/]/??<?+^3M)MA\S9'5
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MBMR5TK6VS];P'+WQ9 1X W0,!-&<&)2<4BTV\9%WJ0[:=_WAA*1O//<0FX/
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MEWV5J#NWH DVJ^ 2".X9*$=$(7H%63+KG7;<=NI2NW6!\X"W#?_Z&=:V;0!
MDCE9BPZBK Y#LD( ZP  8;1WWO"$?L#9EF<QC>4PSTX3I!KV$+S7]&*M\WP7
MDEZGL1R&9(>A&_O ,- T%N4*ZMI7&Y'5@0)6@S/&@I=<:VM"\$R>FV3L/XVE
MM6#LPOW&ZN.&X1+:):=DY$1-JH/('0/G9 !O8U+U_XOI8AJ<ZAB.G9C]^!B.
M73C5RRCM]8DN]&X%6W(@):B6G9&*5-NC(7#'D^"VA&B&ZYAXHE-T]I& 5CSO
MQ\=+_R9=4_>[H2TN*LX#NEKSDY5"VBFIR<Z[ "75$26&M!_+!Y.&;52^)*VQ
M"5*]M .^3]*<RMM10T\3-KCNN(788VF0;5#=V@:S!22]W#O;")0A!^># R,(
M/86>+D3,1&_V0DNO51'#A9@&E94G=<J!1647))KG&<W38]Y]SY.KT><OL]M!
MQI7&C^]^^;#TN1AOG!$U2X;3ZQE)E_0^T:UJ8K(Y*2P=4XXZ+7<,#:0)..-^
M.=LZ^(C37*E91E5I)4%[ C2I1E5= 1]T@N(<$D5D,+%.P<8'7ST'* _@4U]Q
MA'OA$F:53\4(L(DH48ZT'O2,]-PZ<,L)8U7176!;__3YZWPM>-JP^?X&<FZ\
MZ%T(VB<&?"*1WWU9OQW& _C6[YF](4RX4K-8Z1IR)*.J* ]!%@.>9\N*#<7:
M<EI =@GH]H;C+NQJ78LQFDSI]?Z>_ROC9/F4Q)BYSI)!$AYO:@F80%)LT7F1
M5! 6.\"WZ=M'"M_MS^YQ0UXUUG#>%-($-A*%VDD3:4M:L$R/N"&B;*+' Y-V
MWG,K1)?SMW6!YXQB&ZXU/(;3R>Q>XF?@T009+42#I'_Q8 "+CE"*SJZV37'J
ML2AKP6F8\YF^.K=9_Y8O9]/ZISF\<V@?+'C^:M#^_&TX!^:6B&7U30<R.OBT
M=H+[&!ZJ YB_"M\!G.OCM"[K*#73TFD-.G).]W]A$+30X 4684KP8C54=9H
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MQ+O++E:+NVUBPG&9T7B%J+"& +6/GGX>#2MKQ=U;UCA66;=S1H;B-$0C/:B
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M6L6#RIX%%VPQKD2="KHDUN)?6U<Y5@0L92%SD!&L$&3#*%8 @XH@$9/4RH;
MPHDZWQM&P/Y!YWWZVWA^(5\M,/KU#J-W]QI13R\LM]EJQ:',1RC%/,_O,S5
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M.\%]# _4 <Q?A>\ SC6T35;)"<:S)"Q",9'(*6C!RU(@NX+9%R\=/M90[V0
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M7K'$N[R,V[X_[ O9@.W;0=R/9UM?RRW)>#<_KK\$>J'_G__C?P-02P,$%
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ML0SD?34N9A[17IF+9:!Z5.EBH2',U^>_UTE65?E5_J]<+ZZR?17O0(2>EZ
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M:5^HJLPL$)^O,#//XT>[W*[(-KVNK:QC(U,:<)H@$4,'!1Y$)$SD2^U2R*+
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MM=TX<>2$'@GEFI1(UA0>AC%" 0P$YGX<BS ._?'FG+$\Z[;T\%$=]<]]=3Q
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MA[;?KF? $0<>B]MW1VD!O<&%K@M?$V$_<>(8>=*2EE!+PSI4%6WE)IS+[7C
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MA-(0^HQ(XJ$1)X&A@3Q*CK51TN-C;?JT/]HR40+ZLS8F@F"1N; :74 .&EP
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M$0NUJ@[K#K@V,N[;Q31R@T;PZ5O%1[B/WX"/1?,%M]Y+ CE]MST6T!7LL_6
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M.J8"VK.NC'ZTM45GJO+=%6GRL\R7J]]PFI6J'.-5]O:'.IC:I>6->G.O1"<
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M.(R_XX*IH\V]/G7YF;KL3*E9=V:>V=.FTH4GPQ*I'B:@AAKD;1]0<9B&_2S
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M<VC@$>(:AKA,$VAM9ERM0>VS/NHPI;?UB"G2)4![P-MS54C@R8D94/\4>W5
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MT1I1,,\8;WW*7A)W2X1NB/\\7#\6MYZ5P/B1UM:)L<IV5Y'1SYC::^+M#]6
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MR=<Y:5W1EINVCG  'QHV6)\LW3,1FQ.P\)+:5&B@75W:<B 7(.-5W00,_[@
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MH:?VF"CV5!%#3\#$]SR?>HBAV#!*3GOLM=%M*[AJ-ME*?B%_KF4'=TKX1Q6
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MG,( \QPBFB:0BCR".9$1CW*">6)9#=I6A*4MJWOYM0%<'#0 NH@:V!QTT#6
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M;=GI5!P$3(MIGRMZ$<_AY6(NE!PO"8=\T(.<H!9T!-OW F:?5CL5.-\)M3\
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MB\E< BV.O+^JOPE]^,0;@0%M) ;ZF%!_/OO(B6=S+IIEYH8YW_=\>/02*WW
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MS*C67,\8BZ/G6DS0R EJ0<WWX]=P'/9@S(".:[H\!P;\_G>;*GM]")E[*F9
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M;?B5L**NR_KV\-0/-W@CI<N"=AGHRA5C#ZP.3<JJ5\_ZL;=_%M6#C(,T"Z(
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M2#=VX.D0NI-FF(DPM08FA-:S#3 -'TUI&AABY]T@&)(CL!E@",OIXF]ZHWW
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M?(9C2'&4PC3B$N&L0!0C]W.D5K+,C?R^J$GBC\OZZ"/="SSF0*G=U)A:4D$
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M+,<(2<T<-(,X90(6DF)(RZ(H%<NP2!26%2-/1YD;A73E\)XEO0*=K-;E",^
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MC2.:D*)$QH4:^H>:&_%UT@+^+.Y R7U;<(<#G=-!YMT ;-$ZD+2IW^BPI34
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M;=8?.AMD+74TOE;S"N@353M 5KQ. WXPW^F<=&9-HYZ!)BH0N9M.R!5@>Z4
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MA]G.W16,RWI$/F2OOLN<*RN3[;</R_6?VP]*HE^WNJ'FF7/E^X//.(Z)E$S
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M\TV%F>=O.PQ<YI;85+ %,K1<X;,RH$PPZ;&/>F\/9OZ8*'%HW1A=[VJ\O*A
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M19K+)#-=I0S'G-NB="@VT#F%6G9PL])]O/09VP,5S.G.%/_A1<8#JI[7E"-
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M,'3WDFG+0V#9J*P]V!!\?:Q98R'D8)@3Y (4VE/]0>@Q?>.XXVL%06<*?Q0
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MU[^^>_]B3L*85J_J!GDDA4Q&!P'KU8*2S($OB0.OLQ0S)N5=:6+P3US__!3
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MKP3OD\WT[R/ !S/]^W"S%1ALL]LP216MC?3^V3K7F"EP!AUX>@-]T$YF9OL
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M:U(;)*^!%R'HVO4L0F Y:):5CJ++E73/IZ>^;<;2RX?@;%O V/9*"C)Z3NR
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MCL#ND_.O7C=ZOUC\V.24S>:S>__-H1VP_5<^KH?V0$Z,X<*-I7#E%0'=>$=
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M244*SAJ)$:14GK1<,H:"BX'N8F%+$@41XVA0NF^'+4T</ JF#A;+_N"JQO=
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M[&PV0>6JH8=,%SM=QUAJ:*6H9!W=T=S+;NK 0TN<JKMS#S$OAN=YF]!YM;C
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M1D=P42*$H*U24189NV2$]EITZHSB@1_1XS%\8B15.GZ=E%VB??&),ZY .F9
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MTY>*?VS0P+#8>F"3[4%K'Q3< =<0(IDZ$Z$Z638NE>W>/4:N#4^0R>"!NE]
M+SUDE@+SA?XJ=FGX>?N[4]<Z#XJ @QDW=4^BV>K?;Y;YMXS>+14V.LV]LJ1*
MIDW79 Y>"#KIN@:GBJ.'O(LE\O *4Q<B#PZ$@9@Y,21JY4!<Y_2/Q3D)X\;H
M)J$-,40:2$9F4*&RA6=Z?CD&;K7*(G5IO?C0]Z>N)AX<#H,PLA$PU&E>O\9O
M!*^D*&!,H=N-\0A!!@F&5:^J-#[++L_"W2]/7<-[- #LR;R)1?]J]F.6\CS]
MJ\X0W7&B*"%9;8XN!&W?,T5FGM> 4:%3*0MYNWW*O;*_Y]-35[X.+OQ#V3=U
MW.$<X[\_QV_TQ8UW=/>0D?UN,2<$(5,!I5! $/2N91E)O;'HA>E4\'__YZ>N
M(QT<!4.PL0F;\\&&GH;7XE:IP1;):J.S"-Z9 &2+L]J.408_7CGH0:UWFTF^
M'\*1-HB\FD#>W6:02N9@K$20LO8 ,$J"$QC :L-TEHYNV/$@=SJM=WM)OD/K
MW3YB: ))=]N "J69S7406?7,*!\3G3:3022,J&*45HP8E-JK#>NH37Q[B;Q#
M&]8^_-\;0C_R,BR.T/CM:O;MU=%R.EE+:KT3M9VLM8Q^5R3(K%EF*BJ3QZO=
MO&^'4_M:QG\ #Y93$U?6 Y.6'3>U7:* R&T]-V1+H@X<1,[61^1!V/'NK?OW
M./7E=;C\GX34'L*8VL?_V(3V+TN<QV_Y>F",#U*191,AF)I;D+4 ;ZP!@<@-
M%SH&WR4GL=>BK<%F'QDOQF#XQ$CJ/K/=2U7[77O@6%N[\DBFKO7TQ@O+B\50
MLM$=4-1YP:EMO8$1=!Q&-_&X[9OL&6PJ1!""55A[J_,(+J  I"/"5.::NQ&'
M)QRQIWTS-9E#*&1C2+L)6'^>?9W/RBS2(;WC3[S9%8XKEG7.=%0C77@J$T]=
M(+4$<_+,!$1AQG-C=-STU,_S*""Z ]UC2/099(Y_)N4E79[G1:'OO)DM5VOZ
M2])U%O.T56V.GT;>?0]CYY3OR9T#$\P/O.&=]4D&PFY)OH8GR5)"^J.S2F6/
M2 K&>'/T#D[2'LR]0\HW+X'781>1'KXH+#BI28$C7J'2=5K0%%W]>[IWFKF6
M^V.MHWNGCYR:4!4>L!6\TBPC]^ VMD(HK"I:&;CQ)F@C@A)N,KRU::?WEW]7
M]TX?89R4>X<G*3PF#3*YVGL.B;!(RDLQW"2FT6O;I0#^.;AW>LEX;_=.'X8W
M<3V])%7F)S'KQ<7B<KY^$>/E1>T/E=.K3)N*LRO!7=0.AZNKW\_3VXOO.%O6
M(B7ZPU^7B]7JUE?J02V);GAG$%S-C582+=F4==Q/LD5R9W,,XS4Y/Q:54SNB
MQG^4F\!+@R=G>_XC<I4Q,V"9T2T3O0'OZ:$*IM /9#0YCS>5XKX=3GT[MX&?
M)V"]AS";@.0]O-F2$E@Q.B4.3H3:02-'P"(]A"(U%YF;Z,;K(/;@-ML"YSXH
MN#OX9!"13)TGO%UR6Z8\__IRL?J5-YF<=Y[59-?([=6<78S:04C*Z!P"/2E=
M6E4\ML;4S^Q@N!B4F1.#XGU>W\L77=#(+#B(I!.IP,0<M-56T\H6)UV(G;K+
M/O#YJ;-<!H7"$"QLXN%Y,"$Q.$4L$!H8LQD4)X,K:.O(7#<J.VD8 ?XT4H=;
MRYPZ3(L?0EY-(.^>.?+616VR)\L^TY%QEM<K-  /P<F$A6S]$:=]G$SJ<"_)
M=T@=[B.&)I!T-W45L] );8+(F  E"M:D,@0NE=;.9<OC>#[:$T@=[B7R#JG#
M??@_=9%U7LW2)9Y7Y^#.%<AM3BXPB+;V&!.&-/W( \1,>ISE+&04'?2@NU^>
M6AL>1O #<*V-:V//= 7'C;6U,;FPH99J*++\K$C@M)*2&6(:MMHLZ]U)9S@=
MI#B-(>TF8'VCCSY3+J!#!;PR2S'O:EHC_<Z85)PI7-KQ//E]9QZT KX]H?!(
M!+.77!I.1;K13;JFV:S>U^2:PQI4/OG)H1*%^NW]V(TE)0%""6$AYQI\]-J#
MEUA R)@0&884NG3O:*^Q9%8L6*L+!!$U(5UF<#X%8+6B7O.2-8YGTCV?QI)]
M\#),8\D^@FSL&;R1@X(Y%)9S)FP46_4("2X$ ]QR7EBH-4;C!?F>2ZY8+VAT
MRQ7K(Z<FT?:KV1ASGK0#(#.X=I(09!-9^@=3+"<AA34C7G\GE"O62_Z=<\5Z
M"&-BI\0N2^G%UV7.]>K_YVS][57.RU(;UGS$Y7I.Z[S[N'.W!&DLL0Q<#9ZK
MR (XA9H4!.Z+$K:@[)(LUF_5UH"SCY07H[#\1,!T)R7.&IZC-QYRJG.PC!9$
M8V)0<DHZ,JQC&@:$51OIB,?&PAZ0.T@PIP6^+W\LMC22UL"9M09TU)%47%/
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MG/5[/M^NOVQ/TN^#;8TE_P-MVV\+G+]^1\V>$A,*>HP"I"MDC*)R$.B7$&Q
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MH$LN4J8D/!M/TSR!@';E_8VNV',$^$10NNT-]VJY^%#?DJOC2/1XS#J"$]:
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M]3F#?-^?-WF-.L<$0;LZY]60$I4#<4>70'8;-[)3Q<\(6VV7BC Q4(YU7$Y
MR',^,/LJ+NU8JNY\*-H74-%D\(H,4:53,9*3=7#353G^@6D]16)RL!SKR)R
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MB)X"!@]T1:5ML<X#LNRJYZ:0AL U7=9$L? L%7M./.FN-;LA[F_@Z#];(-,
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M,@C6WBO_',4SD3D4M3[8+5]J?  K/^4!4&[R;.L4AGN^NZ64WK&&1T(B?A+
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MD-I1QK@?&'*+7<':^ 3KZ7"D?W)85)U]1CM'U0"!M"]ZLQ0KF0=!K(+]6&T
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MTZ(W.L0JH6Z'#Z*UA<6OI2CG_C$VHZ@&6P'@&-=6*0@[MM5T[(70Q[R%^8V
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MY/2L9F?[+1.#H9UAJ&MU'5,X];W!C$?/SW*_BJB2\9D?OA?;L6S'=+6H,(9
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M2P_CYJ.4SR=]BQWA<Q["E]6S[>*3RXUN'YWC8N X^#\1Z*T&\#S(O40/GY0
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M<1(O7E %H?#X+))&'9@U(;?C *2GATS*WI[;*"N]^70V@0TS/HK1[@&TP=-
M,*C%?"GXHSD8PU/0)S&90_-\!,1Q1Z,$B*I\4$W(US=OKVY2,>\'><,RF@G;
M!44"3@0]!HK7)65"8/""A_-QB(Z#'E32%T5[)@!R]>O"S-*I&H)@<C100%K,
M$D^JI*)C@:L?@FH A<;9GV(.3[H2JK@[M'-C5[Z'H-=8;(!'"L_/W'MT)=BG
M"7 &LS+)%H?H8)8B:P5B:/L9F8!LG(*=&4OJP'@E@ GX)\[F@!?=>S=&CS0,
M(ER^VG*V59AN(O@]T#CRXWFL)*JF%( F2 5!I@MG[7ZC]0,+[LG/18$Z@P6
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MUB)46HP4!TA ((>KX+V1.I.$\PU# T60T.[D2>6JB1UAN_2 2CX8!6CFLO^
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M.!ZLJ O+0(YWM^\^*[JD>X  ]^8/I 9PO"D[4_<0HID")+X@E_V3E/U#KJ]
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MK8'6+.C9?:J@9\5*9Z2I<;>IV5W)"B ;%L\@-1BBQ:+]A"_4(_9#0&7-?Z&
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M=)1"I?+_T^1KYO'$MR?XDF[H]R0YKNJY64R5J_NY/WE TC_"?N[K(?^@>9(
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MD5 =,1(A,D48S+F'K>F'@"F9MTHYK[]=?983K_,D+8H.S^$Y6$N@^U]?)F-
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MQU",0F['03AGUS=OKVYD(T>>8"(4MCNEM[\V[AHLF@1A[,WQ"Q@,&VHVV)>
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MD\:B/!4N04W?):@I/>=%::.;.&I_E 7M0KLF;3G4(UC4J\9*:X$V\:UHGH@
M(W6LP\75R<4V#5@^;\9<[3+AUY'AMB(YFY"DEAC%(6V&H68$UPG':G(&#FC4
M,0$EWL-F*IL2J/4IL-X"$W)9,F]XFK+Z>@2QQE'4O]BF;^%9UP1Y,7V%D#(T
MU\X/,W99:DR=J9/>C8%D(B?)DZ4T9X1IA?/8!6(S/\2\TOY@)=NG$A P\08+
MO7_E3-<;"T=39G&VY$MS]K8W#*@=%EA1UQQOP7WKN>3C\+FF#8!SU2I"28=T
M7*Y4SO&7HIMLW!)ZMQM1,_67>.M9EX6@ABFIE8RY?^UVTBCYQH126U*S6BZI
MM?LJ51S[<HL,QM)5NV-8S:]IQZ&$^]?6TM6QN:T)R[H\*,8+6VIHV2Z(FV86
M' >W^_>A:OB@/?L2AU;+H+P1HT^W'D(\!G$:D^:L"\)7UA]<"4)31&O*0O"=
M!>!>+,L&[VJA^8UP_* *QC< _N7E:MM\(4PZB G<5&0-W ,F8.7Q+?GA2G_$
MCR;JX\!'^F(0R<#28'!?1.JUH/Q%Q'?L\"C1O")%!'I' MON/4%<?V_PW4R+
M4PB%F+Y-JI0NO2R!64+3X!,$V.$I(H U$Z<)N9']M?/^-"7C $>'KS=#<XE$
M$4F::2<.8L<L\DC9A_%-;N*XH-6&4'_\(3A*,YB!=Y^-E[6 61'[K(1NHK["
MZL8H<0%_PSM1'@.L&Y(E&+#WMT\?R_WB1CD^& QD5F1&?V $,V9;2<L08W:T
M9*JM5U.G3H01=X@/' 5;]HZ8F"1X(,XG/\3?6S((G6CEKS <+S4L$0W:S.#Y
M$J&<,",8 @:<GC2@783'ILL5Y25B&C*Y* /XF^.J#M>,-1Q7+X%K/C\[$%SS
M:W?0:]_')Y-W'_R('/YOTP"\M!M']8^ *+EU'Z>E[<1*TA ,J?TR7!'28TWX
M-G%W,?O#.*'OK-W7OU(&]]U0YC2C.77-R?-=Q/.+52[B7JG6/S&<"W-NF8:S
M!E]$^ODVS$91DG%VC8@+[YBSZFN8/1R!VMVV*A5M(*!%R"J9E)C3E)5/B#C^
MJ,[A'\X<CI?F4'B_4IA#C:>2#/.>V2@-AY:.)!-FEY?T*> U(_BKYB]AN4$\
M?M);6PMNJEK@4G%K2H#9YY@U<;J8XV9-IYD]L-9">SPG.F_3N_>-)GW?ZFA+
M+7&IS5*C?3CIW3SK,4S&U?(8I_F%I5^TYSWF;N.W#EEDJ9]O722\ND'N<"&T
MU)=L^][(I[.W52KIPUZ#RM(M5KH43X7Q)-)^+.-FSDN-RKPZ]DL\6*CEOP2'
M=2*<>9B,HR5.X06QKKK$<,ZB-V^$I%-H)FA%&'>71]"CX(DB)^>8D$C>E!.?
M'JF^+W/QF0-)#DA@)$/6!$SW^&%4\/O!/!&5&>LBJ,T6,_#L[>WZH+:WCVG(
M-N'&-N#Z+8&H(I0(]ILCX;\+22__Y9/2ZC8NLF>1).WG2APP/3.H-5+.\)Z8
M;9FMY"1CE059PK69/P[0T#ETSW@"/I\S1S'^\F^P1.:F"8;306WN"A"O? @@
MW)20'VEUA60:"P%BX7+,%T)\1ED'W&_)S. #0X?4VQU;8P:V8:MU^-AK"#2-
M 7.<A^K\U(V10UW*8-3X"91O/M,,>/NMZ)I*K-X@';*(D@AAGL0 ]ZDP5MFL
MTZN.NB.B^4.7P;:J4^=CTWQ]M;/G14^^6\['FXZA9;+P+(@"P_&)7^  6$]F
M 4SN&!;:_0(%4V3E_J;5X3MLVO8>3N[J^>'#8"6G\E[9UZ\!)B5*UC5-XJ00
M L)CB$W-2=.9.?=?N=!(^SR-#[8_\_%EU1O'.N5Y=Q]>FG<V;"/U1K9^BV?[
M"X/!0>GS1[]0%^^;#AY"KGL_)2L"(1?8F/&[GY/D 3^;:XY!T:D/BB7$I0(S
MV#DS5QEITT2M@6BQR*F) 4U()!/B=CV_B4IZ[&QD[K<3<(RS/$G)2\/4>J8/
MUDBX]%8N?ZESF]2(*+$9_7KN>TJ$&Q77Y*Q#XUOFV.T)+>^B1([, 7")RM>0
MGV9"!5ME0O7J:%"3^#Y1,G3J+Q%0SPK#P)KE,%8];5F3EI4R^W,\-:&KI)>#
M/7&2MA'N04Z9KK3V.D\OX+8&#S" :<)]#""^&5$(XFR9MC]%0N$41*PD"<?A
MX]-L$I4KG[1=K>XX>Z<]-!JN:U4B% H&:R$N.3#DEC:VX!*UZGV?DG3,W2AP
M:+(+8,H$ZU7RP/@;\A>)9*M?4^16_9)/HJK?9M.Z:^GHL?(=6NUX^:X2O%2_
MQ_,LUY72&ZMFF^O]68*Z@&OVNW2Y?&WC]KE94V"IH#./X4<O+LB3QR*>R!]I
M"6]9>:2$&&,)M!HY:2R&_Q&L#R[P]9IM$\DK]SC;,:%.''+"S)J@&8JV%T[U
M_%2R('9-F7");R^VP#E4]?D@T^UY;[/C_J,?1J[/8&]\TON&VE]Y"[>U2Y@]
M\.UMS$56D:F2Z5A2#3+Q_E/S,1,6P=.=7"A,!298<(0I=>@);5JT9<U+C>@C
MA+ )'G_J0:W9,EA>55GQ,QUCX)12;9R#E6+O3;.P9R>]?T 4^\7*A41Y^M/M
M">59L;0%!^,N7GFI%>?#VJ*H9=Z,-KNK?BU2U!4\TINTM"W=JM02_.QBM6EY
MMQO;(I RD,G%3[M#M54ZJ)^?#' NN"3%VA3'$)D-7AODT=KCYF<.=@!4X'H]
M7MS3 Y(9[0>[E1G60-?*S##B2R"G3I?';5;4/74]6Y"RMC*05BSD\ZWE0K8+
MN*M[P+J'ZT/N"=VMR9=9DS8V$MP-ISAA(6'+NG%:W&O&A=P%[>GTY9=;[>GD
M]3[\? -^(?V7XT<*I@KP/E+%;=7=X^[FQO2%LK5/#:&?V?@_W]YP_OU3D4)P
M!?'.73"&<"7&0]Q[,"\+\X!/=_8!22H@ ?("G8?(>VH?.WZ)WPOP^N"NM+UT
MF\4N%)-:BE/G;0<R"#'I%,S/<KW?1W@USQ06LA#K$A6:$O!'>)AO3B,G3H/>
MK*:Y##W051I)0FAT34H)ZM:IV2&I6;FW:<1EP')ZI4'3R.!.\<$8?/EC+$(-
MN -<%K*D$TI#BU)A"P7XO9SH+[6W69%-Z_1@M_N@&A$U#BBU(77-HQ)U#/_Q
M0YTUJ+2-Z@2\)P(FF6 '0LUEK.PTYV$C7Y8K5LSA[W"+Z42WB[4)-RXPY87Y
M=&J96F UA>$/Z,SI?HFL)3W#=2'_"]3C G\N)+\NF1>1'I/,!*E#P-? SRV6
MIRKNRBJM=?@JG>O,#<$<C+.1/S?O @*5W=["1GSJ7)W><TA3^PZ=RNV!RK5Y
M<EP BY7V 6)M^*B.3CG%7Q.T<1D_A$=QC,41]3)"[Z2[FW P'.D9;1J$LV$!
M/KCB8#O1[:OH*HZT1%4+68\4V+L(NLZ6[EYDE!ZQB1'IP#Z'+1"/Z:A<.\Q&
ML*Y2SXB0TQ[&I0[T%UR^Q7NE-"R'2V<)G;!2:067DRN.=9QT\M[%$E4!(\9#
M3S=,KJS"V24^S^]\@%S>;ZO*(O$P3#[((EUTPMV)+Z[U_KJ<;>&3'I=ZM2!Q
M3_CCBAASKE2@' 0,MDYJ\R/6D!NH<R?R'6^YC%)7\5+/<)2B0/I3J@=); _Y
MNE/7JGGGC$DP 47H?*J="[CD4Y5V53I=9J8*J?4,1V6N Q(M4Q%0]M,M^S1E
M253(: ]7RK&61O;H==LR4F4 T3@:ZZ+N@SB@6(R+D+0XS)9*MKV9"V'N-&['
M&L?FWC.Y<,J\Y($DO .L]!HQ5C1"7$K!COT\2/.%7JFT;&MD4^RA'7B=G*ZA
M>E5[ITXA7CW?XBC#G%>U"]FD3!F#HR8(NJ,ZGUF844 .D3S[BXD<U#[A!O48
M)NI&3IMTAVI&,L[7A>F866N[$''O,KSA;.Z/#-'9QU__\^7V7?\:Q 43.@M'
MG;SV6EZZ,8-+.($-&,'?^1-B/;]BF;A/UOC?#ZE/* ^+6;%TB/#V(UN3K:A0
M;#D"/F0R9N>"\.&95X6[2_DOAXO&\%M4"V=NNR6_ORID^0UL39=##-*);M?>
MFY]#+""^6AI0X$ZT+@000,"Y V2B!1B,IEP+!;MPEL1Q$'4RW+/E9QA:R(9*
MFH=@KS&S9N1I$L$?'F$Q6F.:$MI#DS0D[*YDNJUD^O1]5S+=K<.6=9C#\Y71
MC4DTGP*FVD0&':*MA,E&Y^<18R8DNP[2;7CO]P6%N!*)E<UA/8"WAV"\3%W-
M,06.DUH@8@6%YR(8R8_PRG"\)3R@91/9!O2VFG@,,UZO"GK[$(S\HGVRF0D4
MJ5H(_;@.F#%#@BB86];:D1\+[=,\Q>KZG &+S ='C@(E&TN_(?!FL$@D32B;
MCM=;)$6/4;^$3X0]8X%SG:_2&&J2$6AU-(&7.4^(N47$2V-/#?Y_#C3"=%3,
M,JKGP'4YB1@;+O/:\B27Y6HT18 SC389C=!S6D9Y,E%5*\[30M-7@CM/>G=@
M%O@\]2DP^12J-X7Q)=$CL1/'CV&:Q(Q8Q47++'NL1LL"I3'!_=-[H6$FRX05
M,? O9]3"'.P/C1LVYXQ8QU'K'>\/+A<)]&!\*YYXTOM$!'DH-T.P,URX?!V1
M_^0YY)54D8G/*(9P!<Q?,6>#@*7VC\2M&R_60\*CJF,>\FD:<.4'O*"(BX\L
M%P1G<<#!7EF;O)ZV"RBKD9NC.@8[7>9(JM!?*)3>4 J[YBD+X77\M(S_IC4F
MC,,6EIW,PYC7;"RXBBAX1$H9,40*W*U%?A?S"HJ[A-TNLM7;AY"D3L,H<.F1
M*6GLWAC_C_7$A["&GL#DBK@,LC(HW%O^.:XPL!B*MT8\=XQGWU&0.Z<E[A9H
MC> 0)\4G1("4'=JS$B+70B:;@NP'&H'_3GU4(R)@Q)6UH$,=3U<*J$8R\6B-
MFB.8$NC="*#46J%6",ZV89:W;$\(#Z.E3YSB1"<3\'!0,/"^T8*M.XDPK]R]
M8Z%N#RWZS:'%7X;)> '_3/-9]-?_ U!+ 0(4 Q0    ( ,0X:%6/"T0P44L
M ,'T P 0              "  0    !A9&,M,C R,C Y,S N:'1M4$L! A0#
M%     @ Q#AH5=S[[O[8(@  IZD! !               ( !?TL  &%D8RTR
M,#(R,#DS,"YX<V102P$"% ,4    " #$.&A5W#D*/5 @   X10$ %
M        @ &%;@  861C+3(P,C(P.3,P7V-A;"YX;6Q02P$"% ,4    " #$
M.&A5.V.?,?4D @#;0!H $P              @ $'CP  861C+3(P,C(P.3,P
M7V0R+FAT;5!+ 0(4 Q0    ( ,0X:%6UA$$6<YP  -[.!@ 4
M  "  2VT @!A9&,M,C R,C Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( ,0X:%5T
M1()C[Q@! -@_#  4              "  =)0 P!A9&,M,C R,C Y,S!?;&%B
M+GAM;%!+ 0(4 Q0    ( ,0X:%7G0X+[#<X   4]"0 4              "
M ?-I! !A9&,M,C R,C Y,S!?<')E+GAM;%!+ 0(4 Q0    ( ,0X:%5E(4=R
MGSH  "OI @ 6              "  3(X!0!A9&-T+3(P,C(P.3,P97@Y.3,N
M:'1M4$L! A0#%     @ Q#AH59\/L[?'>P  MUX% !D              ( !
M!7,% &%D8W0M,C R,C Y,S!X-FME>#DY,BYH=&U02P4&      D "0!0 @
& ^\%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
